{
  "cells": [
    {
      "cell_type": "markdown",
      "id": "0bd9a4d4",
      "metadata": {
        "id": "0bd9a4d4"
      },
      "source": [
        "# Сбор базы статей на основе сервиса OpenAlex"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "542e880f",
      "metadata": {
        "id": "542e880f"
      },
      "source": [
        "## Задача 1\n",
        "- Собрать ~10–100 научных статей из открытых источников (PubMed, bioRxiv) по темам:\n",
        "  - Alzheimer's disease targets;\n",
        "  - Alzheimer therapeutic targets;\n",
        "  - Alzheimer drug targets.\n",
        "\n",
        "*Предлагается провести несколько поисков по вышеперечисленным темам за последние 5 лет и отобрать по 30 наиболее релевантных цитируемых работ.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 5,
      "id": "ccbdbb55",
      "metadata": {
        "id": "ccbdbb55"
      },
      "outputs": [],
      "source": [
        "import requests\n",
        "from bs4 import BeautifulSoup\n",
        "import pandas as pd"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "3a8d665a",
      "metadata": {
        "id": "3a8d665a"
      },
      "outputs": [],
      "source": [
        "search_string = \"Alzheimer's disease targets\"\n",
        "from_publication_date = \"2021-01-01\"\n",
        "to_publication_date = \"2026-01-01\"\n",
        "page = 1\n",
        "per_page = 20   # Между 1 и 200"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "69eac509",
      "metadata": {
        "id": "69eac509"
      },
      "outputs": [],
      "source": [
        "searching = f\"https://api.openalex.org/works?page={page}&per-page={per_page}&filter=display_name.search:{search_string},type:article,is_oa:true,from_publication_date:{from_publication_date},to_publication_date:{to_publication_date}&sort=relevance_score:desc,cited_by_count:desc\""
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "0ff4d92b",
      "metadata": {
        "id": "0ff4d92b",
        "outputId": "f72db645-08ad-4a70-d366-507a1fa8cbed"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "'{\"meta\":{\"count\":293,\"db_response_time_ms\":20,\"page\":1,\"per_page\":20,\"groups_count\":null},\"results\":[{\"id\":\"https://openalex.org/W4206924079\",\"doi\":\"https://doi.org/10.3389/fnagi.2021.809433\",\"title\":\"Salidroside Ameliorates Alzheimer\\'s Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis\",\"display_name\":\"Salidroside Ameliorates Alzheimer\\'s Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis\",\"relevance_score\":233.16838,\"publication_year\":2022,\"publication_date\":\"2022-01-21\",\"ids\":{\"openalex\":\"https://openalex.org/W4206924079\",\"doi\":\"https://doi.org/10.3389/fnagi.2021.809433\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/35126093\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.3389/fnagi.2021.809433\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.3389/fnagi.2021.809433\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S118428158\",\"display_name\":\"Frontiers in Aging Neuroscience\",\"issn_l\":\"1663-4365\",\"issn\":[\"1663-4365\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320527\",\"host_organization_name\":\"Frontiers Media\",\"host_organization_lineage\":[\"https://openalex.org/P4310320527\"],\"host_organization_lineage_names\":[\"Frontiers Media\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in Aging Neuroscience\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://doi.org/10.3389/fnagi.2021.809433\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5050905751\",\"display_name\":\"Yawen Cai\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yawen Cai\",\"raw_affiliation_strings\":[\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5003820071\",\"display_name\":\"Yuhui Chai\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yuhui Chai\",\"raw_affiliation_strings\":[\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5073373032\",\"display_name\":\"Yu Fu\",\"orcid\":\"https://orcid.org/0000-0001-9849-7841\"},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yu Fu\",\"raw_affiliation_strings\":[\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5038934900\",\"display_name\":\"Yingdi Wang\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yingdi Wang\",\"raw_affiliation_strings\":[\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100395353\",\"display_name\":\"Yiming Zhang\",\"orcid\":\"https://orcid.org/0000-0001-8547-6654\"},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yiming Zhang\",\"raw_affiliation_strings\":[\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100445824\",\"display_name\":\"Xue Zhang\",\"orcid\":\"https://orcid.org/0000-0001-5785-8217\"},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Xue Zhang\",\"raw_affiliation_strings\":[\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5030765159\",\"display_name\":\"Lingpeng Zhu\",\"orcid\":\"https://orcid.org/0000-0003-0762-4038\"},\"institutions\":[{\"id\":\"https://openalex.org/I83519826\",\"display_name\":\"Nanjing Medical University\",\"ror\":\"https://ror.org/059gcgy73\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83519826\"]},{\"id\":\"https://openalex.org/I4210158071\",\"display_name\":\"Wuxi People\\'s Hospital\",\"ror\":\"https://ror.org/05pb5hm55\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158071\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Lingpeng Zhu\",\"raw_affiliation_strings\":[\"Center of Clinical Research, The Affiliated Wuxi People\\'s Hospital of Nanjing Medical University, Wuxi, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center of Clinical Research, The Affiliated Wuxi People\\'s Hospital of Nanjing Medical University, Wuxi, China\",\"institution_ids\":[\"https://openalex.org/I4210158071\",\"https://openalex.org/I83519826\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5110782821\",\"display_name\":\"Mingxing Miao\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Mingxing Miao\",\"raw_affiliation_strings\":[\"Center of National Pharmaceutical Experimental Teaching Demonstration, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center of National Pharmaceutical Experimental Teaching Demonstration, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5025941060\",\"display_name\":\"Tianhua Yan\",\"orcid\":\"https://orcid.org/0000-0001-6124-8630\"},\"institutions\":[{\"id\":\"https://openalex.org/I161716053\",\"display_name\":\"China Pharmaceutical University\",\"ror\":\"https://ror.org/01sfm2718\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I161716053\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Tianhua Yan\",\"raw_affiliation_strings\":[\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China\",\"institution_ids\":[\"https://openalex.org/I161716053\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":9,\"corresponding_author_ids\":[\"https://openalex.org/A5030765159\",\"https://openalex.org/A5110782821\",\"https://openalex.org/A5025941060\"],\"corresponding_institution_ids\":[\"https://openalex.org/I161716053\",\"https://openalex.org/I4210158071\",\"https://openalex.org/I83519826\"],\"apc_list\":{\"value\":1950,\"currency\":\"USD\",\"value_usd\":1950},\"apc_paid\":{\"value\":1950,\"currency\":\"USD\",\"value_usd\":1950},\"fwci\":15.62978306,\"has_fulltext\":false,\"cited_by_count\":127,\"citation_normalized_percentile\":{\"value\":0.99268088,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":99,\"max\":100},\"biblio\":{\"volume\":\"13\",\"issue\":null,\"first_page\":\"809433\",\"last_page\":\"809433\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T11078\",\"display_name\":\"Inflammasome and immune disorders\",\"score\":0.9998999834060669,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T11078\",\"display_name\":\"Inflammasome and immune disorders\",\"score\":0.9998999834060669,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T13651\",\"display_name\":\"Medicinal Plants and Bioactive Compounds\",\"score\":0.9962999820709229,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T12975\",\"display_name\":\"Paraoxonase enzyme and polymorphisms\",\"score\":0.96670001745224,\"subfield\":{\"id\":\"https://openalex.org/subfields/1308\",\"display_name\":\"Clinical Biochemistry\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/pyroptosis\",\"display_name\":\"Pyroptosis\",\"score\":0.9779961109161377},{\"id\":\"https://openalex.org/keywords/inflammasome\",\"display_name\":\"Inflammasome\",\"score\":0.9104028344154358},{\"id\":\"https://openalex.org/keywords/pathogenesis\",\"display_name\":\"Pathogenesis\",\"score\":0.6762961745262146},{\"id\":\"https://openalex.org/keywords/caspase-1\",\"display_name\":\"Caspase 1\",\"score\":0.5588692426681519},{\"id\":\"https://openalex.org/keywords/neuroinflammation\",\"display_name\":\"Neuroinflammation\",\"score\":0.4951535761356354},{\"id\":\"https://openalex.org/keywords/proinflammatory-cytokine\",\"display_name\":\"Proinflammatory cytokine\",\"score\":0.4387950599193573},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.4033471941947937},{\"id\":\"https://openalex.org/keywords/cell-biology\",\"display_name\":\"Cell biology\",\"score\":0.4015592336654663},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.3890223503112793},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.3610600233078003},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.3282572627067566},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.27364128828048706},{\"id\":\"https://openalex.org/keywords/immunology\",\"display_name\":\"Immunology\",\"score\":0.25082069635391235},{\"id\":\"https://openalex.org/keywords/inflammation\",\"display_name\":\"Inflammation\",\"score\":0.2142622470855713}],\"concepts\":[{\"id\":\"https://openalex.org/C17172800\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7263707\",\"display_name\":\"Pyroptosis\",\"level\":4,\"score\":0.9779961109161377},{\"id\":\"https://openalex.org/C2777209026\",\"wikidata\":\"https://www.wikidata.org/wiki/Q412405\",\"display_name\":\"Inflammasome\",\"level\":3,\"score\":0.9104028344154358},{\"id\":\"https://openalex.org/C2780942790\",\"wikidata\":\"https://www.wikidata.org/wiki/Q372016\",\"display_name\":\"Pathogenesis\",\"level\":2,\"score\":0.6762961745262146},{\"id\":\"https://openalex.org/C139964883\",\"wikidata\":\"https://www.wikidata.org/wiki/Q14901964\",\"display_name\":\"Caspase 1\",\"level\":4,\"score\":0.5588692426681519},{\"id\":\"https://openalex.org/C87753298\",\"wikidata\":\"https://www.wikidata.org/wiki/Q17157137\",\"display_name\":\"Neuroinflammation\",\"level\":3,\"score\":0.4951535761356354},{\"id\":\"https://openalex.org/C164027704\",\"wikidata\":\"https://www.wikidata.org/wiki/Q3491837\",\"display_name\":\"Proinflammatory cytokine\",\"level\":3,\"score\":0.4387950599193573},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.4033471941947937},{\"id\":\"https://openalex.org/C95444343\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7141\",\"display_name\":\"Cell biology\",\"level\":1,\"score\":0.4015592336654663},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.3890223503112793},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.3610600233078003},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.3282572627067566},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.27364128828048706},{\"id\":\"https://openalex.org/C203014093\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101929\",\"display_name\":\"Immunology\",\"level\":1,\"score\":0.25082069635391235},{\"id\":\"https://openalex.org/C2776914184\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101991\",\"display_name\":\"Inflammation\",\"level\":2,\"score\":0.2142622470855713}],\"mesh\":[],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.3389/fnagi.2021.809433\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.3389/fnagi.2021.809433\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S118428158\",\"display_name\":\"Frontiers in Aging Neuroscience\",\"issn_l\":\"1663-4365\",\"issn\":[\"1663-4365\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320527\",\"host_organization_name\":\"Frontiers Media\",\"host_organization_lineage\":[\"https://openalex.org/P4310320527\"],\"host_organization_lineage_names\":[\"Frontiers Media\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in Aging Neuroscience\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:35126093\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/35126093\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in aging neuroscience\",\"raw_type\":null},{\"id\":\"pmh:oai:doaj.org/article:23e276e4c0ef4392981df875f13f8073\",\"is_oa\":true,\"landing_page_url\":\"https://doaj.org/article/23e276e4c0ef4392981df875f13f8073\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-sa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Frontiers in Aging Neuroscience, Vol 13 (2022)\",\"raw_type\":\"article\"},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:8814655\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/8814655\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Front Aging Neurosci\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.3389/fnagi.2021.809433\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.3389/fnagi.2021.809433\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S118428158\",\"display_name\":\"Frontiers in Aging Neuroscience\",\"issn_l\":\"1663-4365\",\"issn\":[\"1663-4365\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320527\",\"host_organization_name\":\"Frontiers Media\",\"host_organization_lineage\":[\"https://openalex.org/P4310320527\"],\"host_organization_lineage_names\":[\"Frontiers Media\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in Aging Neuroscience\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.7699999809265137,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":75,\"referenced_works\":[\"https://openalex.org/W2019551875\",\"https://openalex.org/W2885800496\",\"https://openalex.org/W4211238543\",\"https://openalex.org/W2751934424\",\"https://openalex.org/W2238232606\",\"https://openalex.org/W2990946693\",\"https://openalex.org/W3100711840\",\"https://openalex.org/W2937259128\",\"https://openalex.org/W3168854088\",\"https://openalex.org/W3162382031\",\"https://openalex.org/W3008443509\",\"https://openalex.org/W3026226739\",\"https://openalex.org/W2517793347\",\"https://openalex.org/W2566478676\",\"https://openalex.org/W3110045126\",\"https://openalex.org/W3177065622\",\"https://openalex.org/W3168997400\",\"https://openalex.org/W2789018622\",\"https://openalex.org/W2909913388\",\"https://openalex.org/W2101399613\",\"https://openalex.org/W1561041814\",\"https://openalex.org/W2583631769\",\"https://openalex.org/W2175794645\",\"https://openalex.org/W1986611577\",\"https://openalex.org/W3186053696\",\"https://openalex.org/W2900976553\",\"https://openalex.org/W2080191967\",\"https://openalex.org/W2615324939\",\"https://openalex.org/W2627048017\",\"https://openalex.org/W2904244708\",\"https://openalex.org/W3181146275\",\"https://openalex.org/W2791508193\",\"https://openalex.org/W2794046825\",\"https://openalex.org/W2803197343\",\"https://openalex.org/W2999621338\",\"https://openalex.org/W3044896953\",\"https://openalex.org/W3124131589\",\"https://openalex.org/W2607216106\",\"https://openalex.org/W2484783870\",\"https://openalex.org/W6773658989\",\"https://openalex.org/W2346799309\",\"https://openalex.org/W2043679754\",\"https://openalex.org/W3005551242\",\"https://openalex.org/W2908040982\",\"https://openalex.org/W3129961151\",\"https://openalex.org/W2560541542\",\"https://openalex.org/W3164720145\",\"https://openalex.org/W3012405369\",\"https://openalex.org/W3081641281\",\"https://openalex.org/W2035230591\",\"https://openalex.org/W1969673449\",\"https://openalex.org/W2941630117\",\"https://openalex.org/W2756716006\",\"https://openalex.org/W2774884303\",\"https://openalex.org/W3175464757\",\"https://openalex.org/W3109271936\",\"https://openalex.org/W2928322300\",\"https://openalex.org/W2596856023\",\"https://openalex.org/W3027898931\",\"https://openalex.org/W3111635935\",\"https://openalex.org/W3008669429\",\"https://openalex.org/W3112999523\",\"https://openalex.org/W3142080073\",\"https://openalex.org/W2901153725\",\"https://openalex.org/W3110200930\",\"https://openalex.org/W3032330490\",\"https://openalex.org/W3132599154\",\"https://openalex.org/W3028288561\",\"https://openalex.org/W2767414526\",\"https://openalex.org/W2983864488\",\"https://openalex.org/W3172774990\",\"https://openalex.org/W2803156147\",\"https://openalex.org/W3009244056\",\"https://openalex.org/W3108954464\",\"https://openalex.org/W2890247074\"],\"related_works\":[\"https://openalex.org/W2775971119\",\"https://openalex.org/W2164406361\",\"https://openalex.org/W2996560206\",\"https://openalex.org/W2775627464\",\"https://openalex.org/W2776798182\",\"https://openalex.org/W3121140360\",\"https://openalex.org/W3205681349\",\"https://openalex.org/W2991708020\",\"https://openalex.org/W3153481028\",\"https://openalex.org/W4223565809\"],\"abstract_inverted_index\":{\"Amyloid\":[0],\"\\\\u03b2-protein\":[1],\"(A\\\\u03b2)\":[2],\"is\":[3,13,33,84],\"reported\":[4],\"to\":[5,42,72,86,115,173,209],\"activate\":[6],\"NLRP3\":[7,124,168,258,274,284],\"inflammasomes\":[8],\"and\":[9,64,91,107,141,156,176,189,194,203,237,263,277,293],\"drive\":[10],\"pyroptosis,\":[11],\"which\":[12,171,205],\"subsequently\":[14],\"involved\":[15],\"in\":[16,113,127,144,239,261,291],\"the\":[17,29,87,95,105,123,154,174,199,210,221,255,265],\"pathogenesis\":[18,30,88],\"of\":[19,31,58,76,89,97,138,151,178,191,201,212,225,257,267,270],\"neurodegenerative\":[20],\"diseases,\":[21],\"such\":[22],\"as\":[23],\"Alzheimer\\'s\":[24],\"disease\":[25],\"(AD).\":[26],\"To\":[27],\"date,\":[28],\"AD\":[32,50,77,98,145,292],\"unfortunately\":[34],\"insufficiently\":[35],\"elucidated.\":[36],\"Therefore,\":[37],\"this\":[38],\"study\":[39,253],\"was\":[40],\"conducted\":[41],\"explore\":[43],\"whether\":[44],\"Salidroside\":[45],\"(Sal)\":[46],\"treatment\":[47,211],\"could\":[48,295],\"benefit\":[49],\"by\":[51,62,99,121,148,197],\"improving\":[52],\"pyroptosis.\":[53,101],\"Firstly,\":[54],\"two\":[55],\"animal\":[56],\"models\":[57],\"AD,\":[59,90,262],\"induced,\":[60],\"respectively,\":[61],\"A\\\\u03b21-42\":[63,152],\"D-galactose\":[65],\"(D-gal)/AlCl\":[66],\"3\":[67,162],\",\":[68],\"have\":[69],\"been\":[70],\"created\":[71],\"assist\":[73],\"our\":[74],\"appreciation\":[75],\"pathophysiology.\":[78],\"We\":[79,214],\"then\":[80],\"confirmed\":[81],\"that\":[82,132,217,283],\"pyroptosis\":[83,119,196,260,276,286],\"related\":[85],\"Sal\":[92,117,218,271,294],\"can\":[93,206,219,272],\"slow\":[94],\"progression\":[96],\"inhibiting\":[100,248],\"Subsequently,\":[102],\"we\":[103,130,281],\"established\":[104],\"D-gal\":[106,159],\"Nigericin-induced\":[108],\"PC12\":[109],\"cells\":[110],\"injury\":[111],\"model\":[112],\"vitro\":[114,240],\"verify\":[116],\"blocks\":[118],\"mainly\":[120],\"targeting\":[122],\"inflammasome.\":[125],\"For\":[126],\"vivo\":[128],\"studies,\":[129],\"observed\":[131],\"A\\\\u03b2\":[133,166,187],\"accumulation,\":[134],\"Tau\":[135,192],\"hyperphosphorylation,\":[136],\"neurons\":[137],\"hippocampal\":[139],\"damage,\":[140],\"cognitive\":[142],\"dysfunction\":[143],\"mice,\":[146],\"caused\":[147],\"bilateral\":[149],\"injection\":[150],\"into\":[153],\"hippocampus\":[155],\"treatments\":[157],\"with\":[158],\"combine\":[160],\"AlCl\":[161],\".\":[163,241],\"Besides,\":[164],\"accumulated\":[165],\"promotes\":[167],\"inflammasome\":[169],\"activation,\":[170],\"leads\":[172],\"activation\":[175],\"release\":[177],\"a\":[179,288,297],\"pro-inflammatory\":[180],\"cytokine,\":[181],\"interleukin-1\":[182],\"beta\":[183],\"(IL-1\\\\u03b2).\":[184],\"Notably,\":[185],\"both\":[186],\"accumulation\":[188],\"hyperphosphorylation\":[190],\"decreased\":[193],\"inhibited\":[195],\"downregulating\":[198],\"expression\":[200,224],\"IL-1\\\\u03b2\":[202],\"IL-18,\":[204],\"be\":[207,246,296],\"attributed\":[208],\"Sal.\":[213],\"further\":[215],\"found\":[216],\"reverse\":[220],\"increased\":[222],\"protein\":[223],\"TLR4,\":[226],\"MyD88,\":[227],\"NF-\\\\u03baB,\":[228],\"P-NF-\\\\u03baB,\":[229],\"NLRP3,\":[230],\"ASC,\":[231],\"cleaved\":[232,234],\"Caspase-1,\":[233],\"GSDMD,\":[235],\"IL-1\\\\u03b2,\":[236],\"IL-18\":[238],\"The\":[242],\"underlying\":[243],\"mechanism\":[244],\"may\":[245],\"through\":[247],\"TLR4/NF-\\\\u03baB/NLRP3/Caspase-1\":[249],\"signaling\":[250],\"pathway.\":[251],\"Our\":[252],\"highlights\":[254],\"importance\":[256],\"inflammasome-mediated\":[259,275,285],\"how\":[264],\"administration\":[266],\"pharmacological\":[268],\"doses\":[269],\"inhibit\":[273],\"ameliorate\":[278],\"AD.\":[279,301],\"Thus,\":[280],\"conclude\":[282],\"plays\":[287],\"significant\":[289],\"role\":[290],\"therapeutic\":[298],\"drug\":[299],\"for\":[300]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":43},{\"year\":2024,\"cited_by_count\":40},{\"year\":2023,\"cited_by_count\":36},{\"year\":2022,\"cited_by_count\":8}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4385704195\",\"doi\":\"https://doi.org/10.1016/j.redox.2023.102846\",\"title\":\"Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer\\'s disease\",\"display_name\":\"Metabolic reprogramming in inflammatory microglia indicates a potential way of targeting inflammation in Alzheimer\\'s disease\",\"relevance_score\":171.79579,\"publication_year\":2023,\"publication_date\":\"2023-08-09\",\"ids\":{\"openalex\":\"https://openalex.org/W4385704195\",\"doi\":\"https://doi.org/10.1016/j.redox.2023.102846\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/37586250\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.redox.2023.102846\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.redox.2023.102846\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764928002\",\"display_name\":\"Redox Biology\",\"issn_l\":\"2213-2317\",\"issn\":[\"2213-2317\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Redox Biology\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://doi.org/10.1016/j.redox.2023.102846\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5042114631\",\"display_name\":\"Moris Sangineto\",\"orcid\":\"https://orcid.org/0000-0002-0936-8843\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":true,\"raw_author_name\":\"Moris Sangineto\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5091981600\",\"display_name\":\"Martina Ciarnelli\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Martina Ciarnelli\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5025521018\",\"display_name\":\"Tommaso Cassano\",\"orcid\":\"https://orcid.org/0000-0001-6330-806X\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Tommaso Cassano\",\"raw_affiliation_strings\":[\"Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5092619880\",\"display_name\":\"Antonio Radesco\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210131058\",\"display_name\":\"Istituto Tumori Bari\",\"ror\":\"https://ror.org/03jxkz251\",\"country_code\":\"IT\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210099368\",\"https://openalex.org/I4210117053\",\"https://openalex.org/I4210131058\",\"https://openalex.org/I4210153126\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Antonio Radesco\",\"raw_affiliation_strings\":[\"Istituto Oncologico \\\\\"Giovanni Paolo II\\\\\", I.R.C.S.S. of Bari, Laboratory of Haematological Diagnostics and Cellular Therapy, Bari, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Istituto Oncologico \\\\\"Giovanni Paolo II\\\\\", I.R.C.S.S. of Bari, Laboratory of Haematological Diagnostics and Cellular Therapy, Bari, Italy\",\"institution_ids\":[\"https://openalex.org/I4210131058\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5089644837\",\"display_name\":\"Archana Moola\",\"orcid\":\"https://orcid.org/0000-0003-0397-5148\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Archana Moola\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5089653592\",\"display_name\":\"Vidyasagar Naik Bukke\",\"orcid\":\"https://orcid.org/0000-0002-2591-8614\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Vidyasagar Naik Bukke\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5055939441\",\"display_name\":\"Antonino Davide Romano\",\"orcid\":\"https://orcid.org/0000-0003-0559-2917\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Antonino Romano\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5005857503\",\"display_name\":\"Rosanna Villani\",\"orcid\":\"https://orcid.org/0000-0001-9875-019X\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Rosanna Villani\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5088347762\",\"display_name\":\"Hina Kanwal\",\"orcid\":\"https://orcid.org/0009-0002-6281-562X\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Hina Kanwal\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5039786016\",\"display_name\":\"Nazzareno Capitanio\",\"orcid\":\"https://orcid.org/0000-0001-9285-051X\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Nazzareno Capitanio\",\"raw_affiliation_strings\":[\"Biochemistry Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Biochemistry Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5081519754\",\"display_name\":\"Loren Duda\",\"orcid\":\"https://orcid.org/0000-0002-8836-4858\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Loren Duda\",\"raw_affiliation_strings\":[\"Pathology Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Pathology Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5024279876\",\"display_name\":\"Carlo Avolio\",\"orcid\":\"https://orcid.org/0000-0002-0987-1967\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Carlo Avolio\",\"raw_affiliation_strings\":[\"Neurology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Neurology Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5024383912\",\"display_name\":\"Gaetano Serviddio\",\"orcid\":\"https://orcid.org/0000-0002-6424-7841\"},\"institutions\":[{\"id\":\"https://openalex.org/I106296451\",\"display_name\":\"University of Foggia\",\"ror\":\"https://ror.org/01xtv3204\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I106296451\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Gaetano Serviddio\",\"raw_affiliation_strings\":[\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"C.U.R.E. (University Center for Liver Disease Research and Treatment), Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy\",\"institution_ids\":[\"https://openalex.org/I106296451\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":13,\"corresponding_author_ids\":[\"https://openalex.org/A5042114631\"],\"corresponding_institution_ids\":[\"https://openalex.org/I106296451\"],\"apc_list\":{\"value\":2850,\"currency\":\"USD\",\"value_usd\":2850},\"apc_paid\":{\"value\":2850,\"currency\":\"USD\",\"value_usd\":2850},\"fwci\":17.55975495,\"has_fulltext\":false,\"cited_by_count\":79,\"citation_normalized_percentile\":{\"value\":0.99094694,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":96,\"max\":100},\"biblio\":{\"volume\":\"66\",\"issue\":null,\"first_page\":\"102846\",\"last_page\":\"102846\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T11266\",\"display_name\":\"Neuroinflammation and Neurodegeneration Mechanisms\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2808\",\"display_name\":\"Neurology\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T11266\",\"display_name\":\"Neuroinflammation and Neurodegeneration Mechanisms\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2808\",\"display_name\":\"Neurology\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9968000054359436,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11313\",\"display_name\":\"Immune cells in cancer\",\"score\":0.996399998664856,\"subfield\":{\"id\":\"https://openalex.org/subfields/2403\",\"display_name\":\"Immunology\"},\"field\":{\"id\":\"https://openalex.org/fields/24\",\"display_name\":\"Immunology and Microbiology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/microglia\",\"display_name\":\"Microglia\",\"score\":0.9551266431808472},{\"id\":\"https://openalex.org/keywords/mitochondrial-biogenesis\",\"display_name\":\"Mitochondrial biogenesis\",\"score\":0.6495341062545776},{\"id\":\"https://openalex.org/keywords/inflammation\",\"display_name\":\"Inflammation\",\"score\":0.6468154191970825},{\"id\":\"https://openalex.org/keywords/cell-biology\",\"display_name\":\"Cell biology\",\"score\":0.5869395732879639},{\"id\":\"https://openalex.org/keywords/tlr4\",\"display_name\":\"TLR4\",\"score\":0.5558529496192932},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.5237596035003662},{\"id\":\"https://openalex.org/keywords/mitochondrion\",\"display_name\":\"Mitochondrion\",\"score\":0.44756028056144714},{\"id\":\"https://openalex.org/keywords/immunology\",\"display_name\":\"Immunology\",\"score\":0.28274667263031006}],\"concepts\":[{\"id\":\"https://openalex.org/C2779830541\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1622829\",\"display_name\":\"Microglia\",\"level\":3,\"score\":0.9551266431808472},{\"id\":\"https://openalex.org/C2777229759\",\"wikidata\":\"https://www.wikidata.org/wiki/Q6881848\",\"display_name\":\"Mitochondrial biogenesis\",\"level\":3,\"score\":0.6495341062545776},{\"id\":\"https://openalex.org/C2776914184\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101991\",\"display_name\":\"Inflammation\",\"level\":2,\"score\":0.6468154191970825},{\"id\":\"https://openalex.org/C95444343\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7141\",\"display_name\":\"Cell biology\",\"level\":1,\"score\":0.5869395732879639},{\"id\":\"https://openalex.org/C2776070231\",\"wikidata\":\"https://www.wikidata.org/wiki/Q14914098\",\"display_name\":\"TLR4\",\"level\":3,\"score\":0.5558529496192932},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.5237596035003662},{\"id\":\"https://openalex.org/C28859421\",\"wikidata\":\"https://www.wikidata.org/wiki/Q39572\",\"display_name\":\"Mitochondrion\",\"level\":2,\"score\":0.44756028056144714},{\"id\":\"https://openalex.org/C203014093\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101929\",\"display_name\":\"Immunology\",\"level\":1,\"score\":0.28274667263031006}],\"mesh\":[{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D017628\",\"descriptor_name\":\"Microglia\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008822\",\"descriptor_name\":\"Mice, Transgenic\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008070\",\"descriptor_name\":\"Lipopolysaccharides\",\"qualifier_ui\":\"Q000009\",\"qualifier_name\":\"adverse effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D051197\",\"descriptor_name\":\"Toll-Like Receptor 4\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D007249\",\"descriptor_name\":\"Inflammation\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":false},{\"descriptor_ui\":\"D007249\",\"descriptor_name\":\"Inflammation\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D017628\",\"descriptor_name\":\"Microglia\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008822\",\"descriptor_name\":\"Mice, Transgenic\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008070\",\"descriptor_name\":\"Lipopolysaccharides\",\"qualifier_ui\":\"Q000009\",\"qualifier_name\":\"adverse effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D051197\",\"descriptor_name\":\"Toll-Like Receptor 4\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D007249\",\"descriptor_name\":\"Inflammation\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":false},{\"descriptor_ui\":\"D007249\",\"descriptor_name\":\"Inflammation\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false}],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.1016/j.redox.2023.102846\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.redox.2023.102846\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764928002\",\"display_name\":\"Redox Biology\",\"issn_l\":\"2213-2317\",\"issn\":[\"2213-2317\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Redox Biology\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:37586250\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/37586250\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Redox biology\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:10457454\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/10457454\",\"pdf_url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10457454/pdf/main.pdf\",\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Redox Biol\",\"raw_type\":\"Text\"},{\"id\":\"pmh:oai:doaj.org/article:7a9317a9321844d280c6509e9a4ec4f2\",\"is_oa\":false,\"landing_page_url\":\"https://doaj.org/article/7a9317a9321844d280c6509e9a4ec4f2\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Redox Biology, Vol 66, Iss , Pp 102846- (2023)\",\"raw_type\":\"article\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.redox.2023.102846\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.redox.2023.102846\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764928002\",\"display_name\":\"Redox Biology\",\"issn_l\":\"2213-2317\",\"issn\":[\"2213-2317\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Redox Biology\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":69,\"referenced_works\":[\"https://openalex.org/W2066918975\",\"https://openalex.org/W3107395714\",\"https://openalex.org/W3019520705\",\"https://openalex.org/W3080522152\",\"https://openalex.org/W3217012249\",\"https://openalex.org/W2009034382\",\"https://openalex.org/W2166078611\",\"https://openalex.org/W2076260194\",\"https://openalex.org/W2125946419\",\"https://openalex.org/W3093277171\",\"https://openalex.org/W2789258764\",\"https://openalex.org/W3110931287\",\"https://openalex.org/W4309508062\",\"https://openalex.org/W2604693432\",\"https://openalex.org/W2468925656\",\"https://openalex.org/W3153026103\",\"https://openalex.org/W2889961434\",\"https://openalex.org/W2619332462\",\"https://openalex.org/W2522038806\",\"https://openalex.org/W6846863120\",\"https://openalex.org/W2088358053\",\"https://openalex.org/W1977002082\",\"https://openalex.org/W2788331446\",\"https://openalex.org/W2889700070\",\"https://openalex.org/W6849317109\",\"https://openalex.org/W59466077\",\"https://openalex.org/W3131818692\",\"https://openalex.org/W2157999222\",\"https://openalex.org/W2775054989\",\"https://openalex.org/W2122213881\",\"https://openalex.org/W2156078403\",\"https://openalex.org/W2042062152\",\"https://openalex.org/W3034733248\",\"https://openalex.org/W2971353141\",\"https://openalex.org/W2162826697\",\"https://openalex.org/W2020823643\",\"https://openalex.org/W2153586956\",\"https://openalex.org/W2089532303\",\"https://openalex.org/W1968140809\",\"https://openalex.org/W4205367287\",\"https://openalex.org/W2510362766\",\"https://openalex.org/W2774947569\",\"https://openalex.org/W2291238710\",\"https://openalex.org/W4281383997\",\"https://openalex.org/W2205330006\",\"https://openalex.org/W2157648547\",\"https://openalex.org/W2140718540\",\"https://openalex.org/W6632947331\",\"https://openalex.org/W2076272449\",\"https://openalex.org/W4306964094\",\"https://openalex.org/W2119828139\",\"https://openalex.org/W1977039417\",\"https://openalex.org/W2773698836\",\"https://openalex.org/W3012111315\",\"https://openalex.org/W1876879275\",\"https://openalex.org/W2162994292\",\"https://openalex.org/W2191169263\",\"https://openalex.org/W2018576241\",\"https://openalex.org/W1909117315\",\"https://openalex.org/W3044368910\",\"https://openalex.org/W3093223526\",\"https://openalex.org/W3203151570\",\"https://openalex.org/W3014943546\",\"https://openalex.org/W2975440312\",\"https://openalex.org/W3094667565\",\"https://openalex.org/W3132095850\",\"https://openalex.org/W4312172075\",\"https://openalex.org/W4319319632\",\"https://openalex.org/W1551711701\"],\"related_works\":[\"https://openalex.org/W2885325217\",\"https://openalex.org/W4287448745\",\"https://openalex.org/W2546440307\",\"https://openalex.org/W4308968236\",\"https://openalex.org/W3130437983\",\"https://openalex.org/W3176323037\",\"https://openalex.org/W2076096323\",\"https://openalex.org/W3031604050\",\"https://openalex.org/W2365450153\",\"https://openalex.org/W2972749215\"],\"abstract_inverted_index\":{\"Microglia\":[0],\"activation\":[1,229],\"drives\":[2],\"the\":[3,7,15,21,57,74,97,120,127,137,150,195,210,220,234],\"pro-inflammatory\":[4,235],\"activity\":[5,58,236],\"in\":[6,109,149,185,219,237],\"early\":[8],\"stages\":[9],\"of\":[10,23,59,76,122,129,139,161,173,182,199,213,222],\"Alzheimer\\'s\":[11],\"disease\":[12],\"(AD).\":[13],\"However,\":[14],\"mechanistic\":[16],\"basis\":[17],\"is\":[18,30,65,70,93],\"elusive,\":[19],\"and\":[20,50,113,141,164,193,233,239],\"hypothesis\":[22],\"targeting\":[24],\"microglia\":[25,40,151,196,221],\"to\":[26,73,95,177,247],\"prevent\":[27,248],\"AD\":[28,154,174,223,249],\"onset\":[29],\"little\":[31],\"explored.\":[32],\"Here,\":[33],\"we\":[34],\"demonstrated\":[35],\"that\":[36,82],\"upon\":[37],\"LPS\":[38,163],\"exposure,\":[39],\"shift\":[41],\"towards\":[42],\"an\":[43,102],\"energetic\":[44],\"phenotype\":[45],\"characterised\":[46],\"by\":[47,67,83,114],\"high\":[48,51,159],\"glycolysis\":[49,140],\"mitochondrial\":[52,107,117],\"respiration\":[53],\"with\":[54,88,124],\"dysfunction.\":[55],\"Although\":[56],\"electron\":[60],\"transport\":[61],\"chain\":[62],\"(ETC)\":[63],\"complexes\":[64],\"boosted\":[66],\"LPS,\":[68],\"this\":[69,170],\"mostly\":[71],\"devoted\":[72],\"generation\":[75],\"reactive\":[77],\"oxygen\":[78],\"species.\":[79],\"We\":[80],\"showed\":[81],\"inhibiting\":[84],\"succinate\":[85],\"dehydrogenase\":[86],\"(SDH)\":[87],\"dimethyl\":[89],\"malonate\":[90],\"(DMM),\":[91],\"it\":[92],\"possible\":[94],\"modulate\":[96],\"LPS-induced\":[98,116],\"metabolic\":[99,197,231],\"rewiring,\":[100],\"facilitating\":[101],\"anti-inflammatory\":[103],\"phenotype.\":[104],\"DMM\":[105,125,188],\"improves\":[106],\"function\":[108],\"a\":[110,179,206,243],\"direct\":[111],\"way\":[112],\"reducing\":[115],\"biogenesis.\":[118],\"Moreover,\":[119,169],\"block\":[121],\"SDH\":[123,183,240],\"inhibits\":[126],\"recruitment\":[128],\"hypoxia\":[130],\"inducible-factor\":[131],\"1\":[132],\"\\\\u03b1\":[133],\"(HIF-1\\\\u03b1),\":[134],\"which\":[135,157],\"mediates\":[136],\"induction\":[138],\"cytokine\":[142],\"expression.\":[143],\"Similar\":[144],\"bioenergetic\":[145],\"alterations\":[146,198],\"were\":[147],\"observed\":[148],\"isolated\":[152],\"from\":[153,205],\"mice\":[155,224],\"(3xTg-AD),\":[156],\"present\":[158],\"levels\":[160],\"circulating\":[162],\"brain\":[165,191],\"toll-like\":[166],\"receptor4\":[167],\"(TLR4).\":[168],\"well-established\":[171],\"model\":[172],\"was\":[175],\"used\":[176],\"show\":[178],\"potential\":[180],\"effect\":[181],\"inhibition\":[184],\"vivo\":[186],\"as\":[187],\"administration\":[189],\"abrogated\":[190],\"inflammation\":[192],\"modulated\":[194],\"3xTg-AD\":[200],\"mice.\":[201],\"The\":[202],\"RNA-sequencing\":[203],\"analysis\":[204],\"public\":[207],\"dataset\":[208],\"confirmed\":[209],\"consistent\":[211],\"transcription\":[212],\"genes\":[214],\"encoding\":[215],\"for\":[216],\"ETC\":[217],\"subunits\":[218],\"(5xFAD).\":[225],\"In\":[226],\"conclusion,\":[227],\"TLR4\":[228],\"promotes\":[230],\"changes\":[232],\"microglia,\":[238],\"might\":[241],\"represent\":[242],\"promising\":[244],\"therapeutic\":[245],\"target\":[246],\"development.\":[250]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":45},{\"year\":2024,\"cited_by_count\":31},{\"year\":2023,\"cited_by_count\":3}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4394063820\",\"doi\":\"https://doi.org/10.1016/j.ejmcr.2024.100154\",\"title\":\"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer\\'s disease\",\"display_name\":\"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer\\'s disease\",\"relevance_score\":158.0612,\"publication_year\":2024,\"publication_date\":\"2024-04-07\",\"ids\":{\"openalex\":\"https://openalex.org/W4394063820\",\"doi\":\"https://doi.org/10.1016/j.ejmcr.2024.100154\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.ejmcr.2024.100154\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmcr.2024.100154\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210220500\",\"display_name\":\"European Journal of Medicinal Chemistry Reports\",\"issn_l\":\"2772-4174\",\"issn\":[\"2772-4174\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry Reports\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://doi.org/10.1016/j.ejmcr.2024.100154\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5002138946\",\"display_name\":\"Gajendra Kumar\",\"orcid\":\"https://orcid.org/0000-0002-7437-6743\"},\"institutions\":[{\"id\":\"https://openalex.org/I1314596251\",\"display_name\":\"Allen Institute for Brain Science\",\"ror\":\"https://ror.org/00dcv1019\",\"country_code\":\"US\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I1314596251\",\"https://openalex.org/I4210140341\"]},{\"id\":\"https://openalex.org/I2800634083\",\"display_name\":\"Bradley Hospital\",\"ror\":\"https://ror.org/02mx8nz45\",\"country_code\":\"US\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I2800634083\",\"https://openalex.org/I4210151747\"]},{\"id\":\"https://openalex.org/I27804330\",\"display_name\":\"Brown University\",\"ror\":\"https://ror.org/05gq02987\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I27804330\"]}],\"countries\":[\"US\"],\"is_corresponding\":true,\"raw_author_name\":\"Kumar Gajendra\",\"raw_affiliation_strings\":[\"Center for Translational Neuroscience, Robert J. and Nancy D. Carney Institute for Brain Science and Brown Institute for Translational Science, Brown University, Providence, RI, USA\",\"Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA\",\"Developmental Disorders Genetics Research Program, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, and Emma Pendleton Bradley Hospital, East Providence, RI, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Translational Neuroscience, Robert J. and Nancy D. Carney Institute for Brain Science and Brown Institute for Translational Science, Brown University, Providence, RI, USA\",\"institution_ids\":[\"https://openalex.org/I1314596251\",\"https://openalex.org/I27804330\"]},{\"raw_affiliation_string\":\"Developmental Disorders Genetics Research Program, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, and Emma Pendleton Bradley Hospital, East Providence, RI, USA\",\"institution_ids\":[\"https://openalex.org/I27804330\",\"https://openalex.org/I2800634083\"]},{\"raw_affiliation_string\":\"Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA\",\"institution_ids\":[\"https://openalex.org/I27804330\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5111599624\",\"display_name\":\"G. Pratap\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I214657376\",\"display_name\":\"Davangere University\",\"ror\":\"https://ror.org/05w9k9t67\",\"country_code\":\"IN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I214657376\"]}],\"countries\":[\"IN\"],\"is_corresponding\":false,\"raw_author_name\":\"G.K. Pratap\",\"raw_affiliation_strings\":[\"Department of Studies in Biochemistry, Davangere University Shivagangothri, Davangere, 577007, Karnataka, India\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Studies in Biochemistry, Davangere University Shivagangothri, Davangere, 577007, Karnataka, India\",\"institution_ids\":[\"https://openalex.org/I214657376\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5025513230\",\"display_name\":\"D. V. Poornima\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I214657376\",\"display_name\":\"Davangere University\",\"ror\":\"https://ror.org/05w9k9t67\",\"country_code\":\"IN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I214657376\"]}],\"countries\":[\"IN\"],\"is_corresponding\":false,\"raw_author_name\":\"D.V. Poornima\",\"raw_affiliation_strings\":[\"Department of Studies in Food Technology, Davangere University Shivagangothri, Davangere, 577007, Karnataka, India\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Studies in Food Technology, Davangere University Shivagangothri, Davangere, 577007, Karnataka, India\",\"institution_ids\":[\"https://openalex.org/I214657376\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5019153965\",\"display_name\":\"Manjula Shantaram\",\"orcid\":\"https://orcid.org/0000-0002-3874-4465\"},\"institutions\":[{\"id\":\"https://openalex.org/I19008122\",\"display_name\":\"Mangalore University\",\"ror\":\"https://ror.org/05fep3933\",\"country_code\":\"IN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I19008122\"]}],\"countries\":[\"IN\"],\"is_corresponding\":false,\"raw_author_name\":\"Manjula Shantaram\",\"raw_affiliation_strings\":[\"Department of Studies and Research in Biochemistry, Mangalore University, Jnana Kaveri Post Graduate Centre, Chikka Aluvara, 571 232, Kodagu, Karnataka, India\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Studies and Research in Biochemistry, Mangalore University, Jnana Kaveri Post Graduate Centre, Chikka Aluvara, 571 232, Kodagu, Karnataka, India\",\"institution_ids\":[\"https://openalex.org/I19008122\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5095101243\",\"display_name\":\"G. Ranjita\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I19008122\",\"display_name\":\"Mangalore University\",\"ror\":\"https://ror.org/05fep3933\",\"country_code\":\"IN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I19008122\"]}],\"countries\":[\"IN\"],\"is_corresponding\":false,\"raw_author_name\":\"G. Ranjita\",\"raw_affiliation_strings\":[\"Department of Studies and Research in Biochemistry, Mangalore University, Jnana Kaveri Post Graduate Centre, Chikka Aluvara, 571 232, Kodagu, Karnataka, India\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Studies and Research in Biochemistry, Mangalore University, Jnana Kaveri Post Graduate Centre, Chikka Aluvara, 571 232, Kodagu, Karnataka, India\",\"institution_ids\":[\"https://openalex.org/I19008122\"]}]}],\"institutions\":[],\"countries_distinct_count\":2,\"institutions_distinct_count\":5,\"corresponding_author_ids\":[\"https://openalex.org/A5002138946\"],\"corresponding_institution_ids\":[\"https://openalex.org/I1314596251\",\"https://openalex.org/I27804330\",\"https://openalex.org/I2800634083\"],\"apc_list\":{\"value\":1500,\"currency\":\"USD\",\"value_usd\":1500},\"apc_paid\":{\"value\":1500,\"currency\":\"USD\",\"value_usd\":1500},\"fwci\":45.4632225,\"has_fulltext\":false,\"cited_by_count\":54,\"citation_normalized_percentile\":{\"value\":0.99875978,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":99,\"max\":100},\"biblio\":{\"volume\":\"11\",\"issue\":null,\"first_page\":\"100154\",\"last_page\":\"100154\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9984999895095825,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12891\",\"display_name\":\"Medicinal Plants and Neuroprotection\",\"score\":0.9934999942779541,\"subfield\":{\"id\":\"https://openalex.org/subfields/2707\",\"display_name\":\"Complementary and alternative medicine\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/acetylcholinesterase\",\"display_name\":\"Acetylcholinesterase\",\"score\":0.8440226912498474},{\"id\":\"https://openalex.org/keywords/rivastigmine\",\"display_name\":\"Rivastigmine\",\"score\":0.776418924331665},{\"id\":\"https://openalex.org/keywords/galantamine\",\"display_name\":\"Galantamine\",\"score\":0.7579734325408936},{\"id\":\"https://openalex.org/keywords/donepezil\",\"display_name\":\"Donepezil\",\"score\":0.7572042942047119},{\"id\":\"https://openalex.org/keywords/neuroprotection\",\"display_name\":\"Neuroprotection\",\"score\":0.6980529427528381},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.5634368658065796},{\"id\":\"https://openalex.org/keywords/amyloid\",\"display_name\":\"Amyloid (mycology)\",\"score\":0.5164132714271545},{\"id\":\"https://openalex.org/keywords/dementia\",\"display_name\":\"Dementia\",\"score\":0.48101478815078735},{\"id\":\"https://openalex.org/keywords/cholinesterase\",\"display_name\":\"Cholinesterase\",\"score\":0.4422956109046936},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.36251819133758545},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.3364157974720001},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.2892148494720459},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.2723727524280548},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.17746788263320923},{\"id\":\"https://openalex.org/keywords/pathology\",\"display_name\":\"Pathology\",\"score\":0.16167870163917542},{\"id\":\"https://openalex.org/keywords/enzyme\",\"display_name\":\"Enzyme\",\"score\":0.13024672865867615}],\"concepts\":[{\"id\":\"https://openalex.org/C2778816929\",\"wikidata\":\"https://www.wikidata.org/wiki/Q22676679\",\"display_name\":\"Acetylcholinesterase\",\"level\":3,\"score\":0.8440226912498474},{\"id\":\"https://openalex.org/C2776332859\",\"wikidata\":\"https://www.wikidata.org/wiki/Q411887\",\"display_name\":\"Rivastigmine\",\"level\":5,\"score\":0.776418924331665},{\"id\":\"https://openalex.org/C2779056891\",\"wikidata\":\"https://www.wikidata.org/wiki/Q412690\",\"display_name\":\"Galantamine\",\"level\":5,\"score\":0.7579734325408936},{\"id\":\"https://openalex.org/C2780904820\",\"wikidata\":\"https://www.wikidata.org/wiki/Q415081\",\"display_name\":\"Donepezil\",\"level\":4,\"score\":0.7572042942047119},{\"id\":\"https://openalex.org/C25498285\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1981368\",\"display_name\":\"Neuroprotection\",\"level\":2,\"score\":0.6980529427528381},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.5634368658065796},{\"id\":\"https://openalex.org/C2777633098\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2736051\",\"display_name\":\"Amyloid (mycology)\",\"level\":2,\"score\":0.5164132714271545},{\"id\":\"https://openalex.org/C2779483572\",\"wikidata\":\"https://www.wikidata.org/wiki/Q83030\",\"display_name\":\"Dementia\",\"level\":3,\"score\":0.48101478815078735},{\"id\":\"https://openalex.org/C31896038\",\"wikidata\":\"https://www.wikidata.org/wiki/Q415635\",\"display_name\":\"Cholinesterase\",\"level\":2,\"score\":0.4422956109046936},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.36251819133758545},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.3364157974720001},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.2892148494720459},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.2723727524280548},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.17746788263320923},{\"id\":\"https://openalex.org/C142724271\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7208\",\"display_name\":\"Pathology\",\"level\":1,\"score\":0.16167870163917542},{\"id\":\"https://openalex.org/C181199279\",\"wikidata\":\"https://www.wikidata.org/wiki/Q8047\",\"display_name\":\"Enzyme\",\"level\":2,\"score\":0.13024672865867615}],\"mesh\":[],\"locations_count\":2,\"locations\":[{\"id\":\"doi:10.1016/j.ejmcr.2024.100154\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmcr.2024.100154\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210220500\",\"display_name\":\"European Journal of Medicinal Chemistry Reports\",\"issn_l\":\"2772-4174\",\"issn\":[\"2772-4174\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry Reports\",\"raw_type\":\"journal-article\"},{\"id\":\"pmh:oai:doaj.org/article:41fb203f911a41a68f0fd5ee3ef9c7f3\",\"is_oa\":false,\"landing_page_url\":\"https://doaj.org/article/41fb203f911a41a68f0fd5ee3ef9c7f3\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"European Journal of Medicinal Chemistry Reports, Vol 11, Iss , Pp 100154- (2024)\",\"raw_type\":\"article\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.ejmcr.2024.100154\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmcr.2024.100154\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210220500\",\"display_name\":\"European Journal of Medicinal Chemistry Reports\",\"issn_l\":\"2772-4174\",\"issn\":[\"2772-4174\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry Reports\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Life below water\",\"score\":0.8700000047683716,\"id\":\"https://metadata.un.org/sdg/14\"}],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":165,\"referenced_works\":[\"https://openalex.org/W2096410114\",\"https://openalex.org/W2049040769\",\"https://openalex.org/W2019450646\",\"https://openalex.org/W2033797893\",\"https://openalex.org/W2073074836\",\"https://openalex.org/W2009666036\",\"https://openalex.org/W2060085692\",\"https://openalex.org/W2040835222\",\"https://openalex.org/W2083383767\",\"https://openalex.org/W2085907924\",\"https://openalex.org/W2077803783\",\"https://openalex.org/W2587125028\",\"https://openalex.org/W2080363788\",\"https://openalex.org/W6781238791\",\"https://openalex.org/W2119831905\",\"https://openalex.org/W4301396040\",\"https://openalex.org/W4388653555\",\"https://openalex.org/W4385201835\",\"https://openalex.org/W4385515651\",\"https://openalex.org/W4387857159\",\"https://openalex.org/W6804903232\",\"https://openalex.org/W2888814360\",\"https://openalex.org/W6842656942\",\"https://openalex.org/W2005398842\",\"https://openalex.org/W3184117872\",\"https://openalex.org/W2021523302\",\"https://openalex.org/W4229030955\",\"https://openalex.org/W2147461659\",\"https://openalex.org/W3007931728\",\"https://openalex.org/W4362671013\",\"https://openalex.org/W2106914633\",\"https://openalex.org/W1987703244\",\"https://openalex.org/W2090848516\",\"https://openalex.org/W2068042361\",\"https://openalex.org/W2083670710\",\"https://openalex.org/W2916215134\",\"https://openalex.org/W2769618722\",\"https://openalex.org/W3112246556\",\"https://openalex.org/W2131607023\",\"https://openalex.org/W4205601388\",\"https://openalex.org/W3155553186\",\"https://openalex.org/W2082099550\",\"https://openalex.org/W4362692437\",\"https://openalex.org/W3082402684\",\"https://openalex.org/W2791251167\",\"https://openalex.org/W2506572744\",\"https://openalex.org/W2796085145\",\"https://openalex.org/W2264082276\",\"https://openalex.org/W2054600348\",\"https://openalex.org/W6657285763\",\"https://openalex.org/W2754545512\",\"https://openalex.org/W1903705656\",\"https://openalex.org/W314115991\",\"https://openalex.org/W4211158101\",\"https://openalex.org/W2790720306\",\"https://openalex.org/W4388232516\",\"https://openalex.org/W2009128541\",\"https://openalex.org/W6839836961\",\"https://openalex.org/W4223513913\",\"https://openalex.org/W4282835301\",\"https://openalex.org/W2801057181\",\"https://openalex.org/W195122077\",\"https://openalex.org/W2162867091\",\"https://openalex.org/W2403615337\",\"https://openalex.org/W1997287822\",\"https://openalex.org/W2053896245\",\"https://openalex.org/W6693327547\",\"https://openalex.org/W2142587255\",\"https://openalex.org/W2079560849\",\"https://openalex.org/W2080502138\",\"https://openalex.org/W2167249477\",\"https://openalex.org/W2536145336\",\"https://openalex.org/W2793223439\",\"https://openalex.org/W2972128768\",\"https://openalex.org/W4321373252\",\"https://openalex.org/W2052606088\",\"https://openalex.org/W2915331042\",\"https://openalex.org/W2118129085\",\"https://openalex.org/W2148017536\",\"https://openalex.org/W2143284241\",\"https://openalex.org/W2041999499\",\"https://openalex.org/W1983534985\",\"https://openalex.org/W2137246991\",\"https://openalex.org/W2164445115\",\"https://openalex.org/W2021611191\",\"https://openalex.org/W2158984087\",\"https://openalex.org/W2085435800\",\"https://openalex.org/W2134465569\",\"https://openalex.org/W2027186506\",\"https://openalex.org/W1998616690\",\"https://openalex.org/W2040170596\",\"https://openalex.org/W2036288989\",\"https://openalex.org/W4309008677\",\"https://openalex.org/W2133019124\",\"https://openalex.org/W2031251046\",\"https://openalex.org/W1578243658\",\"https://openalex.org/W1867921149\",\"https://openalex.org/W2058994454\",\"https://openalex.org/W1991325324\",\"https://openalex.org/W2042828511\",\"https://openalex.org/W2096601751\",\"https://openalex.org/W2084107396\",\"https://openalex.org/W1994232621\",\"https://openalex.org/W1989586262\",\"https://openalex.org/W1978530682\",\"https://openalex.org/W1997933391\",\"https://openalex.org/W2079430002\",\"https://openalex.org/W1963707072\",\"https://openalex.org/W2564082048\",\"https://openalex.org/W4200563951\",\"https://openalex.org/W6784720218\",\"https://openalex.org/W1673785884\",\"https://openalex.org/W2023742187\",\"https://openalex.org/W1976042714\",\"https://openalex.org/W6735673767\",\"https://openalex.org/W2154425947\",\"https://openalex.org/W2060177739\",\"https://openalex.org/W2029301697\",\"https://openalex.org/W4317821237\",\"https://openalex.org/W3001269920\",\"https://openalex.org/W2233625034\",\"https://openalex.org/W4211238337\",\"https://openalex.org/W2605882613\",\"https://openalex.org/W2156220503\",\"https://openalex.org/W2157627656\",\"https://openalex.org/W1992786646\",\"https://openalex.org/W1976281831\",\"https://openalex.org/W1993807156\",\"https://openalex.org/W2060288971\",\"https://openalex.org/W2013288407\",\"https://openalex.org/W2073471715\",\"https://openalex.org/W2079593468\",\"https://openalex.org/W2035368481\",\"https://openalex.org/W1998890058\",\"https://openalex.org/W2125377984\",\"https://openalex.org/W2028940007\",\"https://openalex.org/W1598703170\",\"https://openalex.org/W2134832655\",\"https://openalex.org/W2040567754\",\"https://openalex.org/W2101400633\",\"https://openalex.org/W1981152626\",\"https://openalex.org/W2180781305\",\"https://openalex.org/W2003701345\",\"https://openalex.org/W2157461655\",\"https://openalex.org/W2053552819\",\"https://openalex.org/W2022997414\",\"https://openalex.org/W4281741949\",\"https://openalex.org/W2923619836\",\"https://openalex.org/W2510690442\",\"https://openalex.org/W2593921779\",\"https://openalex.org/W2798054687\",\"https://openalex.org/W2895381107\",\"https://openalex.org/W2766966847\",\"https://openalex.org/W2027317254\",\"https://openalex.org/W4296598248\",\"https://openalex.org/W3091041563\",\"https://openalex.org/W3216280851\",\"https://openalex.org/W4247260027\",\"https://openalex.org/W4365452971\",\"https://openalex.org/W3049325054\",\"https://openalex.org/W2602012815\",\"https://openalex.org/W2161648900\",\"https://openalex.org/W4286005521\",\"https://openalex.org/W2510708214\",\"https://openalex.org/W4226354001\"],\"related_works\":[\"https://openalex.org/W1994365112\",\"https://openalex.org/W2945624955\",\"https://openalex.org/W2073493866\",\"https://openalex.org/W1608309823\",\"https://openalex.org/W2570228639\",\"https://openalex.org/W38098989\",\"https://openalex.org/W1985090009\",\"https://openalex.org/W4233796751\",\"https://openalex.org/W1987677668\",\"https://openalex.org/W1895538680\"],\"abstract_inverted_index\":{\"Alzheimer\\'s\":[0,57],\"disease\":[1,58],\"(AD),\":[2],\"the\":[3,13,42,45,51,63,88,128,159,197,223,240],\"main\":[4],\"dementia\":[5,15],\"type\":[6],\"accounting\":[7],\"for\":[8,150,158,233,255],\"over\":[9],\"70\":[10],\"%\":[11],\"of\":[12,44,56,65,90,94,130,146,156,161,225,242,246,249],\"entire\":[14],\"population\":[16],\"and\":[17,23,33,59,110,124,165,184,191,200,227],\"exhibits\":[18],\"progressive\":[19],\"decline\":[20],\"in\":[21,41,107,127],\"memory\":[22],\"executive\":[24],\"function.\":[25],\"AD\":[26,179,256],\"pathology\":[27,241],\"is\":[28,54,69,153,219],\"characterized\":[29],\"by\":[30,140,180],\"amyloid\":[31,52,66,95],\"fibrils\":[32],\"neurofibrillary\":[34],\"tangles.\":[35],\"Acetylcholinesterase\":[36],\"(AChE),\":[37],\"an\":[38,133],\"enzyme\":[39],\"involved\":[40],\"hydrolysis\":[43],\"neurotransmitter\":[46],\"acetylcholine,\":[47],\"consistently\":[48],\"colocalizes\":[49],\"with\":[50,76,251],\"deposits\":[53],\"characteristic\":[55],\"may\":[60],\"contribute\":[61],\"to\":[62,86,136,143,173,208,221],\"generation\":[64],\"proteins.\":[67,79],\"AChE\":[68,80],\"a\":[70,83],\"potent\":[71],\"amyloid-promoting\":[72],\"factor\":[73],\"as\":[74,121,178,230],\"compared\":[75,207],\"other\":[77,192],\"associated\":[78],\"inhibitors\":[81,103],\"play\":[82],\"vital\":[84],\"role\":[85,245],\"prevent\":[87],\"formation\":[89],\"toxic\":[91],\"oligomeric\":[92],\"form\":[93],\"peptide.\":[96],\"Recent\":[97],\"studies\":[98],\"have\":[99,169,212],\"reported\":[100],\"that\":[101],\"acetylcholinesterase\":[102,252],\"(ChE-Is)\":[104],\"are\":[105],\"present\":[106],\"plants,\":[108],\"fungi,\":[109],\"marine\":[111],\"products.\":[112],\"Some\":[113],\"cholinesterase\":[114],\"inhibitors,\":[115],\"obtained\":[116],\"from\":[117,203],\"plant\":[118],\"source\":[119],\"such\":[120,177],\"rivastigmine,\":[122],\"donepezil,\":[123],\"galantamine,\":[125],\"used\":[126,172],\"treatment\":[129,160,232],\"AD,\":[131,151,243],\"offer\":[132],\"alternative\":[134],\"approach\":[135],\"alleviate\":[137],\"its\":[138,182],\"symptoms\":[139],\"reducing\":[141],\"A\\\\u03b2.Due\":[142],\"limited\":[144],\"efficacy\":[145],\"currently\":[147],\"available\":[148],\"drugs\":[149],\"there\":[152],\"huge\":[154],\"potential\":[155,224,248],\"phytomedicines\":[157,211,226],\"AD.\":[162,234],\"Medicinal\":[163],\"herbs\":[164],\"herbal\":[166],\"drug\":[167],\"preparations\":[168],\"traditionally\":[170],\"been\":[171],\"treat\":[174],\"neurological\":[175],\"disorders\":[176],\"exhibiting\":[181],\"anti-inflammatory\":[183],\"neuroprotective\":[185],\"properties.\":[186],\"Phytomedicines\":[187],\"containing\":[188],\"flavonoids,\":[189],\"polyphenols,\":[190],\"naturally\":[193],\"occurring\":[194],\"antioxidants\":[195],\"crosses\":[196],\"blood-brain\":[198],\"barrier\":[199],\"protect\":[201],\"neurons\":[202],\"oxidative\":[204],\"stress.\":[205],\"As\":[206],\"synthetic\":[209],\"drugs,\":[210],\"fewer\":[213],\"side\":[214],\"effects.\":[215],\"Therefore,\":[216],\"recent\":[217],\"research\":[218],\"focused\":[220],\"explore\":[222],\"develop\":[228],\"it\":[229],\"effective\":[231],\"In\":[235],\"our\":[236],\"review,\":[237],\"we\":[238],\"summarized\":[239],\"amyloid-deposition,\":[244],\"Acetylcholinesterase,\":[247],\"phytoconstituents\":[250],\"inhibitory\":[253],\"activity\":[254],\"treatment.\":[257]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":39},{\"year\":2024,\"cited_by_count\":15}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4400210362\",\"doi\":\"https://doi.org/10.1111/cns.14818\",\"title\":\"GSK3: A potential target and pending issues for treatment of Alzheimer\\'s disease\",\"display_name\":\"GSK3: A potential target and pending issues for treatment of Alzheimer\\'s disease\",\"relevance_score\":157.03676,\"publication_year\":2024,\"publication_date\":\"2024-07-01\",\"ids\":{\"openalex\":\"https://openalex.org/W4400210362\",\"doi\":\"https://doi.org/10.1111/cns.14818\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/38946682\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1111/cns.14818\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1111/cns.14818\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cns.14818\",\"source\":{\"id\":\"https://openalex.org/S84392608\",\"display_name\":\"CNS Neuroscience & Therapeutics\",\"issn_l\":\"1755-5930\",\"issn\":[\"1755-5930\",\"1755-5949\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"CNS Neuroscience &amp; Therapeutics\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cns.14818\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5068081890\",\"display_name\":\"Jiahui Zhao\",\"orcid\":\"https://orcid.org/0000-0001-5359-3709\"},\"institutions\":[{\"id\":\"https://openalex.org/I114539943\",\"display_name\":\"Zhejiang Chinese Medical University\",\"ror\":\"https://ror.org/04epb4p87\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I114539943\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Jiahui Zhao\",\"raw_affiliation_strings\":[\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I114539943\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5102709196\",\"display_name\":\"Mengying Wei\",\"orcid\":\"https://orcid.org/0000-0001-8661-9610\"},\"institutions\":[{\"id\":\"https://openalex.org/I76130692\",\"display_name\":\"Zhejiang University\",\"ror\":\"https://ror.org/00a2xv884\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I76130692\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Mengying Wei\",\"raw_affiliation_strings\":[\"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China\",\"Future Health Laboratory, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I76130692\"]},{\"raw_affiliation_string\":\"Future Health Laboratory, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing, China\",\"institution_ids\":[\"https://openalex.org/I76130692\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5001313841\",\"display_name\":\"Minsong Guo\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I76130692\",\"display_name\":\"Zhejiang University\",\"ror\":\"https://ror.org/00a2xv884\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I76130692\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Minsong Guo\",\"raw_affiliation_strings\":[\"Cangnan County Qiushi Innovation Research Institute of Traditional Chinese Medicine, Wenzhou, China\",\"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I76130692\"]},{\"raw_affiliation_string\":\"Cangnan County Qiushi Innovation Research Institute of Traditional Chinese Medicine, Wenzhou, China\",\"institution_ids\":[]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100761949\",\"display_name\":\"Mengyao Wang\",\"orcid\":\"https://orcid.org/0000-0002-2681-3873\"},\"institutions\":[{\"id\":\"https://openalex.org/I114539943\",\"display_name\":\"Zhejiang Chinese Medical University\",\"ror\":\"https://ror.org/04epb4p87\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I114539943\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Mengyao Wang\",\"raw_affiliation_strings\":[\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I114539943\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5075581434\",\"display_name\":\"Hongxia Niu\",\"orcid\":\"https://orcid.org/0000-0003-3033-4741\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210124033\",\"display_name\":\"Blood Center of Zhejiang Province\",\"ror\":\"https://ror.org/02p620w18\",\"country_code\":\"CN\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210124033\"]},{\"id\":\"https://openalex.org/I114539943\",\"display_name\":\"Zhejiang Chinese Medical University\",\"ror\":\"https://ror.org/04epb4p87\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I114539943\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Hongxia Niu\",\"raw_affiliation_strings\":[\"Key Laboratory of Blood-stasis-toxin Syndrome of Zhejiang Province, Hangzhou, China\",\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I114539943\"]},{\"raw_affiliation_string\":\"Key Laboratory of Blood-stasis-toxin Syndrome of Zhejiang Province, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I4210124033\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101066270\",\"display_name\":\"Tengfei Xu\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I76130692\",\"display_name\":\"Zhejiang University\",\"ror\":\"https://ror.org/00a2xv884\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I76130692\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Tengfei Xu\",\"raw_affiliation_strings\":[\"Cangnan County Qiushi Innovation Research Institute of Traditional Chinese Medicine, Wenzhou, China\",\"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Cangnan County Qiushi Innovation Research Institute of Traditional Chinese Medicine, Wenzhou, China\",\"institution_ids\":[]},{\"raw_affiliation_string\":\"College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I76130692\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5100669965\",\"display_name\":\"Yuan Zhou\",\"orcid\":\"https://orcid.org/0000-0002-5600-5754\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210124033\",\"display_name\":\"Blood Center of Zhejiang Province\",\"ror\":\"https://ror.org/02p620w18\",\"country_code\":\"CN\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210124033\"]},{\"id\":\"https://openalex.org/I114539943\",\"display_name\":\"Zhejiang Chinese Medical University\",\"ror\":\"https://ror.org/04epb4p87\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I114539943\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Yuan Zhou\",\"raw_affiliation_strings\":[\"Key Laboratory of Blood-stasis-toxin Syndrome of Zhejiang Province, Hangzhou, China\",\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Blood-stasis-toxin Syndrome of Zhejiang Province, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I4210124033\"]},{\"raw_affiliation_string\":\"School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China\",\"institution_ids\":[\"https://openalex.org/I114539943\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":7,\"corresponding_author_ids\":[\"https://openalex.org/A5101066270\",\"https://openalex.org/A5100669965\"],\"corresponding_institution_ids\":[\"https://openalex.org/I114539943\",\"https://openalex.org/I4210124033\",\"https://openalex.org/I76130692\"],\"apc_list\":{\"value\":2150,\"currency\":\"EUR\",\"value_usd\":2530},\"apc_paid\":{\"value\":2150,\"currency\":\"EUR\",\"value_usd\":2530},\"fwci\":36.30313444,\"has_fulltext\":false,\"cited_by_count\":48,\"citation_normalized_percentile\":{\"value\":0.99647184,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":98,\"max\":100},\"biblio\":{\"volume\":\"30\",\"issue\":\"7\",\"first_page\":\"e14818\",\"last_page\":\"e14818\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T10929\",\"display_name\":\"Wnt/\\\\u03b2-catenin signaling in development and cancer\",\"score\":0.9970999956130981,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.992900013923645,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/gsk-3\",\"display_name\":\"GSK-3\",\"score\":0.8510913252830505},{\"id\":\"https://openalex.org/keywords/neuroinflammation\",\"display_name\":\"Neuroinflammation\",\"score\":0.6983895301818848},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.6164549589157104},{\"id\":\"https://openalex.org/keywords/gsk3b\",\"display_name\":\"GSK3B\",\"score\":0.5368002653121948},{\"id\":\"https://openalex.org/keywords/phosphorylation\",\"display_name\":\"Phosphorylation\",\"score\":0.5323427319526672},{\"id\":\"https://openalex.org/keywords/amyloid-precursor-protein\",\"display_name\":\"Amyloid precursor protein\",\"score\":0.4742145538330078},{\"id\":\"https://openalex.org/keywords/glycogen-synthase\",\"display_name\":\"Glycogen synthase\",\"score\":0.4711521863937378},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.46758151054382324},{\"id\":\"https://openalex.org/keywords/kinase\",\"display_name\":\"Kinase\",\"score\":0.46259182691574097},{\"id\":\"https://openalex.org/keywords/amyloid-\\\\u03b2\",\"display_name\":\"Amyloid \\\\u03b2\",\"score\":0.43539297580718994},{\"id\":\"https://openalex.org/keywords/alzheimers-disease\",\"display_name\":\"Alzheimer\\'s disease\",\"score\":0.4344259202480316},{\"id\":\"https://openalex.org/keywords/tau-protein\",\"display_name\":\"Tau protein\",\"score\":0.419833779335022},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.36189666390419006},{\"id\":\"https://openalex.org/keywords/cell-biology\",\"display_name\":\"Cell biology\",\"score\":0.3309691548347473},{\"id\":\"https://openalex.org/keywords/psychology\",\"display_name\":\"Psychology\",\"score\":0.32636159658432007},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.32516616582870483},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.11510223150253296}],\"concepts\":[{\"id\":\"https://openalex.org/C182996813\",\"wikidata\":\"https://www.wikidata.org/wiki/Q910847\",\"display_name\":\"GSK-3\",\"level\":3,\"score\":0.8510913252830505},{\"id\":\"https://openalex.org/C87753298\",\"wikidata\":\"https://www.wikidata.org/wiki/Q17157137\",\"display_name\":\"Neuroinflammation\",\"level\":3,\"score\":0.6983895301818848},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.6164549589157104},{\"id\":\"https://openalex.org/C104629339\",\"wikidata\":\"https://www.wikidata.org/wiki/Q18258585\",\"display_name\":\"GSK3B\",\"level\":4,\"score\":0.5368002653121948},{\"id\":\"https://openalex.org/C11960822\",\"wikidata\":\"https://www.wikidata.org/wiki/Q242736\",\"display_name\":\"Phosphorylation\",\"level\":2,\"score\":0.5323427319526672},{\"id\":\"https://openalex.org/C31705614\",\"wikidata\":\"https://www.wikidata.org/wiki/Q423510\",\"display_name\":\"Amyloid precursor protein\",\"level\":4,\"score\":0.4742145538330078},{\"id\":\"https://openalex.org/C192118531\",\"wikidata\":\"https://www.wikidata.org/wiki/Q86360001\",\"display_name\":\"Glycogen synthase\",\"level\":3,\"score\":0.4711521863937378},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.46758151054382324},{\"id\":\"https://openalex.org/C184235292\",\"wikidata\":\"https://www.wikidata.org/wiki/Q421851\",\"display_name\":\"Kinase\",\"level\":2,\"score\":0.46259182691574097},{\"id\":\"https://openalex.org/C3019447875\",\"wikidata\":\"https://www.wikidata.org/wiki/Q417667\",\"display_name\":\"Amyloid \\\\u03b2\",\"level\":3,\"score\":0.43539297580718994},{\"id\":\"https://openalex.org/C502032728\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11081\",\"display_name\":\"Alzheimer\\'s disease\",\"level\":3,\"score\":0.4344259202480316},{\"id\":\"https://openalex.org/C2778670691\",\"wikidata\":\"https://www.wikidata.org/wiki/Q419507\",\"display_name\":\"Tau protein\",\"level\":4,\"score\":0.419833779335022},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.36189666390419006},{\"id\":\"https://openalex.org/C95444343\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7141\",\"display_name\":\"Cell biology\",\"level\":1,\"score\":0.3309691548347473},{\"id\":\"https://openalex.org/C15744967\",\"wikidata\":\"https://www.wikidata.org/wiki/Q9418\",\"display_name\":\"Psychology\",\"level\":0,\"score\":0.32636159658432007},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.32516616582870483},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.11510223150253296}],\"mesh\":[{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":true},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":true},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":true},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":true},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":true},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":true},{\"descriptor_ui\":\"D038362\",\"descriptor_name\":\"Glycogen Synthase Kinase 3\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false}],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1111/cns.14818\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1111/cns.14818\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cns.14818\",\"source\":{\"id\":\"https://openalex.org/S84392608\",\"display_name\":\"CNS Neuroscience & Therapeutics\",\"issn_l\":\"1755-5930\",\"issn\":[\"1755-5930\",\"1755-5949\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"CNS Neuroscience &amp; Therapeutics\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:38946682\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/38946682\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"CNS neuroscience & therapeutics\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:11215492\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/11215492\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"CNS Neurosci Ther\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.1111/cns.14818\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1111/cns.14818\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cns.14818\",\"source\":{\"id\":\"https://openalex.org/S84392608\",\"display_name\":\"CNS Neuroscience & Therapeutics\",\"issn_l\":\"1755-5930\",\"issn\":[\"1755-5930\",\"1755-5949\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"CNS Neuroscience &amp; Therapeutics\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.41999998688697815,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G3561502091\",\"display_name\":null,\"funder_award_id\":\"LQ23H280011\",\"funder_id\":\"https://openalex.org/F4320338464\",\"funder_display_name\":\"Natural Science Foundation of Zhejiang Province\"},{\"id\":\"https://openalex.org/G8048382666\",\"display_name\":null,\"funder_award_id\":\"82204651\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"},{\"id\":\"https://openalex.org/G8432388599\",\"display_name\":null,\"funder_award_id\":\"82204580\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320321001\",\"display_name\":\"National Natural Science Foundation of China\",\"ror\":\"https://ror.org/01h0zpd94\"},{\"id\":\"https://openalex.org/F4320338464\",\"display_name\":\"Natural Science Foundation of Zhejiang Province\",\"ror\":\"https://ror.org/01h0zpd94\"}],\"has_content\":{\"pdf\":true,\"grobid_xml\":false},\"referenced_works_count\":337,\"referenced_works\":[\"https://openalex.org/W4293242696\",\"https://openalex.org/W1978714931\",\"https://openalex.org/W2589299515\",\"https://openalex.org/W2730832359\",\"https://openalex.org/W1983055247\",\"https://openalex.org/W1963561816\",\"https://openalex.org/W3211091011\",\"https://openalex.org/W2017592134\",\"https://openalex.org/W2051640170\",\"https://openalex.org/W3124236605\",\"https://openalex.org/W2108958930\",\"https://openalex.org/W2053692735\",\"https://openalex.org/W4395009380\",\"https://openalex.org/W4397009139\",\"https://openalex.org/W4220825176\",\"https://openalex.org/W1759290616\",\"https://openalex.org/W2151585937\",\"https://openalex.org/W2510806376\",\"https://openalex.org/W3097527510\",\"https://openalex.org/W2910825225\",\"https://openalex.org/W3130500589\",\"https://openalex.org/W4205335396\",\"https://openalex.org/W4394575333\",\"https://openalex.org/W3199463220\",\"https://openalex.org/W2028315072\",\"https://openalex.org/W2054480260\",\"https://openalex.org/W2073128231\",\"https://openalex.org/W3138760932\",\"https://openalex.org/W3125256209\",\"https://openalex.org/W2041136117\",\"https://openalex.org/W2085240418\",\"https://openalex.org/W893812942\",\"https://openalex.org/W1993145412\",\"https://openalex.org/W1984598826\",\"https://openalex.org/W2119584760\",\"https://openalex.org/W2072693941\",\"https://openalex.org/W2790827967\",\"https://openalex.org/W2167928721\",\"https://openalex.org/W1653014745\",\"https://openalex.org/W1757124661\",\"https://openalex.org/W2067813543\",\"https://openalex.org/W2168024183\",\"https://openalex.org/W2067727463\",\"https://openalex.org/W2011348124\",\"https://openalex.org/W2040448753\",\"https://openalex.org/W2084080552\",\"https://openalex.org/W1496316111\",\"https://openalex.org/W2145808065\",\"https://openalex.org/W2083308747\",\"https://openalex.org/W2133627256\",\"https://openalex.org/W1995120027\",\"https://openalex.org/W2097637421\",\"https://openalex.org/W2067592930\",\"https://openalex.org/W2144589447\",\"https://openalex.org/W2016905504\",\"https://openalex.org/W1895718325\",\"https://openalex.org/W2146209359\",\"https://openalex.org/W2121745326\",\"https://openalex.org/W1833591189\",\"https://openalex.org/W2160003033\",\"https://openalex.org/W2109142098\",\"https://openalex.org/W2142493853\",\"https://openalex.org/W1518972222\",\"https://openalex.org/W2044693162\",\"https://openalex.org/W2490441649\",\"https://openalex.org/W2076892771\",\"https://openalex.org/W2056907950\",\"https://openalex.org/W2021526208\",\"https://openalex.org/W2015531187\",\"https://openalex.org/W2114736131\",\"https://openalex.org/W1917535022\",\"https://openalex.org/W2122937307\",\"https://openalex.org/W2114358785\",\"https://openalex.org/W2095509297\",\"https://openalex.org/W2082905363\",\"https://openalex.org/W3084215241\",\"https://openalex.org/W2077551977\",\"https://openalex.org/W3120373555\",\"https://openalex.org/W2803818187\",\"https://openalex.org/W2038851101\",\"https://openalex.org/W2045696000\",\"https://openalex.org/W1960647274\",\"https://openalex.org/W2193984745\",\"https://openalex.org/W1893185987\",\"https://openalex.org/W2795660725\",\"https://openalex.org/W2039229967\",\"https://openalex.org/W3093312594\",\"https://openalex.org/W2150110395\",\"https://openalex.org/W2158314129\",\"https://openalex.org/W2169200799\",\"https://openalex.org/W2108493635\",\"https://openalex.org/W1983731153\",\"https://openalex.org/W1869318026\",\"https://openalex.org/W2008612988\",\"https://openalex.org/W2973441422\",\"https://openalex.org/W2013891209\",\"https://openalex.org/W3217594716\",\"https://openalex.org/W2109955944\",\"https://openalex.org/W2804775036\",\"https://openalex.org/W2507233193\",\"https://openalex.org/W2016257709\",\"https://openalex.org/W2071986399\",\"https://openalex.org/W3155966446\",\"https://openalex.org/W2159377066\",\"https://openalex.org/W1995562130\",\"https://openalex.org/W2036755018\",\"https://openalex.org/W4323347622\",\"https://openalex.org/W2112136536\",\"https://openalex.org/W2157972442\",\"https://openalex.org/W4220970963\",\"https://openalex.org/W2770191803\",\"https://openalex.org/W2166130307\",\"https://openalex.org/W3087745331\",\"https://openalex.org/W2606513998\",\"https://openalex.org/W215726525\",\"https://openalex.org/W3006083475\",\"https://openalex.org/W3120036520\",\"https://openalex.org/W2268919388\",\"https://openalex.org/W2033595520\",\"https://openalex.org/W2022060333\",\"https://openalex.org/W2585714412\",\"https://openalex.org/W2887398173\",\"https://openalex.org/W2035825704\",\"https://openalex.org/W3175464757\",\"https://openalex.org/W2125616439\",\"https://openalex.org/W2105911676\",\"https://openalex.org/W2111200377\",\"https://openalex.org/W2999452229\",\"https://openalex.org/W2469385416\",\"https://openalex.org/W2133064784\",\"https://openalex.org/W1603448131\",\"https://openalex.org/W2151347791\",\"https://openalex.org/W1937509560\",\"https://openalex.org/W3194796500\",\"https://openalex.org/W2158816574\",\"https://openalex.org/W1980261795\",\"https://openalex.org/W3037412948\",\"https://openalex.org/W1903012165\",\"https://openalex.org/W3032133658\",\"https://openalex.org/W3033798323\",\"https://openalex.org/W2735659505\",\"https://openalex.org/W3118623772\",\"https://openalex.org/W2552792747\",\"https://openalex.org/W2118813218\",\"https://openalex.org/W4200282123\",\"https://openalex.org/W2902055207\",\"https://openalex.org/W2169399187\",\"https://openalex.org/W2079423492\",\"https://openalex.org/W1965844011\",\"https://openalex.org/W2095750495\",\"https://openalex.org/W3133938820\",\"https://openalex.org/W3164061833\",\"https://openalex.org/W2602238152\",\"https://openalex.org/W1697463694\",\"https://openalex.org/W2793605774\",\"https://openalex.org/W2137280740\",\"https://openalex.org/W2918368530\",\"https://openalex.org/W1977892449\",\"https://openalex.org/W2078224613\",\"https://openalex.org/W2000217206\",\"https://openalex.org/W2911225505\",\"https://openalex.org/W2552073351\",\"https://openalex.org/W2801589289\",\"https://openalex.org/W3186468260\",\"https://openalex.org/W2551935034\",\"https://openalex.org/W2053791137\",\"https://openalex.org/W2043785832\",\"https://openalex.org/W2063264874\",\"https://openalex.org/W2114300663\",\"https://openalex.org/W1578127299\",\"https://openalex.org/W2761586559\",\"https://openalex.org/W4200583159\",\"https://openalex.org/W2075259916\",\"https://openalex.org/W1491447344\",\"https://openalex.org/W3192369129\",\"https://openalex.org/W2012525935\",\"https://openalex.org/W3163675851\",\"https://openalex.org/W2127063285\",\"https://openalex.org/W2904693995\",\"https://openalex.org/W2949187527\",\"https://openalex.org/W2528861630\",\"https://openalex.org/W2951557451\",\"https://openalex.org/W4224313650\",\"https://openalex.org/W2515127987\",\"https://openalex.org/W2614989893\",\"https://openalex.org/W2088942395\",\"https://openalex.org/W2888665185\",\"https://openalex.org/W2049408722\",\"https://openalex.org/W2809698427\",\"https://openalex.org/W2034957678\",\"https://openalex.org/W2989667799\",\"https://openalex.org/W3131217026\",\"https://openalex.org/W2308180461\",\"https://openalex.org/W2084272059\",\"https://openalex.org/W4200584307\",\"https://openalex.org/W2022443561\",\"https://openalex.org/W1585567858\",\"https://openalex.org/W2032174851\",\"https://openalex.org/W2039467481\",\"https://openalex.org/W2734651019\",\"https://openalex.org/W2108292688\",\"https://openalex.org/W2034504333\",\"https://openalex.org/W1550794020\",\"https://openalex.org/W4200177887\",\"https://openalex.org/W2088714934\",\"https://openalex.org/W2950700120\",\"https://openalex.org/W2782715813\",\"https://openalex.org/W2083670710\",\"https://openalex.org/W935981454\",\"https://openalex.org/W2809045422\",\"https://openalex.org/W3120886928\",\"https://openalex.org/W1996499871\",\"https://openalex.org/W2336783249\",\"https://openalex.org/W2117004136\",\"https://openalex.org/W2302226813\",\"https://openalex.org/W4285132881\",\"https://openalex.org/W4395110245\",\"https://openalex.org/W2809270825\",\"https://openalex.org/W4396870962\",\"https://openalex.org/W4304959941\",\"https://openalex.org/W1993473208\",\"https://openalex.org/W2025330029\",\"https://openalex.org/W3112055494\",\"https://openalex.org/W3109797254\",\"https://openalex.org/W2970507725\",\"https://openalex.org/W2723007231\",\"https://openalex.org/W3194822488\",\"https://openalex.org/W2074176256\",\"https://openalex.org/W3087504526\",\"https://openalex.org/W2013144126\",\"https://openalex.org/W2992999384\",\"https://openalex.org/W2013316180\",\"https://openalex.org/W4229044956\",\"https://openalex.org/W2113694503\",\"https://openalex.org/W2803694856\",\"https://openalex.org/W2019641285\",\"https://openalex.org/W2062628622\",\"https://openalex.org/W2087961967\",\"https://openalex.org/W4386817650\",\"https://openalex.org/W3154763858\",\"https://openalex.org/W2889487737\",\"https://openalex.org/W2034595626\",\"https://openalex.org/W2161182074\",\"https://openalex.org/W4321488198\",\"https://openalex.org/W4323660143\",\"https://openalex.org/W4322012059\",\"https://openalex.org/W3174785593\",\"https://openalex.org/W2235924786\",\"https://openalex.org/W2914441812\",\"https://openalex.org/W3080958518\",\"https://openalex.org/W1923616468\",\"https://openalex.org/W2014686354\",\"https://openalex.org/W3203780554\",\"https://openalex.org/W3088322240\",\"https://openalex.org/W2576339858\",\"https://openalex.org/W3042892341\",\"https://openalex.org/W3123002413\",\"https://openalex.org/W4214689200\",\"https://openalex.org/W2029960796\",\"https://openalex.org/W2891001172\",\"https://openalex.org/W1964825402\",\"https://openalex.org/W2057558952\",\"https://openalex.org/W4220721550\",\"https://openalex.org/W1967985044\",\"https://openalex.org/W2810868902\",\"https://openalex.org/W2523039730\",\"https://openalex.org/W2794647170\",\"https://openalex.org/W3186521051\",\"https://openalex.org/W3111370423\",\"https://openalex.org/W2956872454\",\"https://openalex.org/W2796299217\",\"https://openalex.org/W2761278528\",\"https://openalex.org/W2290952909\",\"https://openalex.org/W2396477363\",\"https://openalex.org/W1894896545\",\"https://openalex.org/W2106039436\",\"https://openalex.org/W2300360012\",\"https://openalex.org/W2327416498\",\"https://openalex.org/W2950271231\",\"https://openalex.org/W2911227656\",\"https://openalex.org/W3198631777\",\"https://openalex.org/W2536117170\",\"https://openalex.org/W2990393937\",\"https://openalex.org/W2804722427\",\"https://openalex.org/W2769545777\",\"https://openalex.org/W3202562853\",\"https://openalex.org/W2983864488\",\"https://openalex.org/W4214671926\",\"https://openalex.org/W2153249592\",\"https://openalex.org/W3205153985\",\"https://openalex.org/W4298325729\",\"https://openalex.org/W2735118768\",\"https://openalex.org/W2029457316\",\"https://openalex.org/W3039362773\",\"https://openalex.org/W2014923793\",\"https://openalex.org/W2803533463\",\"https://openalex.org/W2735272121\",\"https://openalex.org/W4310668506\",\"https://openalex.org/W2160225882\",\"https://openalex.org/W1599723615\",\"https://openalex.org/W2984108839\",\"https://openalex.org/W4220892594\",\"https://openalex.org/W2109382000\",\"https://openalex.org/W2791917264\",\"https://openalex.org/W3114182776\",\"https://openalex.org/W2909882379\",\"https://openalex.org/W2575262664\",\"https://openalex.org/W2273272200\",\"https://openalex.org/W2792700527\",\"https://openalex.org/W2164074040\",\"https://openalex.org/W2135724524\",\"https://openalex.org/W2913876135\",\"https://openalex.org/W2034930763\",\"https://openalex.org/W2287113872\",\"https://openalex.org/W2124627119\",\"https://openalex.org/W2075965923\",\"https://openalex.org/W4285082302\",\"https://openalex.org/W2051075231\",\"https://openalex.org/W3040145497\",\"https://openalex.org/W2102853605\",\"https://openalex.org/W2898068719\",\"https://openalex.org/W2050912908\",\"https://openalex.org/W2991448135\",\"https://openalex.org/W3205496902\",\"https://openalex.org/W3102327459\",\"https://openalex.org/W2888635902\",\"https://openalex.org/W3019229766\",\"https://openalex.org/W2075721398\",\"https://openalex.org/W3106909214\",\"https://openalex.org/W4210272299\",\"https://openalex.org/W4205336217\",\"https://openalex.org/W2908347736\",\"https://openalex.org/W2896300919\",\"https://openalex.org/W2082429191\",\"https://openalex.org/W4400210362\",\"https://openalex.org/W4376849538\",\"https://openalex.org/W2945072079\"],\"related_works\":[\"https://openalex.org/W4248586904\",\"https://openalex.org/W2318883589\",\"https://openalex.org/W2401632846\",\"https://openalex.org/W2019867611\",\"https://openalex.org/W1831189467\",\"https://openalex.org/W2099143291\",\"https://openalex.org/W1601657500\",\"https://openalex.org/W2366072566\",\"https://openalex.org/W2032842127\",\"https://openalex.org/W2135561672\"],\"abstract_inverted_index\":{\"Abstract\":[0],\"Glycogen\":[1],\"synthase\":[2],\"kinase\\\\u20103\":[3],\"(GSK3),\":[4],\"consisting\":[5],\"of\":[6,29,61,113,129],\"GSK3\\\\u03b1\":[7],\"and\":[8,34,44,52,64,79,96,102,132,138,160],\"GSK3\\\\u03b2\":[9],\"subtypes,\":[10],\"is\":[11,37],\"a\":[12,38,117,150],\"complex\":[13],\"protein\":[14,89],\"kinase\":[15],\"that\":[16],\"regulates\":[17,86],\"numerous\":[18],\"substrates.\":[19],\"Research\":[20],\"has\":[21],\"observed\":[22],\"increased\":[23],\"GSK3\":[24,73,114,134,148],\"expression\":[25],\"in\":[26,143,152],\"the\":[27,111,127],\"brains\":[28],\"Alzheimer\\'s\":[30],\"disease\":[31],\"(AD)\":[32],\"patients\":[33],\"models.\":[35],\"AD\":[36,71,153],\"neurodegenerative\":[39],\"disorder\":[40],\"with\":[41,70,156],\"diverse\":[42],\"pathogenesis\":[43],\"notable\":[45],\"cognitive\":[46],\"impairments,\":[47],\"characterized\":[48],\"by\":[49],\"A\\\\u03b2\":[50,94],\"aggregation\":[51],\"excessive\":[53],\"tau\":[54,84],\"phosphorylation.\":[55],\"This\":[56],\"article\":[57],\"provides\":[58],\"an\":[59],\"overview\":[60],\"GSK3\\'s\":[62],\"structure\":[63],\"regulation,\":[65],\"extensively\":[66],\"analyzing\":[67],\"its\":[68],\"relationship\":[69],\"factors.\":[72],\"overactivation\":[74],\"disrupts\":[75],\"neural\":[76],\"growth,\":[77],\"development,\":[78],\"function.\":[80],\"It\":[81],\"directly\":[82,97],\"promotes\":[83],\"phosphorylation,\":[85],\"amyloid\":[87],\"precursor\":[88],\"(APP)\":[90],\"cleavage,\":[91],\"leading\":[92],\"to\":[93,140],\"formation,\":[95],\"or\":[98],\"indirectly\":[99],\"triggers\":[100],\"neuroinflammation\":[101],\"oxidative\":[103],\"damage.\":[104],\"We\":[105],\"also\":[106],\"summarize\":[107],\"preclinical\":[108],\"research\":[109],\"highlighting\":[110],\"inhibition\":[112],\"activity\":[115],\"as\":[116],\"primary\":[118],\"therapeutic\":[119],\"approach\":[120],\"for\":[121],\"AD.\":[122],\"Finally,\":[123],\"pending\":[124],\"issues\":[125],\"like\":[126],\"lack\":[128],\"highly\":[130],\"specific\":[131],\"affinity\\\\u2010driven\":[133],\"inhibitors,\":[135],\"are\":[136],\"raised\":[137],\"expected\":[139],\"be\":[141],\"addressed\":[142],\"future\":[144],\"research.\":[145],\"In\":[146],\"conclusion,\":[147],\"represents\":[149],\"target\":[151],\"treatment,\":[154],\"filled\":[155],\"hope,\":[157],\"challenges,\":[158],\"opportunities,\":[159],\"obstacles.\":[161]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":42},{\"year\":2024,\"cited_by_count\":6}],\"updated_date\":\"2025-12-29T23:06:16.900395\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4394964578\",\"doi\":\"https://doi.org/10.1016/j.nbd.2024.106505\",\"title\":\"Targeting dysregulated lipid metabolism for the treatment of Alzheimer\\'s disease and Parkinson\\'s disease: Current advancements and future prospects\",\"display_name\":\"Targeting dysregulated lipid metabolism for the treatment of Alzheimer\\'s disease and Parkinson\\'s disease: Current advancements and future prospects\",\"relevance_score\":155.87608,\"publication_year\":2024,\"publication_date\":\"2024-04-19\",\"ids\":{\"openalex\":\"https://openalex.org/W4394964578\",\"doi\":\"https://doi.org/10.1016/j.nbd.2024.106505\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/38642715\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.nbd.2024.106505\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.nbd.2024.106505\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S35878148\",\"display_name\":\"Neurobiology of Disease\",\"issn_l\":\"0969-9961\",\"issn\":[\"0969-9961\",\"1095-953X\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neurobiology of Disease\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://doi.org/10.1016/j.nbd.2024.106505\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5005555128\",\"display_name\":\"Bin Tong\",\"orcid\":\"https://orcid.org/0000-0003-4170-8737\"},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Bin Tong\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"School of Ophthalmology and Optometry of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]},{\"raw_affiliation_string\":\"School of Ophthalmology and Optometry of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5109706979\",\"display_name\":\"Yaoqi Ba\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yaoqi Ba\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"School of Ophthalmology and Optometry of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]},{\"raw_affiliation_string\":\"School of Ophthalmology and Optometry of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100736665\",\"display_name\":\"Zhengyang Li\",\"orcid\":\"https://orcid.org/0000-0002-2212-1220\"},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Zhengyang Li\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]},{\"raw_affiliation_string\":\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101339630\",\"display_name\":\"Caidi Yang\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Caidi Yang\",\"raw_affiliation_strings\":[\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5081966661\",\"display_name\":\"Kangtai Su\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Kangtai Su\",\"raw_affiliation_strings\":[\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100315431\",\"display_name\":\"Haodong Qi\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Haodong Qi\",\"raw_affiliation_strings\":[\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"The First Clinical Medical College of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5016559227\",\"display_name\":\"Deju Zhang\",\"orcid\":\"https://orcid.org/0000-0001-5671-3227\"},\"institutions\":[{\"id\":\"https://openalex.org/I134626604\",\"display_name\":\"Jiujiang University\",\"ror\":\"https://ror.org/0066vpg85\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I134626604\"]},{\"id\":\"https://openalex.org/I889458895\",\"display_name\":\"University of Hong Kong\",\"ror\":\"https://ror.org/02zhqgq86\",\"country_code\":\"HK\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I889458895\"]}],\"countries\":[\"CN\",\"HK\"],\"is_corresponding\":false,\"raw_author_name\":\"Deju Zhang\",\"raw_affiliation_strings\":[\"Center for Clinical Precision Medicine, Jiujiang University, Jiujiang, China\",\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\",\"Food and Nutritional Sciences, School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Food and Nutritional Sciences, School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Hong Kong, China\",\"institution_ids\":[\"https://openalex.org/I889458895\"]},{\"raw_affiliation_string\":\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\",\"institution_ids\":[\"https://openalex.org/I134626604\"]},{\"raw_affiliation_string\":\"Center for Clinical Precision Medicine, Jiujiang University, Jiujiang, China\",\"institution_ids\":[\"https://openalex.org/I134626604\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5078990142\",\"display_name\":\"Xiao Liu\",\"orcid\":\"https://orcid.org/0000-0002-5570-289X\"},\"institutions\":[{\"id\":\"https://openalex.org/I134626604\",\"display_name\":\"Jiujiang University\",\"ror\":\"https://ror.org/0066vpg85\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I134626604\"]},{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Xiao Liu\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\",\"institution_ids\":[\"https://openalex.org/I134626604\"]},{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101285399\",\"display_name\":\"Yuting Wu\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yuting Wu\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100725677\",\"display_name\":\"Yixuan Chen\",\"orcid\":\"https://orcid.org/0000-0001-7390-0622\"},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yixuan Chen\",\"raw_affiliation_strings\":[\"Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5037791866\",\"display_name\":\"Jitao Ling\",\"orcid\":\"https://orcid.org/0000-0002-1720-8620\"},\"institutions\":[{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Jitao Ling\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100345454\",\"display_name\":\"Jing Zhang\",\"orcid\":\"https://orcid.org/0000-0002-9449-6646\"},\"institutions\":[{\"id\":\"https://openalex.org/I134626604\",\"display_name\":\"Jiujiang University\",\"ror\":\"https://ror.org/0066vpg85\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I134626604\"]},{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Jing Zhang\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\",\"institution_ids\":[\"https://openalex.org/I134626604\"]},{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101464680\",\"display_name\":\"Xiaoping Yin\",\"orcid\":\"https://orcid.org/0000-0002-7121-7077\"},\"institutions\":[{\"id\":\"https://openalex.org/I134626604\",\"display_name\":\"Jiujiang University\",\"ror\":\"https://ror.org/0066vpg85\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I134626604\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Xiaoping Yin\",\"raw_affiliation_strings\":[\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\",\"institution_ids\":[\"https://openalex.org/I134626604\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5004456961\",\"display_name\":\"Peng Yu\",\"orcid\":\"https://orcid.org/0000-0002-3948-3340\"},\"institutions\":[{\"id\":\"https://openalex.org/I134626604\",\"display_name\":\"Jiujiang University\",\"ror\":\"https://ror.org/0066vpg85\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I134626604\"]},{\"id\":\"https://openalex.org/I141649914\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I141649914\"]},{\"id\":\"https://openalex.org/I4210108480\",\"display_name\":\"Second Affiliated Hospital of Nanchang University\",\"ror\":\"https://ror.org/01nxv5c88\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210108480\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Peng Yu\",\"raw_affiliation_strings\":[\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology, Affiliated Hospital of Jiujiang University, Jiujiang, China\",\"institution_ids\":[\"https://openalex.org/I134626604\"]},{\"raw_affiliation_string\":\"Department of Metabolism and Endocrinology, The Second Affiliated Hospital of Nanchang University, Jiangxi, Nanchang 330006, China\",\"institution_ids\":[\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"]}]}],\"institutions\":[],\"countries_distinct_count\":2,\"institutions_distinct_count\":14,\"corresponding_author_ids\":[\"https://openalex.org/A5004456961\",\"https://openalex.org/A5100345454\",\"https://openalex.org/A5101464680\"],\"corresponding_institution_ids\":[\"https://openalex.org/I134626604\",\"https://openalex.org/I141649914\",\"https://openalex.org/I4210108480\"],\"apc_list\":{\"value\":2500,\"currency\":\"USD\",\"value_usd\":2500},\"apc_paid\":{\"value\":2500,\"currency\":\"USD\",\"value_usd\":2500},\"fwci\":45.37891805,\"has_fulltext\":false,\"cited_by_count\":60,\"citation_normalized_percentile\":{\"value\":0.99806779,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":99,\"max\":100},\"biblio\":{\"volume\":\"196\",\"issue\":null,\"first_page\":\"106505\",\"last_page\":\"106505\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9991999864578247,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9991999864578247,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11618\",\"display_name\":\"Cholesterol and Lipid Metabolism\",\"score\":0.9984999895095825,\"subfield\":{\"id\":\"https://openalex.org/subfields/2746\",\"display_name\":\"Surgery\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11072\",\"display_name\":\"Peroxisome Proliferator-Activated Receptors\",\"score\":0.9959999918937683,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/lipid-metabolism\",\"display_name\":\"Lipid metabolism\",\"score\":0.7222270965576172},{\"id\":\"https://openalex.org/keywords/parkinsons-disease\",\"display_name\":\"Parkinson\\'s disease\",\"score\":0.5795193910598755},{\"id\":\"https://openalex.org/keywords/apolipoprotein-e\",\"display_name\":\"Apolipoprotein E\",\"score\":0.4932028651237488},{\"id\":\"https://openalex.org/keywords/neuroprotection\",\"display_name\":\"Neuroprotection\",\"score\":0.4232307970523834},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.41365134716033936},{\"id\":\"https://openalex.org/keywords/bioinformatics\",\"display_name\":\"Bioinformatics\",\"score\":0.3870159089565277},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.38179296255111694},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.38071826100349426},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.3716046214103699},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.28428661823272705}],\"concepts\":[{\"id\":\"https://openalex.org/C4733338\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2792936\",\"display_name\":\"Lipid metabolism\",\"level\":2,\"score\":0.7222270965576172},{\"id\":\"https://openalex.org/C2779734285\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11085\",\"display_name\":\"Parkinson\\'s disease\",\"level\":3,\"score\":0.5795193910598755},{\"id\":\"https://openalex.org/C57089818\",\"wikidata\":\"https://www.wikidata.org/wiki/Q424728\",\"display_name\":\"Apolipoprotein E\",\"level\":3,\"score\":0.4932028651237488},{\"id\":\"https://openalex.org/C25498285\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1981368\",\"display_name\":\"Neuroprotection\",\"level\":2,\"score\":0.4232307970523834},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.41365134716033936},{\"id\":\"https://openalex.org/C60644358\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128570\",\"display_name\":\"Bioinformatics\",\"level\":1,\"score\":0.3870159089565277},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.38179296255111694},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.38071826100349426},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.3716046214103699},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.28428661823272705}],\"mesh\":[{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000502\",\"qualifier_name\":\"physiology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000502\",\"qualifier_name\":\"physiology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000502\",\"qualifier_name\":\"physiology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":true},{\"descriptor_ui\":\"D050356\",\"descriptor_name\":\"Lipid Metabolism\",\"qualifier_ui\":\"Q000502\",\"qualifier_name\":\"physiology\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D010300\",\"descriptor_name\":\"Parkinson Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false}],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1016/j.nbd.2024.106505\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.nbd.2024.106505\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S35878148\",\"display_name\":\"Neurobiology of Disease\",\"issn_l\":\"0969-9961\",\"issn\":[\"0969-9961\",\"1095-953X\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neurobiology of Disease\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:38642715\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/38642715\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neurobiology of disease\",\"raw_type\":null},{\"id\":\"pmh:oai:doaj.org/article:77b76ea39b2d42e69c8028588339a076\",\"is_oa\":false,\"landing_page_url\":\"https://doaj.org/article/77b76ea39b2d42e69c8028588339a076\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Neurobiology of Disease, Vol 196, Iss , Pp 106505- (2024)\",\"raw_type\":\"article\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.nbd.2024.106505\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.nbd.2024.106505\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S35878148\",\"display_name\":\"Neurobiology of Disease\",\"issn_l\":\"0969-9961\",\"issn\":[\"0969-9961\",\"1095-953X\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neurobiology of Disease\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.6600000262260437,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[],\"funders\":[{\"id\":\"https://openalex.org/F4320322792\",\"display_name\":\"Nanchang University\",\"ror\":\"https://ror.org/042v6xz23\"}],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":136,\"referenced_works\":[\"https://openalex.org/W2091674068\",\"https://openalex.org/W1967150171\",\"https://openalex.org/W1736033689\",\"https://openalex.org/W2002432816\",\"https://openalex.org/W4310496439\",\"https://openalex.org/W3151552372\",\"https://openalex.org/W3118276045\",\"https://openalex.org/W2032842463\",\"https://openalex.org/W2149259509\",\"https://openalex.org/W2980754698\",\"https://openalex.org/W2793501551\",\"https://openalex.org/W1899889838\",\"https://openalex.org/W2017268270\",\"https://openalex.org/W2997318819\",\"https://openalex.org/W3067641665\",\"https://openalex.org/W4384296800\",\"https://openalex.org/W3104621343\",\"https://openalex.org/W3034639723\",\"https://openalex.org/W4281913335\",\"https://openalex.org/W2135592618\",\"https://openalex.org/W2754967293\",\"https://openalex.org/W4385803674\",\"https://openalex.org/W3008443509\",\"https://openalex.org/W4323349858\",\"https://openalex.org/W2081388499\",\"https://openalex.org/W2906835093\",\"https://openalex.org/W4308435312\",\"https://openalex.org/W4323662020\",\"https://openalex.org/W2003877984\",\"https://openalex.org/W1997183854\",\"https://openalex.org/W3154462320\",\"https://openalex.org/W4321452638\",\"https://openalex.org/W3119600319\",\"https://openalex.org/W3122374666\",\"https://openalex.org/W2791252329\",\"https://openalex.org/W4383619176\",\"https://openalex.org/W2012940782\",\"https://openalex.org/W4280644450\",\"https://openalex.org/W2727376740\",\"https://openalex.org/W3100152956\",\"https://openalex.org/W2583594489\",\"https://openalex.org/W4365149913\",\"https://openalex.org/W2218708885\",\"https://openalex.org/W2342797086\",\"https://openalex.org/W4224219095\",\"https://openalex.org/W4214930996\",\"https://openalex.org/W4207044541\",\"https://openalex.org/W2479133500\",\"https://openalex.org/W2947836101\",\"https://openalex.org/W4223545467\",\"https://openalex.org/W2946373463\",\"https://openalex.org/W3022473425\",\"https://openalex.org/W2168357345\",\"https://openalex.org/W4306666890\",\"https://openalex.org/W3045828365\",\"https://openalex.org/W4365443039\",\"https://openalex.org/W4315650748\",\"https://openalex.org/W4220874791\",\"https://openalex.org/W2103139149\",\"https://openalex.org/W2512777378\",\"https://openalex.org/W1549622883\",\"https://openalex.org/W2004922338\",\"https://openalex.org/W4386162250\",\"https://openalex.org/W4302362360\",\"https://openalex.org/W2080785707\",\"https://openalex.org/W2066463950\",\"https://openalex.org/W4213007972\",\"https://openalex.org/W4296038731\",\"https://openalex.org/W4281696767\",\"https://openalex.org/W2034632760\",\"https://openalex.org/W2923105176\",\"https://openalex.org/W4284959721\",\"https://openalex.org/W3000061011\",\"https://openalex.org/W1674770932\",\"https://openalex.org/W6804553360\",\"https://openalex.org/W2801042920\",\"https://openalex.org/W3091839870\",\"https://openalex.org/W2789374385\",\"https://openalex.org/W2592016869\",\"https://openalex.org/W3132094379\",\"https://openalex.org/W1983756252\",\"https://openalex.org/W1995954863\",\"https://openalex.org/W2940884097\",\"https://openalex.org/W4380739173\",\"https://openalex.org/W2771082365\",\"https://openalex.org/W2956004144\",\"https://openalex.org/W2883622519\",\"https://openalex.org/W1998933601\",\"https://openalex.org/W4226150259\",\"https://openalex.org/W2568890276\",\"https://openalex.org/W2987960305\",\"https://openalex.org/W4382937517\",\"https://openalex.org/W2606546398\",\"https://openalex.org/W2169156123\",\"https://openalex.org/W3158832995\",\"https://openalex.org/W3093367575\",\"https://openalex.org/W2012259571\",\"https://openalex.org/W2004069543\",\"https://openalex.org/W3201084360\",\"https://openalex.org/W2589161214\",\"https://openalex.org/W2153055836\",\"https://openalex.org/W1973756832\",\"https://openalex.org/W2052366303\",\"https://openalex.org/W4206046172\",\"https://openalex.org/W4387761639\",\"https://openalex.org/W3200557486\",\"https://openalex.org/W1989342312\",\"https://openalex.org/W3135161880\",\"https://openalex.org/W4317396521\",\"https://openalex.org/W2600991905\",\"https://openalex.org/W1527671059\",\"https://openalex.org/W3134615608\",\"https://openalex.org/W2762087180\",\"https://openalex.org/W2243731995\",\"https://openalex.org/W3026217555\",\"https://openalex.org/W4214833982\",\"https://openalex.org/W4315707278\",\"https://openalex.org/W2125872855\",\"https://openalex.org/W2724590586\",\"https://openalex.org/W2903322143\",\"https://openalex.org/W1964045660\",\"https://openalex.org/W2798230823\",\"https://openalex.org/W3037497912\",\"https://openalex.org/W6779774112\",\"https://openalex.org/W4310023518\",\"https://openalex.org/W1913024756\",\"https://openalex.org/W2033726284\",\"https://openalex.org/W3127839532\",\"https://openalex.org/W2508296626\",\"https://openalex.org/W3086250786\",\"https://openalex.org/W2807256450\",\"https://openalex.org/W2212256215\",\"https://openalex.org/W4294884802\",\"https://openalex.org/W4214824579\",\"https://openalex.org/W3036617720\",\"https://openalex.org/W4206774749\"],\"related_works\":[\"https://openalex.org/W2077655479\",\"https://openalex.org/W2095198015\",\"https://openalex.org/W2995727304\",\"https://openalex.org/W1517805603\",\"https://openalex.org/W123747276\",\"https://openalex.org/W1593223226\",\"https://openalex.org/W1988725105\",\"https://openalex.org/W2034773528\",\"https://openalex.org/W4295886409\",\"https://openalex.org/W2011757937\"],\"abstract_inverted_index\":{\"Alzheimer\\'s\":[0],\"and\":[1,20,37,44,61,78,100,103,120,133,155,162,177,187],\"Parkinson\\'s\":[2],\"diseases\":[3],\"are\":[4,17],\"two\":[5],\"of\":[6,15,55,82,95,98,118,146,153,159,171,175],\"the\":[7,53,70,80,116,144,151,157,172,181],\"most\":[8],\"frequent\":[9],\"neurological\":[10],\"diseases.\":[11],\"The\":[12],\"clinical\":[13],\"features\":[14],\"AD\":[16,56,119,154,176],\"memory\":[18],\"decline\":[19],\"cognitive\":[21],\"dysfunction,\":[22],\"while\":[23],\"PD\":[24,91,121,178],\"mainly\":[25],\"manifests\":[26],\"as\":[27,31],\"motor\":[28],\"dysfunction\":[29,97],\"such\":[30],\"limb\":[32],\"tremors,\":[33],\"muscle\":[34],\"rigidity\":[35],\"abnormalities,\":[36],\"slow\":[38],\"gait.\":[39],\"Abnormalities\":[40],\"in\":[41,110,122,150],\"cholesterol,\":[42],\"sphingolipid,\":[43],\"glycerophospholipid\":[45],\"metabolism\":[46,88,113,149],\"have\":[47],\"been\":[48,108],\"demonstrated\":[49],\"to\":[50,90],\"directly\":[51],\"exacerbate\":[52],\"progression\":[54],\"by\":[57],\"stimulating\":[58],\"A\\\\u03b2\":[59],\"deposition\":[60],\"tau\":[62],\"protein\":[63],\"tangles.\":[64],\"Indirectly,\":[65],\"abnormal\":[66],\"lipids\":[67],\"can\":[68],\"increase\":[69],\"burden\":[71],\"on\":[72],\"brain\":[73],\"vasculature,\":[74],\"induce\":[75],\"insulin\":[76],\"resistance,\":[77],\"affect\":[79],\"structure\":[81],\"neuronal\":[83],\"cell\":[84],\"membranes.\":[85],\"Abnormal\":[86],\"lipid\":[87,112,148,164],\"leads\":[89],\"through\":[92],\"inducing\":[93],\"accumulation\":[94],\"\\\\u03b1-syn,\":[96],\"mitochondria\":[99],\"endoplasmic\":[101],\"reticulum,\":[102],\"ferroptosis.\":[104],\"Great\":[105],\"progress\":[106],\"has\":[107],\"made\":[109],\"targeting\":[111,136],\"abnormalities\":[114],\"for\":[115,183,190],\"treatment\":[117,188],\"recent\":[123],\"years,\":[124],\"like\":[125],\"metformin,\":[126],\"insulin,\":[127],\"peroxisome\":[128],\"proliferator-activated\":[129],\"receptors\":[130],\"(PPARs)\":[131],\"agonists,\":[132],\"monoclonal\":[134],\"antibodies\":[135],\"apolipoprotein\":[137],\"E\":[138],\"(ApoE).\":[139],\"This\":[140],\"review\":[141],\"comprehensively\":[142],\"summarizes\":[143],\"involvement\":[145],\"dysregulated\":[147],\"pathogenesis\":[152],\"PD,\":[156],\"application\":[158],\"Lipid\":[160],\"Monitoring,\":[161],\"emerging\":[163],\"regulatory\":[165],\"drug\":[166],\"targets.\":[167],\"A\":[168],\"better\":[169],\"understanding\":[170],\"lipidological\":[173],\"bases\":[174],\"may\":[179],\"pave\":[180],\"way\":[182],\"developing\":[184],\"effective\":[185],\"prevention\":[186],\"methods\":[189],\"neurodegenerative\":[191],\"disorders.\":[192]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":49},{\"year\":2024,\"cited_by_count\":11}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4387023253\",\"doi\":\"https://doi.org/10.4103/1673-5374.385847\",\"title\":\"Targeting tau in Alzheimer\\'s disease: from mechanisms to clinical therapy\",\"display_name\":\"Targeting tau in Alzheimer\\'s disease: from mechanisms to clinical therapy\",\"relevance_score\":154.3808,\"publication_year\":2023,\"publication_date\":\"2023-09-22\",\"ids\":{\"openalex\":\"https://openalex.org/W4387023253\",\"doi\":\"https://doi.org/10.4103/1673-5374.385847\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/38051891\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.4103/1673-5374.385847\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.4103/1673-5374.385847\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S80372421\",\"display_name\":\"Neural Regeneration Research\",\"issn_l\":\"1673-5374\",\"issn\":[\"1673-5374\",\"1876-7958\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320448\",\"host_organization_name\":\"Medknow\",\"host_organization_lineage\":[\"https://openalex.org/P4310320448\",\"https://openalex.org/P4310318547\"],\"host_organization_lineage_names\":[\"Medknow\",\"Wolters Kluwer\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-sa\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neural Regeneration Research\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://doi.org/10.4103/1673-5374.385847\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5030854045\",\"display_name\":\"Jinwang Ye\",\"orcid\":\"https://orcid.org/0000-0003-2119-8354\"},\"institutions\":[{\"id\":\"https://openalex.org/I180726961\",\"display_name\":\"Shenzhen University\",\"ror\":\"https://ror.org/01vy4gh70\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I180726961\"]},{\"id\":\"https://openalex.org/I4210119046\",\"display_name\":\"Zero to Three\",\"ror\":\"https://ror.org/01qvk6016\",\"country_code\":\"US\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210119046\"]}],\"countries\":[\"CN\",\"US\"],\"is_corresponding\":true,\"raw_author_name\":\"Jinwang Ye\",\"raw_affiliation_strings\":[\"Both authors contribute equally to this work.\",\"Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong Province, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Both authors contribute equally to this work.\",\"institution_ids\":[\"https://openalex.org/I4210119046\"]},{\"raw_affiliation_string\":\"Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong Province, China\",\"institution_ids\":[\"https://openalex.org/I180726961\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5056593512\",\"display_name\":\"Huali Wan\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210145693\",\"display_name\":\"Guangdong Academy of Medical Sciences\",\"ror\":\"https://ror.org/0432p8t34\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210145693\"]},{\"id\":\"https://openalex.org/I4210153930\",\"display_name\":\"Guangdong Provincial People\\'s Hospital\",\"ror\":\"https://ror.org/045kpgw45\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210153930\"]},{\"id\":\"https://openalex.org/I58200834\",\"display_name\":\"Southern Medical University\",\"ror\":\"https://ror.org/01vjw4z39\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58200834\"]},{\"id\":\"https://openalex.org/I4210119046\",\"display_name\":\"Zero to Three\",\"ror\":\"https://ror.org/01qvk6016\",\"country_code\":\"US\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210119046\"]}],\"countries\":[\"CN\",\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Huali Wan\",\"raw_affiliation_strings\":[\"Both authors contribute equally to this work.\",\"Department of Laboratory Medicine, Guangdong Provincial People\\'s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Laboratory Medicine, Guangdong Provincial People\\'s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, China\",\"institution_ids\":[\"https://openalex.org/I4210145693\",\"https://openalex.org/I4210153930\",\"https://openalex.org/I58200834\"]},{\"raw_affiliation_string\":\"Both authors contribute equally to this work.\",\"institution_ids\":[\"https://openalex.org/I4210119046\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5033464172\",\"display_name\":\"Sihua Chen\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I180726961\",\"display_name\":\"Shenzhen University\",\"ror\":\"https://ror.org/01vy4gh70\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I180726961\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Sihua Chen\",\"raw_affiliation_strings\":[\"Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong Province, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Shenzhen Key Laboratory of Marine Biotechnology and Ecology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong Province, China\",\"institution_ids\":[\"https://openalex.org/I180726961\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5050770630\",\"display_name\":\"Gong\\\\u2010Ping Liu\",\"orcid\":\"https://orcid.org/0000-0001-8501-998X\"},\"institutions\":[{\"id\":\"https://openalex.org/I47720641\",\"display_name\":\"Huazhong University of Science and Technology\",\"ror\":\"https://ror.org/00p991c53\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I47720641\"]},{\"id\":\"https://openalex.org/I199305430\",\"display_name\":\"Nantong University\",\"ror\":\"https://ror.org/02afcvw97\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I199305430\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Gong-Ping Liu\",\"raw_affiliation_strings\":[\"Co-innovation Center of Neurodegeneration, Nantong University, Nantong, Jiangsu Province, China\",\"Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Co-innovation Center of Neurodegeneration, Nantong University, Nantong, Jiangsu Province, China\",\"institution_ids\":[\"https://openalex.org/I199305430\"]},{\"raw_affiliation_string\":\"Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China\",\"institution_ids\":[\"https://openalex.org/I47720641\"]}]}],\"institutions\":[],\"countries_distinct_count\":2,\"institutions_distinct_count\":4,\"corresponding_author_ids\":[\"https://openalex.org/A5050770630\",\"https://openalex.org/A5030854045\"],\"corresponding_institution_ids\":[\"https://openalex.org/I180726961\",\"https://openalex.org/I199305430\",\"https://openalex.org/I4210119046\",\"https://openalex.org/I47720641\"],\"apc_list\":{\"value\":1500,\"currency\":\"USD\",\"value_usd\":1500},\"apc_paid\":{\"value\":1500,\"currency\":\"USD\",\"value_usd\":1500},\"fwci\":13.68489255,\"has_fulltext\":false,\"cited_by_count\":46,\"citation_normalized_percentile\":{\"value\":0.98750298,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":89,\"max\":100},\"biblio\":{\"volume\":\"19\",\"issue\":\"7\",\"first_page\":\"1489\",\"last_page\":\"1498\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.9987999796867371,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11266\",\"display_name\":\"Neuroinflammation and Neurodegeneration Mechanisms\",\"score\":0.9919999837875366,\"subfield\":{\"id\":\"https://openalex.org/subfields/2808\",\"display_name\":\"Neurology\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/neurodegeneration\",\"display_name\":\"Neurodegeneration\",\"score\":0.8503458499908447},{\"id\":\"https://openalex.org/keywords/tau-protein\",\"display_name\":\"Tau protein\",\"score\":0.723767876625061},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.549958348274231},{\"id\":\"https://openalex.org/keywords/alzheimers-disease\",\"display_name\":\"Alzheimer\\'s disease\",\"score\":0.5168153047561646},{\"id\":\"https://openalex.org/keywords/hyperphosphorylation\",\"display_name\":\"Hyperphosphorylation\",\"score\":0.4689081907272339},{\"id\":\"https://openalex.org/keywords/senile-plaques\",\"display_name\":\"Senile plaques\",\"score\":0.4569767415523529},{\"id\":\"https://openalex.org/keywords/amyloid\",\"display_name\":\"Amyloid (mycology)\",\"score\":0.4544740617275238},{\"id\":\"https://openalex.org/keywords/biochemistry-of-alzheimers-disease\",\"display_name\":\"Biochemistry of Alzheimer\\'s disease\",\"score\":0.44338458776474},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.42823994159698486},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.38110867142677307},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.373302698135376},{\"id\":\"https://openalex.org/keywords/amyloid-precursor-protein\",\"display_name\":\"Amyloid precursor protein\",\"score\":0.3705434203147888},{\"id\":\"https://openalex.org/keywords/phosphorylation\",\"display_name\":\"Phosphorylation\",\"score\":0.2892761826515198},{\"id\":\"https://openalex.org/keywords/pathology\",\"display_name\":\"Pathology\",\"score\":0.2696038484573364},{\"id\":\"https://openalex.org/keywords/cell-biology\",\"display_name\":\"Cell biology\",\"score\":0.23614701628684998}],\"concepts\":[{\"id\":\"https://openalex.org/C2776925932\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1755122\",\"display_name\":\"Neurodegeneration\",\"level\":3,\"score\":0.8503458499908447},{\"id\":\"https://openalex.org/C2778670691\",\"wikidata\":\"https://www.wikidata.org/wiki/Q419507\",\"display_name\":\"Tau protein\",\"level\":4,\"score\":0.723767876625061},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.549958348274231},{\"id\":\"https://openalex.org/C502032728\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11081\",\"display_name\":\"Alzheimer\\'s disease\",\"level\":3,\"score\":0.5168153047561646},{\"id\":\"https://openalex.org/C2778198054\",\"wikidata\":\"https://www.wikidata.org/wiki/Q15195154\",\"display_name\":\"Hyperphosphorylation\",\"level\":3,\"score\":0.4689081907272339},{\"id\":\"https://openalex.org/C68026918\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1970256\",\"display_name\":\"Senile plaques\",\"level\":4,\"score\":0.4569767415523529},{\"id\":\"https://openalex.org/C2777633098\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2736051\",\"display_name\":\"Amyloid (mycology)\",\"level\":2,\"score\":0.4544740617275238},{\"id\":\"https://openalex.org/C180081513\",\"wikidata\":\"https://www.wikidata.org/wiki/Q4914721\",\"display_name\":\"Biochemistry of Alzheimer\\'s disease\",\"level\":5,\"score\":0.44338458776474},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.42823994159698486},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.38110867142677307},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.373302698135376},{\"id\":\"https://openalex.org/C31705614\",\"wikidata\":\"https://www.wikidata.org/wiki/Q423510\",\"display_name\":\"Amyloid precursor protein\",\"level\":4,\"score\":0.3705434203147888},{\"id\":\"https://openalex.org/C11960822\",\"wikidata\":\"https://www.wikidata.org/wiki/Q242736\",\"display_name\":\"Phosphorylation\",\"level\":2,\"score\":0.2892761826515198},{\"id\":\"https://openalex.org/C142724271\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7208\",\"display_name\":\"Pathology\",\"level\":1,\"score\":0.2696038484573364},{\"id\":\"https://openalex.org/C95444343\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7141\",\"display_name\":\"Cell biology\",\"level\":1,\"score\":0.23614701628684998}],\"mesh\":[],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.4103/1673-5374.385847\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.4103/1673-5374.385847\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S80372421\",\"display_name\":\"Neural Regeneration Research\",\"issn_l\":\"1673-5374\",\"issn\":[\"1673-5374\",\"1876-7958\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320448\",\"host_organization_name\":\"Medknow\",\"host_organization_lineage\":[\"https://openalex.org/P4310320448\",\"https://openalex.org/P4310318547\"],\"host_organization_lineage_names\":[\"Medknow\",\"Wolters Kluwer\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-sa\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neural Regeneration Research\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:38051891\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/38051891\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neural regeneration research\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:10883484\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/10883484\",\"pdf_url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10883484/pdf/NRR-19-1489.pdf\",\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-nc-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-sa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Neural Regen Res\",\"raw_type\":\"Text\"},{\"id\":\"pmh:oai:doaj.org/article:51fe74dfcc27414db5d0886d6638cd6c\",\"is_oa\":false,\"landing_page_url\":\"https://doaj.org/article/51fe74dfcc27414db5d0886d6638cd6c\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Neural Regeneration Research, Vol 19, Iss 7, Pp 1489-1498 (2024)\",\"raw_type\":\"article\"}],\"best_oa_location\":{\"id\":\"doi:10.4103/1673-5374.385847\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.4103/1673-5374.385847\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S80372421\",\"display_name\":\"Neural Regeneration Research\",\"issn_l\":\"1673-5374\",\"issn\":[\"1673-5374\",\"1876-7958\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320448\",\"host_organization_name\":\"Medknow\",\"host_organization_lineage\":[\"https://openalex.org/P4310320448\",\"https://openalex.org/P4310318547\"],\"host_organization_lineage_names\":[\"Medknow\",\"Wolters Kluwer\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-sa\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neural Regeneration Research\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.7699999809265137,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":202,\"referenced_works\":[\"https://openalex.org/W2884643339\",\"https://openalex.org/W3033431998\",\"https://openalex.org/W2942813518\",\"https://openalex.org/W4294550854\",\"https://openalex.org/W4205239057\",\"https://openalex.org/W3005492459\",\"https://openalex.org/W2190404250\",\"https://openalex.org/W2121713269\",\"https://openalex.org/W3012272172\",\"https://openalex.org/W4298109598\",\"https://openalex.org/W2134028802\",\"https://openalex.org/W2353776455\",\"https://openalex.org/W4225315599\",\"https://openalex.org/W2982627322\",\"https://openalex.org/W3154991192\",\"https://openalex.org/W2067485575\",\"https://openalex.org/W1990986671\",\"https://openalex.org/W2610352112\",\"https://openalex.org/W2804439626\",\"https://openalex.org/W6848671853\",\"https://openalex.org/W2991354941\",\"https://openalex.org/W1998344552\",\"https://openalex.org/W2118101413\",\"https://openalex.org/W2808028315\",\"https://openalex.org/W1973401711\",\"https://openalex.org/W2138795173\",\"https://openalex.org/W2005759199\",\"https://openalex.org/W2903973081\",\"https://openalex.org/W2795504192\",\"https://openalex.org/W3191692701\",\"https://openalex.org/W2088185367\",\"https://openalex.org/W340652394\",\"https://openalex.org/W2022285303\",\"https://openalex.org/W3078141069\",\"https://openalex.org/W2082970812\",\"https://openalex.org/W4200077158\",\"https://openalex.org/W2911248861\",\"https://openalex.org/W2951019346\",\"https://openalex.org/W1532078866\",\"https://openalex.org/W4362452437\",\"https://openalex.org/W2019219179\",\"https://openalex.org/W2796828859\",\"https://openalex.org/W1509571186\",\"https://openalex.org/W2148570557\",\"https://openalex.org/W2750379609\",\"https://openalex.org/W3170190396\",\"https://openalex.org/W3127967490\",\"https://openalex.org/W3156936349\",\"https://openalex.org/W3133453048\",\"https://openalex.org/W3114163999\",\"https://openalex.org/W1968553823\",\"https://openalex.org/W2290400089\",\"https://openalex.org/W2554598802\",\"https://openalex.org/W2022532556\",\"https://openalex.org/W3180805748\",\"https://openalex.org/W4304481342\",\"https://openalex.org/W3158856741\",\"https://openalex.org/W3214109787\",\"https://openalex.org/W1985090720\",\"https://openalex.org/W3081654023\",\"https://openalex.org/W2994094700\",\"https://openalex.org/W1984939118\",\"https://openalex.org/W3180978278\",\"https://openalex.org/W3139430110\",\"https://openalex.org/W6838564454\",\"https://openalex.org/W1590917599\",\"https://openalex.org/W2744353305\",\"https://openalex.org/W1601433695\",\"https://openalex.org/W3111151889\",\"https://openalex.org/W3123054665\",\"https://openalex.org/W2108549874\",\"https://openalex.org/W6675332501\",\"https://openalex.org/W3135733909\",\"https://openalex.org/W3154112996\",\"https://openalex.org/W4210866627\",\"https://openalex.org/W4296101830\",\"https://openalex.org/W2341603395\",\"https://openalex.org/W2944387674\",\"https://openalex.org/W2572710398\",\"https://openalex.org/W2899927624\",\"https://openalex.org/W2164029759\",\"https://openalex.org/W2171758504\",\"https://openalex.org/W2146647866\",\"https://openalex.org/W2102479656\",\"https://openalex.org/W2156073394\",\"https://openalex.org/W2560024672\",\"https://openalex.org/W2978630201\",\"https://openalex.org/W3085498329\",\"https://openalex.org/W1522284801\",\"https://openalex.org/W1541944730\",\"https://openalex.org/W1996406602\",\"https://openalex.org/W2168681379\",\"https://openalex.org/W4212914340\",\"https://openalex.org/W4308469604\",\"https://openalex.org/W3182356919\",\"https://openalex.org/W4285724952\",\"https://openalex.org/W2563169901\",\"https://openalex.org/W2901340183\",\"https://openalex.org/W2795642715\",\"https://openalex.org/W1983523416\",\"https://openalex.org/W2182763281\",\"https://openalex.org/W4310773157\",\"https://openalex.org/W2012781495\",\"https://openalex.org/W3036210937\",\"https://openalex.org/W2229830115\",\"https://openalex.org/W2909649716\",\"https://openalex.org/W6642437410\",\"https://openalex.org/W1919353\",\"https://openalex.org/W2559946394\",\"https://openalex.org/W3167556772\",\"https://openalex.org/W4313625436\",\"https://openalex.org/W3045997188\",\"https://openalex.org/W2000655392\",\"https://openalex.org/W3012646333\",\"https://openalex.org/W2168079270\",\"https://openalex.org/W2617930056\",\"https://openalex.org/W2290722071\",\"https://openalex.org/W3120101889\",\"https://openalex.org/W4292583665\",\"https://openalex.org/W4212950915\",\"https://openalex.org/W2081768153\",\"https://openalex.org/W3014222043\",\"https://openalex.org/W2093227585\",\"https://openalex.org/W2047163245\",\"https://openalex.org/W3101430868\",\"https://openalex.org/W2229426556\",\"https://openalex.org/W2046196399\",\"https://openalex.org/W2001428953\",\"https://openalex.org/W2044799286\",\"https://openalex.org/W3013878630\",\"https://openalex.org/W2971696841\",\"https://openalex.org/W2754798875\",\"https://openalex.org/W2049146362\",\"https://openalex.org/W1561023982\",\"https://openalex.org/W4214677932\",\"https://openalex.org/W2883780404\",\"https://openalex.org/W2914862125\",\"https://openalex.org/W3152963650\",\"https://openalex.org/W1974068776\",\"https://openalex.org/W4324129007\",\"https://openalex.org/W2995638148\",\"https://openalex.org/W195118146\",\"https://openalex.org/W2045374982\",\"https://openalex.org/W2032095475\",\"https://openalex.org/W4280641207\",\"https://openalex.org/W4282547758\",\"https://openalex.org/W2327032644\",\"https://openalex.org/W4206572489\",\"https://openalex.org/W4306729263\",\"https://openalex.org/W3096112623\",\"https://openalex.org/W4366824412\",\"https://openalex.org/W2072662321\",\"https://openalex.org/W2838969028\",\"https://openalex.org/W4310461604\",\"https://openalex.org/W2030602441\",\"https://openalex.org/W2010907557\",\"https://openalex.org/W2143996951\",\"https://openalex.org/W3136419100\",\"https://openalex.org/W4223521725\",\"https://openalex.org/W2002930469\",\"https://openalex.org/W2023926705\",\"https://openalex.org/W3025571398\",\"https://openalex.org/W3118652952\",\"https://openalex.org/W3037497912\",\"https://openalex.org/W3029234273\",\"https://openalex.org/W3139364923\",\"https://openalex.org/W2089141103\",\"https://openalex.org/W3048816596\",\"https://openalex.org/W3031176037\",\"https://openalex.org/W2747562354\",\"https://openalex.org/W3155966446\",\"https://openalex.org/W2953812575\",\"https://openalex.org/W4292415786\",\"https://openalex.org/W2966517161\",\"https://openalex.org/W4310024009\",\"https://openalex.org/W3102160053\",\"https://openalex.org/W2007472518\",\"https://openalex.org/W3021166500\",\"https://openalex.org/W4300979984\",\"https://openalex.org/W1990280689\",\"https://openalex.org/W2085078083\",\"https://openalex.org/W4287009192\",\"https://openalex.org/W2985852763\",\"https://openalex.org/W2429713509\",\"https://openalex.org/W2059207866\",\"https://openalex.org/W1755998818\",\"https://openalex.org/W2899319078\",\"https://openalex.org/W2026077861\",\"https://openalex.org/W2599676172\",\"https://openalex.org/W4294884802\",\"https://openalex.org/W2530330371\",\"https://openalex.org/W3180812375\",\"https://openalex.org/W2589104144\",\"https://openalex.org/W4220970963\",\"https://openalex.org/W4294169024\",\"https://openalex.org/W2901667029\",\"https://openalex.org/W1968641736\",\"https://openalex.org/W2100359094\",\"https://openalex.org/W4292865371\",\"https://openalex.org/W2082429191\",\"https://openalex.org/W4281294723\",\"https://openalex.org/W4313225630\"],\"related_works\":[\"https://openalex.org/W2349405660\",\"https://openalex.org/W2419396135\",\"https://openalex.org/W1991130877\",\"https://openalex.org/W2741230928\",\"https://openalex.org/W1997515239\",\"https://openalex.org/W2139018071\",\"https://openalex.org/W4220686120\",\"https://openalex.org/W2062914907\",\"https://openalex.org/W3142852359\",\"https://openalex.org/W1484463237\"],\"abstract_inverted_index\":{\"Abstract\":[0],\"Alzheimer\\'s\":[1,15,45,66,129,195,202],\"disease\":[2,8,16,196],\"is\":[3],\"the\":[4,24,34,42,81,108,137,179,183,190],\"most\":[5],\"prevalent\":[6],\"neurodegenerative\":[7],\"affecting\":[9],\"older\":[10],\"adults.\":[11],\"Primary\":[12],\"features\":[13],\"of\":[14,20,26,44,62,83,99,105,136,186,194,201],\"include\":[17],\"extracellular\":[18],\"aggregation\":[19],\"amyloid-\\\\u03b2\":[21,106],\"plaques\":[22],\"and\":[23,51,86,120,127,149,157,167,173,192,197],\"accumulation\":[25,104],\"neurofibrillary\":[27],\"tangles,\":[28],\"formed\":[29],\"by\":[30],\"tau\":[31,63,74,100,114,138,187],\"protein,\":[32,73,139],\"in\":[33,65,79,107,133,189],\"cells.\":[35],\"While\":[36],\"there\":[37],\"are\":[38,49,121],\"amyloid-\\\\u03b2-targeting\":[39],\"therapies\":[40,48],\"for\":[41],\"treatment\":[43,200],\"disease,\":[46],\"these\":[47],\"costly\":[50],\"exhibit\":[52],\"potential\":[53],\"negative\":[54],\"side\":[55],\"effects.\":[56],\"Mounting\":[57],\"evidence\":[58],\"suggests\":[59],\"significant\":[60],\"involvement\":[61],\"protein\":[64,101,115,188],\"disease-related\":[67],\"neurodegeneration.\":[68],\"As\":[69],\"an\":[70,76],\"important\":[71,77],\"microtubule-associated\":[72],\"plays\":[75],\"role\":[78],\"maintaining\":[80],\"stability\":[82],\"neuronal\":[84],\"microtubules\":[85],\"promoting\":[87],\"axonal\":[88],\"growth.\":[89],\"In\":[90],\"fact,\":[91],\"clinical\":[92],\"studies\":[93],\"have\":[94,116],\"shown\":[95],\"that\":[96],\"abnormal\":[97],\"phosphorylation\":[98],\"occurs\":[102],\"before\":[103],\"brain.\":[109],\"Various\":[110],\"therapeutic\":[111],\"strategies\":[112],\"targeting\":[113],\"begun\":[117],\"to\":[118,125,152,171],\"emerge,\":[119],\"considered\":[122],\"possible\":[123],\"methods\":[124],\"prevent\":[126],\"treat\":[128],\"disease.\":[130,203],\"Specifically,\":[131],\"abnormalities\":[132],\"post-translational\":[134],\"modifications\":[135],\"including\":[140],\"aberrant\":[141],\"phosphorylation,\":[142],\"ubiquitination,\":[143],\"small\":[144],\"ubiquitin-like\":[145],\"modifier\":[146],\"(SUMO)ylation,\":[147],\"acetylation,\":[148],\"truncation,\":[150],\"contribute\":[151],\"its\":[153],\"microtubule\":[154],\"dissociation,\":[155],\"misfolding,\":[156],\"subcellular\":[158],\"missorting.\":[159],\"This\":[160,176],\"causes\":[161],\"mitochondrial\":[162],\"damage,\":[163],\"synaptic\":[164],\"impairments,\":[165],\"gliosis,\":[166],\"neuroinflammation,\":[168],\"eventually\":[169],\"leading\":[170],\"neurodegeneration\":[172],\"cognitive\":[174],\"deficits.\":[175],\"review\":[177],\"summarizes\":[178],\"recent\":[180],\"findings\":[181],\"on\":[182],\"underlying\":[184],\"mechanisms\":[185],\"onset\":[191],\"progression\":[193],\"discusses\":[198],\"tau-targeted\":[199]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":30},{\"year\":2024,\"cited_by_count\":15},{\"year\":2023,\"cited_by_count\":1}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4211075592\",\"doi\":\"https://doi.org/10.1016/j.apsb.2022.02.001\",\"title\":\"Intelligent lesion blood\\\\u2013brain barrier targeting nano-missiles for Alzheimer\\'s disease treatment by anti-neuroinflammation and neuroprotection\",\"display_name\":\"Intelligent lesion blood\\\\u2013brain barrier targeting nano-missiles for Alzheimer\\'s disease treatment by anti-neuroinflammation and neuroprotection\",\"relevance_score\":151.7437,\"publication_year\":2022,\"publication_date\":\"2022-02-09\",\"ids\":{\"openalex\":\"https://openalex.org/W4211075592\",\"doi\":\"https://doi.org/10.1016/j.apsb.2022.02.001\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/35847512\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.apsb.2022.02.001\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.apsb.2022.02.001\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2736993989\",\"display_name\":\"Acta Pharmaceutica Sinica B\",\"issn_l\":\"2211-3835\",\"issn\":[\"2211-3835\",\"2211-3843\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Acta Pharmaceutica Sinica B\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"diamond\",\"oa_url\":\"https://doi.org/10.1016/j.apsb.2022.02.001\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5004744817\",\"display_name\":\"Xueqin He\",\"orcid\":\"https://orcid.org/0000-0002-1480-2026\"},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Xueqin He\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100641033\",\"display_name\":\"Xiaorong Wang\",\"orcid\":\"https://orcid.org/0009-0007-6700-1277\"},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Xiaorong Wang\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5016176280\",\"display_name\":\"Lianyi Yang\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Lianyi Yang\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100436454\",\"display_name\":\"Zhihang Yang\",\"orcid\":\"https://orcid.org/0000-0002-7675-0401\"},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Zhihang Yang\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5054404772\",\"display_name\":\"Wenqi Yu\",\"orcid\":\"https://orcid.org/0000-0002-1891-4703\"},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Wenqi Yu\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100650495\",\"display_name\":\"Yazhen Wang\",\"orcid\":\"https://orcid.org/0000-0003-0502-5146\"},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yazhen Wang\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100448557\",\"display_name\":\"Rui Liu\",\"orcid\":\"https://orcid.org/0000-0002-8578-0733\"},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Rui Liu\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5103103310\",\"display_name\":\"Meiwan Chen\",\"orcid\":\"https://orcid.org/0000-0002-8642-5979\"},\"institutions\":[{\"id\":\"https://openalex.org/I204512498\",\"display_name\":\"University of Macau\",\"ror\":\"https://ror.org/01r4q9n85\",\"country_code\":\"MO\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I204512498\"]}],\"countries\":[\"MO\"],\"is_corresponding\":false,\"raw_author_name\":\"Meiwan Chen\",\"raw_affiliation_strings\":[\"State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China\",\"institution_ids\":[\"https://openalex.org/I204512498\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5100624428\",\"display_name\":\"Huile Gao\",\"orcid\":\"https://orcid.org/0000-0002-5355-7238\"},\"institutions\":[{\"id\":\"https://openalex.org/I24185976\",\"display_name\":\"Sichuan University\",\"ror\":\"https://ror.org/011ashp19\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I24185976\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Huile Gao\",\"raw_affiliation_strings\":[\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China\",\"institution_ids\":[\"https://openalex.org/I24185976\"]}]}],\"institutions\":[],\"countries_distinct_count\":2,\"institutions_distinct_count\":9,\"corresponding_author_ids\":[\"https://openalex.org/A5100624428\"],\"corresponding_institution_ids\":[\"https://openalex.org/I24185976\"],\"apc_list\":null,\"apc_paid\":null,\"fwci\":14.00071677,\"has_fulltext\":false,\"cited_by_count\":78,\"citation_normalized_percentile\":{\"value\":0.98839942,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":99,\"max\":100},\"biblio\":{\"volume\":\"12\",\"issue\":\"4\",\"first_page\":\"1987\",\"last_page\":\"1999\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9997000098228455,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9997000098228455,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11266\",\"display_name\":\"Neuroinflammation and Neurodegeneration Mechanisms\",\"score\":0.9993000030517578,\"subfield\":{\"id\":\"https://openalex.org/subfields/2808\",\"display_name\":\"Neurology\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T11872\",\"display_name\":\"Barrier Structure and Function Studies\",\"score\":0.9969000220298767,\"subfield\":{\"id\":\"https://openalex.org/subfields/2808\",\"display_name\":\"Neurology\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/neuroinflammation\",\"display_name\":\"Neuroinflammation\",\"score\":0.9158775210380554},{\"id\":\"https://openalex.org/keywords/neuroprotection\",\"display_name\":\"Neuroprotection\",\"score\":0.8338673710823059},{\"id\":\"https://openalex.org/keywords/lesion\",\"display_name\":\"Lesion\",\"score\":0.6335400342941284},{\"id\":\"https://openalex.org/keywords/blood\\\\u2013brain-barrier\",\"display_name\":\"Blood\\\\u2013brain barrier\",\"score\":0.6034736633300781},{\"id\":\"https://openalex.org/keywords/neurotoxicity\",\"display_name\":\"Neurotoxicity\",\"score\":0.5461318492889404},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.5455619096755981},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.5418357253074646},{\"id\":\"https://openalex.org/keywords/neurodegeneration\",\"display_name\":\"Neurodegeneration\",\"score\":0.47262927889823914},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.452333927154541},{\"id\":\"https://openalex.org/keywords/inflammation\",\"display_name\":\"Inflammation\",\"score\":0.3521748185157776},{\"id\":\"https://openalex.org/keywords/central-nervous-system\",\"display_name\":\"Central nervous system\",\"score\":0.316877543926239},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.2691381871700287},{\"id\":\"https://openalex.org/keywords/immunology\",\"display_name\":\"Immunology\",\"score\":0.2263331115245819},{\"id\":\"https://openalex.org/keywords/pathology\",\"display_name\":\"Pathology\",\"score\":0.22044846415519714},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.19281330704689026},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.18342885375022888},{\"id\":\"https://openalex.org/keywords/toxicity\",\"display_name\":\"Toxicity\",\"score\":0.0859755277633667}],\"concepts\":[{\"id\":\"https://openalex.org/C87753298\",\"wikidata\":\"https://www.wikidata.org/wiki/Q17157137\",\"display_name\":\"Neuroinflammation\",\"level\":3,\"score\":0.9158775210380554},{\"id\":\"https://openalex.org/C25498285\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1981368\",\"display_name\":\"Neuroprotection\",\"level\":2,\"score\":0.8338673710823059},{\"id\":\"https://openalex.org/C2781156865\",\"wikidata\":\"https://www.wikidata.org/wiki/Q827023\",\"display_name\":\"Lesion\",\"level\":2,\"score\":0.6335400342941284},{\"id\":\"https://openalex.org/C2778402981\",\"wikidata\":\"https://www.wikidata.org/wiki/Q221694\",\"display_name\":\"Blood\\\\u2013brain barrier\",\"level\":3,\"score\":0.6034736633300781},{\"id\":\"https://openalex.org/C2779491297\",\"wikidata\":\"https://www.wikidata.org/wiki/Q3338704\",\"display_name\":\"Neurotoxicity\",\"level\":3,\"score\":0.5461318492889404},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.5455619096755981},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.5418357253074646},{\"id\":\"https://openalex.org/C2776925932\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1755122\",\"display_name\":\"Neurodegeneration\",\"level\":3,\"score\":0.47262927889823914},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.452333927154541},{\"id\":\"https://openalex.org/C2776914184\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101991\",\"display_name\":\"Inflammation\",\"level\":2,\"score\":0.3521748185157776},{\"id\":\"https://openalex.org/C529278444\",\"wikidata\":\"https://www.wikidata.org/wiki/Q47273\",\"display_name\":\"Central nervous system\",\"level\":2,\"score\":0.316877543926239},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.2691381871700287},{\"id\":\"https://openalex.org/C203014093\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101929\",\"display_name\":\"Immunology\",\"level\":1,\"score\":0.2263331115245819},{\"id\":\"https://openalex.org/C142724271\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7208\",\"display_name\":\"Pathology\",\"level\":1,\"score\":0.22044846415519714},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.19281330704689026},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.18342885375022888},{\"id\":\"https://openalex.org/C29730261\",\"wikidata\":\"https://www.wikidata.org/wiki/Q274160\",\"display_name\":\"Toxicity\",\"level\":2,\"score\":0.0859755277633667}],\"mesh\":[],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.1016/j.apsb.2022.02.001\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.apsb.2022.02.001\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2736993989\",\"display_name\":\"Acta Pharmaceutica Sinica B\",\"issn_l\":\"2211-3835\",\"issn\":[\"2211-3835\",\"2211-3843\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Acta Pharmaceutica Sinica B\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:35847512\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/35847512\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Acta pharmaceutica Sinica. B\",\"raw_type\":null},{\"id\":\"pmh:oai:doaj.org/article:882dba810676447b85a4f3d2f060edff\",\"is_oa\":true,\"landing_page_url\":\"https://doaj.org/article/882dba810676447b85a4f3d2f060edff\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-sa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Acta Pharmaceutica Sinica B, Vol 12, Iss 4, Pp 1987-1999 (2022)\",\"raw_type\":\"article\"},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:9279705\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/9279705\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Acta Pharm Sin B\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.apsb.2022.02.001\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.apsb.2022.02.001\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2736993989\",\"display_name\":\"Acta Pharmaceutica Sinica B\",\"issn_l\":\"2211-3835\",\"issn\":[\"2211-3835\",\"2211-3843\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Acta Pharmaceutica Sinica B\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.7200000286102295,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":59,\"referenced_works\":[\"https://openalex.org/W4211213171\",\"https://openalex.org/W3045897262\",\"https://openalex.org/W2556389549\",\"https://openalex.org/W6738808965\",\"https://openalex.org/W2907888739\",\"https://openalex.org/W3111509171\",\"https://openalex.org/W2358666620\",\"https://openalex.org/W2077261568\",\"https://openalex.org/W3011845531\",\"https://openalex.org/W2158215064\",\"https://openalex.org/W2031876291\",\"https://openalex.org/W6683229669\",\"https://openalex.org/W2118906709\",\"https://openalex.org/W2169101493\",\"https://openalex.org/W2736610923\",\"https://openalex.org/W2257570777\",\"https://openalex.org/W2140131793\",\"https://openalex.org/W2055092854\",\"https://openalex.org/W1993510408\",\"https://openalex.org/W2035302673\",\"https://openalex.org/W2076199082\",\"https://openalex.org/W2405454903\",\"https://openalex.org/W2896418617\",\"https://openalex.org/W2945165543\",\"https://openalex.org/W2802088161\",\"https://openalex.org/W3130378078\",\"https://openalex.org/W6717582187\",\"https://openalex.org/W2409679855\",\"https://openalex.org/W2805421262\",\"https://openalex.org/W3024323523\",\"https://openalex.org/W3162484413\",\"https://openalex.org/W2137603130\",\"https://openalex.org/W1977520300\",\"https://openalex.org/W2078241249\",\"https://openalex.org/W1977581685\",\"https://openalex.org/W2091910339\",\"https://openalex.org/W2171809815\",\"https://openalex.org/W3007581937\",\"https://openalex.org/W2940105050\",\"https://openalex.org/W2752897349\",\"https://openalex.org/W2917214973\",\"https://openalex.org/W2310415701\",\"https://openalex.org/W2152429732\",\"https://openalex.org/W2280162925\",\"https://openalex.org/W2176124759\",\"https://openalex.org/W3128065629\",\"https://openalex.org/W2945501847\",\"https://openalex.org/W2947517468\",\"https://openalex.org/W3161053446\",\"https://openalex.org/W2897827263\",\"https://openalex.org/W2924699622\",\"https://openalex.org/W2082276462\",\"https://openalex.org/W3009189929\",\"https://openalex.org/W1991909451\",\"https://openalex.org/W2238460669\",\"https://openalex.org/W2435053065\",\"https://openalex.org/W3043145818\",\"https://openalex.org/W2157404189\",\"https://openalex.org/W2903710086\"],\"related_works\":[\"https://openalex.org/W4210608876\",\"https://openalex.org/W2884031535\",\"https://openalex.org/W4225758926\",\"https://openalex.org/W1539544057\",\"https://openalex.org/W2944532057\",\"https://openalex.org/W4390974293\",\"https://openalex.org/W3101974539\",\"https://openalex.org/W4379184778\",\"https://openalex.org/W4390109195\",\"https://openalex.org/W1973362554\"],\"abstract_inverted_index\":null,\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":24},{\"year\":2024,\"cited_by_count\":23},{\"year\":2023,\"cited_by_count\":22},{\"year\":2022,\"cited_by_count\":9}],\"updated_date\":\"2025-11-09T23:09:16.995542\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4213306104\",\"doi\":\"https://doi.org/10.1016/j.jep.2022.115107\",\"title\":\"Multi-target neuroprotective effects of herbal medicines for Alzheimer\\'s disease\",\"display_name\":\"Multi-target neuroprotective effects of herbal medicines for Alzheimer\\'s disease\",\"relevance_score\":143.90543,\"publication_year\":2022,\"publication_date\":\"2022-02-14\",\"ids\":{\"openalex\":\"https://openalex.org/W4213306104\",\"doi\":\"https://doi.org/10.1016/j.jep.2022.115107\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/35176467\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.jep.2022.115107\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.jep.2022.115107\",\"pdf_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0378874122001453-ga1_lrg.jpg\",\"source\":{\"id\":\"https://openalex.org/S29564236\",\"display_name\":\"Journal of Ethnopharmacology\",\"issn_l\":\"0378-8741\",\"issn\":[\"0378-8741\",\"1872-7573\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Journal of Ethnopharmacology\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"bronze\",\"oa_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0378874122001453-ga1_lrg.jpg\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5013000590\",\"display_name\":\"Filipe Fernandes\",\"orcid\":\"https://orcid.org/0000-0002-2931-8536\"},\"institutions\":[{\"id\":\"https://openalex.org/I83863532\",\"display_name\":\"Polytechnic Institute of Porto\",\"ror\":\"https://ror.org/04988re48\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83863532\"]},{\"id\":\"https://openalex.org/I4210138594\",\"display_name\":\"Rede de Qu\\\\u00edmica e Tecnologia\",\"ror\":\"https://ror.org/04j14t006\",\"country_code\":\"PT\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210138594\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Filipe Fernandes\",\"raw_affiliation_strings\":[\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\"],\"affiliations\":[{\"raw_affiliation_string\":\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\",\"institution_ids\":[\"https://openalex.org/I4210138594\",\"https://openalex.org/I83863532\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5046104806\",\"display_name\":\"M. F\\\\u00e1tima Barroso\",\"orcid\":\"https://orcid.org/0000-0001-9011-5992\"},\"institutions\":[{\"id\":\"https://openalex.org/I83863532\",\"display_name\":\"Polytechnic Institute of Porto\",\"ror\":\"https://ror.org/04988re48\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83863532\"]},{\"id\":\"https://openalex.org/I4210138594\",\"display_name\":\"Rede de Qu\\\\u00edmica e Tecnologia\",\"ror\":\"https://ror.org/04j14t006\",\"country_code\":\"PT\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210138594\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"M F\\\\u00e1tima Barroso\",\"raw_affiliation_strings\":[\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\"],\"affiliations\":[{\"raw_affiliation_string\":\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\",\"institution_ids\":[\"https://openalex.org/I4210138594\",\"https://openalex.org/I83863532\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5072918615\",\"display_name\":\"Angela De Simone\",\"orcid\":\"https://orcid.org/0000-0003-1915-458X\"},\"institutions\":[{\"id\":\"https://openalex.org/I55143463\",\"display_name\":\"University of Turin\",\"ror\":\"https://ror.org/048tbm396\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I55143463\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Angela De Simone\",\"raw_affiliation_strings\":[\"Department of Drug Science and Technology University of Turin, via P.Giuria 9, 10125, Torino, Italy.\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Drug Science and Technology University of Turin, via P.Giuria 9, 10125, Torino, Italy.\",\"institution_ids\":[\"https://openalex.org/I55143463\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5028664471\",\"display_name\":\"Eli\\\\u0161ka Emrikov\\\\u00e1\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I9360294\",\"display_name\":\"University of Bologna\",\"ror\":\"https://ror.org/01111rn36\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I9360294\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Eli\\\\u0161ka Emrikov\\\\u00e1\",\"raw_affiliation_strings\":[\"Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, 47921, Rimini, Italy.\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, 47921, Rimini, Italy.\",\"institution_ids\":[\"https://openalex.org/I9360294\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101597067\",\"display_name\":\"M\\\\u00f3nica Dias-Teixeira\",\"orcid\":\"https://orcid.org/0000-0003-0038-1168\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210147845\",\"display_name\":\"Escola Superior de Sa\\\\u00fade Ribeiro Sanches\",\"ror\":\"https://ror.org/04bpf7m84\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I4210147845\"]},{\"id\":\"https://openalex.org/I83863532\",\"display_name\":\"Polytechnic Institute of Porto\",\"ror\":\"https://ror.org/04988re48\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83863532\"]},{\"id\":\"https://openalex.org/I4210138594\",\"display_name\":\"Rede de Qu\\\\u00edmica e Tecnologia\",\"ror\":\"https://ror.org/04j14t006\",\"country_code\":\"PT\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210138594\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"M\\\\u00f3nica Dias-Teixeira\",\"raw_affiliation_strings\":[\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal; NICiTeS-N\\\\u00facleo de Investiga\\\\u00e7\\\\u00e3o em Ci\\\\u00eancias e Tecnologias da Sa\\\\u00fade, Escola Superior de Sa\\\\u00fade Ribeiro Sanches, Lisboa, Portugal.\"],\"affiliations\":[{\"raw_affiliation_string\":\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal; NICiTeS-N\\\\u00facleo de Investiga\\\\u00e7\\\\u00e3o em Ci\\\\u00eancias e Tecnologias da Sa\\\\u00fade, Escola Superior de Sa\\\\u00fade Ribeiro Sanches, Lisboa, Portugal.\",\"institution_ids\":[\"https://openalex.org/I4210138594\",\"https://openalex.org/I4210147845\",\"https://openalex.org/I83863532\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5104031539\",\"display_name\":\"Jos\\\\u00e9 Paulo Pereira\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210147845\",\"display_name\":\"Escola Superior de Sa\\\\u00fade Ribeiro Sanches\",\"ror\":\"https://ror.org/04bpf7m84\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I4210147845\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Jos\\\\u00e9 Paulo Pereira\",\"raw_affiliation_strings\":[\"NICiTeS-N\\\\u00facleo de Investiga\\\\u00e7\\\\u00e3o em Ci\\\\u00eancias e Tecnologias da Sa\\\\u00fade, Escola Superior de Sa\\\\u00fade Ribeiro Sanches, Lisboa, Portugal.\"],\"affiliations\":[{\"raw_affiliation_string\":\"NICiTeS-N\\\\u00facleo de Investiga\\\\u00e7\\\\u00e3o em Ci\\\\u00eancias e Tecnologias da Sa\\\\u00fade, Escola Superior de Sa\\\\u00fade Ribeiro Sanches, Lisboa, Portugal.\",\"institution_ids\":[\"https://openalex.org/I4210147845\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5007859071\",\"display_name\":\"Jakub Chlebek\",\"orcid\":\"https://orcid.org/0000-0002-0697-5242\"},\"institutions\":[{\"id\":\"https://openalex.org/I21250087\",\"display_name\":\"Charles University\",\"ror\":\"https://ror.org/024d6js02\",\"country_code\":\"CZ\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I21250087\"]},{\"id\":\"https://openalex.org/I75092371\",\"display_name\":\"University of Hradec Kr\\\\u00e1lov\\\\u00e9\",\"ror\":\"https://ror.org/05k238v14\",\"country_code\":\"CZ\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I75092371\"]}],\"countries\":[\"CZ\"],\"is_corresponding\":false,\"raw_author_name\":\"Jakub Chlebek\",\"raw_affiliation_strings\":[\"Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.\",\"institution_ids\":[\"https://openalex.org/I21250087\",\"https://openalex.org/I75092371\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5053435709\",\"display_name\":\"Virg\\\\u00ednia Cruz Fernandes\",\"orcid\":\"https://orcid.org/0000-0003-3979-7523\"},\"institutions\":[{\"id\":\"https://openalex.org/I83863532\",\"display_name\":\"Polytechnic Institute of Porto\",\"ror\":\"https://ror.org/04988re48\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83863532\"]},{\"id\":\"https://openalex.org/I4210138594\",\"display_name\":\"Rede de Qu\\\\u00edmica e Tecnologia\",\"ror\":\"https://ror.org/04j14t006\",\"country_code\":\"PT\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210138594\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Virg\\\\u00ednia Cruz Fernandes\",\"raw_affiliation_strings\":[\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\"],\"affiliations\":[{\"raw_affiliation_string\":\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\",\"institution_ids\":[\"https://openalex.org/I4210138594\",\"https://openalex.org/I83863532\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5029587710\",\"display_name\":\"Francisca Rodrigues\",\"orcid\":\"https://orcid.org/0000-0001-8803-0041\"},\"institutions\":[{\"id\":\"https://openalex.org/I83863532\",\"display_name\":\"Polytechnic Institute of Porto\",\"ror\":\"https://ror.org/04988re48\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83863532\"]},{\"id\":\"https://openalex.org/I4210138594\",\"display_name\":\"Rede de Qu\\\\u00edmica e Tecnologia\",\"ror\":\"https://ror.org/04j14t006\",\"country_code\":\"PT\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210138594\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Francisca Rodrigues\",\"raw_affiliation_strings\":[\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\"],\"affiliations\":[{\"raw_affiliation_string\":\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\",\"institution_ids\":[\"https://openalex.org/I4210138594\",\"https://openalex.org/I83863532\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5074424627\",\"display_name\":\"Vincenza Andrisano\",\"orcid\":\"https://orcid.org/0000-0003-4396-1904\"},\"institutions\":[{\"id\":\"https://openalex.org/I9360294\",\"display_name\":\"University of Bologna\",\"ror\":\"https://ror.org/01111rn36\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I9360294\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Vincenza Andrisano\",\"raw_affiliation_strings\":[\"Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, 47921, Rimini, Italy.\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, 47921, Rimini, Italy.\",\"institution_ids\":[\"https://openalex.org/I9360294\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5013971426\",\"display_name\":\"Cristina Delerue\\\\u2010Matos\",\"orcid\":\"https://orcid.org/0000-0002-3924-776X\"},\"institutions\":[{\"id\":\"https://openalex.org/I83863532\",\"display_name\":\"Polytechnic Institute of Porto\",\"ror\":\"https://ror.org/04988re48\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83863532\"]},{\"id\":\"https://openalex.org/I4210138594\",\"display_name\":\"Rede de Qu\\\\u00edmica e Tecnologia\",\"ror\":\"https://ror.org/04j14t006\",\"country_code\":\"PT\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210138594\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Cristina Delerue-Matos\",\"raw_affiliation_strings\":[\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\"],\"affiliations\":[{\"raw_affiliation_string\":\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal.\",\"institution_ids\":[\"https://openalex.org/I4210138594\",\"https://openalex.org/I83863532\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5052710341\",\"display_name\":\"Clara Grosso\",\"orcid\":\"https://orcid.org/0000-0002-2457-8267\"},\"institutions\":[{\"id\":\"https://openalex.org/I83863532\",\"display_name\":\"Polytechnic Institute of Porto\",\"ror\":\"https://ror.org/04988re48\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I83863532\"]},{\"id\":\"https://openalex.org/I4210138594\",\"display_name\":\"Rede de Qu\\\\u00edmica e Tecnologia\",\"ror\":\"https://ror.org/04j14t006\",\"country_code\":\"PT\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210138594\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Clara Grosso\",\"raw_affiliation_strings\":[\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal. Electronic address: claragrosso@graq.isep.ipp.pt.\"],\"affiliations\":[{\"raw_affiliation_string\":\"REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Polit\\\\u00e9cnico do Porto, Rua Dr. Ant\\\\u00f3nio Bernardino de Almeida, 431, 4249-015, Porto, Portugal. Electronic address: claragrosso@graq.isep.ipp.pt.\",\"institution_ids\":[\"https://openalex.org/I4210138594\",\"https://openalex.org/I83863532\"]}]}],\"institutions\":[],\"countries_distinct_count\":3,\"institutions_distinct_count\":12,\"corresponding_author_ids\":[],\"corresponding_institution_ids\":[],\"apc_list\":{\"value\":3500,\"currency\":\"USD\",\"value_usd\":3500},\"apc_paid\":null,\"fwci\":7.94742081,\"has_fulltext\":true,\"cited_by_count\":39,\"citation_normalized_percentile\":{\"value\":0.97663784,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":97,\"max\":100},\"biblio\":{\"volume\":\"290\",\"issue\":null,\"first_page\":\"115107\",\"last_page\":\"115107\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12582\",\"display_name\":\"Flavonoids in Medical Research\",\"score\":0.9994000196456909,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11613\",\"display_name\":\"Phytochemistry and Biological Activities\",\"score\":0.9970999956130981,\"subfield\":{\"id\":\"https://openalex.org/subfields/1110\",\"display_name\":\"Plant Science\"},\"field\":{\"id\":\"https://openalex.org/fields/11\",\"display_name\":\"Agricultural and Biological Sciences\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/neuroprotection\",\"display_name\":\"Neuroprotection\",\"score\":0.7541600465774536},{\"id\":\"https://openalex.org/keywords/dpph\",\"display_name\":\"DPPH\",\"score\":0.5827769637107849},{\"id\":\"https://openalex.org/keywords/butyrylcholinesterase\",\"display_name\":\"Butyrylcholinesterase\",\"score\":0.5736188888549805},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.5508855581283569},{\"id\":\"https://openalex.org/keywords/traditional-medicine\",\"display_name\":\"Traditional medicine\",\"score\":0.5305308103561401},{\"id\":\"https://openalex.org/keywords/acetylcholinesterase\",\"display_name\":\"Acetylcholinesterase\",\"score\":0.4746202528476715},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.4432786703109741},{\"id\":\"https://openalex.org/keywords/viability-assay\",\"display_name\":\"Viability assay\",\"score\":0.4423932433128357},{\"id\":\"https://openalex.org/keywords/curcumin\",\"display_name\":\"Curcumin\",\"score\":0.43851137161254883},{\"id\":\"https://openalex.org/keywords/ginkgo-biloba\",\"display_name\":\"Ginkgo biloba\",\"score\":0.434631884098053},{\"id\":\"https://openalex.org/keywords/salvia-officinalis\",\"display_name\":\"Salvia officinalis\",\"score\":0.43190568685531616},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.4271638095378876},{\"id\":\"https://openalex.org/keywords/antioxidant\",\"display_name\":\"Antioxidant\",\"score\":0.36289137601852417},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.3004121780395508},{\"id\":\"https://openalex.org/keywords/officinalis\",\"display_name\":\"Officinalis\",\"score\":0.2871154248714447},{\"id\":\"https://openalex.org/keywords/ach\\\\u00e9\",\"display_name\":\"Ach\\\\u00e9\",\"score\":0.1803244650363922},{\"id\":\"https://openalex.org/keywords/enzyme\",\"display_name\":\"Enzyme\",\"score\":0.15723779797554016},{\"id\":\"https://openalex.org/keywords/apoptosis\",\"display_name\":\"Apoptosis\",\"score\":0.10970437526702881}],\"concepts\":[{\"id\":\"https://openalex.org/C25498285\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1981368\",\"display_name\":\"Neuroprotection\",\"level\":2,\"score\":0.7541600465774536},{\"id\":\"https://openalex.org/C2781401929\",\"wikidata\":\"https://www.wikidata.org/wiki/Q5205953\",\"display_name\":\"DPPH\",\"level\":3,\"score\":0.5827769637107849},{\"id\":\"https://openalex.org/C2779101902\",\"wikidata\":\"https://www.wikidata.org/wiki/Q22679015\",\"display_name\":\"Butyrylcholinesterase\",\"level\":5,\"score\":0.5736188888549805},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.5508855581283569},{\"id\":\"https://openalex.org/C556039675\",\"wikidata\":\"https://www.wikidata.org/wiki/Q771035\",\"display_name\":\"Traditional medicine\",\"level\":1,\"score\":0.5305308103561401},{\"id\":\"https://openalex.org/C2778816929\",\"wikidata\":\"https://www.wikidata.org/wiki/Q22676679\",\"display_name\":\"Acetylcholinesterase\",\"level\":3,\"score\":0.4746202528476715},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.4432786703109741},{\"id\":\"https://openalex.org/C53227056\",\"wikidata\":\"https://www.wikidata.org/wiki/Q189152\",\"display_name\":\"Viability assay\",\"level\":3,\"score\":0.4423932433128357},{\"id\":\"https://openalex.org/C2778250585\",\"wikidata\":\"https://www.wikidata.org/wiki/Q312266\",\"display_name\":\"Curcumin\",\"level\":2,\"score\":0.43851137161254883},{\"id\":\"https://openalex.org/C2778998842\",\"wikidata\":\"https://www.wikidata.org/wiki/Q43284\",\"display_name\":\"Ginkgo biloba\",\"level\":2,\"score\":0.434631884098053},{\"id\":\"https://openalex.org/C2911011617\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1111359\",\"display_name\":\"Salvia officinalis\",\"level\":3,\"score\":0.43190568685531616},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.4271638095378876},{\"id\":\"https://openalex.org/C2778004101\",\"wikidata\":\"https://www.wikidata.org/wiki/Q133948\",\"display_name\":\"Antioxidant\",\"level\":2,\"score\":0.36289137601852417},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.3004121780395508},{\"id\":\"https://openalex.org/C2780886089\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7079617\",\"display_name\":\"Officinalis\",\"level\":2,\"score\":0.2871154248714447},{\"id\":\"https://openalex.org/C2779059548\",\"wikidata\":\"https://www.wikidata.org/wiki/Q383701\",\"display_name\":\"Ach\\\\u00e9\",\"level\":4,\"score\":0.1803244650363922},{\"id\":\"https://openalex.org/C181199279\",\"wikidata\":\"https://www.wikidata.org/wiki/Q8047\",\"display_name\":\"Enzyme\",\"level\":2,\"score\":0.15723779797554016},{\"id\":\"https://openalex.org/C190283241\",\"wikidata\":\"https://www.wikidata.org/wiki/Q14599311\",\"display_name\":\"Apoptosis\",\"level\":2,\"score\":0.10970437526702881}],\"mesh\":[{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000473\",\"qualifier_name\":\"pathology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002460\",\"descriptor_name\":\"Cell Line\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D002470\",\"descriptor_name\":\"Cell Survival\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002802\",\"descriptor_name\":\"Cholinesterases\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D004305\",\"descriptor_name\":\"Dose-Response Relationship, Drug\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D016166\",\"descriptor_name\":\"Free Radical Scavengers\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006006\",\"descriptor_name\":\"Glycogen Synthase\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008516\",\"descriptor_name\":\"Medicine, Chinese Traditional\",\"qualifier_ui\":\"Q000379\",\"qualifier_name\":\"methods\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000009\",\"qualifier_name\":\"adverse effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010573\",\"descriptor_name\":\"Pesticide Residues\",\"qualifier_ui\":\"Q000032\",\"qualifier_name\":\"analysis\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010936\",\"descriptor_name\":\"Plant Extracts\",\"qualifier_ui\":\"Q000009\",\"qualifier_name\":\"adverse effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010936\",\"descriptor_name\":\"Plant Extracts\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010946\",\"descriptor_name\":\"Plants, Medicinal\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000473\",\"qualifier_name\":\"pathology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002460\",\"descriptor_name\":\"Cell Line\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D002470\",\"descriptor_name\":\"Cell Survival\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002802\",\"descriptor_name\":\"Cholinesterases\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D004305\",\"descriptor_name\":\"Dose-Response Relationship, Drug\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D016166\",\"descriptor_name\":\"Free Radical Scavengers\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006006\",\"descriptor_name\":\"Glycogen Synthase\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008516\",\"descriptor_name\":\"Medicine, Chinese Traditional\",\"qualifier_ui\":\"Q000379\",\"qualifier_name\":\"methods\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000009\",\"qualifier_name\":\"adverse effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010573\",\"descriptor_name\":\"Pesticide Residues\",\"qualifier_ui\":\"Q000032\",\"qualifier_name\":\"analysis\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010936\",\"descriptor_name\":\"Plant Extracts\",\"qualifier_ui\":\"Q000009\",\"qualifier_name\":\"adverse effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010936\",\"descriptor_name\":\"Plant Extracts\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010946\",\"descriptor_name\":\"Plants, Medicinal\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false}],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1016/j.jep.2022.115107\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.jep.2022.115107\",\"pdf_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0378874122001453-ga1_lrg.jpg\",\"source\":{\"id\":\"https://openalex.org/S29564236\",\"display_name\":\"Journal of Ethnopharmacology\",\"issn_l\":\"0378-8741\",\"issn\":[\"0378-8741\",\"1872-7573\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Journal of Ethnopharmacology\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:35176467\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/35176467\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Journal of ethnopharmacology\",\"raw_type\":null},{\"id\":\"pmh:oai:cris.unibo.it:11585/902721\",\"is_oa\":true,\"landing_page_url\":\"https://hdl.handle.net/11585/902721\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306402579\",\"display_name\":\"Archivio istituzionale della ricerca (Alma Mater Studiorum Universit\\\\u00e0 di Bologna)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I4210117483\",\"host_organization_name\":\"Istituto di Ematologia di Bologna\",\"host_organization_lineage\":[\"https://openalex.org/I4210117483\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"\",\"raw_type\":\"info:eu-repo/semantics/article\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.jep.2022.115107\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.jep.2022.115107\",\"pdf_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0378874122001453-ga1_lrg.jpg\",\"source\":{\"id\":\"https://openalex.org/S29564236\",\"display_name\":\"Journal of Ethnopharmacology\",\"issn_l\":\"0378-8741\",\"issn\":[\"0378-8741\",\"1872-7573\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Journal of Ethnopharmacology\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":true,\"grobid_xml\":true},\"referenced_works_count\":88,\"referenced_works\":[\"https://openalex.org/W1967774489\",\"https://openalex.org/W2031507955\",\"https://openalex.org/W1919130263\",\"https://openalex.org/W2006830489\",\"https://openalex.org/W3087572176\",\"https://openalex.org/W2073533877\",\"https://openalex.org/W2302324860\",\"https://openalex.org/W2120114323\",\"https://openalex.org/W2081450791\",\"https://openalex.org/W2107371784\",\"https://openalex.org/W2119717989\",\"https://openalex.org/W3082151022\",\"https://openalex.org/W2584148086\",\"https://openalex.org/W1867339397\",\"https://openalex.org/W3165481569\",\"https://openalex.org/W2883437447\",\"https://openalex.org/W3113759919\",\"https://openalex.org/W3097416047\",\"https://openalex.org/W3045519352\",\"https://openalex.org/W2219621746\",\"https://openalex.org/W2915250580\",\"https://openalex.org/W2808803893\",\"https://openalex.org/W2079977910\",\"https://openalex.org/W3028521488\",\"https://openalex.org/W2963499334\",\"https://openalex.org/W2991246038\",\"https://openalex.org/W2401800422\",\"https://openalex.org/W3169123974\",\"https://openalex.org/W2964748240\",\"https://openalex.org/W2958543162\",\"https://openalex.org/W2035651308\",\"https://openalex.org/W2093051812\",\"https://openalex.org/W1877022095\",\"https://openalex.org/W2016719964\",\"https://openalex.org/W2017029484\",\"https://openalex.org/W1985520015\",\"https://openalex.org/W2601973518\",\"https://openalex.org/W2595131948\",\"https://openalex.org/W6779848354\",\"https://openalex.org/W3084138668\",\"https://openalex.org/W146203688\",\"https://openalex.org/W2017210237\",\"https://openalex.org/W1980755526\",\"https://openalex.org/W2047599599\",\"https://openalex.org/W2948495618\",\"https://openalex.org/W2090967298\",\"https://openalex.org/W3111274490\",\"https://openalex.org/W2587826324\",\"https://openalex.org/W2024826746\",\"https://openalex.org/W3048274245\",\"https://openalex.org/W2080415175\",\"https://openalex.org/W1690235847\",\"https://openalex.org/W2884843164\",\"https://openalex.org/W2556661692\",\"https://openalex.org/W2970374077\",\"https://openalex.org/W2163403192\",\"https://openalex.org/W2157639241\",\"https://openalex.org/W2899582414\",\"https://openalex.org/W6649544612\",\"https://openalex.org/W3033167612\",\"https://openalex.org/W2107330191\",\"https://openalex.org/W2593745455\",\"https://openalex.org/W2607864522\",\"https://openalex.org/W2018220467\",\"https://openalex.org/W1993306191\",\"https://openalex.org/W3147653121\",\"https://openalex.org/W1988158524\",\"https://openalex.org/W2094771345\",\"https://openalex.org/W3164959702\",\"https://openalex.org/W3211772254\",\"https://openalex.org/W3160167550\",\"https://openalex.org/W2805799188\",\"https://openalex.org/W1967963281\",\"https://openalex.org/W2055846091\",\"https://openalex.org/W3012558556\",\"https://openalex.org/W2008300272\",\"https://openalex.org/W1968015823\",\"https://openalex.org/W2922961022\",\"https://openalex.org/W2608558871\",\"https://openalex.org/W2560263933\",\"https://openalex.org/W3044136434\",\"https://openalex.org/W2614471994\",\"https://openalex.org/W2112243412\",\"https://openalex.org/W1995203863\",\"https://openalex.org/W2955075898\",\"https://openalex.org/W1997288864\",\"https://openalex.org/W2785747577\",\"https://openalex.org/W3036307245\"],\"related_works\":[\"https://openalex.org/W1991066817\",\"https://openalex.org/W2319557544\",\"https://openalex.org/W3106873016\",\"https://openalex.org/W2055788347\",\"https://openalex.org/W1963508769\",\"https://openalex.org/W2776013959\",\"https://openalex.org/W3217345044\",\"https://openalex.org/W2460062919\",\"https://openalex.org/W2938375625\",\"https://openalex.org/W4243528320\"],\"abstract_inverted_index\":null,\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":9},{\"year\":2024,\"cited_by_count\":16},{\"year\":2023,\"cited_by_count\":10},{\"year\":2022,\"cited_by_count\":4}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4403703331\",\"doi\":\"https://doi.org/10.1002/alz.14313\",\"title\":\"Associations of semaglutide with first\\\\u2010time diagnosis of Alzheimer\\'s disease in patients with type 2 diabetes: Target trial emulation using nationwide real\\\\u2010world data in the US\",\"display_name\":\"Associations of semaglutide with first\\\\u2010time diagnosis of Alzheimer\\'s disease in patients with type 2 diabetes: Target trial emulation using nationwide real\\\\u2010world data in the US\",\"relevance_score\":138.76292,\"publication_year\":2024,\"publication_date\":\"2024-10-24\",\"ids\":{\"openalex\":\"https://openalex.org/W4403703331\",\"doi\":\"https://doi.org/10.1002/alz.14313\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/39445596\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1002/alz.14313\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/alz.14313\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.14313\",\"source\":{\"id\":\"https://openalex.org/S108427512\",\"display_name\":\"Alzheimer s & Dementia\",\"issn_l\":\"1552-5260\",\"issn\":[\"1552-5260\",\"1552-5279\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s &amp; Dementia\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"hybrid\",\"oa_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.14313\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5100702488\",\"display_name\":\"William Yang Wang\",\"orcid\":\"https://orcid.org/0000-0002-0878-1257\"},\"institutions\":[{\"id\":\"https://openalex.org/I58956616\",\"display_name\":\"Case Western Reserve University\",\"ror\":\"https://ror.org/051fd9666\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58956616\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"William Wang\",\"raw_affiliation_strings\":[\"Center for Science, Health, and Society Case Western Reserve University School of Medicine  Cleveland Ohio USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Science, Health, and Society Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"institution_ids\":[\"https://openalex.org/I58956616\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5087148950\",\"display_name\":\"QuangQiu Wang\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I58956616\",\"display_name\":\"Case Western Reserve University\",\"ror\":\"https://ror.org/051fd9666\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58956616\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"QuangQiu Wang\",\"raw_affiliation_strings\":[\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"institution_ids\":[\"https://openalex.org/I58956616\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5065652716\",\"display_name\":\"Xin Qi\",\"orcid\":\"https://orcid.org/0000-0002-9578-3890\"},\"institutions\":[{\"id\":\"https://openalex.org/I58956616\",\"display_name\":\"Case Western Reserve University\",\"ror\":\"https://ror.org/051fd9666\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58956616\"]},{\"id\":\"https://openalex.org/I4210153792\",\"display_name\":\"University School\",\"ror\":\"https://ror.org/05ap66461\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I4210153792\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Xin Qi\",\"raw_affiliation_strings\":[\"Department of Physiology and Biophysics Case Western Reserve University School of Medicine  Cleveland Ohio USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Physiology and Biophysics Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"institution_ids\":[\"https://openalex.org/I4210153792\",\"https://openalex.org/I58956616\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5103256518\",\"display_name\":\"Mark E. Gurney\",\"orcid\":\"https://orcid.org/0000-0003-4901-3083\"},\"institutions\":[{\"id\":\"https://openalex.org/I58956616\",\"display_name\":\"Case Western Reserve University\",\"ror\":\"https://ror.org/051fd9666\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58956616\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Mark Gurney\",\"raw_affiliation_strings\":[\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"institution_ids\":[\"https://openalex.org/I58956616\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5075477128\",\"display_name\":\"George Perry\",\"orcid\":\"https://orcid.org/0000-0002-6547-0172\"},\"institutions\":[{\"id\":\"https://openalex.org/I58956616\",\"display_name\":\"Case Western Reserve University\",\"ror\":\"https://ror.org/051fd9666\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58956616\"]},{\"id\":\"https://openalex.org/I45438204\",\"display_name\":\"The University of Texas at San Antonio\",\"ror\":\"https://ror.org/01kd65564\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I45438204\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"George Perry\",\"raw_affiliation_strings\":[\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"Department of Neuroscience, Development and Regenerative Biology, College of Sciences The University of Texas at San Antonio  San Antonio Texas USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"institution_ids\":[\"https://openalex.org/I58956616\"]},{\"raw_affiliation_string\":\"Department of Neuroscience, Development and Regenerative Biology, College of Sciences The University of Texas at San Antonio  San Antonio Texas USA\",\"institution_ids\":[\"https://openalex.org/I45438204\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5002969658\",\"display_name\":\"Nora D. Volkow\",\"orcid\":\"https://orcid.org/0000-0001-6668-0908\"},\"institutions\":[{\"id\":\"https://openalex.org/I1327069482\",\"display_name\":\"National Institute on Drug Abuse\",\"ror\":\"https://ror.org/00fq5cm18\",\"country_code\":\"US\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I1299022934\",\"https://openalex.org/I1299303238\",\"https://openalex.org/I1327069482\"]},{\"id\":\"https://openalex.org/I1299303238\",\"display_name\":\"National Institutes of Health\",\"ror\":\"https://ror.org/01cwqze88\",\"country_code\":\"US\",\"type\":\"government\",\"lineage\":[\"https://openalex.org/I1299022934\",\"https://openalex.org/I1299303238\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Nora D. Volkow\",\"raw_affiliation_strings\":[\"National Institute on Drug Abuse National Institutes of Health  Maryland USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"National Institute on Drug Abuse National Institutes of Health  Maryland USA\",\"institution_ids\":[\"https://openalex.org/I1299303238\",\"https://openalex.org/I1327069482\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5021719854\",\"display_name\":\"Pamela B. Davis\",\"orcid\":\"https://orcid.org/0000-0002-7113-5338\"},\"institutions\":[{\"id\":\"https://openalex.org/I58956616\",\"display_name\":\"Case Western Reserve University\",\"ror\":\"https://ror.org/051fd9666\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58956616\"]},{\"id\":\"https://openalex.org/I4210153792\",\"display_name\":\"University School\",\"ror\":\"https://ror.org/05ap66461\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I4210153792\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Pamela B. Davis\",\"raw_affiliation_strings\":[\"Center for Community Health Integration Case Western Reserve University School of Medicine  Cleveland Ohio USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Community Health Integration Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"institution_ids\":[\"https://openalex.org/I4210153792\",\"https://openalex.org/I58956616\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5075366571\",\"display_name\":\"David C. Kaelber\",\"orcid\":\"https://orcid.org/0000-0001-7855-9515\"},\"institutions\":[{\"id\":\"https://openalex.org/I1299218025\",\"display_name\":\"MetroHealth\",\"ror\":\"https://ror.org/0377srw41\",\"country_code\":\"US\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I1299218025\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"David C. Kaelber\",\"raw_affiliation_strings\":[\"Center for Clinical Informatics Research and Education The MetroHealth System  Ohio USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Clinical Informatics Research and Education The MetroHealth System  Ohio USA\",\"institution_ids\":[\"https://openalex.org/I1299218025\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5050134236\",\"display_name\":\"Rong Xu\",\"orcid\":\"https://orcid.org/0000-0003-3127-4795\"},\"institutions\":[{\"id\":\"https://openalex.org/I58956616\",\"display_name\":\"Case Western Reserve University\",\"ror\":\"https://ror.org/051fd9666\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I58956616\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Rong Xu\",\"raw_affiliation_strings\":[\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Center for Artificial Intelligence in Drug Discovery Case Western Reserve University School of Medicine  Cleveland Ohio USA\",\"institution_ids\":[\"https://openalex.org/I58956616\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":9,\"corresponding_author_ids\":[],\"corresponding_institution_ids\":[],\"apc_list\":{\"value\":4000,\"currency\":\"USD\",\"value_usd\":4000},\"apc_paid\":{\"value\":4000,\"currency\":\"USD\",\"value_usd\":4000},\"fwci\":86.29525769,\"has_fulltext\":false,\"cited_by_count\":100,\"citation_normalized_percentile\":{\"value\":0.99894904,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":96,\"max\":100},\"biblio\":{\"volume\":\"20\",\"issue\":\"12\",\"first_page\":\"8661\",\"last_page\":\"8672\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10401\",\"display_name\":\"Diabetes Treatment and Management\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2712\",\"display_name\":\"Endocrinology, Diabetes and Metabolism\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10401\",\"display_name\":\"Diabetes Treatment and Management\",\"score\":1.0,\"subfield\":{\"id\":\"https://openalex.org/subfields/2712\",\"display_name\":\"Endocrinology, Diabetes and Metabolism\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11339\",\"display_name\":\"Metabolism, Diabetes, and Cancer\",\"score\":0.9952999949455261,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T10560\",\"display_name\":\"Diabetes Management and Research\",\"score\":0.986299991607666,\"subfield\":{\"id\":\"https://openalex.org/subfields/2712\",\"display_name\":\"Endocrinology, Diabetes and Metabolism\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/semaglutide\",\"display_name\":\"Semaglutide\",\"score\":0.9804239273071289},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.7811942100524902},{\"id\":\"https://openalex.org/keywords/hazard-ratio\",\"display_name\":\"Hazard ratio\",\"score\":0.6521081328392029},{\"id\":\"https://openalex.org/keywords/type-2-diabetes\",\"display_name\":\"Type 2 diabetes\",\"score\":0.571077823638916},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.4830673038959503},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.48104360699653625},{\"id\":\"https://openalex.org/keywords/diabetes-mellitus\",\"display_name\":\"Diabetes mellitus\",\"score\":0.433313250541687},{\"id\":\"https://openalex.org/keywords/clinical-trial\",\"display_name\":\"Clinical trial\",\"score\":0.42098474502563477},{\"id\":\"https://openalex.org/keywords/endocrinology\",\"display_name\":\"Endocrinology\",\"score\":0.21797150373458862},{\"id\":\"https://openalex.org/keywords/confidence-interval\",\"display_name\":\"Confidence interval\",\"score\":0.17112961411476135},{\"id\":\"https://openalex.org/keywords/liraglutide\",\"display_name\":\"Liraglutide\",\"score\":0.11698636412620544}],\"concepts\":[{\"id\":\"https://openalex.org/C2909862629\",\"wikidata\":\"https://www.wikidata.org/wiki/Q27261089\",\"display_name\":\"Semaglutide\",\"level\":5,\"score\":0.9804239273071289},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.7811942100524902},{\"id\":\"https://openalex.org/C207103383\",\"wikidata\":\"https://www.wikidata.org/wiki/Q3930246\",\"display_name\":\"Hazard ratio\",\"level\":3,\"score\":0.6521081328392029},{\"id\":\"https://openalex.org/C2777180221\",\"wikidata\":\"https://www.wikidata.org/wiki/Q3025883\",\"display_name\":\"Type 2 diabetes\",\"level\":3,\"score\":0.571077823638916},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.4830673038959503},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.48104360699653625},{\"id\":\"https://openalex.org/C555293320\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12206\",\"display_name\":\"Diabetes mellitus\",\"level\":2,\"score\":0.433313250541687},{\"id\":\"https://openalex.org/C535046627\",\"wikidata\":\"https://www.wikidata.org/wiki/Q30612\",\"display_name\":\"Clinical trial\",\"level\":2,\"score\":0.42098474502563477},{\"id\":\"https://openalex.org/C134018914\",\"wikidata\":\"https://www.wikidata.org/wiki/Q162606\",\"display_name\":\"Endocrinology\",\"level\":1,\"score\":0.21797150373458862},{\"id\":\"https://openalex.org/C44249647\",\"wikidata\":\"https://www.wikidata.org/wiki/Q208498\",\"display_name\":\"Confidence interval\",\"level\":2,\"score\":0.17112961411476135},{\"id\":\"https://openalex.org/C2781308992\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2526479\",\"display_name\":\"Liraglutide\",\"level\":4,\"score\":0.11698636412620544}],\"mesh\":[{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D003924\",\"descriptor_name\":\"Diabetes Mellitus, Type 2\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D004763\",\"descriptor_name\":\"Glucagon-Like Peptides\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D007004\",\"descriptor_name\":\"Hypoglycemic Agents\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D014481\",\"descriptor_name\":\"United States\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008875\",\"descriptor_name\":\"Middle Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000369\",\"descriptor_name\":\"Aged, 80 and over\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D003924\",\"descriptor_name\":\"Diabetes Mellitus, Type 2\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D004763\",\"descriptor_name\":\"Glucagon-Like Peptides\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D007004\",\"descriptor_name\":\"Hypoglycemic Agents\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D014481\",\"descriptor_name\":\"United States\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008875\",\"descriptor_name\":\"Middle Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000369\",\"descriptor_name\":\"Aged, 80 and over\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D003924\",\"descriptor_name\":\"Diabetes Mellitus, Type 2\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D004763\",\"descriptor_name\":\"Glucagon-Like Peptides\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D007004\",\"descriptor_name\":\"Hypoglycemic Agents\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D014481\",\"descriptor_name\":\"United States\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008875\",\"descriptor_name\":\"Middle Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000369\",\"descriptor_name\":\"Aged, 80 and over\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D003924\",\"descriptor_name\":\"Diabetes Mellitus, Type 2\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D004763\",\"descriptor_name\":\"Glucagon-Like Peptides\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D007004\",\"descriptor_name\":\"Hypoglycemic Agents\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":true},{\"descriptor_ui\":\"D014481\",\"descriptor_name\":\"United States\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008875\",\"descriptor_name\":\"Middle Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000369\",\"descriptor_name\":\"Aged, 80 and over\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false}],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1002/alz.14313\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/alz.14313\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.14313\",\"source\":{\"id\":\"https://openalex.org/S108427512\",\"display_name\":\"Alzheimer s & Dementia\",\"issn_l\":\"1552-5260\",\"issn\":[\"1552-5260\",\"1552-5279\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s &amp; Dementia\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:39445596\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/39445596\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s & dementia : the journal of the Alzheimer\\'s Association\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:11667504\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/11667504\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Alzheimers Dement\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.1002/alz.14313\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/alz.14313\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.14313\",\"source\":{\"id\":\"https://openalex.org/S108427512\",\"display_name\":\"Alzheimer s & Dementia\",\"issn_l\":\"1552-5260\",\"issn\":[\"1552-5260\",\"1552-5279\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s &amp; Dementia\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.6100000143051147,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G4521546619\",\"display_name\":null,\"funder_award_id\":\"TR004528\",\"funder_id\":\"https://openalex.org/F4320337472\",\"funder_display_name\":\"National Center for Advancing Translational Sciences\"},{\"id\":\"https://openalex.org/G6722196244\",\"display_name\":null,\"funder_award_id\":\"AG057557 AG061388 AG062272 AG076649\",\"funder_id\":\"https://openalex.org/F4320337337\",\"funder_display_name\":\"National Institute on Aging\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320337337\",\"display_name\":\"National Institute on Aging\",\"ror\":\"https://ror.org/049v75w11\"},{\"id\":\"https://openalex.org/F4320337472\",\"display_name\":\"National Center for Advancing Translational Sciences\",\"ror\":\"https://ror.org/04pw6fb54\"}],\"has_content\":{\"pdf\":true,\"grobid_xml\":false},\"referenced_works_count\":37,\"referenced_works\":[\"https://openalex.org/W4396560090\",\"https://openalex.org/W3046275966\",\"https://openalex.org/W2519510391\",\"https://openalex.org/W4388592674\",\"https://openalex.org/W4399113868\",\"https://openalex.org/W2298338128\",\"https://openalex.org/W4311204752\",\"https://openalex.org/W4311115106\",\"https://openalex.org/W4223992610\",\"https://openalex.org/W4390616108\",\"https://openalex.org/W4389432356\",\"https://openalex.org/W4396231664\",\"https://openalex.org/W4400354928\",\"https://openalex.org/W4311182072\",\"https://openalex.org/W4281763444\",\"https://openalex.org/W3092981856\",\"https://openalex.org/W4386832565\",\"https://openalex.org/W3036438870\",\"https://openalex.org/W4214676574\",\"https://openalex.org/W3045828365\",\"https://openalex.org/W4224248806\",\"https://openalex.org/W1553669285\",\"https://openalex.org/W2106339546\",\"https://openalex.org/W2801388762\",\"https://openalex.org/W3038036007\",\"https://openalex.org/W3214770882\",\"https://openalex.org/W4311187428\",\"https://openalex.org/W4311761391\",\"https://openalex.org/W4283165920\",\"https://openalex.org/W4389920694\",\"https://openalex.org/W4229439744\",\"https://openalex.org/W4391294421\",\"https://openalex.org/W4286821205\",\"https://openalex.org/W4288702326\",\"https://openalex.org/W4401068727\",\"https://openalex.org/W4392817429\",\"https://openalex.org/W2346485000\"],\"related_works\":[\"https://openalex.org/W2914029654\",\"https://openalex.org/W2997605969\",\"https://openalex.org/W2988339773\",\"https://openalex.org/W2949243461\",\"https://openalex.org/W3216092642\",\"https://openalex.org/W3014953461\",\"https://openalex.org/W3004390131\",\"https://openalex.org/W2526168187\",\"https://openalex.org/W4320022142\",\"https://openalex.org/W4391088565\"],\"abstract_inverted_index\":{\"Abstract\":[0],\"INTRODUCTION\":[1],\"Emerging\":[2],\"preclinical\":[3],\"evidence\":[4,29,221],\"suggests\":[5],\"that\":[6],\"semaglutide,\":[7],\"a\":[8,49,93],\"glucagon\\\\u2010like\":[9],\"peptide\":[10],\"receptor\":[11],\"agonist\":[12],\"(GLP\\\\u20101RA)\":[13],\"for\":[14,30,116],\"type\":[15],\"2\":[16],\"diabetes\":[17],\"mellitus\":[18],\"(T2DM)\":[19],\"and\":[20,25,97,104,134,156,214,233],\"obesity,\":[21],\"protects\":[22],\"against\":[23,35],\"neurodegeneration\":[24],\"neuroinflammation.\":[26],\"However,\":[27],\"real\\\\u2010world\":[28,220],\"its\":[31],\"ability\":[32],\"to\":[33,132,146,165,178,190,245],\"protect\":[34],\"Alzheimer\\'s\":[36],\"disease\":[37],\"(AD)\":[38],\"is\":[39],\"lacking.\":[40],\"METHODS\":[41],\"We\":[42],\"conducted\":[43],\"emulation\":[44],\"target\":[45,63],\"trials\":[46,64,244],\"based\":[47],\"on\":[48],\"nationwide\":[50],\"database\":[51],\"of\":[52,57,89,182,227],\"electronic\":[53],\"health\":[54],\"records\":[55],\"(EHRs)\":[56],\"116\":[58],\"million\":[59],\"US\":[60],\"patients.\":[61],\"Seven\":[62],\"were\":[65,150,208],\"emulated\":[66],\"among\":[67],\"1,094,761\":[68],\"eligible\":[69],\"patients\":[70,188,236],\"with\":[71,82,112,123,138,176,200,237],\"T2DM\":[72,187],\"who\":[73],\"had\":[74],\"no\":[75],\"prior\":[76],\"AD\":[77,90,118,184,231],\"diagnosis\":[78,88,185],\"by\":[79],\"comparing\":[80],\"semaglutide\":[81,228],\"seven\":[83],\"other\":[84,139,191,195],\"antidiabetic\":[85,192],\"medications.\":[86],\"First\\\\u2010ever\":[87],\"occurred\":[91],\"within\":[92],\"3\\\\u2010year\":[94],\"follow\\\\u2010up\":[95],\"period\":[96],\"was\":[98,110,174,198],\"examined\":[99],\"using\":[100],\"Cox\":[101],\"proportional\":[102],\"hazards\":[103],\"Kaplan\\\\u2013Meier\":[105],\"survival\":[106],\"analyses.\":[107],\"RESULTS\":[108],\"Semaglutide\":[109,173,197],\"associated\":[111,175,199],\"significantly\":[113,201],\"reduced\":[114,180],\"risk\":[115],\"first\\\\u2010time\":[117,183],\"diagnosis,\":[119],\"most\":[120,135],\"strongly\":[121],\"compared\":[122,137,189],\"insulin\":[124],\"(hazard\":[125],\"ratio\":[126],\"[HR],\":[127],\"0.33\":[128],\"[95%\":[129,143],\"CI:\":[130,144],\"0.21\":[131],\"0.51])\":[133],\"weakly\":[136],\"GLP\\\\u20101RAs\":[140],\"(HR,\":[141],\"0.59\":[142],\"0.37\":[145],\"0.95]).\":[147],\"Similar\":[148,206],\"results\":[149],\"seen\":[151,209],\"across\":[152,210],\"obesity\":[153,211],\"status,\":[154,212],\"gender,\":[155,213],\"age\":[157,215],\"groups.\":[158,216],\"DISCUSSION\":[159],\"These\":[160,239],\"findings\":[161,218,240],\"support\":[162,241],\"further\":[163,242],\"studies\":[164],\"assess\":[166,246],\"semaglutide\\'s\":[167,247],\"potential\":[168,224,248],\"in\":[169,186,229,235,249],\"preventing\":[170,252],\"AD.\":[171,253],\"Highlights\":[172],\"40%\":[177],\"70%\":[179],\"risks\":[181],\"medications,\":[193],\"including\":[194],\"GLP\\\\u20101RAs.\":[196],\"lower\":[202],\"AD\\\\u2010related\":[203],\"medication\":[204],\"prescriptions.\":[205],\"reductions\":[207],\"Our\":[217],\"provide\":[219],\"supporting\":[222],\"the\":[223],\"clinical\":[225,243],\"benefits\":[226],\"mitigating\":[230],\"initiation\":[232],\"development\":[234],\"T2DM.\":[238],\"delaying\":[250],\"or\":[251]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":97},{\"year\":2024,\"cited_by_count\":3}],\"updated_date\":\"2025-12-24T23:09:58.560324\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4306391550\",\"doi\":\"https://doi.org/10.3389/fpsyt.2022.1039725\",\"title\":\"The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer\\'s disease\",\"display_name\":\"The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer\\'s disease\",\"relevance_score\":138.55995,\"publication_year\":2022,\"publication_date\":\"2022-10-17\",\"ids\":{\"openalex\":\"https://openalex.org/W4306391550\",\"doi\":\"https://doi.org/10.3389/fpsyt.2022.1039725\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/36325523\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.3389/fpsyt.2022.1039725\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2022.1039725\",\"pdf_url\":\"https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1039725/pdf\",\"source\":{\"id\":\"https://openalex.org/S92766711\",\"display_name\":\"Frontiers in Psychiatry\",\"issn_l\":\"1664-0640\",\"issn\":[\"1664-0640\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320527\",\"host_organization_name\":\"Frontiers Media\",\"host_organization_lineage\":[\"https://openalex.org/P4310320527\"],\"host_organization_lineage_names\":[\"Frontiers Media\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in Psychiatry\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1039725/pdf\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5017071544\",\"display_name\":\"Paraskevi Krashia\",\"orcid\":\"https://orcid.org/0000-0002-8476-9233\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210150112\",\"display_name\":\"Fondazione Santa Lucia\",\"ror\":\"https://ror.org/05rcxtd95\",\"country_code\":\"IT\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210150112\",\"https://openalex.org/I4210153126\"]},{\"id\":\"https://openalex.org/I155125353\",\"display_name\":\"Universit\\\\u00e0 Campus Bio-Medico\",\"ror\":\"https://ror.org/04gqx4x78\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I155125353\"]}],\"countries\":[\"IT\"],\"is_corresponding\":true,\"raw_author_name\":\"Paraskevi Krashia\",\"raw_affiliation_strings\":[\"Department of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Rome, Italy\",\"Department of Science and Technology for Humans and the Environment, Universit\\\\u00e0 Campus Bio-Medico di Roma, Rome, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Science and Technology for Humans and the Environment, Universit\\\\u00e0 Campus Bio-Medico di Roma, Rome, Italy\",\"institution_ids\":[\"https://openalex.org/I155125353\"]},{\"raw_affiliation_string\":\"Department of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Rome, Italy\",\"institution_ids\":[\"https://openalex.org/I4210150112\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5031231158\",\"display_name\":\"Elena Spoleti\",\"orcid\":\"https://orcid.org/0000-0002-6555-785X\"},\"institutions\":[{\"id\":\"https://openalex.org/I155125353\",\"display_name\":\"Universit\\\\u00e0 Campus Bio-Medico\",\"ror\":\"https://ror.org/04gqx4x78\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I155125353\"]}],\"countries\":[\"IT\"],\"is_corresponding\":false,\"raw_author_name\":\"Elena Spoleti\",\"raw_affiliation_strings\":[\"Department of Science and Technology for Humans and the Environment, Universit\\\\u00e0 Campus Bio-Medico di Roma, Rome, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Science and Technology for Humans and the Environment, Universit\\\\u00e0 Campus Bio-Medico di Roma, Rome, Italy\",\"institution_ids\":[\"https://openalex.org/I155125353\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5013635827\",\"display_name\":\"Marcello D\\\\u2019Amelio\",\"orcid\":\"https://orcid.org/0000-0001-6526-1832\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210150112\",\"display_name\":\"Fondazione Santa Lucia\",\"ror\":\"https://ror.org/05rcxtd95\",\"country_code\":\"IT\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210150112\",\"https://openalex.org/I4210153126\"]},{\"id\":\"https://openalex.org/I155125353\",\"display_name\":\"Universit\\\\u00e0 Campus Bio-Medico\",\"ror\":\"https://ror.org/04gqx4x78\",\"country_code\":\"IT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I155125353\"]}],\"countries\":[\"IT\"],\"is_corresponding\":true,\"raw_author_name\":\"Marcello D\\'Amelio\",\"raw_affiliation_strings\":[\"Department of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Rome, Italy\",\"Department of Medicine and Surgery, Universit\\\\u00e0 Campus Bio-Medico di Roma, Rome, Italy\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Medicine and Surgery, Universit\\\\u00e0 Campus Bio-Medico di Roma, Rome, Italy\",\"institution_ids\":[\"https://openalex.org/I155125353\"]},{\"raw_affiliation_string\":\"Department of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Rome, Italy\",\"institution_ids\":[\"https://openalex.org/I4210150112\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":3,\"corresponding_author_ids\":[\"https://openalex.org/A5017071544\",\"https://openalex.org/A5013635827\"],\"corresponding_institution_ids\":[\"https://openalex.org/I155125353\",\"https://openalex.org/I4210150112\"],\"apc_list\":{\"value\":2950,\"currency\":\"USD\",\"value_usd\":2950},\"apc_paid\":{\"value\":2950,\"currency\":\"USD\",\"value_usd\":2950},\"fwci\":6.46186928,\"has_fulltext\":true,\"cited_by_count\":36,\"citation_normalized_percentile\":{\"value\":0.95946622,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":89,\"max\":100},\"biblio\":{\"volume\":\"13\",\"issue\":null,\"first_page\":\"1039725\",\"last_page\":\"1039725\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.9973999857902527,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T10009\",\"display_name\":\"Dementia and Cognitive Impairment Research\",\"score\":0.9965000152587891,\"subfield\":{\"id\":\"https://openalex.org/subfields/2738\",\"display_name\":\"Psychiatry and Mental health\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/dopaminergic\",\"display_name\":\"Dopaminergic\",\"score\":0.8864994049072266},{\"id\":\"https://openalex.org/keywords/apathy\",\"display_name\":\"Apathy\",\"score\":0.8028942346572876},{\"id\":\"https://openalex.org/keywords/ventral-tegmental-area\",\"display_name\":\"Ventral tegmental area\",\"score\":0.8017889857292175},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.6188022494316101},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.5864728689193726},{\"id\":\"https://openalex.org/keywords/dopamine\",\"display_name\":\"Dopamine\",\"score\":0.5146554708480835},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.48720329999923706},{\"id\":\"https://openalex.org/keywords/psychology\",\"display_name\":\"Psychology\",\"score\":0.4690172076225281},{\"id\":\"https://openalex.org/keywords/dopaminergic-pathways\",\"display_name\":\"Dopaminergic pathways\",\"score\":0.45479562878608704},{\"id\":\"https://openalex.org/keywords/depression\",\"display_name\":\"Depression (economics)\",\"score\":0.43813902139663696},{\"id\":\"https://openalex.org/keywords/biomarker\",\"display_name\":\"Biomarker\",\"score\":0.41087400913238525},{\"id\":\"https://openalex.org/keywords/cognition\",\"display_name\":\"Cognition\",\"score\":0.28392118215560913},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.19466817378997803},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.11916163563728333}],\"concepts\":[{\"id\":\"https://openalex.org/C137183658\",\"wikidata\":\"https://www.wikidata.org/wiki/Q461076\",\"display_name\":\"Dopaminergic\",\"level\":3,\"score\":0.8864994049072266},{\"id\":\"https://openalex.org/C2776509080\",\"wikidata\":\"https://www.wikidata.org/wiki/Q309406\",\"display_name\":\"Apathy\",\"level\":3,\"score\":0.8028942346572876},{\"id\":\"https://openalex.org/C2780948874\",\"wikidata\":\"https://www.wikidata.org/wiki/Q640562\",\"display_name\":\"Ventral tegmental area\",\"level\":4,\"score\":0.8017889857292175},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.6188022494316101},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.5864728689193726},{\"id\":\"https://openalex.org/C513476851\",\"wikidata\":\"https://www.wikidata.org/wiki/Q170304\",\"display_name\":\"Dopamine\",\"level\":2,\"score\":0.5146554708480835},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.48720329999923706},{\"id\":\"https://openalex.org/C15744967\",\"wikidata\":\"https://www.wikidata.org/wiki/Q9418\",\"display_name\":\"Psychology\",\"level\":0,\"score\":0.4690172076225281},{\"id\":\"https://openalex.org/C2776286997\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2880966\",\"display_name\":\"Dopaminergic pathways\",\"level\":4,\"score\":0.45479562878608704},{\"id\":\"https://openalex.org/C2776867660\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1814941\",\"display_name\":\"Depression (economics)\",\"level\":2,\"score\":0.43813902139663696},{\"id\":\"https://openalex.org/C2781197716\",\"wikidata\":\"https://www.wikidata.org/wiki/Q864574\",\"display_name\":\"Biomarker\",\"level\":2,\"score\":0.41087400913238525},{\"id\":\"https://openalex.org/C169900460\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2200417\",\"display_name\":\"Cognition\",\"level\":2,\"score\":0.28392118215560913},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.19466817378997803},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.11916163563728333},{\"id\":\"https://openalex.org/C139719470\",\"wikidata\":\"https://www.wikidata.org/wiki/Q39680\",\"display_name\":\"Macroeconomics\",\"level\":1,\"score\":0.0},{\"id\":\"https://openalex.org/C162324750\",\"wikidata\":\"https://www.wikidata.org/wiki/Q8134\",\"display_name\":\"Economics\",\"level\":0,\"score\":0.0},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.0}],\"mesh\":[],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.3389/fpsyt.2022.1039725\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2022.1039725\",\"pdf_url\":\"https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1039725/pdf\",\"source\":{\"id\":\"https://openalex.org/S92766711\",\"display_name\":\"Frontiers in Psychiatry\",\"issn_l\":\"1664-0640\",\"issn\":[\"1664-0640\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320527\",\"host_organization_name\":\"Frontiers Media\",\"host_organization_lineage\":[\"https://openalex.org/P4310320527\"],\"host_organization_lineage_names\":[\"Frontiers Media\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in Psychiatry\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:36325523\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/36325523\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in psychiatry\",\"raw_type\":null},{\"id\":\"pmh:oai:doaj.org/article:06b5d9be81374fa09dd7299b9437f406\",\"is_oa\":true,\"landing_page_url\":\"https://doaj.org/article/06b5d9be81374fa09dd7299b9437f406\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-sa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Frontiers in Psychiatry, Vol 13 (2022)\",\"raw_type\":\"article\"},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:9618946\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/9618946\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Front Psychiatry\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.3389/fpsyt.2022.1039725\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.3389/fpsyt.2022.1039725\",\"pdf_url\":\"https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1039725/pdf\",\"source\":{\"id\":\"https://openalex.org/S92766711\",\"display_name\":\"Frontiers in Psychiatry\",\"issn_l\":\"1664-0640\",\"issn\":[\"1664-0640\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320527\",\"host_organization_name\":\"Frontiers Media\",\"host_organization_lineage\":[\"https://openalex.org/P4310320527\"],\"host_organization_lineage_names\":[\"Frontiers Media\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Frontiers in Psychiatry\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.800000011920929,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":true,\"grobid_xml\":true},\"referenced_works_count\":165,\"referenced_works\":[\"https://openalex.org/W2143461767\",\"https://openalex.org/W4211156109\",\"https://openalex.org/W2556389549\",\"https://openalex.org/W2040174321\",\"https://openalex.org/W2167720733\",\"https://openalex.org/W2168283959\",\"https://openalex.org/W2132766843\",\"https://openalex.org/W2081533023\",\"https://openalex.org/W1967823816\",\"https://openalex.org/W2052742260\",\"https://openalex.org/W2621653237\",\"https://openalex.org/W2758104141\",\"https://openalex.org/W2021809156\",\"https://openalex.org/W2108335346\",\"https://openalex.org/W3159103876\",\"https://openalex.org/W3004098102\",\"https://openalex.org/W1785160854\",\"https://openalex.org/W2605672047\",\"https://openalex.org/W2124214624\",\"https://openalex.org/W2460296584\",\"https://openalex.org/W1988767840\",\"https://openalex.org/W2107664912\",\"https://openalex.org/W2096513004\",\"https://openalex.org/W3203708058\",\"https://openalex.org/W3136920246\",\"https://openalex.org/W2062698830\",\"https://openalex.org/W2333842187\",\"https://openalex.org/W2745045744\",\"https://openalex.org/W2025967734\",\"https://openalex.org/W2141448905\",\"https://openalex.org/W1997659839\",\"https://openalex.org/W3112927237\",\"https://openalex.org/W2726746745\",\"https://openalex.org/W2116806027\",\"https://openalex.org/W1563387106\",\"https://openalex.org/W2571116337\",\"https://openalex.org/W2039731390\",\"https://openalex.org/W3173338425\",\"https://openalex.org/W1994184254\",\"https://openalex.org/W3084128787\",\"https://openalex.org/W2569240731\",\"https://openalex.org/W2008438340\",\"https://openalex.org/W2011482255\",\"https://openalex.org/W2067147530\",\"https://openalex.org/W2118491675\",\"https://openalex.org/W1971690948\",\"https://openalex.org/W2046081005\",\"https://openalex.org/W2033080466\",\"https://openalex.org/W3198497866\",\"https://openalex.org/W1870304014\",\"https://openalex.org/W2063209112\",\"https://openalex.org/W2016090395\",\"https://openalex.org/W1992595542\",\"https://openalex.org/W1480201820\",\"https://openalex.org/W2966256425\",\"https://openalex.org/W4213213781\",\"https://openalex.org/W3207876808\",\"https://openalex.org/W2203198628\",\"https://openalex.org/W2047790410\",\"https://openalex.org/W2045821490\",\"https://openalex.org/W3179632423\",\"https://openalex.org/W2887114149\",\"https://openalex.org/W2513128864\",\"https://openalex.org/W2111873046\",\"https://openalex.org/W2095088925\",\"https://openalex.org/W2076457657\",\"https://openalex.org/W1998152406\",\"https://openalex.org/W1980737345\",\"https://openalex.org/W2080617748\",\"https://openalex.org/W2114984406\",\"https://openalex.org/W1974741591\",\"https://openalex.org/W1725191478\",\"https://openalex.org/W2017814058\",\"https://openalex.org/W2184138621\",\"https://openalex.org/W2072531628\",\"https://openalex.org/W1539176877\",\"https://openalex.org/W2117782909\",\"https://openalex.org/W2071815275\",\"https://openalex.org/W1998939463\",\"https://openalex.org/W2058578514\",\"https://openalex.org/W1606236576\",\"https://openalex.org/W2803240761\",\"https://openalex.org/W2130788353\",\"https://openalex.org/W6637923128\",\"https://openalex.org/W1967574445\",\"https://openalex.org/W2134181639\",\"https://openalex.org/W2001405361\",\"https://openalex.org/W2791646560\",\"https://openalex.org/W2074882701\",\"https://openalex.org/W2093078508\",\"https://openalex.org/W2169896537\",\"https://openalex.org/W2073108196\",\"https://openalex.org/W2066491797\",\"https://openalex.org/W2152866161\",\"https://openalex.org/W1970396556\",\"https://openalex.org/W2060464965\",\"https://openalex.org/W2040426212\",\"https://openalex.org/W2015429211\",\"https://openalex.org/W2033673027\",\"https://openalex.org/W2085258054\",\"https://openalex.org/W4297738240\",\"https://openalex.org/W1990836357\",\"https://openalex.org/W2022416480\",\"https://openalex.org/W2001210466\",\"https://openalex.org/W1968014528\",\"https://openalex.org/W2148911867\",\"https://openalex.org/W1886575365\",\"https://openalex.org/W2130473558\",\"https://openalex.org/W2411216007\",\"https://openalex.org/W2136901555\",\"https://openalex.org/W2152304945\",\"https://openalex.org/W1984293506\",\"https://openalex.org/W3016048375\",\"https://openalex.org/W2604754546\",\"https://openalex.org/W2803237253\",\"https://openalex.org/W4206484586\",\"https://openalex.org/W2946450511\",\"https://openalex.org/W1970084030\",\"https://openalex.org/W2161451109\",\"https://openalex.org/W1931174500\",\"https://openalex.org/W2131570638\",\"https://openalex.org/W2029181104\",\"https://openalex.org/W1964820825\",\"https://openalex.org/W1963666458\",\"https://openalex.org/W3133740594\",\"https://openalex.org/W3201769508\",\"https://openalex.org/W2019333118\",\"https://openalex.org/W2288964146\",\"https://openalex.org/W2944053790\",\"https://openalex.org/W4283015188\",\"https://openalex.org/W2022564524\",\"https://openalex.org/W2114520249\",\"https://openalex.org/W2888617722\",\"https://openalex.org/W1982974584\",\"https://openalex.org/W2115614582\",\"https://openalex.org/W2789457320\",\"https://openalex.org/W2796162350\",\"https://openalex.org/W2138883123\",\"https://openalex.org/W3023784418\",\"https://openalex.org/W4280492508\",\"https://openalex.org/W2105121811\",\"https://openalex.org/W3134974328\",\"https://openalex.org/W3134824701\",\"https://openalex.org/W3163508460\",\"https://openalex.org/W3094792487\",\"https://openalex.org/W1972343395\",\"https://openalex.org/W2941187970\",\"https://openalex.org/W2136603773\",\"https://openalex.org/W2337539519\",\"https://openalex.org/W4210482244\",\"https://openalex.org/W3205202121\",\"https://openalex.org/W2110811289\",\"https://openalex.org/W2082903897\",\"https://openalex.org/W3042332457\",\"https://openalex.org/W3129800934\",\"https://openalex.org/W2115235249\",\"https://openalex.org/W2075478727\",\"https://openalex.org/W3164214667\",\"https://openalex.org/W2137014450\",\"https://openalex.org/W3217206081\",\"https://openalex.org/W3202834366\",\"https://openalex.org/W2030994918\",\"https://openalex.org/W3184254488\",\"https://openalex.org/W2754324746\",\"https://openalex.org/W2619097621\"],\"related_works\":[\"https://openalex.org/W2254666077\",\"https://openalex.org/W2091458758\",\"https://openalex.org/W1972796309\",\"https://openalex.org/W4303968924\",\"https://openalex.org/W2092822643\",\"https://openalex.org/W4289347123\",\"https://openalex.org/W2134164757\",\"https://openalex.org/W4291754630\",\"https://openalex.org/W2006507085\",\"https://openalex.org/W2188195658\"],\"abstract_inverted_index\":{\"Neuropsychiatric\":[0],\"symptoms\":[1,33,88],\"(NPS)\":[2],\"occur\":[3],\"in\":[4,69,81,109,114,136,192,198],\"nearly\":[5],\"all\":[6],\"patients\":[7,140,219],\"with\":[8,171,190,220],\"Alzheimer\\'s\":[9],\"Disease\":[10],\"(AD).\":[11],\"Most\":[12],\"frequently\":[13],\"they\":[14],\"appear\":[15,161],\"since\":[16,125,163],\"the\":[17,36,46,57,74,98,110,151,164,172,182,187,200,226,231],\"mild\":[18],\"cognitive\":[19],\"impairment\":[20,232],\"(MCI)\":[21],\"stage\":[22],\"preceding\":[23],\"clinical\":[24,134],\"AD,\":[25,132],\"and\":[26,44,54,63,112,133,138,147,155,167,194,229],\"have\":[27,89],\"a\":[28,104,142,196,208],\"prognostic\":[29],\"importance.\":[30],\"Unfortunately,\":[31],\"these\":[32,61,87],\"also\":[34],\"worsen\":[35],\"daily\":[37,234],\"functioning\":[38],\"of\":[39,60,97,131,144,174,181,203,218,233],\"patients,\":[40],\"increase\":[41],\"caregiver\":[42],\"stress\":[43],\"accelerate\":[45],\"disease\":[47,227],\"progression\":[48,228],\"from\":[49],\"MCI\":[50,137,165],\"to\":[51,72,78,92,95,169],\"AD.\":[52,82],\"Apathy\":[53],\"depression\":[55],\"are\":[56],\"most\":[58],\"common\":[59],\"NPS,\":[62],\"much\":[64],\"attention\":[65],\"has\":[66,116],\"been\":[67,90,118],\"given\":[68],\"recent\":[70,126,183],\"years\":[71],\"understand\":[73],\"biological\":[75],\"mechanisms\":[76],\"related\":[77,94],\"their\":[79,156],\"appearance\":[80,173],\"Although\":[83],\"for\":[84,211],\"many\":[85],\"decades\":[86],\"known\":[91],\"be\":[93,207],\"abnormalities\":[96],\"dopaminergic\":[99,153,188,204,221],\"ventral\":[100],\"tegmental\":[101],\"area\":[102],\"(VTA),\":[103],\"direct\":[105],\"association\":[106],\"between\":[107],\"deficits\":[108,205],\"VTA\":[111,152,189],\"NPS\":[113,191],\"AD\":[115,139,193],\"never\":[117],\"investigated.\":[119],\"Fortunately,\":[120],\"this\":[121,215],\"scenario\":[122],\"is\":[123],\"changing\":[124],\"studies\":[127,135],\"using\":[128],\"preclinical\":[129],\"models\":[130],\"demonstrated\":[141],\"number\":[143],\"functional,\":[145],\"structural\":[146],\"metabolic\":[148],\"alterations\":[149],\"affecting\":[150],\"neurons\":[154],\"mesocorticolimbic\":[157],\"targets.\":[158],\"These\":[159],\"findings\":[160],\"early,\":[162],\"stage,\":[166],\"seem\":[168],\"correlate\":[170],\"NPS.\":[175],\"Here,\":[176],\"we\":[177],\"provide\":[178],\"an\":[179],\"overview\":[180],\"evidence\":[184],\"directly\":[185],\"linking\":[186],\"propose\":[195],\"setting\":[197],\"which\":[199],\"precocious\":[201],\"identification\":[202],\"can\":[206],\"helpful\":[209],\"biomarker\":[210],\"early\":[212],\"diagnosis.\":[213],\"In\":[214],\"scenario,\":[216],\"treatments\":[217],\"drugs\":[222],\"might\":[223],\"slow\":[224],\"down\":[225],\"delay\":[230],\"living\":[235],\"activities.\":[236]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":14},{\"year\":2024,\"cited_by_count\":13},{\"year\":2023,\"cited_by_count\":8},{\"year\":2022,\"cited_by_count\":1}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W3193178485\",\"doi\":\"https://doi.org/10.1016/j.neuropharm.2021.108737\",\"title\":\"Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer\\'s disease\",\"display_name\":\"Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer\\'s disease\",\"relevance_score\":136.89996,\"publication_year\":2021,\"publication_date\":\"2021-07-31\",\"ids\":{\"openalex\":\"https://openalex.org/W3193178485\",\"doi\":\"https://doi.org/10.1016/j.neuropharm.2021.108737\",\"mag\":\"3193178485\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/34343610\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.neuropharm.2021.108737\",\"is_oa\":false,\"landing_page_url\":\"https://doi.org/10.1016/j.neuropharm.2021.108737\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S160566677\",\"display_name\":\"Neuropharmacology\",\"issn_l\":\"0028-3908\",\"issn\":[\"0028-3908\",\"1873-7064\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neuropharmacology\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"green\",\"oa_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/8478860\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5035779878\",\"display_name\":\"Jianming Liao\",\"orcid\":\"https://orcid.org/0000-0002-6196-0510\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210140357\",\"display_name\":\"Renmin Hospital of Wuhan University\",\"ror\":\"https://ror.org/03ekhbz91\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210140357\"]},{\"id\":\"https://openalex.org/I37461747\",\"display_name\":\"Wuhan University\",\"ror\":\"https://ror.org/033vjfk17\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I37461747\"]},{\"id\":\"https://openalex.org/I150468666\",\"display_name\":\"Emory University\",\"ror\":\"https://ror.org/03czfpz43\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I150468666\"]}],\"countries\":[\"CN\",\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Jianming Liao\",\"raw_affiliation_strings\":[\"Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China\",\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\",\"institution_ids\":[\"https://openalex.org/I150468666\"]},{\"raw_affiliation_string\":\"Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, China\",\"institution_ids\":[\"https://openalex.org/I37461747\",\"https://openalex.org/I4210140357\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100727512\",\"display_name\":\"Chun Chen\",\"orcid\":\"https://orcid.org/0000-0003-3041-3263\"},\"institutions\":[{\"id\":\"https://openalex.org/I150468666\",\"display_name\":\"Emory University\",\"ror\":\"https://ror.org/03czfpz43\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I150468666\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Chun Chen\",\"raw_affiliation_strings\":[\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\",\"institution_ids\":[\"https://openalex.org/I150468666\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5089802557\",\"display_name\":\"Eun Hee Ahn\",\"orcid\":\"https://orcid.org/0000-0002-1833-6720\"},\"institutions\":[{\"id\":\"https://openalex.org/I150468666\",\"display_name\":\"Emory University\",\"ror\":\"https://ror.org/03czfpz43\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I150468666\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Eun Hee Ahn\",\"raw_affiliation_strings\":[\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\",\"institution_ids\":[\"https://openalex.org/I150468666\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100373211\",\"display_name\":\"Xia Liu\",\"orcid\":\"https://orcid.org/0000-0002-0180-2166\"},\"institutions\":[{\"id\":\"https://openalex.org/I150468666\",\"display_name\":\"Emory University\",\"ror\":\"https://ror.org/03czfpz43\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I150468666\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Xia Liu\",\"raw_affiliation_strings\":[\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\",\"institution_ids\":[\"https://openalex.org/I150468666\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100344257\",\"display_name\":\"Hua Li\",\"orcid\":\"https://orcid.org/0000-0003-1903-836X\"},\"institutions\":[{\"id\":\"https://openalex.org/I47720641\",\"display_name\":\"Huazhong University of Science and Technology\",\"ror\":\"https://ror.org/00p991c53\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I47720641\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Hua Li\",\"raw_affiliation_strings\":[\"School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China\",\"institution_ids\":[\"https://openalex.org/I47720641\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5082201331\",\"display_name\":\"Laura E. Edgington\\\\u2010Mitchell\",\"orcid\":\"https://orcid.org/0000-0002-6810-6149\"},\"institutions\":[{\"id\":\"https://openalex.org/I56590836\",\"display_name\":\"Monash University\",\"ror\":\"https://ror.org/02bfwt286\",\"country_code\":\"AU\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I56590836\"]},{\"id\":\"https://openalex.org/I165779595\",\"display_name\":\"The University of Melbourne\",\"ror\":\"https://ror.org/01ej9dk98\",\"country_code\":\"AU\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I165779595\"]},{\"id\":\"https://openalex.org/I4210152177\",\"display_name\":\"Center for Clinical Research (United States)\",\"ror\":\"https://ror.org/05fnzzk18\",\"country_code\":\"US\",\"type\":\"company\",\"lineage\":[\"https://openalex.org/I4210152177\"]},{\"id\":\"https://openalex.org/I57206974\",\"display_name\":\"New York University\",\"ror\":\"https://ror.org/0190ak572\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I57206974\"]}],\"countries\":[\"AU\",\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Laura E. Edgington-Mitchell\",\"raw_affiliation_strings\":[\"Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, 3052, Australia\",\"Department of Oral and Maxillofacial Surgery, New York University College of Dentistry, Bluestone Center for Clinical Research, New York, NY, 10010, USA\",\"Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Oral and Maxillofacial Surgery, New York University College of Dentistry, Bluestone Center for Clinical Research, New York, NY, 10010, USA\",\"institution_ids\":[\"https://openalex.org/I4210152177\",\"https://openalex.org/I57206974\"]},{\"raw_affiliation_string\":\"Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia\",\"institution_ids\":[\"https://openalex.org/I56590836\"]},{\"raw_affiliation_string\":\"Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, 3052, Australia\",\"institution_ids\":[\"https://openalex.org/I165779595\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5031627471\",\"display_name\":\"Zhonghua Lu\",\"orcid\":\"https://orcid.org/0000-0002-7102-5956\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210145761\",\"display_name\":\"Shenzhen Institutes of Advanced Technology\",\"ror\":\"https://ror.org/04gh4er46\",\"country_code\":\"CN\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I19820366\",\"https://openalex.org/I4210145761\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Zhonghua Lu\",\"raw_affiliation_strings\":[\"Shenzhen Key Laboratory for Molecular Biology of Neural Development, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences\",\"Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, 518055, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Shenzhen Key Laboratory for Molecular Biology of Neural Development, The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences\",\"institution_ids\":[\"https://openalex.org/I4210145761\"]},{\"raw_affiliation_string\":\"Shenzhen-Hong Kong Institute of Brain Science, Shenzhen, 518055, China\",\"institution_ids\":[]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5047902230\",\"display_name\":\"Shuping Ming\",\"orcid\":\"https://orcid.org/0000-0003-1591-3462\"},\"institutions\":[{\"id\":\"https://openalex.org/I205016115\",\"display_name\":\"Hubei University of Chinese Medicine\",\"ror\":\"https://ror.org/02my3bx32\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I205016115\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Shuping Ming\",\"raw_affiliation_strings\":[\"First Clinical College, Hubei University of Chinese Medicine, Wuhan, 430060, Hubei Province, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"First Clinical College, Hubei University of Chinese Medicine, Wuhan, 430060, Hubei Province, China\",\"institution_ids\":[\"https://openalex.org/I205016115\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5073266870\",\"display_name\":\"Keqiang Ye\",\"orcid\":\"https://orcid.org/0000-0002-7657-8154\"},\"institutions\":[{\"id\":\"https://openalex.org/I150468666\",\"display_name\":\"Emory University\",\"ror\":\"https://ror.org/03czfpz43\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I150468666\"]}],\"countries\":[\"US\"],\"is_corresponding\":true,\"raw_author_name\":\"Keqiang Ye\",\"raw_affiliation_strings\":[\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA\",\"institution_ids\":[\"https://openalex.org/I150468666\"]}]}],\"institutions\":[],\"countries_distinct_count\":3,\"institutions_distinct_count\":9,\"corresponding_author_ids\":[\"https://openalex.org/A5073266870\",\"https://openalex.org/A5047902230\"],\"corresponding_institution_ids\":[\"https://openalex.org/I150468666\",\"https://openalex.org/I205016115\"],\"apc_list\":{\"value\":4050,\"currency\":\"USD\",\"value_usd\":4050},\"apc_paid\":null,\"fwci\":4.95222101,\"has_fulltext\":false,\"cited_by_count\":43,\"citation_normalized_percentile\":{\"value\":0.94380298,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":97,\"max\":99},\"biblio\":{\"volume\":\"197\",\"issue\":null,\"first_page\":\"108737\",\"last_page\":\"108737\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9995999932289124,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9995999932289124,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T10814\",\"display_name\":\"Neuropeptides and Animal Physiology\",\"score\":0.9990000128746033,\"subfield\":{\"id\":\"https://openalex.org/subfields/2804\",\"display_name\":\"Cellular and Molecular Neuroscience\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T10483\",\"display_name\":\"Nerve injury and regeneration\",\"score\":0.9990000128746033,\"subfield\":{\"id\":\"https://openalex.org/subfields/2804\",\"display_name\":\"Cellular and Molecular Neuroscience\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/tropomyosin-receptor-kinase-b\",\"display_name\":\"Tropomyosin receptor kinase B\",\"score\":0.6845312118530273},{\"id\":\"https://openalex.org/keywords/amyloid-precursor-protein-secretase\",\"display_name\":\"Amyloid precursor protein secretase\",\"score\":0.5992222428321838},{\"id\":\"https://openalex.org/keywords/amyloid-precursor-protein\",\"display_name\":\"Amyloid precursor protein\",\"score\":0.5033809542655945},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.4803113341331482},{\"id\":\"https://openalex.org/keywords/pathogenesis\",\"display_name\":\"Pathogenesis\",\"score\":0.45356816053390503},{\"id\":\"https://openalex.org/keywords/presenilin\",\"display_name\":\"Presenilin\",\"score\":0.4391670823097229},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.4319089651107788},{\"id\":\"https://openalex.org/keywords/gamma-secretase\",\"display_name\":\"Gamma secretase\",\"score\":0.4193834364414215},{\"id\":\"https://openalex.org/keywords/alzheimers-disease\",\"display_name\":\"Alzheimer\\'s disease\",\"score\":0.4187707304954529},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.38497334718704224},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.3574862480163574},{\"id\":\"https://openalex.org/keywords/receptor\",\"display_name\":\"Receptor\",\"score\":0.2920911908149719},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.27942103147506714},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.23476490378379822},{\"id\":\"https://openalex.org/keywords/neurotrophic-factors\",\"display_name\":\"Neurotrophic factors\",\"score\":0.2001335620880127},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.19408559799194336},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.1753479540348053}],\"concepts\":[{\"id\":\"https://openalex.org/C97124661\",\"wikidata\":\"https://www.wikidata.org/wiki/Q14897782\",\"display_name\":\"Tropomyosin receptor kinase B\",\"level\":4,\"score\":0.6845312118530273},{\"id\":\"https://openalex.org/C36103677\",\"wikidata\":\"https://www.wikidata.org/wiki/Q4749551\",\"display_name\":\"Amyloid precursor protein secretase\",\"level\":5,\"score\":0.5992222428321838},{\"id\":\"https://openalex.org/C31705614\",\"wikidata\":\"https://www.wikidata.org/wiki/Q423510\",\"display_name\":\"Amyloid precursor protein\",\"level\":4,\"score\":0.5033809542655945},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.4803113341331482},{\"id\":\"https://openalex.org/C2780942790\",\"wikidata\":\"https://www.wikidata.org/wiki/Q372016\",\"display_name\":\"Pathogenesis\",\"level\":2,\"score\":0.45356816053390503},{\"id\":\"https://openalex.org/C175344181\",\"wikidata\":\"https://www.wikidata.org/wiki/Q907198\",\"display_name\":\"Presenilin\",\"level\":4,\"score\":0.4391670823097229},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.4319089651107788},{\"id\":\"https://openalex.org/C2778171954\",\"wikidata\":\"https://www.wikidata.org/wiki/Q15328541\",\"display_name\":\"Gamma secretase\",\"level\":2,\"score\":0.4193834364414215},{\"id\":\"https://openalex.org/C502032728\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11081\",\"display_name\":\"Alzheimer\\'s disease\",\"level\":3,\"score\":0.4187707304954529},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.38497334718704224},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.3574862480163574},{\"id\":\"https://openalex.org/C170493617\",\"wikidata\":\"https://www.wikidata.org/wiki/Q208467\",\"display_name\":\"Receptor\",\"level\":2,\"score\":0.2920911908149719},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.27942103147506714},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.23476490378379822},{\"id\":\"https://openalex.org/C160539049\",\"wikidata\":\"https://www.wikidata.org/wiki/Q3064187\",\"display_name\":\"Neurotrophic factors\",\"level\":3,\"score\":0.2001335620880127},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.19408559799194336},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.1753479540348053}],\"mesh\":[{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000523\",\"qualifier_name\":\"psychology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D001921\",\"descriptor_name\":\"Brain\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D001921\",\"descriptor_name\":\"Brain\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D019208\",\"descriptor_name\":\"Brain-Derived Neurotrophic Factor\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D003071\",\"descriptor_name\":\"Cognition\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D003546\",\"descriptor_name\":\"Cysteine Endopeptidases\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D004791\",\"descriptor_name\":\"Enzyme Inhibitors\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D018782\",\"descriptor_name\":\"Maze Learning\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008562\",\"descriptor_name\":\"Membrane Glycoproteins\",\"qualifier_ui\":\"Q000819\",\"qualifier_name\":\"agonists\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008562\",\"descriptor_name\":\"Membrane Glycoproteins\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008810\",\"descriptor_name\":\"Mice, Inbred C57BL\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000493\",\"qualifier_name\":\"pharmacokinetics\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":false},{\"descriptor_ui\":\"D051381\",\"descriptor_name\":\"Rats\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D020813\",\"descriptor_name\":\"Receptor, trkB\",\"qualifier_ui\":\"Q000819\",\"qualifier_name\":\"agonists\",\"is_major_topic\":false},{\"descriptor_ui\":\"D020813\",\"descriptor_name\":\"Receptor, trkB\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D015398\",\"descriptor_name\":\"Signal Transduction\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000523\",\"qualifier_name\":\"psychology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016564\",\"descriptor_name\":\"Amyloid beta-Protein Precursor\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D001921\",\"descriptor_name\":\"Brain\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D001921\",\"descriptor_name\":\"Brain\",\"qualifier_ui\":\"Q000201\",\"qualifier_name\":\"enzymology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D019208\",\"descriptor_name\":\"Brain-Derived Neurotrophic Factor\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D003071\",\"descriptor_name\":\"Cognition\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D003546\",\"descriptor_name\":\"Cysteine Endopeptidases\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D004791\",\"descriptor_name\":\"Enzyme Inhibitors\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D018782\",\"descriptor_name\":\"Maze Learning\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008562\",\"descriptor_name\":\"Membrane Glycoproteins\",\"qualifier_ui\":\"Q000819\",\"qualifier_name\":\"agonists\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008562\",\"descriptor_name\":\"Membrane Glycoproteins\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008810\",\"descriptor_name\":\"Mice, Inbred C57BL\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000493\",\"qualifier_name\":\"pharmacokinetics\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018696\",\"descriptor_name\":\"Neuroprotective Agents\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":false},{\"descriptor_ui\":\"D051381\",\"descriptor_name\":\"Rats\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D020813\",\"descriptor_name\":\"Receptor, trkB\",\"qualifier_ui\":\"Q000819\",\"qualifier_name\":\"agonists\",\"is_major_topic\":false},{\"descriptor_ui\":\"D020813\",\"descriptor_name\":\"Receptor, trkB\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D015398\",\"descriptor_name\":\"Signal Transduction\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false}],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1016/j.neuropharm.2021.108737\",\"is_oa\":false,\"landing_page_url\":\"https://doi.org/10.1016/j.neuropharm.2021.108737\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S160566677\",\"display_name\":\"Neuropharmacology\",\"issn_l\":\"0028-3908\",\"issn\":[\"0028-3908\",\"1873-7064\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neuropharmacology\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:34343610\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/34343610\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Neuropharmacology\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:8478860\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/8478860\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Neuropharmacology\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"pmh:oai:pubmedcentral.nih.gov:8478860\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/8478860\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Neuropharmacology\",\"raw_type\":\"Text\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.7900000214576721,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G5740819821\",\"display_name\":null,\"funder_award_id\":\"AG051538\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G6639737835\",\"display_name\":null,\"funder_award_id\":\"UL1TR002378\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G3853919675\",\"display_name\":null,\"funder_award_id\":\"P30NS055077\",\"funder_id\":\"https://openalex.org/F4320337359\",\"funder_display_name\":\"National Institute of Neurological Disorders and Stroke\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320316438\",\"display_name\":\"Georgia Clinical and Translational Science Alliance\",\"ror\":null},{\"id\":\"https://openalex.org/F4320332161\",\"display_name\":\"National Institutes of Health\",\"ror\":\"https://ror.org/01cwqze88\"},{\"id\":\"https://openalex.org/F4320332554\",\"display_name\":\"School of Medicine, Emory University\",\"ror\":\"https://ror.org/03czfpz43\"},{\"id\":\"https://openalex.org/F4320337359\",\"display_name\":\"National Institute of Neurological Disorders and Stroke\",\"ror\":\"https://ror.org/01s5ya894\"}],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":42,\"referenced_works\":[\"https://openalex.org/W2116784956\",\"https://openalex.org/W2109820768\",\"https://openalex.org/W1963500709\",\"https://openalex.org/W2997373980\",\"https://openalex.org/W3168942664\",\"https://openalex.org/W2782414674\",\"https://openalex.org/W2057415261\",\"https://openalex.org/W2066110504\",\"https://openalex.org/W2617072792\",\"https://openalex.org/W1794050985\",\"https://openalex.org/W1979702721\",\"https://openalex.org/W2517741499\",\"https://openalex.org/W2999437268\",\"https://openalex.org/W2086135754\",\"https://openalex.org/W2096410114\",\"https://openalex.org/W1987782076\",\"https://openalex.org/W2154727263\",\"https://openalex.org/W2006733352\",\"https://openalex.org/W2908411107\",\"https://openalex.org/W2142181595\",\"https://openalex.org/W2103126447\",\"https://openalex.org/W2057889532\",\"https://openalex.org/W2071610467\",\"https://openalex.org/W1750462345\",\"https://openalex.org/W2055979394\",\"https://openalex.org/W2048789360\",\"https://openalex.org/W2000083942\",\"https://openalex.org/W258122973\",\"https://openalex.org/W2041806769\",\"https://openalex.org/W2001537852\",\"https://openalex.org/W2968638119\",\"https://openalex.org/W2799913710\",\"https://openalex.org/W2888065392\",\"https://openalex.org/W2959131130\",\"https://openalex.org/W1986184556\",\"https://openalex.org/W2936022182\",\"https://openalex.org/W2004855983\",\"https://openalex.org/W2599676172\",\"https://openalex.org/W2026077861\",\"https://openalex.org/W2192805543\",\"https://openalex.org/W2082429191\",\"https://openalex.org/W2000209446\"],\"related_works\":[\"https://openalex.org/W1973130935\",\"https://openalex.org/W1995108270\",\"https://openalex.org/W2120860069\",\"https://openalex.org/W2194208597\",\"https://openalex.org/W2076444547\",\"https://openalex.org/W2775777157\",\"https://openalex.org/W2047271826\",\"https://openalex.org/W2005249952\",\"https://openalex.org/W2429817792\",\"https://openalex.org/W2329847864\"],\"abstract_inverted_index\":null,\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":12},{\"year\":2024,\"cited_by_count\":11},{\"year\":2023,\"cited_by_count\":15},{\"year\":2022,\"cited_by_count\":5}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W3137955774\",\"doi\":\"https://doi.org/10.1080/10717544.2021.1895909\",\"title\":\"Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer\\'s disease\",\"display_name\":\"Intranasal administration of dauricine loaded on graphene oxide: multi-target therapy for Alzheimer\\'s disease\",\"relevance_score\":134.79832,\"publication_year\":2021,\"publication_date\":\"2021-01-01\",\"ids\":{\"openalex\":\"https://openalex.org/W3137955774\",\"doi\":\"https://doi.org/10.1080/10717544.2021.1895909\",\"mag\":\"3137955774\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/33729067\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1080/10717544.2021.1895909\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1080/10717544.2021.1895909\",\"pdf_url\":\"https://www.tandfonline.com/doi/pdf/10.1080/10717544.2021.1895909?needAccess=true\",\"source\":{\"id\":\"https://openalex.org/S70174254\",\"display_name\":\"Drug Delivery\",\"issn_l\":\"1071-7544\",\"issn\":[\"1071-7544\",\"1521-0464\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320547\",\"host_organization_name\":\"Taylor & Francis\",\"host_organization_lineage\":[\"https://openalex.org/P4310320547\"],\"host_organization_lineage_names\":[\"Taylor & Francis\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Drug Delivery\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://www.tandfonline.com/doi/pdf/10.1080/10717544.2021.1895909?needAccess=true\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5100619524\",\"display_name\":\"Kaixuan Wang\",\"orcid\":\"https://orcid.org/0000-0001-8091-6083\"},\"institutions\":[{\"id\":\"https://openalex.org/I176134282\",\"display_name\":\"Guilin Medical University\",\"ror\":\"https://ror.org/000prga03\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I176134282\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Kaixuan Wang\",\"raw_affiliation_strings\":[\"School of Pharmacy, Guilin Medical University, Guilin, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Pharmacy, Guilin Medical University, Guilin, China\",\"institution_ids\":[\"https://openalex.org/I176134282\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100629695\",\"display_name\":\"Lingfeng Wang\",\"orcid\":\"https://orcid.org/0000-0001-7198-421X\"},\"institutions\":[{\"id\":\"https://openalex.org/I114539943\",\"display_name\":\"Zhejiang Chinese Medical University\",\"ror\":\"https://ror.org/04epb4p87\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I114539943\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Lingfeng Wang\",\"raw_affiliation_strings\":[\"School of Pharmacy, Zhejiang Chinese Medical University, Zhejiang, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Pharmacy, Zhejiang Chinese Medical University, Zhejiang, China\",\"institution_ids\":[\"https://openalex.org/I114539943\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5100411084\",\"display_name\":\"Ling Chen\",\"orcid\":\"https://orcid.org/0000-0001-6074-523X\"},\"institutions\":[{\"id\":\"https://openalex.org/I176134282\",\"display_name\":\"Guilin Medical University\",\"ror\":\"https://ror.org/000prga03\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I176134282\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Ling Chen\",\"raw_affiliation_strings\":[\"School of Pharmacy, Guilin Medical University, Guilin, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Pharmacy, Guilin Medical University, Guilin, China\",\"institution_ids\":[\"https://openalex.org/I176134282\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5022347336\",\"display_name\":\"Chiwei Peng\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I176134282\",\"display_name\":\"Guilin Medical University\",\"ror\":\"https://ror.org/000prga03\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I176134282\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Chiwei Peng\",\"raw_affiliation_strings\":[\"School of Pharmacy, Guilin Medical University, Guilin, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Pharmacy, Guilin Medical University, Guilin, China\",\"institution_ids\":[\"https://openalex.org/I176134282\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5039199399\",\"display_name\":\"Beijiao Luo\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I176134282\",\"display_name\":\"Guilin Medical University\",\"ror\":\"https://ror.org/000prga03\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I176134282\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Beijiao Luo\",\"raw_affiliation_strings\":[\"School of Pharmacy, Guilin Medical University, Guilin, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Pharmacy, Guilin Medical University, Guilin, China\",\"institution_ids\":[\"https://openalex.org/I176134282\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5036556687\",\"display_name\":\"Jingxin Mo\",\"orcid\":\"https://orcid.org/0000-0002-9574-6037\"},\"institutions\":[{\"id\":\"https://openalex.org/I176134282\",\"display_name\":\"Guilin Medical University\",\"ror\":\"https://ror.org/000prga03\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I176134282\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Jingxin Mo\",\"raw_affiliation_strings\":[\"Department of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, China\",\"institution_ids\":[\"https://openalex.org/I176134282\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5100344556\",\"display_name\":\"Wei Chen\",\"orcid\":\"https://orcid.org/0000-0003-2106-4284\"},\"institutions\":[{\"id\":\"https://openalex.org/I176134282\",\"display_name\":\"Guilin Medical University\",\"ror\":\"https://ror.org/000prga03\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I176134282\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Wei Chen\",\"raw_affiliation_strings\":[\"Department of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Pharmacy, Affiliated Hospital of Guilin Medical University, Guilin, China\",\"institution_ids\":[\"https://openalex.org/I176134282\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":7,\"corresponding_author_ids\":[\"https://openalex.org/A5036556687\",\"https://openalex.org/A5100344556\"],\"corresponding_institution_ids\":[\"https://openalex.org/I176134282\"],\"apc_list\":{\"value\":2335,\"currency\":\"GBP\",\"value_usd\":2864},\"apc_paid\":{\"value\":2335,\"currency\":\"GBP\",\"value_usd\":2864},\"fwci\":3.51128729,\"has_fulltext\":false,\"cited_by_count\":46,\"citation_normalized_percentile\":{\"value\":0.9245539,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":98,\"max\":99},\"biblio\":{\"volume\":\"28\",\"issue\":\"1\",\"first_page\":\"580\",\"last_page\":\"593\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T12627\",\"display_name\":\"Graphene and Nanomaterials Applications\",\"score\":0.9995999932289124,\"subfield\":{\"id\":\"https://openalex.org/subfields/2204\",\"display_name\":\"Biomedical Engineering\"},\"field\":{\"id\":\"https://openalex.org/fields/22\",\"display_name\":\"Engineering\"},\"domain\":{\"id\":\"https://openalex.org/domains/3\",\"display_name\":\"Physical Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T12627\",\"display_name\":\"Graphene and Nanomaterials Applications\",\"score\":0.9995999932289124,\"subfield\":{\"id\":\"https://openalex.org/subfields/2204\",\"display_name\":\"Biomedical Engineering\"},\"field\":{\"id\":\"https://openalex.org/fields/22\",\"display_name\":\"Engineering\"},\"domain\":{\"id\":\"https://openalex.org/domains/3\",\"display_name\":\"Physical Sciences\"}},{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9988999962806702,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12891\",\"display_name\":\"Medicinal Plants and Neuroprotection\",\"score\":0.9954000115394592,\"subfield\":{\"id\":\"https://openalex.org/subfields/2707\",\"display_name\":\"Complementary and alternative medicine\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/oxidative-stress\",\"display_name\":\"Oxidative stress\",\"score\":0.758574366569519},{\"id\":\"https://openalex.org/keywords/in-vivo\",\"display_name\":\"In vivo\",\"score\":0.6936981081962585},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.6907697319984436},{\"id\":\"https://openalex.org/keywords/malondialdehyde\",\"display_name\":\"Malondialdehyde\",\"score\":0.6099510192871094},{\"id\":\"https://openalex.org/keywords/superoxide-dismutase\",\"display_name\":\"Superoxide dismutase\",\"score\":0.5602489113807678},{\"id\":\"https://openalex.org/keywords/reactive-oxygen-species\",\"display_name\":\"Reactive oxygen species\",\"score\":0.5530154705047607},{\"id\":\"https://openalex.org/keywords/nasal-administration\",\"display_name\":\"Nasal administration\",\"score\":0.5387511849403381},{\"id\":\"https://openalex.org/keywords/in-vitro\",\"display_name\":\"In vitro\",\"score\":0.48086291551589966},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.43287187814712524},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.34971100091934204},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.18884247541427612},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.17433640360832214},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.13153091073036194}],\"concepts\":[{\"id\":\"https://openalex.org/C2776151105\",\"wikidata\":\"https://www.wikidata.org/wiki/Q898814\",\"display_name\":\"Oxidative stress\",\"level\":2,\"score\":0.758574366569519},{\"id\":\"https://openalex.org/C207001950\",\"wikidata\":\"https://www.wikidata.org/wiki/Q141124\",\"display_name\":\"In vivo\",\"level\":2,\"score\":0.6936981081962585},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.6907697319984436},{\"id\":\"https://openalex.org/C2778401633\",\"wikidata\":\"https://www.wikidata.org/wiki/Q418661\",\"display_name\":\"Malondialdehyde\",\"level\":3,\"score\":0.6099510192871094},{\"id\":\"https://openalex.org/C2775838275\",\"wikidata\":\"https://www.wikidata.org/wiki/Q410776\",\"display_name\":\"Superoxide dismutase\",\"level\":3,\"score\":0.5602489113807678},{\"id\":\"https://openalex.org/C48349386\",\"wikidata\":\"https://www.wikidata.org/wiki/Q424361\",\"display_name\":\"Reactive oxygen species\",\"level\":2,\"score\":0.5530154705047607},{\"id\":\"https://openalex.org/C85663871\",\"wikidata\":\"https://www.wikidata.org/wiki/Q6966562\",\"display_name\":\"Nasal administration\",\"level\":2,\"score\":0.5387511849403381},{\"id\":\"https://openalex.org/C202751555\",\"wikidata\":\"https://www.wikidata.org/wiki/Q221681\",\"display_name\":\"In vitro\",\"level\":2,\"score\":0.48086291551589966},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.43287187814712524},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.34971100091934204},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.18884247541427612},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.17433640360832214},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.13153091073036194},{\"id\":\"https://openalex.org/C150903083\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7108\",\"display_name\":\"Biotechnology\",\"level\":1,\"score\":0.0}],\"mesh\":[{\"descriptor_ui\":\"D000281\",\"descriptor_name\":\"Administration, Intranasal\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000894\",\"descriptor_name\":\"Anti-Inflammatory Agents, Non-Steroidal\",\"qualifier_ui\":\"Q000008\",\"qualifier_name\":\"administration & dosage\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000894\",\"descriptor_name\":\"Anti-Inflammatory Agents, Non-Steroidal\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D044182\",\"descriptor_name\":\"Benzylisoquinolines\",\"qualifier_ui\":\"Q000008\",\"qualifier_name\":\"administration & dosage\",\"is_major_topic\":false},{\"descriptor_ui\":\"D044182\",\"descriptor_name\":\"Benzylisoquinolines\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002460\",\"descriptor_name\":\"Cell Line\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D002626\",\"descriptor_name\":\"Chemistry, Pharmaceutical\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D004195\",\"descriptor_name\":\"Disease Models, Animal\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D004337\",\"descriptor_name\":\"Drug Carriers\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006108\",\"descriptor_name\":\"Graphite\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008810\",\"descriptor_name\":\"Mice, Inbred C57BL\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D053758\",\"descriptor_name\":\"Nanoparticles\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D009457\",\"descriptor_name\":\"Neuroglia\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018384\",\"descriptor_name\":\"Oxidative Stress\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010316\",\"descriptor_name\":\"Particle Size\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D017382\",\"descriptor_name\":\"Reactive Oxygen Species\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D013482\",\"descriptor_name\":\"Superoxide Dismutase\",\"qualifier_ui\":\"Q000096\",\"qualifier_name\":\"biosynthesis\",\"is_major_topic\":false},{\"descriptor_ui\":\"D013499\",\"descriptor_name\":\"Surface Properties\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D044005\",\"descriptor_name\":\"Tetrahydroisoquinolines\",\"qualifier_ui\":\"Q000008\",\"qualifier_name\":\"administration & dosage\",\"is_major_topic\":false},{\"descriptor_ui\":\"D044005\",\"descriptor_name\":\"Tetrahydroisoquinolines\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000281\",\"descriptor_name\":\"Administration, Intranasal\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000894\",\"descriptor_name\":\"Anti-Inflammatory Agents, Non-Steroidal\",\"qualifier_ui\":\"Q000008\",\"qualifier_name\":\"administration & dosage\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000894\",\"descriptor_name\":\"Anti-Inflammatory Agents, Non-Steroidal\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D044182\",\"descriptor_name\":\"Benzylisoquinolines\",\"qualifier_ui\":\"Q000008\",\"qualifier_name\":\"administration & dosage\",\"is_major_topic\":false},{\"descriptor_ui\":\"D044182\",\"descriptor_name\":\"Benzylisoquinolines\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002460\",\"descriptor_name\":\"Cell Line\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D002626\",\"descriptor_name\":\"Chemistry, Pharmaceutical\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D004195\",\"descriptor_name\":\"Disease Models, Animal\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D004337\",\"descriptor_name\":\"Drug Carriers\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006108\",\"descriptor_name\":\"Graphite\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008810\",\"descriptor_name\":\"Mice, Inbred C57BL\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D053758\",\"descriptor_name\":\"Nanoparticles\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D009457\",\"descriptor_name\":\"Neuroglia\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018384\",\"descriptor_name\":\"Oxidative Stress\",\"qualifier_ui\":\"Q000187\",\"qualifier_name\":\"drug effects\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010316\",\"descriptor_name\":\"Particle Size\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D017382\",\"descriptor_name\":\"Reactive Oxygen Species\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D013482\",\"descriptor_name\":\"Superoxide Dismutase\",\"qualifier_ui\":\"Q000096\",\"qualifier_name\":\"biosynthesis\",\"is_major_topic\":false},{\"descriptor_ui\":\"D013499\",\"descriptor_name\":\"Surface Properties\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D044005\",\"descriptor_name\":\"Tetrahydroisoquinolines\",\"qualifier_ui\":\"Q000008\",\"qualifier_name\":\"administration & dosage\",\"is_major_topic\":false},{\"descriptor_ui\":\"D044005\",\"descriptor_name\":\"Tetrahydroisoquinolines\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false}],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.1080/10717544.2021.1895909\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1080/10717544.2021.1895909\",\"pdf_url\":\"https://www.tandfonline.com/doi/pdf/10.1080/10717544.2021.1895909?needAccess=true\",\"source\":{\"id\":\"https://openalex.org/S70174254\",\"display_name\":\"Drug Delivery\",\"issn_l\":\"1071-7544\",\"issn\":[\"1071-7544\",\"1521-0464\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320547\",\"host_organization_name\":\"Taylor & Francis\",\"host_organization_lineage\":[\"https://openalex.org/P4310320547\"],\"host_organization_lineage_names\":[\"Taylor & Francis\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Drug Delivery\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:33729067\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/33729067\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Drug delivery\",\"raw_type\":null},{\"id\":\"pmh:oai:doaj.org/article:6f3d5a6714804984b928f531d0acee7c\",\"is_oa\":true,\"landing_page_url\":\"https://doaj.org/article/6f3d5a6714804984b928f531d0acee7c\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-sa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Drug Delivery, Vol 28, Iss 1, Pp 580-593 (2021)\",\"raw_type\":\"article\"},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:7971267\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/7971267\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Drug Deliv\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.1080/10717544.2021.1895909\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1080/10717544.2021.1895909\",\"pdf_url\":\"https://www.tandfonline.com/doi/pdf/10.1080/10717544.2021.1895909?needAccess=true\",\"source\":{\"id\":\"https://openalex.org/S70174254\",\"display_name\":\"Drug Delivery\",\"issn_l\":\"1071-7544\",\"issn\":[\"1071-7544\",\"1521-0464\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320547\",\"host_organization_name\":\"Taylor & Francis\",\"host_organization_lineage\":[\"https://openalex.org/P4310320547\"],\"host_organization_lineage_names\":[\"Taylor & Francis\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Drug Delivery\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":true,\"grobid_xml\":true},\"referenced_works_count\":55,\"referenced_works\":[\"https://openalex.org/W2998689040\",\"https://openalex.org/W2952254740\",\"https://openalex.org/W3049215616\",\"https://openalex.org/W2789253060\",\"https://openalex.org/W2048718653\",\"https://openalex.org/W2330508045\",\"https://openalex.org/W2770913560\",\"https://openalex.org/W2765587090\",\"https://openalex.org/W2274672134\",\"https://openalex.org/W3081059887\",\"https://openalex.org/W2913404400\",\"https://openalex.org/W2767280000\",\"https://openalex.org/W2978635127\",\"https://openalex.org/W2124088010\",\"https://openalex.org/W2911895374\",\"https://openalex.org/W2810013872\",\"https://openalex.org/W2902572621\",\"https://openalex.org/W2960814873\",\"https://openalex.org/W3025594202\",\"https://openalex.org/W2899305594\",\"https://openalex.org/W1971008601\",\"https://openalex.org/W2892138659\",\"https://openalex.org/W2336168148\",\"https://openalex.org/W2901239213\",\"https://openalex.org/W3048536871\",\"https://openalex.org/W3125947227\",\"https://openalex.org/W3016539121\",\"https://openalex.org/W2894968499\",\"https://openalex.org/W2894126058\",\"https://openalex.org/W1928822904\",\"https://openalex.org/W2811135471\",\"https://openalex.org/W2793975280\",\"https://openalex.org/W3013279041\",\"https://openalex.org/W2896129998\",\"https://openalex.org/W2734031337\",\"https://openalex.org/W2948022003\",\"https://openalex.org/W2575631536\",\"https://openalex.org/W2071124587\",\"https://openalex.org/W2877013216\",\"https://openalex.org/W2914267785\",\"https://openalex.org/W6678779555\",\"https://openalex.org/W2783111469\",\"https://openalex.org/W2998630448\",\"https://openalex.org/W1032835167\",\"https://openalex.org/W2935794888\",\"https://openalex.org/W2972217616\",\"https://openalex.org/W2767220819\",\"https://openalex.org/W1959859936\",\"https://openalex.org/W2151283457\",\"https://openalex.org/W1907461832\",\"https://openalex.org/W2790576314\",\"https://openalex.org/W2972038856\",\"https://openalex.org/W2789548840\",\"https://openalex.org/W2898810388\",\"https://openalex.org/W2772401389\"],\"related_works\":[\"https://openalex.org/W2154735061\",\"https://openalex.org/W4384695327\",\"https://openalex.org/W2918895489\",\"https://openalex.org/W2945407096\",\"https://openalex.org/W2387681069\",\"https://openalex.org/W4393004449\",\"https://openalex.org/W2363390613\",\"https://openalex.org/W1963764635\",\"https://openalex.org/W3032685127\",\"https://openalex.org/W2423865176\"],\"abstract_inverted_index\":{\"Alzheimer\\'s\":[0],\"disease\":[1,6],\"(AD)\":[2],\"is\":[3],\"a\":[4,40],\"degenerative\":[5],\"of\":[7,34,42,54,62,67,71,183],\"the\":[8,31,35,55,65,72,90,127,171,180],\"central\":[9],\"nervous\":[10],\"system\":[11],\"characterized\":[12],\"by\":[13,76],\"progressive\":[14],\"cognitive\":[15,128],\"and\":[16,58,64,69,81,89,114,119,131,154,160,177],\"memory-related\":[17],\"impairment.\":[18],\"However,\":[19],\"current\":[20],\"therapeutic\":[21],\"treatments\":[22],\"have\":[23],\"not\":[24],\"proved\":[25,142],\"sufficiently\":[26],\"effective,\":[27],\"mainly\":[28],\"due\":[29],\"to\":[30,173],\"complicated\":[32],\"pathogenesis\":[33],\"disease.\":[36],\"In\":[37],\"this\":[38],\"study,\":[39],\"nano-formulation\":[41],\"graphene\":[43],\"oxide\":[44],\"(GO)\":[45],\"loaded\":[46,102,145,167],\"with\":[47,103,138,146,168],\"dauricine\":[48],\"(Dau)\":[49],\"was\":[50,92],\"investigated\":[51],\"in\":[52,95,136,156],\"terms\":[53],\"combined\":[56],\"anti-inflammatory\":[57],\"anti-oxidative\":[59],\"stress\":[60,108],\"effects\":[61],\"Dau\":[63,104,147,169],\"inhibition\":[66],\"misfolding\":[68],\"aggregation\":[70],\"amyloid-\\\\u03b2\":[73],\"(A\\\\u03b2)\":[74],\"protein\":[75],\"GO.\":[77],\"Both\":[78],\"<i>in\":[79,82,122,158,161],\"vivo</i>\":[80,162],\"vitro</i>\":[83,159],\"models\":[84],\"were\":[85],\"induced\":[86],\"using\":[87],\"A\\\\u03b2<sub>1-42</sub>,\":[88],\"formulation\":[91],\"administered\":[93],\"nasally\":[94],\"mice.\":[96],\"The\":[97],\"results\":[98],\"showed\":[99],\"that\":[100,143],\"GO\":[101,144,166],\"greatly\":[105],\"reduced\":[106],\"oxidative\":[107,152],\"through\":[109],\"increasing\":[110],\"superoxide\":[111],\"dismutase\":[112],\"levels\":[113,121],\"decreasing\":[115],\"reactive\":[116],\"oxygen\":[117],\"species\":[118],\"malondialdehyde\":[120],\"vitro</i>;\":[123],\"it\":[124],\"also\":[125],\"alleviated\":[126],\"memory\":[129],\"deficits\":[130],\"brain\":[132],\"glial\":[133],\"cell\":[134],\"activation\":[135],\"mice\":[137],\"A\\\\u03b2<sub>1-42</sub>-induced\":[139,151],\"AD.\":[140,184],\"This\":[141],\"could\":[148],\"protect\":[149],\"against\":[150],\"damage\":[153],\"apoptosis\":[155],\"both\":[157],\"AD\":[163],\"models;\":[164],\"therefore,\":[165],\"has\":[170],\"potential\":[172],\"be\":[174],\"an\":[175],\"effective\":[176],\"agent\":[178],\"for\":[179],\"rapid\":[181],\"treatment\":[182]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":8},{\"year\":2024,\"cited_by_count\":14},{\"year\":2023,\"cited_by_count\":10},{\"year\":2022,\"cited_by_count\":6},{\"year\":2021,\"cited_by_count\":8}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W3201572544\",\"doi\":\"https://doi.org/10.1016/j.ejmech.2021.113847\",\"title\":\"Targeting transthyretin in Alzheimer\\'s disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\\'s disease\",\"display_name\":\"Targeting transthyretin in Alzheimer\\'s disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer\\'s disease\",\"relevance_score\":126.67973,\"publication_year\":2021,\"publication_date\":\"2021-09-14\",\"ids\":{\"openalex\":\"https://openalex.org/W3201572544\",\"doi\":\"https://doi.org/10.1016/j.ejmech.2021.113847\",\"mag\":\"3201572544\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/34555615\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.ejmech.2021.113847\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmech.2021.113847\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210169613\",\"display_name\":\"European Journal of Medicinal Chemistry\",\"issn_l\":\"0223-5234\",\"issn\":[\"0223-5234\",\"1768-3254\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"hybrid\",\"oa_url\":\"https://doi.org/10.1016/j.ejmech.2021.113847\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5045173175\",\"display_name\":\"Ellen Y. Cotrina\",\"orcid\":\"https://orcid.org/0000-0001-5331-3244\"},\"institutions\":[],\"countries\":[],\"is_corresponding\":false,\"raw_author_name\":\"Ellen Y. Cotrina\",\"raw_affiliation_strings\":[\"Institut de Qu\\\\u00edmica Avan\\\\u00e7ada de Catalunya (I.Q.A.C.-C.S.I.C.), E-08034, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Institut de Qu\\\\u00edmica Avan\\\\u00e7ada de Catalunya (I.Q.A.C.-C.S.I.C.), E-08034, Barcelona, Spain\",\"institution_ids\":[]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5009955484\",\"display_name\":\"Lu\\\\u00eds Miguel Santos\",\"orcid\":\"https://orcid.org/0000-0003-2971-6515\"},\"institutions\":[{\"id\":\"https://openalex.org/I4387153674\",\"display_name\":\"Instituto de Biologia Molecular e Celular\",\"ror\":\"https://ror.org/005dkht93\",\"country_code\":null,\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4387153674\"]},{\"id\":\"https://openalex.org/I4210158732\",\"display_name\":\"i3S - Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto\",\"ror\":\"https://ror.org/04wjk1035\",\"country_code\":\"PT\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4210158732\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Luis Miguel Santos\",\"raw_affiliation_strings\":[\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\"],\"affiliations\":[{\"raw_affiliation_string\":\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4387153674\"]},{\"raw_affiliation_string\":\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4210158732\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5026609447\",\"display_name\":\"Josep Rivas\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I2801864671\",\"display_name\":\"Barcelona Biomedical Research Park\",\"ror\":\"https://ror.org/05sajct49\",\"country_code\":\"ES\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I2801864671\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Josep Rivas\",\"raw_affiliation_strings\":[\"Plataforma Drug Discovery, Parc Cient\\\\u00edfic de Barcelona (PCB), E-08028, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Plataforma Drug Discovery, Parc Cient\\\\u00edfic de Barcelona (PCB), E-08028, Barcelona, Spain\",\"institution_ids\":[\"https://openalex.org/I2801864671\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5016538506\",\"display_name\":\"Daniel Blasi\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I2801864671\",\"display_name\":\"Barcelona Biomedical Research Park\",\"ror\":\"https://ror.org/05sajct49\",\"country_code\":\"ES\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I2801864671\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Daniel Blasi\",\"raw_affiliation_strings\":[\"Plataforma Drug Discovery, Parc Cient\\\\u00edfic de Barcelona (PCB), E-08028, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Plataforma Drug Discovery, Parc Cient\\\\u00edfic de Barcelona (PCB), E-08028, Barcelona, Spain\",\"institution_ids\":[\"https://openalex.org/I2801864671\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5014027399\",\"display_name\":\"Jos\\\\u00e9 P. Leite\",\"orcid\":\"https://orcid.org/0000-0001-5063-515X\"},\"institutions\":[{\"id\":\"https://openalex.org/I4387153674\",\"display_name\":\"Instituto de Biologia Molecular e Celular\",\"ror\":\"https://ror.org/005dkht93\",\"country_code\":null,\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4387153674\"]},{\"id\":\"https://openalex.org/I182534213\",\"display_name\":\"Universidade do Porto\",\"ror\":\"https://ror.org/043pwc612\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\"]},{\"id\":\"https://openalex.org/I4210158732\",\"display_name\":\"i3S - Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto\",\"ror\":\"https://ror.org/04wjk1035\",\"country_code\":\"PT\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4210158732\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Jos\\\\u00e9 Pedro Leite\",\"raw_affiliation_strings\":[\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"Instituto de Ci\\\\u00eancias Biom\\\\u00e9dicas Abel Salazar (ICBAS), PT-4050-013, Porto, Portugal\",\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\"],\"affiliations\":[{\"raw_affiliation_string\":\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4210158732\"]},{\"raw_affiliation_string\":\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4387153674\"]},{\"raw_affiliation_string\":\"Instituto de Ci\\\\u00eancias Biom\\\\u00e9dicas Abel Salazar (ICBAS), PT-4050-013, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I182534213\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5051545186\",\"display_name\":\"M\\\\u00e1rcia A. Liz\",\"orcid\":\"https://orcid.org/0000-0002-5126-663X\"},\"institutions\":[{\"id\":\"https://openalex.org/I4387153674\",\"display_name\":\"Instituto de Biologia Molecular e Celular\",\"ror\":\"https://ror.org/005dkht93\",\"country_code\":null,\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4387153674\"]},{\"id\":\"https://openalex.org/I4210158732\",\"display_name\":\"i3S - Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto\",\"ror\":\"https://ror.org/04wjk1035\",\"country_code\":\"PT\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4210158732\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"M\\\\u00e1rcia A. Liz\",\"raw_affiliation_strings\":[\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\"],\"affiliations\":[{\"raw_affiliation_string\":\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4210158732\"]},{\"raw_affiliation_string\":\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4387153674\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5113915760\",\"display_name\":\"Maria Ant\\\\u00f2nia Busquets\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I71999127\",\"display_name\":\"Universitat de Barcelona\",\"ror\":\"https://ror.org/021018s57\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I71999127\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Maria Ant\\\\u00f2nia Busquets\",\"raw_affiliation_strings\":[\"Facultat de Farm\\\\u00e0cia i Ci\\\\u00e8ncies de l\\'Alimentaci\\\\u00f3, University of Barcelona, E-08028, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Facultat de Farm\\\\u00e0cia i Ci\\\\u00e8ncies de l\\'Alimentaci\\\\u00f3, University of Barcelona, E-08028, Barcelona, Spain\",\"institution_ids\":[\"https://openalex.org/I71999127\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5079082841\",\"display_name\":\"Antoni Planas\",\"orcid\":\"https://orcid.org/0000-0001-7073-3320\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210150658\",\"display_name\":\"Institut Qu\\\\u00edmic de Sarri\\\\u00e0\",\"ror\":\"https://ror.org/04y3yya25\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I4210150658\",\"https://openalex.org/I5593406\"]},{\"id\":\"https://openalex.org/I5593406\",\"display_name\":\"Universitat Ramon Llull\",\"ror\":\"https://ror.org/04p9k2z50\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I5593406\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Antoni Planas\",\"raw_affiliation_strings\":[\"Institut Qu\\\\u00edmic de Sarri\\\\u00e0, Universitat Ramon Llull, E-08017, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Institut Qu\\\\u00edmic de Sarri\\\\u00e0, Universitat Ramon Llull, E-08017, Barcelona, Spain\",\"institution_ids\":[\"https://openalex.org/I4210150658\",\"https://openalex.org/I5593406\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5070080960\",\"display_name\":\"Rafel Prohens\",\"orcid\":\"https://orcid.org/0000-0003-0294-1720\"},\"institutions\":[{\"id\":\"https://openalex.org/I71999127\",\"display_name\":\"Universitat de Barcelona\",\"ror\":\"https://ror.org/021018s57\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I71999127\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Rafel Prohens\",\"raw_affiliation_strings\":[\"Centres Cient\\\\u00edfics i Tecnologics, Universitat de Barcelona, E-08028, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Centres Cient\\\\u00edfics i Tecnologics, Universitat de Barcelona, E-08028, Barcelona, Spain\",\"institution_ids\":[\"https://openalex.org/I71999127\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5025486809\",\"display_name\":\"Ana Gimeno\",\"orcid\":\"https://orcid.org/0000-0001-9668-2605\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210112728\",\"display_name\":\"CIC bioGUNE\",\"ror\":\"https://ror.org/02x5c5y60\",\"country_code\":\"ES\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I4210112728\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Ana Gimeno\",\"raw_affiliation_strings\":[\"CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 800, E-48160, Derio, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 800, E-48160, Derio, Spain\",\"institution_ids\":[\"https://openalex.org/I4210112728\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5063186779\",\"display_name\":\"Jes\\\\u00fas Jim\\\\u00e9nez\\\\u2010Barbero\",\"orcid\":\"https://orcid.org/0000-0001-5421-8513\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210112728\",\"display_name\":\"CIC bioGUNE\",\"ror\":\"https://ror.org/02x5c5y60\",\"country_code\":\"ES\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I4210112728\"]},{\"id\":\"https://openalex.org/I110594554\",\"display_name\":\"Ikerbasque\",\"ror\":\"https://ror.org/01cc3fy72\",\"country_code\":\"ES\",\"type\":\"other\",\"lineage\":[\"https://openalex.org/I110594554\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Jes\\\\u00fas Jim\\\\u00e9nez-Barbero\",\"raw_affiliation_strings\":[\"CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 800, E-48160, Derio, Spain\",\"Ikerbasque, Basque Foundation for Science, E-48009, Bilbao, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 800, E-48160, Derio, Spain\",\"institution_ids\":[\"https://openalex.org/I4210112728\"]},{\"raw_affiliation_string\":\"Ikerbasque, Basque Foundation for Science, E-48009, Bilbao, Spain\",\"institution_ids\":[\"https://openalex.org/I110594554\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5034927209\",\"display_name\":\"Lu\\\\u0131\\\\u0301s Gales\",\"orcid\":\"https://orcid.org/0000-0002-8352-6539\"},\"institutions\":[{\"id\":\"https://openalex.org/I4387153674\",\"display_name\":\"Instituto de Biologia Molecular e Celular\",\"ror\":\"https://ror.org/005dkht93\",\"country_code\":null,\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4387153674\"]},{\"id\":\"https://openalex.org/I182534213\",\"display_name\":\"Universidade do Porto\",\"ror\":\"https://ror.org/043pwc612\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\"]},{\"id\":\"https://openalex.org/I4210158732\",\"display_name\":\"i3S - Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto\",\"ror\":\"https://ror.org/04wjk1035\",\"country_code\":\"PT\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4210158732\"]}],\"countries\":[\"PT\"],\"is_corresponding\":false,\"raw_author_name\":\"Luis Gales\",\"raw_affiliation_strings\":[\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"Instituto de Ci\\\\u00eancias Biom\\\\u00e9dicas Abel Salazar (ICBAS), PT-4050-013, Porto, Portugal\",\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\"],\"affiliations\":[{\"raw_affiliation_string\":\"Instituto de Ci\\\\u00eancias Biom\\\\u00e9dicas Abel Salazar (ICBAS), PT-4050-013, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I182534213\"]},{\"raw_affiliation_string\":\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4387153674\"]},{\"raw_affiliation_string\":\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4210158732\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5039085181\",\"display_name\":\"Jordi Llop\",\"orcid\":\"https://orcid.org/0000-0002-0821-9838\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210087187\",\"display_name\":\"CIC biomaGUNE\",\"ror\":\"https://ror.org/004g03602\",\"country_code\":\"ES\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I4210087187\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Jordi Llop\",\"raw_affiliation_strings\":[\"CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), E-20014, San Sebastian, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), E-20014, San Sebastian, Spain\",\"institution_ids\":[\"https://openalex.org/I4210087187\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5051726782\",\"display_name\":\"Jordi Quintana\",\"orcid\":\"https://orcid.org/0000-0002-7059-7418\"},\"institutions\":[{\"id\":\"https://openalex.org/I2801864671\",\"display_name\":\"Barcelona Biomedical Research Park\",\"ror\":\"https://ror.org/05sajct49\",\"country_code\":\"ES\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I2801864671\"]}],\"countries\":[\"ES\"],\"is_corresponding\":true,\"raw_author_name\":\"Jordi Quintana\",\"raw_affiliation_strings\":[\"Plataforma Drug Discovery, Parc Cient\\\\u00edfic de Barcelona (PCB), E-08028, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Plataforma Drug Discovery, Parc Cient\\\\u00edfic de Barcelona (PCB), E-08028, Barcelona, Spain\",\"institution_ids\":[\"https://openalex.org/I2801864671\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5084034441\",\"display_name\":\"Isabel Cardoso\",\"orcid\":\"https://orcid.org/0000-0003-2472-7055\"},\"institutions\":[{\"id\":\"https://openalex.org/I4387153674\",\"display_name\":\"Instituto de Biologia Molecular e Celular\",\"ror\":\"https://ror.org/005dkht93\",\"country_code\":null,\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4387153674\"]},{\"id\":\"https://openalex.org/I182534213\",\"display_name\":\"Universidade do Porto\",\"ror\":\"https://ror.org/043pwc612\",\"country_code\":\"PT\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182534213\"]},{\"id\":\"https://openalex.org/I4210158732\",\"display_name\":\"i3S - Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto\",\"ror\":\"https://ror.org/04wjk1035\",\"country_code\":\"PT\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I4210158732\"]}],\"countries\":[\"PT\"],\"is_corresponding\":true,\"raw_author_name\":\"Isabel Cardoso\",\"raw_affiliation_strings\":[\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"Instituto de Ci\\\\u00eancias Biom\\\\u00e9dicas Abel Salazar (ICBAS), PT-4050-013, Porto, Portugal\",\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\"],\"affiliations\":[{\"raw_affiliation_string\":\"IBMC - Instituto de Biologia Molecular e Celular, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4387153674\"]},{\"raw_affiliation_string\":\"i3S \\\\u2013 Instituto de Investiga\\\\u00e7\\\\u00e3o e Inova\\\\u00e7\\\\u00e3o em Sa\\\\u00fade, Universidade do Porto, PT-4200-135, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I4210158732\"]},{\"raw_affiliation_string\":\"Instituto de Ci\\\\u00eancias Biom\\\\u00e9dicas Abel Salazar (ICBAS), PT-4050-013, Porto, Portugal\",\"institution_ids\":[\"https://openalex.org/I182534213\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5036651504\",\"display_name\":\"Gemma Arsequell\",\"orcid\":\"https://orcid.org/0000-0002-7009-3738\"},\"institutions\":[],\"countries\":[],\"is_corresponding\":true,\"raw_author_name\":\"Gemma Arsequell\",\"raw_affiliation_strings\":[\"Institut de Qu\\\\u00edmica Avan\\\\u00e7ada de Catalunya (I.Q.A.C.-C.S.I.C.), E-08034, Barcelona, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Institut de Qu\\\\u00edmica Avan\\\\u00e7ada de Catalunya (I.Q.A.C.-C.S.I.C.), E-08034, Barcelona, Spain\",\"institution_ids\":[]}]}],\"institutions\":[],\"countries_distinct_count\":2,\"institutions_distinct_count\":16,\"corresponding_author_ids\":[\"https://openalex.org/A5036651504\",\"https://openalex.org/A5051726782\",\"https://openalex.org/A5084034441\"],\"corresponding_institution_ids\":[\"https://openalex.org/I182534213\",\"https://openalex.org/I2801864671\",\"https://openalex.org/I4210158732\",\"https://openalex.org/I4387153674\"],\"apc_list\":{\"value\":4710,\"currency\":\"USD\",\"value_usd\":4710},\"apc_paid\":{\"value\":3890,\"currency\":\"EUR\",\"value_usd\":4195},\"fwci\":1.95064854,\"has_fulltext\":false,\"cited_by_count\":26,\"citation_normalized_percentile\":{\"value\":0.85172124,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":false},\"cited_by_percentile_year\":{\"min\":97,\"max\":99},\"biblio\":{\"volume\":\"226\",\"issue\":null,\"first_page\":\"113847\",\"last_page\":\"113847\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10169\",\"display_name\":\"Protein Kinase Regulation and GTPase Signaling\",\"score\":0.9991000294685364,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10169\",\"display_name\":\"Protein Kinase Regulation and GTPase Signaling\",\"score\":0.9991000294685364,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T10044\",\"display_name\":\"Protein Structure and Dynamics\",\"score\":0.9987000226974487,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T12505\",\"display_name\":\"Peptidase Inhibition and Analysis\",\"score\":0.9987000226974487,\"subfield\":{\"id\":\"https://openalex.org/subfields/2730\",\"display_name\":\"Oncology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/drug-discovery\",\"display_name\":\"Drug discovery\",\"score\":0.7634470462799072},{\"id\":\"https://openalex.org/keywords/drug-repositioning\",\"display_name\":\"Drug repositioning\",\"score\":0.7319363355636597},{\"id\":\"https://openalex.org/keywords/drug\",\"display_name\":\"Drug\",\"score\":0.5916879773139954},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.5873713493347168},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.5863847732543945},{\"id\":\"https://openalex.org/keywords/transthyretin\",\"display_name\":\"Transthyretin\",\"score\":0.44311395287513733},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.22270706295967102},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.17158356308937073}],\"concepts\":[{\"id\":\"https://openalex.org/C74187038\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1418791\",\"display_name\":\"Drug discovery\",\"level\":2,\"score\":0.7634470462799072},{\"id\":\"https://openalex.org/C103637391\",\"wikidata\":\"https://www.wikidata.org/wiki/Q5308921\",\"display_name\":\"Drug repositioning\",\"level\":3,\"score\":0.7319363355636597},{\"id\":\"https://openalex.org/C2780035454\",\"wikidata\":\"https://www.wikidata.org/wiki/Q8386\",\"display_name\":\"Drug\",\"level\":2,\"score\":0.5916879773139954},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.5873713493347168},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.5863847732543945},{\"id\":\"https://openalex.org/C121157162\",\"wikidata\":\"https://www.wikidata.org/wiki/Q419999\",\"display_name\":\"Transthyretin\",\"level\":2,\"score\":0.44311395287513733},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.22270706295967102},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.17158356308937073},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.0}],\"mesh\":[{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002151\",\"descriptor_name\":\"Calorimetry\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D004305\",\"descriptor_name\":\"Dose-Response Relationship, Drug\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D055808\",\"descriptor_name\":\"Drug Discovery\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":true},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008958\",\"descriptor_name\":\"Models, Molecular\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D018832\",\"descriptor_name\":\"Molecular Chaperones\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018832\",\"descriptor_name\":\"Molecular Chaperones\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D015394\",\"descriptor_name\":\"Molecular Structure\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D011228\",\"descriptor_name\":\"Prealbumin\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D011228\",\"descriptor_name\":\"Prealbumin\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D054852\",\"descriptor_name\":\"Small Molecule Libraries\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D054852\",\"descriptor_name\":\"Small Molecule Libraries\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012984\",\"descriptor_name\":\"Software\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D013329\",\"descriptor_name\":\"Structure-Activity Relationship\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D002151\",\"descriptor_name\":\"Calorimetry\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D004305\",\"descriptor_name\":\"Dose-Response Relationship, Drug\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D055808\",\"descriptor_name\":\"Drug Discovery\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":true},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D008958\",\"descriptor_name\":\"Models, Molecular\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D018832\",\"descriptor_name\":\"Molecular Chaperones\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018832\",\"descriptor_name\":\"Molecular Chaperones\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D015394\",\"descriptor_name\":\"Molecular Structure\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D011228\",\"descriptor_name\":\"Prealbumin\",\"qualifier_ui\":\"Q000037\",\"qualifier_name\":\"antagonists & inhibitors\",\"is_major_topic\":false},{\"descriptor_ui\":\"D011228\",\"descriptor_name\":\"Prealbumin\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D054852\",\"descriptor_name\":\"Small Molecule Libraries\",\"qualifier_ui\":\"Q000737\",\"qualifier_name\":\"chemistry\",\"is_major_topic\":false},{\"descriptor_ui\":\"D054852\",\"descriptor_name\":\"Small Molecule Libraries\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012984\",\"descriptor_name\":\"Software\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D013329\",\"descriptor_name\":\"Structure-Activity Relationship\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false}],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1016/j.ejmech.2021.113847\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmech.2021.113847\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210169613\",\"display_name\":\"European Journal of Medicinal Chemistry\",\"issn_l\":\"0223-5234\",\"issn\":[\"0223-5234\",\"1768-3254\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:34555615\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/34555615\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European journal of medicinal chemistry\",\"raw_type\":null},{\"id\":\"pmh:oai:digital.csic.es:10261/251685\",\"is_oa\":false,\"landing_page_url\":\"http://hdl.handle.net/10261/251685\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306400616\",\"display_name\":\"DIGITAL.CSIC (Spanish National Research Council (CSIC))\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I134820265\",\"host_organization_name\":\"Consejo Superior de Investigaciones Cient\\\\u00edficas\",\"host_organization_lineage\":[\"https://openalex.org/I134820265\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"\",\"raw_type\":\"art\\\\u00edculo\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.ejmech.2021.113847\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmech.2021.113847\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210169613\",\"display_name\":\"European Journal of Medicinal Chemistry\",\"issn_l\":\"0223-5234\",\"issn\":[\"0223-5234\",\"1768-3254\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.6899999976158142,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G8221157982\",\"display_name\":null,\"funder_award_id\":\"20140330-31-32-33-34\",\"funder_id\":\"https://openalex.org/F4320310701\",\"funder_display_name\":\"Fundaci\\\\u00f3 la Marat\\\\u00f3 de TV3\"},{\"id\":\"https://openalex.org/G525096714\",\"display_name\":null,\"funder_award_id\":\"20140330-31-32-33-34\",\"funder_id\":\"https://openalex.org/F4320325614\",\"funder_display_name\":\"Fundaci\\\\u00f3 Catalana de Trasplantament\"},{\"id\":\"https://openalex.org/G6789292383\",\"display_name\":null,\"funder_award_id\":\"20140330-31-32-33-34\",\"funder_id\":\"https://openalex.org/F4320335322\",\"funder_display_name\":\"European Regional Development Fund\"},{\"id\":\"https://openalex.org/G1362831744\",\"display_name\":null,\"funder_award_id\":\"20140330-31-32-33-34\",\"funder_id\":\"https://openalex.org/F4320338080\",\"funder_display_name\":\"European Social Fund\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320310701\",\"display_name\":\"Fundaci\\\\u00f3 la Marat\\\\u00f3 de TV3\",\"ror\":\"https://ror.org/00t5xc355\"},{\"id\":\"https://openalex.org/F4320325614\",\"display_name\":\"Fundaci\\\\u00f3 Catalana de Trasplantament\",\"ror\":null},{\"id\":\"https://openalex.org/F4320335322\",\"display_name\":\"European Regional Development Fund\",\"ror\":\"https://ror.org/00k4n6c32\"},{\"id\":\"https://openalex.org/F4320338080\",\"display_name\":\"European Social Fund\",\"ror\":\"https://ror.org/00k4n6c32\"}],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":88,\"referenced_works\":[\"https://openalex.org/W2752287204\",\"https://openalex.org/W6754884395\",\"https://openalex.org/W6799220950\",\"https://openalex.org/W3178151400\",\"https://openalex.org/W3190969996\",\"https://openalex.org/W3186275776\",\"https://openalex.org/W3095153932\",\"https://openalex.org/W6738808965\",\"https://openalex.org/W2740614417\",\"https://openalex.org/W2793324595\",\"https://openalex.org/W3134387309\",\"https://openalex.org/W2789238556\",\"https://openalex.org/W1967144890\",\"https://openalex.org/W3011051402\",\"https://openalex.org/W2134010906\",\"https://openalex.org/W2577162173\",\"https://openalex.org/W2001179326\",\"https://openalex.org/W2101681445\",\"https://openalex.org/W1534314329\",\"https://openalex.org/W1974326834\",\"https://openalex.org/W1506822111\",\"https://openalex.org/W2126911722\",\"https://openalex.org/W30428193\",\"https://openalex.org/W1978632887\",\"https://openalex.org/W2082708034\",\"https://openalex.org/W1975046995\",\"https://openalex.org/W3009819438\",\"https://openalex.org/W3047578856\",\"https://openalex.org/W2807409522\",\"https://openalex.org/W3005458426\",\"https://openalex.org/W2415830294\",\"https://openalex.org/W2963324860\",\"https://openalex.org/W3106660936\",\"https://openalex.org/W2557045419\",\"https://openalex.org/W2733669935\",\"https://openalex.org/W1977191559\",\"https://openalex.org/W2048305209\",\"https://openalex.org/W2280016073\",\"https://openalex.org/W2162710350\",\"https://openalex.org/W3086559466\",\"https://openalex.org/W2313351262\",\"https://openalex.org/W2606258630\",\"https://openalex.org/W1972355793\",\"https://openalex.org/W2617747149\",\"https://openalex.org/W2329183655\",\"https://openalex.org/W2295890540\",\"https://openalex.org/W2061691618\",\"https://openalex.org/W2284643705\",\"https://openalex.org/W2013074349\",\"https://openalex.org/W2142822529\",\"https://openalex.org/W2066486669\",\"https://openalex.org/W2128847415\",\"https://openalex.org/W1483850554\",\"https://openalex.org/W2279500636\",\"https://openalex.org/W1739046993\",\"https://openalex.org/W2951512731\",\"https://openalex.org/W2295325831\",\"https://openalex.org/W2146778032\",\"https://openalex.org/W3130727496\",\"https://openalex.org/W2402506318\",\"https://openalex.org/W2123696227\",\"https://openalex.org/W2622854062\",\"https://openalex.org/W2208203352\",\"https://openalex.org/W2478397531\",\"https://openalex.org/W3100915627\",\"https://openalex.org/W2973355207\",\"https://openalex.org/W1965274265\",\"https://openalex.org/W2141102146\",\"https://openalex.org/W2046477056\",\"https://openalex.org/W1973544766\",\"https://openalex.org/W2000208781\",\"https://openalex.org/W2064146660\",\"https://openalex.org/W1990580716\",\"https://openalex.org/W3113352045\",\"https://openalex.org/W1982340002\",\"https://openalex.org/W2000840258\",\"https://openalex.org/W2001641653\",\"https://openalex.org/W1996607909\",\"https://openalex.org/W2163341755\",\"https://openalex.org/W2124026197\",\"https://openalex.org/W2180229411\",\"https://openalex.org/W4214740576\",\"https://openalex.org/W3164214667\",\"https://openalex.org/W3216197504\",\"https://openalex.org/W4285132881\",\"https://openalex.org/W3185184038\",\"https://openalex.org/W2892067140\",\"https://openalex.org/W3014251530\"],\"related_works\":[\"https://openalex.org/W2899084033\",\"https://openalex.org/W1965193086\",\"https://openalex.org/W3010058077\",\"https://openalex.org/W2399140686\",\"https://openalex.org/W2920569584\",\"https://openalex.org/W1980001478\",\"https://openalex.org/W2951512731\",\"https://openalex.org/W3166711969\",\"https://openalex.org/W4400243266\",\"https://openalex.org/W2046431380\"],\"abstract_inverted_index\":{\"Transthyretin\":[0],\"(TTR)\":[1],\"has\":[2],\"a\":[3,15,46,86,135,146],\"well-established\":[4],\"role\":[5],\"in\":[6,8,39,45,88,122,137],\"neuroprotection\":[7],\"Alzheimer\\'s\":[9],\"Disease\":[10],\"(AD).\":[11],\"We\":[12],\"have\":[13,43,76],\"setup\":[14],\"drug\":[16,35,94,144],\"discovery\":[17,90],\"program\":[18],\"of\":[19,33,48,65],\"small-molecule\":[20],\"compounds\":[21],\"that\":[22],\"act\":[23],\"as\":[24,120,134,145,152],\"chaperones\":[25,66,75,121,127],\"enhancing\":[26],\"TTR/Amyloid-beta\":[27],\"peptide\":[28],\"(A\\\\u03b2)\":[29],\"interactions.\":[30],\"A\":[31,62],\"combination\":[32],\"computational\":[34],\"repurposing\":[36],\"approaches\":[37],\"and\":[38,69,96,102,139],\"vitro\":[40],\"biological\":[41],\"assays\":[42],\"resulted\":[44],\"set\":[47],\"molecules\":[49],\"which\":[50,104],\"were\":[51],\"then\":[52],\"screened\":[53],\"with\":[54,71],\"our\":[55,81],\"in-house\":[56],\"validated\":[57],\"high-throughput\":[58],\"screening\":[59],\"ternary\":[60],\"test.\":[61],\"prioritized\":[63],\"list\":[64],\"was\":[67],\"obtained\":[68],\"corroborated\":[70],\"ITC\":[72],\"studies.\":[73],\"Small-molecule\":[74],\"been\":[77],\"discovered,\":[78],\"among\":[79],\"them\":[80],\"lead\":[82],\"compound\":[83],\"Iododiflunisal\":[84],\"(IDIF),\":[85],\"molecule\":[87],\"the\":[89],\"phase;\":[91],\"one\":[92,142],\"investigational\":[93],\"(luteolin);\":[95],\"3\":[97],\"marketed\":[98],\"drugs\":[99],\"(sulindac,\":[100],\"olsalazine\":[101],\"flufenamic),\":[103],\"could\":[105],\"be\":[106,129],\"directly\":[107],\"repurposed\":[108,143],\"or\":[109],\"repositioned\":[110],\"for\":[111,131],\"clinical\":[112,150],\"use.\":[113],\"Not\":[114],\"all\":[115],\"TTR\":[116,133],\"tetramer\":[117],\"stabilizers\":[118],\"behave\":[119],\"vitro.\":[123],\"These\":[124],\"chemically\":[125],\"diverse\":[126],\"will\":[128],\"used\":[130],\"validating\":[132],\"target\":[136],\"vivo,\":[138],\"to\":[140,148],\"select\":[141],\"candidate\":[147],\"enter\":[149],\"trials\":[151],\"AD\":[153],\"disease-modifying\":[154],\"drug.\":[155]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":6},{\"year\":2024,\"cited_by_count\":9},{\"year\":2023,\"cited_by_count\":7},{\"year\":2022,\"cited_by_count\":4}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4395000918\",\"doi\":\"https://doi.org/10.1002/advs.202306675\",\"title\":\"Hybrid Membrane\\\\u2010Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer\\'s Disease\",\"display_name\":\"Hybrid Membrane\\\\u2010Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer\\'s Disease\",\"relevance_score\":126.56562,\"publication_year\":2024,\"publication_date\":\"2024-04-22\",\"ids\":{\"openalex\":\"https://openalex.org/W4395000918\",\"doi\":\"https://doi.org/10.1002/advs.202306675\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1002/advs.202306675\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/advs.202306675\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/advs.202306675\",\"source\":{\"id\":\"https://openalex.org/S2737737698\",\"display_name\":\"Advanced Science\",\"issn_l\":\"2198-3844\",\"issn\":[\"2198-3844\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Advanced Science\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/advs.202306675\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5110492401\",\"display_name\":\"Rongrong Lin\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Rong\\\\u2010Rong Lin\",\"raw_affiliation_strings\":[\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5112795708\",\"display_name\":\"Lulu Jin\",\"orcid\":\"https://orcid.org/0009-0009-6825-0878\"},\"institutions\":[{\"id\":\"https://openalex.org/I76130692\",\"display_name\":\"Zhejiang University\",\"ror\":\"https://ror.org/00a2xv884\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I76130692\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Lu\\\\u2010Lu Jin\",\"raw_affiliation_strings\":[\"MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027 China\",\"institution_ids\":[\"https://openalex.org/I76130692\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5104004871\",\"display_name\":\"Yan\\\\u2010Yan Xue\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yan\\\\u2010Yan Xue\",\"raw_affiliation_strings\":[\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5062986625\",\"display_name\":\"Zhe\\\\u2010Sheng Zhang\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Zhe\\\\u2010Sheng Zhang\",\"raw_affiliation_strings\":[\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5104284790\",\"display_name\":\"Hui\\\\u2010Feng Huang\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Hui\\\\u2010Feng Huang\",\"raw_affiliation_strings\":[\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5113868755\",\"display_name\":\"Dian\\\\u2010Fu Chen\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Dian\\\\u2010Fu Chen\",\"raw_affiliation_strings\":[\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5104284791\",\"display_name\":\"Qian Liu\",\"orcid\":\"https://orcid.org/0009-0005-7816-3744\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Qian Liu\",\"raw_affiliation_strings\":[\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5015891432\",\"display_name\":\"Zhengwei Mao\",\"orcid\":\"https://orcid.org/0000-0001-7990-2856\"},\"institutions\":[{\"id\":\"https://openalex.org/I76130692\",\"display_name\":\"Zhejiang University\",\"ror\":\"https://ror.org/00a2xv884\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I76130692\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Zheng\\\\u2010Wei Mao\",\"raw_affiliation_strings\":[\"MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, 310027 China\",\"institution_ids\":[\"https://openalex.org/I76130692\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5065162774\",\"display_name\":\"Zhi\\\\u2010Ying Wu\",\"orcid\":\"https://orcid.org/0000-0003-2106-572X\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210097554\",\"display_name\":\"Center for Excellence in Brain Science and Intelligence Technology\",\"ror\":\"https://ror.org/00vpwhm04\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I19820366\",\"https://openalex.org/I4210097554\"]},{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]},{\"id\":\"https://openalex.org/I76130692\",\"display_name\":\"Zhejiang University\",\"ror\":\"https://ror.org/00a2xv884\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I76130692\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Zhi\\\\u2010Ying Wu\",\"raw_affiliation_strings\":[\"CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, 200031 China\",\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"MOE Frontier Science Center for Brain Science and Brain-Machine Integration, School of Brain Science and Brain Medicine, Zhejiang University, Hangzhou, 310058 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, 200031 China\",\"institution_ids\":[\"https://openalex.org/I4210097554\"]},{\"raw_affiliation_string\":\"MOE Frontier Science Center for Brain Science and Brain-Machine Integration, School of Brain Science and Brain Medicine, Zhejiang University, Hangzhou, 310058 China\",\"institution_ids\":[\"https://openalex.org/I76130692\"]},{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5103059616\",\"display_name\":\"Qing\\\\u2010Qing Tao\",\"orcid\":\"https://orcid.org/0000-0002-3318-1747\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210158318\",\"display_name\":\"Second Affiliated Hospital of Zhejiang University\",\"ror\":\"https://ror.org/059cjpv64\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210158318\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Qing\\\\u2010Qing Tao\",\"raw_affiliation_strings\":[\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310009 China\",\"institution_ids\":[\"https://openalex.org/I4210158318\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":10,\"corresponding_author_ids\":[\"https://openalex.org/A5103059616\",\"https://openalex.org/A5015891432\",\"https://openalex.org/A5065162774\"],\"corresponding_institution_ids\":[\"https://openalex.org/I4210097554\",\"https://openalex.org/I4210158318\",\"https://openalex.org/I76130692\"],\"apc_list\":{\"value\":5000,\"currency\":\"USD\",\"value_usd\":5000},\"apc_paid\":{\"value\":5000,\"currency\":\"USD\",\"value_usd\":5000},\"fwci\":6.0963903,\"has_fulltext\":false,\"cited_by_count\":36,\"citation_normalized_percentile\":{\"value\":0.98317052,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":98,\"max\":100},\"biblio\":{\"volume\":\"11\",\"issue\":\"24\",\"first_page\":null,\"last_page\":null},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T12149\",\"display_name\":\"Nanocluster Synthesis and Applications\",\"score\":0.9980000257492065,\"subfield\":{\"id\":\"https://openalex.org/subfields/2505\",\"display_name\":\"Materials Chemistry\"},\"field\":{\"id\":\"https://openalex.org/fields/25\",\"display_name\":\"Materials Science\"},\"domain\":{\"id\":\"https://openalex.org/domains/3\",\"display_name\":\"Physical Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T12149\",\"display_name\":\"Nanocluster Synthesis and Applications\",\"score\":0.9980000257492065,\"subfield\":{\"id\":\"https://openalex.org/subfields/2505\",\"display_name\":\"Materials Chemistry\"},\"field\":{\"id\":\"https://openalex.org/fields/25\",\"display_name\":\"Materials Science\"},\"domain\":{\"id\":\"https://openalex.org/domains/3\",\"display_name\":\"Physical Sciences\"}},{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9973000288009644,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11342\",\"display_name\":\"Carbon and Quantum Dots Applications\",\"score\":0.9943000078201294,\"subfield\":{\"id\":\"https://openalex.org/subfields/2505\",\"display_name\":\"Materials Chemistry\"},\"field\":{\"id\":\"https://openalex.org/fields/25\",\"display_name\":\"Materials Science\"},\"domain\":{\"id\":\"https://openalex.org/domains/3\",\"display_name\":\"Physical Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/neuroinflammation\",\"display_name\":\"Neuroinflammation\",\"score\":0.850304901599884},{\"id\":\"https://openalex.org/keywords/drug-delivery\",\"display_name\":\"Drug delivery\",\"score\":0.5670199394226074},{\"id\":\"https://openalex.org/keywords/liposome\",\"display_name\":\"Liposome\",\"score\":0.5416754484176636},{\"id\":\"https://openalex.org/keywords/targeted-drug-delivery\",\"display_name\":\"Targeted drug delivery\",\"score\":0.45141956210136414},{\"id\":\"https://openalex.org/keywords/cell\",\"display_name\":\"Cell\",\"score\":0.44923830032348633},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.39870133996009827},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.3860810399055481},{\"id\":\"https://openalex.org/keywords/drug\",\"display_name\":\"Drug\",\"score\":0.36438673734664917},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.2964467704296112},{\"id\":\"https://openalex.org/keywords/materials-science\",\"display_name\":\"Materials science\",\"score\":0.28015226125717163},{\"id\":\"https://openalex.org/keywords/nanotechnology\",\"display_name\":\"Nanotechnology\",\"score\":0.25418031215667725},{\"id\":\"https://openalex.org/keywords/inflammation\",\"display_name\":\"Inflammation\",\"score\":0.22454625368118286},{\"id\":\"https://openalex.org/keywords/immunology\",\"display_name\":\"Immunology\",\"score\":0.22381284832954407},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.07149815559387207}],\"concepts\":[{\"id\":\"https://openalex.org/C87753298\",\"wikidata\":\"https://www.wikidata.org/wiki/Q17157137\",\"display_name\":\"Neuroinflammation\",\"level\":3,\"score\":0.850304901599884},{\"id\":\"https://openalex.org/C2779820397\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1392806\",\"display_name\":\"Drug delivery\",\"level\":2,\"score\":0.5670199394226074},{\"id\":\"https://openalex.org/C185154212\",\"wikidata\":\"https://www.wikidata.org/wiki/Q410454\",\"display_name\":\"Liposome\",\"level\":2,\"score\":0.5416754484176636},{\"id\":\"https://openalex.org/C126511603\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1261145\",\"display_name\":\"Targeted drug delivery\",\"level\":3,\"score\":0.45141956210136414},{\"id\":\"https://openalex.org/C1491633281\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7868\",\"display_name\":\"Cell\",\"level\":2,\"score\":0.44923830032348633},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.39870133996009827},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.3860810399055481},{\"id\":\"https://openalex.org/C2780035454\",\"wikidata\":\"https://www.wikidata.org/wiki/Q8386\",\"display_name\":\"Drug\",\"level\":2,\"score\":0.36438673734664917},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.2964467704296112},{\"id\":\"https://openalex.org/C192562407\",\"wikidata\":\"https://www.wikidata.org/wiki/Q228736\",\"display_name\":\"Materials science\",\"level\":0,\"score\":0.28015226125717163},{\"id\":\"https://openalex.org/C171250308\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11468\",\"display_name\":\"Nanotechnology\",\"level\":1,\"score\":0.25418031215667725},{\"id\":\"https://openalex.org/C2776914184\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101991\",\"display_name\":\"Inflammation\",\"level\":2,\"score\":0.22454625368118286},{\"id\":\"https://openalex.org/C203014093\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101929\",\"display_name\":\"Immunology\",\"level\":1,\"score\":0.22381284832954407},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.07149815559387207}],\"mesh\":[],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1002/advs.202306675\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/advs.202306675\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/advs.202306675\",\"source\":{\"id\":\"https://openalex.org/S2737737698\",\"display_name\":\"Advanced Science\",\"issn_l\":\"2198-3844\",\"issn\":[\"2198-3844\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Advanced Science\",\"raw_type\":\"journal-article\"},{\"id\":\"pmh:oai:doaj.org/article:ee4f8ff681c04f27bd4f57306e42e74f\",\"is_oa\":false,\"landing_page_url\":\"https://doaj.org/article/ee4f8ff681c04f27bd4f57306e42e74f\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Advanced Science, Vol 11, Iss 24, Pp n/a-n/a (2024)\",\"raw_type\":\"article\"},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:11200089\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/11200089\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Adv Sci (Weinh)\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.1002/advs.202306675\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/advs.202306675\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/advs.202306675\",\"source\":{\"id\":\"https://openalex.org/S2737737698\",\"display_name\":\"Advanced Science\",\"issn_l\":\"2198-3844\",\"issn\":[\"2198-3844\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Advanced Science\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.7599999904632568,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G5234272603\",\"display_name\":null,\"funder_award_id\":\"LBY21H090003\",\"funder_id\":\"https://openalex.org/F4320338464\",\"funder_display_name\":\"Natural Science Foundation of Zhejiang Province\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320338464\",\"display_name\":\"Natural Science Foundation of Zhejiang Province\",\"ror\":\"https://ror.org/01h0zpd94\"}],\"has_content\":{\"pdf\":true,\"grobid_xml\":false},\"referenced_works_count\":62,\"referenced_works\":[\"https://openalex.org/W2190350005\",\"https://openalex.org/W2903710086\",\"https://openalex.org/W2215404676\",\"https://openalex.org/W2088393400\",\"https://openalex.org/W3045771122\",\"https://openalex.org/W2145479354\",\"https://openalex.org/W4207029755\",\"https://openalex.org/W4295560643\",\"https://openalex.org/W3036306531\",\"https://openalex.org/W3028854163\",\"https://openalex.org/W3111509171\",\"https://openalex.org/W4281569188\",\"https://openalex.org/W4292320039\",\"https://openalex.org/W4309742850\",\"https://openalex.org/W2007618030\",\"https://openalex.org/W2110488126\",\"https://openalex.org/W2875834840\",\"https://openalex.org/W4322495020\",\"https://openalex.org/W4283717411\",\"https://openalex.org/W2327547544\",\"https://openalex.org/W2930060644\",\"https://openalex.org/W3106951507\",\"https://openalex.org/W2049599293\",\"https://openalex.org/W2086477221\",\"https://openalex.org/W2886636578\",\"https://openalex.org/W3112030344\",\"https://openalex.org/W2907252505\",\"https://openalex.org/W3047868968\",\"https://openalex.org/W3160244181\",\"https://openalex.org/W3028192110\",\"https://openalex.org/W2735946732\",\"https://openalex.org/W3014730208\",\"https://openalex.org/W4321168396\",\"https://openalex.org/W4324352339\",\"https://openalex.org/W2040062469\",\"https://openalex.org/W2955802834\",\"https://openalex.org/W3216081153\",\"https://openalex.org/W4225337625\",\"https://openalex.org/W4293769694\",\"https://openalex.org/W3183586141\",\"https://openalex.org/W4320492422\",\"https://openalex.org/W3021968482\",\"https://openalex.org/W1768846296\",\"https://openalex.org/W1966634013\",\"https://openalex.org/W1993894887\",\"https://openalex.org/W2147180300\",\"https://openalex.org/W4385350354\",\"https://openalex.org/W3092032238\",\"https://openalex.org/W2889658841\",\"https://openalex.org/W4385844988\",\"https://openalex.org/W4366824059\",\"https://openalex.org/W4285591054\",\"https://openalex.org/W4366446382\",\"https://openalex.org/W3208954200\",\"https://openalex.org/W4213183937\",\"https://openalex.org/W4283755068\",\"https://openalex.org/W4285217791\",\"https://openalex.org/W1994580609\",\"https://openalex.org/W4225473883\",\"https://openalex.org/W4378470000\",\"https://openalex.org/W4390510168\",\"https://openalex.org/W4395000918\"],\"related_works\":[\"https://openalex.org/W3157244191\",\"https://openalex.org/W4361283779\",\"https://openalex.org/W1991750263\",\"https://openalex.org/W2066459637\",\"https://openalex.org/W2149824250\",\"https://openalex.org/W2013980844\",\"https://openalex.org/W3205983928\",\"https://openalex.org/W2310386210\",\"https://openalex.org/W4225149236\",\"https://openalex.org/W2186824132\"],\"abstract_inverted_index\":{\"Abstract\":[0],\"The\":[1],\"blood\":[2],\"brain\":[3],\"barrier\":[4],\"(BBB)\":[5],\"limits\":[6],\"the\":[7,28,34,55,76,92,106,140,163],\"application\":[8],\"of\":[9,33,57,108,120,142],\"most\":[10],\"therapeutic\":[11,43],\"drugs\":[12,116],\"for\":[13,136,171,183],\"neurological\":[14],\"diseases\":[15],\"(NDs).\":[16],\"Hybrid\":[17],\"cell\":[18,24,69,146,165],\"membrane\\\\u2010coated\":[19,166],\"nanoparticles\":[20],\"derived\":[21],\"from\":[22,78],\"different\":[23,118],\"types\":[25],\"can\":[26],\"mimic\":[27],\"surface\":[29],\"properties\":[30],\"and\":[31,42,80,94,159,175],\"functionalities\":[32],\"source\":[35],\"cells,\":[36],\"further\":[37],\"enhancing\":[38],\"their\":[39],\"targeting\":[40],\"precision\":[41],\"efficacy.\":[44],\"Neuroinflammation\":[45],\"has\":[46],\"been\":[47],\"increasingly\":[48],\"recognized\":[49],\"as\":[50],\"a\":[51,67,132,151,180],\"critical\":[52],\"factor\":[53],\"in\":[54,101,150,154,186],\"pathogenesis\":[56],\"various\":[58],\"NDs,\":[59],\"especially\":[60],\"Alzheimer\\'s\":[61],\"disease\":[62],\"(AD).\":[63],\"In\":[64,131],\"this\":[65],\"study,\":[66],\"novel\":[68],\"membrane\":[70,77,147],\"coating\":[71],\"is\":[72],\"designed\":[73],\"by\":[74],\"hybridizing\":[75],\"platelets\":[79],\"chemokine\":[81],\"(C\\\\u2013C\":[82],\"motif)\":[83],\"receptor\":[84],\"2\":[85],\"(CCR2)\":[86],\"cells\":[87],\"are\":[88,124],\"overexpressed\":[89],\"to\":[90,127],\"cross\":[91],\"BBB\":[93],\"target\":[95],\"neuroinflammatory\":[96],\"lesions.\":[97],\"Past\":[98],\"unsuccessful\":[99],\"endeavors\":[100],\"AD\":[102,138],\"drug\":[103,173],\"development\":[104],\"underscore\":[105],\"challenge\":[107],\"achieving\":[109],\"favorable\":[110],\"outcomes\":[111],\"when\":[112],\"utilizing\":[113],\"single\\\\u2010mechanism\":[114],\"drugs.Two\":[115],\"with\":[117],\"mechanisms\":[119],\"actions\":[121],\"into\":[122],\"liposomes\":[123,148],\"successfully\":[125],\"loaded\":[126],\"realize\":[128],\"multitargeting\":[129],\"treatment.\":[130],\"transgenic\":[133],\"mouse\":[134],\"model\":[135],\"familial\":[137],\"(5xFAD),\":[139],\"administration\":[141],\"these\":[143],\"drug\\\\u2010loaded\":[144],\"hybrid\":[145,164],\"results\":[149],\"significant\":[152],\"reduction\":[153],\"amyloid\":[155],\"plaque\":[156],\"deposition,\":[157],\"neuroinflammation,\":[158],\"cognitive\":[160],\"impairments.\":[161],\"Collectively,\":[162],\"nanomaterials\":[167],\"offer\":[168],\"new\":[169],\"opportunities\":[170],\"precise\":[172],\"delivery\":[174],\"disease\\\\u2010specific\":[176],\"targeting,\":[177],\"which\":[178],\"represent\":[179],\"versatile\":[181],\"platform\":[182],\"targeted\":[184],\"therapy\":[185],\"AD.\":[187]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":30},{\"year\":2024,\"cited_by_count\":6}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4323033062\",\"doi\":\"https://doi.org/10.1016/j.ejmech.2023.115245\",\"title\":\"C-glycosides analogues of the okadaic acid central fragment exert neuroprotection via restoration of PP2A-phosphatase activity: A rational design of potential drugs for Alzheimer\\'s disease targeting tauopathies\",\"display_name\":\"C-glycosides analogues of the okadaic acid central fragment exert neuroprotection via restoration of PP2A-phosphatase activity: A rational design of potential drugs for Alzheimer\\'s disease targeting tauopathies\",\"relevance_score\":123.072296,\"publication_year\":2023,\"publication_date\":\"2023-03-03\",\"ids\":{\"openalex\":\"https://openalex.org/W4323033062\",\"doi\":\"https://doi.org/10.1016/j.ejmech.2023.115245\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/36905916\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.ejmech.2023.115245\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmech.2023.115245\",\"pdf_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0223523423002118-ga1_lrg.jpg\",\"source\":{\"id\":\"https://openalex.org/S4210169613\",\"display_name\":\"European Journal of Medicinal Chemistry\",\"issn_l\":\"0223-5234\",\"issn\":[\"0223-5234\",\"1768-3254\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"hybrid\",\"oa_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0223523423002118-ga1_lrg.jpg\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5057643181\",\"display_name\":\"Raquel L. Arribas\",\"orcid\":\"https://orcid.org/0000-0002-2507-1521\"},\"institutions\":[{\"id\":\"https://openalex.org/I63634437\",\"display_name\":\"Universidad Aut\\\\u00f3noma de Madrid\",\"ror\":\"https://ror.org/01cby8j38\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I63634437\"]},{\"id\":\"https://openalex.org/I182083151\",\"display_name\":\"Universidad Rey Juan Carlos\",\"ror\":\"https://ror.org/01v5cv687\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182083151\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Raquel L. Arribas\",\"raw_affiliation_strings\":[\"Departamento de Ciencias B\\\\u00e1sicas de la Salud, Universidad Rey Juan Carlos, 28922, Alcorc\\\\u00f3n, Spain\",\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Departamento de Ciencias B\\\\u00e1sicas de la Salud, Universidad Rey Juan Carlos, 28922, Alcorc\\\\u00f3n, Spain\",\"institution_ids\":[\"https://openalex.org/I182083151\"]},{\"raw_affiliation_string\":\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I63634437\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5017721607\",\"display_name\":\"Luc\\\\u00eda Viejo\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I4210130498\",\"display_name\":\"Hospital Universitario de La Princesa\",\"ror\":\"https://ror.org/03cg5md32\",\"country_code\":\"ES\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210130498\",\"https://openalex.org/I4210139293\"]},{\"id\":\"https://openalex.org/I63634437\",\"display_name\":\"Universidad Aut\\\\u00f3noma de Madrid\",\"ror\":\"https://ror.org/01cby8j38\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I63634437\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Luc\\\\u00eda Viejo\",\"raw_affiliation_strings\":[\"Instituto de Investigaci\\\\u00f3n Sanitaria, Hospital Universitario de la Princesa, C/ Diego de Le\\\\u00f3n, 62, 28006, Madrid, Spain\",\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I63634437\"]},{\"raw_affiliation_string\":\"Instituto de Investigaci\\\\u00f3n Sanitaria, Hospital Universitario de la Princesa, C/ Diego de Le\\\\u00f3n, 62, 28006, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I4210130498\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5064562047\",\"display_name\":\"Isaac Bravo\",\"orcid\":\"https://orcid.org/0000-0002-7950-0838\"},\"institutions\":[{\"id\":\"https://openalex.org/I134820265\",\"display_name\":\"Consejo Superior de Investigaciones Cient\\\\u00edficas\",\"ror\":\"https://ror.org/02gfc7t72\",\"country_code\":\"ES\",\"type\":\"government\",\"lineage\":[\"https://openalex.org/I134820265\"]},{\"id\":\"https://openalex.org/I4210130498\",\"display_name\":\"Hospital Universitario de La Princesa\",\"ror\":\"https://ror.org/03cg5md32\",\"country_code\":\"ES\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210130498\",\"https://openalex.org/I4210139293\"]},{\"id\":\"https://openalex.org/I4210118429\",\"display_name\":\"Instituto de Ciencia de Materiales de Madrid\",\"ror\":\"https://ror.org/02qqy8j09\",\"country_code\":\"ES\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I134820265\",\"https://openalex.org/I4210118429\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Isaac Bravo\",\"raw_affiliation_strings\":[\"Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Cient\\\\u00edficas, 28049, Madrid, Spain\",\"Instituto de Investigaci\\\\u00f3n Sanitaria, Hospital Universitario de la Princesa, C/ Diego de Le\\\\u00f3n, 62, 28006, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Cient\\\\u00edficas, 28049, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I134820265\",\"https://openalex.org/I4210118429\"]},{\"raw_affiliation_string\":\"Instituto de Investigaci\\\\u00f3n Sanitaria, Hospital Universitario de la Princesa, C/ Diego de Le\\\\u00f3n, 62, 28006, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I4210130498\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5004624195\",\"display_name\":\"Minerva Mart\\\\u00ednez\",\"orcid\":\"https://orcid.org/0000-0002-9036-2595\"},\"institutions\":[{\"id\":\"https://openalex.org/I63634437\",\"display_name\":\"Universidad Aut\\\\u00f3noma de Madrid\",\"ror\":\"https://ror.org/01cby8j38\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I63634437\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Minerva Mart\\\\u00ednez\",\"raw_affiliation_strings\":[\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I63634437\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5011686317\",\"display_name\":\"Eva Ramos\",\"orcid\":\"https://orcid.org/0000-0001-5791-0687\"},\"institutions\":[{\"id\":\"https://openalex.org/I121748325\",\"display_name\":\"Universidad Complutense de Madrid\",\"ror\":\"https://ror.org/02p0gd045\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I121748325\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Eva Ramos\",\"raw_affiliation_strings\":[\"Departamento de Farmacolog\\\\u00eda y Toxicolog\\\\u00eda, Facultad de Veterinaria, Universidad Complutense, 28040, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Departamento de Farmacolog\\\\u00eda y Toxicolog\\\\u00eda, Facultad de Veterinaria, Universidad Complutense, 28040, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I121748325\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5017542552\",\"display_name\":\"Alejandro Romero\",\"orcid\":\"https://orcid.org/0000-0001-5483-4973\"},\"institutions\":[{\"id\":\"https://openalex.org/I121748325\",\"display_name\":\"Universidad Complutense de Madrid\",\"ror\":\"https://ror.org/02p0gd045\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I121748325\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Alejandro Romero\",\"raw_affiliation_strings\":[\"Departamento de Farmacolog\\\\u00eda y Toxicolog\\\\u00eda, Facultad de Veterinaria, Universidad Complutense, 28040, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Departamento de Farmacolog\\\\u00eda y Toxicolog\\\\u00eda, Facultad de Veterinaria, Universidad Complutense, 28040, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I121748325\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5066329127\",\"display_name\":\"Eva M. Garc\\\\u00eda\\\\u2010Frutos\",\"orcid\":\"https://orcid.org/0000-0001-6270-1126\"},\"institutions\":[{\"id\":\"https://openalex.org/I134820265\",\"display_name\":\"Consejo Superior de Investigaciones Cient\\\\u00edficas\",\"ror\":\"https://ror.org/02gfc7t72\",\"country_code\":\"ES\",\"type\":\"government\",\"lineage\":[\"https://openalex.org/I134820265\"]},{\"id\":\"https://openalex.org/I4210118429\",\"display_name\":\"Instituto de Ciencia de Materiales de Madrid\",\"ror\":\"https://ror.org/02qqy8j09\",\"country_code\":\"ES\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I134820265\",\"https://openalex.org/I4210118429\"]},{\"id\":\"https://openalex.org/I189268942\",\"display_name\":\"Universidad de Alcal\\\\u00e1\",\"ror\":\"https://ror.org/04pmn0e78\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I189268942\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Eva M. Garc\\\\u00eda-Frutos\",\"raw_affiliation_strings\":[\"Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Cient\\\\u00edficas, 28049, Madrid, Spain\",\"Universidad de Alcal\\\\u00e1, Departamento de Qu\\\\u00edmica Org\\\\u00e1nica y Qu\\\\u00edmica Inorg\\\\u00e1nica, Ctra. Madrid-Barcelona Km.33,600, 28871, Alcal\\\\u00e1 de Henares, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Instituto de Ciencia de Materiales de Madrid, Consejo Superior de Investigaciones Cient\\\\u00edficas, 28049, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I134820265\",\"https://openalex.org/I4210118429\"]},{\"raw_affiliation_string\":\"Universidad de Alcal\\\\u00e1, Departamento de Qu\\\\u00edmica Org\\\\u00e1nica y Qu\\\\u00edmica Inorg\\\\u00e1nica, Ctra. Madrid-Barcelona Km.33,600, 28871, Alcal\\\\u00e1 de Henares, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I189268942\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5052092471\",\"display_name\":\"Veerle Janssens\",\"orcid\":\"https://orcid.org/0000-0002-6772-8448\"},\"institutions\":[{\"id\":\"https://openalex.org/I99464096\",\"display_name\":\"KU Leuven\",\"ror\":\"https://ror.org/05f950310\",\"country_code\":\"BE\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I99464096\"]},{\"id\":\"https://openalex.org/I4210153928\",\"display_name\":\"VIB-KU Leuven Center for Brain & Disease Research\",\"ror\":\"https://ror.org/045c7t348\",\"country_code\":\"BE\",\"type\":\"facility\",\"lineage\":[\"https://openalex.org/I2802017950\",\"https://openalex.org/I4210153928\",\"https://openalex.org/I99464096\"]}],\"countries\":[\"BE\"],\"is_corresponding\":false,\"raw_author_name\":\"Veerle Janssens\",\"raw_affiliation_strings\":[\"Department of Cellular & Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven, B-3000, Leuven, Belgium\",\"LBI (KU Leuven Brain Institute), B-3000, Leuven, Belgium\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Cellular & Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven, B-3000, Leuven, Belgium\",\"institution_ids\":[\"https://openalex.org/I99464096\"]},{\"raw_affiliation_string\":\"LBI (KU Leuven Brain Institute), B-3000, Leuven, Belgium\",\"institution_ids\":[\"https://openalex.org/I4210153928\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101946778\",\"display_name\":\"Carmen Montiel\",\"orcid\":\"https://orcid.org/0000-0003-4845-0484\"},\"institutions\":[{\"id\":\"https://openalex.org/I63634437\",\"display_name\":\"Universidad Aut\\\\u00f3noma de Madrid\",\"ror\":\"https://ror.org/01cby8j38\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I63634437\"]}],\"countries\":[\"ES\"],\"is_corresponding\":false,\"raw_author_name\":\"Carmen Montiel\",\"raw_affiliation_strings\":[\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I63634437\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5080800757\",\"display_name\":\"Crist\\\\u00f3bal de los R\\\\u0131\\\\u0301os\",\"orcid\":\"https://orcid.org/0000-0002-6456-7589\"},\"institutions\":[{\"id\":\"https://openalex.org/I4210130498\",\"display_name\":\"Hospital Universitario de La Princesa\",\"ror\":\"https://ror.org/03cg5md32\",\"country_code\":\"ES\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210130498\",\"https://openalex.org/I4210139293\"]},{\"id\":\"https://openalex.org/I63634437\",\"display_name\":\"Universidad Aut\\\\u00f3noma de Madrid\",\"ror\":\"https://ror.org/01cby8j38\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I63634437\"]},{\"id\":\"https://openalex.org/I182083151\",\"display_name\":\"Universidad Rey Juan Carlos\",\"ror\":\"https://ror.org/01v5cv687\",\"country_code\":\"ES\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I182083151\"]}],\"countries\":[\"ES\"],\"is_corresponding\":true,\"raw_author_name\":\"Crist\\\\u00f3bal de los R\\\\u00edos\",\"raw_affiliation_strings\":[\"Departamento de Ciencias B\\\\u00e1sicas de la Salud, Universidad Rey Juan Carlos, 28922, Alcorc\\\\u00f3n, Spain\",\"Instituto de Investigaci\\\\u00f3n Sanitaria, Hospital Universitario de la Princesa, C/ Diego de Le\\\\u00f3n, 62, 28006, Madrid, Spain\",\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\"],\"affiliations\":[{\"raw_affiliation_string\":\"Instituto-Fundaci\\\\u00f3n Te\\\\u00f3filo Hernando, Universidad Aut\\\\u00f3noma de Madrid, 28029, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I63634437\"]},{\"raw_affiliation_string\":\"Departamento de Ciencias B\\\\u00e1sicas de la Salud, Universidad Rey Juan Carlos, 28922, Alcorc\\\\u00f3n, Spain\",\"institution_ids\":[\"https://openalex.org/I182083151\"]},{\"raw_affiliation_string\":\"Instituto de Investigaci\\\\u00f3n Sanitaria, Hospital Universitario de la Princesa, C/ Diego de Le\\\\u00f3n, 62, 28006, Madrid, Spain\",\"institution_ids\":[\"https://openalex.org/I4210130498\"]}]}],\"institutions\":[],\"countries_distinct_count\":2,\"institutions_distinct_count\":10,\"corresponding_author_ids\":[\"https://openalex.org/A5080800757\"],\"corresponding_institution_ids\":[\"https://openalex.org/I182083151\",\"https://openalex.org/I4210130498\",\"https://openalex.org/I63634437\"],\"apc_list\":{\"value\":4710,\"currency\":\"USD\",\"value_usd\":4710},\"apc_paid\":{\"value\":4710,\"currency\":\"USD\",\"value_usd\":4710},\"fwci\":1.78498598,\"has_fulltext\":true,\"cited_by_count\":6,\"citation_normalized_percentile\":{\"value\":0.78398416,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":false},\"cited_by_percentile_year\":{\"min\":96,\"max\":97},\"biblio\":{\"volume\":\"251\",\"issue\":null,\"first_page\":\"115245\",\"last_page\":\"115245\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.9998000264167786,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T13127\",\"display_name\":\"Biotin and Related Studies\",\"score\":0.9902999997138977,\"subfield\":{\"id\":\"https://openalex.org/subfields/1307\",\"display_name\":\"Cell Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/protein-phosphatase-2\",\"display_name\":\"Protein phosphatase 2\",\"score\":0.934872031211853},{\"id\":\"https://openalex.org/keywords/okadaic-acid\",\"display_name\":\"Okadaic acid\",\"score\":0.8449942469596863},{\"id\":\"https://openalex.org/keywords/neuroprotection\",\"display_name\":\"Neuroprotection\",\"score\":0.7525202035903931},{\"id\":\"https://openalex.org/keywords/neurodegeneration\",\"display_name\":\"Neurodegeneration\",\"score\":0.7236241102218628},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.632753849029541},{\"id\":\"https://openalex.org/keywords/phosphatase\",\"display_name\":\"Phosphatase\",\"score\":0.5964314937591553},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.4562133848667145},{\"id\":\"https://openalex.org/keywords/phosphorylation\",\"display_name\":\"Phosphorylation\",\"score\":0.3771861791610718},{\"id\":\"https://openalex.org/keywords/pharmacology\",\"display_name\":\"Pharmacology\",\"score\":0.31076693534851074},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.21982958912849426},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.1363733410835266},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.12174639105796814}],\"concepts\":[{\"id\":\"https://openalex.org/C389152\",\"wikidata\":\"https://www.wikidata.org/wiki/Q6593007\",\"display_name\":\"Protein phosphatase 2\",\"level\":4,\"score\":0.934872031211853},{\"id\":\"https://openalex.org/C2776953658\",\"wikidata\":\"https://www.wikidata.org/wiki/Q414042\",\"display_name\":\"Okadaic acid\",\"level\":4,\"score\":0.8449942469596863},{\"id\":\"https://openalex.org/C25498285\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1981368\",\"display_name\":\"Neuroprotection\",\"level\":2,\"score\":0.7525202035903931},{\"id\":\"https://openalex.org/C2776925932\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1755122\",\"display_name\":\"Neurodegeneration\",\"level\":3,\"score\":0.7236241102218628},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.632753849029541},{\"id\":\"https://openalex.org/C178666793\",\"wikidata\":\"https://www.wikidata.org/wiki/Q422476\",\"display_name\":\"Phosphatase\",\"level\":3,\"score\":0.5964314937591553},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.4562133848667145},{\"id\":\"https://openalex.org/C11960822\",\"wikidata\":\"https://www.wikidata.org/wiki/Q242736\",\"display_name\":\"Phosphorylation\",\"level\":2,\"score\":0.3771861791610718},{\"id\":\"https://openalex.org/C98274493\",\"wikidata\":\"https://www.wikidata.org/wiki/Q128406\",\"display_name\":\"Pharmacology\",\"level\":1,\"score\":0.31076693534851074},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.21982958912849426},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.1363733410835266},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.12174639105796814},{\"id\":\"https://openalex.org/C142724271\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7208\",\"display_name\":\"Pathology\",\"level\":1,\"score\":0.0}],\"mesh\":[{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D019319\",\"descriptor_name\":\"Okadaic Acid\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D019319\",\"descriptor_name\":\"Okadaic Acid\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000066829\",\"descriptor_name\":\"Neuroprotection\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D024801\",\"descriptor_name\":\"Tauopathies\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D024801\",\"descriptor_name\":\"Tauopathies\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D054648\",\"descriptor_name\":\"Protein Phosphatase 2\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010766\",\"descriptor_name\":\"Phosphorylation\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D019319\",\"descriptor_name\":\"Okadaic Acid\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D019319\",\"descriptor_name\":\"Okadaic Acid\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000066829\",\"descriptor_name\":\"Neuroprotection\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D024801\",\"descriptor_name\":\"Tauopathies\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D024801\",\"descriptor_name\":\"Tauopathies\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016875\",\"descriptor_name\":\"tau Proteins\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D054648\",\"descriptor_name\":\"Protein Phosphatase 2\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D010766\",\"descriptor_name\":\"Phosphorylation\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false}],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.1016/j.ejmech.2023.115245\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmech.2023.115245\",\"pdf_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0223523423002118-ga1_lrg.jpg\",\"source\":{\"id\":\"https://openalex.org/S4210169613\",\"display_name\":\"European Journal of Medicinal Chemistry\",\"issn_l\":\"0223-5234\",\"issn\":[\"0223-5234\",\"1768-3254\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:36905916\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/36905916\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European journal of medicinal chemistry\",\"raw_type\":null},{\"id\":\"pmh:oai:lirias2repo.kuleuven.be:20.500.12942/716111\",\"is_oa\":false,\"landing_page_url\":\"https://lirias.kuleuven.be/handle/20.500.12942/716111\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401954\",\"display_name\":\"Lirias (KU Leuven)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I99464096\",\"host_organization_name\":\"KU Leuven\",\"host_organization_lineage\":[\"https://openalex.org/I99464096\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"acceptedVersion\",\"is_accepted\":true,\"is_published\":false,\"raw_source_name\":\"\",\"raw_type\":\"info:eu-repo/semantics/article\"},{\"id\":\"pmh:oai:eciencia.urjc.es:10115/21889\",\"is_oa\":true,\"landing_page_url\":\"https://hdl.handle.net/10115/21889\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4377196484\",\"display_name\":\"BURJC Digital (King Juan Carlos University)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I182083151\",\"host_organization_name\":\"Universidad Rey Juan Carlos\",\"host_organization_lineage\":[\"https://openalex.org/I182083151\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"\",\"raw_type\":\"info:eu-repo/semantics/article\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.ejmech.2023.115245\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.ejmech.2023.115245\",\"pdf_url\":\"https://ars.els-cdn.com/content/image/1-s2.0-S0223523423002118-ga1_lrg.jpg\",\"source\":{\"id\":\"https://openalex.org/S4210169613\",\"display_name\":\"European Journal of Medicinal Chemistry\",\"issn_l\":\"0223-5234\",\"issn\":[\"0223-5234\",\"1768-3254\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"European Journal of Medicinal Chemistry\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":true,\"grobid_xml\":true},\"referenced_works_count\":100,\"referenced_works\":[\"https://openalex.org/W2883486552\",\"https://openalex.org/W2809347312\",\"https://openalex.org/W2004589450\",\"https://openalex.org/W2316147511\",\"https://openalex.org/W4206399986\",\"https://openalex.org/W2652333723\",\"https://openalex.org/W4220922008\",\"https://openalex.org/W1992060900\",\"https://openalex.org/W151043947\",\"https://openalex.org/W2165421630\",\"https://openalex.org/W2810742876\",\"https://openalex.org/W4284974624\",\"https://openalex.org/W6686970072\",\"https://openalex.org/W6796483154\",\"https://openalex.org/W2883780404\",\"https://openalex.org/W3008581670\",\"https://openalex.org/W2767014526\",\"https://openalex.org/W2275844993\",\"https://openalex.org/W2613638456\",\"https://openalex.org/W4254813010\",\"https://openalex.org/W3174470840\",\"https://openalex.org/W4200313415\",\"https://openalex.org/W3169418599\",\"https://openalex.org/W2783753716\",\"https://openalex.org/W1974894246\",\"https://openalex.org/W3015317152\",\"https://openalex.org/W2036011584\",\"https://openalex.org/W2767311859\",\"https://openalex.org/W2036755018\",\"https://openalex.org/W2091864083\",\"https://openalex.org/W2084623733\",\"https://openalex.org/W2063618925\",\"https://openalex.org/W2916954261\",\"https://openalex.org/W2039252864\",\"https://openalex.org/W3199233950\",\"https://openalex.org/W3092680517\",\"https://openalex.org/W3149626258\",\"https://openalex.org/W2747341145\",\"https://openalex.org/W4200082477\",\"https://openalex.org/W2079766520\",\"https://openalex.org/W2888777811\",\"https://openalex.org/W2923298018\",\"https://openalex.org/W3092800327\",\"https://openalex.org/W1986689904\",\"https://openalex.org/W3094478904\",\"https://openalex.org/W3007884563\",\"https://openalex.org/W3016570710\",\"https://openalex.org/W2809901315\",\"https://openalex.org/W2751682851\",\"https://openalex.org/W3157581595\",\"https://openalex.org/W2488225289\",\"https://openalex.org/W2027223952\",\"https://openalex.org/W2092149740\",\"https://openalex.org/W2418241164\",\"https://openalex.org/W2884605655\",\"https://openalex.org/W2104973420\",\"https://openalex.org/W2159527263\",\"https://openalex.org/W2215536036\",\"https://openalex.org/W2077338973\",\"https://openalex.org/W3019582910\",\"https://openalex.org/W2053087530\",\"https://openalex.org/W2034998855\",\"https://openalex.org/W2320978996\",\"https://openalex.org/W2105890788\",\"https://openalex.org/W2130285555\",\"https://openalex.org/W2085074107\",\"https://openalex.org/W1978293942\",\"https://openalex.org/W2135093769\",\"https://openalex.org/W3133010899\",\"https://openalex.org/W1652692682\",\"https://openalex.org/W2212369426\",\"https://openalex.org/W6623138178\",\"https://openalex.org/W2097724095\",\"https://openalex.org/W2046487040\",\"https://openalex.org/W1971626394\",\"https://openalex.org/W1954244449\",\"https://openalex.org/W2026976753\",\"https://openalex.org/W2084087750\",\"https://openalex.org/W2764338099\",\"https://openalex.org/W2971383976\",\"https://openalex.org/W2438137602\",\"https://openalex.org/W3094901675\",\"https://openalex.org/W2405438293\",\"https://openalex.org/W2515738886\",\"https://openalex.org/W2490914809\",\"https://openalex.org/W2901069861\",\"https://openalex.org/W1985995915\",\"https://openalex.org/W2048326203\",\"https://openalex.org/W2345745719\",\"https://openalex.org/W2902089216\",\"https://openalex.org/W1888784858\",\"https://openalex.org/W3192198384\",\"https://openalex.org/W1984855334\",\"https://openalex.org/W4230225138\",\"https://openalex.org/W3186759140\",\"https://openalex.org/W2043855224\",\"https://openalex.org/W3127508675\",\"https://openalex.org/W813117701\",\"https://openalex.org/W2188311484\",\"https://openalex.org/W3169258609\"],\"related_works\":[\"https://openalex.org/W2401222492\",\"https://openalex.org/W2106104578\",\"https://openalex.org/W2042377147\",\"https://openalex.org/W2006645013\",\"https://openalex.org/W1749352888\",\"https://openalex.org/W2064248967\",\"https://openalex.org/W1977451227\",\"https://openalex.org/W1972714621\",\"https://openalex.org/W1968790372\",\"https://openalex.org/W1545615234\"],\"abstract_inverted_index\":null,\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":3},{\"year\":2023,\"cited_by_count\":3}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4390725672\",\"doi\":\"https://doi.org/10.1186/s40035-023-00395-5\",\"title\":\"Death-associated protein kinase 1 as a therapeutic target for Alzheimer\\'s disease\",\"display_name\":\"Death-associated protein kinase 1 as a therapeutic target for Alzheimer\\'s disease\",\"relevance_score\":122.8518,\"publication_year\":2024,\"publication_date\":\"2024-01-09\",\"ids\":{\"openalex\":\"https://openalex.org/W4390725672\",\"doi\":\"https://doi.org/10.1186/s40035-023-00395-5\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/38195518\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1186/s40035-023-00395-5\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1186/s40035-023-00395-5\",\"pdf_url\":\"https://translationalneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s40035-023-00395-5\",\"source\":{\"id\":\"https://openalex.org/S2764798395\",\"display_name\":\"Translational Neurodegeneration\",\"issn_l\":\"2047-9158\",\"issn\":[\"2047-9158\",\"2096-6466\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320256\",\"host_organization_name\":\"BioMed Central\",\"host_organization_lineage\":[\"https://openalex.org/P4310320256\",\"https://openalex.org/P4310319965\"],\"host_organization_lineage_names\":[\"BioMed Central\",\"Springer Nature\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Translational Neurodegeneration\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://translationalneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s40035-023-00395-5\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5100375846\",\"display_name\":\"Tao Zhang\",\"orcid\":\"https://orcid.org/0000-0002-8157-7674\"},\"institutions\":[{\"id\":\"https://openalex.org/I129708740\",\"display_name\":\"Fujian Medical University\",\"ror\":\"https://ror.org/050s6ns64\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I129708740\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Tao Zhang\",\"raw_affiliation_strings\":[\"Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute of Basic Medicine, School of Basic Medical Sciences, Fujian Medical University, 1 Xuefu North Road, Fuzhou, 350122, Fujian, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute of Basic Medicine, School of Basic Medical Sciences, Fujian Medical University, 1 Xuefu North Road, Fuzhou, 350122, Fujian, China\",\"institution_ids\":[\"https://openalex.org/I129708740\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5075750843\",\"display_name\":\"Byeong Mo Kim\",\"orcid\":\"https://orcid.org/0000-0002-0582-3132\"},\"institutions\":[],\"countries\":[],\"is_corresponding\":true,\"raw_author_name\":\"Byeong Mo Kim\",\"raw_affiliation_strings\":[\"Research Center for New Drug Development, AgingTarget Inc., 10F Ace Cheonggye Tower, 53, Seonggogae-Ro, Uiwang-Si, 16006, Gyeonggi-Do, Korea\"],\"affiliations\":[{\"raw_affiliation_string\":\"Research Center for New Drug Development, AgingTarget Inc., 10F Ace Cheonggye Tower, 53, Seonggogae-Ro, Uiwang-Si, 16006, Gyeonggi-Do, Korea\",\"institution_ids\":[]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5100699664\",\"display_name\":\"Tae Ho Lee\",\"orcid\":\"https://orcid.org/0000-0001-5968-1478\"},\"institutions\":[{\"id\":\"https://openalex.org/I129708740\",\"display_name\":\"Fujian Medical University\",\"ror\":\"https://ror.org/050s6ns64\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I129708740\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Tae Ho Lee\",\"raw_affiliation_strings\":[\"Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute of Basic Medicine, School of Basic Medical Sciences, Fujian Medical University, 1 Xuefu North Road, Fuzhou, 350122, Fujian, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Institute of Basic Medicine, School of Basic Medical Sciences, Fujian Medical University, 1 Xuefu North Road, Fuzhou, 350122, Fujian, China\",\"institution_ids\":[\"https://openalex.org/I129708740\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":3,\"corresponding_author_ids\":[\"https://openalex.org/A5075750843\"],\"corresponding_institution_ids\":[],\"apc_list\":{\"value\":1700,\"currency\":\"GBP\",\"value_usd\":2085},\"apc_paid\":{\"value\":1700,\"currency\":\"GBP\",\"value_usd\":2085},\"fwci\":22.68945902,\"has_fulltext\":true,\"cited_by_count\":30,\"citation_normalized_percentile\":{\"value\":0.99190339,\"is_in_top_1_percent\":true,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":99,\"max\":100},\"biblio\":{\"volume\":\"13\",\"issue\":\"1\",\"first_page\":\"4\",\"last_page\":\"4\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9987000226974487,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9987000226974487,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.9973000288009644,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T10301\",\"display_name\":\"Mitochondrial Function and Pathology\",\"score\":0.980400025844574,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/neurology\",\"display_name\":\"Neurology\",\"score\":0.717073380947113},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.6279195547103882},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.5251469612121582},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.4802834689617157},{\"id\":\"https://openalex.org/keywords/alzheimers-disease\",\"display_name\":\"Alzheimer\\'s disease\",\"score\":0.4303939938545227},{\"id\":\"https://openalex.org/keywords/psychology\",\"display_name\":\"Psychology\",\"score\":0.26927176117897034},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.23426395654678345}],\"concepts\":[{\"id\":\"https://openalex.org/C16568411\",\"wikidata\":\"https://www.wikidata.org/wiki/Q83042\",\"display_name\":\"Neurology\",\"level\":2,\"score\":0.717073380947113},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.6279195547103882},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.5251469612121582},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.4802834689617157},{\"id\":\"https://openalex.org/C502032728\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11081\",\"display_name\":\"Alzheimer\\'s disease\",\"level\":3,\"score\":0.4303939938545227},{\"id\":\"https://openalex.org/C15744967\",\"wikidata\":\"https://www.wikidata.org/wiki/Q9418\",\"display_name\":\"Psychology\",\"level\":0,\"score\":0.26927176117897034},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.23426395654678345}],\"mesh\":[{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D064550\",\"descriptor_name\":\"Death-Associated Protein Kinases\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D002490\",\"descriptor_name\":\"Central Nervous System\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D016874\",\"descriptor_name\":\"Neurofibrillary Tangles\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D064550\",\"descriptor_name\":\"Death-Associated Protein Kinases\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D002490\",\"descriptor_name\":\"Central Nervous System\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D016874\",\"descriptor_name\":\"Neurofibrillary Tangles\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D064550\",\"descriptor_name\":\"Death-Associated Protein Kinases\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D002490\",\"descriptor_name\":\"Central Nervous System\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D016874\",\"descriptor_name\":\"Neurofibrillary Tangles\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false}],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.1186/s40035-023-00395-5\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1186/s40035-023-00395-5\",\"pdf_url\":\"https://translationalneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s40035-023-00395-5\",\"source\":{\"id\":\"https://openalex.org/S2764798395\",\"display_name\":\"Translational Neurodegeneration\",\"issn_l\":\"2047-9158\",\"issn\":[\"2047-9158\",\"2096-6466\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320256\",\"host_organization_name\":\"BioMed Central\",\"host_organization_lineage\":[\"https://openalex.org/P4310320256\",\"https://openalex.org/P4310319965\"],\"host_organization_lineage_names\":[\"BioMed Central\",\"Springer Nature\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Translational Neurodegeneration\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:38195518\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/38195518\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Translational neurodegeneration\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:10775678\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/10775678\",\"pdf_url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10775678/pdf/40035_2023_Article_395.pdf\",\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Transl Neurodegener\",\"raw_type\":\"Text\"},{\"id\":\"pmh:oai:doaj.org/article:ae372be1bc6e41c18c455cd52796feca\",\"is_oa\":false,\"landing_page_url\":\"https://doaj.org/article/ae372be1bc6e41c18c455cd52796feca\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Translational Neurodegeneration, Vol 13, Iss 1, Pp 1-26 (2024)\",\"raw_type\":\"article\"}],\"best_oa_location\":{\"id\":\"doi:10.1186/s40035-023-00395-5\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1186/s40035-023-00395-5\",\"pdf_url\":\"https://translationalneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s40035-023-00395-5\",\"source\":{\"id\":\"https://openalex.org/S2764798395\",\"display_name\":\"Translational Neurodegeneration\",\"issn_l\":\"2047-9158\",\"issn\":[\"2047-9158\",\"2096-6466\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320256\",\"host_organization_name\":\"BioMed Central\",\"host_organization_lineage\":[\"https://openalex.org/P4310320256\",\"https://openalex.org/P4310319965\"],\"host_organization_lineage_names\":[\"BioMed Central\",\"Springer Nature\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Translational Neurodegeneration\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.8199999928474426,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G225543353\",\"display_name\":null,\"funder_award_id\":\"82001128\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"},{\"id\":\"https://openalex.org/G7037724957\",\"display_name\":null,\"funder_award_id\":\"81970993\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"},{\"id\":\"https://openalex.org/G7045544197\",\"display_name\":null,\"funder_award_id\":\"82271449\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"},{\"id\":\"https://openalex.org/G5952689808\",\"display_name\":null,\"funder_award_id\":\"2021J01672\",\"funder_id\":\"https://openalex.org/F4320321878\",\"funder_display_name\":\"Natural Science Foundation of Fujian Province\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320321001\",\"display_name\":\"National Natural Science Foundation of China\",\"ror\":\"https://ror.org/01h0zpd94\"},{\"id\":\"https://openalex.org/F4320321878\",\"display_name\":\"Natural Science Foundation of Fujian Province\",\"ror\":null}],\"has_content\":{\"pdf\":true,\"grobid_xml\":true},\"referenced_works_count\":237,\"referenced_works\":[\"https://openalex.org/W4206055706\",\"https://openalex.org/W4221074325\",\"https://openalex.org/W4281717038\",\"https://openalex.org/W1988332799\",\"https://openalex.org/W2044365168\",\"https://openalex.org/W4308787152\",\"https://openalex.org/W3167427671\",\"https://openalex.org/W4283645535\",\"https://openalex.org/W3154609307\",\"https://openalex.org/W3094335331\",\"https://openalex.org/W2891796239\",\"https://openalex.org/W2074274706\",\"https://openalex.org/W2353776455\",\"https://openalex.org/W2293378393\",\"https://openalex.org/W2907547898\",\"https://openalex.org/W2129085204\",\"https://openalex.org/W1504590764\",\"https://openalex.org/W2599851926\",\"https://openalex.org/W1968900405\",\"https://openalex.org/W2946546847\",\"https://openalex.org/W2734651019\",\"https://openalex.org/W4280489557\",\"https://openalex.org/W1750598644\",\"https://openalex.org/W3198052269\",\"https://openalex.org/W2067960064\",\"https://openalex.org/W2559911659\",\"https://openalex.org/W2101198372\",\"https://openalex.org/W4320725274\",\"https://openalex.org/W3173990459\",\"https://openalex.org/W2566006671\",\"https://openalex.org/W2611941014\",\"https://openalex.org/W2149117501\",\"https://openalex.org/W2996968585\",\"https://openalex.org/W2047509412\",\"https://openalex.org/W2903634707\",\"https://openalex.org/W2131242591\",\"https://openalex.org/W1529356860\",\"https://openalex.org/W2039363263\",\"https://openalex.org/W2072128563\",\"https://openalex.org/W2171128065\",\"https://openalex.org/W2811337037\",\"https://openalex.org/W2030291243\",\"https://openalex.org/W2013275758\",\"https://openalex.org/W657056040\",\"https://openalex.org/W1987579092\",\"https://openalex.org/W2170883726\",\"https://openalex.org/W2464666781\",\"https://openalex.org/W2095777706\",\"https://openalex.org/W1992544868\",\"https://openalex.org/W2053875448\",\"https://openalex.org/W2001812643\",\"https://openalex.org/W2057871351\",\"https://openalex.org/W2028200399\",\"https://openalex.org/W2010323640\",\"https://openalex.org/W1974954701\",\"https://openalex.org/W1964801647\",\"https://openalex.org/W2041352318\",\"https://openalex.org/W4386209304\",\"https://openalex.org/W2145923454\",\"https://openalex.org/W2041329507\",\"https://openalex.org/W1879825028\",\"https://openalex.org/W2025140437\",\"https://openalex.org/W2148359476\",\"https://openalex.org/W2158830017\",\"https://openalex.org/W3178020494\",\"https://openalex.org/W3170458329\",\"https://openalex.org/W2616773834\",\"https://openalex.org/W3154107584\",\"https://openalex.org/W1992517146\",\"https://openalex.org/W2435874442\",\"https://openalex.org/W2024790646\",\"https://openalex.org/W4366753626\",\"https://openalex.org/W2112215250\",\"https://openalex.org/W1972764026\",\"https://openalex.org/W2481414842\",\"https://openalex.org/W3177331132\",\"https://openalex.org/W4282018440\",\"https://openalex.org/W2336130860\",\"https://openalex.org/W1985025450\",\"https://openalex.org/W4310493829\",\"https://openalex.org/W4286002175\",\"https://openalex.org/W2904655861\",\"https://openalex.org/W2266996964\",\"https://openalex.org/W2164868723\",\"https://openalex.org/W2016229866\",\"https://openalex.org/W2288441382\",\"https://openalex.org/W3001510487\",\"https://openalex.org/W2736307756\",\"https://openalex.org/W2888674814\",\"https://openalex.org/W2965401191\",\"https://openalex.org/W3133577453\",\"https://openalex.org/W2000003300\",\"https://openalex.org/W1765891430\",\"https://openalex.org/W1934830575\",\"https://openalex.org/W2606314411\",\"https://openalex.org/W2135816796\",\"https://openalex.org/W2107962371\",\"https://openalex.org/W2922392851\",\"https://openalex.org/W2782247629\",\"https://openalex.org/W2154499565\",\"https://openalex.org/W2025877033\",\"https://openalex.org/W2076677973\",\"https://openalex.org/W2602575049\",\"https://openalex.org/W3161886511\",\"https://openalex.org/W4282923007\",\"https://openalex.org/W2013298471\",\"https://openalex.org/W4224145767\",\"https://openalex.org/W3039858658\",\"https://openalex.org/W2609093534\",\"https://openalex.org/W4312998965\",\"https://openalex.org/W4311114246\",\"https://openalex.org/W2536783646\",\"https://openalex.org/W1516034495\",\"https://openalex.org/W3097878253\",\"https://openalex.org/W2964994792\",\"https://openalex.org/W3164434555\",\"https://openalex.org/W4223899051\",\"https://openalex.org/W2887375527\",\"https://openalex.org/W2742120708\",\"https://openalex.org/W2093823051\",\"https://openalex.org/W2076409812\",\"https://openalex.org/W2131081669\",\"https://openalex.org/W4382932595\",\"https://openalex.org/W2480735346\",\"https://openalex.org/W4220970963\",\"https://openalex.org/W1969417329\",\"https://openalex.org/W3104103000\",\"https://openalex.org/W3180800189\",\"https://openalex.org/W3021576841\",\"https://openalex.org/W3097434651\",\"https://openalex.org/W4229370959\",\"https://openalex.org/W2037162598\",\"https://openalex.org/W2614627885\",\"https://openalex.org/W3106024955\",\"https://openalex.org/W4200221148\",\"https://openalex.org/W3172557627\",\"https://openalex.org/W3141120829\",\"https://openalex.org/W3007641349\",\"https://openalex.org/W2993429139\",\"https://openalex.org/W3016006538\",\"https://openalex.org/W3155966446\",\"https://openalex.org/W3093965237\",\"https://openalex.org/W3092007569\",\"https://openalex.org/W3102160053\",\"https://openalex.org/W2007837288\",\"https://openalex.org/W1934412961\",\"https://openalex.org/W1541944730\",\"https://openalex.org/W3025571398\",\"https://openalex.org/W1586035563\",\"https://openalex.org/W2104449396\",\"https://openalex.org/W3118496727\",\"https://openalex.org/W4323294238\",\"https://openalex.org/W3203517638\",\"https://openalex.org/W1974036368\",\"https://openalex.org/W2313725855\",\"https://openalex.org/W2091077008\",\"https://openalex.org/W2809941199\",\"https://openalex.org/W2789018622\",\"https://openalex.org/W3171124897\",\"https://openalex.org/W3178830196\",\"https://openalex.org/W2261085470\",\"https://openalex.org/W2085435800\",\"https://openalex.org/W2121802881\",\"https://openalex.org/W3154026152\",\"https://openalex.org/W2083063570\",\"https://openalex.org/W1966134982\",\"https://openalex.org/W2063563698\",\"https://openalex.org/W2584068329\",\"https://openalex.org/W1703528746\",\"https://openalex.org/W2145962946\",\"https://openalex.org/W2074300163\",\"https://openalex.org/W1970543690\",\"https://openalex.org/W1983693972\",\"https://openalex.org/W2324327757\",\"https://openalex.org/W1981720385\",\"https://openalex.org/W2142296555\",\"https://openalex.org/W4226325779\",\"https://openalex.org/W4387159130\",\"https://openalex.org/W2131039108\",\"https://openalex.org/W1985241009\",\"https://openalex.org/W2625709293\",\"https://openalex.org/W3015282949\",\"https://openalex.org/W2166747217\",\"https://openalex.org/W2056293200\",\"https://openalex.org/W4362473302\",\"https://openalex.org/W4211072901\",\"https://openalex.org/W2774947569\",\"https://openalex.org/W3135516129\",\"https://openalex.org/W4220672384\",\"https://openalex.org/W2148914027\",\"https://openalex.org/W2925620762\",\"https://openalex.org/W2953948138\",\"https://openalex.org/W3173194636\",\"https://openalex.org/W2099588975\",\"https://openalex.org/W1994411647\",\"https://openalex.org/W1994239968\",\"https://openalex.org/W1990126127\",\"https://openalex.org/W2109781014\",\"https://openalex.org/W2553424415\",\"https://openalex.org/W4385064357\",\"https://openalex.org/W4316495567\",\"https://openalex.org/W2106622563\",\"https://openalex.org/W1964917807\",\"https://openalex.org/W2017338994\",\"https://openalex.org/W1978031869\",\"https://openalex.org/W2074446289\",\"https://openalex.org/W2749870290\",\"https://openalex.org/W2898877713\",\"https://openalex.org/W4293207190\",\"https://openalex.org/W1980046354\",\"https://openalex.org/W2085971293\",\"https://openalex.org/W4382632093\",\"https://openalex.org/W4282917663\",\"https://openalex.org/W2261131592\",\"https://openalex.org/W3114553900\",\"https://openalex.org/W4376224377\",\"https://openalex.org/W3017071941\",\"https://openalex.org/W4381715842\",\"https://openalex.org/W3093864441\",\"https://openalex.org/W4381432200\",\"https://openalex.org/W2140476569\",\"https://openalex.org/W2078351994\",\"https://openalex.org/W1986623293\",\"https://openalex.org/W1860382351\",\"https://openalex.org/W3199648870\",\"https://openalex.org/W4212959738\",\"https://openalex.org/W4386700766\",\"https://openalex.org/W3040958797\",\"https://openalex.org/W2932882403\",\"https://openalex.org/W2037053607\",\"https://openalex.org/W1522284801\",\"https://openalex.org/W2001796870\",\"https://openalex.org/W4213210311\",\"https://openalex.org/W2955080130\",\"https://openalex.org/W3022694800\",\"https://openalex.org/W4221049185\",\"https://openalex.org/W4226373958\"],\"related_works\":[\"https://openalex.org/W2899084033\",\"https://openalex.org/W2748952813\",\"https://openalex.org/W3031052312\",\"https://openalex.org/W4389568370\",\"https://openalex.org/W3032375762\",\"https://openalex.org/W1995515455\",\"https://openalex.org/W2080531066\",\"https://openalex.org/W3108674512\",\"https://openalex.org/W1506200166\",\"https://openalex.org/W1489783725\"],\"abstract_inverted_index\":{\"Abstract\":[0],\"Alzheimer\\\\u2019s\":[1],\"disease\":[2,85],\"(AD)\":[3],\"is\":[4,59,128],\"the\":[5,12,21,39,63,114,160,164,187],\"most\":[6],\"prevalent\":[7],\"form\":[8],\"of\":[9,26,32,41,68,93,111,116,150,166,189],\"dementia\":[10],\"in\":[11,20,62,113,130,153,174],\"elderly\":[13],\"and\":[14,51,83,97,100,143,170,195],\"represents\":[15],\"a\":[16,108,182],\"major\":[17],\"clinical\":[18],\"challenge\":[19],\"ageing\":[22],\"society.\":[23],\"Neuropathological\":[24],\"hallmarks\":[25],\"AD\":[27,132,154,175,194],\"include\":[28],\"neurofibrillary\":[29],\"tangles\":[30],\"composed\":[31],\"hyperphosphorylated\":[33],\"tau,\":[34],\"senile\":[35],\"plaques\":[36],\"derived\":[37],\"from\":[38],\"deposition\":[40],\"amyloid-\\\\u03b2\":[42],\"(A\\\\u03b2)\":[43],\"peptides,\":[44],\"brain\":[45],\"atrophy\":[46],\"induced\":[47],\"by\":[48],\"neuronal\":[49,101,140],\"loss,\":[50],\"synaptic\":[52,144],\"dysfunctions.\":[53],\"Death-associated\":[54],\"protein\":[55,105],\"kinase\":[56],\"1\":[57],\"(DAPK1)\":[58],\"ubiquitously\":[60],\"expressed\":[61],\"central\":[64],\"nervous\":[65],\"system.\":[66],\"Dysregulation\":[67],\"DAPK1\":[69,94,112,127,151,168,180],\"has\":[70],\"been\":[71],\"shown\":[72],\"to\":[73,75],\"contribute\":[74],\"various\":[76,131],\"neurological\":[77,197],\"diseases\":[78],\"including\":[79,135],\"AD,\":[80],\"ischemic\":[81],\"stroke\":[82],\"Parkinson\\\\u2019s\":[84],\"(PD).\":[86],\"We\":[87,157],\"have\":[88],\"established\":[89],\"an\":[90],\"upstream\":[91],\"effect\":[92],\"on\":[95],\"A\\\\u03b2\":[96,138],\"tau\":[98,136],\"pathologies\":[99],\"apoptosis\":[102],\"through\":[103],\"kinase-mediated\":[104],\"phosphorylation,\":[106],\"supporting\":[107],\"causal\":[109],\"role\":[110],\"pathophysiology\":[115],\"AD.\":[117],\"In\":[118],\"this\":[119],\"review,\":[120],\"we\":[121],\"summarize\":[122],\"current\":[123],\"knowledge\":[124],\"about\":[125],\"how\":[126],\"involved\":[129],\"pathological\":[133],\"changes\":[134],\"hyperphosphorylation,\":[137],\"deposition,\":[139],\"cell\":[141],\"death\":[142],\"degeneration.\":[145],\"The\":[146],\"underlying\":[147],\"molecular\":[148],\"mechanisms\":[149],\"dysregulation\":[152],\"are\":[155],\"discussed.\":[156],\"also\":[158],\"review\":[159],\"recent\":[161],\"progress\":[162],\"regarding\":[163],\"development\":[165,188],\"novel\":[167,183],\"modulators\":[169],\"their\":[171],\"potential\":[172],\"applications\":[173],\"intervention.\":[176],\"These\":[177],\"findings\":[178],\"substantiate\":[179],\"as\":[181],\"therapeutic\":[184],\"target\":[185],\"for\":[186,193],\"multifunctional\":[190],\"disease-modifying\":[191],\"treatments\":[192],\"other\":[196],\"disorders.\":[198]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":22},{\"year\":2024,\"cited_by_count\":8}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4375954973\",\"doi\":\"https://doi.org/10.1002/alz.13095\",\"title\":\"Sex\\\\u2010specific declines in cholinergic\\\\u2010targeting tRNA fragments in the nucleus accumbens in Alzheimer\\'s disease\",\"display_name\":\"Sex\\\\u2010specific declines in cholinergic\\\\u2010targeting tRNA fragments in the nucleus accumbens in Alzheimer\\'s disease\",\"relevance_score\":121.24502,\"publication_year\":2023,\"publication_date\":\"2023-05-09\",\"ids\":{\"openalex\":\"https://openalex.org/W4375954973\",\"doi\":\"https://doi.org/10.1002/alz.13095\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/37158312\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1002/alz.13095\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/alz.13095\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.13095\",\"source\":{\"id\":\"https://openalex.org/S108427512\",\"display_name\":\"Alzheimer s & Dementia\",\"issn_l\":\"1552-5260\",\"issn\":[\"1552-5260\",\"1552-5279\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by-nc\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s &amp; Dementia\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"hybrid\",\"oa_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.13095\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5013750163\",\"display_name\":\"Dana Shulman\",\"orcid\":\"https://orcid.org/0000-0002-2272-3723\"},\"institutions\":[{\"id\":\"https://openalex.org/I197251160\",\"display_name\":\"Hebrew University of Jerusalem\",\"ror\":\"https://ror.org/03qxff017\",\"country_code\":\"IL\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I197251160\"]}],\"countries\":[\"IL\"],\"is_corresponding\":false,\"raw_author_name\":\"Dana Shulman\",\"raw_affiliation_strings\":[\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"The Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Rachel and Selim Benin School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5068579397\",\"display_name\":\"Serafima Dubnov\",\"orcid\":\"https://orcid.org/0000-0001-7982-6195\"},\"institutions\":[{\"id\":\"https://openalex.org/I197251160\",\"display_name\":\"Hebrew University of Jerusalem\",\"ror\":\"https://ror.org/03qxff017\",\"country_code\":\"IL\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I197251160\"]}],\"countries\":[\"IL\"],\"is_corresponding\":false,\"raw_author_name\":\"Serafima Dubnov\",\"raw_affiliation_strings\":[\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5062391042\",\"display_name\":\"Tamara Zorbaz\",\"orcid\":\"https://orcid.org/0000-0002-6367-8690\"},\"institutions\":[{\"id\":\"https://openalex.org/I197251160\",\"display_name\":\"Hebrew University of Jerusalem\",\"ror\":\"https://ror.org/03qxff017\",\"country_code\":\"IL\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I197251160\"]}],\"countries\":[\"IL\"],\"is_corresponding\":false,\"raw_author_name\":\"Tamara Zorbaz\",\"raw_affiliation_strings\":[\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5028287875\",\"display_name\":\"Nimrod Madrer\",\"orcid\":\"https://orcid.org/0000-0002-8467-5085\"},\"institutions\":[{\"id\":\"https://openalex.org/I197251160\",\"display_name\":\"Hebrew University of Jerusalem\",\"ror\":\"https://ror.org/03qxff017\",\"country_code\":\"IL\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I197251160\"]}],\"countries\":[\"IL\"],\"is_corresponding\":false,\"raw_author_name\":\"Nimrod Madrer\",\"raw_affiliation_strings\":[\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5014756671\",\"display_name\":\"Iddo Paldor\",\"orcid\":\"https://orcid.org/0000-0001-8737-5953\"},\"institutions\":[{\"id\":\"https://openalex.org/I2801962034\",\"display_name\":\"Shaare Zedek Medical Center\",\"ror\":\"https://ror.org/04d0szq68\",\"country_code\":\"IL\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I2801962034\"]}],\"countries\":[\"IL\"],\"is_corresponding\":false,\"raw_author_name\":\"Iddo Paldor\",\"raw_affiliation_strings\":[\"The Neurosurgery Department, Shaare Zedek Medical Center, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Neurosurgery Department, Shaare Zedek Medical Center, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I2801962034\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5014075642\",\"display_name\":\"David A. Bennett\",\"orcid\":\"https://orcid.org/0000-0003-3689-554X\"},\"institutions\":[{\"id\":\"https://openalex.org/I1285301757\",\"display_name\":\"Rush University Medical Center\",\"ror\":\"https://ror.org/01j7c0b24\",\"country_code\":\"US\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I1285301757\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"David A. Bennett\",\"raw_affiliation_strings\":[\"Rush Alzheimer\\'s Disease Center, Rush University Medical Center, Chicago, Illinois, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Rush Alzheimer\\'s Disease Center, Rush University Medical Center, Chicago, Illinois, USA\",\"institution_ids\":[\"https://openalex.org/I1285301757\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5011863508\",\"display_name\":\"Sudha Seshadri\",\"orcid\":\"https://orcid.org/0000-0001-6135-2622\"},\"institutions\":[{\"id\":\"https://openalex.org/I919571938\",\"display_name\":\"The University of Texas Health Science Center at Houston\",\"ror\":\"https://ror.org/03gds6c39\",\"country_code\":\"US\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I919571938\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Sudha Seshadri\",\"raw_affiliation_strings\":[\"UT Health Medical Arts &amp; Research Center San Antonio Texas USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"UT Health Medical Arts &amp; Research Center San Antonio Texas USA\",\"institution_ids\":[\"https://openalex.org/I919571938\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5072527270\",\"display_name\":\"Elliott J. Mufson\",\"orcid\":\"https://orcid.org/0000-0003-4438-7334\"},\"institutions\":[{\"id\":\"https://openalex.org/I1324766304\",\"display_name\":\"Barrow Neurological Institute\",\"ror\":\"https://ror.org/01fwrsq33\",\"country_code\":\"US\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I1324766304\",\"https://openalex.org/I1325481341\",\"https://openalex.org/I2802827176\"]},{\"id\":\"https://openalex.org/I1325481341\",\"display_name\":\"St. Joseph\\'s Hospital and Medical Center\",\"ror\":\"https://ror.org/00m72wv30\",\"country_code\":\"US\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I1325481341\",\"https://openalex.org/I2802827176\"]}],\"countries\":[\"US\"],\"is_corresponding\":false,\"raw_author_name\":\"Elliott J. Mufson\",\"raw_affiliation_strings\":[\"Barrow Neurological Institute, St. Joseph\\'s Medical Center, Phoenix, Arizona, USA\"],\"affiliations\":[{\"raw_affiliation_string\":\"Barrow Neurological Institute, St. Joseph\\'s Medical Center, Phoenix, Arizona, USA\",\"institution_ids\":[\"https://openalex.org/I1324766304\",\"https://openalex.org/I1325481341\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5028844100\",\"display_name\":\"David Greenberg\",\"orcid\":\"https://orcid.org/0000-0001-8959-8640\"},\"institutions\":[{\"id\":\"https://openalex.org/I197251160\",\"display_name\":\"Hebrew University of Jerusalem\",\"ror\":\"https://ror.org/03qxff017\",\"country_code\":\"IL\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I197251160\"]}],\"countries\":[\"IL\"],\"is_corresponding\":false,\"raw_author_name\":\"David S. Greenberg\",\"raw_affiliation_strings\":[\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5074945649\",\"display_name\":\"Yonatan Loewenstein\",\"orcid\":\"https://orcid.org/0000-0003-2577-2317\"},\"institutions\":[{\"id\":\"https://openalex.org/I197251160\",\"display_name\":\"Hebrew University of Jerusalem\",\"ror\":\"https://ror.org/03qxff017\",\"country_code\":\"IL\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I197251160\"]},{\"id\":\"https://openalex.org/I2800263366\",\"display_name\":\"Jerusalem Institute for Israel Studies\",\"ror\":\"https://ror.org/02zax3c17\",\"country_code\":\"IL\",\"type\":\"nonprofit\",\"lineage\":[\"https://openalex.org/I2800263366\"]}],\"countries\":[\"IL\"],\"is_corresponding\":false,\"raw_author_name\":\"Yonatan Loewenstein\",\"raw_affiliation_strings\":[\"The Department of Cognitive Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"The Department of Neurobiology, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"The Federmann Center for the Study of Rationality, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Department of Neurobiology, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Department of Cognitive Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Federmann Center for the Study of Rationality, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I2800263366\"]},{\"raw_affiliation_string\":\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5003680413\",\"display_name\":\"Hermona Soreq\",\"orcid\":\"https://orcid.org/0000-0002-0955-526X\"},\"institutions\":[{\"id\":\"https://openalex.org/I197251160\",\"display_name\":\"Hebrew University of Jerusalem\",\"ror\":\"https://ror.org/03qxff017\",\"country_code\":\"IL\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I197251160\"]}],\"countries\":[\"IL\"],\"is_corresponding\":true,\"raw_author_name\":\"Hermona Soreq\",\"raw_affiliation_strings\":[\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\"],\"affiliations\":[{\"raw_affiliation_string\":\"The Edmond &amp; Lily Safra Center for Brain Sciences The Hebrew University of Jerusalem Jerusalem Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]},{\"raw_affiliation_string\":\"The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel\",\"institution_ids\":[\"https://openalex.org/I197251160\"]}]}],\"institutions\":[],\"countries_distinct_count\":2,\"institutions_distinct_count\":11,\"corresponding_author_ids\":[\"https://openalex.org/A5003680413\"],\"corresponding_institution_ids\":[\"https://openalex.org/I197251160\"],\"apc_list\":{\"value\":4000,\"currency\":\"USD\",\"value_usd\":4000},\"apc_paid\":{\"value\":4000,\"currency\":\"USD\",\"value_usd\":4000},\"fwci\":6.68413467,\"has_fulltext\":true,\"cited_by_count\":36,\"citation_normalized_percentile\":{\"value\":0.97302379,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":99,\"max\":100},\"biblio\":{\"volume\":\"19\",\"issue\":\"11\",\"first_page\":\"5159\",\"last_page\":\"5172\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10301\",\"display_name\":\"Mitochondrial Function and Pathology\",\"score\":0.9991999864578247,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10301\",\"display_name\":\"Mitochondrial Function and Pathology\",\"score\":0.9991999864578247,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T11772\",\"display_name\":\"Genetics and Neurodevelopmental Disorders\",\"score\":0.998199999332428,\"subfield\":{\"id\":\"https://openalex.org/subfields/1311\",\"display_name\":\"Genetics\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T11482\",\"display_name\":\"RNA modifications and cancer\",\"score\":0.991599977016449,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/nucleus-accumbens\",\"display_name\":\"Nucleus accumbens\",\"score\":0.8548508882522583},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.6380123496055603},{\"id\":\"https://openalex.org/keywords/cholinergic\",\"display_name\":\"Cholinergic\",\"score\":0.611477792263031},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.5945567488670349},{\"id\":\"https://openalex.org/keywords/cholinergic-neuron\",\"display_name\":\"Cholinergic neuron\",\"score\":0.4438607692718506},{\"id\":\"https://openalex.org/keywords/psychology\",\"display_name\":\"Psychology\",\"score\":0.4026623070240021},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.3979087173938751},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.3898801803588867},{\"id\":\"https://openalex.org/keywords/dopamine\",\"display_name\":\"Dopamine\",\"score\":0.2586566209793091},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.243779718875885}],\"concepts\":[{\"id\":\"https://openalex.org/C2776552330\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1476178\",\"display_name\":\"Nucleus accumbens\",\"level\":3,\"score\":0.8548508882522583},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.6380123496055603},{\"id\":\"https://openalex.org/C22885893\",\"wikidata\":\"https://www.wikidata.org/wiki/Q4862743\",\"display_name\":\"Cholinergic\",\"level\":2,\"score\":0.611477792263031},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.5945567488670349},{\"id\":\"https://openalex.org/C104966671\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12167532\",\"display_name\":\"Cholinergic neuron\",\"level\":3,\"score\":0.4438607692718506},{\"id\":\"https://openalex.org/C15744967\",\"wikidata\":\"https://www.wikidata.org/wiki/Q9418\",\"display_name\":\"Psychology\",\"level\":0,\"score\":0.4026623070240021},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.3979087173938751},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.3898801803588867},{\"id\":\"https://openalex.org/C513476851\",\"wikidata\":\"https://www.wikidata.org/wiki/Q170304\",\"display_name\":\"Dopamine\",\"level\":2,\"score\":0.2586566209793091},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.243779718875885}],\"mesh\":[{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D008297\",\"descriptor_name\":\"Male\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D005260\",\"descriptor_name\":\"Female\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000235\",\"qualifier_name\":\"genetics\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D009714\",\"descriptor_name\":\"Nucleus Accumbens\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D059329\",\"descriptor_name\":\"Cholinergic Neurons\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D018678\",\"descriptor_name\":\"Cholinergic Agents\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012313\",\"descriptor_name\":\"RNA\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D012343\",\"descriptor_name\":\"RNA, Transfer\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false}],\"locations_count\":3,\"locations\":[{\"id\":\"doi:10.1002/alz.13095\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/alz.13095\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.13095\",\"source\":{\"id\":\"https://openalex.org/S108427512\",\"display_name\":\"Alzheimer s & Dementia\",\"issn_l\":\"1552-5260\",\"issn\":[\"1552-5260\",\"1552-5279\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by-nc\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s &amp; Dementia\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:37158312\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/37158312\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s & dementia : the journal of the Alzheimer\\'s Association\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:10632545\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/10632545\",\"pdf_url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10632545/pdf/nihms-1889309.pdf\",\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Alzheimers Dement\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.1002/alz.13095\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/alz.13095\",\"pdf_url\":\"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.13095\",\"source\":{\"id\":\"https://openalex.org/S108427512\",\"display_name\":\"Alzheimer s & Dementia\",\"issn_l\":\"1552-5260\",\"issn\":[\"1552-5260\",\"1552-5279\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by-nc\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Alzheimer\\'s &amp; Dementia\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.7900000214576721,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G1300837600\",\"display_name\":null,\"funder_award_id\":\"3213/19\",\"funder_id\":\"https://openalex.org/F4320322252\",\"funder_display_name\":\"Israel Science Foundation\"},{\"id\":\"https://openalex.org/G4406027993\",\"display_name\":null,\"funder_award_id\":\"1016/18\",\"funder_id\":\"https://openalex.org/F4320322252\",\"funder_display_name\":\"Israel Science Foundation\"},{\"id\":\"https://openalex.org/G6812816563\",\"display_name\":null,\"funder_award_id\":\"P30AG10161\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G7236275076\",\"display_name\":null,\"funder_award_id\":\"5P01AG014449\\\\u201021\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G4628925741\",\"display_name\":null,\"funder_award_id\":\"P30AG72975\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G5635590448\",\"display_name\":null,\"funder_award_id\":\"R01AG15819\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G4920313038\",\"display_name\":null,\"funder_award_id\":\"R01AG17917\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G3718314765\",\"display_name\":null,\"funder_award_id\":\"U01AG61356\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"},{\"id\":\"https://openalex.org/G3609886758\",\"display_name\":null,\"funder_award_id\":\"U01AG46152\",\"funder_id\":\"https://openalex.org/F4320332161\",\"funder_display_name\":\"National Institutes of Health\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320320033\",\"display_name\":\"Gatsby Charitable Foundation\",\"ror\":\"https://ror.org/0290hax27\"},{\"id\":\"https://openalex.org/F4320322252\",\"display_name\":\"Israel Science Foundation\",\"ror\":\"https://ror.org/04sazxf24\"},{\"id\":\"https://openalex.org/F4320332161\",\"display_name\":\"National Institutes of Health\",\"ror\":\"https://ror.org/01cwqze88\"}],\"has_content\":{\"pdf\":true,\"grobid_xml\":true},\"referenced_works_count\":78,\"referenced_works\":[\"https://openalex.org/W2760285987\",\"https://openalex.org/W2548348201\",\"https://openalex.org/W1584825376\",\"https://openalex.org/W3010942637\",\"https://openalex.org/W2790974918\",\"https://openalex.org/W2793063033\",\"https://openalex.org/W2834941082\",\"https://openalex.org/W2342797086\",\"https://openalex.org/W2944862235\",\"https://openalex.org/W2100464372\",\"https://openalex.org/W3012860009\",\"https://openalex.org/W2909141710\",\"https://openalex.org/W1994067502\",\"https://openalex.org/W3132547308\",\"https://openalex.org/W1984458220\",\"https://openalex.org/W4220993307\",\"https://openalex.org/W2075527287\",\"https://openalex.org/W2011879529\",\"https://openalex.org/W2805257646\",\"https://openalex.org/W2781783827\",\"https://openalex.org/W4211064852\",\"https://openalex.org/W2096128947\",\"https://openalex.org/W2996255187\",\"https://openalex.org/W3019632053\",\"https://openalex.org/W2992035784\",\"https://openalex.org/W2417123930\",\"https://openalex.org/W3113366819\",\"https://openalex.org/W2624905717\",\"https://openalex.org/W3215571011\",\"https://openalex.org/W2809330972\",\"https://openalex.org/W2033848869\",\"https://openalex.org/W1984283611\",\"https://openalex.org/W2075464796\",\"https://openalex.org/W2179438025\",\"https://openalex.org/W2168173728\",\"https://openalex.org/W2171398108\",\"https://openalex.org/W2027988197\",\"https://openalex.org/W2121025439\",\"https://openalex.org/W2000885272\",\"https://openalex.org/W2104912427\",\"https://openalex.org/W2763456538\",\"https://openalex.org/W2168271199\",\"https://openalex.org/W2981104605\",\"https://openalex.org/W2018424479\",\"https://openalex.org/W2800474634\",\"https://openalex.org/W2774098908\",\"https://openalex.org/W2749159502\",\"https://openalex.org/W3047740285\",\"https://openalex.org/W1556440977\",\"https://openalex.org/W2123300858\",\"https://openalex.org/W2157190000\",\"https://openalex.org/W2553654192\",\"https://openalex.org/W2279197036\",\"https://openalex.org/W2576113955\",\"https://openalex.org/W1516578895\",\"https://openalex.org/W4231403277\",\"https://openalex.org/W2056015216\",\"https://openalex.org/W2795215203\",\"https://openalex.org/W1806432442\",\"https://openalex.org/W2788669874\",\"https://openalex.org/W2041986831\",\"https://openalex.org/W2029187758\",\"https://openalex.org/W4309034012\",\"https://openalex.org/W2573280973\",\"https://openalex.org/W2030787126\",\"https://openalex.org/W2591733518\",\"https://openalex.org/W2104287008\",\"https://openalex.org/W2049111961\",\"https://openalex.org/W2072308972\",\"https://openalex.org/W2582524520\",\"https://openalex.org/W1528213115\",\"https://openalex.org/W4283786359\",\"https://openalex.org/W3018541302\",\"https://openalex.org/W2783644856\",\"https://openalex.org/W2143787026\",\"https://openalex.org/W2958689915\",\"https://openalex.org/W4308683241\",\"https://openalex.org/W2115017507\"],\"related_works\":[\"https://openalex.org/W2476048018\",\"https://openalex.org/W945989265\",\"https://openalex.org/W1951208502\",\"https://openalex.org/W324094240\",\"https://openalex.org/W2088479689\",\"https://openalex.org/W2744660949\",\"https://openalex.org/W4241186036\",\"https://openalex.org/W1994135233\",\"https://openalex.org/W2103669147\",\"https://openalex.org/W1991480100\"],\"abstract_inverted_index\":{\"Abstract\":[0],\"Introduction\":[1],\"Females\":[2],\"with\":[3,97],\"Alzheimer\\'s\":[4],\"disease\":[5],\"(AD)\":[6],\"suffer\":[7],\"accelerated\":[8],\"dementia\":[9],\"and\":[10,73,151],\"loss\":[11,150],\"of\":[12,88,116],\"cholinergic\":[13,41,62,83,117,128,141,149],\"neurons\":[14],\"compared\":[15,64],\"to\":[16,27,65,140],\"males,\":[17],\"but\":[18],\"the\":[19,52],\"underlying\":[20],\"mechanisms\":[21],\"are\":[22],\"unknown.\":[23],\"Seeking\":[24],\"causal\":[25],\"contributors\":[26],\"both\":[28],\"these\":[29],\"phenomena,\":[30],\"we\":[31],\"pursued\":[32],\"changes\":[33],\"in\":[34,61,78,99,119,146],\"transfer\":[35],\"RNS\":[36],\"(tRNA)\":[37],\"fragments\":[38],\"(tRFs)\":[39],\"targeting\":[40],\"transcripts\":[42,118],\"(CholinotRFs).\":[43],\"Methods\":[44],\"We\":[45],\"analyzed\":[46],\"small\":[47,75],\"RNA\\\\u2010sequencing\":[48],\"(RNA\\\\u2010Seq)\":[49],\"data\":[50],\"from\":[51,70,108],\"nucleus\":[53],\"accumbens\":[54],\"(NAc)\":[55],\"brain\":[56],\"region\":[57],\"which\":[58],\"is\":[59],\"enriched\":[60],\"neurons,\":[63],\"hypothalamic\":[66],\"or\":[67],\"cortical\":[68],\"tissues\":[69],\"AD\":[71,109,147],\"brains;\":[72],\"explored\":[74],\"RNA\":[76,106],\"expression\":[77],\"neuronal\":[79],\"cell\":[80,121],\"lines\":[81],\"undergoing\":[82],\"differentiation.\":[84],\"Results\":[85],\"NAc\":[86],\"CholinotRFs\":[87,138],\"mitochondrial\":[89],\"genome\":[90],\"origin\":[91],\"showed\":[92,112],\"reduced\":[93],\"levels\":[94,115],\"that\":[95],\"correlated\":[96],\"elevations\":[98],\"their\":[100,144],\"predicted\":[101],\"cholinergic\\\\u2010associated\":[102],\"mRNA\":[103],\"targets.\":[104],\"Single\\\\u2010cell\":[105],\"seq\":[107],\"temporal\":[110],\"cortices\":[111],\"altered\":[113],\"sex\\\\u2010specific\":[114,131,148],\"diverse\":[120],\"types;\":[122],\"inversely,\":[123],\"human\\\\u2010originated\":[124],\"neuroblastoma\":[125],\"cells\":[126],\"under\":[127],\"differentiation\":[129],\"presented\":[130],\"CholinotRF\":[132],\"elevations.\":[133],\"Discussion\":[134],\"Our\":[135],\"findings\":[136],\"support\":[137],\"contributions\":[139],\"regulation,\":[142],\"predicting\":[143],\"involvement\":[145],\"dementia.\":[152]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":15},{\"year\":2024,\"cited_by_count\":13},{\"year\":2023,\"cited_by_count\":8}],\"updated_date\":\"2025-11-20T23:13:51.555489\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4366446382\",\"doi\":\"https://doi.org/10.1002/advs.202301361\",\"title\":\"Study on the Role of an Erythrocyte Membrane\\\\u2010Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer\\'s Disease\",\"display_name\":\"Study on the Role of an Erythrocyte Membrane\\\\u2010Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer\\'s Disease\",\"relevance_score\":121.01738,\"publication_year\":2023,\"publication_date\":\"2023-04-19\",\"ids\":{\"openalex\":\"https://openalex.org/W4366446382\",\"doi\":\"https://doi.org/10.1002/advs.202301361\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/37075744\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1002/advs.202301361\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/advs.202301361\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2737737698\",\"display_name\":\"Advanced Science\",\"issn_l\":\"2198-3844\",\"issn\":[\"2198-3844\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Advanced Science\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://doi.org/10.1002/advs.202301361\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5003572052\",\"display_name\":\"Yanrong Su\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yanrong Su\",\"raw_affiliation_strings\":[\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5083859974\",\"display_name\":\"Yu\\\\u2010Fen Huang\",\"orcid\":\"https://orcid.org/0000-0001-7686-8090\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yufen Huang\",\"raw_affiliation_strings\":[\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5001661106\",\"display_name\":\"Qinjie Kou\",\"orcid\":\"https://orcid.org/0009-0008-9272-4685\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Qinjie Kou\",\"raw_affiliation_strings\":[\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5108047787\",\"display_name\":\"Lu Lu\",\"orcid\":\"https://orcid.org/0000-0002-0960-1529\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Lu Lu\",\"raw_affiliation_strings\":[\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5065803420\",\"display_name\":\"Haiye Jiang\",\"orcid\":\"https://orcid.org/0000-0001-6745-9578\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Haiye Jiang\",\"raw_affiliation_strings\":[\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5022228815\",\"display_name\":\"Xisheng Li\",\"orcid\":\"https://orcid.org/0000-0001-8172-5342\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Xisheng Li\",\"raw_affiliation_strings\":[\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5008932652\",\"display_name\":\"Rong Gui\",\"orcid\":\"https://orcid.org/0000-0001-7790-0291\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Rong Gui\",\"raw_affiliation_strings\":[\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101530547\",\"display_name\":\"Rong Huang\",\"orcid\":\"https://orcid.org/0000-0001-9933-9538\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Rong Huang\",\"raw_affiliation_strings\":[\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5010630605\",\"display_name\":\"Xueyuan Huang\",\"orcid\":\"https://orcid.org/0000-0003-1482-7415\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Xueyuan Huang\",\"raw_affiliation_strings\":[\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5027995967\",\"display_name\":\"Jinqi Ma\",\"orcid\":\"https://orcid.org/0000-0003-1437-9296\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Jinqi Ma\",\"raw_affiliation_strings\":[\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101872241\",\"display_name\":\"Jian Li\",\"orcid\":\"https://orcid.org/0000-0001-6562-6483\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Jian Li\",\"raw_affiliation_strings\":[\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Blood Transfusion, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5006337183\",\"display_name\":\"Xinmin Nie\",\"orcid\":\"https://orcid.org/0000-0003-3104-2505\"},\"institutions\":[{\"id\":\"https://openalex.org/I139660479\",\"display_name\":\"Central South University\",\"ror\":\"https://ror.org/00f1zfq44\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I139660479\"]},{\"id\":\"https://openalex.org/I4210156904\",\"display_name\":\"Third Xiangya Hospital\",\"ror\":\"https://ror.org/05akvb491\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I4210156904\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Xinmin Nie\",\"raw_affiliation_strings\":[\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"Hunan Engineering Technology Research Center of Optoelectronic Health Detection, Changsha, Hunan, 410000 China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Laboratory Medicine, The Third Xiangya Hospital, Central South University, No.138,Tongzipo Road,Yuelu District, Changsha, Hunan, 410013 China\",\"institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"]},{\"raw_affiliation_string\":\"Hunan Engineering Technology Research Center of Optoelectronic Health Detection, Changsha, Hunan, 410000 China\",\"institution_ids\":[]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":12,\"corresponding_author_ids\":[\"https://openalex.org/A5006337183\",\"https://openalex.org/A5101872241\"],\"corresponding_institution_ids\":[\"https://openalex.org/I139660479\",\"https://openalex.org/I4210156904\"],\"apc_list\":{\"value\":5000,\"currency\":\"USD\",\"value_usd\":5000},\"apc_paid\":{\"value\":5000,\"currency\":\"USD\",\"value_usd\":5000},\"fwci\":8.66873979,\"has_fulltext\":false,\"cited_by_count\":39,\"citation_normalized_percentile\":{\"value\":0.96713933,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":97,\"max\":100},\"biblio\":{\"volume\":\"10\",\"issue\":\"18\",\"first_page\":\"e2301361\",\"last_page\":\"e2301361\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T11266\",\"display_name\":\"Neuroinflammation and Neurodegeneration Mechanisms\",\"score\":0.9998999834060669,\"subfield\":{\"id\":\"https://openalex.org/subfields/2808\",\"display_name\":\"Neurology\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T11266\",\"display_name\":\"Neuroinflammation and Neurodegeneration Mechanisms\",\"score\":0.9998999834060669,\"subfield\":{\"id\":\"https://openalex.org/subfields/2808\",\"display_name\":\"Neurology\"},\"field\":{\"id\":\"https://openalex.org/fields/28\",\"display_name\":\"Neuroscience\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}},{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9983000159263611,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T10407\",\"display_name\":\"Lipid Membrane Structure and Behavior\",\"score\":0.9948999881744385,\"subfield\":{\"id\":\"https://openalex.org/subfields/1312\",\"display_name\":\"Molecular Biology\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/microglia\",\"display_name\":\"Microglia\",\"score\":0.6881723403930664},{\"id\":\"https://openalex.org/keywords/immune-system\",\"display_name\":\"Immune system\",\"score\":0.6516714096069336},{\"id\":\"https://openalex.org/keywords/transferrin-receptor\",\"display_name\":\"Transferrin receptor\",\"score\":0.5227599143981934},{\"id\":\"https://openalex.org/keywords/phagocytosis\",\"display_name\":\"Phagocytosis\",\"score\":0.47211897373199463},{\"id\":\"https://openalex.org/keywords/inflammation\",\"display_name\":\"Inflammation\",\"score\":0.4718741476535797},{\"id\":\"https://openalex.org/keywords/population\",\"display_name\":\"Population\",\"score\":0.44637051224708557},{\"id\":\"https://openalex.org/keywords/aptamer\",\"display_name\":\"Aptamer\",\"score\":0.4347335994243622},{\"id\":\"https://openalex.org/keywords/cell-biology\",\"display_name\":\"Cell biology\",\"score\":0.42216843366622925},{\"id\":\"https://openalex.org/keywords/immunology\",\"display_name\":\"Immunology\",\"score\":0.4155479371547699},{\"id\":\"https://openalex.org/keywords/chemistry\",\"display_name\":\"Chemistry\",\"score\":0.4147435128688812},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.3465201258659363},{\"id\":\"https://openalex.org/keywords/biology\",\"display_name\":\"Biology\",\"score\":0.3335076570510864},{\"id\":\"https://openalex.org/keywords/transferrin\",\"display_name\":\"Transferrin\",\"score\":0.3253978490829468},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.2940100431442261},{\"id\":\"https://openalex.org/keywords/molecular-biology\",\"display_name\":\"Molecular biology\",\"score\":0.14775222539901733},{\"id\":\"https://openalex.org/keywords/biochemistry\",\"display_name\":\"Biochemistry\",\"score\":0.13939407467842102}],\"concepts\":[{\"id\":\"https://openalex.org/C2779830541\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1622829\",\"display_name\":\"Microglia\",\"level\":3,\"score\":0.6881723403930664},{\"id\":\"https://openalex.org/C8891405\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1059\",\"display_name\":\"Immune system\",\"level\":2,\"score\":0.6516714096069336},{\"id\":\"https://openalex.org/C32264632\",\"wikidata\":\"https://www.wikidata.org/wiki/Q1134983\",\"display_name\":\"Transferrin receptor\",\"level\":3,\"score\":0.5227599143981934},{\"id\":\"https://openalex.org/C160448771\",\"wikidata\":\"https://www.wikidata.org/wiki/Q184726\",\"display_name\":\"Phagocytosis\",\"level\":2,\"score\":0.47211897373199463},{\"id\":\"https://openalex.org/C2776914184\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101991\",\"display_name\":\"Inflammation\",\"level\":2,\"score\":0.4718741476535797},{\"id\":\"https://openalex.org/C2908647359\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2625603\",\"display_name\":\"Population\",\"level\":2,\"score\":0.44637051224708557},{\"id\":\"https://openalex.org/C128972844\",\"wikidata\":\"https://www.wikidata.org/wiki/Q418722\",\"display_name\":\"Aptamer\",\"level\":2,\"score\":0.4347335994243622},{\"id\":\"https://openalex.org/C95444343\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7141\",\"display_name\":\"Cell biology\",\"level\":1,\"score\":0.42216843366622925},{\"id\":\"https://openalex.org/C203014093\",\"wikidata\":\"https://www.wikidata.org/wiki/Q101929\",\"display_name\":\"Immunology\",\"level\":1,\"score\":0.4155479371547699},{\"id\":\"https://openalex.org/C185592680\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2329\",\"display_name\":\"Chemistry\",\"level\":0,\"score\":0.4147435128688812},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.3465201258659363},{\"id\":\"https://openalex.org/C86803240\",\"wikidata\":\"https://www.wikidata.org/wiki/Q420\",\"display_name\":\"Biology\",\"level\":0,\"score\":0.3335076570510864},{\"id\":\"https://openalex.org/C22814914\",\"wikidata\":\"https://www.wikidata.org/wiki/Q410473\",\"display_name\":\"Transferrin\",\"level\":2,\"score\":0.3253978490829468},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.2940100431442261},{\"id\":\"https://openalex.org/C153911025\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7202\",\"display_name\":\"Molecular biology\",\"level\":1,\"score\":0.14775222539901733},{\"id\":\"https://openalex.org/C55493867\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7094\",\"display_name\":\"Biochemistry\",\"level\":1,\"score\":0.13939407467842102},{\"id\":\"https://openalex.org/C99454951\",\"wikidata\":\"https://www.wikidata.org/wiki/Q932068\",\"display_name\":\"Environmental health\",\"level\":1,\"score\":0.0}],\"mesh\":[{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":false},{\"descriptor_ui\":\"D004910\",\"descriptor_name\":\"Erythrocyte Membrane\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000068936\",\"descriptor_name\":\"Theranostic Nanomedicine\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D001921\",\"descriptor_name\":\"Brain\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":false},{\"descriptor_ui\":\"D004910\",\"descriptor_name\":\"Erythrocyte Membrane\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000068936\",\"descriptor_name\":\"Theranostic Nanomedicine\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D001921\",\"descriptor_name\":\"Brain\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000368\",\"descriptor_name\":\"Aged\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D051379\",\"descriptor_name\":\"Mice\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D006801\",\"descriptor_name\":\"Humans\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000818\",\"descriptor_name\":\"Animals\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000188\",\"qualifier_name\":\"drug therapy\",\"is_major_topic\":true},{\"descriptor_ui\":\"D000544\",\"descriptor_name\":\"Alzheimer Disease\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":true},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000494\",\"qualifier_name\":\"pharmacology\",\"is_major_topic\":false},{\"descriptor_ui\":\"D016229\",\"descriptor_name\":\"Amyloid beta-Peptides\",\"qualifier_ui\":\"Q000627\",\"qualifier_name\":\"therapeutic use\",\"is_major_topic\":false},{\"descriptor_ui\":\"D004910\",\"descriptor_name\":\"Erythrocyte Membrane\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false},{\"descriptor_ui\":\"D000068936\",\"descriptor_name\":\"Theranostic Nanomedicine\",\"qualifier_ui\":null,\"qualifier_name\":null,\"is_major_topic\":false},{\"descriptor_ui\":\"D001921\",\"descriptor_name\":\"Brain\",\"qualifier_ui\":\"Q000378\",\"qualifier_name\":\"metabolism\",\"is_major_topic\":false}],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.1002/advs.202301361\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/advs.202301361\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2737737698\",\"display_name\":\"Advanced Science\",\"issn_l\":\"2198-3844\",\"issn\":[\"2198-3844\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Advanced Science\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:37075744\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/37075744\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\"raw_type\":null},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:10288270\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/10288270\",\"pdf_url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC10288270/pdf/ADVS-10-2301361.pdf\",\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Adv Sci (Weinh)\",\"raw_type\":\"Text\"},{\"id\":\"pmh:oai:doaj.org/article:4206edb3c09c470c818c9c8b4518b328\",\"is_oa\":false,\"landing_page_url\":\"https://doaj.org/article/4206edb3c09c470c818c9c8b4518b328\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Advanced Science, Vol 10, Iss 18, Pp n/a-n/a (2023)\",\"raw_type\":\"article\"}],\"best_oa_location\":{\"id\":\"doi:10.1002/advs.202301361\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1002/advs.202301361\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2737737698\",\"display_name\":\"Advanced Science\",\"issn_l\":\"2198-3844\",\"issn\":[\"2198-3844\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320595\",\"host_organization_name\":\"Wiley\",\"host_organization_lineage\":[\"https://openalex.org/P4310320595\"],\"host_organization_lineage_names\":[\"Wiley\"],\"type\":\"journal\"},\"license\":\"cc-by\",\"license_id\":\"https://openalex.org/licenses/cc-by\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Advanced Science\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.75,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G8614057625\",\"display_name\":null,\"funder_award_id\":\"82001165\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"},{\"id\":\"https://openalex.org/G7458495653\",\"display_name\":null,\"funder_award_id\":\"81971748\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320321001\",\"display_name\":\"National Natural Science Foundation of China\",\"ror\":\"https://ror.org/01h0zpd94\"}],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":53,\"referenced_works\":[\"https://openalex.org/W4220825176\",\"https://openalex.org/W2103440561\",\"https://openalex.org/W2084972185\",\"https://openalex.org/W2087243986\",\"https://openalex.org/W2759351857\",\"https://openalex.org/W2750718695\",\"https://openalex.org/W3010337769\",\"https://openalex.org/W2163179762\",\"https://openalex.org/W2314634699\",\"https://openalex.org/W2921781039\",\"https://openalex.org/W4200041296\",\"https://openalex.org/W2018708829\",\"https://openalex.org/W2934339908\",\"https://openalex.org/W2591798217\",\"https://openalex.org/W2318173837\",\"https://openalex.org/W3119786711\",\"https://openalex.org/W2316561960\",\"https://openalex.org/W2994700726\",\"https://openalex.org/W2145479354\",\"https://openalex.org/W2286941691\",\"https://openalex.org/W3008396563\",\"https://openalex.org/W1517477926\",\"https://openalex.org/W2912471195\",\"https://openalex.org/W2738239402\",\"https://openalex.org/W3134309694\",\"https://openalex.org/W4309410878\",\"https://openalex.org/W2037283553\",\"https://openalex.org/W4296311472\",\"https://openalex.org/W2810634892\",\"https://openalex.org/W2952980848\",\"https://openalex.org/W2900583139\",\"https://openalex.org/W2139418176\",\"https://openalex.org/W2544837642\",\"https://openalex.org/W2124502931\",\"https://openalex.org/W3091026034\",\"https://openalex.org/W2767364115\",\"https://openalex.org/W1988556506\",\"https://openalex.org/W2572710398\",\"https://openalex.org/W2700330585\",\"https://openalex.org/W1924919590\",\"https://openalex.org/W2038274440\",\"https://openalex.org/W2101099185\",\"https://openalex.org/W2116158786\",\"https://openalex.org/W2510006838\",\"https://openalex.org/W2054480309\",\"https://openalex.org/W2887293045\",\"https://openalex.org/W2111940573\",\"https://openalex.org/W2134812356\",\"https://openalex.org/W3215264862\",\"https://openalex.org/W2996105902\",\"https://openalex.org/W2950636079\",\"https://openalex.org/W2989642609\",\"https://openalex.org/W4366446382\"],\"related_works\":[\"https://openalex.org/W2164956116\",\"https://openalex.org/W3202108394\",\"https://openalex.org/W1985279299\",\"https://openalex.org/W2001564713\",\"https://openalex.org/W1991250386\",\"https://openalex.org/W1155390618\",\"https://openalex.org/W2066822786\",\"https://openalex.org/W1754259525\",\"https://openalex.org/W2110968446\",\"https://openalex.org/W2025935935\"],\"abstract_inverted_index\":{\"Abstract\":[0],\"Alzheimer\\'s\":[1],\"disease\":[2],\"(AD)\":[3],\"is\":[4,27,58,66,114],\"one\":[5],\"of\":[6,21,89,127],\"the\":[7,13,22,50,73,87,109,148],\"most\":[8],\"common\":[9],\"neurodegenerative\":[10],\"diseases\":[11],\"in\":[12,19,79,108,131,143,153],\"elderly\":[14],\"population.\":[15],\"Despite\":[16],\"significant\":[17],\"advances\":[18],\"studies\":[20],\"pathobiology\":[23],\"on\":[24,61],\"AD,\":[25],\"there\":[26],\"still\":[28],\"no\":[29],\"effective\":[30],\"treatment.\":[31],\"Here,\":[32],\"an\":[33],\"erythrocyte\":[34],\"membrane\\\\u2010camouflaged\":[35],\"nanodrug\":[36],\"delivery\":[37,150],\"system\":[38],\"(TR\\\\u2010ZRA)\":[39],\"modified\":[40],\"with\":[41,68,117,135],\"transferrin\":[42],\"receptor\":[43],\"aptamers\":[44],\"that\":[45],\"can\":[46,85,100],\"be\":[47],\"targeted\":[48],\"across\":[49],\"blood\\\\u2013brain\":[51],\"barrier\":[52],\"to\":[53,71,91],\"ameliorate\":[54],\"AD\":[55,110,144,165],\"immune\":[56,162],\"environment\":[57],\"established.\":[59],\"Based\":[60],\"metal\\\\u2010organic\":[62],\"framework\":[63],\"(Zn\\\\u2010CA),\":[64],\"TR\\\\u2010ZRA\":[65,84,113,152],\"loaded\":[67,116],\"CD22shRNA\":[69],\"plasmid\":[70],\"silence\":[72],\"abnormally\":[74],\"high\":[75],\"expression\":[76],\"molecule\":[77],\"CD22\":[78],\"aging\":[80],\"microglia.\":[81],\"Most\":[82],\"importantly,\":[83],\"enhance\":[86],\"ability\":[88],\"microglia\":[90],\"phagocytose\":[92],\"A\":[93,118,128],\"\\\\u03b2\":[94,119,129],\"and\":[95,104,124,138,160],\"alleviate\":[96],\"complement\":[97],\"activation,\":[98],\"which\":[99,121],\"promote\":[101],\"neuronal\":[102],\"activity\":[103],\"decrease\":[105],\"inflammation\":[106],\"level\":[107],\"brain.\":[111],\"Moreover,\":[112],\"also\":[115],\"aptamers,\":[120],\"allow\":[122],\"rapid\":[123],\"low\\\\u2010cost\":[125],\"monitoring\":[126],\"plaques\":[130],\"vitro.\":[132],\"After\":[133],\"treatment\":[134],\"TR\\\\u2010ZRA,\":[136],\"learning,\":[137],\"memory\":[139],\"abilities\":[140],\"are\":[141],\"enhanced\":[142],\"mice.\":[145],\"In\":[146],\"conclusion,\":[147],\"biomimetic\":[149],\"nanosystem\":[151],\"this\":[154],\"study\":[155],\"provides\":[156],\"a\":[157],\"promising\":[158],\"strategy\":[159],\"novel\":[161],\"targets\":[163],\"for\":[164],\"therapy.\":[166]},\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":18},{\"year\":2024,\"cited_by_count\":17},{\"year\":2023,\"cited_by_count\":4}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W3196956808\",\"doi\":\"https://doi.org/10.1016/j.xinn.2021.100160\",\"title\":\"A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer\\'s disease\",\"display_name\":\"A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer\\'s disease\",\"relevance_score\":120.74254,\"publication_year\":2021,\"publication_date\":\"2021-08-31\",\"ids\":{\"openalex\":\"https://openalex.org/W3196956808\",\"doi\":\"https://doi.org/10.1016/j.xinn.2021.100160\",\"mag\":\"3196956808\",\"pmid\":\"https://pubmed.ncbi.nlm.nih.gov/34901904\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.1016/j.xinn.2021.100160\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.xinn.2021.100160\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210236180\",\"display_name\":\"The Innovation\",\"issn_l\":\"2666-6758\",\"issn\":[\"2666-6758\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"The Innovation\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\",\"doaj\",\"pubmed\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"gold\",\"oa_url\":\"https://doi.org/10.1016/j.xinn.2021.100160\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5091383657\",\"display_name\":\"Dongju Zhao\",\"orcid\":\"https://orcid.org/0000-0002-0589-5670\"},\"institutions\":[{\"id\":\"https://openalex.org/I162868743\",\"display_name\":\"Tianjin University\",\"ror\":\"https://ror.org/012tb2g32\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I162868743\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Dongju Zhao\",\"raw_affiliation_strings\":[\"School of Life Sciences, Tianjin University, Tianjin 300072, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Life Sciences, Tianjin University, Tianjin 300072, China\",\"institution_ids\":[\"https://openalex.org/I162868743\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5101892780\",\"display_name\":\"Yuqing Tang\",\"orcid\":\"https://orcid.org/0000-0003-4483-2688\"},\"institutions\":[{\"id\":\"https://openalex.org/I162868743\",\"display_name\":\"Tianjin University\",\"ror\":\"https://ror.org/012tb2g32\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I162868743\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Yuqing Tang\",\"raw_affiliation_strings\":[\"School of Life Sciences, Tianjin University, Tianjin 300072, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Life Sciences, Tianjin University, Tianjin 300072, China\",\"institution_ids\":[\"https://openalex.org/I162868743\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5110657545\",\"display_name\":\"Xinjun Suo\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I2802534033\",\"display_name\":\"Tianjin Medical University General Hospital\",\"ror\":\"https://ror.org/003sav965\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I2802534033\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Xinjun Suo\",\"raw_affiliation_strings\":[\"Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China\",\"institution_ids\":[\"https://openalex.org/I2802534033\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5074150254\",\"display_name\":\"Chaonan Zhang\",\"orcid\":null},\"institutions\":[{\"id\":\"https://openalex.org/I162868743\",\"display_name\":\"Tianjin University\",\"ror\":\"https://ror.org/012tb2g32\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I162868743\"]}],\"countries\":[\"CN\"],\"is_corresponding\":false,\"raw_author_name\":\"Chaonan Zhang\",\"raw_affiliation_strings\":[\"School of Life Sciences, Tianjin University, Tianjin 300072, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Life Sciences, Tianjin University, Tianjin 300072, China\",\"institution_ids\":[\"https://openalex.org/I162868743\"]}]},{\"author_position\":\"middle\",\"author\":{\"id\":\"https://openalex.org/A5021016615\",\"display_name\":\"Yan Dou\",\"orcid\":\"https://orcid.org/0000-0002-6905-2787\"},\"institutions\":[{\"id\":\"https://openalex.org/I2802534033\",\"display_name\":\"Tianjin Medical University General Hospital\",\"ror\":\"https://ror.org/003sav965\",\"country_code\":\"CN\",\"type\":\"healthcare\",\"lineage\":[\"https://openalex.org/I2802534033\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Yan Dou\",\"raw_affiliation_strings\":[\"Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China\",\"institution_ids\":[\"https://openalex.org/I2802534033\"]}]},{\"author_position\":\"last\",\"author\":{\"id\":\"https://openalex.org/A5042143812\",\"display_name\":\"Jin Chang\",\"orcid\":\"https://orcid.org/0000-0002-6752-8526\"},\"institutions\":[{\"id\":\"https://openalex.org/I162868743\",\"display_name\":\"Tianjin University\",\"ror\":\"https://ror.org/012tb2g32\",\"country_code\":\"CN\",\"type\":\"education\",\"lineage\":[\"https://openalex.org/I162868743\"]}],\"countries\":[\"CN\"],\"is_corresponding\":true,\"raw_author_name\":\"Jin Chang\",\"raw_affiliation_strings\":[\"School of Life Sciences, Tianjin University, Tianjin 300072, China\"],\"affiliations\":[{\"raw_affiliation_string\":\"School of Life Sciences, Tianjin University, Tianjin 300072, China\",\"institution_ids\":[\"https://openalex.org/I162868743\"]}]}],\"institutions\":[],\"countries_distinct_count\":1,\"institutions_distinct_count\":6,\"corresponding_author_ids\":[\"https://openalex.org/A5042143812\",\"https://openalex.org/A5021016615\"],\"corresponding_institution_ids\":[\"https://openalex.org/I162868743\",\"https://openalex.org/I2802534033\"],\"apc_list\":{\"value\":5000,\"currency\":\"USD\",\"value_usd\":5000},\"apc_paid\":{\"value\":5000,\"currency\":\"USD\",\"value_usd\":5000},\"fwci\":3.51447943,\"has_fulltext\":false,\"cited_by_count\":29,\"citation_normalized_percentile\":{\"value\":0.90752704,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":89,\"max\":99},\"biblio\":{\"volume\":\"2\",\"issue\":\"4\",\"first_page\":\"100160\",\"last_page\":\"100160\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9983999729156494,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.9983999729156494,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T13551\",\"display_name\":\"Biochemical effects in animals\",\"score\":0.9909999966621399,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T11319\",\"display_name\":\"Curcumin\\'s Biomedical Applications\",\"score\":0.9868999719619751,\"subfield\":{\"id\":\"https://openalex.org/subfields/1313\",\"display_name\":\"Molecular Medicine\"},\"field\":{\"id\":\"https://openalex.org/fields/13\",\"display_name\":\"Biochemistry, Genetics and Molecular Biology\"},\"domain\":{\"id\":\"https://openalex.org/domains/1\",\"display_name\":\"Life Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.6040210127830505},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.5503864884376526},{\"id\":\"https://openalex.org/keywords/dual\",\"display_name\":\"Dual (grammatical number)\",\"score\":0.524241030216217},{\"id\":\"https://openalex.org/keywords/alzheimers-disease\",\"display_name\":\"Alzheimer\\'s disease\",\"score\":0.4321008324623108},{\"id\":\"https://openalex.org/keywords/intensive-care-medicine\",\"display_name\":\"Intensive care medicine\",\"score\":0.33948689699172974},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.15149205923080444},{\"id\":\"https://openalex.org/keywords/philosophy\",\"display_name\":\"Philosophy\",\"score\":0.05799669027328491}],\"concepts\":[{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.6040210127830505},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.5503864884376526},{\"id\":\"https://openalex.org/C2780980858\",\"wikidata\":\"https://www.wikidata.org/wiki/Q110022\",\"display_name\":\"Dual (grammatical number)\",\"level\":2,\"score\":0.524241030216217},{\"id\":\"https://openalex.org/C502032728\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11081\",\"display_name\":\"Alzheimer\\'s disease\",\"level\":3,\"score\":0.4321008324623108},{\"id\":\"https://openalex.org/C177713679\",\"wikidata\":\"https://www.wikidata.org/wiki/Q679690\",\"display_name\":\"Intensive care medicine\",\"level\":1,\"score\":0.33948689699172974},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.15149205923080444},{\"id\":\"https://openalex.org/C138885662\",\"wikidata\":\"https://www.wikidata.org/wiki/Q5891\",\"display_name\":\"Philosophy\",\"level\":0,\"score\":0.05799669027328491},{\"id\":\"https://openalex.org/C41895202\",\"wikidata\":\"https://www.wikidata.org/wiki/Q8162\",\"display_name\":\"Linguistics\",\"level\":1,\"score\":0.0}],\"mesh\":[],\"locations_count\":4,\"locations\":[{\"id\":\"doi:10.1016/j.xinn.2021.100160\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.xinn.2021.100160\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210236180\",\"display_name\":\"The Innovation\",\"issn_l\":\"2666-6758\",\"issn\":[\"2666-6758\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"The Innovation\",\"raw_type\":\"journal-article\"},{\"id\":\"pmid:34901904\",\"is_oa\":false,\"landing_page_url\":\"https://pubmed.ncbi.nlm.nih.gov/34901904\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306525036\",\"display_name\":\"PubMed\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"Innovation (Cambridge (Mass.))\",\"raw_type\":null},{\"id\":\"pmh:oai:doaj.org/article:075fcd76bbe94a41bff1b9118de1097e\",\"is_oa\":true,\"landing_page_url\":\"https://doaj.org/article/075fcd76bbe94a41bff1b9118de1097e\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4306401280\",\"display_name\":\"DOAJ (DOAJ: Directory of Open Access Journals)\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"cc-by-sa\",\"license_id\":\"https://openalex.org/licenses/cc-by-sa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"The Innovation, Vol 2, Iss 4, Pp 100160- (2021)\",\"raw_type\":\"article\"},{\"id\":\"pmh:oai:pubmedcentral.nih.gov:8640585\",\"is_oa\":true,\"landing_page_url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/8640585\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S2764455111\",\"display_name\":\"PubMed Central\",\"issn_l\":null,\"issn\":null,\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":false,\"host_organization\":\"https://openalex.org/I1299303238\",\"host_organization_name\":\"National Institutes of Health\",\"host_organization_lineage\":[\"https://openalex.org/I1299303238\"],\"host_organization_lineage_names\":[],\"type\":\"repository\"},\"license\":\"other-oa\",\"license_id\":\"https://openalex.org/licenses/other-oa\",\"version\":\"submittedVersion\",\"is_accepted\":false,\"is_published\":false,\"raw_source_name\":\"Innovation (Camb)\",\"raw_type\":\"Text\"}],\"best_oa_location\":{\"id\":\"doi:10.1016/j.xinn.2021.100160\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.1016/j.xinn.2021.100160\",\"pdf_url\":null,\"source\":{\"id\":\"https://openalex.org/S4210236180\",\"display_name\":\"The Innovation\",\"issn_l\":\"2666-6758\",\"issn\":[\"2666-6758\"],\"is_oa\":true,\"is_in_doaj\":true,\"is_core\":true,\"host_organization\":\"https://openalex.org/P4310320990\",\"host_organization_name\":\"Elsevier BV\",\"host_organization_lineage\":[\"https://openalex.org/P4310320990\"],\"host_organization_lineage_names\":[\"Elsevier BV\"],\"type\":\"journal\"},\"license\":\"cc-by-nc-nd\",\"license_id\":\"https://openalex.org/licenses/cc-by-nc-nd\",\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"The Innovation\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.7300000190734863,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[{\"id\":\"https://openalex.org/G8476051780\",\"display_name\":null,\"funder_award_id\":\"51873150\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"},{\"id\":\"https://openalex.org/G5447354444\",\"display_name\":null,\"funder_award_id\":\"51573128\",\"funder_id\":\"https://openalex.org/F4320321001\",\"funder_display_name\":\"National Natural Science Foundation of China\"}],\"funders\":[{\"id\":\"https://openalex.org/F4320321001\",\"display_name\":\"National Natural Science Foundation of China\",\"ror\":\"https://ror.org/01h0zpd94\"}],\"has_content\":{\"pdf\":false,\"grobid_xml\":false},\"referenced_works_count\":45,\"referenced_works\":[\"https://openalex.org/W3023013291\",\"https://openalex.org/W2535730691\",\"https://openalex.org/W2755558750\",\"https://openalex.org/W2788048790\",\"https://openalex.org/W2165201727\",\"https://openalex.org/W2788808587\",\"https://openalex.org/W3013352992\",\"https://openalex.org/W2759665961\",\"https://openalex.org/W2215956681\",\"https://openalex.org/W2159821105\",\"https://openalex.org/W2946487204\",\"https://openalex.org/W2085800477\",\"https://openalex.org/W2310415701\",\"https://openalex.org/W2756282825\",\"https://openalex.org/W2884855541\",\"https://openalex.org/W2923350517\",\"https://openalex.org/W2082517369\",\"https://openalex.org/W2793159348\",\"https://openalex.org/W2121806371\",\"https://openalex.org/W2071214407\",\"https://openalex.org/W1492443634\",\"https://openalex.org/W2016787780\",\"https://openalex.org/W2995770731\",\"https://openalex.org/W2970566248\",\"https://openalex.org/W2296523452\",\"https://openalex.org/W3099031341\",\"https://openalex.org/W2900354882\",\"https://openalex.org/W6746094779\",\"https://openalex.org/W3016518159\",\"https://openalex.org/W2786474781\",\"https://openalex.org/W2849172012\",\"https://openalex.org/W2900969673\",\"https://openalex.org/W2263173985\",\"https://openalex.org/W2252054300\",\"https://openalex.org/W3004110416\",\"https://openalex.org/W2766388141\",\"https://openalex.org/W2027783468\",\"https://openalex.org/W2018659142\",\"https://openalex.org/W2940915183\",\"https://openalex.org/W2294586018\",\"https://openalex.org/W1977178308\",\"https://openalex.org/W2324917897\",\"https://openalex.org/W3006949946\",\"https://openalex.org/W2977696708\",\"https://openalex.org/W2768499679\"],\"related_works\":[\"https://openalex.org/W2748952813\",\"https://openalex.org/W3031052312\",\"https://openalex.org/W4389568370\",\"https://openalex.org/W3032375762\",\"https://openalex.org/W1995515455\",\"https://openalex.org/W2080531066\",\"https://openalex.org/W3108674512\",\"https://openalex.org/W1506200166\",\"https://openalex.org/W1489783725\",\"https://openalex.org/W2148612803\"],\"abstract_inverted_index\":null,\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":7},{\"year\":2024,\"cited_by_count\":9},{\"year\":2023,\"cited_by_count\":6},{\"year\":2022,\"cited_by_count\":6},{\"year\":2021,\"cited_by_count\":1}],\"updated_date\":\"2025-11-14T23:14:49.485078\",\"created_date\":\"2025-10-10T00:00:00\"},{\"id\":\"https://openalex.org/W4408233425\",\"doi\":\"https://doi.org/10.36838/v7i2.3\",\"title\":\"Diagnosis and Treatment of Alzheimer\\'s Disease Targeting the Amyloid Beta (A\\\\u03b2\",\"display_name\":\"Diagnosis and Treatment of Alzheimer\\'s Disease Targeting the Amyloid Beta (A\\\\u03b2\",\"relevance_score\":118.78865,\"publication_year\":2025,\"publication_date\":\"2025-02-28\",\"ids\":{\"openalex\":\"https://openalex.org/W4408233425\",\"doi\":\"https://doi.org/10.36838/v7i2.3\"},\"language\":\"en\",\"primary_location\":{\"id\":\"doi:10.36838/v7i2.3\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.36838/v7i2.3\",\"pdf_url\":\"https://doi.org/10.36838/v7i2.3\",\"source\":{\"id\":\"https://openalex.org/S4210181049\",\"display_name\":\"International journal of high school research\",\"issn_l\":\"2642-1046\",\"issn\":[\"2642-1046\",\"2642-1054\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"International Journal of High School Research\",\"raw_type\":\"journal-article\"},\"type\":\"article\",\"indexed_in\":[\"crossref\"],\"open_access\":{\"is_oa\":true,\"oa_status\":\"bronze\",\"oa_url\":\"https://doi.org/10.36838/v7i2.3\",\"any_repository_has_fulltext\":false},\"authorships\":[{\"author_position\":\"first\",\"author\":{\"id\":\"https://openalex.org/A5055886920\",\"display_name\":\"Sunghwan Bang\",\"orcid\":null},\"institutions\":[],\"countries\":[],\"is_corresponding\":true,\"raw_author_name\":\"Seoyeon Bang\",\"raw_affiliation_strings\":[],\"affiliations\":[]}],\"institutions\":[],\"countries_distinct_count\":0,\"institutions_distinct_count\":1,\"corresponding_author_ids\":[\"https://openalex.org/A5055886920\"],\"corresponding_institution_ids\":[],\"apc_list\":null,\"apc_paid\":null,\"fwci\":4.10667583,\"has_fulltext\":true,\"cited_by_count\":1,\"citation_normalized_percentile\":{\"value\":0.80641646,\"is_in_top_1_percent\":false,\"is_in_top_10_percent\":true},\"cited_by_percentile_year\":{\"min\":91,\"max\":95},\"biblio\":{\"volume\":\"7\",\"issue\":\"1\",\"first_page\":\"15\",\"last_page\":\"19\"},\"is_retracted\":false,\"is_paratext\":false,\"is_xpac\":false,\"primary_topic\":{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.8331999778747559,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},\"topics\":[{\"id\":\"https://openalex.org/T10086\",\"display_name\":\"Alzheimer\\'s disease research and treatments\",\"score\":0.8331999778747559,\"subfield\":{\"id\":\"https://openalex.org/subfields/2737\",\"display_name\":\"Physiology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}},{\"id\":\"https://openalex.org/T12023\",\"display_name\":\"Cholinesterase and Neurodegenerative Diseases\",\"score\":0.7102000117301941,\"subfield\":{\"id\":\"https://openalex.org/subfields/2736\",\"display_name\":\"Pharmacology\"},\"field\":{\"id\":\"https://openalex.org/fields/27\",\"display_name\":\"Medicine\"},\"domain\":{\"id\":\"https://openalex.org/domains/4\",\"display_name\":\"Health Sciences\"}}],\"keywords\":[{\"id\":\"https://openalex.org/keywords/beta\",\"display_name\":\"BETA (programming language)\",\"score\":0.6305856108665466},{\"id\":\"https://openalex.org/keywords/amyloid\",\"display_name\":\"Amyloid (mycology)\",\"score\":0.6157182455062866},{\"id\":\"https://openalex.org/keywords/disease\",\"display_name\":\"Disease\",\"score\":0.5830684304237366},{\"id\":\"https://openalex.org/keywords/amyloid-beta\",\"display_name\":\"Amyloid beta\",\"score\":0.5037619471549988},{\"id\":\"https://openalex.org/keywords/medicine\",\"display_name\":\"Medicine\",\"score\":0.49944615364074707},{\"id\":\"https://openalex.org/keywords/neuroscience\",\"display_name\":\"Neuroscience\",\"score\":0.3271838128566742},{\"id\":\"https://openalex.org/keywords/internal-medicine\",\"display_name\":\"Internal medicine\",\"score\":0.2745192348957062},{\"id\":\"https://openalex.org/keywords/psychology\",\"display_name\":\"Psychology\",\"score\":0.2665925621986389},{\"id\":\"https://openalex.org/keywords/pathology\",\"display_name\":\"Pathology\",\"score\":0.19233763217926025},{\"id\":\"https://openalex.org/keywords/computer-science\",\"display_name\":\"Computer science\",\"score\":0.14432033896446228}],\"concepts\":[{\"id\":\"https://openalex.org/C2776174256\",\"wikidata\":\"https://www.wikidata.org/wiki/Q830842\",\"display_name\":\"BETA (programming language)\",\"level\":2,\"score\":0.6305856108665466},{\"id\":\"https://openalex.org/C2777633098\",\"wikidata\":\"https://www.wikidata.org/wiki/Q2736051\",\"display_name\":\"Amyloid (mycology)\",\"level\":2,\"score\":0.6157182455062866},{\"id\":\"https://openalex.org/C2779134260\",\"wikidata\":\"https://www.wikidata.org/wiki/Q12136\",\"display_name\":\"Disease\",\"level\":2,\"score\":0.5830684304237366},{\"id\":\"https://openalex.org/C2776156579\",\"wikidata\":\"https://www.wikidata.org/wiki/Q417667\",\"display_name\":\"Amyloid beta\",\"level\":3,\"score\":0.5037619471549988},{\"id\":\"https://openalex.org/C71924100\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11190\",\"display_name\":\"Medicine\",\"level\":0,\"score\":0.49944615364074707},{\"id\":\"https://openalex.org/C169760540\",\"wikidata\":\"https://www.wikidata.org/wiki/Q207011\",\"display_name\":\"Neuroscience\",\"level\":1,\"score\":0.3271838128566742},{\"id\":\"https://openalex.org/C126322002\",\"wikidata\":\"https://www.wikidata.org/wiki/Q11180\",\"display_name\":\"Internal medicine\",\"level\":1,\"score\":0.2745192348957062},{\"id\":\"https://openalex.org/C15744967\",\"wikidata\":\"https://www.wikidata.org/wiki/Q9418\",\"display_name\":\"Psychology\",\"level\":0,\"score\":0.2665925621986389},{\"id\":\"https://openalex.org/C142724271\",\"wikidata\":\"https://www.wikidata.org/wiki/Q7208\",\"display_name\":\"Pathology\",\"level\":1,\"score\":0.19233763217926025},{\"id\":\"https://openalex.org/C41008148\",\"wikidata\":\"https://www.wikidata.org/wiki/Q21198\",\"display_name\":\"Computer science\",\"level\":0,\"score\":0.14432033896446228},{\"id\":\"https://openalex.org/C199360897\",\"wikidata\":\"https://www.wikidata.org/wiki/Q9143\",\"display_name\":\"Programming language\",\"level\":1,\"score\":0.0}],\"mesh\":[],\"locations_count\":1,\"locations\":[{\"id\":\"doi:10.36838/v7i2.3\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.36838/v7i2.3\",\"pdf_url\":\"https://doi.org/10.36838/v7i2.3\",\"source\":{\"id\":\"https://openalex.org/S4210181049\",\"display_name\":\"International journal of high school research\",\"issn_l\":\"2642-1046\",\"issn\":[\"2642-1046\",\"2642-1054\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"International Journal of High School Research\",\"raw_type\":\"journal-article\"}],\"best_oa_location\":{\"id\":\"doi:10.36838/v7i2.3\",\"is_oa\":true,\"landing_page_url\":\"https://doi.org/10.36838/v7i2.3\",\"pdf_url\":\"https://doi.org/10.36838/v7i2.3\",\"source\":{\"id\":\"https://openalex.org/S4210181049\",\"display_name\":\"International journal of high school research\",\"issn_l\":\"2642-1046\",\"issn\":[\"2642-1046\",\"2642-1054\"],\"is_oa\":false,\"is_in_doaj\":false,\"is_core\":true,\"host_organization\":null,\"host_organization_name\":null,\"host_organization_lineage\":[],\"host_organization_lineage_names\":[],\"type\":\"journal\"},\"license\":null,\"license_id\":null,\"version\":\"publishedVersion\",\"is_accepted\":true,\"is_published\":true,\"raw_source_name\":\"International Journal of High School Research\",\"raw_type\":\"journal-article\"},\"sustainable_development_goals\":[{\"display_name\":\"Good health and well-being\",\"score\":0.6700000166893005,\"id\":\"https://metadata.un.org/sdg/3\"}],\"awards\":[],\"funders\":[],\"has_content\":{\"pdf\":true,\"grobid_xml\":true},\"referenced_works_count\":0,\"referenced_works\":[],\"related_works\":[\"https://openalex.org/W2606891670\",\"https://openalex.org/W2081140305\",\"https://openalex.org/W1261866575\",\"https://openalex.org/W2947698027\",\"https://openalex.org/W1995290659\",\"https://openalex.org/W2103683440\",\"https://openalex.org/W1989980891\",\"https://openalex.org/W3118850092\",\"https://openalex.org/W4386046672\",\"https://openalex.org/W1546139722\"],\"abstract_inverted_index\":null,\"counts_by_year\":[{\"year\":2025,\"cited_by_count\":1}],\"updated_date\":\"2025-11-06T03:46:38.306776\",\"created_date\":\"2025-10-10T00:00:00\"}],\"group_by\":[]}\\n'"
            ]
          },
          "execution_count": 4,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "response = requests.get(searching)\n",
        "response.text"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "e0792ac5",
      "metadata": {
        "id": "e0792ac5",
        "outputId": "36c45893-f088-4a47-e9bb-60fd95bb6cf9"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "dict_keys(['meta', 'results', 'group_by'])"
            ]
          },
          "execution_count": 5,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "data = response.json()\n",
        "data.keys()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "dfc20894",
      "metadata": {
        "id": "dfc20894",
        "outputId": "c5486abd-6bfa-4986-f3fa-d23859cd11a2"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "{'count': 293,\n",
              " 'db_response_time_ms': 20,\n",
              " 'page': 1,\n",
              " 'per_page': 20,\n",
              " 'groups_count': None}"
            ]
          },
          "execution_count": 6,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "data['meta']"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "6d2a4d2f",
      "metadata": {
        "id": "6d2a4d2f",
        "outputId": "0decb6bf-3b3e-4c05-a8b8-9e48e0ac5f5a"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "{'id': 'https://openalex.org/W4206924079',\n",
              " 'doi': 'https://doi.org/10.3389/fnagi.2021.809433',\n",
              " 'title': \"Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis\",\n",
              " 'display_name': \"Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis\",\n",
              " 'relevance_score': 233.16838,\n",
              " 'publication_year': 2022,\n",
              " 'publication_date': '2022-01-21',\n",
              " 'ids': {'openalex': 'https://openalex.org/W4206924079',\n",
              "  'doi': 'https://doi.org/10.3389/fnagi.2021.809433',\n",
              "  'pmid': 'https://pubmed.ncbi.nlm.nih.gov/35126093'},\n",
              " 'language': 'en',\n",
              " 'primary_location': {'id': 'doi:10.3389/fnagi.2021.809433',\n",
              "  'is_oa': True,\n",
              "  'landing_page_url': 'https://doi.org/10.3389/fnagi.2021.809433',\n",
              "  'pdf_url': None,\n",
              "  'source': {'id': 'https://openalex.org/S118428158',\n",
              "   'display_name': 'Frontiers in Aging Neuroscience',\n",
              "   'issn_l': '1663-4365',\n",
              "   'issn': ['1663-4365'],\n",
              "   'is_oa': True,\n",
              "   'is_in_doaj': True,\n",
              "   'is_core': True,\n",
              "   'host_organization': 'https://openalex.org/P4310320527',\n",
              "   'host_organization_name': 'Frontiers Media',\n",
              "   'host_organization_lineage': ['https://openalex.org/P4310320527'],\n",
              "   'host_organization_lineage_names': ['Frontiers Media'],\n",
              "   'type': 'journal'},\n",
              "  'license': 'cc-by',\n",
              "  'license_id': 'https://openalex.org/licenses/cc-by',\n",
              "  'version': 'publishedVersion',\n",
              "  'is_accepted': True,\n",
              "  'is_published': True,\n",
              "  'raw_source_name': 'Frontiers in Aging Neuroscience',\n",
              "  'raw_type': 'journal-article'},\n",
              " 'type': 'article',\n",
              " 'indexed_in': ['crossref', 'doaj', 'pubmed'],\n",
              " 'open_access': {'is_oa': True,\n",
              "  'oa_status': 'gold',\n",
              "  'oa_url': 'https://doi.org/10.3389/fnagi.2021.809433',\n",
              "  'any_repository_has_fulltext': False},\n",
              " 'authorships': [{'author_position': 'first',\n",
              "   'author': {'id': 'https://openalex.org/A5050905751',\n",
              "    'display_name': 'Yawen Cai',\n",
              "    'orcid': None},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': False,\n",
              "   'raw_author_name': 'Yawen Cai',\n",
              "   'raw_affiliation_strings': ['Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]},\n",
              "  {'author_position': 'middle',\n",
              "   'author': {'id': 'https://openalex.org/A5003820071',\n",
              "    'display_name': 'Yuhui Chai',\n",
              "    'orcid': None},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': False,\n",
              "   'raw_author_name': 'Yuhui Chai',\n",
              "   'raw_affiliation_strings': ['Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]},\n",
              "  {'author_position': 'middle',\n",
              "   'author': {'id': 'https://openalex.org/A5073373032',\n",
              "    'display_name': 'Yu Fu',\n",
              "    'orcid': 'https://orcid.org/0000-0001-9849-7841'},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': False,\n",
              "   'raw_author_name': 'Yu Fu',\n",
              "   'raw_affiliation_strings': ['Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]},\n",
              "  {'author_position': 'middle',\n",
              "   'author': {'id': 'https://openalex.org/A5038934900',\n",
              "    'display_name': 'Yingdi Wang',\n",
              "    'orcid': None},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': False,\n",
              "   'raw_author_name': 'Yingdi Wang',\n",
              "   'raw_affiliation_strings': ['Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]},\n",
              "  {'author_position': 'middle',\n",
              "   'author': {'id': 'https://openalex.org/A5100395353',\n",
              "    'display_name': 'Yiming Zhang',\n",
              "    'orcid': 'https://orcid.org/0000-0001-8547-6654'},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': False,\n",
              "   'raw_author_name': 'Yiming Zhang',\n",
              "   'raw_affiliation_strings': ['Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]},\n",
              "  {'author_position': 'middle',\n",
              "   'author': {'id': 'https://openalex.org/A5100445824',\n",
              "    'display_name': 'Xue Zhang',\n",
              "    'orcid': 'https://orcid.org/0000-0001-5785-8217'},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': False,\n",
              "   'raw_author_name': 'Xue Zhang',\n",
              "   'raw_affiliation_strings': ['Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]},\n",
              "  {'author_position': 'middle',\n",
              "   'author': {'id': 'https://openalex.org/A5030765159',\n",
              "    'display_name': 'Lingpeng Zhu',\n",
              "    'orcid': 'https://orcid.org/0000-0003-0762-4038'},\n",
              "   'institutions': [{'id': 'https://openalex.org/I83519826',\n",
              "     'display_name': 'Nanjing Medical University',\n",
              "     'ror': 'https://ror.org/059gcgy73',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I83519826']},\n",
              "    {'id': 'https://openalex.org/I4210158071',\n",
              "     'display_name': \"Wuxi People's Hospital\",\n",
              "     'ror': 'https://ror.org/05pb5hm55',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'healthcare',\n",
              "     'lineage': ['https://openalex.org/I4210158071']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': True,\n",
              "   'raw_author_name': 'Lingpeng Zhu',\n",
              "   'raw_affiliation_strings': [\"Center of Clinical Research, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China\"],\n",
              "   'affiliations': [{'raw_affiliation_string': \"Center of Clinical Research, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China\",\n",
              "     'institution_ids': ['https://openalex.org/I4210158071',\n",
              "      'https://openalex.org/I83519826']}]},\n",
              "  {'author_position': 'middle',\n",
              "   'author': {'id': 'https://openalex.org/A5110782821',\n",
              "    'display_name': 'Mingxing Miao',\n",
              "    'orcid': None},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': True,\n",
              "   'raw_author_name': 'Mingxing Miao',\n",
              "   'raw_affiliation_strings': ['Center of National Pharmaceutical Experimental Teaching Demonstration, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Center of National Pharmaceutical Experimental Teaching Demonstration, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]},\n",
              "  {'author_position': 'last',\n",
              "   'author': {'id': 'https://openalex.org/A5025941060',\n",
              "    'display_name': 'Tianhua Yan',\n",
              "    'orcid': 'https://orcid.org/0000-0001-6124-8630'},\n",
              "   'institutions': [{'id': 'https://openalex.org/I161716053',\n",
              "     'display_name': 'China Pharmaceutical University',\n",
              "     'ror': 'https://ror.org/01sfm2718',\n",
              "     'country_code': 'CN',\n",
              "     'type': 'education',\n",
              "     'lineage': ['https://openalex.org/I161716053']}],\n",
              "   'countries': ['CN'],\n",
              "   'is_corresponding': True,\n",
              "   'raw_author_name': 'Tianhua Yan',\n",
              "   'raw_affiliation_strings': ['Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China'],\n",
              "   'affiliations': [{'raw_affiliation_string': 'Department of Physiology and Pharmacology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China',\n",
              "     'institution_ids': ['https://openalex.org/I161716053']}]}],\n",
              " 'institutions': [],\n",
              " 'countries_distinct_count': 1,\n",
              " 'institutions_distinct_count': 9,\n",
              " 'corresponding_author_ids': ['https://openalex.org/A5030765159',\n",
              "  'https://openalex.org/A5110782821',\n",
              "  'https://openalex.org/A5025941060'],\n",
              " 'corresponding_institution_ids': ['https://openalex.org/I161716053',\n",
              "  'https://openalex.org/I4210158071',\n",
              "  'https://openalex.org/I83519826'],\n",
              " 'apc_list': {'value': 1950, 'currency': 'USD', 'value_usd': 1950},\n",
              " 'apc_paid': {'value': 1950, 'currency': 'USD', 'value_usd': 1950},\n",
              " 'fwci': 15.62978306,\n",
              " 'has_fulltext': False,\n",
              " 'cited_by_count': 127,\n",
              " 'citation_normalized_percentile': {'value': 0.99268088,\n",
              "  'is_in_top_1_percent': True,\n",
              "  'is_in_top_10_percent': True},\n",
              " 'cited_by_percentile_year': {'min': 99, 'max': 100},\n",
              " 'biblio': {'volume': '13',\n",
              "  'issue': None,\n",
              "  'first_page': '809433',\n",
              "  'last_page': '809433'},\n",
              " 'is_retracted': False,\n",
              " 'is_paratext': False,\n",
              " 'is_xpac': False,\n",
              " 'primary_topic': {'id': 'https://openalex.org/T11078',\n",
              "  'display_name': 'Inflammasome and immune disorders',\n",
              "  'score': 0.9998999834060669,\n",
              "  'subfield': {'id': 'https://openalex.org/subfields/1312',\n",
              "   'display_name': 'Molecular Biology'},\n",
              "  'field': {'id': 'https://openalex.org/fields/13',\n",
              "   'display_name': 'Biochemistry, Genetics and Molecular Biology'},\n",
              "  'domain': {'id': 'https://openalex.org/domains/1',\n",
              "   'display_name': 'Life Sciences'}},\n",
              " 'topics': [{'id': 'https://openalex.org/T11078',\n",
              "   'display_name': 'Inflammasome and immune disorders',\n",
              "   'score': 0.9998999834060669,\n",
              "   'subfield': {'id': 'https://openalex.org/subfields/1312',\n",
              "    'display_name': 'Molecular Biology'},\n",
              "   'field': {'id': 'https://openalex.org/fields/13',\n",
              "    'display_name': 'Biochemistry, Genetics and Molecular Biology'},\n",
              "   'domain': {'id': 'https://openalex.org/domains/1',\n",
              "    'display_name': 'Life Sciences'}},\n",
              "  {'id': 'https://openalex.org/T13651',\n",
              "   'display_name': 'Medicinal Plants and Bioactive Compounds',\n",
              "   'score': 0.9962999820709229,\n",
              "   'subfield': {'id': 'https://openalex.org/subfields/1312',\n",
              "    'display_name': 'Molecular Biology'},\n",
              "   'field': {'id': 'https://openalex.org/fields/13',\n",
              "    'display_name': 'Biochemistry, Genetics and Molecular Biology'},\n",
              "   'domain': {'id': 'https://openalex.org/domains/1',\n",
              "    'display_name': 'Life Sciences'}},\n",
              "  {'id': 'https://openalex.org/T12975',\n",
              "   'display_name': 'Paraoxonase enzyme and polymorphisms',\n",
              "   'score': 0.96670001745224,\n",
              "   'subfield': {'id': 'https://openalex.org/subfields/1308',\n",
              "    'display_name': 'Clinical Biochemistry'},\n",
              "   'field': {'id': 'https://openalex.org/fields/13',\n",
              "    'display_name': 'Biochemistry, Genetics and Molecular Biology'},\n",
              "   'domain': {'id': 'https://openalex.org/domains/1',\n",
              "    'display_name': 'Life Sciences'}}],\n",
              " 'keywords': [{'id': 'https://openalex.org/keywords/pyroptosis',\n",
              "   'display_name': 'Pyroptosis',\n",
              "   'score': 0.9779961109161377},\n",
              "  {'id': 'https://openalex.org/keywords/inflammasome',\n",
              "   'display_name': 'Inflammasome',\n",
              "   'score': 0.9104028344154358},\n",
              "  {'id': 'https://openalex.org/keywords/pathogenesis',\n",
              "   'display_name': 'Pathogenesis',\n",
              "   'score': 0.6762961745262146},\n",
              "  {'id': 'https://openalex.org/keywords/caspase-1',\n",
              "   'display_name': 'Caspase 1',\n",
              "   'score': 0.5588692426681519},\n",
              "  {'id': 'https://openalex.org/keywords/neuroinflammation',\n",
              "   'display_name': 'Neuroinflammation',\n",
              "   'score': 0.4951535761356354},\n",
              "  {'id': 'https://openalex.org/keywords/proinflammatory-cytokine',\n",
              "   'display_name': 'Proinflammatory cytokine',\n",
              "   'score': 0.4387950599193573},\n",
              "  {'id': 'https://openalex.org/keywords/chemistry',\n",
              "   'display_name': 'Chemistry',\n",
              "   'score': 0.4033471941947937},\n",
              "  {'id': 'https://openalex.org/keywords/cell-biology',\n",
              "   'display_name': 'Cell biology',\n",
              "   'score': 0.4015592336654663},\n",
              "  {'id': 'https://openalex.org/keywords/medicine',\n",
              "   'display_name': 'Medicine',\n",
              "   'score': 0.3890223503112793},\n",
              "  {'id': 'https://openalex.org/keywords/neuroscience',\n",
              "   'display_name': 'Neuroscience',\n",
              "   'score': 0.3610600233078003},\n",
              "  {'id': 'https://openalex.org/keywords/pharmacology',\n",
              "   'display_name': 'Pharmacology',\n",
              "   'score': 0.3282572627067566},\n",
              "  {'id': 'https://openalex.org/keywords/biology',\n",
              "   'display_name': 'Biology',\n",
              "   'score': 0.27364128828048706},\n",
              "  {'id': 'https://openalex.org/keywords/immunology',\n",
              "   'display_name': 'Immunology',\n",
              "   'score': 0.25082069635391235},\n",
              "  {'id': 'https://openalex.org/keywords/inflammation',\n",
              "   'display_name': 'Inflammation',\n",
              "   'score': 0.2142622470855713}],\n",
              " 'concepts': [{'id': 'https://openalex.org/C17172800',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q7263707',\n",
              "   'display_name': 'Pyroptosis',\n",
              "   'level': 4,\n",
              "   'score': 0.9779961109161377},\n",
              "  {'id': 'https://openalex.org/C2777209026',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q412405',\n",
              "   'display_name': 'Inflammasome',\n",
              "   'level': 3,\n",
              "   'score': 0.9104028344154358},\n",
              "  {'id': 'https://openalex.org/C2780942790',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q372016',\n",
              "   'display_name': 'Pathogenesis',\n",
              "   'level': 2,\n",
              "   'score': 0.6762961745262146},\n",
              "  {'id': 'https://openalex.org/C139964883',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q14901964',\n",
              "   'display_name': 'Caspase 1',\n",
              "   'level': 4,\n",
              "   'score': 0.5588692426681519},\n",
              "  {'id': 'https://openalex.org/C87753298',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q17157137',\n",
              "   'display_name': 'Neuroinflammation',\n",
              "   'level': 3,\n",
              "   'score': 0.4951535761356354},\n",
              "  {'id': 'https://openalex.org/C164027704',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q3491837',\n",
              "   'display_name': 'Proinflammatory cytokine',\n",
              "   'level': 3,\n",
              "   'score': 0.4387950599193573},\n",
              "  {'id': 'https://openalex.org/C185592680',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q2329',\n",
              "   'display_name': 'Chemistry',\n",
              "   'level': 0,\n",
              "   'score': 0.4033471941947937},\n",
              "  {'id': 'https://openalex.org/C95444343',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q7141',\n",
              "   'display_name': 'Cell biology',\n",
              "   'level': 1,\n",
              "   'score': 0.4015592336654663},\n",
              "  {'id': 'https://openalex.org/C71924100',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q11190',\n",
              "   'display_name': 'Medicine',\n",
              "   'level': 0,\n",
              "   'score': 0.3890223503112793},\n",
              "  {'id': 'https://openalex.org/C169760540',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q207011',\n",
              "   'display_name': 'Neuroscience',\n",
              "   'level': 1,\n",
              "   'score': 0.3610600233078003},\n",
              "  {'id': 'https://openalex.org/C98274493',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q128406',\n",
              "   'display_name': 'Pharmacology',\n",
              "   'level': 1,\n",
              "   'score': 0.3282572627067566},\n",
              "  {'id': 'https://openalex.org/C86803240',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q420',\n",
              "   'display_name': 'Biology',\n",
              "   'level': 0,\n",
              "   'score': 0.27364128828048706},\n",
              "  {'id': 'https://openalex.org/C203014093',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q101929',\n",
              "   'display_name': 'Immunology',\n",
              "   'level': 1,\n",
              "   'score': 0.25082069635391235},\n",
              "  {'id': 'https://openalex.org/C2776914184',\n",
              "   'wikidata': 'https://www.wikidata.org/wiki/Q101991',\n",
              "   'display_name': 'Inflammation',\n",
              "   'level': 2,\n",
              "   'score': 0.2142622470855713}],\n",
              " 'mesh': [],\n",
              " 'locations_count': 4,\n",
              " 'locations': [{'id': 'doi:10.3389/fnagi.2021.809433',\n",
              "   'is_oa': True,\n",
              "   'landing_page_url': 'https://doi.org/10.3389/fnagi.2021.809433',\n",
              "   'pdf_url': None,\n",
              "   'source': {'id': 'https://openalex.org/S118428158',\n",
              "    'display_name': 'Frontiers in Aging Neuroscience',\n",
              "    'issn_l': '1663-4365',\n",
              "    'issn': ['1663-4365'],\n",
              "    'is_oa': True,\n",
              "    'is_in_doaj': True,\n",
              "    'is_core': True,\n",
              "    'host_organization': 'https://openalex.org/P4310320527',\n",
              "    'host_organization_name': 'Frontiers Media',\n",
              "    'host_organization_lineage': ['https://openalex.org/P4310320527'],\n",
              "    'host_organization_lineage_names': ['Frontiers Media'],\n",
              "    'type': 'journal'},\n",
              "   'license': 'cc-by',\n",
              "   'license_id': 'https://openalex.org/licenses/cc-by',\n",
              "   'version': 'publishedVersion',\n",
              "   'is_accepted': True,\n",
              "   'is_published': True,\n",
              "   'raw_source_name': 'Frontiers in Aging Neuroscience',\n",
              "   'raw_type': 'journal-article'},\n",
              "  {'id': 'pmid:35126093',\n",
              "   'is_oa': False,\n",
              "   'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/35126093',\n",
              "   'pdf_url': None,\n",
              "   'source': {'id': 'https://openalex.org/S4306525036',\n",
              "    'display_name': 'PubMed',\n",
              "    'issn_l': None,\n",
              "    'issn': None,\n",
              "    'is_oa': False,\n",
              "    'is_in_doaj': False,\n",
              "    'is_core': False,\n",
              "    'host_organization': 'https://openalex.org/I1299303238',\n",
              "    'host_organization_name': 'National Institutes of Health',\n",
              "    'host_organization_lineage': ['https://openalex.org/I1299303238'],\n",
              "    'host_organization_lineage_names': [],\n",
              "    'type': 'repository'},\n",
              "   'license': None,\n",
              "   'license_id': None,\n",
              "   'version': 'publishedVersion',\n",
              "   'is_accepted': True,\n",
              "   'is_published': True,\n",
              "   'raw_source_name': 'Frontiers in aging neuroscience',\n",
              "   'raw_type': None},\n",
              "  {'id': 'pmh:oai:doaj.org/article:23e276e4c0ef4392981df875f13f8073',\n",
              "   'is_oa': True,\n",
              "   'landing_page_url': 'https://doaj.org/article/23e276e4c0ef4392981df875f13f8073',\n",
              "   'pdf_url': None,\n",
              "   'source': {'id': 'https://openalex.org/S4306401280',\n",
              "    'display_name': 'DOAJ (DOAJ: Directory of Open Access Journals)',\n",
              "    'issn_l': None,\n",
              "    'issn': None,\n",
              "    'is_oa': False,\n",
              "    'is_in_doaj': False,\n",
              "    'is_core': False,\n",
              "    'host_organization': None,\n",
              "    'host_organization_name': None,\n",
              "    'host_organization_lineage': [],\n",
              "    'host_organization_lineage_names': [],\n",
              "    'type': 'repository'},\n",
              "   'license': 'cc-by-sa',\n",
              "   'license_id': 'https://openalex.org/licenses/cc-by-sa',\n",
              "   'version': 'submittedVersion',\n",
              "   'is_accepted': False,\n",
              "   'is_published': False,\n",
              "   'raw_source_name': 'Frontiers in Aging Neuroscience, Vol 13 (2022)',\n",
              "   'raw_type': 'article'},\n",
              "  {'id': 'pmh:oai:pubmedcentral.nih.gov:8814655',\n",
              "   'is_oa': True,\n",
              "   'landing_page_url': 'https://www.ncbi.nlm.nih.gov/pmc/articles/8814655',\n",
              "   'pdf_url': None,\n",
              "   'source': {'id': 'https://openalex.org/S2764455111',\n",
              "    'display_name': 'PubMed Central',\n",
              "    'issn_l': None,\n",
              "    'issn': None,\n",
              "    'is_oa': False,\n",
              "    'is_in_doaj': False,\n",
              "    'is_core': False,\n",
              "    'host_organization': 'https://openalex.org/I1299303238',\n",
              "    'host_organization_name': 'National Institutes of Health',\n",
              "    'host_organization_lineage': ['https://openalex.org/I1299303238'],\n",
              "    'host_organization_lineage_names': [],\n",
              "    'type': 'repository'},\n",
              "   'license': 'other-oa',\n",
              "   'license_id': 'https://openalex.org/licenses/other-oa',\n",
              "   'version': 'submittedVersion',\n",
              "   'is_accepted': False,\n",
              "   'is_published': False,\n",
              "   'raw_source_name': 'Front Aging Neurosci',\n",
              "   'raw_type': 'Text'}],\n",
              " 'best_oa_location': {'id': 'doi:10.3389/fnagi.2021.809433',\n",
              "  'is_oa': True,\n",
              "  'landing_page_url': 'https://doi.org/10.3389/fnagi.2021.809433',\n",
              "  'pdf_url': None,\n",
              "  'source': {'id': 'https://openalex.org/S118428158',\n",
              "   'display_name': 'Frontiers in Aging Neuroscience',\n",
              "   'issn_l': '1663-4365',\n",
              "   'issn': ['1663-4365'],\n",
              "   'is_oa': True,\n",
              "   'is_in_doaj': True,\n",
              "   'is_core': True,\n",
              "   'host_organization': 'https://openalex.org/P4310320527',\n",
              "   'host_organization_name': 'Frontiers Media',\n",
              "   'host_organization_lineage': ['https://openalex.org/P4310320527'],\n",
              "   'host_organization_lineage_names': ['Frontiers Media'],\n",
              "   'type': 'journal'},\n",
              "  'license': 'cc-by',\n",
              "  'license_id': 'https://openalex.org/licenses/cc-by',\n",
              "  'version': 'publishedVersion',\n",
              "  'is_accepted': True,\n",
              "  'is_published': True,\n",
              "  'raw_source_name': 'Frontiers in Aging Neuroscience',\n",
              "  'raw_type': 'journal-article'},\n",
              " 'sustainable_development_goals': [{'display_name': 'Good health and well-being',\n",
              "   'score': 0.7699999809265137,\n",
              "   'id': 'https://metadata.un.org/sdg/3'}],\n",
              " 'awards': [],\n",
              " 'funders': [],\n",
              " 'has_content': {'pdf': False, 'grobid_xml': False},\n",
              " 'referenced_works_count': 75,\n",
              " 'referenced_works': ['https://openalex.org/W2019551875',\n",
              "  'https://openalex.org/W2885800496',\n",
              "  'https://openalex.org/W4211238543',\n",
              "  'https://openalex.org/W2751934424',\n",
              "  'https://openalex.org/W2238232606',\n",
              "  'https://openalex.org/W2990946693',\n",
              "  'https://openalex.org/W3100711840',\n",
              "  'https://openalex.org/W2937259128',\n",
              "  'https://openalex.org/W3168854088',\n",
              "  'https://openalex.org/W3162382031',\n",
              "  'https://openalex.org/W3008443509',\n",
              "  'https://openalex.org/W3026226739',\n",
              "  'https://openalex.org/W2517793347',\n",
              "  'https://openalex.org/W2566478676',\n",
              "  'https://openalex.org/W3110045126',\n",
              "  'https://openalex.org/W3177065622',\n",
              "  'https://openalex.org/W3168997400',\n",
              "  'https://openalex.org/W2789018622',\n",
              "  'https://openalex.org/W2909913388',\n",
              "  'https://openalex.org/W2101399613',\n",
              "  'https://openalex.org/W1561041814',\n",
              "  'https://openalex.org/W2583631769',\n",
              "  'https://openalex.org/W2175794645',\n",
              "  'https://openalex.org/W1986611577',\n",
              "  'https://openalex.org/W3186053696',\n",
              "  'https://openalex.org/W2900976553',\n",
              "  'https://openalex.org/W2080191967',\n",
              "  'https://openalex.org/W2615324939',\n",
              "  'https://openalex.org/W2627048017',\n",
              "  'https://openalex.org/W2904244708',\n",
              "  'https://openalex.org/W3181146275',\n",
              "  'https://openalex.org/W2791508193',\n",
              "  'https://openalex.org/W2794046825',\n",
              "  'https://openalex.org/W2803197343',\n",
              "  'https://openalex.org/W2999621338',\n",
              "  'https://openalex.org/W3044896953',\n",
              "  'https://openalex.org/W3124131589',\n",
              "  'https://openalex.org/W2607216106',\n",
              "  'https://openalex.org/W2484783870',\n",
              "  'https://openalex.org/W6773658989',\n",
              "  'https://openalex.org/W2346799309',\n",
              "  'https://openalex.org/W2043679754',\n",
              "  'https://openalex.org/W3005551242',\n",
              "  'https://openalex.org/W2908040982',\n",
              "  'https://openalex.org/W3129961151',\n",
              "  'https://openalex.org/W2560541542',\n",
              "  'https://openalex.org/W3164720145',\n",
              "  'https://openalex.org/W3012405369',\n",
              "  'https://openalex.org/W3081641281',\n",
              "  'https://openalex.org/W2035230591',\n",
              "  'https://openalex.org/W1969673449',\n",
              "  'https://openalex.org/W2941630117',\n",
              "  'https://openalex.org/W2756716006',\n",
              "  'https://openalex.org/W2774884303',\n",
              "  'https://openalex.org/W3175464757',\n",
              "  'https://openalex.org/W3109271936',\n",
              "  'https://openalex.org/W2928322300',\n",
              "  'https://openalex.org/W2596856023',\n",
              "  'https://openalex.org/W3027898931',\n",
              "  'https://openalex.org/W3111635935',\n",
              "  'https://openalex.org/W3008669429',\n",
              "  'https://openalex.org/W3112999523',\n",
              "  'https://openalex.org/W3142080073',\n",
              "  'https://openalex.org/W2901153725',\n",
              "  'https://openalex.org/W3110200930',\n",
              "  'https://openalex.org/W3032330490',\n",
              "  'https://openalex.org/W3132599154',\n",
              "  'https://openalex.org/W3028288561',\n",
              "  'https://openalex.org/W2767414526',\n",
              "  'https://openalex.org/W2983864488',\n",
              "  'https://openalex.org/W3172774990',\n",
              "  'https://openalex.org/W2803156147',\n",
              "  'https://openalex.org/W3009244056',\n",
              "  'https://openalex.org/W3108954464',\n",
              "  'https://openalex.org/W2890247074'],\n",
              " 'related_works': ['https://openalex.org/W2775971119',\n",
              "  'https://openalex.org/W2164406361',\n",
              "  'https://openalex.org/W2996560206',\n",
              "  'https://openalex.org/W2775627464',\n",
              "  'https://openalex.org/W2776798182',\n",
              "  'https://openalex.org/W3121140360',\n",
              "  'https://openalex.org/W3205681349',\n",
              "  'https://openalex.org/W2991708020',\n",
              "  'https://openalex.org/W3153481028',\n",
              "  'https://openalex.org/W4223565809'],\n",
              " 'abstract_inverted_index': {'Amyloid': [0],\n",
              "  'β-protein': [1],\n",
              "  '(Aβ)': [2],\n",
              "  'is': [3, 13, 33, 84],\n",
              "  'reported': [4],\n",
              "  'to': [5, 42, 72, 86, 115, 173, 209],\n",
              "  'activate': [6],\n",
              "  'NLRP3': [7, 124, 168, 258, 274, 284],\n",
              "  'inflammasomes': [8],\n",
              "  'and': [9, 64, 91, 107, 141, 156, 176, 189, 194, 203, 237, 263, 277, 293],\n",
              "  'drive': [10],\n",
              "  'pyroptosis,': [11],\n",
              "  'which': [12, 171, 205],\n",
              "  'subsequently': [14],\n",
              "  'involved': [15],\n",
              "  'in': [16, 113, 127, 144, 239, 261, 291],\n",
              "  'the': [17, 29, 87, 95, 105, 123, 154, 174, 199, 210, 221, 255, 265],\n",
              "  'pathogenesis': [18, 30, 88],\n",
              "  'of': [19,\n",
              "   31,\n",
              "   58,\n",
              "   76,\n",
              "   89,\n",
              "   97,\n",
              "   138,\n",
              "   151,\n",
              "   178,\n",
              "   191,\n",
              "   201,\n",
              "   212,\n",
              "   225,\n",
              "   257,\n",
              "   267,\n",
              "   270],\n",
              "  'neurodegenerative': [20],\n",
              "  'diseases,': [21],\n",
              "  'such': [22],\n",
              "  'as': [23],\n",
              "  \"Alzheimer's\": [24],\n",
              "  'disease': [25],\n",
              "  '(AD).': [26],\n",
              "  'To': [27],\n",
              "  'date,': [28],\n",
              "  'AD': [32, 50, 77, 98, 145, 292],\n",
              "  'unfortunately': [34],\n",
              "  'insufficiently': [35],\n",
              "  'elucidated.': [36],\n",
              "  'Therefore,': [37],\n",
              "  'this': [38],\n",
              "  'study': [39, 253],\n",
              "  'was': [40],\n",
              "  'conducted': [41],\n",
              "  'explore': [43],\n",
              "  'whether': [44],\n",
              "  'Salidroside': [45],\n",
              "  '(Sal)': [46],\n",
              "  'treatment': [47, 211],\n",
              "  'could': [48, 295],\n",
              "  'benefit': [49],\n",
              "  'by': [51, 62, 99, 121, 148, 197],\n",
              "  'improving': [52],\n",
              "  'pyroptosis.': [53, 101],\n",
              "  'Firstly,': [54],\n",
              "  'two': [55],\n",
              "  'animal': [56],\n",
              "  'models': [57],\n",
              "  'AD,': [59, 90, 262],\n",
              "  'induced,': [60],\n",
              "  'respectively,': [61],\n",
              "  'Aβ1-42': [63, 152],\n",
              "  'D-galactose': [65],\n",
              "  '(D-gal)/AlCl': [66],\n",
              "  '3': [67, 162],\n",
              "  ',': [68],\n",
              "  'have': [69],\n",
              "  'been': [70],\n",
              "  'created': [71],\n",
              "  'assist': [73],\n",
              "  'our': [74],\n",
              "  'appreciation': [75],\n",
              "  'pathophysiology.': [78],\n",
              "  'We': [79, 214],\n",
              "  'then': [80],\n",
              "  'confirmed': [81],\n",
              "  'that': [82, 132, 217, 283],\n",
              "  'pyroptosis': [83, 119, 196, 260, 276, 286],\n",
              "  'related': [85],\n",
              "  'Sal': [92, 117, 218, 271, 294],\n",
              "  'can': [93, 206, 219, 272],\n",
              "  'slow': [94],\n",
              "  'progression': [96],\n",
              "  'inhibiting': [100, 248],\n",
              "  'Subsequently,': [102],\n",
              "  'we': [103, 130, 281],\n",
              "  'established': [104],\n",
              "  'D-gal': [106, 159],\n",
              "  'Nigericin-induced': [108],\n",
              "  'PC12': [109],\n",
              "  'cells': [110],\n",
              "  'injury': [111],\n",
              "  'model': [112],\n",
              "  'vitro': [114, 240],\n",
              "  'verify': [116],\n",
              "  'blocks': [118],\n",
              "  'mainly': [120],\n",
              "  'targeting': [122],\n",
              "  'inflammasome.': [125],\n",
              "  'For': [126],\n",
              "  'vivo': [128],\n",
              "  'studies,': [129],\n",
              "  'observed': [131],\n",
              "  'Aβ': [133, 166, 187],\n",
              "  'accumulation,': [134],\n",
              "  'Tau': [135, 192],\n",
              "  'hyperphosphorylation,': [136],\n",
              "  'neurons': [137],\n",
              "  'hippocampal': [139],\n",
              "  'damage,': [140],\n",
              "  'cognitive': [142],\n",
              "  'dysfunction': [143],\n",
              "  'mice,': [146],\n",
              "  'caused': [147],\n",
              "  'bilateral': [149],\n",
              "  'injection': [150],\n",
              "  'into': [153],\n",
              "  'hippocampus': [155],\n",
              "  'treatments': [157],\n",
              "  'with': [158],\n",
              "  'combine': [160],\n",
              "  'AlCl': [161],\n",
              "  '.': [163, 241],\n",
              "  'Besides,': [164],\n",
              "  'accumulated': [165],\n",
              "  'promotes': [167],\n",
              "  'inflammasome': [169],\n",
              "  'activation,': [170],\n",
              "  'leads': [172],\n",
              "  'activation': [175],\n",
              "  'release': [177],\n",
              "  'a': [179, 288, 297],\n",
              "  'pro-inflammatory': [180],\n",
              "  'cytokine,': [181],\n",
              "  'interleukin-1': [182],\n",
              "  'beta': [183],\n",
              "  '(IL-1β).': [184],\n",
              "  'Notably,': [185],\n",
              "  'both': [186],\n",
              "  'accumulation': [188],\n",
              "  'hyperphosphorylation': [190],\n",
              "  'decreased': [193],\n",
              "  'inhibited': [195],\n",
              "  'downregulating': [198],\n",
              "  'expression': [200, 224],\n",
              "  'IL-1β': [202],\n",
              "  'IL-18,': [204],\n",
              "  'be': [207, 246, 296],\n",
              "  'attributed': [208],\n",
              "  'Sal.': [213],\n",
              "  'further': [215],\n",
              "  'found': [216],\n",
              "  'reverse': [220],\n",
              "  'increased': [222],\n",
              "  'protein': [223],\n",
              "  'TLR4,': [226],\n",
              "  'MyD88,': [227],\n",
              "  'NF-κB,': [228],\n",
              "  'P-NF-κB,': [229],\n",
              "  'NLRP3,': [230],\n",
              "  'ASC,': [231],\n",
              "  'cleaved': [232, 234],\n",
              "  'Caspase-1,': [233],\n",
              "  'GSDMD,': [235],\n",
              "  'IL-1β,': [236],\n",
              "  'IL-18': [238],\n",
              "  'The': [242],\n",
              "  'underlying': [243],\n",
              "  'mechanism': [244],\n",
              "  'may': [245],\n",
              "  'through': [247],\n",
              "  'TLR4/NF-κB/NLRP3/Caspase-1': [249],\n",
              "  'signaling': [250],\n",
              "  'pathway.': [251],\n",
              "  'Our': [252],\n",
              "  'highlights': [254],\n",
              "  'importance': [256],\n",
              "  'inflammasome-mediated': [259, 275, 285],\n",
              "  'how': [264],\n",
              "  'administration': [266],\n",
              "  'pharmacological': [268],\n",
              "  'doses': [269],\n",
              "  'inhibit': [273],\n",
              "  'ameliorate': [278],\n",
              "  'AD.': [279, 301],\n",
              "  'Thus,': [280],\n",
              "  'conclude': [282],\n",
              "  'plays': [287],\n",
              "  'significant': [289],\n",
              "  'role': [290],\n",
              "  'therapeutic': [298],\n",
              "  'drug': [299],\n",
              "  'for': [300]},\n",
              " 'counts_by_year': [{'year': 2025, 'cited_by_count': 43},\n",
              "  {'year': 2024, 'cited_by_count': 40},\n",
              "  {'year': 2023, 'cited_by_count': 36},\n",
              "  {'year': 2022, 'cited_by_count': 8}],\n",
              " 'updated_date': '2025-11-06T03:46:38.306776',\n",
              " 'created_date': '2025-10-10T00:00:00'}"
            ]
          },
          "execution_count": 7,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "data['results'][0]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "a897bbea",
      "metadata": {
        "id": "a897bbea"
      },
      "outputs": [],
      "source": [
        "def save_dois(search_string, from_publication_date, to_publication_date, quantity):\n",
        "\n",
        "    page = 1\n",
        "    per_page = min(quantity + 10, 200) # Берем чуть больше на случай, если в результатах окажутся одинаковые работы\n",
        "\n",
        "    searching = f\"https://api.openalex.org/works?page={page}&per-page={per_page}&filter=display_name.search:{search_string},type:article,is_oa:true,from_publication_date:{from_publication_date},to_publication_date:{to_publication_date}&sort=relevance_score:desc,cited_by_count:desc\"\n",
        "    response = requests.get(searching)\n",
        "    data = response.json()\n",
        "\n",
        "    quantity_found = data['meta'][\"count\"]\n",
        "    print(f\"Количество найденных статей для запроса '{search_string}': {quantity_found}\")\n",
        "\n",
        "    if quantity_found < quantity:\n",
        "        quantity = quantity_found\n",
        "\n",
        "    articles_dict = {}\n",
        "    i = 0\n",
        "    while len(articles_dict) < quantity:\n",
        "        if data['results'][i][\"title\"] not in list(articles_dict.keys()):\n",
        "            articles_dict[data['results'][i][\"title\"]] = [data['results'][i][\"title\"], data['results'][i][\"doi\"], data['results'][i][\"publication_year\"]]\n",
        "        i += 1\n",
        "\n",
        "    return articles_dict"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "dd52e4cf",
      "metadata": {
        "id": "dd52e4cf",
        "outputId": "dfcd018e-33af-4842-e4a5-0fd310bb2709"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Количество найденных статей для запроса 'Alzheimer's disease targets': 293\n",
            "Количество найденных статей для запроса 'Alzheimer therapeutic targets': 5\n",
            "Количество найденных статей для запроса 'Alzheimer drug targets': 8\n"
          ]
        }
      ],
      "source": [
        "search_strings = [\"Alzheimer's disease targets\", \"Alzheimer therapeutic targets\", \"Alzheimer drug targets\"]\n",
        "from_publication_date = \"2021-01-01\"\n",
        "to_publication_date = \"2026-01-01\"\n",
        "quantity = 20\n",
        "\n",
        "dicts = []\n",
        "for search_string in search_strings:\n",
        "    dicts.append(save_dois(search_string, from_publication_date, to_publication_date, quantity))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "bfecf476",
      "metadata": {
        "id": "bfecf476",
        "outputId": "4131835a-b4b6-41a7-f767-c36e10368ab7"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "33"
            ]
          },
          "execution_count": 10,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_links = {}\n",
        "for dict in dicts:\n",
        "    articles_links.update(dict)\n",
        "\n",
        "len(articles_links)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "e099280f",
      "metadata": {
        "id": "e099280f",
        "outputId": "809431cc-d6ad-42d7-df2a-45792ef6f8a3"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[\"Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis\",\n",
              " 'https://doi.org/10.3389/fnagi.2021.809433',\n",
              " 2022]"
            ]
          },
          "execution_count": 11,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "list(articles_links.items())[0][1]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "32876dbb",
      "metadata": {
        "id": "32876dbb",
        "outputId": "1ce3a5d0-9b75-4b07-e9e2-543788698737"
      },
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>url</th>\n",
              "      <th>year</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>2022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Natural acetylcholinesterase inhibitors: A mul...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmcr.2024.100154</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>GSK3: A potential target and pending issues fo...</td>\n",
              "      <td>https://doi.org/10.1111/cns.14818</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Targeting dysregulated lipid metabolism for th...</td>\n",
              "      <td>https://doi.org/10.1016/j.nbd.2024.106505</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Targeting tau in Alzheimer's disease: from mec...</td>\n",
              "      <td>https://doi.org/10.4103/1673-5374.385847</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Intelligent lesion blood–brain barrier targeti...</td>\n",
              "      <td>https://doi.org/10.1016/j.apsb.2022.02.001</td>\n",
              "      <td>2022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Multi-target neuroprotective effects of herbal...</td>\n",
              "      <td>https://doi.org/10.1016/j.jep.2022.115107</td>\n",
              "      <td>2022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Associations of semaglutide with first‐time di...</td>\n",
              "      <td>https://doi.org/10.1002/alz.14313</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>The VTA dopaminergic system as diagnostic and ...</td>\n",
              "      <td>https://doi.org/10.3389/fpsyt.2022.1039725</td>\n",
              "      <td>2022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>Targeting both BDNF/TrkB pathway and delta-sec...</td>\n",
              "      <td>https://doi.org/10.1016/j.neuropharm.2021.108737</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>Intranasal administration of dauricine loaded ...</td>\n",
              "      <td>https://doi.org/10.1080/10717544.2021.1895909</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2021.113847</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>Hybrid Membrane‐Coated Nanoparticles for Preci...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202306675</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>C-glycosides analogues of the okadaic acid cen...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2023.115245</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>Death-associated protein kinase 1 as a therape...</td>\n",
              "      <td>https://doi.org/10.1186/s40035-023-00395-5</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>Sex‐specific declines in cholinergic‐targeting...</td>\n",
              "      <td>https://doi.org/10.1002/alz.13095</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>Study on the Role of an Erythrocyte Membrane‐C...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202301361</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "      <td>https://doi.org/10.1016/j.xinn.2021.100160</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Diagnosis and Treatment of Alzheimer's Disease...</td>\n",
              "      <td>https://doi.org/10.36838/v7i2.3</td>\n",
              "      <td>2025</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>Mechanism of quercetin therapeutic targets for...</td>\n",
              "      <td>https://doi.org/10.1038/s41598-021-02248-5</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>Multiomics Identification of Potential Targets...</td>\n",
              "      <td>https://doi.org/10.3390/pharmaceutics13101555</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>Targeting the post-synaptic proteome has thera...</td>\n",
              "      <td>https://doi.org/10.1038/s42003-023-04961-5</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>Metabolic resistance of Aβ3pE-42, a target epi...</td>\n",
              "      <td>https://doi.org/10.26508/lsa.202402650</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>Neuroinflammation as a Potential Therapeutic T...</td>\n",
              "      <td>None</td>\n",
              "      <td>2022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>Genetic Variation in Targets of Antidiabetic D...</td>\n",
              "      <td>https://doi.org/10.1212/wnl.0000000000200771</td>\n",
              "      <td>2022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>A hybrid approach unveils drug repurposing can...</td>\n",
              "      <td>https://doi.org/10.1016/j.patter.2021.100433</td>\n",
              "      <td>2022</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>Amyloid-Targeting Drugs for the Treatment of A...</td>\n",
              "      <td>https://doi.org/10.17340/jkna.2021.3.4</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>Green Synthesis of Barbituric Acid Derivative ...</td>\n",
              "      <td>https://doi.org/10.14233/ajomc.2021.ajomc-p332</td>\n",
              "      <td>2021</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>Genomics and Drug Research Approach in Identif...</td>\n",
              "      <td>https://doi.org/10.52403/gijhsr.20240115</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>Current Status and Future Prospects of Drug Ta...</td>\n",
              "      <td>https://doi.org/10.1254/jpssuppl.97.0_1-b-s03-3</td>\n",
              "      <td>2023</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>Identification of Sirtuin 1-Targeted Anti-Alzh...</td>\n",
              "      <td>https://doi.org/10.56042/ijc.v63i12.13637</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>2024</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                                title  \\\n",
              "0   Salidroside Ameliorates Alzheimer's Disease by...   \n",
              "1   Metabolic reprogramming in inflammatory microg...   \n",
              "2   Natural acetylcholinesterase inhibitors: A mul...   \n",
              "3   GSK3: A potential target and pending issues fo...   \n",
              "4   Targeting dysregulated lipid metabolism for th...   \n",
              "5   Targeting tau in Alzheimer's disease: from mec...   \n",
              "6   Intelligent lesion blood–brain barrier targeti...   \n",
              "7   Multi-target neuroprotective effects of herbal...   \n",
              "8   Associations of semaglutide with first‐time di...   \n",
              "9   The VTA dopaminergic system as diagnostic and ...   \n",
              "10  Targeting both BDNF/TrkB pathway and delta-sec...   \n",
              "11  Intranasal administration of dauricine loaded ...   \n",
              "12  Targeting transthyretin in Alzheimer's disease...   \n",
              "13  Hybrid Membrane‐Coated Nanoparticles for Preci...   \n",
              "14  C-glycosides analogues of the okadaic acid cen...   \n",
              "15  Death-associated protein kinase 1 as a therape...   \n",
              "16  Sex‐specific declines in cholinergic‐targeting...   \n",
              "17  Study on the Role of an Erythrocyte Membrane‐C...   \n",
              "18  A dual-targeted multifunctional nanoformulatio...   \n",
              "19  Diagnosis and Treatment of Alzheimer's Disease...   \n",
              "20  Mechanism of quercetin therapeutic targets for...   \n",
              "21  Multiomics Identification of Potential Targets...   \n",
              "22  Targeting the post-synaptic proteome has thera...   \n",
              "23  Metabolic resistance of Aβ3pE-42, a target epi...   \n",
              "24  Neuroinflammation as a Potential Therapeutic T...   \n",
              "25  Genetic Variation in Targets of Antidiabetic D...   \n",
              "26  A hybrid approach unveils drug repurposing can...   \n",
              "27  Amyloid-Targeting Drugs for the Treatment of A...   \n",
              "28  Green Synthesis of Barbituric Acid Derivative ...   \n",
              "29  Genomics and Drug Research Approach in Identif...   \n",
              "30  Current Status and Future Prospects of Drug Ta...   \n",
              "31  Identification of Sirtuin 1-Targeted Anti-Alzh...   \n",
              "32  Generation and validation of anti‐TREM2 agonis...   \n",
              "\n",
              "                                                 url  year  \n",
              "0          https://doi.org/10.3389/fnagi.2021.809433  2022  \n",
              "1        https://doi.org/10.1016/j.redox.2023.102846  2023  \n",
              "2        https://doi.org/10.1016/j.ejmcr.2024.100154  2024  \n",
              "3                  https://doi.org/10.1111/cns.14818  2024  \n",
              "4          https://doi.org/10.1016/j.nbd.2024.106505  2024  \n",
              "5           https://doi.org/10.4103/1673-5374.385847  2023  \n",
              "6         https://doi.org/10.1016/j.apsb.2022.02.001  2022  \n",
              "7          https://doi.org/10.1016/j.jep.2022.115107  2022  \n",
              "8                  https://doi.org/10.1002/alz.14313  2024  \n",
              "9         https://doi.org/10.3389/fpsyt.2022.1039725  2022  \n",
              "10  https://doi.org/10.1016/j.neuropharm.2021.108737  2021  \n",
              "11     https://doi.org/10.1080/10717544.2021.1895909  2021  \n",
              "12      https://doi.org/10.1016/j.ejmech.2021.113847  2021  \n",
              "13            https://doi.org/10.1002/advs.202306675  2024  \n",
              "14      https://doi.org/10.1016/j.ejmech.2023.115245  2023  \n",
              "15        https://doi.org/10.1186/s40035-023-00395-5  2024  \n",
              "16                 https://doi.org/10.1002/alz.13095  2023  \n",
              "17            https://doi.org/10.1002/advs.202301361  2023  \n",
              "18        https://doi.org/10.1016/j.xinn.2021.100160  2021  \n",
              "19                   https://doi.org/10.36838/v7i2.3  2025  \n",
              "20        https://doi.org/10.1038/s41598-021-02248-5  2021  \n",
              "21     https://doi.org/10.3390/pharmaceutics13101555  2021  \n",
              "22        https://doi.org/10.1038/s42003-023-04961-5  2023  \n",
              "23            https://doi.org/10.26508/lsa.202402650  2024  \n",
              "24                                              None  2022  \n",
              "25      https://doi.org/10.1212/wnl.0000000000200771  2022  \n",
              "26      https://doi.org/10.1016/j.patter.2021.100433  2022  \n",
              "27            https://doi.org/10.17340/jkna.2021.3.4  2021  \n",
              "28    https://doi.org/10.14233/ajomc.2021.ajomc-p332  2021  \n",
              "29          https://doi.org/10.52403/gijhsr.20240115  2024  \n",
              "30   https://doi.org/10.1254/jpssuppl.97.0_1-b-s03-3  2023  \n",
              "31         https://doi.org/10.56042/ijc.v63i12.13637  2024  \n",
              "32                https://doi.org/10.1002/alz.088509  2024  "
            ]
          },
          "execution_count": 12,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "titles = []\n",
        "urls = []\n",
        "years = []\n",
        "\n",
        "items = list(articles_links.items())\n",
        "\n",
        "for i in range (len(items)):\n",
        "    titles.append(items[i][1][0])\n",
        "    urls.append(items[i][1][1])\n",
        "    years.append(items[i][1][2])\n",
        "\n",
        "articles_links_df = pd.DataFrame({'title': titles, 'url': urls, 'year': years})\n",
        "articles_links_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "3f377f7c",
      "metadata": {
        "id": "3f377f7c"
      },
      "outputs": [],
      "source": [
        "# В одной строке None, удалим\n",
        "articles_links_df = articles_links_df.dropna(subset=['url'])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "8aa2605e",
      "metadata": {
        "id": "8aa2605e",
        "outputId": "b5a2172e-8ee9-4040-cd9e-d3abf9ad3918"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "'text/html; charset=utf-8'"
            ]
          },
          "execution_count": 14,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "response = requests.get(articles_links_df['url'][16])\n",
        "response.headers.get(\"Content-Type\", \"\").lower()"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "dc7ded65",
      "metadata": {
        "id": "dc7ded65"
      },
      "source": [
        "## Задача 2\n",
        "- Извлечь и очистить текст (абстракты + введение + заключение)\n",
        "\n",
        "*Вероятно, структура разных сайтов различается, из-за чего может усложниться парсинг.*\n",
        "\n",
        "*Были попытки использовать selenium, а также trafilatura для извлечения текстов статей из гипертекстов, который по идее должен был позволить собрать быстро все статьи \"без страданий\", однако из-за переадресации у некоторых ссылок и дополнительной проверки с капчей возвращаются пустые строки, и скрапинг становится очень сложным или почти невозможным.*\n",
        "\n",
        "*Попробуем скачать все статьи в пдф формате, а затем извлечь из файлов саммари с использованием локальной языковой модели. Локальная  позволяет быстрее обработать данные. Используется qwen2.5:7b-instruct. Среди официальных моделей (<8млрд параметров) на лидерборде Hugging Face она занимает второе место. По сравнению с моделью на первом месте контекстное окно текущей модели в 3 раза больше. Для извлечения конкретных разделов статьи лучше подойдут более крупные БЯМ, которые сложнее запускать локально.*"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "1d9a913d",
      "metadata": {
        "id": "1d9a913d"
      },
      "source": [
        "Одна статья недоступна, две на китайском (надо было изначально задать критерии включения), остается 29."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "b403bad6",
      "metadata": {
        "id": "b403bad6"
      },
      "outputs": [],
      "source": [
        "import os\n",
        "import re\n",
        "from pypdf import PdfReader"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "f65c7f35",
      "metadata": {
        "id": "f65c7f35",
        "outputId": "3a6db9a9-774b-4f06-ce03-5b631f196b81"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "['db\\\\0.pdf', 'db\\\\1.pdf', 'db\\\\2.pdf', 'db\\\\3.pdf', 'db\\\\4.pdf', 'db\\\\5.pdf', 'db\\\\6.pdf', 'db\\\\7.pdf', 'db\\\\8.pdf', 'db\\\\9.pdf', 'db\\\\11.pdf', 'db\\\\12.pdf', 'db\\\\13.pdf', 'db\\\\14.pdf', 'db\\\\15.pdf', 'db\\\\16.pdf', 'db\\\\17.pdf', 'db\\\\18.pdf', 'db\\\\19.pdf', 'db\\\\20.pdf', 'db\\\\21.pdf', 'db\\\\22.pdf', 'db\\\\23.pdf', 'db\\\\25.pdf', 'db\\\\26.pdf', 'db\\\\28.pdf', 'db\\\\29.pdf', 'db\\\\31.pdf', 'db\\\\32.pdf']\n"
          ]
        }
      ],
      "source": [
        "folder = \"db\"\n",
        "files = []\n",
        "for name in os.listdir(folder):\n",
        "    if name.endswith(\".pdf\"):\n",
        "        full_path = os.path.join(folder, name)\n",
        "        files.append(full_path)\n",
        "\n",
        "\n",
        "def get_number(file_path):\n",
        "    numbers = re.findall(r'\\d+', file_path)\n",
        "    return int(numbers[-1]) if numbers else 0\n",
        "files.sort(key=get_number)\n",
        "\n",
        "print(files)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "5e3609a5",
      "metadata": {
        "id": "5e3609a5",
        "outputId": "e3c204cb-8022-42e4-ded1-5812f4c0f32d"
      },
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>url</th>\n",
              "      <th>year</th>\n",
              "      <th>filename</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\0.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\1.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Natural acetylcholinesterase inhibitors: A mul...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmcr.2024.100154</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\2.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>GSK3: A potential target and pending issues fo...</td>\n",
              "      <td>https://doi.org/10.1111/cns.14818</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\3.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Targeting dysregulated lipid metabolism for th...</td>\n",
              "      <td>https://doi.org/10.1016/j.nbd.2024.106505</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\4.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Targeting tau in Alzheimer's disease: from mec...</td>\n",
              "      <td>https://doi.org/10.4103/1673-5374.385847</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\5.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Intelligent lesion blood–brain barrier targeti...</td>\n",
              "      <td>https://doi.org/10.1016/j.apsb.2022.02.001</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\6.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Multi-target neuroprotective effects of herbal...</td>\n",
              "      <td>https://doi.org/10.1016/j.jep.2022.115107</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\7.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Associations of semaglutide with first‐time di...</td>\n",
              "      <td>https://doi.org/10.1002/alz.14313</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\8.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>The VTA dopaminergic system as diagnostic and ...</td>\n",
              "      <td>https://doi.org/10.3389/fpsyt.2022.1039725</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\9.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>Intranasal administration of dauricine loaded ...</td>\n",
              "      <td>https://doi.org/10.1080/10717544.2021.1895909</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\11.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2021.113847</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\12.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>Hybrid Membrane‐Coated Nanoparticles for Preci...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202306675</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\13.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>C-glycosides analogues of the okadaic acid cen...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2023.115245</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\14.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>Death-associated protein kinase 1 as a therape...</td>\n",
              "      <td>https://doi.org/10.1186/s40035-023-00395-5</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\15.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>Sex‐specific declines in cholinergic‐targeting...</td>\n",
              "      <td>https://doi.org/10.1002/alz.13095</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\16.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>Study on the Role of an Erythrocyte Membrane‐C...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202301361</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\17.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "      <td>https://doi.org/10.1016/j.xinn.2021.100160</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\18.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Diagnosis and Treatment of Alzheimer's Disease...</td>\n",
              "      <td>https://doi.org/10.36838/v7i2.3</td>\n",
              "      <td>2025</td>\n",
              "      <td>db\\19.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>Mechanism of quercetin therapeutic targets for...</td>\n",
              "      <td>https://doi.org/10.1038/s41598-021-02248-5</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\20.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>Multiomics Identification of Potential Targets...</td>\n",
              "      <td>https://doi.org/10.3390/pharmaceutics13101555</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\21.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>Targeting the post-synaptic proteome has thera...</td>\n",
              "      <td>https://doi.org/10.1038/s42003-023-04961-5</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\22.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>Metabolic resistance of Aβ3pE-42, a target epi...</td>\n",
              "      <td>https://doi.org/10.26508/lsa.202402650</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\23.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>Genetic Variation in Targets of Antidiabetic D...</td>\n",
              "      <td>https://doi.org/10.1212/wnl.0000000000200771</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\25.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>A hybrid approach unveils drug repurposing can...</td>\n",
              "      <td>https://doi.org/10.1016/j.patter.2021.100433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\26.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>Green Synthesis of Barbituric Acid Derivative ...</td>\n",
              "      <td>https://doi.org/10.14233/ajomc.2021.ajomc-p332</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\28.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>Genomics and Drug Research Approach in Identif...</td>\n",
              "      <td>https://doi.org/10.52403/gijhsr.20240115</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\29.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>Identification of Sirtuin 1-Targeted Anti-Alzh...</td>\n",
              "      <td>https://doi.org/10.56042/ijc.v63i12.13637</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\31.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\32.pdf</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                                title  \\\n",
              "0   Salidroside Ameliorates Alzheimer's Disease by...   \n",
              "1   Metabolic reprogramming in inflammatory microg...   \n",
              "2   Natural acetylcholinesterase inhibitors: A mul...   \n",
              "3   GSK3: A potential target and pending issues fo...   \n",
              "4   Targeting dysregulated lipid metabolism for th...   \n",
              "5   Targeting tau in Alzheimer's disease: from mec...   \n",
              "6   Intelligent lesion blood–brain barrier targeti...   \n",
              "7   Multi-target neuroprotective effects of herbal...   \n",
              "8   Associations of semaglutide with first‐time di...   \n",
              "9   The VTA dopaminergic system as diagnostic and ...   \n",
              "11  Intranasal administration of dauricine loaded ...   \n",
              "12  Targeting transthyretin in Alzheimer's disease...   \n",
              "13  Hybrid Membrane‐Coated Nanoparticles for Preci...   \n",
              "14  C-glycosides analogues of the okadaic acid cen...   \n",
              "15  Death-associated protein kinase 1 as a therape...   \n",
              "16  Sex‐specific declines in cholinergic‐targeting...   \n",
              "17  Study on the Role of an Erythrocyte Membrane‐C...   \n",
              "18  A dual-targeted multifunctional nanoformulatio...   \n",
              "19  Diagnosis and Treatment of Alzheimer's Disease...   \n",
              "20  Mechanism of quercetin therapeutic targets for...   \n",
              "21  Multiomics Identification of Potential Targets...   \n",
              "22  Targeting the post-synaptic proteome has thera...   \n",
              "23  Metabolic resistance of Aβ3pE-42, a target epi...   \n",
              "25  Genetic Variation in Targets of Antidiabetic D...   \n",
              "26  A hybrid approach unveils drug repurposing can...   \n",
              "28  Green Synthesis of Barbituric Acid Derivative ...   \n",
              "29  Genomics and Drug Research Approach in Identif...   \n",
              "31  Identification of Sirtuin 1-Targeted Anti-Alzh...   \n",
              "32  Generation and validation of anti‐TREM2 agonis...   \n",
              "\n",
              "                                               url  year   filename  \n",
              "0        https://doi.org/10.3389/fnagi.2021.809433  2022   db\\0.pdf  \n",
              "1      https://doi.org/10.1016/j.redox.2023.102846  2023   db\\1.pdf  \n",
              "2      https://doi.org/10.1016/j.ejmcr.2024.100154  2024   db\\2.pdf  \n",
              "3                https://doi.org/10.1111/cns.14818  2024   db\\3.pdf  \n",
              "4        https://doi.org/10.1016/j.nbd.2024.106505  2024   db\\4.pdf  \n",
              "5         https://doi.org/10.4103/1673-5374.385847  2023   db\\5.pdf  \n",
              "6       https://doi.org/10.1016/j.apsb.2022.02.001  2022   db\\6.pdf  \n",
              "7        https://doi.org/10.1016/j.jep.2022.115107  2022   db\\7.pdf  \n",
              "8                https://doi.org/10.1002/alz.14313  2024   db\\8.pdf  \n",
              "9       https://doi.org/10.3389/fpsyt.2022.1039725  2022   db\\9.pdf  \n",
              "11   https://doi.org/10.1080/10717544.2021.1895909  2021  db\\11.pdf  \n",
              "12    https://doi.org/10.1016/j.ejmech.2021.113847  2021  db\\12.pdf  \n",
              "13          https://doi.org/10.1002/advs.202306675  2024  db\\13.pdf  \n",
              "14    https://doi.org/10.1016/j.ejmech.2023.115245  2023  db\\14.pdf  \n",
              "15      https://doi.org/10.1186/s40035-023-00395-5  2024  db\\15.pdf  \n",
              "16               https://doi.org/10.1002/alz.13095  2023  db\\16.pdf  \n",
              "17          https://doi.org/10.1002/advs.202301361  2023  db\\17.pdf  \n",
              "18      https://doi.org/10.1016/j.xinn.2021.100160  2021  db\\18.pdf  \n",
              "19                 https://doi.org/10.36838/v7i2.3  2025  db\\19.pdf  \n",
              "20      https://doi.org/10.1038/s41598-021-02248-5  2021  db\\20.pdf  \n",
              "21   https://doi.org/10.3390/pharmaceutics13101555  2021  db\\21.pdf  \n",
              "22      https://doi.org/10.1038/s42003-023-04961-5  2023  db\\22.pdf  \n",
              "23          https://doi.org/10.26508/lsa.202402650  2024  db\\23.pdf  \n",
              "25    https://doi.org/10.1212/wnl.0000000000200771  2022  db\\25.pdf  \n",
              "26    https://doi.org/10.1016/j.patter.2021.100433  2022  db\\26.pdf  \n",
              "28  https://doi.org/10.14233/ajomc.2021.ajomc-p332  2021  db\\28.pdf  \n",
              "29        https://doi.org/10.52403/gijhsr.20240115  2024  db\\29.pdf  \n",
              "31       https://doi.org/10.56042/ijc.v63i12.13637  2024  db\\31.pdf  \n",
              "32              https://doi.org/10.1002/alz.088509  2024  db\\32.pdf  "
            ]
          },
          "execution_count": 20,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_df = articles_links_df.copy()\n",
        "\n",
        "def extract_id(path):\n",
        "    return int(re.findall(r'\\d+', os.path.basename(path))[0])\n",
        "\n",
        "file_mapping = {extract_id(f): f for f in files}\n",
        "\n",
        "articles_df['filename'] = articles_df.index.map(file_mapping)\n",
        "articles_df = articles_df.dropna(subset=['filename'])\n",
        "articles_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "e67580fe",
      "metadata": {
        "id": "e67580fe"
      },
      "outputs": [],
      "source": [
        "article_texts = []\n",
        "\n",
        "for file in files:\n",
        "    reader = PdfReader(file)\n",
        "    article_text = \"\"\n",
        "\n",
        "    for page in reader.pages:\n",
        "        text = page.extract_text()\n",
        "        if text:\n",
        "            article_text += text + \" \"\n",
        "\n",
        "    article_texts.append(article_text)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "26b7d89b",
      "metadata": {
        "id": "26b7d89b",
        "outputId": "da3461f4-71ad-47a7-986d-a2ead7a8b883"
      },
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>url</th>\n",
              "      <th>year</th>\n",
              "      <th>filename</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\0.pdf</td>\n",
              "      <td>ORIGINAL RESEARCH\\npublished: 21 January 2022\\...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\1.pdf</td>\n",
              "      <td>Redox Biology 66 (2023) 102846\\nAvailable onli...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Natural acetylcholinesterase inhibitors: A mul...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmcr.2024.100154</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\2.pdf</td>\n",
              "      <td>European Journal of Medicinal Chemistry Report...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>GSK3: A potential target and pending issues fo...</td>\n",
              "      <td>https://doi.org/10.1111/cns.14818</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\3.pdf</td>\n",
              "      <td>CNS Neurosci Ther. 2024;30:e14818.\\t \\t\\t \\t |...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Targeting dysregulated lipid metabolism for th...</td>\n",
              "      <td>https://doi.org/10.1016/j.nbd.2024.106505</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\4.pdf</td>\n",
              "      <td>Neurobiology of Disease 196 (2024) 106505\\nAva...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Targeting tau in Alzheimer's disease: from mec...</td>\n",
              "      <td>https://doi.org/10.4103/1673-5374.385847</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\5.pdf</td>\n",
              "      <td>NEURAL REGENERATION RESEARCH｜Vol 19｜No. 7｜July...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Intelligent lesion blood–brain barrier targeti...</td>\n",
              "      <td>https://doi.org/10.1016/j.apsb.2022.02.001</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\6.pdf</td>\n",
              "      <td>ORIGINAL ARTICLE\\nIntelligent lesion blood ebr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Multi-target neuroprotective effects of herbal...</td>\n",
              "      <td>https://doi.org/10.1016/j.jep.2022.115107</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\7.pdf</td>\n",
              "      <td>Journal of Ethnopharmacology 290 (2022) 115107...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Associations of semaglutide with first‐time di...</td>\n",
              "      <td>https://doi.org/10.1002/alz.14313</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\8.pdf</td>\n",
              "      <td>Received:29July2024 Revised:10September2024 Ac...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>The VTA dopaminergic system as diagnostic and ...</td>\n",
              "      <td>https://doi.org/10.3389/fpsyt.2022.1039725</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\9.pdf</td>\n",
              "      <td>TYPE Perspective\\nPUBLISHED /one.tnum/seven.tn...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>Intranasal administration of dauricine loaded ...</td>\n",
              "      <td>https://doi.org/10.1080/10717544.2021.1895909</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\11.pdf</td>\n",
              "      <td>Drug Delivery\\nISSN: 1071-7544 (Print) 1521-04...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2021.113847</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\12.pdf</td>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>Hybrid Membrane‐Coated Nanoparticles for Preci...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202306675</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\13.pdf</td>\n",
              "      <td>RESEARCH ARTICLE\\nwww.advancedscience.com\\nHyb...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>C-glycosides analogues of the okadaic acid cen...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2023.115245</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\14.pdf</td>\n",
              "      <td>European Journal of Medicinal Chemistry 251 (2...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>Death-associated protein kinase 1 as a therape...</td>\n",
              "      <td>https://doi.org/10.1186/s40035-023-00395-5</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\15.pdf</td>\n",
              "      <td>Zhang et al. Translational Neurodegeneration  ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>Sex‐specific declines in cholinergic‐targeting...</td>\n",
              "      <td>https://doi.org/10.1002/alz.13095</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\16.pdf</td>\n",
              "      <td>Received: 23 February 2023 Accepted: 21 March ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>Study on the Role of an Erythrocyte Membrane‐C...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202301361</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\17.pdf</td>\n",
              "      <td>RESEARCH ARTICLE\\nwww.advancedscience.com\\nStu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "      <td>https://doi.org/10.1016/j.xinn.2021.100160</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\18.pdf</td>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Diagnosis and Treatment of Alzheimer's Disease...</td>\n",
              "      <td>https://doi.org/10.36838/v7i2.3</td>\n",
              "      <td>2025</td>\n",
              "      <td>db\\19.pdf</td>\n",
              "      <td>© 2025 Terra Science and Education 15  \\nDiagn...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>Mechanism of quercetin therapeutic targets for...</td>\n",
              "      <td>https://doi.org/10.1038/s41598-021-02248-5</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\20.pdf</td>\n",
              "      <td>1\\nVol.:(0123456789)Scientific Reports |      ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>Multiomics Identification of Potential Targets...</td>\n",
              "      <td>https://doi.org/10.3390/pharmaceutics13101555</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\21.pdf</td>\n",
              "      <td>pharmaceutics\\nArticle\\nMultiomics Identiﬁcati...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>Targeting the post-synaptic proteome has thera...</td>\n",
              "      <td>https://doi.org/10.1038/s42003-023-04961-5</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\22.pdf</td>\n",
              "      <td>ARTICLE\\nTargeting the post-synaptic proteome ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>Metabolic resistance of Aβ3pE-42, a target epi...</td>\n",
              "      <td>https://doi.org/10.26508/lsa.202402650</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\23.pdf</td>\n",
              "      <td>Research Article\\nMetabolic resistance of Aβ3p...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>Genetic Variation in Targets of Antidiabetic D...</td>\n",
              "      <td>https://doi.org/10.1212/wnl.0000000000200771</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\25.pdf</td>\n",
              "      <td>RESEARCH ARTICLE OPEN ACCESS\\nGenetic Variatio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>A hybrid approach unveils drug repurposing can...</td>\n",
              "      <td>https://doi.org/10.1016/j.patter.2021.100433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\26.pdf</td>\n",
              "      <td>Article\\nA hybrid approach unveils drug repurp...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>Green Synthesis of Barbituric Acid Derivative ...</td>\n",
              "      <td>https://doi.org/10.14233/ajomc.2021.ajomc-p332</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\28.pdf</td>\n",
              "      <td>Asian Pub. Corp.\\nwww.asianpubs.org\\nAsian Jou...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>Genomics and Drug Research Approach in Identif...</td>\n",
              "      <td>https://doi.org/10.52403/gijhsr.20240115</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\29.pdf</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>Identification of Sirtuin 1-Targeted Anti-Alzh...</td>\n",
              "      <td>https://doi.org/10.56042/ijc.v63i12.13637</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\31.pdf</td>\n",
              "      <td>Indian Journal o\\nf Chemistry \\nVol. 63, Decem...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\32.pdf</td>\n",
              "      <td>DOI: 10.1002/alz.088509\\nDRUG DEVELOPMENT\\nPOS...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                                title  \\\n",
              "0   Salidroside Ameliorates Alzheimer's Disease by...   \n",
              "1   Metabolic reprogramming in inflammatory microg...   \n",
              "2   Natural acetylcholinesterase inhibitors: A mul...   \n",
              "3   GSK3: A potential target and pending issues fo...   \n",
              "4   Targeting dysregulated lipid metabolism for th...   \n",
              "5   Targeting tau in Alzheimer's disease: from mec...   \n",
              "6   Intelligent lesion blood–brain barrier targeti...   \n",
              "7   Multi-target neuroprotective effects of herbal...   \n",
              "8   Associations of semaglutide with first‐time di...   \n",
              "9   The VTA dopaminergic system as diagnostic and ...   \n",
              "11  Intranasal administration of dauricine loaded ...   \n",
              "12  Targeting transthyretin in Alzheimer's disease...   \n",
              "13  Hybrid Membrane‐Coated Nanoparticles for Preci...   \n",
              "14  C-glycosides analogues of the okadaic acid cen...   \n",
              "15  Death-associated protein kinase 1 as a therape...   \n",
              "16  Sex‐specific declines in cholinergic‐targeting...   \n",
              "17  Study on the Role of an Erythrocyte Membrane‐C...   \n",
              "18  A dual-targeted multifunctional nanoformulatio...   \n",
              "19  Diagnosis and Treatment of Alzheimer's Disease...   \n",
              "20  Mechanism of quercetin therapeutic targets for...   \n",
              "21  Multiomics Identification of Potential Targets...   \n",
              "22  Targeting the post-synaptic proteome has thera...   \n",
              "23  Metabolic resistance of Aβ3pE-42, a target epi...   \n",
              "25  Genetic Variation in Targets of Antidiabetic D...   \n",
              "26  A hybrid approach unveils drug repurposing can...   \n",
              "28  Green Synthesis of Barbituric Acid Derivative ...   \n",
              "29  Genomics and Drug Research Approach in Identif...   \n",
              "31  Identification of Sirtuin 1-Targeted Anti-Alzh...   \n",
              "32  Generation and validation of anti‐TREM2 agonis...   \n",
              "\n",
              "                                               url  year   filename  \\\n",
              "0        https://doi.org/10.3389/fnagi.2021.809433  2022   db\\0.pdf   \n",
              "1      https://doi.org/10.1016/j.redox.2023.102846  2023   db\\1.pdf   \n",
              "2      https://doi.org/10.1016/j.ejmcr.2024.100154  2024   db\\2.pdf   \n",
              "3                https://doi.org/10.1111/cns.14818  2024   db\\3.pdf   \n",
              "4        https://doi.org/10.1016/j.nbd.2024.106505  2024   db\\4.pdf   \n",
              "5         https://doi.org/10.4103/1673-5374.385847  2023   db\\5.pdf   \n",
              "6       https://doi.org/10.1016/j.apsb.2022.02.001  2022   db\\6.pdf   \n",
              "7        https://doi.org/10.1016/j.jep.2022.115107  2022   db\\7.pdf   \n",
              "8                https://doi.org/10.1002/alz.14313  2024   db\\8.pdf   \n",
              "9       https://doi.org/10.3389/fpsyt.2022.1039725  2022   db\\9.pdf   \n",
              "11   https://doi.org/10.1080/10717544.2021.1895909  2021  db\\11.pdf   \n",
              "12    https://doi.org/10.1016/j.ejmech.2021.113847  2021  db\\12.pdf   \n",
              "13          https://doi.org/10.1002/advs.202306675  2024  db\\13.pdf   \n",
              "14    https://doi.org/10.1016/j.ejmech.2023.115245  2023  db\\14.pdf   \n",
              "15      https://doi.org/10.1186/s40035-023-00395-5  2024  db\\15.pdf   \n",
              "16               https://doi.org/10.1002/alz.13095  2023  db\\16.pdf   \n",
              "17          https://doi.org/10.1002/advs.202301361  2023  db\\17.pdf   \n",
              "18      https://doi.org/10.1016/j.xinn.2021.100160  2021  db\\18.pdf   \n",
              "19                 https://doi.org/10.36838/v7i2.3  2025  db\\19.pdf   \n",
              "20      https://doi.org/10.1038/s41598-021-02248-5  2021  db\\20.pdf   \n",
              "21   https://doi.org/10.3390/pharmaceutics13101555  2021  db\\21.pdf   \n",
              "22      https://doi.org/10.1038/s42003-023-04961-5  2023  db\\22.pdf   \n",
              "23          https://doi.org/10.26508/lsa.202402650  2024  db\\23.pdf   \n",
              "25    https://doi.org/10.1212/wnl.0000000000200771  2022  db\\25.pdf   \n",
              "26    https://doi.org/10.1016/j.patter.2021.100433  2022  db\\26.pdf   \n",
              "28  https://doi.org/10.14233/ajomc.2021.ajomc-p332  2021  db\\28.pdf   \n",
              "29        https://doi.org/10.52403/gijhsr.20240115  2024  db\\29.pdf   \n",
              "31       https://doi.org/10.56042/ijc.v63i12.13637  2024  db\\31.pdf   \n",
              "32              https://doi.org/10.1002/alz.088509  2024  db\\32.pdf   \n",
              "\n",
              "                                                 text  \n",
              "0   ORIGINAL RESEARCH\\npublished: 21 January 2022\\...  \n",
              "1   Redox Biology 66 (2023) 102846\\nAvailable onli...  \n",
              "2   European Journal of Medicinal Chemistry Report...  \n",
              "3   CNS Neurosci Ther. 2024;30:e14818.\\t \\t\\t \\t |...  \n",
              "4   Neurobiology of Disease 196 (2024) 106505\\nAva...  \n",
              "5   NEURAL REGENERATION RESEARCH｜Vol 19｜No. 7｜July...  \n",
              "6   ORIGINAL ARTICLE\\nIntelligent lesion blood ebr...  \n",
              "7   Journal of Ethnopharmacology 290 (2022) 115107...  \n",
              "8   Received:29July2024 Revised:10September2024 Ac...  \n",
              "9   TYPE Perspective\\nPUBLISHED /one.tnum/seven.tn...  \n",
              "11  Drug Delivery\\nISSN: 1071-7544 (Print) 1521-04...  \n",
              "12  Targeting transthyretin in Alzheimer's disease...  \n",
              "13  RESEARCH ARTICLE\\nwww.advancedscience.com\\nHyb...  \n",
              "14  European Journal of Medicinal Chemistry 251 (2...  \n",
              "15  Zhang et al. Translational Neurodegeneration  ...  \n",
              "16  Received: 23 February 2023 Accepted: 21 March ...  \n",
              "17  RESEARCH ARTICLE\\nwww.advancedscience.com\\nStu...  \n",
              "18  A dual-targeted multifunctional nanoformulatio...  \n",
              "19  © 2025 Terra Science and Education 15  \\nDiagn...  \n",
              "20  1\\nVol.:(0123456789)Scientific Reports |      ...  \n",
              "21  pharmaceutics\\nArticle\\nMultiomics Identiﬁcati...  \n",
              "22  ARTICLE\\nTargeting the post-synaptic proteome ...  \n",
              "23  Research Article\\nMetabolic resistance of Aβ3p...  \n",
              "25  RESEARCH ARTICLE OPEN ACCESS\\nGenetic Variatio...  \n",
              "26  Article\\nA hybrid approach unveils drug repurp...  \n",
              "28  Asian Pub. Corp.\\nwww.asianpubs.org\\nAsian Jou...  \n",
              "29                                                ...  \n",
              "31  Indian Journal o\\nf Chemistry \\nVol. 63, Decem...  \n",
              "32  DOI: 10.1002/alz.088509\\nDRUG DEVELOPMENT\\nPOS...  "
            ]
          },
          "execution_count": 22,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_df['text'] = article_texts\n",
        "articles_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "d4a93e22",
      "metadata": {
        "id": "d4a93e22"
      },
      "outputs": [],
      "source": [
        "from langchain_ollama import ChatOllama\n",
        "from langchain_core.prompts import ChatPromptTemplate\n",
        "from langchain_core.output_parsers import StrOutputParser"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "3f4b3c62",
      "metadata": {
        "id": "3f4b3c62"
      },
      "outputs": [],
      "source": [
        "llm_articles_analyzer = ChatOllama(\n",
        "    model=\"qwen2.5:7b-instruct\",\n",
        "    validate_model_on_init=True,\n",
        "    temperature=0.5,\n",
        "    num_predict=-1,\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "15a5d3a7",
      "metadata": {
        "id": "15a5d3a7",
        "outputId": "79258168-3f53-4d9a-c88d-18272d54376c"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "I am Qwen, an AI assistant created by Alibaba Cloud. I'm here to help with a wide range of tasks and provide information on various topics. How can I assist you today?\n"
          ]
        }
      ],
      "source": [
        "print(llm_articles_analyzer.invoke(\"Who are you?\").content)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "6b0821b4",
      "metadata": {
        "id": "6b0821b4",
        "outputId": "1d044d5d-2bd9-421e-d2f8-863c4712808c"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "\"                                                                                 Galore International Journal of Health Sciences and Research \\n                  Vol. 9; Issue: 1; Jan.-March 2024 \\n                               Website: www.gijhsr.com                                                   \\nResearch Article                                                                                                                                              P-ISSN: 2456-9321                                                                                          \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  138 \\nVolume 9; Issue: 1; January-March 2024 \\nGenomics and Drug Research Approach in \\nIdentifying Potential Drug Target Highlighting \\nAlzheimer Disease \\n \\nAnupriya1,2, Ayushi Poddar1,2, Sneha Priya1,3, Priyangulta Beck1,  \\nHarsimran Kaur1,4, Seema Kumari1,6, Barkha Kachhap1,6, Nisha Rani Soreng1,2, \\nSwati Shalika1,6, Mukesh Nitin1* \\n \\n1Department of Tech. Biosciences, Digianalix, South Samaj Street, Tharpakhna, Ranchi, Jharkhand, INDIA.  \\n2Department of Biotechnology, Gossner College, Ranchi, Jharkhand, INDIA. \\n3Department of Biotechnology, Ranchi Women’s College, Ranchi, Jharkhand, INDIA. \\n4School of Biotechnology, Devi Ahilya Vishwavidyalaya, Indore, INDIA. \\n5University Department of Botany, Ranchi University, Ranchi, Jharkhand, INDIA.  \\n6Department of Biotechnology, Marwari College, Ranchi, Jharkhand, INDIA.  \\n \\n*Corresponding Author: Dr. Mukesh Nitin \\nDepartment of Tech. Biosciences, Digianalix, South Samaj Street, Tharpakhna, Ranchi-834001, Jharkhand, \\nINDIA. \\nScientist and Head, Dept. of Tech. Biosciences, Digianalix, INDIA \\nGenomic Scientific Consultant, Gentan, Izmir, TURKEY \\nEmail: digianalix@gmail.com \\n \\nDOI: https://doi.org/10.52403/gijhsr.20240115 \\n \\n \\nABSTRACT  \\n \\nOver the past few years research on Alzheimer’s \\ndisease (AD) has been grown experimentally \\nwhich is a neurodegenerative disease and the \\nmost common form of dementia that cause \\nmemory loss and affect the ability to think \\nwhich can interfere with daily life. The main \\ncause of AD is on the growth of plagues and \\ntangles. AD is most commonly found in the age \\nof 60s, starts with mild memory loss and other \\ndisabilities which lead the person t o forget \\nthings on their daily life. In our research we are \\ntrying to ide ntify potential natural based \\nbioactive drug source compound using advanced \\ncomputational biology to help in exploring clues \\nfor the treatment of AD patients using molecular \\ndocking method. BACE1 was screened as a \\npotential target receptor in our study for the \\ndisease research. We also observed chromen -4-\\none as potent bioactive compound p resenting \\nhigh docking score of -5.60 K cal/mol against \\nBACE1 followed by other compounds. This \\nidentification will open new scope to future \\nresearchers to explor e more bioa ctive \\ncompounds which may aid new treatment \\noptions against AD followed with wet lab \\nexperimentation. \\n \\nKeywords: APP (Amyloid Precursor Protein), \\nBACE1, Alzheimer disease, Neurodegenerative, \\nMolecular docking, Hydrophobicity  \\n \\nINTRODUCTION  \\nAlzheimer disease (AD) is a most common \\ndisease, predominately found in elder age \\ngroup, which is a form of dementia caused \\nby plaques and tangles. AD is considered as \\nneurodegenerative disease that cause \\ndegeneration or loss of neurons in the brain \\nand get sh runk. It is a serious problem \\nwhich affects the ability to  remember, \\nimagine or learn. Nowadays every third \\nperson is facing this AD problems, which \\nresulted our research objective to explore  \\nmore on this disease, its type , causes, \\ntreatment and precau tions. It depends on \\ntwo factors, plaques (abnormal clusters of \\nprotein fragments) and tangles (made up of \\ntwisted strands of another p rotein). In a bi - Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  139 \\nVolume 9; Issue: 1; January-March 2024 \\nlipid cell membrane APP (Amyloid \\nPrecursor Protein) is present which helps in \\nthe growth and repair of neuro n. APP is a \\nsingle-pass transmembrane protein \\nexpressed at  high levels in the brain and \\nmetabolized in a rapid and highly complex \\nmanner by a series of sequential proteases, \\nincluding the intramembranous γ -secretase \\ncomplex, which process other key \\nregulatory molecules. \\nHalf part of APP protein is inside the ce ll \\nand half of it is present outside of the cell. \\nAlpha secretase is a type of enzyme which \\ncuts the APP pro tein at some pa rticular \\npoints.[1] There is another enzyme known as \\ngamma secretase which is also used to \\ndivide the APP protein into two parts. These \\nsections were cut by the alpha and gamma \\nsecretase enzyme which are soluble in water \\nthat causes APP protein to be dissolved and \\nnew APP protein can be developed but \\nwhen stimulation of beta secretase takes \\nplace it cannot be dissolved in water due to \\nside cut which form s plaque. This plaque \\ncan obstruc t the signals between neurons \\nwhich produce inflammation leads to \\ndegeneration of neurons.  \\nTau protein can be found in neurons and one \\nof its key roles is to support the microtubule \\nhighway system.  In AD, tau proteins \\nchanges and become abnormally \\nhyperphosphorylated which stop supporting \\nmicrotubules. Instead, the tau protein binds \\nwith other tau proteins, forming long protein \\nthreads within the neuron. T hese threads \\nbecome protein tangles and interfere with \\nthe neuron’s ability to function. The \\nproteolysis of APP protein b y β - and γ -\\nsecretase activities [2] also incur with past \\nresearch with identification of APP-cleaving \\nenzyme 1 (BACE1) which is the major β - \\nsecretase responsible for plaq ue formation \\nin the brain. [3-6] BACE1 is present in most \\nof body tissues including bra in highlighted \\nit as important enzyme protein used as a \\nbiomarker for AD.[7-9] \\nWith current advancement in bioinformatics \\nand drug discovery research has opened new \\nareas for exploring the treatment of AD with \\nthe help of system biology. In this research, \\nwe discovered target receptor BACE1 as \\npotential drug target fo r AD , it inhibits Aβ \\nproduction.[10] Bioactive compounds were \\nextracted from plants which act as potent \\nherbal medicine and helps to form a \\ncomplex which can be used a s drug for the \\ntreatment of AD. Further, docking studies \\nwere carried out in which BACE1 is be st \\ndocked with chromen -4-one followed by \\nsome other bioactive compounds with \\npositive potential result. To cross validate \\nour docking research hypothesis we \\nconducted computational based molecular \\ndynamic (MD) simulation analysis to find \\npotential drug compounds for futurist \\nresearch. \\n \\nMATERIALS & METHOD \\nCollection of data \\nThe protein samples were selected on the \\nbasis of extensive bibl iographic research \\nliterature resulting in identification of \\ncertain proteins that can play a vital role in \\ntarget predic tion which will help in the \\nidentification of treatment process in \\nAlzheimer’s disease. Target protein or \\nreceptor sequence was  further extracte d \\nfrom universal public domain U niprot \\ndatabase. \\n \\nHomology modeling and physiological \\ncharacteristics \\nThe target protein sequence was exported to \\nSwiss model server  for homology \\nmodeling,[11] to determine the 3-dimensional \\nstructure. Further, the analysis of the \\nphysiochemical properties of target receptor \\nwere evaluated using Protparam tool for \\nfinding no. of amino  acid, molecular weight \\nand theoretical PI and GRAVY value. [12] \\nWith the help of SOPMA server secondary \\nstructure of target receptor was predi cted.[13] \\nTransmembrane properties study were  \\ncarried out by SOSUI server [14] and \\nRamachandran plot was created by \\nProcheck server.[15]  \\n \\nReceptor preparation \\nThe pro tein file s extracted from Swiss \\nmodel were forwarded for receptor  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  140 \\nVolume 9; Issue: 1; January-March 2024 \\npreparation using UCSF Chimera .[16] \\nReceptor preparation with Chimera was \\npreceded further with the removal of \\nresidues such as ions, liga nds and solvents \\nfrom protein, for the next step SPDBV is \\nused to carry the energy minimization of the \\nprotein. Finally, in receptor preparation \\npipeline chimera is again used to add \\nhydrogen and charge to the protein then \\nsurface binding analysi s is done and save \\nthe file as final receptor in default .pdb \\nformat. \\n \\nLigand Preparation \\nExtensive research literature study \\nsuggested us to explore various bioactive \\ncompounds that are present in environment \\nas plants and herbs which are useful in the \\ntreatment of  Alzheimer disease. We \\nscreened and downloaded  various \\ncompounds from PUBCHEM [17] which \\nleads into the library preparation. With the \\nhelp of OSIRIS and DruLito software, we \\nscreened ADMET properties of bio active \\ncompounds. OSIRIS Property Explor er \\nhelps to design the  chemical structures and \\ncalculates on -the-fly numerous drug -\\nrelevant characteristics to be reasonable for \\na candidate drug. Prediction results are \\nvalued and color coded. Properties with \\nhigh prospects of unwanted results like \\nmutagenicity or a poor intestinal immersion \\nare shown in red whereas green color \\nindicates drug - behavior.[18] DruoLito \\n(Drug-likeness tools) rules are set of \\nguidelines for the structural properties of \\ncompounds, used for fast calculation of \\ndrug-like properties of a molecule. These \\nguidelines are not absolute, nor are th ey \\nintended to form strict cutoff values for \\nwhich property values are drug -like and \\nwhich are not drug -like. Nevertheless, they \\ncan be quite effective and efficient.  \\n \\nMolecular docking \\nMolecular docking is a key tool in structural \\nmolecular biology and computer -assisted \\ndrug design. The goal of ligand -protein \\ndocking is to forecast the foremost binding \\nmode(s) of a ligand with a protein of known \\nthree-dimensional structure. Docking can be \\nused to perform virtual screening o n large \\nlibraries of compounds. [19] The receptor \\nBACE1 with target ligands were further \\nsubjected for docking studies in \\nCHIMERA-Auto dock Vina. The docking \\nstudies states that the docked complex \\nconvey a high negative binding energy score \\nΔG which specify the concept of minimum \\nenergy and high security leading to best \\ninter connection between  proteins and the \\nligands. The obtained ligand -receptor \\ndocked complex was  further predicted in \\nBiovia Discovery studio to explain docking \\nanalysis b etween the bonds of ligands and \\nreceptors. \\n \\nMD simulations \\nWe use molecular dynamics (MD) \\nsimulation to computationally validate  our \\nanalysis using iMOD server [20]. It is a \\ncomputer program that stimulates the \\natomic behaviour of molecules. \\n \\nRESULTS \\nPhysiochemical property analysis of \\nreceptor \\nThe analysis of the target receptor was \\nselected on the bas is of their GRAVY value \\nin the P rotParam tool, BACE1 receptor was \\nfinally selected for target protein receptor \\nstudy having GRAVY -0.064 shown in \\nTable 1. With the help of SOSUI online tool \\namino acid sequences of the selected \\nreceptor BACE1 can help in the prognosis \\nof the portion of secondary structure of \\nprotein shown in Figure 1. SOPMA is a tool \\nto predict the secondary structure of protein \\nwhich is b ased on the homologue methods \\nfor sequencing. The graph shows expected \\nscore curve and different patterns of coils, \\nhelix, sheet and turn shown in F igure 2 and \\nTable 2 . It also displays parameter like \\nwindow width and the number states. The \\nBACE1 sequence was  also prepared for \\nhomology modeling study resulted in the \\ngeneration of pdb structure for receptor \\ndesign and docking studies as shown in \\nFigure 3.  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  141 \\nVolume 9; Issue: 1; January-March 2024 \\nTable 1: Parameters computerized by using Expasy ProtParam tool \\nProtein No of amino \\nacids \\nMolecular \\nweight \\nTheoretical pl Instability \\nindex \\nAliphatic index Grand average of \\nhydropathicity \\nBACE1 501 55763.79 5.31 44.23 88.14 -0.064 \\n \\n \\n \\n \\n \\nFigure 1: (a) Hydrophobicity of BACE1 receptor (b) Net charge density of BACE1 receptor (c) wheel plot of transmembrane \\nhelices.  \\n \\n \\nFigure 2: Showing the representational distribution of secondary structure prediction of BACE1 receptor having different pattern \\nof Helix, sheet, turn and coil. \\n \\nTable 2: Secondary structure elements calculated using SOPMA \\nProtein BACE1 \\nAlpha helix (Hh) 20.76% \\n310 helix (Gg) 0.00% \\nPi helix(Ii) 0.00% \\nBeta bridge (Bb) 0.00% \\nExtended strand(Ee) 26.55% \\nBeta turn(Tt) 6.59% \\nBend region(Ss) 0.00% \\nRandom coil(Cc) 46.11% \\nAmbiguous State (?) 0.00% \\nOther states 0.00%  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  142 \\nVolume 9; Issue: 1; January-March 2024 \\n \\nFigure 3: 3-dimensional protein structure of BACE1 receptor. \\n \\nScreening of ligands \\nFor our research analysis we extracted total \\n400 bioactive compounds which are Caffeic, \\nFerulic acid, Gallotannins, P rocyanidins, \\nRhamentin, Acetylcholine, Bilobetin, \\nCarotenoids, Donepeziel, Hydroxyethul \\nstarch, Isorhamnetin, L.Rhamnose, \\nL.Glutamate, Luteolin, Memantine, \\nRivastigmine, Tacrine, Tamarixetin, \\nTerpenoid etc. through Pubchem database. \\nMoreover, OSIRIS and D ruLito resulted in \\nscreening of the drug likeness and prepare \\nlibraries of these bioactive compounds. \\nFinally, 20 bioac tive compounds  were \\nextracted as ligands for molecular docking \\nusing AutoDock vina. Further, we evaluate \\nthe docking of these ligands with the \\nselected receptor BACE1 and produced \\ndifferent docking scores; among these \\ndockings we selected best five bioactive \\ncompounds or ligands. The ligands were \\nselected with the parameters of higher the \\nnegative score which is directly proportional \\nto high binding  efficiency. Moreover, we \\nuse P ubchem to cross -check the chemical \\ninformation of these five selected bioactive \\ncompounds such as Pubchem CID:16830 \\nwith  ΔG -5.3 kcal/mol, Puchem CID:14546 \\nwith  ΔG -5.3 kcal/mol and Pubchem CID: \\n16848 with ΔG -5.5 kcal/mol docking \\nscores are t he isomers of ferulic acid, \\nPubchem CID:10286 with ΔG -5.6 kcal/mol \\ndocking score i s the isomers of rhamentin \\nand P ubchem CID:23879 with ΔG -5.4 \\nkcal/mol docking score is t he isomers of \\ncaffeic shown in Table3 and Figure 4-8). \\n \\nTable 3: Pubchem CIDs with IUPAC Name, Molecular Weight and Docking Scores. \\nPubchem CID IUPAC Name Molecular Weight Docking Scores \\n10286 chromen-4-one 146.14g/mol -5.6 \\n16848 3-(3,4-dimethoxyphenyl) prop-2-enoic acid 208.21g/mol -5.5 \\n23879 3-(3-chlorophenyl) prop-2-ynoic acid 180.59g/mol -5.4 \\n14546 3-(2,4-dichlorophenyl) prop-2-enoic acid 217.05g/mol -5.3 \\n16830 methyl 3-(4-hydroxy-3-methoxyphenyl) prop-2-enoate 208.21g/mol -5.3 \\n  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  143 \\nVolume 9; Issue: 1; January-March 2024 \\n \\nFigure 4: 2D and 3D structure of docking complex between BACE1 receptor and chromen-4-one through Biovia Discovery. \\n \\n     \\n  \\nFigure 5: 2D and 3D structure of docking complex between BACE1 receptor and ligand 3-(3,4-dimethoxyphenyl) prop-2-enoic acid \\nthrough Biovia Discovery. \\n \\n \\nFigure 6: 2D and 3D structure of docking complex between BACE1 receptor and ligand 3-(3-chlorophenyl) prop-2-ynoic acid \\nthrough Biovia Discovery. \\n \\n \\n \\n \\nFigure 7: 2D and 3D structure of docking complex between BACE1 receptor and ligand 3-(2,4-dichlorophenyl) prop-2-enoic acid \\nthrough Biovia Discovery.  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  144 \\nVolume 9; Issue: 1; January-March 2024 \\n \\nFigure 8: 2D and 3D structure of docking complex between BACE1 receptor and ligand methyl 3-(4-hydroxy-3-methoxyphenyl) \\nprop-2-enoate through Biovia Discovery. \\n \\nThe best docking score having P ubchem \\nCID 10286 with ΔG -5.6 Kcal/mol docking \\nscore was selected for further analysis by \\nusing iMOD server. The result obtained \\nwere graphs based on deformability, \\nbfactor, ato m index etc. The eigenvalue of \\nPubchem CID 10286 is 5.223176e -04 as \\nshown in Figure 9-10. \\n \\n \\nFigure 9: Showing 3D structure obtained from iMod server. \\n \\n  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  145 \\nVolume 9; Issue: 1; January-March 2024 \\n \\nFigure 10: (a) Molecular dynamics simulations done through iMODS  server of rhamentin against BACE1 receptor depicting (a) \\nDeformability (b) bfactor  (c)Varience (d) Eigenvalue 5.223176e-04 (e) Covarience matrix  (f) Atom index.  \\n \\nDISCUSSION \\nAD is a progressive disease that destroys \\nmemories and other important cognitive \\nfunctions. In our research we collected \\ninformation of different properties of \\nseveral bioactive natural compounds by \\nusing different web servers like SO PMA, \\nSOSUI, DruLito, Prochecker [21], OSIRIS [22] \\nand concluded that BACE1 act as a \\npotential receptor that plays an important \\nrole in curing  AD[23]. BACE1 inhibition \\ntogether with other strategies , including \\nimmunotherapy which is designed  to clear \\nbrain amyloid plaques or neurofibri llary \\ntangles, is likely to be more effective in \\nimproving cognition in AD.  \\nBACE1 receptor is essential for the \\ngeneration of all monomeric forms of \\namyloid-β. BACE1 initiates production of \\nβ-amyloid peptides (Aβ), which is \\nconnected with reasonable disorder in \\nAlzheimer’s disease (AD) due to unusual \\noligomerization and accumulation.[23] In our \\nstudy BACE1 receptor was finally selected \\nfor target protein receptor study having \\nhydrophobic property with GRAVY -0.064 \\nfollowed by secondary structure analysis. \\nSimilarly, various research studies on \\nBACE 1 as a prime drug target for the \\nremedial inhibition of Aβ production in AD. \\nBACE1 inhibitors should offer benefit for \\nAD patients and structural analysis of \\nBACE1 inhibitor complexes has prov ed \\nuseful for drug development. [24] \\nVarious dataset contain various compounds \\nwith different physical and chemical \\nproperties covering an extensive ch emical \\nspace in drug like range. Screening of \\nbioactive compounds such as P ubchem \\nCID:16830 with ΔG -5.3 kcal/mol, P uchem \\nCID:14546 with ΔG -5.3 kcal/mol and \\nPubchem CID: 16848 with ΔG -5.5 \\nkcal/mol docking scores, P ubchem \\nCID:10286 with ΔG -5.6 kcal/m ol docking \\nscore and P ubchem CID:23879 with ΔG -\\n5.4 kcal/mol docking score show active \\npotential candidate drug compound in AD \\ntreatment. Similar research studies show \\nantioxidant and anti -inflammatory \\nproperties with natural bi oactive drug \\ncompound complex , Rasmarinic acid \\nagainst CASP8 with a docking score of -8.0 \\nkcal/mol and PTPN11 against Carnosol with \\na docking score of -9.1 kcal/mol helps in the \\ntreatment of AD . [25]  Another, similar \\nliteratures shows variety of natural bioactive \\ncompounds having pure pharmacological \\nmoieties showing multitargeting activities  \\nand others exhibiting specific beta -site \\namyloid precursor protein -cleaving enzyme \\n1 inhibition have superior biosafety . [26] \\nMany of these compounds, which are \\nisolated from medicinal herbs and marine \\nflora, have been long used for the treatment. \\nThus, with the use of this potential bioactive \\ncompounds like chromen -4-one with \\npositive MD simulation provide us new \\nresearch perception to explore more \\nbioactive compounds against AD treatment \\nfollowed by wet lab validations. \\n \\nCONCLUSION \\nSeveral studies proposed that BACE1 \\ninhibitor highlighted therapeutic potential \\nfor deceleration of long term progression of \\nAD. In our study BACE1 protein was  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  146 \\nVolume 9; Issue: 1; January-March 2024 \\nselected as target receptor fo llowed by \\ndocking studies against screened potential \\nnatural bioactive compounds like chromen -\\n4-one as best docked complex. This \\ncomputational bioinformatics based finding \\nwill explore more potential scope in \\nexploring bioactive compounds against AD \\ntreatment and  its cure followed by wet -lab \\nexperimental validation by fu turistic \\nresearchers leading to effective new \\ncandidate drugs against AD.  \\n \\nDeclaration by Authors \\nEthical Approval: Not Applicable. \\nAcknowledgement: We would be thankful \\nto Head, Digianalix, INDIA for providing us \\nresearch facilities for conducting research. \\nSource of Funding: None \\nConflict of Interest: The authors declare no \\nconflict of interest. \\n \\nREFERENCES  \\n1. O'brien RJ, Wong PC. Amyloid precursor \\nprotein processing and Alzheimer's disease. \\nAnnu. Rev. Neurosci. 2011 Jul 21;34:185 -\\n204. Doi: 10.1146/annurev-neuro-061010-\\n113613. \\n2. Brouwers N, Sleegers K, Van Broeckhoven \\nC. Molecular genetics of Alzheimer's \\ndisease: an update. Ann . Med. 2008 Jan \\n1;40(8):562-83. Doi:  \\n10.1080/07853890802186905. \\n3. Dominguez D, Tournoy J, Hartmann D, et \\nal. Phenotypic and biochemical analyses of \\nBACE1-and BACE2-deficient mice. J . Bio. \\nChem. 2005 Sep 2;280(35):30797-806. Doi: \\nhttps://doi.org/10.1074/jbc.M505249200. \\n4. Sankaranarayanan S, Price EA, Wu G, et al. \\nIn vivo β -secretase 1 inhibition leads to \\nbrain Aβ lowering and increased α-secretase \\nprocessing of amyloid precursor protein \\nwithout effect on neuregulin -1. J . \\nPharmacol. Exp. Ther. 2008 Mar \\n1;324(3):957-69.  Doi: \\n10.1124/jpet.107.130039. \\n5. McConlogue L, Buttini M, Anderson JP, et \\nal. Partial reduction of BACE1 has dramatic \\neffects on Alzheimer plaque and synaptic \\npathology in APP transgenic mice. J . Biol. \\nChem. 2007 Sep 7;282(36):26326 -34. Doi: \\n10.1074/jbc.M611687200. \\n6. Luo Y, Bolon B, Kahn S, Bennett BD, et al . \\nMice deficient in BACE1, the Alzheimer's \\nβ-secretase, have normal phenotype and \\nabolished β -amyloid generation. Nat . \\nNeurosci. 2001 Mar;4(3):231 -2. Doi: \\n10.1038/85059. \\n7. Sinha S, Anderson JP, Barbour R, et al. \\nPurification and cloning of amyloid \\nprecursor protein β -secretase from human \\nbrain. Nature. 1999 Dec 2;402(6761):537 -\\n40. Doi: 10.1038/990114. \\n8. Vassar R, Bennett BD, Babu -Khan S, et al. \\nβ-Secretase cleavage of Alzheimer's \\namyloid precursor protein by the \\ntransmembrane aspartic protease BACE. \\nScience. 19 99 Oct 22;286(5440):735 -41. \\nDoi: 10.1126/science.286.5440.735. \\n9. Yan R, Bienkowski MJ, Shuck ME, et al. \\nMembrane-anchored aspartyl protease with \\nAlzheimer's disease β -secretase activity. \\nNature. 1999 Dec 2;402(6761):533 -7. Doi: \\nhttps://doi.org/10.1038/990107.  \\n10. Vassar R, Cole SL. The basic biology of \\nBACE1: A key therapeutic target for \\nAlzheimer's disease. Curr . G enomics. 2007 \\nDec 1;8(8):509 -30. Doi: \\n10.2174/138920207783769512. \\n11. Schwede T, Kopp J, Guex N, et al. SWISS -\\nMODEL: an automated protein homology -\\nmodeling server. Nucleic acids Res. 2003 \\nJul 1;31(13):3381 -5. Doi: \\n10.1093/nar/gkg520. \\n12. Suhaibun SR, Elengoe A, Poddar R. \\nTechnology Advance in Drug Design Using \\nComputational Biology Tool. Malaysian J . \\nMed. Health Sci. 2020 Nov 3;16.   \\n13. Geourjon C, Deleage G. SOP MA: \\nsignificant improvements in protein \\nsecondary structure prediction by consensus \\nprediction from multiple alignments. \\nBioinformatics. 1995 Dec 1;11(6):681 -4. \\nDoi: 10.1093/bioinformatics/11.6.681. \\n14. Hirokawa T, Boon -Chieng S, Mitaku S. \\nSOSUI: classification and secondary \\nstructure prediction system for membrane \\nproteins. Bioinformatics (Oxford, England). \\n1998;14(4):378-9. Doi: \\n10.1093/bioinformatics/14.4.378. \\n15. Laskowski RA, MacArthur MW, Moss DS, \\nThornton JM. PROCHECK: a program to \\ncheck the stereochemical q uality of protein \\nstructures. J . Appl. C ryst. 1993 Apr \\n1;26(2):283-91. Doi:  Anupriya et.al. Genomics and drug research approach in identifying potential drug target highlighting \\nalzheimer disease \\n \\n                       Galore International Journal of Health Sciences and Research (www.gijhsr.com)  147 \\nVolume 9; Issue: 1; January-March 2024 \\nhttps://doi.org/10.1107/S002188989200994\\n4. \\n16. Pettersen EF, Goddard TD, Huang CC,. \\nUCSF Chimera - a visualization system for \\nexploratory research and analysis. J . \\nComput. Chem. 2004 Oct;25(13):1605 -12. \\nDoi: 10.1002/jcc.20084. \\n17. Wang Y, Xiao J, Suzek TO, et al. PubChem: \\na public information system for analyzing \\nbioactivities of small molecules. Nucleic \\nAcids Res. 2 009 Jul 1;37(suppl_2):W623 -\\n33. Doi: 10.1093/nar/gkp456. \\n18. Othman N, Dorizzi B, Garcia -Salicetti S. \\nOSIRIS: An open source iris recognition \\nsoftware. Pattern Recognit . Lett . 2016 Oct \\n15;82:124-31. Doi:  \\nhttps://doi.org/10.1016/j.patrec.2015.09.002 \\n19. Morris GM, Lim -Wilby M. Molecular \\ndocking. Molecular modeling of proteins. \\n2008:365-82. Doi: 10.1007/978-1-59745-\\n177-2_19. \\n20. Kar S, Leszczynski  J. Open access in silico \\ntools to predict the ADMET profiling of \\ndrug candidates. Expert Opinion Drug \\nDiscov. 2020 Dec 1;15(12):1473 -87. Doi: \\n10.1080/17460441.2020.1798926. \\n21. Ligier Y, Funk M, Ratib O, et al. The \\nOSIRIS user interface for manipula ting \\nmedical images. InPicture Archiving and \\nCommunication Systems (PACS) in \\nMedicine 1991 (pp. 395 -398). Springer \\nBerlin Heidelberg.  Doi: \\nhttps://doi.org/10.1007/978-3-642-76566-\\n7_60. \\n22. Lopéz-Blanco JR, Garzón JI, Chacón P. \\niMod: multipurpose normal mode analysis \\nin internal coordinates. Bioinformatics. \\n2011 Oct 15;27(20):2843 -50. Doi: \\nhttps://doi.org/10.1093/bioinformatics/btr49\\n7. \\n23. Das B, Singh N, Yao AY, et al. BACE1 \\ncontrols synaptic function th rough \\nmodulating release of synaptic vesicles. \\nMol. Psychiatry. 2021 Nov;26(11):6394 -\\n410. Doi: https://doi.org/10.1038/s41380-\\n021-01166-2. \\n24. Hong L, Koelsch G, Lin X, et al. Structure \\nof the protease domain of memapsin 2 (β -\\nsecretase) complexed with inhibitor. \\nScience. 2000 Oct 6;290(5489):150 -3. Doi: \\n10.1126/science.290.5489.150. \\n25. Mishra S, Aziz T, Toppo JA, et al. \\nGenomics and Drug Discovery S trategies: \\nThe Role of Natural Compounds and Its \\nReceptor in Alzheimer’s Disease. Cureus. \\n2024 Jan 17;16(1).  Doi: \\n10.7759/cureus.52423. \\n26. Naushad M, Durairajan SS, Bera AK, et al. \\nNatural compounds with anti -BACE1 \\nactivity as promising therapeutic drugs for \\ntreating Alzheimerʼs disease. Planta M ed. \\n2019 Nov;85(17):1316 -25. Doi: 10.1055/a-\\n1019-9819. \\n \\n \\nHow to cite this article: Anupriya, Ayushi \\nPoddar, Sneha Priya , Priyangulta Beck , \\nHarsimran Kaur, Seema Kumari et.al. Genomics \\nand drug research approach in identifyin g \\npotential drug target highlighting Alzheimer \\ndisease. Gal Int J Health Sci Res. 202 4; 9(1): \\n138-147. DOI: 10.52403/gijhsr.20240115 \\n \\n \\n******  \""
            ]
          },
          "execution_count": 26,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_df['text'][29]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "b81d204e",
      "metadata": {
        "id": "b81d204e"
      },
      "outputs": [],
      "source": [
        "prompt = ChatPromptTemplate.from_template(\"\"\"\n",
        "You are an AI assistant.\n",
        "You receive a scientific article: {text}\n",
        "\n",
        "Read the article and return the summary.\n",
        "\n",
        "Output rules:\n",
        "- Output MUST be relevant clean text only without any option words.\n",
        "- Do NOT invent content that is not present in the provided text.\n",
        "\"\"\")\n",
        "\n",
        "article_analysing = prompt | llm_articles_analyzer | StrOutputParser()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "b2a66691",
      "metadata": {
        "id": "b2a66691",
        "outputId": "d45458c5-bba4-4372-d0f3-8fec48443a5d"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "\"Salidroside, a natural compound derived from Rhodiola plants, has been shown to exert neuroprotective effects against cognitive decline associated with Alzheimer's disease (AD). Studies indicate its potential through multiple mechanisms including inhibition of pyroptosis, reduction of oxidative stress and inflammation, as well as modulation of tau protein phosphorylation. The review highlights the recent advances in synthetic pathways and pharmacological properties of salidroside, emphasizing its therapeutic value for AD management. Additionally, it discusses the underlying molecular mechanisms involved such as activation of Nrf2 signaling pathway and targeting of AMPK/NLRP3 inflammasome pathway. Overall, these findings suggest that salidroside could serve as a promising candidate for treating cognitive impairment in AD patients.\""
            ]
          },
          "execution_count": 28,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "article_analysing.invoke({\"text\": articles_df['text'][0]})"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "887d77b3",
      "metadata": {
        "id": "887d77b3"
      },
      "outputs": [],
      "source": [
        "import tqdm"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "a285f85f",
      "metadata": {
        "id": "a285f85f",
        "outputId": "36be88f9-e9a3-47d6-9bcd-0457b61e0458"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "100%|██████████| 29/29 [02:22<00:00,  4.92s/it]\n"
          ]
        }
      ],
      "source": [
        "summary = []\n",
        "for text in tqdm.tqdm(articles_df['text'], total=len(articles_df['text'])):\n",
        "    summary.append(article_analysing.invoke({\"text\": text}))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "b451960f",
      "metadata": {
        "id": "b451960f",
        "outputId": "daa67018-886d-4942-b149-2dbd31c7868e"
      },
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>url</th>\n",
              "      <th>year</th>\n",
              "      <th>filename</th>\n",
              "      <th>text</th>\n",
              "      <th>summary</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\0.pdf</td>\n",
              "      <td>ORIGINAL RESEARCH\\npublished: 21 January 2022\\...</td>\n",
              "      <td>Salidroside a natural compound has been shown ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\1.pdf</td>\n",
              "      <td>Redox Biology 66 (2023) 102846\\nAvailable onli...</td>\n",
              "      <td>This article discusses the role of metabolic r...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Natural acetylcholinesterase inhibitors: A mul...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmcr.2024.100154</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\2.pdf</td>\n",
              "      <td>European Journal of Medicinal Chemistry Report...</td>\n",
              "      <td>The review discusses the role of cholinesteras...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>GSK3: A potential target and pending issues fo...</td>\n",
              "      <td>https://doi.org/10.1111/cns.14818</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\3.pdf</td>\n",
              "      <td>CNS Neurosci Ther. 2024;30:e14818.\\t \\t\\t \\t |...</td>\n",
              "      <td>GSK3 (glycogen synthase kinase 3) serves as a ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Targeting dysregulated lipid metabolism for th...</td>\n",
              "      <td>https://doi.org/10.1016/j.nbd.2024.106505</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\4.pdf</td>\n",
              "      <td>Neurobiology of Disease 196 (2024) 106505\\nAva...</td>\n",
              "      <td>Sphingomyelin levels amyloid-β deposition P-gl...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Targeting tau in Alzheimer's disease: from mec...</td>\n",
              "      <td>https://doi.org/10.4103/1673-5374.385847</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\5.pdf</td>\n",
              "      <td>NEURAL REGENERATION RESEARCH｜Vol 19｜No. 7｜July...</td>\n",
              "      <td>The articles discuss various aspects of tau pr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Intelligent lesion blood–brain barrier targeti...</td>\n",
              "      <td>https://doi.org/10.1016/j.apsb.2022.02.001</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\6.pdf</td>\n",
              "      <td>ORIGINAL ARTICLE\\nIntelligent lesion blood ebr...</td>\n",
              "      <td>The article discusses targeted nano-missiles f...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Multi-target neuroprotective effects of herbal...</td>\n",
              "      <td>https://doi.org/10.1016/j.jep.2022.115107</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\7.pdf</td>\n",
              "      <td>Journal of Ethnopharmacology 290 (2022) 115107...</td>\n",
              "      <td>The review discusses various studies on the po...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Associations of semaglutide with first‐time di...</td>\n",
              "      <td>https://doi.org/10.1002/alz.14313</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\8.pdf</td>\n",
              "      <td>Received:29July2024 Revised:10September2024 Ac...</td>\n",
              "      <td>The article investigates the association betwe...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>The VTA dopaminergic system as diagnostic and ...</td>\n",
              "      <td>https://doi.org/10.3389/fpsyt.2022.1039725</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\9.pdf</td>\n",
              "      <td>TYPE Perspective\\nPUBLISHED /one.tnum/seven.tn...</td>\n",
              "      <td>Genetic and neurobiological factors influence ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>Intranasal administration of dauricine loaded ...</td>\n",
              "      <td>https://doi.org/10.1080/10717544.2021.1895909</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\11.pdf</td>\n",
              "      <td>Drug Delivery\\nISSN: 1071-7544 (Print) 1521-04...</td>\n",
              "      <td>The study describes a novel approach using dau...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2021.113847</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\12.pdf</td>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "      <td>The study focuses on transthyretin (TTR) as a ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>Hybrid Membrane‐Coated Nanoparticles for Preci...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202306675</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\13.pdf</td>\n",
              "      <td>RESEARCH ARTICLE\\nwww.advancedscience.com\\nHyb...</td>\n",
              "      <td>The study describes a novel approach to treati...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>C-glycosides analogues of the okadaic acid cen...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2023.115245</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\14.pdf</td>\n",
              "      <td>European Journal of Medicinal Chemistry 251 (2...</td>\n",
              "      <td>The article discusses research on protein phos...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>Death-associated protein kinase 1 as a therape...</td>\n",
              "      <td>https://doi.org/10.1186/s40035-023-00395-5</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\15.pdf</td>\n",
              "      <td>Zhang et al. Translational Neurodegeneration  ...</td>\n",
              "      <td>This article reviews research on death-associa...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>Sex‐specific declines in cholinergic‐targeting...</td>\n",
              "      <td>https://doi.org/10.1002/alz.13095</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\16.pdf</td>\n",
              "      <td>Received: 23 February 2023 Accepted: 21 March ...</td>\n",
              "      <td>The study investigates sex-specific declines i...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>Study on the Role of an Erythrocyte Membrane‐C...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202301361</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\17.pdf</td>\n",
              "      <td>RESEARCH ARTICLE\\nwww.advancedscience.com\\nStu...</td>\n",
              "      <td>Titled \"A Novel Liposomal Nanocarrier for Targ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "      <td>https://doi.org/10.1016/j.xinn.2021.100160</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\18.pdf</td>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "      <td>PTFE-based Prussian blue nanoparticles (PBNPs)...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Diagnosis and Treatment of Alzheimer's Disease...</td>\n",
              "      <td>https://doi.org/10.36838/v7i2.3</td>\n",
              "      <td>2025</td>\n",
              "      <td>db\\19.pdf</td>\n",
              "      <td>© 2025 Terra Science and Education 15  \\nDiagn...</td>\n",
              "      <td>The article discusses advancements in diagnosi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>Mechanism of quercetin therapeutic targets for...</td>\n",
              "      <td>https://doi.org/10.1038/s41598-021-02248-5</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\20.pdf</td>\n",
              "      <td>1\\nVol.:(0123456789)Scientific Reports |      ...</td>\n",
              "      <td>The study investigates potential mechanisms of...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>Multiomics Identification of Potential Targets...</td>\n",
              "      <td>https://doi.org/10.3390/pharmaceutics13101555</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\21.pdf</td>\n",
              "      <td>pharmaceutics\\nArticle\\nMultiomics Identiﬁcati...</td>\n",
              "      <td>The article discusses computational approaches...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>Targeting the post-synaptic proteome has thera...</td>\n",
              "      <td>https://doi.org/10.1038/s42003-023-04961-5</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\22.pdf</td>\n",
              "      <td>ARTICLE\\nTargeting the post-synaptic proteome ...</td>\n",
              "      <td>The study identified differential protein expr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>Metabolic resistance of Aβ3pE-42, a target epi...</td>\n",
              "      <td>https://doi.org/10.26508/lsa.202402650</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\23.pdf</td>\n",
              "      <td>Research Article\\nMetabolic resistance of Aβ3p...</td>\n",
              "      <td>The article discusses metabolic resistance of ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>Genetic Variation in Targets of Antidiabetic D...</td>\n",
              "      <td>https://doi.org/10.1212/wnl.0000000000200771</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\25.pdf</td>\n",
              "      <td>RESEARCH ARTICLE OPEN ACCESS\\nGenetic Variatio...</td>\n",
              "      <td>The article discusses the relationship between...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>A hybrid approach unveils drug repurposing can...</td>\n",
              "      <td>https://doi.org/10.1016/j.patter.2021.100433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\26.pdf</td>\n",
              "      <td>Article\\nA hybrid approach unveils drug repurp...</td>\n",
              "      <td>The article discusses various databases and to...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>Green Synthesis of Barbituric Acid Derivative ...</td>\n",
              "      <td>https://doi.org/10.14233/ajomc.2021.ajomc-p332</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\28.pdf</td>\n",
              "      <td>Asian Pub. Corp.\\nwww.asianpubs.org\\nAsian Jou...</td>\n",
              "      <td>Gold nanoparticles (AuNPs) were used as cataly...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>Genomics and Drug Research Approach in Identif...</td>\n",
              "      <td>https://doi.org/10.52403/gijhsr.20240115</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\29.pdf</td>\n",
              "      <td>...</td>\n",
              "      <td>The article discusses a genomics-based approac...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>Identification of Sirtuin 1-Targeted Anti-Alzh...</td>\n",
              "      <td>https://doi.org/10.56042/ijc.v63i12.13637</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\31.pdf</td>\n",
              "      <td>Indian Journal o\\nf Chemistry \\nVol. 63, Decem...</td>\n",
              "      <td>The study targeted Sirtuin 1 (Sirt1), which el...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\32.pdf</td>\n",
              "      <td>DOI: 10.1002/alz.088509\\nDRUG DEVELOPMENT\\nPOS...</td>\n",
              "      <td>Background: TREM2 signaling is involved in Alz...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                                title  \\\n",
              "0   Salidroside Ameliorates Alzheimer's Disease by...   \n",
              "1   Metabolic reprogramming in inflammatory microg...   \n",
              "2   Natural acetylcholinesterase inhibitors: A mul...   \n",
              "3   GSK3: A potential target and pending issues fo...   \n",
              "4   Targeting dysregulated lipid metabolism for th...   \n",
              "5   Targeting tau in Alzheimer's disease: from mec...   \n",
              "6   Intelligent lesion blood–brain barrier targeti...   \n",
              "7   Multi-target neuroprotective effects of herbal...   \n",
              "8   Associations of semaglutide with first‐time di...   \n",
              "9   The VTA dopaminergic system as diagnostic and ...   \n",
              "11  Intranasal administration of dauricine loaded ...   \n",
              "12  Targeting transthyretin in Alzheimer's disease...   \n",
              "13  Hybrid Membrane‐Coated Nanoparticles for Preci...   \n",
              "14  C-glycosides analogues of the okadaic acid cen...   \n",
              "15  Death-associated protein kinase 1 as a therape...   \n",
              "16  Sex‐specific declines in cholinergic‐targeting...   \n",
              "17  Study on the Role of an Erythrocyte Membrane‐C...   \n",
              "18  A dual-targeted multifunctional nanoformulatio...   \n",
              "19  Diagnosis and Treatment of Alzheimer's Disease...   \n",
              "20  Mechanism of quercetin therapeutic targets for...   \n",
              "21  Multiomics Identification of Potential Targets...   \n",
              "22  Targeting the post-synaptic proteome has thera...   \n",
              "23  Metabolic resistance of Aβ3pE-42, a target epi...   \n",
              "25  Genetic Variation in Targets of Antidiabetic D...   \n",
              "26  A hybrid approach unveils drug repurposing can...   \n",
              "28  Green Synthesis of Barbituric Acid Derivative ...   \n",
              "29  Genomics and Drug Research Approach in Identif...   \n",
              "31  Identification of Sirtuin 1-Targeted Anti-Alzh...   \n",
              "32  Generation and validation of anti‐TREM2 agonis...   \n",
              "\n",
              "                                               url  year   filename  \\\n",
              "0        https://doi.org/10.3389/fnagi.2021.809433  2022   db\\0.pdf   \n",
              "1      https://doi.org/10.1016/j.redox.2023.102846  2023   db\\1.pdf   \n",
              "2      https://doi.org/10.1016/j.ejmcr.2024.100154  2024   db\\2.pdf   \n",
              "3                https://doi.org/10.1111/cns.14818  2024   db\\3.pdf   \n",
              "4        https://doi.org/10.1016/j.nbd.2024.106505  2024   db\\4.pdf   \n",
              "5         https://doi.org/10.4103/1673-5374.385847  2023   db\\5.pdf   \n",
              "6       https://doi.org/10.1016/j.apsb.2022.02.001  2022   db\\6.pdf   \n",
              "7        https://doi.org/10.1016/j.jep.2022.115107  2022   db\\7.pdf   \n",
              "8                https://doi.org/10.1002/alz.14313  2024   db\\8.pdf   \n",
              "9       https://doi.org/10.3389/fpsyt.2022.1039725  2022   db\\9.pdf   \n",
              "11   https://doi.org/10.1080/10717544.2021.1895909  2021  db\\11.pdf   \n",
              "12    https://doi.org/10.1016/j.ejmech.2021.113847  2021  db\\12.pdf   \n",
              "13          https://doi.org/10.1002/advs.202306675  2024  db\\13.pdf   \n",
              "14    https://doi.org/10.1016/j.ejmech.2023.115245  2023  db\\14.pdf   \n",
              "15      https://doi.org/10.1186/s40035-023-00395-5  2024  db\\15.pdf   \n",
              "16               https://doi.org/10.1002/alz.13095  2023  db\\16.pdf   \n",
              "17          https://doi.org/10.1002/advs.202301361  2023  db\\17.pdf   \n",
              "18      https://doi.org/10.1016/j.xinn.2021.100160  2021  db\\18.pdf   \n",
              "19                 https://doi.org/10.36838/v7i2.3  2025  db\\19.pdf   \n",
              "20      https://doi.org/10.1038/s41598-021-02248-5  2021  db\\20.pdf   \n",
              "21   https://doi.org/10.3390/pharmaceutics13101555  2021  db\\21.pdf   \n",
              "22      https://doi.org/10.1038/s42003-023-04961-5  2023  db\\22.pdf   \n",
              "23          https://doi.org/10.26508/lsa.202402650  2024  db\\23.pdf   \n",
              "25    https://doi.org/10.1212/wnl.0000000000200771  2022  db\\25.pdf   \n",
              "26    https://doi.org/10.1016/j.patter.2021.100433  2022  db\\26.pdf   \n",
              "28  https://doi.org/10.14233/ajomc.2021.ajomc-p332  2021  db\\28.pdf   \n",
              "29        https://doi.org/10.52403/gijhsr.20240115  2024  db\\29.pdf   \n",
              "31       https://doi.org/10.56042/ijc.v63i12.13637  2024  db\\31.pdf   \n",
              "32              https://doi.org/10.1002/alz.088509  2024  db\\32.pdf   \n",
              "\n",
              "                                                 text  \\\n",
              "0   ORIGINAL RESEARCH\\npublished: 21 January 2022\\...   \n",
              "1   Redox Biology 66 (2023) 102846\\nAvailable onli...   \n",
              "2   European Journal of Medicinal Chemistry Report...   \n",
              "3   CNS Neurosci Ther. 2024;30:e14818.\\t \\t\\t \\t |...   \n",
              "4   Neurobiology of Disease 196 (2024) 106505\\nAva...   \n",
              "5   NEURAL REGENERATION RESEARCH｜Vol 19｜No. 7｜July...   \n",
              "6   ORIGINAL ARTICLE\\nIntelligent lesion blood ebr...   \n",
              "7   Journal of Ethnopharmacology 290 (2022) 115107...   \n",
              "8   Received:29July2024 Revised:10September2024 Ac...   \n",
              "9   TYPE Perspective\\nPUBLISHED /one.tnum/seven.tn...   \n",
              "11  Drug Delivery\\nISSN: 1071-7544 (Print) 1521-04...   \n",
              "12  Targeting transthyretin in Alzheimer's disease...   \n",
              "13  RESEARCH ARTICLE\\nwww.advancedscience.com\\nHyb...   \n",
              "14  European Journal of Medicinal Chemistry 251 (2...   \n",
              "15  Zhang et al. Translational Neurodegeneration  ...   \n",
              "16  Received: 23 February 2023 Accepted: 21 March ...   \n",
              "17  RESEARCH ARTICLE\\nwww.advancedscience.com\\nStu...   \n",
              "18  A dual-targeted multifunctional nanoformulatio...   \n",
              "19  © 2025 Terra Science and Education 15  \\nDiagn...   \n",
              "20  1\\nVol.:(0123456789)Scientific Reports |      ...   \n",
              "21  pharmaceutics\\nArticle\\nMultiomics Identiﬁcati...   \n",
              "22  ARTICLE\\nTargeting the post-synaptic proteome ...   \n",
              "23  Research Article\\nMetabolic resistance of Aβ3p...   \n",
              "25  RESEARCH ARTICLE OPEN ACCESS\\nGenetic Variatio...   \n",
              "26  Article\\nA hybrid approach unveils drug repurp...   \n",
              "28  Asian Pub. Corp.\\nwww.asianpubs.org\\nAsian Jou...   \n",
              "29                                                ...   \n",
              "31  Indian Journal o\\nf Chemistry \\nVol. 63, Decem...   \n",
              "32  DOI: 10.1002/alz.088509\\nDRUG DEVELOPMENT\\nPOS...   \n",
              "\n",
              "                                              summary  \n",
              "0   Salidroside a natural compound has been shown ...  \n",
              "1   This article discusses the role of metabolic r...  \n",
              "2   The review discusses the role of cholinesteras...  \n",
              "3   GSK3 (glycogen synthase kinase 3) serves as a ...  \n",
              "4   Sphingomyelin levels amyloid-β deposition P-gl...  \n",
              "5   The articles discuss various aspects of tau pr...  \n",
              "6   The article discusses targeted nano-missiles f...  \n",
              "7   The review discusses various studies on the po...  \n",
              "8   The article investigates the association betwe...  \n",
              "9   Genetic and neurobiological factors influence ...  \n",
              "11  The study describes a novel approach using dau...  \n",
              "12  The study focuses on transthyretin (TTR) as a ...  \n",
              "13  The study describes a novel approach to treati...  \n",
              "14  The article discusses research on protein phos...  \n",
              "15  This article reviews research on death-associa...  \n",
              "16  The study investigates sex-specific declines i...  \n",
              "17  Titled \"A Novel Liposomal Nanocarrier for Targ...  \n",
              "18  PTFE-based Prussian blue nanoparticles (PBNPs)...  \n",
              "19  The article discusses advancements in diagnosi...  \n",
              "20  The study investigates potential mechanisms of...  \n",
              "21  The article discusses computational approaches...  \n",
              "22  The study identified differential protein expr...  \n",
              "23  The article discusses metabolic resistance of ...  \n",
              "25  The article discusses the relationship between...  \n",
              "26  The article discusses various databases and to...  \n",
              "28  Gold nanoparticles (AuNPs) were used as cataly...  \n",
              "29  The article discusses a genomics-based approac...  \n",
              "31  The study targeted Sirtuin 1 (Sirt1), which el...  \n",
              "32  Background: TREM2 signaling is involved in Alz...  "
            ]
          },
          "execution_count": 31,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_df['summary'] = summary\n",
        "articles_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "30d01d08",
      "metadata": {
        "id": "30d01d08"
      },
      "outputs": [],
      "source": [
        "articles_df.to_csv(\"articles_df.csv\")"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "41c8d1b1",
      "metadata": {
        "id": "41c8d1b1"
      },
      "source": [
        "Для извлечения разделов статей будет использоваться gemini 2 flash, к которой можно получить доступ через API. Маленькие локальные модели интеллектуально слабы и недостаточно хорошо следуют указаниям для данной задачи."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "id": "jhCoU8lQMmNq",
      "metadata": {
        "id": "jhCoU8lQMmNq"
      },
      "outputs": [],
      "source": [
        "import pandas as pd"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 9,
      "id": "khjAG6VSMilK",
      "metadata": {
        "id": "khjAG6VSMilK"
      },
      "outputs": [],
      "source": [
        "articles_df = pd.read_csv(\"articles_df.csv\", index_col=0)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "id": "0a9c511a",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0a9c511a",
        "outputId": "24de2e4a-c514-4693-f294-392aa5e1a5f2"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "execution_count": 2,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "from dotenv import load_dotenv\n",
        "\n",
        "load_dotenv()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "ec0ae301",
      "metadata": {
        "id": "ec0ae301"
      },
      "outputs": [],
      "source": [
        "import time\n",
        "import tqdm\n",
        "from langchain_google_genai import ChatGoogleGenerativeAI\n",
        "from langchain_core.prompts import ChatPromptTemplate\n",
        "from langchain_core.output_parsers import JsonOutputParser"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "NI9NH1PYKPh8",
      "metadata": {
        "id": "NI9NH1PYKPh8"
      },
      "outputs": [],
      "source": [
        "llm_articles_extraction = ChatGoogleGenerativeAI(\n",
        "    model=\"gemini-2.5-flash\",\n",
        "    temperature=0,\n",
        "    google_api_key=os.environ.get(\"GEMINI_API_KEY\")\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 38,
      "id": "f6c4a43c",
      "metadata": {
        "id": "f6c4a43c"
      },
      "outputs": [],
      "source": [
        "prompt = ChatPromptTemplate.from_template(\"\"\"\n",
        "You are an AI assistant.\n",
        "\n",
        "Each acrticle includes different sections.\n",
        "Read the article and return clean readable text of the abstract, introduction and results without \"/n\", \"/t\" and similiar symbols.\n",
        "Extract full of the Abstract, Introduction, and Results from the article: {text}\n",
        "\n",
        "Return ONLY a valid raw JSON object with no markdown formatting or extra text.\n",
        "Required JSON structure:\n",
        "  \"abstract\": full abstract here,\n",
        "  \"introduction\": full introduction here,\n",
        "  \"results\": full results here\n",
        "\n",
        "\"\"\")\n",
        "\n",
        "article_extracting = prompt | llm_articles_extraction | JsonOutputParser()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 34,
      "id": "eqEuTOWCNMTY",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "eqEuTOWCNMTY",
        "outputId": "9811267e-aea9-40ee-ae00-0af594252f54"
      },
      "outputs": [
        {
          "data": {
            "text/plain": [
              "{'abstract': 'Amyloid β -protein (A β ) is reported to activate NLRP3 inﬂammasomes and drive pyroptosis, which is subsequently involved in the pathogenesis of neurodegenerative diseases, such as Alzheimer’s disease (AD). To date, the pathogenesis of AD is unfortunately insufﬁciently elucidated. Therefore, this study was conducted to explore whether Salidroside (Sal) treatment could beneﬁt AD by improving pyroptosis. Firstly, two animal models of AD, induced, respectively, by A β 1-42 and D-galactose (D-gal)/AlCl 3, have been created to assist our appreciation of AD pathophysiology. We then conﬁrmed that pyroptosis is related to the pathogenesis of AD, and Sal can slow the progression of AD by inhibiting pyroptosis. Subsequently, we established the D-gal and Nigericin-induced PC12 cells injury model in vitro to verify Sal blocks pyroptosis mainly by targeting the NLRP3 inﬂammasome. For in vivo studies, we observed that A β accumulation, Tau hyperphosphorylation, neurons of hippocampal damage, and cognitive dysfunction in AD mice, caused by bilateral injection of A β 1-42 into the hippocampus and treatments with D-gal combine AlCl 3. Besides, accumulated Aβ promotes NLRP3 inﬂammasome activation, which leads to the activation and release of a pro-inﬂammatory cytokine, interleukin-1 beta (IL-1β ). Notably, both A β accumulation and hyperphosphorylation of Tau decreased and inhibited pyroptosis by downregulating the expression of IL-1 β and IL-18, which can be attributed to the treatment of Sal. We further found that Sal can reverse the increased protein expression of TLR4, MyD88, NF- κ B, P-NF-κ B, NLRP3, ASC, cleaved Caspase-1, cleaved GSDMD, IL-1β , and IL-18 in vitro . The underlying mechanism may be through inhibiting TLR4/NF-κ B/NLRP3/Caspase-1 signaling pathway. Our study highlights the importance of NLRP3 inﬂammasome-mediated pyroptosis in AD, and how the administration of pharmacological doses of Sal can inhibit NLRP3 inﬂammasome-mediated pyroptosis and ameliorate AD. Thus, we conclude that NLRP3 inﬂammasome-mediated pyroptosis plays a signiﬁcant role in AD and Sal could be a therapeutic drug for AD.',\n",
              " 'introduction': 'Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder characterized by memory loss and language deterioration, and its incidence rate ranks ﬁrst globally (Alzheimer’s Association, 2021). The World Alzheimer Report 2021 reported that 50 million people worldwide have dementia. Every 3 s, someone in the world develops dementia. It is estimated that those suﬀering from dementia will grow from 55 to 139 million people during the period 2019–2050 (World Alzheimer Report 2021, 2021). β -Amyloid (A β ) deposits, Tau proteins hyperphosphorylated, and neuroinﬂammation are neuropathological hallmarks in AD (Emre et al., 2021). According to the hypothesis of A β , on the one hand, the aggregation of A β can initiate a cascade of reactions, including triggering hyperphosphorylation of Tau to form neuroﬁbrillary tangles (NFTs), neuroinﬂammation, and neuronal degeneration, contributing to the onset of AD (Zhou and Fukushima, 2020). On the other hand, the activation and proliferation of astrocytes and microglia caused by A β accumulation (Terrill-Usery et al., 2014) leads to the continuous exposure of neurons to pro-inﬂammatory mediators and results in neuronal dysfunction or death (Heneka et al., 2014). Thus, the vital pathological features of AD outlined above can cause diﬀerent degrees of neuronal loss and brain atrophy (Zhuang et al., 2019). Therefore, death neuronal is a root reason for AD and other neurodegenerative diseases (Hambright et al., 2017). Furthermore, emerging evidence indicates pyroptosis may serve as the predominant form of neuronal death in AD following apoptosis, autophagy, and necrosis (Fricker et al., 2018; Shen et al., 2021). Pyroptosis is a programmed cell death mediated by Gasdermin D (GSDMD) (Shi et al., 2017), characterized by swelling, rupture of the cell membrane, drive to release pro-inﬂammatory cytokines, and intracellular contents, and then triggering the inﬂammatory response (Yu et al., 2021). Pyroptosis occurs when activated caspase-1 or caspase-4/5/11 cleaves the protein GSDMD, releasing the GSDMD-N subunit to form cell membrane pores (Kovacs and Miao, 2017), which has been tightly linked to AD pathogenesis. Suppressed pyroptosis may be a protective measure for neurons (Zhao et al., 2019). Studies have suggested that the inﬂammasome was involved in the onset of AD through triggering pyroptosis (Dempsey et al., 2017). Among all inﬂammasomes, including nod-like receptor protein 1 (NLRP1), nod-like receptor protein 3 (NLRP3), the nuclear eﬀector protein 4 (NLRC4), and absent in melanoma 2 (AIM2), extensive studies have focused on the NLRP3 inﬂammasome. NLRP3 inﬂammasome comprises three main components: receptor protein NLRP3, the adaptor protein apoptosis-associated speck-like protein (ASC), and the eﬀector protein caspase-1 (Rathinam and Fitzgerald, 2016). It is initiated by a variety of stimuli, namely, microbial infection PAMPs (such as viral DNA, microbes, and the components of the bacterial cell wall) and DAMPs (such as adenosine triphosphate (ATP), uric acid (UA) crystals, Aluminum adjuvant, and A β peptide) (Huang et al., 2021). Numerous research studies have examined how NLRP3 inﬂammasome is involved in AD pathogenesis through mediating pyroptosis. A study by Daniels et al. (2016) demonstrated that Fenamate NSAIDs improved the microglia-mediated neuroinﬂammation and memory loss in 3×TgAD mice by indirectly inhibiting the activation of NLRP3 inﬂammasome. Then, Chiu et al. (2021) found that SG-Tang could act as a neuroprotective agent against A β aggregation and neuroinﬂammation by regulating the NLRP1/NLRP3 pathway. Subsequently, Kuwar et al. (2021) suggested that loaded A β can be reduced signiﬁcantly, alleviate neuroinﬂammation, improve hippocampal neuronal activity, and relieve cognitive function in APP/PS1 mice via inhibiting NLRP3 inﬂammasome with JC124. Even though limited studies have probed the role and underlying mechanism of NLRP3 inﬂammasome-mediated pyroptosis in AD, the mechanisms of how NLRP3 inﬂammasome drive pyroptosis need further study. So far, clinical treatment of AD therapeutics has been dominated by the use of western medicine, that is to say, acetylcholinesterase (AChE) inhibitors, NMDA receptor (NMDAR) antagonists, amyloid production or secretion inhibitors, and inﬂammation inhibitors (Orlov, 2019). Nevertheless, these drugs only partially relieve symptoms for a short time but cannot delay the progression of AD. To our relief, recent studies have reported that phytopharmaceutica ls, Salidroside can improve neuron impairments and cognitive deﬁcits in AD (Xie et al., 2020). Rhodiola rosea L., a small genus of the Crassulaceae family, has a long history of wide use as a botanical medicine in Europe, Asia, and the US (Zhong et al., 2018). With the continuous development and improvement of scientiﬁc research technology, many studies have examined the chemical constituents of Rhodiola plants at home and abroad. The main pharmacological active ingredients isolated from various Rhodiola are salidroside and its aglycone (tyrosol), rosavin or rosavidine, pyridine, and rhodiosin and rhodionin, etc (Zhang et al., 2021). Among them, Salidroside is widely studied. Sal (2-(4-hydroxyphenyl)ethyl-β -D-glucopyranoside) (Figure 2A) is a phenolic glycoside compound that is the main active ingredient extracted from Rhodiola Rose (Fan et al., 2021). It has potent pharmacological activities, mainly for preventing or treating disorders like neurodegenerative diseases, cerebral ischemia, fatigue, hypoxia, diabetes, and cancer (Grech-Baran et al., 2015). Furthermore, studies have demonstrated that Sal can eﬀectively reduce A β 1-42 deposition and neuroinﬂammation in the brains of AD mice (Xie et al., 2020), improve cognitive decline during aging, and thus exert neuronal protective eﬀects (Jin et al., 2016). In their study, Xing et al. (2020) found that Sal attenuated pyroptosis by inhibiting caspase-1 activation, GSDMD cleaving, and reducing the interleukin-1 β (IL-1β ) release, ultimately reducing the form of atherosclerotic plaque. In addition, in PD-related studies Zhang X. et al. (2020) also demonstrated that Sal has a therapeutic eﬀect on PD by inhibiting pyroptosis and thus dopamine neuron death. All in all, the above studies consistently conclude that Sal plays a potential neuroprotective role by inhibiting pyroptosis. Regrettably, the mechanism of how Sal protects neurons in AD through inhibiting pyroptosis is incomplete and has not been clariﬁed to date. This study aimed to investigate the interaction between AD and NLRP3 inﬂammasome-mediated pyroptosis via established Aβ 1-42, D-gal/AlCl 3 mouse models in vivo, and a D-gal, Nigericin treated PC12 cells damage model in vitro.',\n",
              " 'results': 'Sal Improved A β 1-42 and D-gal/AlCl 3 Induced Cognitive Dysfunction in Mice Open-Field Test An open-ﬁeld test was used to observe the spontaneous exploration activities of mice. As shown in Figure 2, compared with the control group, there were signiﬁcant diﬀerences in the A β 1-42 group in the total distance (Figure 2B), the average velocity (Figure 2D), and the intermediate region motion time (Figure 2E), indicating that spontaneous exploration activities defect of A β 1-42-mice group. Above all, the AD mice treatment by Sal or DNP signiﬁcantly prolonged the intermediate region motion time and total distance, increasing the average velocity compared to A β 1-42-mice. The moving track of the mice in the center and surrounding areas is exhibited in Figure 2C. Thus, the results suggested that Sal can substantially improve the autonomous exploration activities of AD mice. The athletic capacity and anxiety levels of the mice were assessed by OFT (Liu et al., 2021). In the OFT, the AD mice induced by D-gal/AlCl3 had fewer total distances than the control mice. The Sal or DNP group exhibited a total distance traveled than the D-gal/AlCl 3 group (Figure 2B). In terms of the time spent in intermediate quadrant results, the D-gal/AlCl 3-mice spent less time in intermediate quadrant than the normal mice (Figure 2E). However, the time spent in the middle quadrant was increased in the Sal or DNP group, compared with the D-gal/AlCl3 group, and the diﬀerence had statistical signiﬁcance. In addition, the average velocity of the D-gal/AlCl 3-mice was lower than the control group (Figure 2D). Conversely, the average speed has signiﬁcantly increased in the Sal or DNP group, compared to the D-gal/AlCl 3 group. Therefore, the result suggested that Sal can improve athletic capacity and anxiety in AD mice. Morris Water Maze We assessed the learning and memory functions of the AD mice by MWM. First, two-way ANOV A was conducted to analyze the escape latency in the place navigation trial. The results showed that mice treated with A β 1-42 exhibited prolonged escape latency compared to controls. In contrast, A β 1-42-mice with Sal or DNP treatment show shorter escape latency than A β 1-42-mice (Figure 3A). Second, during the spatial probe trial, the one-way ANOV A result indicated that performance was generally worse for the Aβ 1-42 group compared with the control group, including a decrease of the number of platform crossings (Figure 3B), curtailing the time spent in the target quadrant (Figure 3C), and reduced the total distance traveled in the target quadrant (Figure 3D). Meanwhile, in this test, Sal and DNP groups where Aβ 1-42 was co-administered with Sal or DNP were signiﬁcantly better than the A β 1-42 group (Figures 3B–D). Thus, the results revealed that Sal could ameliorate the learning and memory impairments induced by A β 1-42 in AD mice. The moving track of A β 1-42 induced mice during the place navigation trial (Figure 3E) and the spatial probe trial (Figure 3F). To investigate the eﬀect of Sal on the learning and memory function of AD mice induced by D-gal/AlCl 3, we tested the mice in a Morris Water Maze. This result is consistent with previous reports (Zhang et al., 2019). An increase in escape latency in AD model mice was observed (Figure 3A). In contrast, the escape latency progressively shortened in the Sal or DNP group as time went on. On the sixth day, the number of platform crossings, the time spent in the target quadrant, total distance traveled in the D-gal/AlCl3-induced AD mice decreased in the D-gal/AlCl 3-mice when compared with the control group. Furthermore, the above-mentioned behavior improved after treatment with Sal or DNP (Figures 3B–D). These data suggest that Sal can ameliorate the learning and memory function of D-gal/AlCl 3-induced AD mice. The moving track of D-gal/AlCl3 induced mice during the place navigation trial (Figure 3E) and the spatial probe trial (Figure 3F). Sal Mitigated A β 1-42 and D-gal/AlCl 3 Induced Hippocampus Neuronal Injury in Mice The neuron is believed to play a vital role in learning and memory functions. We, therefore, analyzed the number of neurons in the CA1, CA3, and DG regions of the hippocampus by Nissl staining to investigate the eﬀects of Sal treatment on the neuronal morphology change. The neurons in the hippocampus area were in a larger quantity, arranged in neat rows, and rich in Nissl Bodies in the control group. In contrast, the neurons were decreased in quantity, arranged in a disorderedly fashion, with an obscure or disappeared karyopyknosis, or karyolysis, and poor in Nissl Bodies in the A β 1-42 group (Figure 4A). The Sal or DNP-treated groups reversed the above pathological features, namely, the neurons were high in quantity, arranged neatly, with more Nissl Bodies, little karyopyknosis, and karyolysis as seen in Figure 4A. All in all, these data demonstrated that Sal could attenuate its neuronal death. To determine whether Sal protects the neurons from D-gal/AlCl3-induced damage, we performed Nissl staining to analyze the shape of neurons in the hippocampus of AD mice. Nissl staining revealed that D-gal/AlCl 3-mice exhibited neuronal pyknosis and signiﬁcantly reduced neuronal counts. Conversely, in the Sal or DNP group, the above mentioned pathological features were ameliorated, and the density of neurons also increased signiﬁcantly (Figure 4A). Together, these results indicate that Sal ameliorated the damage of neurons induced by D-gal/AlCl 3. Sal Decreased A β 1-42 and D-gal/AlCl 3 Induced the Increased of A β 1-42 and P-Tau in Mice Aggregation of both A β and hyperphosphorylated Tau protein is a primary hallmark of AD (Bakota and Brandt, 2016). To explore the eﬀect of Sal on A β 1-42-mice, we examined the expression of A β and p-Tau in the brain of AD mice by Enzyme-linked immunoassay kits (ELISA), Immunohistochemical staining, and Western blotting analysis. Figures 4, 5 exhibit that the level of Aβ was signiﬁcantly increased for the A β 1-42-mice compared with the regular group, as measured by the ELISA kit. This data indicates that the AD model was prepared successfully. In addition, the levels of A β 1-42 in the Sal or DNP group were lower compared with A β 1-42-mice (Figure 4B), suggesting that Sal treatment was not inferior to DNP. The expression of A β and P-Tau protein was upregulated in the A β 1-42 group, as indicated by western blotting while the presentation of A β 1-42, p-Tau dropped in the DNP group. For comparison, this downregulate tendency was more pronounced in the Sal group (Figure 4C). Furthermore, Immunohistochemical staining showed that A β and p-Tau positive areas were signiﬁcantly increased in the hippocampal region of the A β 1-42 group, with a signiﬁcant diﬀerence compared with the regular group. Increased yellowish-brown A β plaque deposition and brown P-Tau deposits in the model group. Conversely, treatment with Sal or DNP marked reduced the positive area of A β and P-Tau in the hippocampal region, the yellowish-brown A β plaque deposition and brown P-Tau deposits are both decreased, with a signiﬁcant diﬀerence compared with the A β 1-42 group (Figures 5A,B). In short, the above results demonstrated that Sal could exert therapeutic eﬀects on AD by directly reducing both deposition of the A β peptide levels and the hyperphosphorylation of Tau. To determine whether Sal treatment can decrease the A β accumulation and hyperphosphorylation of Tau in D-gal/AlCl 3-mice, we ﬁrst carried out analyses by ELISA kits. The results indicated that the deposition of A β increased in the model group, which implied that the AD model was established successfully. Nevertheless, Sal, DNP groups all presented reductions in the Aβ deposition compared with the D-gal/AlCl 3 group, meaning Sal has similar eﬃcacy to DNP to exert therapy eﬀect on AD (Figure 4B). Next, to further conﬁrm the impact of Sal on the accumulation of A β and hyperphosphorylation of Tau in AD mice, the relative expression levels of Tau, p-Tau, and A β in the brain of AD mice were examined by Western blotting (Figure 4C). The result demonstrated that the expressions of p-Tau and A β were reduced in the Sal or DNP group, and the statistical signiﬁcance of the diﬀerences for comparison D-gal/AlCl3 group. Finally, IHC was performed. As shown in Figures 5A,B, the yellowish-brown A β plaque deposition and brown P-Tau deposits are both decreased in the Sal or DNP group. In summary, these ﬁndings suggest that Sal can improve the A β loaded and phosphorylation of Tau and subsequent pathology of D-gal/AlCl 3-mice. Sal Inhibited A β 1-42 and D-gal/AlCl 3 Induced Pyroptosis in Mice In the present study, ELISA was used to evaluate the inﬂammatory cytokines, namely, IL-1 β and IL-18. Based on the ELISA results, the expression level of IL-1 β and IL-18 were signiﬁcantly elevated in the brain of AD mice induced by A β 1-42, suggesting that IL-1 β and IL-18 are cytokines that play crucial roles in pyroptosis and the onset of AD. As Figure 6 shows, the A β 1-42-mice treat applied Sal, the expression of IL-1β and IL-18 was signiﬁcantly lower than that in the A β 1-42 group (Figures 6A,B). Subsequently, we further investigated the expression of pyroptosis-related proteins, that is to say, IL-1β , IL-18, and cleaved GSDMD by western blotting. Results demonstrated that the protein level of IL-1 β , IL-18, and cleaved GSDMD increased in the A β 1-42 group compared with the regular group (Figure 6C). In comparison, the Sal group found a markedly reduced expression level of IL-1 β , IL-18, and cleaved GSDMD. Notably, GSDMD-N was cleaved by activated GSDMD, which could motivate the secretion of IL-1 β , IL-18, and subsequently drive pyroptosis (He et al., 2015). These results imply that pyroptosis is closely related to AD, and Sal could prevent pyroptosis in A β 1-42-induced AD mice. GSDMD is a crucial biomarker of pyroptosis. To explore the action and mechanism of Sal in pyroptosis, we assessed both the IL-1 β and IL-18 and the expression of GSDMD proteins related to the pyroptosis by ELISA kits and Western blotting analysis. ELISA results indicated that treatment with Sal gradually downregulated the secretion of IL-1 β and IL-18 induced by D-gal/AlCl 3 (Figures 6A,B). Western blot further conﬁrmed our results. The result showed that the protein levels of IL-1 β . IL-18, and cleaved GSDMD decreased in the Sal group (Figure 6C). These results demonstrate that pyroptosis may involve AD onset, and Sal could ameliorate the course of AD through inhibited pyroptosis. Sal Attenuated A β 1-42-Induced Pyroptosis Through Modulation of the NLRP3/Caspase-1 Signaling Pathways in Mice To explore Sal’s action and underlying mechanism in pyroptosis induced by A β 1-42, we validated it using IHC and western blotting. The western blotting results suggested that the expression of the proteins of NLRP3, ASC and cleaved Caspase-1 levels were increased in the A β 1-42-group (Figure 7A), the high expression of these proteins could be inhibited by administration with Sal. Consistently, the IHC exhibited that the increased brown NLRP3, cleaved Caspase-1 deposits were seen in the hippocampus of AD mice, and the brown deposits were suppressed with Sal, which indicates Sal can inhibit NLRP3/Caspase-1 (Figures 8A,B). Thus, the above data show that Sal can mitigate pyroptosis by inhibiting the NLRP3/caspase-1 signaling pathway. Sal Attenuated D-gal/AlCl 3-Induced Pyroptosis Through Modulation of the TLR4/NF-κ B/MyD88/NLRP3 and NLRP3/Caspase-1 Signaling Pathways in Mice Aβ 1-42 models for the potential mechanisms of Sal have revealed that Sal can ameliorate the pathological features of AD via inhibited pyroptosis. To further conﬁrm how Sal modulates pyroptosis, and in turn, intervenes in the pathogenesis of AD, we validated the results obtained from the A β 1-42 mice model using the D-gal/AlCl 3 mice model. As expected, Western blotting results showed an increase of TLR4, MyD88, p-NF- κ B, NLRP3, ASC, and Cleaved Caspase-1 protein expression levels in the model group. Conversely, these protein expressions were reduced in the Sal group (Figures 7A,B). Furthermore, the result of IHC is consistent with A β 1-42-mice (Figures 7C, 8A,B). Normal brain tissue sections showed no signiﬁcant positive expression under high magniﬁcation and increased brown TLR4, NLRP3, cleaved Caspase-1 deposits were seen in the hippocampus of AD mice, and small amounts of brown deposits were seen in the Sal groups. Thus, the above experiments veriﬁed that Sal inhibits pyroptosis by suppressing the TLR4/MyD88/NF-κ B/NLRP3 and NLRP3/Caspase-1 signaling pathway. Sal Protected PC12 Cells Against D-gal-Induced Cytotoxicity and Improved Viability To screen an optimum action concentration of D-gal, we ﬁrst added D-gal (10, 15, 30, 40, 50 mg/ml) to 96-well culture plates and allowed it to act on the PC12 cells for 48 h. As Figure 9 shows, cell viability decreased with the increase of D-gal action concentration, detected by the CCK8 assay (Figure 9B). Finally, D-gal (15 mg/ml), was selected as working concentrations for the subsequent experiments. To explore the action of Sal in D-gal induced cytotoxic and neuroprotective eﬀects on PC12 cells, assays were performed using a CCK-8 assay. As shown in Figure 9, after PC12 cells were exposed to Sal (2, 10, 50 µ M) for 24 h, there were no signiﬁcant hits for the viability of PC-12 cells (Figure 9A), suggesting that Sal did not alter the survival of PC12 cells. Subsequently, 2, 10, and 50 µ M of Sal were added to the culture media, and cells were pre-incubated for 2 h. Then, the cells were incubated with D-gal (15 mg/ml) for 48 h, ﬁnally using CCK-8 for analyses. As shown in Figure 9C, the percentage of PC12 cells was signiﬁcantly increased in the Sal-treated group compared to the D-gal group. The result implied that Sal might act to prevent PC12 cells from damage. Protective Effects of Sal Against PC12 Cells Damage Induced by D-gal via Regulating TLR4/NF-κ B/NLRP3/Caspase-1 Signaling Pathway To explore the underlying mechanisms of D-gal induced PC12 cells damage, ELISA was applied to determine the secretion of IL-1 β and IL-18. Results indicated that Sal considerably decreased the expression of IL-18 and IL-1 β in D-gal-induced PC12 cells, suggesting that Sal can exert mitigated pyroptosis via the decreased release of inﬂammatory factors (Figure 9E). Meanwhile, Western blotting analysis was used to analyze the TLR4-related and the NLRP3-related signaling pathway protein to verify the above hypothesis further. Consistent results were obtained. Protein expression was downregulated in the Sal group, including TLR4, MyD88, p-NF- κ B, NLRP3, ASC, Cleaved Caspase-1, Cleaved GSDMD, IL-1 β , and IL-18 (Figures 9F–H). Furthermore, immunoﬂuorescence assays conﬁrmed that the expression of TLR4, NLRP3, and cleaved Caspase-1 were signiﬁcantly reduced by treatment with Sal (Figure 9I). The above result is consistent with the previous two AD mice model results, indicating that Sal could suppress pyroptosis by inhibiting TLR4/MyD88/NF-κ B/NLRP3 and NLRP3/Caspase-1 signaling pathways in D-gal-induced PC-12 cells. Effect of Sal on Nigericin-Induced NLRP3 Activation in PC12 Cells CCK-8 assays were conducted to screen a suitable concentration of Nigericin for our experiment. The Nigericin concentration chosen for this screening was 10 µ M (Figure 9D). As demonstrated for A β 1-42 and D-gal/AlCl 3 AD mice models and PC12 cells model, pyroptosis plays a critical role in the progression of various nervous system diseases (such as AD, PD, HD, and ALS) (Voet et al., 2019). In the present experiment, we aimed to explore the mechanism of Sal during the pathogenesis of AD. To further explore the action of Sal on NLRP3 activation, Western blotting was used to assess changes in NLRP3 and its downstream proteins in Nigericin + Sal-treated PC12 cells. As indicated in the ﬁgure, the level of NLRP3 and its downstream proteins was noticeably increased in the D-gal group compared to the normal group. By contrast, the level of NLRP3 was decreased in the Sal group compared with the D-gal group. Interestingly, compared with the Sal group, the Nigericin group eﬃciently reversed the reduced level of NLRP3 eﬀectively while increasing the level of ASC, cleaved Caspase-1, cleaved GSDMD, IL-1 β , and IL-18, a downstream target of NLRP3 (Figure 9J). Thus, the above results conﬁrmed that Sal inhibited pyroptosis mainly through targeting suppression of the NLRP3 inﬂammasome. NLRP3 Is Involved in the Inhibitory Effect of Sal on D-gal-Induced PC12 Cells Pyroptosis We hypothesized that Sal acts against D-gal-induced NLRP3 inﬂammasome activation by downregulating NLRP3. To test this, we knocked down NLRP3 expression in PC12 cells by siRNA. Firstly, the Western blot result showed that the sequence 1 of NLRP3 siRNA had a better eﬀect in silencing NLRP3 (Figure 10A). As shown in Figure 10B, we found that the NLRP3 siRNA group or Salidroside signiﬁcantly reversed D-gal induces upregulation of cleaved Caspase-1, GSDMD, IL-1β , and IL-18, further suggesting that NLRP3 inﬂammasome-mediated pyroptosis plays a central role in AD. At the same time, compared with the NLRP3 siRNA group, the Salidroside combined NLRP3 siRNA group failed to change the protein expression of cleaved Caspase-1, GSDMD, IL-1 β , and IL-18 in PC12 cells (Figure 10B). Moreover, NLRP3 siRNA or Salidroside rescued in cell viability induced by D-gal, and the Salidroside combined NLRP3 siRNA group failed to change cell viability compared with NLRP3 siRNA (Figure 10C). Collectively, the above data demonstrate that Salidroside inhibited pyroptosis by targeting the NLRP3 inﬂammasome.'}"
            ]
          },
          "execution_count": 34,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "article_sections = article_extracting.invoke(articles_df['text'][0])\n",
        "article_sections"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 35,
      "id": "IQfF3HSONW7t",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 139
        },
        "id": "IQfF3HSONW7t",
        "outputId": "ea65e8b9-d25e-47e2-a514-18ab8a2b5527"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            },
            "text/plain": [
              "'Amyloid β -protein (A β ) is reported to activate NLRP3 inﬂammasomes and drive pyroptosis, which is subsequently involved in the pathogenesis of neurodegenerative diseases, such as Alzheimer’s disease (AD). To date, the pathogenesis of AD is unfortunately insufﬁciently elucidated. Therefore, this study was conducted to explore whether Salidroside (Sal) treatment could beneﬁt AD by improving pyroptosis. Firstly, two animal models of AD, induced, respectively, by A β 1-42 and D-galactose (D-gal)/AlCl 3, have been created to assist our appreciation of AD pathophysiology. We then conﬁrmed that pyroptosis is related to the pathogenesis of AD, and Sal can slow the progression of AD by inhibiting pyroptosis. Subsequently, we established the D-gal and Nigericin-induced PC12 cells injury model in vitro to verify Sal blocks pyroptosis mainly by targeting the NLRP3 inﬂammasome. For in vivo studies, we observed that A β accumulation, Tau hyperphosphorylation, neurons of hippocampal damage, and cognitive dysfunction in AD mice, caused by bilateral injection of A β 1-42 into the hippocampus and treatments with D-gal combine AlCl 3. Besides, accumulated Aβ promotes NLRP3 inﬂammasome activation, which leads to the activation and release of a pro-inﬂammatory cytokine, interleukin-1 beta (IL-1β ). Notably, both A β accumulation and hyperphosphorylation of Tau decreased and inhibited pyroptosis by downregulating the expression of IL-1 β and IL-18, which can be attributed to the treatment of Sal. We further found that Sal can reverse the increased protein expression of TLR4, MyD88, NF- κ B, P-NF-κ B, NLRP3, ASC, cleaved Caspase-1, cleaved GSDMD, IL-1β , and IL-18 in vitro . The underlying mechanism may be through inhibiting TLR4/NF-κ B/NLRP3/Caspase-1 signaling pathway. Our study highlights the importance of NLRP3 inﬂammasome-mediated pyroptosis in AD, and how the administration of pharmacological doses of Sal can inhibit NLRP3 inﬂammasome-mediated pyroptosis and ameliorate AD. Thus, we conclude that NLRP3 inﬂammasome-mediated pyroptosis plays a signiﬁcant role in AD and Sal could be a therapeutic drug for AD.'"
            ]
          },
          "execution_count": 35,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "article_sections['abstract']"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 36,
      "id": "GA2xrHu-NbKW",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GA2xrHu-NbKW",
        "outputId": "46a82f9e-e7a7-4212-90bc-7b14b32bd828"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "100%|██████████| 15/15 [11:07<00:00, 44.50s/it]\n"
          ]
        }
      ],
      "source": [
        "abstract = []\n",
        "intro = []\n",
        "results = []\n",
        "\n",
        "for text in tqdm.tqdm(articles_df['text'][:15], total=len(articles_df['text'][:15])):\n",
        "    article_sections = article_extracting.invoke({\"text\": text})\n",
        "\n",
        "    abstract.append(article_sections['abstract'])\n",
        "    intro.append(article_sections['introduction'])\n",
        "    results.append(article_sections['results'])\n",
        "\n",
        "    time.sleep(11)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 39,
      "id": "6g9WKcetOfmf",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "6g9WKcetOfmf",
        "outputId": "42e119e2-e51a-4a45-96d4-013c3a178f7a"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "100%|██████████| 14/14 [10:47<00:00, 46.24s/it]\n"
          ]
        }
      ],
      "source": [
        "for text in tqdm.tqdm(articles_df['text'][15:], total=len(articles_df['text'][15:])):\n",
        "    article_sections = article_extracting.invoke({\"text\": text})\n",
        "\n",
        "    abstract.append(article_sections['abstract'])\n",
        "    intro.append(article_sections['introduction'])\n",
        "    results.append(article_sections['results'])\n",
        "\n",
        "    time.sleep(11)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 40,
      "id": "wacrKYcpPUcP",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "wacrKYcpPUcP",
        "outputId": "e2c826e7-b334-4c16-fe05-83158982a60b"
      },
      "outputs": [
        {
          "data": {
            "application/vnd.google.colaboratory.intrinsic+json": {
              "summary": "{\n  \"name\": \"articles_df\",\n  \"rows\": 29,\n  \"fields\": [\n    {\n      \"column\": \"title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"Identification of Sirtuin 1-Targeted Anti-Alzheimer Agents Using Structure-Based Drug Design and Multi-Database Screening\",\n          \"Study on the Role of an Erythrocyte Membrane\\u2010Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease\",\n          \"Hybrid Membrane\\u2010Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"url\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"https://doi.org/10.56042/ijc.v63i12.13637\",\n          \"https://doi.org/10.1002/advs.202301361\",\n          \"https://doi.org/10.1002/advs.202306675\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"year\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 1,\n        \"min\": 2021,\n        \"max\": 2025,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          2023,\n          2025,\n          2024\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"filename\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"db\\\\31.pdf\",\n          \"db\\\\17.pdf\",\n          \"db\\\\13.pdf\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"Indian Journal o\\nf Chemistry \\nVol. 63, December 2024, pp. 1240-1249 \\nDOI: 10.56042/ijc.v63i12.13637 \\nIdentification of Sirtuin 1-targeted anti-Alzheimer agents using structure-based \\ndrug design and multi-database screening \\nPreeti Chandola#a, Smita Jain#b, Ritu Singhc, Mohammad Chand Jamalid, Jaya Dwivedi*a & Swapnil Sharmac \\na Department of Chemistry, Banasthali Vidyapith, Banasthali 304 022, Rajasthan, India \\nb Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Kishangarh 305 817, \\nRajasthan, India \\nc Department of Pharmacy, Banasthali Vidyapith, Banasthali 304 022, Rajasthan, India \\nd Department of Health Sciences, Khawarizmi International College, Abu Dhabi, UAE \\nE-mail: jayadwivedi@yahoo.co.in, smitajain1994@gmail.com\\nReceived 10 September 2024; accepted (revised) 22 November 2024 \\nSirtuin 1 (Sirt1) is a critical enzyme involved in cellula r stress responses and neuroprot ection, making it a significant \\ntarget in Alzheimer's disease (AD) research. Dysregulati on of Sirt1 contributes to amyloid-beta accumulation, tau \\nhyperphosphorylation, and neuroinflammation\\u2014hallmarks of AD pathology. Structure-based drug design (SBDD) aims to \\ndevelop small molecules that enhance Si rt1 activity, offering a novel therapeutic approach. By targeting Sirt1, these \\nmolecules can potentially mitigate AD progre ssion, providing a promising strategy fo r developing effective treatments. In \\nthis present work, a pharmacophor e containing six features has been design ed using the Sirt1 m acromolecule crystal \\nstructure using the Discovery Studio 2.0 software and validated by the Gune ry-Henery (GH) Scoring method. The GH \\nscores have been found in the acceptable range. Further, validated pharmacophores have been used for exploring the plant-\\nderived database to retrieve the novel hits employing various parameters viz fit value, Lipinski rule of five violation, feature \\nmapping, in silico pharmacokinetics and toxicological studies. After the virtual screening process, 24-24 molecules from the \\nZINC and FDA-approved database have been retrieved which have been further subjected to molecular docking to \\ndetermine the binding interactio ns with the Sirt1 enzyme's active binding sites using the LibDock module in DS 2.0 \\nsoftware. Based on binding energy and binding interactions  2-2 molecules from the ZINC database and FDA-approved \\ndatabase have been selected for the mo lecular dynamic simulation. The knowledge obtained in this study may help reveal \\ncommercially available compounds that can become potent activators of Sirt1. \\nKeywords: Sirtuin 1, Alzheimer\\u2019s disease, Structure-based drug design, Pharmacophore modeling, Molecular docking \\nAlzheimer's disease (AD) is a devastating \\nneurodegenerative disorder characterised by \\nprogressive cognitive decline, memory impairment, \\nand behavioural changes\\n1,2. It is marked by the \\npathological accumulation of amyloid-beta (A \\u03b2) \\nplaques and neurofibrillary tangles composed of \\nhyperphosphorylated tau protein in the brain\\n3. Despite \\nextensive research, there is  still no cure for AD, and \\ncurrent treatments only offer limited symptomatic \\nrelief. Consequently, there is a pressing need for \\nnovel therapeutic approaches to address the disease's \\nunderlying causes and halt its progression\\n4,5. Sirtuin1 \\n(SIRT1) is a member of the Sirtuin family of NAD+-\\ndependent deacetylases and has garnered significant \\nattention due to its involvement in regulating various \\ncellular processes, including ageing, metabolism, and \\nstress responses\\n6. In the context of neurodegeneration, \\nSIRT1 is particularly noteworthy for its potential \\nneuroprotective effects\\n7. SIRT1 exerts its beneficial \\neffects by deacetylating and modulating the activity of \\nseveral key proteins and transcription factors involved \\nin neuronal survival, inflammation, and metabolic \\nregulation. These properties make SIRT1 an attractive \\ntarget for therapeutic intervention in AD\\n8. \\nResearch has demonstrated that SIRT1 activation \\ncan positively influence several pathological \\nprocesses associated with AD 9. For instance, SIRT1 \\nactivation has been shown to reduce the production of \\nA\\u03b2 peptides, one of the primary culprits in AD \\npathology10. This is achieved through the \\ndeacetylation and activation of retinoic acid receptor \\nbeta (RAR \\u03b2), which subsequently increases the \\nexpression of ADAM10, an enzyme that promotes the \\nnon-amyloidogenic processing of amyloid precursor \\n\\u2014 \\u2014\\u2014\\u2014\\u2014 \\u2014  \\n# These authors contributed equally and share first authorship  CHANDOLA et al.: SIRTUIN 1-TARGETED ANTI-ALZHEIMER AGENTS \\n \\n \\n1241\\nprotein (APP) 11. Additionally, SIRT1 can modulate \\ntau pathology by deacetylating and stabilizing \\nmicrotubules, thus reducing tau hyperphosphorylation \\nand aggregation. These findings suggest that SIRT1 \\nactivation could mitigate key pathological features of \\nAD and confer neuroprotection\\n11. \\nStructure-based drug design (SBDD) is a powerful \\nstrategy in modern medicinal chemistry that involves \\ndesigning molecules with specific interactions based \\non the three-dimensional structure of a target \\nprotein\\n12. The resolved crystal structure of SIRT1 \\nprovides critical insights into its active site and \\nbinding pockets, facilitating the design of small \\nmolecules that can specifically bind to and modulate \\nSIRT1 activity\\n13. This rational approach allows for the \\nidentification and optimization of compounds that \\nenhance SIRT1 activity, offering a promising pathway \\nfor developing new therapeutic agents for AD. \\nIn the SBDD process, computational techniques \\nsuch as molecular docking and virtual screening are \\nemployed to identify potential SIRT1 activators from \\nextensive libraries of compounds\\n13. These initial hits \\nare then subject to medicinal chemistry efforts to \\noptimize their binding affinity, specificity, and \\npharmacokinetic properties. The goal is to create \\nmolecules that are not only potent SIRT1 activators \\nbut also possess favourable characteristics for brain \\ndelivery and stability. \\nWe intended to find novel modulators using online \\navailable databases as prospective therapies targeted \\nto SIRT1 in AD based on the views discussed above. \\nBy using the sirt1 structural protein with \\nnicotinamide-adenine-dinucleotide (NAD) interaction \\nas a template structure, we conducted in silico \\nresearch that considered the construction of a \\nreceptor-based pharmacophore model for virtual \\nscreening. Following using the created \\npharmacophore model to virtually screen from the \\ndatabase, the obtained compounds were further \\nfiltered for their drug-likeness using Lipinski's \\nVeber's and ADMET filters. An investigation was \\nconducted to determine th e binding relationship \\nbetween the drug-like compounds that were obtained \\nand the sirt1 structural protein with NAD domain \\npocket residues. In addition, the compounds that were \\nacquired from docking research with the tubulin \\nstructural protein were put through significant \\nmolecular dynamics (MD) si mulations to determine \\nwhether or not they remained stable for a period of \\nfifty nanoseconds. In addition, the compounds that \\nexhibited binding interactions with critical residues of \\nthe tubulin structural protein, which were comparable \\nto those shown in the crystallographic structure of the \\nsirt1 structural protein \\u2013NAD, were docked with the \\nmutant structure that was produced. \\n \\nMaterial and methodology \\n \\nDevelopment of structure-based pharmacophore \\nFinding the precise location of the catalytic \\ninteraction between the protein and its bound  \\nco-crystallized ligand is accomplished using the \\nstructure-based pharmacophore model. The essential \\npharmacophoric properties that hinder protein activity \\nmay be identified by analysing this model's data.  \\nA structure-based pharmacophore was created  \\nusing the 3D structure of sirt1 (4i4i) and its  \\nco-crystallized modulator NAD. Discovery Studio  \\n2.0 was used to build six structure-based \\npharmacophore characteristics. HBA, HY, HBD, and \\naromatic rings were these properties\\n14. \\n \\nValidation of Receptor-Ligand Pharmacophore \\nModel \\nThe Guner-Henry (GH) technique, also known as \\nthe decoy set validation method, is used in \\ncomputational chemistry and cheminformatics to \\nevaluate the developed pharmacophore model \\nrobustness\\n15. This technique involves the following \\nsteps: \\n \\nGH = \\uf0f7\\n\\uf0f8\\n\\uf0f6\\uf0e7\\n\\uf0e8\\n\\uf0e6 \\uf02d\\uf02b NA\\nRA\\nNH\\nA 14\\n3  \\n \\nWhere: A is the number of active compounds  \\nNH is the number of hits (compounds predicted as \\nactive). \\nNA is the total number of active compounds in the \\ndataset. \\nR is the number of hits that are active compounds. \\n \\nVirtual Screening \\nThere are 1,64,919 compounds in the Zinc and \\n1,168 in FDA FDA-approved database were \\ndownloaded. The verified pharmacophore was used as \\na 3D query using the ligand Pharmacophore Mapping \\nmodule in Discovery Studio 2.0 to identify chemicals \\nthat potentially affect Sirt1. Additionally, the possible \\ncompounds were sorted by feature mapping, fit value, \\nand the Lipinski rule of five. Using the pkCSM web \\ntool, the discovered chemicals underwent a further \\nin silico pharmacokinetic and toxicological study to  INDIAN J. CHEM., DECEMBER 2024 \\n \\n \\n1242\\nfurther refine the mixture. Following the filtering \\nprocedure, the drug-like compounds were extracted \\nand subjected to molecular docking with the sirt1 \\nmacromolecule\\n16. \\n \\nMolecular Docking of Drug-Like Compounds with \\nSirt1 \\nMolecular docking was used to build bioactive \\nbinding poses within the Sirt1 protein enzyme's \\ncatalytic site from the drug-like chemicals obtained \\nvia filtering. The protein structure (4i5i) was retrieved \\nfrom PDB. The protein structure was built using \\nSWISPDB viewer and used to determine binding \\nscore and chemical binding interactions using the \\nPyrx virtual screening tool and Autodock Vina \\nmodule. Pymol and Discovery Studio Visualizer \\nanalysed protein-ligand binding\\n17. \\n \\nMolecular dynamic simulation \\nMolecular dynamics (MD) simulation is a \\ncomputational technique used to study the physical \\nmovements of atoms and molecules over time, \\nproviding insights into molecular structure and \\nbehaviour (The Desmond 2020.1 from Schr\\u00f6dinger, \\nLLC). This process begins with the selection and \\npreparation of the molecular system, including the \\nchoice of an appropriate force field to define the \\npotential energy. The system is then solvated, \\ntypically in a water box, and ionized to mimic \\nphysiological conditions. Energy minimization is \\nperformed to remove any steric clashes, followed by \\nequilibration under controlled temperature and \\npressure conditions. During the production run (100 \\nns), Newton\\u2019s equations of motion are integrated over \\ntime to simulate atom movements, with trajectories \\nrecorded for subsequent analysis. Post-simulation, the \\ntrajectory data is analysed to assess molecular \\nproperties such as stability, conformational changes, \\nand interactions, often visualized using specialized \\nsoftware. Advanced analyses may further refine the \\ninsights gained from the simulation\\n18. \\n \\nResult and Discussion \\n \\nGeneration and validation of receptor-ligand pharmacophore \\nmodel \\nUsing Discovery Studio 2.0 software, six feature \\npharmacophore were devel oped which included two \\nhydrogen bond acceptors, two hydrophobic and two \\nhydrogen donors as shown in Fig. 1. \\nThis six-feature-based pharmacophore was \\nvalidated using the Gunery Henery scoring method. \\nThe database included 90 decoy compounds and 13 \\ninhibitors that were known to have sirt1. To assess the \\nmodel's capability to differentiate between active and \\ndecoy compounds, the pharmacophore model was \\nused as a 3D query to explore the internal decoy \\ndatabase. The following metrics were computed: total \\nhits (Ht), active hits (Ha), percentage yield of actives, \\npercentage ratio of actives, and GH score. A GH score \\nbetween 0.7 - 0.8 implies a very commendable model. \\nThe observed value for the pharmacophore model was \\n0.752, as seen in Table 1. The verified findings \\ndemonstrate that the model was very effective for \\ndatabase screening. \\n \\nDrug-like compounds retrieved from virtual \\nscreening \\nA highly reliable pharmacophore was employed to \\nexplore the test compounds database and 1,64,919 \\ncompounds from the Zinc database and 1,168 in the \\nFDA-approved database were retrieved. Afterwards, \\nusing various filtration parameters including fit \\nvalues, and feature mapping 167 and 1128 \\ncompounds were separated respectively. In addition, \\n \\nFig. 1 \\u2014 Six feature pharmacophore developed using the Sirt1 \\nmacromolecule crystallographic structure \\n \\nTable 1 \\u2014 GH scoring \\nSerial \\nNo. \\nParameter Pharmacophore \\nmodel \\n1 Total molecules in database (D) 90 \\n2 Total number of actives  in the database (A) 13 \\n3 Total hits (Ht) 16 \\n4 Active hits (Ha) 12 \\n5 % Yield of actives[(Ha/Ht) \\u00d7 100] 75 \\n6 % Ratio of actives [(Ha/A) \\u00d7 100] 92.30769231 \\n8 False negatives [A \\u2212 Ha] 1 \\n9 False positives [Ht \\u2212 Ha] 4 \\n10 Goodness of hit score (GH) 0.75206044 \\n CHANDOLA et al.: SIRTUIN 1-TARGETED ANTI-ALZHEIMER AGENTS \\n \\n \\n1243\\nRo5, veber's filters, and in silico pharmacokinetic and \\ntoxicological parameters also sorted the compounds \\n(Table S1 and S2) and found 24-24 compounds from \\nthe ZINC and FDA-approved databases as shown in \\nTable 2 and Table 3. \\n \\nMolecular docking \\nFollowing the retrieval of compounds from the \\nZINC and FDA-approved databases, the molecular \\ndocking technique was used to investigate the binding \\ninteractions of the compounds that were recovered \\nwith the active binding sites of the Sirt1 enzyme \\ndomain. The efficiency of the AutoDock Vina \\ntechnique was assessed before docking these \\ncompounds. This was accomplished by re-docking the \\nco-crystallized ligand, NAD, into the Sirt1-binding \\npocket. Pyrx software was used for this evaluation. \\nThe purpose of this re-docking procedure is to act as a \\nvalidation phase, which ensures that the docking \\nalgorithm properly repro duces the known binding \\nmode of the co-crystallized ligand. This, in turn, \\nconfirms the dependability of the docking \\nmethodology for the following study of the flavonoid \\ncompounds. For this reason, we carried out docking \\nof 24-24 compounds derived from ZINC  and  FDA- \\nTable 3 \\u2014 Compounds retrieved from the FDA-approved \\ndatabase using the virtual screening \\nCompd Feature \\nmapping \\nFit value Pharmaprint \\nOctreotide 5 0.278623 '101111' \\nErythromycin 5 0.90498 '101111' \\nAzithromycin 5 0.233393 '111110' \\nBleomycin 5 0.269106 '011111' \\nAnidulafungin 5 1.79671 '011111' \\nMupirocin 5 0.071551 '111110' \\nCarboprost Tromethamine 5 0.05182 '111110' \\nTeicoplanin 5 0.801434 '111110' \\nHyperoside 5 0.149155 '111110' \\nLoganin 5 0.091427 '111110' \\nAcarbose 5 1.71839 '111110' \\nSennoside A 5 0.580643 '111110' \\nDirithromycin 5 0.202533 '111110' \\nBicalutamide 5 0.04608 '111011' \\nGlutathione 4 0.121314 '111100' \\nFolic Acid 4 0.597669 '011110' \\nAdenosine triphosphate 4 0.456684 '111100' \\nPravastatin 4 1.31799 '011110' \\nValsartan 4 0.450008 '100111' \\nMasoprocol 4 0.508436 '101110' \\nFlunisolide 4 1.27205 '101110' \\nPentagastrin 4 2.29931 '111100' \\nBortezomib 4 2.2592 '101110' \\nDesmopressin 4 2.01664 '011110' \\nTable 2 \\u2014 Compounds retrieved from the ZINC  database using the virtual screening \\nCompd Feature mapping Fit value Pharmaprint RMSD \\nZINC000096305829 5 1.53895 '111011' 0.78679 \\nZINC000001761773 4 0.913347 '110011' 0.730013 \\nZINC000004051748 4 0.418103 '110011' 0.59624 \\nZINC000029531980  1.37659 '101011' 0.876012 \\nZINC000061721897 4 0.0055947 '101011' 0.607984 \\nZINC000010385344 4 2.2263 '101011' 0.642002 \\nZINC001704324595 4 2.03028 '111010' 0.661957 \\nZINC000072310938 4 0.22949 '110011' 0.683539 \\nZINC000012633961 4 1.45456 '110011' 0.783514 \\nZINC000004902971 4 0.619084 '110011' 0.960868 \\nZINC000072403507 4 1.28423 '110011' 0.701416 \\nZINC000004280063 4 0.774454 '110011' 0.590432 \\nZINC000089702267 4 0.975683 '110011' 0.620019 \\nZINC000101465017 4 1.39425 '110011' 0.795978 \\nZINC000072405659 4 1.47417 '111010' 0.702612 \\nZINC000006581968 4 0.742085 '101011' 0.703027 \\nZINC000012947980 4 0.816387 '110011' 0.717542 \\nZINC000061721465 4 0.90965 '101011' 0.71698 \\nZINC000005258344 4 1.33655 '101011' 0.905207 \\nZINC001857703352 4 0.0803832 '110011' 0.521082 \\nZINC000000864920 4 0.959451 '110011' 0.387595 \\nZINC000019593876 4 2.45019 '110011' 0.767137 \\nZINC000012528461 4 2.18306 '110011' 0.444501 \\nZINC000096361335 4 0.711884 '110011' 0.508208 \\nZINC000096361333 4 0.771853 '111010' 0.473336  INDIAN J. CHEM., DECEMBER 2024 \\n \\n \\n1244\\napproved databases to evaluate the manner in which \\nthese compounds interact with the particular residues \\nthat are located in the catalytic site of the Sirt1 \\nenzyme. All of the compounds that were retrieved \\nwere able to bind themselves to the Sirt1 enzyme with \\na high docking score, which was higher than the score \\nfor the reference compound. It was shown that these \\nchemicals interact with the essential amino acid \\nresidues that are found in the Sirt1 protein. The amino \\nacid residues Gln294, Phe297, Tyr280, His363, \\nGln345, Glu467, Asn465, Asp272, and Asp471 are \\nshown in the Sirt1 crystal structure. For effective \\nbinding interactions, it is essential to have Phe273, \\nAla262, Ser441, Ser442, Arg466, Cys482, Phe414, \\nVal266, and Arg274. The compounds that were \\nrecovered showed evidence of binding to the required \\namino acids, which indicates that they have the \\nqualities needed to interact with the Sirt1 enzyme\\n19,20. \\nThis is supported by Table 4, Table 5, Fig. 2 and \\nFig. 3. \\n \\nMolecular dynamic simulation \\nMD simulation is used to explore the binding \\nstability of protein-ligand docking complexes. The \\nMD simulation also provid es information regarding \\nintermolecular interaction within a reference time. \\nHerein, the complexes docking file of selected two \\nNCI and two plant-based compounds with Sirt1 \\nprotein were analysed by utilising MD simulation \\napproaches to confirm the stability and intermolecular \\ninteractions between protein and molecules against \\n100 ns time intervals\\n21. In MD modelling, RMSD was \\nevaluated between the initial and final simulated \\ntrajectories, and crucial features including binding \\ninteractions and conforma tion characteristics of the \\ncomplex were also evaluated. For the enzyme-ligand \\ncomplex (4i5i) involving ZINC000000864920, \\nZINC000096361333, Folic acid and Bicalutamide, the \\naverage RMSD values were found as 2.87, 3.08, 3.03 \\nand 3.10 \\u00c5 respectively as shown in Fig. 4. These \\nvalues suggest efficient binding of the ligands with \\nthe sirt1 enzyme\\n22,23. The lower RMSD values \\nindicate a relatively stable and consistent binding of \\nthese ligands within the enzyme\\u2019s active site across \\nthe simulation time frame. \\nRoot Mean Square Fluctuation (RMSF), is an \\nimportant feature that has to be considered when \\nevaluating the structural flexibility of proteins during \\n \\nTable 4 \\u2014 Molecular docking analys is of ZINC database retrieved compounds with Sirt1 macromolecule \\nS. No. Compd Docking score Hydrogen bond amino acids Hydrophobic bond amino acid \\n1. ZINC000000864920 \\u201311.9 O-Ile347 (3.028), O-Gln320 (3.047) Phe414, Val445, Phe297, Phe273, \\nIle316, Ile270 \\n2. ZINC000096361333 \\u201311.2 H-Gln345 (2.367), O-Arg274 (3.195) Ile411, Ile347, Phe273, Ala262, \\nSer442, Glu467, Asp272 \\n3. ZINC000096361335 \\u201311.0 O-Arg274 (3.222), H-Val412 (1.839) Glu467, Ser442, Ala262, Phe297, \\nPhe273, Ile347, Ile411 \\n4. ZINC000004706789 \\u201310.7 O-Gln345 (3.007), O-Val445 (3.278), O-Lys444 \\n(3.239), O-Lys444 (3.088), O-Ser442 (2.744),  \\nH-Ser442 (2.841), H-Asp272 (2.841) \\nSer275, Gly440, Ala262, Phe297, \\nIle411, Phe413 \\n5. ZINC000010385344 \\u201310.5 H-Asn346 (2.445), O-Ser441 (3.107), O-Ser442 \\n(3.084), O-Ser442 (3.182), O-Ser275 (3.016) \\nPhe297, Phe414, Tyr280, Val445, \\nPhe273, Arg274, Ala262, Asp272, \\nGlu467 \\n6. ZINC000089702267 \\u201310.5 O-Gln345 (2.892), O-Ser441 (2.729), O-His363 \\n(2.981), O-Ser442 (2.969), O-Lys444 (3.179),  \\nO-Gly263 (3.285) \\nPhe273, Val445, Ala262, Arg466, \\nGlu467 \\n7. ZINC000012528461 \\u201310.4 O-Ser441 (2.685), O-Ser442 (3.097), O-Ser442 \\n(2.822), O-Arg274 (3.012), O-Lys444 (3.103), \\nIle316, Ile347, Phe297, Ile411, Phe273, \\nHis363, Ala262 \\n8. ZINC000072405659 \\u201310.4 H-His363 (2.478), O-His363 (3.007), O-Val412 \\n(2.799), O-G;n345 (3.048), O-Ser441 (3.036),  \\nH-Ser441 (2.189) \\nVal445, Phe273, Ile316, Ile347 \\n9. ZINC000004051748 \\u201310.2 O-His363 (3.101), O-Ser441 (3.095), O-Lys444 \\n(3.289), O-Lys444 (3.139), O-Gln345 (3.101),  \\nH-Gln345 (1.965), O-Ser442 (2.722), H-Ser442 \\n(2.317), S-Asn465 (3.689) \\nAla262, Cys482, Arg466, Val266, \\nAsp272 \\n10. ZINC000012947980 \\u201310.1 O-Gln345 (3.252), O-Gln345 (2.996), O-Ser441 \\n(3.051), O-Gly263 (3.148), O-Ser442 (3.123),  \\nO-Arg274 (3.320), O-Lys444 (2.882) \\nIle347, Ile411, Phe297, Ile316, Phe273, \\nVal445, His363, Ala262  CHANDOLA et al.: SIRTUIN 1-TARGETED ANTI-ALZHEIMER AGENTS \\n \\n \\n1245\\n \\nTable 5 \\u2014 Molecular docking analysis  of FDA-approved database retrieved compounds with Sirt1 macromolecule \\n Compd Docking score Hydrogen bond amino acids Hydrophobic bond amino acid \\n1. Folic acid \\u201311.5 H-Asn346 (2.375), O-Ala262 (3.140), H-Asp481 (2.400),  \\nO-Arg466 (2.975), H-Asn465 (2.543), O-Ser441 (2.776),  \\nH-Ser442 (2.146), O-Ser442 (2.983), O-Leu443 (3.055),  \\nO-Arg274 (2.868), O-Arg274 (3.071), H-Asp272 (2.648) \\nVal266, Cys482, Leu443 \\n2. Bicalutamide \\u201310.9 O-Gln345 (2.801), O-His363 (3.682), O-Gly261 (3.793),  \\nO-Ala262 (3.291), O-Asp272 (3.172), F-Tyr280 (3.044) \\nPhe414, Glu467, Asp272 \\n3. Valsartan \\u20139.8 O-Asp348 (3.243), C-Gln345 (3.515) Arg274, Val445, Phe414, Ala262, \\nIle411, Phe273, Ile347 \\n4. Carboprost  \\nTromethamine \\n\\u20139.6 O-Lys444 (3.032), O-Val445 (3.123), O-Gln345 (3.164),  \\nO-Ser441 (2.946), O-Ser441 (3.044), O-Ser442 (2.826),  \\nO-Lys444 (3.032), H-Phe297 (2.383), H-Tyr280 (2.256) \\nPhe414, His363, Phe273, Ile411, \\nIle347, Ile316 \\n5. Masoprocol \\u20139.2 O-Arg274 (3.052) Val445, Ile411, Phe413, Phe273, \\nPhe297, Ile347 \\n6. Mupirocin \\u20139.0 H-Asn346 (2.965), O-Ser441 (2.786), O-Ser442 (3.086),  \\nO-Tyr280 (3.211), O-Arg274 (2.613) \\nVal445, Phe414, His363, Phe297, \\nPhe173, Ile411, Ile347, Ala262 \\n7. Pravastatin \\u20138.9 H-Asp348 (3.041), C-Asn346 (3.561), H-Asn346 (2.312),  \\nH-Gln345 (2.550), O-Arg274 (2.978), O-Arg274 (3.079),  \\nH-Phe273 (3.313) \\nVal445, His363, Phe297, Ile411, \\nIle347 \\n8. Loganin \\u20138.5 O-Gln345 (2.888), O-Ser442 (2.824), O-Phe273 (3.129),  \\nO-Phe414 (2.951), C-Tyr280 (3.748) \\nPhe297, His363, Ile347 \\n9. Flunisolide \\u20138.4 O-Phe413 (3.751), H-Phe414 (2.736)  Ile316, His363, Phe273, Val445 \\n10. Glutathione \\u20138.2 O-Leu443 (3.384), O-Ser442 (2.835), O-Ser442 (2.847),  \\nH-Ser442 (2.740), O-Gly263 (3.071), H-Asn465 (2.374),  \\nO-Cys482 (3.153), O-Arg466 (3.702), H-Asp272 (2.275) \\n \\n \\n \\n \\nFig. 2 \\u2014 Molecular docking analysis of ZINC da tabase retrieved compounds with Sirt1 macromolecule \\n \\nMD. In addition to assisting in the evaluation of the \\ninfluence that ligand binding has on the stability of \\nproteins, it offers knowledge on the fluctuations of \\ncertain amino acid residues. For this investigation, we \\ncompute RMSF values to investigate the fluctuations \\nthat occur within the prot ein residues when they are \\nattached to ligands. The protein's structural stability \\nmight be disrupted if the RMSF value is more  \\nthan three angstroms, which indicates that there  \\nis a possibility   of   higher  amino  acid  fluctuations  \\n INDIAN J. CHEM., DECEMBER 2024 \\n \\n \\n1246\\n  \\n   \\nFig. 3 \\u2014 Molecular docking analysis of FDA approved database retrieved compounds with Sirt1 macromolecule \\n \\n \\n \\nFig. 4 \\u2014 RMSD analysis of (a) ZINC000000864920 (b ) ZINC000096361333 (c) Folic acid (d) Bicalutamide \\n CHANDOLA et al.: SIRTUIN 1-TARGETED ANTI-ALZHEIMER AGENTS 1247\\n \\nfollowing ligand binding. On the other hand, a value \\nof RMSF that is less than three angstroms indicates \\nthat there are fewer variations in amino acids, which \\nindicates that the protein is more stable and resistant \\nto structural alterations. The values of the RMSF for \\nthe complexes that were chosen for this investigation \\nvaried from 0.4 to 3 \\u00c5, which indicates that there \\nwere moderate variations in the amino acid residues. \\nIn terms of the ligands that the protein bound, the \\naverage RMSF values were as follows: 1.78, 1.49, \\n1.70, and 1.60 \\u00c5 for ZINC000000864920, \\nZINC000096361333, Folic acid and Bicalutamide \\ncorrespondingly as shown in Fig. 5. Collectively, \\nthese RMSF values provide an indication of the \\ncomplexes' stability as well as their flexibility while \\nthe MD simulations were being performed. \\nCompound ZINC000000864920 showed hydrogen \\nbonding interactions with Tyr280, Arg282, Asp286, \\nGln294, Glu315, Gln345 and Asp348, hydrophobic \\ninteractions with Asp286, Glu315, Gln320, Asn346 \\nand Asp348 amino acid residues with active binding \\nactive sites of sirt1 enzyme. Similarly, \\nZINC000096361333 showed hydrogen bonding \\ninteractions with Gly261, Ala262, Gly263, Ser266, \\nPhe273, Tyr280, Gln294, Gln345, Asn346, His363, \\nPhe414, Ser442 and Glu467; hydrophobic interactions \\nwith Arg274 and Lys444 amino acid residues of sirt1 \\nmacromolecules as shown in Fig. 6. \\nInterestingly, Folic acid compound showed \\nhydrogen bond interactions with Ala262, Gly263, \\nVal266, Ser267, Arg274, Asp292, Gln294, Gln345, \\nGly440, Ser441, Ser442, Leu443, Lys444, Asn465, \\nArg466, Asp481 and Cyt482 and Bicalutamide \\nshowed hydrogen bond inte ractions with Ala262, \\nGly263, Val266, Asp272, Phe273, Arg274, Tyr280, \\nHis363, Val412, Gly440 and Asn465 amino acid \\nresidues of sirt1 active binding sites. Folic acid and \\nBicalutamide compounds also formed hydrophobic \\ninteractions with Ala262, Phe273, Phe297 and \\nPhe414 amino acid residues of sir1 enzyme active \\nbinding cavities as shown in Fig. 6. \\nMoreover, to evaluate the protein complexes to \\nsolvent molecules and their structural stability, several \\nsurface area measurements, such as SASA and rGyr, \\nwere analysed. The results revealed that the SASA \\nvalues for ZINC000000864920, ZINC000096361333, \\nFolic acid and Bicalutamide were 13282-14624 \\u00c5, \\n13575-15578 \\u00c5, 13523-14792 \\u00c5, and 13271-14791 \\n\\u00c5, respectively. Additionally, the rGyr values \\nfor ZINC000000864920, ZINC000096361333, Folic \\nacid and Bicalutamide were 20.09, 19.81, 19.9, and \\n22.85 \\u00c5, respectively. \\nFig. 5 \\u2014 RMSF analysis of (a) ZINC000000864920 (b) ZINC000096361333 (c) Folic acid (d) Bicalutamide \\n INDIAN J. CHEM., DECEMBER 2024 1248\\nIn the field of drug disco very research, the use of \\nComputer-Aided Drug Design (CADD) techniques \\nhas resulted in the establishment of new standards for \\nthe identification of promising chemical compounds \\nthat target particular receptors. There is no denying \\nthe fact that CADD techniques make a major \\ncontribution to the improvement of the drug \\ndevelopment pipeline. Through molecular docking, \\nMM-GBSA calculations, and MD simu\\nlation\\ninvestigations, it has been shown that the four\\nco\\nmpounds that have been offered have a promising\\naffinity for Sirt1  20. At the same time, to  evaluate the\\npotential of these co\\nmpounds against sirt1, mu ltiple\\nexperim\\nental verifications must be ca rried out. An\\nefficient way to deter\\nmine whether or not th e\\nm\\nolecules have a strong affinity for one another is th e\\nSurface Plas\\nmon Resonance (SPR) test. A kinetic\\nstudy is an appropriate method to i nvestigate the\\nprocesses that are r esponsible for the binding and\\nunbinding of \\nthese molecules. Based on  the results of\\nthe experim\\nents, more optimization of the mo lecules\\nmay\\n be required to enhance their therap eutic potential\\nand m\\naximize their effectiveness.\\nConclusion \\nThis study\\n targeted sirt1, which elevates the \\nmetabolism of amyloid-beta (A \\u03b2) peptides, which are \\ncentral to the pathology of AD. The research screened \\nNCI and plant-based databases using an in silico \\nstructure-based pharmacophore model. LOR5, \\nWeber\\u2019s filter, and fit value enhanced the screening \\nprocedure, giving 24 (ZINC database) and 24 (FDA-\\napproved database) lead compounds with better \\nbinding affinity than the co-crystalized modulator. \\nA further refinement utilizing Prime/MM-GBSA \\nsimulations led to the discovery of seven molecules \\nthat had binding energies that were higher than those \\nof the reference ligand. The sirt1 modulator potential \\nand stability of the lead compounds were validated \\nby the use of MD simulations, which demonstrated \\nthat the lead compounds showed stable binding \\ninteractions with the sirt1protein. There was a \\nsignificant sirt1 protein affinity shown by four \\ndifferent compounds: ZINC000000864920, \\nZINC000096361333, Folic acid and Bicalutamide. \\nSupplementary Information \\nSupplem\\nentary information is available in \\nthe website http://nopr.niscpr.res.in/handle/ \\n123456789/58776. \\nReferences \\n1 Spinelli M, Fusco S & Grassi C, Front Neurosci, 10 (2019) \\n469184.  \\n2 Jain S, Chauhan N, Sharma  S, Reddy K.R, Sadhu V & \\nKulkarni R. V, Nanomat Diag Tools Devices , (2020) 331. \\n(https://doi.org/10.1016/b978-0-12-817923-9.00012-2). \\nFig. 6 \\u2014 Binding interactions of (a) ZINC000000864920 (b) ZINC000096361333 (c) Folic acid (d) Bicalu tamide with Sirt1\\nmacromolecule \\n CHANDOLA et al.: SIRTUIN 1-TARGETED ANTI-ALZHEIMER AGENTS 1249\\n3 Jain S, Bisht A, Verma K, Negi S, Paliwal S & Sharma S, \\nCell Biochem Fun, 40 (2022) 106. \\n4 Cort\\u00e9s N, Andrade V, Guzm\\u00e1n-Mart\\u00ednez L, Estrella M & \\nMaccioni R. B, Int J Mol Sci, 19 (2018) 956. \\n5 Jain S, Singh R, Paliwal S & Sharma S, Mini-Rev Med \\nChem, 23 (2023) 2097. \\n6 Lefranc C, Friederich-Persson M, Braud L, Palacios-Ramirez \\nR, Karlsson S, Boujardine N, Motterlini R, Jaisser F & Cat A \\nN D, Hypertension, 73 (2019) 458. \\n7 Ibi D, Kondo S, Ohmi A, Kojima Y, Nakasai G, Takaba R & \\nHiramatsu M, Neurochem Res, 47 (2022) 2333. \\n8 Lei Y, Wang J, Wang D, Li C, Liu B, Fang X, You J, Guo M \\n& Lu X.Y, Mol Psychiatry, 25 (2019) 1094. \\n9 Zhang M & Tang Z, Biomed Pharm, 161 (2023) 114474. \\n10 Roda A, Serra-Mir G, Mont oliu-Gaya L, Tiessler L & \\nVillegas S, Neural Regen Res, 17 (2022) 1666. \\n11 Khatib T, Chisholm D R, Whiting A, Platt B & McCaffery P, \\nJ Alzheimer\\u2019s Dis, 73 (2020) 935. \\n12 Mortier J, Dhakal P & Volkamer A, 23 (2018) 1959. \\n13 Pulla V.K, Alvala M, Sriram D S, Viswanadha S, Sriram D \\n& Yogeeswari P, J Mol Graph Model, 52 (2014) 46. \\n14 Jain S, Bhole D R & Labhade D S D, Indian J Chem , 63 \\n(2024) 473. \\n15 Moussa N, Hassan A & Gharaghani S, Heliyon, 7 (2021) \\ne06605. \\n16 Gentile D, Floresta G, Pa tamia V, Chiaramonte R, \\nMauro G L, Rescifina A & Vecchio M, Int J Mol Sci ,  \\n21 (2020) 1. \\n17 Patel S, Gururani R, Jain S, Paliwal V, Paliwal S, Paliwal S, \\nDwivedi J, Sharma A, Lee H & Sharma S, J Bio Reg Hom \\nAge, 38 (2024) 5343. \\n18 Jain S, Sharma S, Paliwal A, Dwivedi J, Paliwal S, \\nPaliwal V, Paliwal S & Sharma J, Med Chem Res , 33 \\n (2024) 136. \\n19 Azm\\ninah A, Erlina L, Radji M,  Mun\\u2019im A, Syahdi R R & \\nYanuar A, Comp Bio Chem, 83 (2019) 107096. \\n20 Alrouji M, Alhumaydhi F A, Alsayari A, Sharaf S E, Shafi S, \\nAnwar S, Shahwan M, Atiya A & Shamsi A, PLoS One , 18 \\n(2023) e0293185. \\n21 Liu F, Pang N, Xu R-M & Yang N, Protein Cell, 14 (2023) \\n387. \\n22 Karaman B, Alhalabi  Z, Swyter S R, Mihigo S O, Andrae-\\nMarobela K, Jung M, Sippl W & Ntie-Kang F, Molecules, 23 \\n(2018) 416.  \\n23 Abbotto E, Scarano N, Piacente F, Millo E, Cichero E & \\nBruzzone S, Molecules,. 27 (2022) 5641.  \",\n          \"RESEARCH ARTICLE\\nwww.advancedscience.com\\nStudyontheRoleofanErythrocyteMembrane-Coated\\nNanotheranosticSysteminTargetedImmuneRegulationof\\nAlzheimer\\u2019sDisease\\nYanrong Su, Yufen Huang, Qinjie Kou, Lu Lu, Haiye Jiang, Xisheng Li, Rong Gui,\\nRong Huang, Xueyuan Huang, Jinqi Ma, Jian Li,* and Xinmin Nie*\\nAlzheimer\\u2019sdisease(AD)isoneofthemostcommonneurodegenerative\\ndiseasesintheelderlypopulation.Despitesigni\\ufb01cantadvancesinstudiesof\\nthepathobiologyonAD,thereisstillnoe\\ufb00ectivetreatment.Here,an\\nerythrocytemembrane-camou\\ufb02agednanodrugdeliverysystem(TR-ZRA)\\nmodi\\ufb01edwithtransferrinreceptoraptamersthatcanbetargetedacrossthe\\nblood\\u2013brainbarriertoameliorateADimmuneenvironmentisestablished.\\nBasedonmetal-organicframework(Zn-CA),TR-ZRAisloadedwith\\nCD22shRNAplasmidtosilencetheabnormallyhighexpressionmolecule\\nCD22inagingmicroglia.Mostimportantly,TR-ZRAcanenhancetheabilityof\\nmicrogliatophagocytoseA \\ud835\\udf37 andalleviatecomplementactivation,whichcan\\npromoteneuronalactivityanddecreasein\\ufb02ammationlevelintheADbrain.\\nMoreover,TR-ZRAisalsoloadedwithA \\ud835\\udf37 aptamers,whichallowrapidand\\nlow-costmonitoringofA \\ud835\\udf37 plaquesinvitro.AftertreatmentwithTR-ZRA,\\nlearning,andmemoryabilitiesareenhancedinADmice.Inconclusion,the\\nbiomimeticdeliverynanosystemTR-ZRAinthisstudyprovidesapromising\\nstrategyandnovelimmunetargetsforADtherapy.\\nY .Su,Y .Huang,Q.K ou,H.Jiang,X.Li,X.Nie\\nDepartmentofLaboratoryMedicine\\nTheThirdXiangyaHospital\\nCentralSouthUniversity\\nNo.138,TongzipoRoad,YueluDistrict,Changsha,Hunan410013,China\\nE-mail:niexinmin@csu.edu.cn\\nL.Lu,R.Gui,R.Huang,X.Huang,J.Ma,J.Li\\nDepartmentofBloodTransfusion\\nTheThirdXiangyaHospital\\nCentralSouthUniversity\\nNo.138,TongzipoRoad,YueluDistrict,Changsha,Hunan410013,China\\nE-mail:603196@csu.edu.cn\\nX.Nie\\nHunanEngineeringTechnologyResearchCenterofOptoelectronic\\nHealthDetection\\nChangsha,Hunan410000,China\\nThe ORCID identi\\ufb01cation number(s) for the author(s) of this article\\ncanbefoundunderhttps://doi.org/10.1002/advs.202301361\\n\\u00a92023TheAuthors.AdvancedSciencepublishedbyWiley-VCHGmbH.\\nThisisanopenaccessarticleunderthetermsoftheCreativeCommons\\nAttributionLicense,whichpermitsuse,distributionandreproductionin\\nanymedium,providedtheoriginalworkisproperlycited.\\nDOI:10.1002/advs.202301361\\n1.Introduction\\nAlzheimer\\u2019s disease (AD) is gradually be-\\ncoming the leading cause of dementia\\nworldwide, with the prevalence of AD\\ngradually increasing from 5.0% in peo-\\nple aged 65\\u201374 years to 33.2% in peo-\\nple aged 85 years and older, resulting in\\nmore than 52 million people being af-\\nfected worldwide.[1] The pathogenesis of\\nAD remains complex, but the most com-\\nmon explanation in recent studies is the\\namyloidcascadehypothesis. [2,3] Theforma-\\ntion of A\\ud835\\udefd plaques results from a series\\nof amyloid peptides that are abnormally\\nsheared. Excessive A\\ud835\\udefd plaque accumula-\\ntion could disrupt brain microvascular en-\\ndothelial cells, impair the integrity of the\\nblood\\u2012brainbarrier,andinducein\\ufb01ltration\\nof innate immune cells and adaptive im-\\nmunecellsfromoutsidethebrain,resulting\\nin disorders of the immune microenvironment in the brain.[4,5]\\nTherefore, remodeling the immune microenvironment and\\neliminatingtheaccumulationofabnormalA \\ud835\\udefd inthebrainisone\\nofthemostimportantstrategiesforthetreatmentofAD.\\nMicroglia are macrophages in the brain and spinal cord, and\\nthey represent the primary line of immune defense in the cen-\\ntral nervous system, as they are mainly responsible for clearing\\ndamagedneurons,A \\ud835\\udefd plaques,andinfectioussubstancesinthe\\ncentralnervoussystem. [6] However,agingmicrogliainthebrains\\nofADpatientsmaybecomedysfunctionalandmetabolicallyim-\\npaired, and their ability to clear A\\ud835\\udefd is reduced, which results in\\ntheformationofalargenumberofA \\ud835\\udefd plaques.[7,8] Ontheother\\nhand, microglia in the AD brain show excessive activation and\\nan uncontrolled state, and they can release many proin\\ufb02amma-\\ntory factors (such as tumor necrosis factor TNF-\\ud835\\udefc, interleukin\\nIL-1\\ud835\\udefd, IL-6, etc.) and complement components, further causing\\nimmunein\\ufb02ammatorydamage. [9,10] Atthesametime,themem-\\nbrane attack complex formed by complement activation can di-\\nrectlydamageneuronsthatarehighlysensitivetocomplementor\\nstimulatemicrogliatoreleasemorein\\ufb02ammatoryfactors,form-\\ningapositivefeedbacklooptofurtheraggravateimmunein\\ufb02am-\\nmatorydamagetoneurons. [11] Inaddition,proin\\ufb02ammatoryme-\\ndiatorsdecreasetheexpressionofreceptorscapableofbindingto\\nA\\ud835\\udefd onthesurfaceofmicroglia,whichdecreasesA \\ud835\\udefd phagocytosis\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(1of19)\\n www.advancedsciencenews.com www.advancedscience.com\\nby microglia and further promotes the production and deposi-\\ntionofA \\ud835\\udefd.[12] Therefore,modulatingtheimmuneresponseand\\nenhancing microglial phagocytosis to promote clearance of A\\ud835\\udefd\\nwhile inhibiting complement to reduce immune in\\ufb02ammatory\\ndamageandsynergisticallyprotectneuronsinthebrainisapos-\\nsiblestrategytoimproveADpathology.\\nInpreviousresearch,CD22wasfoundtobehighlyexpressed\\ninagingmicroglia. [13] ItwasproposedthatsilencingCD22might\\nenhanceA\\ud835\\udefd clearancebymicroglia.Thus,ane\\ufb00ectivegenevec-\\ntor loaded with CD22 shRNA (RNAi) was designed to test this\\nhypothesis.Inaddition,anA \\ud835\\udefd aptamer(AAP),whichcandetect\\nA\\ud835\\udefd inthebraininrealtime,wasdesignedtospeci\\ufb01callybindto\\nA\\ud835\\udefd andindicatethecontentofA \\ud835\\udefd viaa\\ufb02uorescencesignalbased\\non the \\ufb02uorescence resonance energy transfer e\\ufb00ect. However,\\nthenegativechargeofthenucleicacidhindersitsentryintothe\\ncellularcytoplasm.Moreover,thesenakednucleicacidmolecules\\nare easily digested by intracellular nucleases.[14] At present, the\\nvectors for gene therapy mainly include viral vectors such as\\nlentivirus, adenovirus, and adeno-associated virus and nonviral\\nvectorssuchascationicliposomes,butduetotheirdrawbacksof\\nimmunogenicity,oncogenicity,highcosts,andasinglefunction,\\nthey are di\\ufb03cult to translate to the clinic, and their applications\\narelimited.Notably,metal-organicframeworks(MOFs)arecrys-\\ntalline porous materials with periodic lattice structures that are\\nformedviatheself-assemblyoftransitionmetalionsandorganic\\nligands; these structures have high porosity and a large speci\\ufb01c\\nsurfaceareaandcanadsorbplasmidDNAvianoncovalentforces\\nsuch as electrostatic interactions, hydrophobic interactions, and\\nhydrogenbondingwhileprotectingitfromchemical and/oren-\\nzymatic degradation.[15,16] Chlorogenic acid (CA) is a phenolic\\nacid extracted from honeysuckle that can be used as an organic\\nligand for the structure of metal-organic framework (MOF) CA\\nhas antibacterial, antiviral, anti-in\\ufb02ammatory, and complement\\nactivationinhibitorye\\ufb00ects. [17] Therefore,ourresearchaimedto\\nsynthesizeaZn-CAMOFbycombiningzincions(Zn 2+)withCA\\nforthee\\ufb03cientloadingofCD22shRNAandA \\ud835\\udefd aptamer.\\nHowever, nanoparticles can be easily recognized and cleared\\nas exogenous substances by the reticuloendothelial phagocytic\\nsystem in the body.[18] Red blood cells (RBCs), the most abun-\\ndant blood cells without nuclei in mammals, are the main\\nmedium for oxygen delivery, and their cell membranes are\\neasy to prepare.[19,20] Moreover, the self-recognition molecule\\nCD47 on the surface of erythrocytes endows the encapsulated\\nnanoparticles with a long circulating half-life and immune eva-\\nsionfunction.[21,22] Inaddition,receptor-mediatedtranscytosisis\\ncurrently one of the most e\\ufb00ective ways to mediate crossing of\\ntheblood\\u2012brainbarrierbybiomolecules. [23] Transferrinreceptor\\n(TfR),oneofthemostrepresentativetranscytosisreceptors,was\\ndistributedwidelyinendothelialcells,plexusepithelialcells,neu-\\nrons,andcommonglialcellinbraintissue.Inthisstudy,inspired\\nbymostreports,aTfRaptamerwasdesignedasaTfRligand. [24]\\nAfter binding to TfR, the nanosystem entered the blood\\u2013brain\\nbarrier through transcytosis of brain endothelial cells, and was\\nthentakenupbymicroglia,neurons,andothercellscontaining\\nTfRs.[25,26]Thus, the resulting erythrocyte-camou\\ufb02aged nanopar-\\nticles were expected to protect the whole system from degrada-\\ntion, and the TfR aptamer, which was attached to the surface\\nof the erythrocyte membrane by lipid insertion, was predicted\\nto improve the ability of the system to reach the blood\\u2012brain\\nbarrier, both of which could play essential roles in enhancing\\ne\\ufb03cacy.\\nHence, in this study, we proposed the use of Zn2+ and CA\\nto construct a metal-organic framework Zn-CA (ZC), which si-\\nmultaneously transports CD22 shRNA (RNAi) and A\\ud835\\udefd aptamer\\n(AAP)toformaZC/RNAi/AAP(ZRA)nanocore.Finally,theTfR\\naptamer-RBCm(TR)shellstructureencapsulatesZRAtoforma\\nnovelerythrocytemembrane-camou\\ufb02agednanodrugsystem:TR-\\nZC/RNAi/AAP(TR-ZRA).Asshownin Figure1a,b,TR-ZRAwas\\ncamou\\ufb02aged by an autologous erythrocyte membrane and tar-\\ngetedtopenetratetheblood \\u2012brainbarrierundertheactionofTfR\\naptamer.Afterphagocytosisanddecompositionbymicroglia,ZC\\nactsasaninhibitorofcomplementactivation,andAAPindicates\\nA\\ud835\\udefd levelsinthebrainvia\\ufb02uorescenceintensity.CD22shRNAin-\\nhibitstheexpression ofCD22inmicrogliaat thegenelevel and\\npromotesthephagocyticclearanceofA \\ud835\\udefd bymicroglia,whichfur-\\ntherreducesimmunein\\ufb02ammatorydamageinthebrainandim-\\nprovesneuronalactivity.Thus,TR-ZRAwasdesignedtoimprove\\ntheimmuneenvironmentofADandprovideapossiblestrategy\\ntocureAD.\\n2.ResultsandDiscussion\\n2.1.PreparationandCharacterizationofTR-ZC/RNAi/AAP\\nThe primary process of TR-ZC/RNAi/AAP included incubation\\nofZn2+ andCAtosynthesizeametal \\u2212organicframework(with\\nPEI, positive charge) and loading with RNAi and AAP (nega-\\ntive charge), which resulted in the formation of ZC/RNAi/AAP\\nnanocores via charge adsorption. The TfR-A aptamer was in-\\nserted into erythrocyte membrane vesicles (RBCm) to form the\\nT-R shell structure. Finally, TR was used to encapsulate the\\nZC/RNAi/AAP nanocore and form TR-ZC/RNAi/AAP by ultra-\\nsound (Figure 1a). Afterward, changes in the morphology, size,\\nand zeta potential of these nanoparticles were measured. As\\nshown inFigure 2a, ZC exhibited 3D and quadrate crystal par-\\nticleswhileZRAwasclosertothedispersedsphericalstructure,\\nwhichmaybecausedbythemodi\\ufb01cationofPEI,APP,andRNAi\\non the surface of ZC. TR-ZRA was synthesized after ultrasonic\\ntreatment and \\ufb01ltration, and it can be seen that there was an\\nerythrocyte membrane structure (\\u22488n m )a r o u n dZ R A .M o r e -\\nover, the elemental mapping images of TR-ZRA showed the co-\\nlocalization of Zn, the characteristic element of nanoparticles,\\nin the elements (P and S) of RBCm, which also con\\ufb01rmed that\\nZRA was encapsulated by RBCm (Figure 2b). As shown in Fig-\\nure 2c, the sizes of the ZC, ZRA, RBCm, and TR-ZRA particles\\nmeasured by TEM were\\u224837.5, 60.1, 84.0, and 93.3 nm, respec-\\ntively. In addition, as shown in Figure 2d, the zeta potentials of\\nZCandZC-PEIwere \\u221214.9and13.6mV,respectively.Aftercoin-\\ncubationwiththecationicpolymerizerpolyethyleneimine(PEI),\\nZ Cc a r r i e dap o s i t i v ec h a r g eo ni t ss u r f a c e ,w i t hal a r g e rs i z e\\nand improved dispersion (Figure S1, Supporting Information).\\nThese results showed that the PEI modi\\ufb01cation of ZC caused a\\nslight in\\ufb02uence on the size, morphology, and potential of ZC,\\nwhichwereattributedtothecharacteristicofPEI. [27] Thedisper-\\nsionofZCwasalsoimprovedbecausethepositivechargesrepel\\neach other, and this behavior can be employed to achieve bind-\\ningofmorenucleicacidmoleculeswithnegativechargestoform\\nZRA.[28] TheTR,ZRA,andTR-ZRAparticleshadvaluesof \\u221210.2,\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(2of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure 1.Schematic illustration of TR-ZC/RNAi/AAPa)preparationand b) its regulation for AD therapy. After intravenous administration, TR-ZRA can\\nreachtheblood\\u2013brainbarrierandenterthebrainenvironment,andthenregulatetheexpressionofCD22inagingmicroglia,promotethephagocytosis\\nand degradation of A\\ud835\\udefd in microglia. CA inhibits complement activation and reduces neuroin\\ufb02ammation. AAP can monitor A\\ud835\\udefd plaque in vitro. TR-ZRA\\nimmunologicallyregulatesAlzheimer\\u2019sdiseaseindi\\ufb00erentways.\\n3.05, and\\u22124.0 mV, respectively(Figure 2d). It can be seen from\\nthezetapotentialchangesoftheparticlesthattheplasmidsand\\naptamers successfully combined with ZC, and TR was success-\\nfully attached to ZRA to synthesize TR-ZRA. In addition, a gel\\nelectrophoresis assay was adopted to evaluate the complexation\\nabilityofCD22shRNAandA \\ud835\\udefd aptamer.AsshowninFigure2e,\\nZC-AAPformationwaslimitedtotheinitialgumholewheneach\\nmicromoleofAAPcouldcombinewith0.27 \\u03bcgormoreZC(the\\nratiowas \\u22484:15).Inthesameway,therewasnofreeAAPorCD22\\nshRNA at the bottom of the gel when 1\\u03bcgC D 2 2s h R N Aw a s\\ncarried by 8\\u03bcg ZC-AAP (with a surface-mass ratio of 8:1) (Fig-\\nure 2f). These results con\\ufb01rmed that ZRA could be synthesized\\nstep by step with the above proportions for subsequent experi-\\nments.Moreover,asshownintheUV \\u2212visspectrum(FigureS2,\\nSupporting Information), TR-ZRA had absorption peaks at 280\\nand405nm,consistentwiththecharacteristicabsorptionpeaks\\nofRNAi,AAP,andTR,respectively.SDS \\u2012PAGE(FigureS3,Sup-\\nporting Information) showed that TR-ZRA possessed a protein\\npro\\ufb01lesimilartothatoftheerythrocytemembrane.DSPE-PEG-\\nTfR-A-FAM was employed to prove that the targeting molecule\\nTfR-Acouldvoluntarilyinsertintothesurfaceoftheerythrocyte\\nmembrane. As shown in Figure S4a, Supporting Information,\\ngreen\\ufb02uorescencewasapparentonthesurfaceoftheerythrocyte\\nmembrane,whichcon\\ufb01rmedinlayingofthetargetedprobeTfR-\\nA onto the surface of the erythrocyte membrane via lipid inser-\\ntion.AndinFigureS4b,SupportingInformation,itwasobserved\\nthatmostoftheerythrocytemembranewithgreen\\ufb02uorescence\\nwas co-located with RhB-nanoparticles. Therefore, the obtained\\nnanoparticlesmightexhibitthecharacteristicsofimmuneescape\\nandalongcirculationperiod,whichwouldincreasethechances\\nofpassagethroughtheBBB. [29]\\n2.2.BiocompatibilityoftheNanoparticles\\nThebiosafetyofnanoparticlesisvitalforfutureapplications.The\\ncytotoxicityofthenanoparticleswasevaluatedbyastandardCell\\nCounting Kit-8 (CCK8) assay. The nanoparticles were incubated\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(3of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure2. CharacterizationoftheNPs.a)TEMimageofZC,ZRA,RBCm,andTR-ZRA.Scalebar:100and200nm.b)Theelementalmappingimagesof\\nTR-ZRA,scalebar:100nm.c)SizeofNPsmeasuredbyTEM.d)ZetapotentialofNPsdetectedbyDLS.Theappropriateratioofe)ZCandAAPandf)\\nZC-AAPandRNAivalidatedbygelimageassay.Dataarerepresentedasthemean \\u00b1 SD(n= 3).\\nwith various types of cells, including mouse brain endothe-\\nlioma cells (bEnd.3), HT22 cells, and BV-2 cells. After 24 h of\\nincubation, all these cells retained>80% viability with di\\ufb00erent\\nnanoparticles at concentrations from 0 to 125\\u03bcgm L\\u22121 (Figure\\n3a\\u2013c).Inaddition,weincubatedRBCsfrommicewithdi\\ufb00erent\\nconcentrations of ZC and TR-ZC (0\\u2013250\\u03bcgm L\\u22121)f o r2ha t\\n37 \\u00b0C to evaluate the safety of the nanoparticles in the blood\\ncirculation. As shown in Figure 3d, no signi\\ufb01cant hemolysis\\n(less than 2%) was observed after incubation of ZC or TR-ZC\\nwith RBC suspension. In addition, when ZC was coated with\\nRBC membrane, the degree of hemolysis was further reduced,\\nindicating that the ZC nanoparticles had good biological safety,\\nand the erythrocyte membrane provided a further guarantee\\nof the function of the nanoparticles in the blood circulation.\\nNanodrugssafelyreachthetargetsiteandavoidbeingdegraded\\nby the immune system, which is one of the challenges for\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(4of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure3. BiocompabilityofNPs.a\\u2013c)CCK8assaytoevaluatethecellviabilityofvariousconcentrationsofNPstowardbEnd.3,HT22andBV2cellsfor\\n24hincubation.d)HemolysistestresultsofNPsafterincubationwith5%ofthemice\\u2019sRBCsuspensionfor2hat37 \\u00b0C.Thenormalsalinewasusedas\\nanegativecontrolandwaterwasusedasapositivecontrol.**** p< 0.0001determinedby t-tests.e)Representative\\ufb02uorescenceimageofRAW264.7\\nafter incubation with di\\ufb00erent nanoparticles for 6 h at 37\\u00b0C, scale bar: 50\\u03bcm. f) Quanti\\ufb01cation of mean \\ufb02uorescence intensity from (e). ***p < 0.001\\ndeterminedbyone-wayANOVAandTukeyposthoctests.Dataarerepresentedasmean \\u00b1 SD(n= 3).\\nthe e\\ufb00ective delivery of nanomedicines to the central nervous\\nsystem. We incubated mouse RAW 264.7 macrophages with\\nZC, ZC, and TR-ZC. As shown in Figure 3e,f, we found that\\nR-ZC and TR-ZC can evade phagocytosis by immune cells due\\nto camou\\ufb02aging by the erythrocyte membrane. It is possible\\nthat erythrocyte membrane proteins, such as CD47, mediated\\nthelong-termcirculationofthenanoparticlesintheexperiment\\nby interacting with phagocytic receptors to escape phagocytic\\ncells.[30,31] Therefore, more nanoparticles had the opportunity\\nto cross the BBB. In our system, CD22 shRNA, aptamers, and\\nRBCswereendogenousmaterials,andZCwasalsosafe,soTR-\\nZRA had little e\\ufb00ect on nerve cells, highlighting the advantages\\nof this system as a therapeutic agent for AD therapy. Therefore,\\nthe biocompatibility of these nanoparticles in vitro con\\ufb01rmed\\ntheirsuitabilityforadditionalinvitroandinvivoexperiments.\\n2.3.EstablishmentofBlood \\u2012BrainBarrierandPenetrationof\\nNanoparticlesInVitro\\nTheblood\\u2012brainbarrier(BBB)contributessubstantiallytomain-\\ntainingthestabilityoftheinternalenvironmentaroundthebrain\\ntissue and preventing harmful substances from entering the\\nbraintissue.Thetightjunctionsestablishedbetweenendothelial\\ncells limit the passage of many neurotherapeutic drugs across\\nthe BBB.[32] In addition, the size, lipid solubility, and other\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(5of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure 4.Establishment of blood\\u2012brain barrier and penetration of nanoparticles in vitro. a) The schematic illustration of BBB transwell model in vitro.\\nb) The CLSM \\ufb02uorescence images after building the BBB model for 24 h, which contained bEnd.3 (nucleus: blue, CD34: red) and astrocyte (nucleus:\\ngray,GFAP:green);scalebar:50 \\u03bcm.c)Theendo/lysosomalescapeofvariousNPswasassessedbyCLSMafter2and6hincubation,respectively;scale\\nbar:50 \\u03bcm.*P< 0.05determinedby t-test.d)Overlapcoe\\ufb03cientoflyso-tracker(green)andRhB-NPs(red)ofFigure3cat2and6hwasquanti\\ufb01edby\\nImageJsoftware.e)TherelativepermeabilityofvariousNPsafterincubationfor24hinBBBmodel.*** P<0.001determinedbyone-wayANOVAand\\nTukeyposthoctests.Dataarepresentedasthemean \\u00b1 SD(n= 3).\\nphysical and chemical properties of a drug also limit its ability\\nto cross the BBB. Therefore, we next explored whether these\\nsynthetic nanoparticles could cross the blood\\u2012brain barrier,\\nwhich was simulated with a Transwell model in vitro. bEnd.3\\nandastrocytecellswereseededintheupperandlowerchambers,\\nand BV2 was seeded in the bottom wells to simulate the BBB\\n(Figure4a).After12\\u201324hofinoculation,confocallaserscanning\\nmicroscopy (CLSM) was used to verify the construction of the\\nBBBmodelinvitro.AsshowninFigure4b,bEnd.3andastrocyte\\ncells were labeled with Cy 3 and FITC, respectively, and their\\ncon\\ufb02uence was 90% on both sides of the insert, which was\\nconsideredtoindicatesuccessfulBBBconstruction.\\nHow to allow medicines with therapeutic e\\ufb00ects within the\\ncentral nervous system to transfer across the blood\\u2012brain bar-\\nrier(BBB)remainsachallenge.Cerebralmicrovascularendothe-\\nlial cells are regarded as some of the most important parts of\\nthe blood\\u2012brain barrier, and they limit the \\ufb02ow of soluble sub-\\nstances and cells from the blood into the brain. The abundant\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(6of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nexpressionofTfRsonmostnervecellsmadeitpossiblefornano-\\nmaterials to cross the blood\\u2013brain barrier (Figure S5, Support-\\ningInformation).WiththehelpofTfRaptamer,alargenumber\\nof nanoparticles could be selectively transported into the brain\\nenvironmentviananoparticle-speci\\ufb01ctargetingmediatedbythe\\nTfR on bEnd.3 cells. Therefore, RhB-labeled nanoparticles were\\nincubatedwithbEnd.3cellsfor2and6h,andthelocalizationof\\nnanoparticles in the cells was observed by CLSM. As shown in\\nFigureS6,SupportingInformation,thecellularuptakeofTR-ZC\\nwas much greater than that of ZC and R-ZC, which also indi-\\ncated that TfR-A could enhance targeted cellular uptake. Mean-\\nwhile,asshowninFigure4c,after2hofincubationthered\\ufb02uo-\\nrescenceofRhB-nanoparticlesmainlycolocalizedwiththegreen\\n\\ufb02uorescenceofendo/lysosomesasyellowspotsinthesegroups.\\nHowever, after incubation for 6 h, most of the red signals sepa-\\nratedfromthegreensignalsintheTR-ZCgroup,indicatingthat\\nthe nanoparticles had escaped from lysosomes. In contrast, the\\nsignals in the ZC and R-ZC groups were still located in endo-\\nsomes/lysosomesafter6hofincubation.Theoverlapcoe\\ufb03cient\\nresults were shown in Figure 4d. These results indicated that\\nTfR aptamer-TfR-mediated trans endocytosis could be an e\\ufb00ec-\\ntivedrug-speci\\ufb01cdeliverypathwaythatfacilitatesendo/lysosome\\nescapeandmakesitpossibleformorenanoparticlestocrossthe\\nblood\\u2012brainbarrierandbetakenbymicroglialcells.\\nTherefore, after establishment of the BBB model, Cy5.5-\\nlabeled nanoparticles were added to the upper culture medium\\ntotesttheirpenetration.Speci\\ufb01cally,the\\ufb02uorescenceintensityof\\nequalquantitiesofdi\\ufb00erentnanoparticlesinthelowermedium\\nre\\ufb02ectstheirabilitytocrosstheblood \\u2012brainbarrierinvitro(Fig-\\nure S7, Supporting Information). As shown in Figure 4e, free\\nZC showed minimal intensity due to its lack of lipid solubility\\nand poor BBB penetration. Upon coating with RBCm, however,\\nthetransportofZCwasslightlyenhanced.Notably,thebestBBB\\npenetratione\\ufb03cacywasobservedforTR-ZRAduetothesurface\\nTfR aptamer modi\\ufb01cation that facilitated cell transportation via\\nbindingwithTfRonbEnd.3cells.ThepenetrationinTR-ZCwas\\nonlyslightlyenhanced,whichmaybeattributedtotheshorttotal\\nobservationtimeandthestationarysuperiorculturemediumin\\nthe in vitro blood\\u2013brain barrier model. Generally, these results\\nsuggested that TR-ZRA can escape from bEnd.3 cells and e\\ufb03-\\ncientlycrosstheblood \\u2012brainbarrier,enablingfurtherendocyto-\\nsisbyBV2cellsandregulationofmicroglialdysfunction.\\n2.4.AnticomplementActivityofNanoparticlesandA \\ud835\\udf37 Detection\\nbyA\\ud835\\udf37 Aptamer\\nThe complement system is a double-edged sword that is neuro-\\nprotective but can also be neurotoxic, depending on its starting\\ntarget and activation level.[33] It has been reported that the lev-\\nels of C1q, C3, C4, and other complement components in the\\nbrainsofratswithADarehigher,andthesecomponentslargely\\ncolocalize with A\\ud835\\udefd plaques in the brain, especially in the hip-\\npocampusandcortex,suggestingthatthesecomplementcompo-\\nnents may be related to neurodegeneration caused by neuroin-\\n\\ufb02ammation and synapse loss in the brain.[11] As designed, ZC\\nnotonlycanbeusedasadrugtransportcarrierbutalsohasan-\\nticomplementactivity.ThechlorogenicacidofZCboundtopro-\\nteins through hydrophobic interactions and hydrogen bonding\\nandplayedaroleininhibitingcomplementactivity. [34] Fifty per-\\ncenthemolyticinhibitionthroughtheclassicalpathway(CH50)\\nwas used to evaluate the anticomplement activities. Guinea pig\\nserum(complement)wasdilutedto1:10,1:20,1:40,1:80,1:160,\\nand 1:320 with PBS and added to the hemolysis system to eval-\\nuate titers. As shown inFigure 5a, the hemolysis rate was close\\nto 100% when the dilution of complement was 1:10\\u20131:20, and\\nthe system achieved complete hemolysis. Guinea pig serum di-\\nluted 1:20 was selected to ensure complete hemolysis and im-\\nprovethesensitivityofthesystem.AsshowninFigure5b,inthe\\nanticomplement assays, compared with the 1:20 diluted guinea\\npigserumgroupandthepositivecontrol,theZC,R-ZC,andTR-\\nZC groups all displayed much lower hemolysis capacities, with\\nvalues of 3.25%, 3.42%, and 2.99%, respectively. These results\\ndemonstrated that these treatments all possessed strong anti-\\ncomplementactivity,andtheircomplementinhibitionrateswere\\nupto96.4%,96.6%,and96.8%,respectively.Thisresultsigni\\ufb01ed\\nthattheredcellmembranecoatingonthesurfaceoftheZCdid\\nnota\\ufb00ecttheanticomplementactivitiesoftheZC.Moreover,the\\nanticomplementcharacteristicsofZCwereveri\\ufb01edinmicewith\\nAD. After nanodrug treatment for a month, Western blot (WB)\\nassay showed that the content of complement components (C3,\\nC4b,C1q)inthebraintissueofTR-ZRAtreatedgroupwasinhib-\\nited(Figure5candFigureS8,SupportingInformation).Besides,\\nasshowninFigure5d,eandFigureS9a,SupportingInformation,\\nthe red \\ufb02uorescence representing the level of complement C1q\\naroundastrocytes(red\\ufb02uorescence)wassigni\\ufb01cantlyreducedin\\nthe TR-ZRA group but not in the ZC and ZRA groups. In addi-\\ntion, compared with that in the AD group, the \\ufb02uorescence in-\\ntensity of C3 and C4 was decreased in the TR-ZRA group but\\nthe complement components of other experimental groups re-\\nmainedactivatedinthebrain,whichalsore\\ufb02ectedtheinhibition\\nof complement activity to a certain extent (Figure S9b, Support-\\ningInformation).Moreover,GFAP,theindicatorofactivatedas-\\ntrocytes, was also reduced, which indicated that the in\\ufb02amma-\\ntioninbrainwasrelievedtosomeextent(FigureS9c,Supporting\\nInformation). These results were slightly inconsistent with the\\nin vitro results, which may be because TR-ZRA, which reached\\nthebrainmoreabundantlyundertheactionoftargetingfactors,\\nfully reduced complement activity. In short, these experimental\\nresults indicated that the chlorogenic acid in the nanoparticles\\ncan inhibit the overactivation of complement in the brain envi-\\nronmentandprotectthenervoussystem.\\nNucleic acid aptamers, which are oligonucleotides that have\\nhigh a\\ufb03nities and speci\\ufb01cities for their targets because of their\\nsimilarities as receptors, have received much attention.[35] It is\\ngenerally believed that these aptamers form secondary/tertiary\\nstructuresthatprovidebindingopportunitiesfortheirtargets. [36]\\nIn our design, the aptamer was folded into a secondary hairpin\\nstructure. In the absence of A\\ud835\\udefd1-42, \\ufb02uorescence was quenched\\nwhen the FAM group labeling the 3\\u2032 end was close to the BHQ\\ngrouplabelingthe5 \\u2032 end.TheaptamercouldbindtoA \\ud835\\udefd1-42 when\\nA\\ud835\\udefd1-42 was present. FAM and BHQ then moved far away from\\neachother,andthegreen\\ufb02uorescencewasrestored( Figure 6a).\\nAs shown in Figure 6b, after optimizing the experimental con-\\nditions, the relationship between the \\ufb02uorescence intensity of\\nAAP and the concentration of A\\ud835\\udefd1-42 was analyzed. The results\\nshowed that the \\ufb02uorescence signal of AAP increased gradually\\nwith increasing A\\ud835\\udefd1-42 concentration, which indicated that AAP\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(7of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure 5.Anticomplement activity of NPs. a) The complement titer assessment of guinea pig serum by complement hemolytic assay in vitro. b) The\\nhemolysis capacity of NPs after incubation with the guinea pig serum, the hemolysin, and the 2% SRBC at 37\\u00b0C for 30 min. PC: positive control; Cp:\\ncomplement. c) Main complement C3, C4b, C1q expression in brain tissue evaluated by Western blot assay after di\\ufb00erent treatments in WT and AD\\nmice. CLSM images of d) GFAP and C1q and e) C3 and C4b in brain sections after treatment of NPs in WT and AD mice; scale bar: 50\\u03bcm. ****p <\\n0.0001determinedbyone-wayANOVAandTukeyposthoctests.Dataarerepresentedasthemean \\u00b1 SD(n= 3).\\ncan indicate the A\\ud835\\udefd1-42 concentration in vitro under certain con-\\nditions (Figure S10a, Supporting Information). In addition, the\\nsameconcentrationsofA \\ud835\\udefd1-42 andBSAwereincubatedwithdif-\\nferentconcentrationsofAAP(0\\u2013160 \\u03bcgmL\\u22121)for2hat37 \\u00b0C to\\nexplore the reactivity of AAP (Figure 6c). Meanwhile, as shown\\nintheFigureS10b,SupportingInformation,di\\ufb00erentA \\ud835\\udefd aggre-\\ngates (A\\ud835\\udefd1-42,A \\ud835\\udefd1-40,A \\ud835\\udefd1-20) were respectively co-incubated with\\naptamersat37 \\u00b0Cfor2h.The\\ufb02uorescenceintensitydetectedin\\nA\\ud835\\udefd1-42 group was signi\\ufb01cantly higher than that in the other two\\ngroups, indicating that the designed \\ufb02uorescence aptamers had\\nstrongspeci\\ufb01cityandcouldbindtotheproteinsequenceofA \\ud835\\udefd1-42\\nfor \\ufb02uorescence recovery. As shown in Figure S10c, Supporting\\nInformation,the\\ufb02uorescenceintensityofAAPwasbothstablein\\ntheTBEand10%FBS,whichshowedthatthe\\ufb02uorescenceinten-\\nsitychangedlittlewithin24h.AAPcouldalsobeusedtomonitor\\nA\\ud835\\udefd plaquesinbrainslicesinvitro.Weincubated10 \\u03bcmAAPwith\\nbrainsectionsfor2hat37 \\u00b0C andthenobservedthelocalization\\nofA\\ud835\\udefd onthebrainsectionsundera\\ufb02uorescencemicroscope.As\\nshowninFigure6d,AAPcouldspeci\\ufb01callybindtoA \\ud835\\udefd plaquesin\\nbrainslicesfromAPP/PS1miceandemitspeci\\ufb01cgreen\\ufb02uores-\\ncence.Besides,the\\ufb02uorescenceimageofAAPinthemicebrain\\nof TR-ZRA group was observed directly, which showed a little\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(8of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure6. A\\ud835\\udefd detectionbyA \\ud835\\udefd aptamer.a)SchematicdiagramofA \\ud835\\udefd aptamerdesignedtodetectA \\ud835\\udefd1-42.b)The\\ufb02uorescenceintensitychangeofAAPafter\\nincubationwithdi\\ufb00erentconcentrationsofA \\ud835\\udefd1-42 at37 \\u00b0Cfor2h.c)The\\ufb02uorescenceintensityofAAPafterincubatingwithdi\\ufb00erentconcentrationsof\\nA\\ud835\\udefd1-42,withBSArespectivelyat37 \\u00b0Cfor2h,BSAwasasnegativecontrol.d)Representative\\ufb02uorescenceimagesofthebrainsliceincubatingwithAAP\\nat37 \\u00b0Cfor2h;scalebar = 50\\u03bcm.** p<0.01,and*** p< 0.001,****p< 0.0001determinedby t-test.Dataarepresentedasmean \\u00b1 SD(n= 3).\\nobvious green signal compared with AD-PBS group (Figure\\nS10d, Supporting Information). Thus, these results indicated\\nthatthisassaypossessestheadvantagesofbeingeconomicaland\\nconvenient and provides a new approach for monitoring A\\ud835\\udefd in\\nbraintissueinvitro.\\n2.5.CD22DownregulationinMicrogliaandDegradationof\\nIn\\ufb02ammatoryFactors\\nAfter simulating the BBB transport of the nanoparticles, we de-\\nsigned mCherry\\u2212CD22shRNA to reduce CD22 expression in BV2\\ncell. We chose the commercial reagent Lipo8000 as the control.\\nAs can be seen fromFigure 7a and Figure S11, Supporting In-\\nformation, the transfection e\\ufb03ciency of TR-ZRA was more ex-\\ncellent in BV2 and the mean \\ufb02uorescence intensity of the TR-\\nZRA group was\\u22481.56 times that of the ZRA group, which may\\nbe due to the action of targeting factors and erythrocytes mem-\\nbrane. There was no signi\\ufb01cant di\\ufb00erence in plasmid delivery\\nin normal and aging microglia (Figure S12, Supporting Infor-\\nmation). Next, qRT-PCR and Western blotting were employed\\nto detect the expression of CD22 to determine the silencing ef-\\n\\ufb01cacy of the nanoparticles. After treatment with A\\ud835\\udefd1-42, the ex-\\npressionofCD22inBV2cellswaselevated.Comparedwithother\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(9of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure7. CD22down-regulation.a)Representative\\ufb02uorescenceimagesofBV2cellsafterincubationwithmCherrylabeledRNAi +lipo,ZRAorTR-ZRA\\nat37 \\u00b0Cfor24h;scalebar:50 \\u03bcm.b)TheCD22mRNAlevelsinBV2werequanti\\ufb01edbyqRT-PCRafterdi\\ufb00erenttreatments.PBSgroupwasascontrol.c)\\nCD22expressioninBV2cellevaluatedbyWesternblotassayafterdi\\ufb00erenttreatmentsfor48hat37 \\u00b0Candd)quanti\\ufb01cationresultsofCD22expression\\ninBV2. e)Westernblotandf)quanti\\ufb01edresultsofCD22inthebraintissueofWTandADmicewithdi\\ufb00erenttreatments.AD-PBSgroupwasascontrol.\\ng)Representative\\ufb02uorescenceimagesshowingtheexpressionofCD22inbraintissue(IBAl:redandCD22:green;scalebar:50 \\u03bcm).* p<0.05,** p<\\n0.01,*** p<0.001,****p<0.0001determinedbyone-wayANOVAandTukeyposthoctests.Dataarepresentedasmean \\u00b1 SD(n= 3).\\ngroups, TR-ZRA groups showed signi\\ufb01cant inhibition of CD22,\\nindicating regulatory activity of delivered CD22shRNA. Among\\nthem, TR-ZRA combined with targeting factors and erythrocyte\\nmembrane achieved higher delivery e\\ufb03ciency and thus had the\\nstrongestinhibitorye\\ufb00ectonmRNA( Figure 7b)andproteinex-\\npression of CD22 in BV2 cells (Figure 7c,d). CD22 silencing by\\nthenanoparticleswasalsodemonstratedinmice.After1month\\nof treatment, the brain tissue of mice was employed for WB\\nand immuno\\ufb02uorescence assays. The WB results showed that\\nthe expression of CD22 in the AD-TR-ZRA group was signi\\ufb01-\\ncantly lower than that in the AD group, indicating that CD22\\nshRNA loaded with ZC e\\ufb00ectively inhibited gene expression\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(10of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure8. Degradationofin\\ufb02ammatorycytokine.a)IL-1 \\ud835\\udefd,TNF-\\ud835\\udefc,andIL-6expressioninBV2evaluatedbyWesternblotassayafterdi\\ufb00erenttreatments\\nfor 48 h at 37\\u00b0C and b) quanti\\ufb01cation of in\\ufb02ammatory cytokine expression. c) Representative immuno\\ufb02uorescence images of in\\ufb02ammatory cytokines\\n(IL-1\\ud835\\udefd,T N F -\\ud835\\udefc, IL-6) expressed in WT and AD mice brain tissue; scale bar: 50\\u03bcm. ***p < 0.001 determined by one-way ANOVA and Tukey post hoc\\ntests.Dataarepresentedasmean \\u00b1 SD(n= 3).\\n(Figure 7e,f). In addition, as observed in the immuno\\ufb02uores-\\ncenceassay,CD22expression(green)wassigni\\ufb01cantlydownreg-\\nulated in IBA1-labeled microglia (red) after TR-ZRA treatment\\n(Figure 7g). These results all demonstrated the higher silencing\\ne\\ufb03ciency of TR-ZRA, which can probably be attributed to TfR-\\nA\\u2019s targetability and e\\ufb03cient transport of ZC. What\\u2019s more, the\\nactivity of HT22 cells incubating with TR-ZRA was investigated\\nbyLive/deadstaining.AsshowninFigureS13,SupportingInfor-\\nmation,therewasnosigni\\ufb01cantdi\\ufb00erenceinthe\\ufb02uorescencein-\\ntensityofdeadcellsbetweenthePBSandTR-ZRAgroups.These\\nresultsindicatethatCD22silencingdoesnota\\ufb00ectneuronalac-\\ntivityTheseresultsindicatethatCD22silencingcouldnota\\ufb00ect\\nneuronalactivity.\\nMoreover, A\\ud835\\udefd1-42 can continuously stimulate microglial toxic-\\nityunderthepathologicalconditionofAD,resultinginthedeath\\nof microglia and increased levels of proin\\ufb02ammatory cytokines,\\nsuchasIL-1 \\ud835\\udefd,IL-6,andTNF- \\ud835\\udefc,inthebrain.Theseproin\\ufb02amma-\\ntoryfactorsinturntriggerandexacerbateA \\ud835\\udefd aggregation,form-\\ningaviciouscycleduringthepathologicalprocessandultimately\\nexacerbating AD.[37,38] Therefore, the levels of proin\\ufb02ammatory\\ncytokines in BV2 cells were evaluated by Western blotting. As\\nshown inFigure 8a,b, we proved that the levels of IL-1\\ud835\\udefd,T N F -\\n\\ud835\\udefc,andIL-6wereobviouslyincreasedwhenBV2cellswerecocul-\\ntured with A\\ud835\\udefd1-42 or the commercial transfection reagent Lipo,\\nwhich might be associated with the toxicity caused by A\\ud835\\udefd1-42 or\\nLipo. The levels of these proin\\ufb02ammatory cytokines remained\\nrelatively high after ZC treatment alone, which might be due to\\nthecorrelationbetweencellularuptakeofthedrugandthelevel\\nofintracellulargeneexpressioninagingBV2cells.Nevertheless,\\nthelevelsoftheseproin\\ufb02ammatorycytokinesweredecreasedin\\ntheZRA-andTR-ZRA-treatedgroups,whichmightberelatedto\\ntheCD22levelinBV2cells. [39] Inparticular,decreasedCD22lev-\\nels could facilitate microglial status and promote phagocytosis\\nof A\\ud835\\udefd, which would further reduce in\\ufb02ammation levels. In ad-\\ndition,animmuno\\ufb02uorescenceassaywasadoptedtodetecttyp-\\nical proin\\ufb02ammatory factors, including IL-1\\ud835\\udefd,T N F -\\ud835\\udefc, and IL-6\\n(green), in the cortex and hippocampus (Figure 8c and Figure\\nS14, Supporting Information). The results showed that the lev-\\nelsofthesecytokinesweresigni\\ufb01cantlyreduced,con\\ufb01rmingthe\\nanti-in\\ufb02ammatoryactivityoftheTR-ZRAnanosystem.Neuroin-\\n\\ufb02ammation is mediated not only by the activation of glial cells\\n(suchasmicroglia)andtheproductionofcytokines,chemokines,\\nand ROS but also by the complement system. A\\ud835\\udefd activates the\\nNF-\\ud835\\udf05B pathway, leading to increased release of C3, which can\\nbind to C3aR on neurons and microglia, activate microglia, and\\ninduce the release of proin\\ufb02ammatory cytokines.[40] C1q bind-\\ning to A\\ud835\\udefd and tau proteins in the AD brain can also cause com-\\nplementactivation,whichleadstoneuroin\\ufb02ammationandneu-\\nrodegeneration in AD patients.[41,42] Thus, complement levels\\nmaydecrease,andtheassociatedneuroin\\ufb02ammationmayalsobe\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(11of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nrelievedafterTR-ZRAtreatment.Hence,thein\\ufb02ammatoryenvi-\\nronmentintheADbrainwasalleviatedafterTR-ZRAtreatment.\\n2.6.A\\ud835\\udf37 DegradationandIncreasedNeuronalActivity\\nMicroglia, a crucial line of immune defense in the central ner-\\nvous system, play an important role in maintaining immune\\nhomeostasis in the brain. In the AD brain, activated microglia\\nhave an impaired ability to phagocytose A\\ud835\\udefd, resulting in A\\ud835\\udefd ac-\\ncumulation and further intensifying brain in\\ufb02ammation.[43,44]\\nTherefore,A\\ud835\\udefd degradationinBV-2cellsiscrucialtoimprovethe\\nAD environment. To simulate the AD environment, BV2 cells\\nwere incubated with A\\ud835\\udefd1-42 for 12 h to induce an in\\ufb02ammatory\\nstate.Toinvestigatethee\\ufb00ectofnanoparticlesonthephagocyto-\\nsisofA \\ud835\\udefd byBV2cells,FITC-A \\ud835\\udefd1-42 wasco-incubatedwithproin-\\n\\ufb02ammatorymicroglialcellsintheabsenceorpresenceofdi\\ufb00er-\\nent preparations, including ZC, ZRA, and TR-ZRA. After 6 h,\\ncolocalizationoftheFITC-A \\ud835\\udefd1-42 oligomerwithendo/lysosomes\\nwasobservedbyCLSM.Endo/lysosomesarethemainorganelles\\nof A\\ud835\\udefd degradation in microglia. As shown inFigure 9aa n d\\nFigure S15, Supporting Information, FITC-A\\ud835\\udefd1-42 oligomer and\\nendo/lysosomeweremostlycolocalizedasyellowspotsintheTR-\\nZRA group, indicating that the phagocytosis of A\\ud835\\udefd1-42 by BV2\\ncells was enhanced in the presence of CD22 shRNA, while ZC\\nalonedidnotsigni\\ufb01cantlyimprovethephagocytosise\\ufb00ect,which\\nwas consistent with the hypothesis that the inhibition of CD22\\nin microglia promotes the elimination of A\\ud835\\udefd by microglia. A\\nconsistent trend was observed in the brain tissue of AD mice.\\nTo observe the capture and degradation of A\\ud835\\udefd by microglia in\\nvivo, microglia and A\\ud835\\udefd labeled with an anti-IBA1 antibody and\\nanti-A\\ud835\\udefd antibody, respectively, were analyzed by immuno\\ufb02uo-\\nrescence.ComparedwithobservationsinWTmice,aggregation\\nof the A\\ud835\\udefd green \\ufb02uorescence signal was obviously observed in\\nAD mice suggesting microglial dysfunction of A\\ud835\\udefd phagocytosis\\nin AD mice (Figure 9b and Figure S16a, Supporting Informa-\\ntion). In addition, in ZC- and ZRA-treated AD mice, a mass of\\nA\\ud835\\udefd plaquesandactivatedmicrogliawerebothobserved,indicat-\\ningthatthesenanoparticlescouldnotreachthebraine\\ufb03ciently\\nenough to encourage microglia to phagocytose A\\ud835\\udefd. However, in\\nthe TR-ZRA groups, only a few A\\ud835\\udefd plaques were observed, and\\nthe area of activated microglia decreased in the brain (Figure\\nS16b,c, Supporting Information). These phenomena suggested\\nthataftertreatmentwithnanoparticles,theexpressionofCD22in\\nmicrogliawasdownregulated,whichcouldenhancethedysfunc-\\ntionofhealthymicroglia,alleviateactivatedmicroglialin\\ufb01ltration\\nandpromotephagocytosisofA \\ud835\\udefd inthebraintissueofADmice.\\nInconclusion,TR-ZRA,comparedwiththeothertreatments,sig-\\nni\\ufb01cantly ameliorated A\\ud835\\udefd clearance and microglial dysfunction\\ninthebraintissue.\\nIt is generally considered that aggregated A\\ud835\\udefd1-42 can lead to\\ncytotoxicity.[45] It has been proven that TR-ZRA can downregu-\\nlate CD22 in microglia, which could improve the ability of BV2\\ncellstophagocytoseA \\ud835\\udefd andreducethetoxicityofA \\ud835\\udefd toneurons.\\nWe performed live/dead staining to investigate the e\\ufb00ect of the\\nnanoparticlesonA \\ud835\\udefd-inducedcytotoxicity.BV2cellsweretreated\\nwith A\\ud835\\udefd 1-42 in the absence or presence of nanoparticles. After\\n24\\u201348 h, the culture medium of BV2 cells was removed and in-\\ncubatedwithHT22cellsfor24htoevaluatecellactivity.Asshown\\ninFigure9candFigureS17,SupportingInformation,therewere\\nanumberofdeadcellsafterincubationwithA \\ud835\\udefd1-42 alonefor24h.\\nInaddition,freeZCorCD22shRNAhadlittlee\\ufb00ectduetotheir\\npoor cellular uptake and A\\ud835\\udefd clearance. Nevertheless, the num-\\nberofdeadcellsdecreasedsigni\\ufb01cantlyaftertreatmentwithTR-\\nZRA medium, which means that the cells\\u2019 functions had been\\nimproved. This indicated that the TR-ZRA nanoparticles could\\nreduce A\\ud835\\udefd-induced cytotoxicity and promote cell proliferation.\\nSimilarly,bothHEstainingandNisslstainingshowedimprove-\\nments in neuron health after TR-ZRA treatment. As shown in\\nFigure 9d, the nucleoli became clearer, the cells were arranged\\nneatly, and the intracellular Nissl bodies were more abundant,\\nindicatingthattheneuronswererepairede\\ufb00ectively.\\n2.7.Biodistribution,MagneticResonanceImaging,and\\nImprovedMemoryCapabilityInVivo\\nTo evaluate the therapeutic e\\ufb00ect of the nanoparticles in vivo,\\n6-month-old APP/PS1 mice were intravenously injected every 5\\ndays for a month (Figure 10a). To observe the distribution of\\nnanoparticlesinvivo,weinjectedCy5.5-labelednanoparticlesin-\\ntravenously into mice. As expected, after intravenous adminis-\\ntration,\\ufb02uorescenceimagesshowedthatTR-ZRAgroupshowed\\na strong \\ufb02uorescence signal in the brain tissue in vivo 72 h af-\\nter injection (Figure 10b). Besides, we observed the circulation\\nof RhB labeled nanoparticles in mice. As shown in the Figure\\nS18, Supporting Information, free ZC was rapidly cleared from\\nthe mouse after injection through the tail vein with a brief half-\\nlife. In contrast, for R-ZC, a signi\\ufb01cant increase in half-life was\\nobserved. It should also be noted that the amount of nanopar-\\nticles in the TR-ZC group also showed a rapid decrease in the\\namount of circulating in vivo with the shorter half-life, but the\\namount in vivo was still relatively higher than that of free ZC.\\nThis result may be related to the loading of targeted factors on\\nthenanoparticlesaftercoating,whichmademostofthenanopar-\\nticles concentrate in the brain. This is mainly attributed to the\\nTfR-A aptamer and erythrocyte membrane modi\\ufb01cation on the\\nnanoparticles, which helped TR-ZRA target endothelial cells in\\nthemousebrainandprolongthecirculationinvivo,respectively.\\n72hafterinjection,thesemiceweresacri\\ufb01cedbythecervicaldis-\\nlocation method. Their brain, heart, liver, spleen, lung, and kid-\\nneytissueswerecollectedfor\\ufb02uorescenceimaginginvitro,and\\nthe results were consistent with the previous results. As shown\\nin Figure 10c, the ZC and ZRA groups showed a small amount\\nofaggregationinthebrain,liver,andkidney,whiletheaccumu-\\nlationofTR-ZRAinthebrainwassigni\\ufb01cantlyhigherthanthat\\nintheothergroups.ComparedtoZCandZRA,TR-ZRAshowed\\n2.0/1.24-fold-enhancedCy5.5signalsrespectively72hafterinjec-\\ntion,indicatingastrongerabilitytotargetandpenetratetheBBB\\n(Figure 10d). These results indicated that TR-ZRA had a great\\ntargetinge\\ufb00ecttobraintissueinvivo.\\nMagnetic resonance imaging (MRI) can clearly display\\nanatomicalstructureswithhighresolution,distinguishgraymat-\\nterfromwhitematter,andmeasuretheareaandvolumeofhip-\\npocampalstructuresinthebrain,whichmeansthatMRIstudies\\nhavebeenimportantfortheclinicalidenti\\ufb01cationofAD.Aftera\\nmonthoftreatment,thebrainsofWTandADmicewereimaged\\nby MRI. As shown in Figure 10e,f, a reduction in hippocampal\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(12of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure9. A\\ud835\\udefd degradationandincreasedneuronalactivity.a)ColocalizationofFITC-A \\ud835\\udefd1\\u221242 andlysosomesinBV2afterincubationwithdi\\ufb00erentprepa-\\nrations for 6 h. BV2 treated with FITC-A\\ud835\\udefd1\\u221242 alone were used as a control. (Scale bar: 100\\u03bcm). b) Representative \\ufb02uorescence images and enlarged\\nvision images showing the location of microglia and A\\ud835\\udefd plaque in brain tissue slice.(IBA1: red and A\\ud835\\udefd: green); scale bar: 100 and 50\\u03bcm).c) Live/dead\\nstaining \\ufb02uorescence images of HT22 cells after incubating with BV2 cells culture medium (after incubation with di\\ufb00erent preparations for 24 h) for\\n24h;scalebar:100 \\u03bcm.d)RepresentativeimagesofHEstainingandNisslstainingofWTandADmiceafterthedi\\ufb00erenttreatments;scalebar:100 \\u03bcm.\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(13of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(14of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nregion volume was observed in AD mice (17.985 mm3) relative\\nto healthy WT mice (21.8 mm3), which was consistent with\\nprevious reports.[46,47] However, after TR-ZRA treatment for a\\nmonth,therewasaslightupwardtrendinhippocampalvolume\\n(18.29 mm3), which might also be related to the amount of\\ndrug reaching the brain and the duration of treatment. This\\ndemonstratedthattherapeuticcomponents,suchaschlorogenic\\nacid and RNAi, have the potential to protect neurons, alleviate\\nneuroin\\ufb02ammationandremovemoreA \\ud835\\udefd.\\nOn the other hand, the Morris water maze (MWM) experi-\\nment is an experiment in which mice are forced to swim and\\nlearn to \\ufb01nd hidden platforms in the water. It is mainly used to\\ntest experimental animals\\u2019 learning and memory ability in the\\ncontext of sensing spatial position and direction. Therefore, the\\nMWM experiment was employed to compare the spatial learn-\\ning and memory abilities of the mice after a month of treat-\\nment.AsshowninFigure10g,thetypicalswimmingtrackroute\\nandthenumberoftargetplatformpassesineachgroupofmice\\nwere recorded. On the test day, the platform was removed, and\\nAD mice treated with PBS had severe memory de\\ufb01cits and dis-\\nplayed no signi\\ufb01cant improvement after 5 days of spatial learn-\\ning (Figure S19, Supporting Information). However, AD mice\\ntreated with TR-ZRA displayed substantially shorter escape la-\\ntenciestotarget,witha58.7%decreasecomparedwiththePBS-\\ntreatedgroup(Figure10h).Inaddition,comparedwiththeother\\ngroups,theTR-ZRAgroupcrossedtheplatformmoretimes(1.7\\ntimes)andspentmoretime(22.1%)inthetargetquadrant(Fig-\\nure10i,j).ThesebehavioralexperimentalresultsindicatethatTR-\\nZRAcouldalleviatememoryimpairmentinADmicetoacertain\\nextent. Moreover, when all treatments were \\ufb01nished, the major\\norgans of the mice were analyzed by HE staining (Figure S20,\\nSupporting Information). The nanoparticles did not cause any\\npathologic changes in the major organs in these mice, indicat-\\ning clear biocompatibility in vivo after 4 weeks of treatment via\\nintravenousinjection.\\n3.Conclusion\\nIn conclusion, the BBB-penetrating nanodrug system described\\nhere regulates the brain immune microenvironment in AD by\\nenhancing microglial phagocytosis and inhibiting complement\\nactivation. It was found that TR-ZRA is a nanoscale agent and\\nhas satisfactory biosafety for cells, the blood\\u2012brain barrier, and\\nvarious tissues and organs in in vivo and in vitro experiments.\\nThechlorogenicacidcarriedbythenanosystemwascon\\ufb01rmedto\\nhavetheabilitytomodulatecomplementlevelsinthebrainenvi-\\nronmentinAD,whichwasimportantforalleviatingimmunein-\\n\\ufb02ammatorydamage.Inaddition,TR-ZRAregulatesCD22levels\\nin cells by delivering CD22 shRNA, which promotes microglial\\nphagocytosisofA \\ud835\\udefd,reducestheA \\ud835\\udefd burdenincellsandADmice,\\ninhibits microglial neuroin\\ufb02ammation, and facilitates memory\\ncapacity in AD mice. Thus, chlorogenic acid has synergistic ef-\\nfects with CD22 shRNA in regulating the immune microenvi-\\nronment in the brain. In addition, the A\\ud835\\udefd aptamer contained in\\nTR-ZRAwas shown tobeappropriate forin vitromonitoringof\\nA\\ud835\\udefd,whichalsoprovidesanewwaytoobserveA \\ud835\\udefd plaquesinthe\\nbrain.TheseresultssuggestedthatTR-ZRAhasabroadmodula-\\ntory e\\ufb00ect, and thus, this nanodelivery system o\\ufb00ers new possi-\\nbilitiesforthetreatmentofbrainagingandotherneurodegener-\\nativediseases,includingbutnotlimitedtoAD.\\n4.ExperimentalSection\\nMaterials: Chlorogenicacid(327-97-9)andZnNO3(10196-18-6)were\\npurchased from Aladdin (Shanghai, China). DSPE-PEG2000-NH2 (R-\\n0038) was obtained from Xi\\u2019an Ruixi Biological Technology (China). Cell\\nCounting Kit-8 (CCK8) (K1018) was purchased from Apexbio (China).\\nDAPI (C0060), Hoechst 33342 (C0031), RIPA lysis bu\\ufb00er (R0010), sheep\\nerythrocytehemolysin(H8360),4%sheepredbloodcell(SRBC)(S9045),\\nguinea pig serum (complement) (S4990), and Albumin Bovine V(A8020)\\nwere purchasedfromSolarbioLifeScience(China).TheCalcein/PIAssay\\nKit (C2015S) and Lyso-Tracker Red (C1046)/green (C1047S) \\ufb02uorescent\\nprobe were purchased from Beyotime Biotechnology (China). A\\ud835\\udefd1-42 and\\nFITC-A\\ud835\\udefd1-42 wereobtainedfromQYAOBIO(Shanghai,China).Dulbecco\\u2019s\\nmodi\\ufb01ed Eagle\\u2019s medium (DMEM), RPMI-1640, and fetal bovine serum\\n(FBS) were obtained from Procell (China). The cell culture chamber was\\npurchased from Corning Incorporated (ME, USA). TfR aptamer (TfR-A),\\nA\\ud835\\udefd aptamer(AAP),andCD22shRNAplasmid(RNAi)weresynthesizedby\\nGenechemCo.,Ltd.Biotech(Shanghai,China).\\nTheirsequencesareasfollows:\\nTfR-A\\naptamer\\n5\\u2033-CGTAAATCAGTCAGAAGGCGTGGTACCACGCGCT/\\niFAMdT/TC-3\\u2033\\nA\\ud835\\udefd aptamer 5 \\u2032 6-FAM1-TGGGGGGCGGACGATAGGGGCCCCCCGGTA-\\nGGATGGAC\\nG-3\\u2032 BHQ1\\nCD22\\nshRNA-a\\n5\\u2032-CCCGGGCAACAAACTACACCTGGTATCTCGAGATACC-\\nAGGTGTAGT\\nTTGTTGCTTTTTG-3\\u2032\\nCD22\\nshRNA-b\\n5\\u2032-AATTCAAAAAGCAACAAACTACACCTGGTATCTCGAGA-\\nTACCAGG\\nTGTAGTTTGTTGC-3\\u2032\\nCell Culture: bEnd.3 and HT22 cells were purchased from the Ad-\\nvancedResearchCenter,CentralSouthUniversity;BV2cellswereobtained\\nfrom Procell (Wuhan, China). bEnd.3 cells were cultured in RPMI-1640\\nmediumsupplementedwith10%fetalbovineserum.HT22andBV2cells\\nwereculturedinDMEMcontaining10%fetalbovineserum(FBS)and1%\\nantibiotics(penicillin/streptomycin)at37 \\u00b0Cina5%CO 2 environment.\\nPreparation of TR-ZRA: First, fresh whole blood from mice was cen-\\ntrifuged at 3000 rpm for 10 min to gather the red blood cells. Cold\\nPBS (0.25\\u00d7) was added to lyse the erythrocytes and release hemoglobin.\\nThe cells were then repeatedly centrifuged \\ufb01ve to six times at 5000\\u00d7 g\\nfor 10 min to collect the erythrocyte membrane precipitate. Then, PBS\\n(1.0\\u00d7) was added for resuspension, followed by water bath sonication\\nfor 5 min. Finally, nanoscale erythrocyte membrane vesicles were ex-\\ntracted repeatedly with a syringe \\ufb01lter with a pore size of 0.45\\u03bcm.[48]\\nFigure 10. Biodistribution, magnetic resonance imaging, and improved memory capability in vivo. a) The schedule of treatment in mice. b) In vivo\\nimagingofCy5.5labelednanoparticlesinAPP/PS1ADmice.c)Exvivoimagingofmainorgans(heart,liver,spleen,lung,kidney,andbrain)within72h\\nafterinjectionofdi\\ufb00erentnanoparticles.d)Thequantitative\\ufb02uorescenceintensityinthebrain( n= 3).e)RepresentativeMRIimagesandf)hippocampal\\nregion volume of every group of mice (n = 3). g) Representative swimming trajectories of mice in MWM. h) The time of latency to target platform on\\nthetestdayinMWM,i)thetimesofcrossingovertheplatform,andj)thepercentageoftimeinthetargetedquadrantofdi\\ufb00erentgroups( n= 6).*p<\\n0.05,**p<0.01,*** p<0.001determinedbyone-wayANOVAandTukeyposthoctests.Dataarepresentedasmean \\u00b1 SD.\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(15of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nTfR-A (10 \\u03bcg), DSPE-PEG2000-NH 2 (10 mg), 1-ethyl-3-(3\\u2032-dimethyl\\naminopropyl)-carbodiimide (EDC, 2.8 mg), and N-hydroxysuccinimide\\n(NHS,1.7mg)weredissolvedindeionizedwater(5mL)andstirredat37\\n\\u00b0Cfor6h.ThecarboxylgroupinTfR-AcouldbeactivatedbyEDCandNHS\\ntoformanamidebondwithDSPE-PEG2000-NH 2.Then,DSPE-PEG2000-\\nNH2-TfR-A (0.1 mL) and erythrocyte membrane vesicles (0.9 mL) were\\nblended at 37\\u00b0C for 6 h. TR was acquired by high-speed centrifugation\\nto eliminate dissociated molecules. Second, chlorogenic acid (0.8 g) and\\nZnNO3 (0.1 g) were dissolved in 5 mL of double-distilled water. Chloro-\\ngenic acid was added dropwise into the ZnNO3 and stirred magneti-\\ncally until the solution became milky white. The solution was then cen-\\ntrifuged, washed three times with double-distilled water, and lyophilized\\ninto a powder with a vacuum freeze dryer for subsequent application.\\nThird, ZC was resuspended in ultra-pure water and treated with ultra-\\nsound for 10 min. The PEI polymer was then added to the nanoparticle\\nsolution and magnetically stirred overnight at room temperature to ob-\\ntain ZC-PEI nanoparticles, which were recovered by centrifugation (5000\\n\\u00d7 g, centrifugation at 25\\u00b0C for 20 min) and cleaned multiple times with\\nultra-pure water to remove the unlinked PEI.[49] CD22 shRNA and AAP\\nwere mixed with ZC-PEI at di\\ufb00erent ratios, and the \\ufb01nal volume of each\\nsolutionwas20 \\u03bcL.Thesolutionswereincubatedatroomtemperaturefor\\n30min.Agarosegelelectrophoresiswasperformedat120Vfor20minto\\nobserve the binding ability at di\\ufb00erent ratios of gene vector to plasmid.\\nFinally,ZC/RNAi/AAP(ZRA)wasconstructedaccordingtotheoptimalra-\\ntio. TR was ultrasonicated (42 kHz, 100 W) for 2 min with ZC/RNAi/AAP\\nmixturetoformTR-ZC/RNAi/AAP.\\nCharacterization of Nanomaterials: The particle size distribution and\\nzetapotentialofthenanoparticlesweremeasuredusingaZeta-sizerNano\\nZS (Malvern Nano, Malvern, U.K.). The size and shape of the nanoparti-\\ncles were measured by transmission electron microscopy (TEM). Mem-\\nbrane proteins of RBCm, TR, and TR-ZRA were obtained with RIPA ly-\\nsis bu\\ufb00er and quanti\\ufb01ed with a BCA protein assay kit (Beyotime, China).\\nSodium dodecyl sulfate\\u2012polyacrylamide gel electrophoresis (SDS\\u2012PAGE)\\nwas used to identify erythrocyte membrane proteins. Gels were stained\\nwithKomasBrilliantBluestainingreagent(Beyotime,China)andimaged\\nwithagelimagingsystem(Bio-Rad,USA).\\nCytotoxicity of the Nanoparticles: The cytotoxicity of the nanoparticles\\nto cells was determined according to the manufacturer\\u2019s instructions for\\nCCK8.bEnd.3,HT22,andBV2cellswereaddedto96-wellplatesataden-\\nsity of 1\\u00d7 104 cells per well. After 24 h, 10\\u03bcL ZC, ZRA, and TR-ZRA at\\ndi\\ufb00erent concentrations (0\\u2013250\\u03bcgm L\\u22121) were added to each well, and\\nthe cells were incubated for 24 h. After 24 h, each well received 100\\u03bcL\\nfreshmediumand10 \\u03bcLCCK8reagentfor2\\u20134hofincubation.Finally,the\\nabsorbanceofeachwellwasmeasuredat450nmwithamicroplatereader.\\nCell ability (%)= [(As-Ab)/(Ac-Ab)] \\u00d7 100%. As: Abs of the experimental\\nhole;Ab:Absoftheblankhole;Ac:Absofthecontrolhole.\\nBiocompatibility and Immune Escape Ability of the Nanoparticles: The\\nhemocompatibility of nanoparticles was investigated by a hemolysis as-\\nsay. Di\\ufb00erent concentrations (0\\u2013250\\u03bcgm L\\u22121)o fZ Ca n dT R - Z Cw e r ei n -\\ncubatedwith5%erythrocytesofmiceat37 \\u00b0Cfor2h.Then,thecellswere\\ncentrifugedat3500rpmfor5min,andtheabsorbanceofthesupernatant\\nwas measured at 545 nm using a microplate detector. Ultra-pure water\\nandPBS(pH7.4)wereusedaspositiveandnegativecontrolsforhemoly-\\nsis,respectively.Thehemolysisratewascalculatedfromthemeasuredab-\\nsorbance.Hemolyticrate = 100%\\u00d7 [(ODex-ODneg)/(ODpo-ODneg)].ODex:\\nAbs of the experimental group; ODneg: Abs of the negative group; ODpo:\\nAbsofthepositivegroup.\\nThe immune escape ability of the nanoparticles was assessed with\\nmurinemacrophages(RAW264.7).RAW264.7cells(1 \\u00d7 106)wereseeded\\nina6-wellplateandculturedovernight.Then,ZC,R-ZC,andTR-ZC, with\\nZC 20\\u03bcgm L\\u22121, were cocultured with the RAW264.7 cells for 6 h at 37\\u00b0C\\nand5%CO 2.Thefreenanoparticleswerediscardedbywashingthemwith\\nPBS three times. The nuclei were stained with DAPI, followed by imaging\\nvialaserscanningmicroscopy.\\nPrimary Astrocyte Extraction: Primary astrocytes were isolated from\\nthe brains of neonatal 7-day-old mice according to previously described\\nprocedures.[50] 7-day-oldC57BL/6femalemiceweresacri\\ufb01cedunderasep-\\ntic conditions, and the brain tissue was removed from the ultraclean ta-\\nble into Hanks solution. The meninges and blood vessels were removed\\nwith pointed forceps, and the intact cerebral cortex was minced, added\\nto trypsin, and then placed in a cell culture incubator (37\\u00b0C, 5% CO2)\\nfor 10 min after being mixed thoroughly. The samples were removed and\\nmixed every 5 min until no obvious brain tissue clumps were observed.\\nAfter the addition of DMEM-F12 medium containing serum to terminate\\nthe digestion, the samples were \\ufb01ltered through a 0.44\\u03bcms i e v ea n d\\ncentrifuged at 1000 rpm for 5 min. The supernatant was discarded, and\\nthe pellet was resuspended in fresh complete medium, added to culture\\ndishes at a density of 1\\u00d7 107 cells per well, and incubated at 37\\u00b0Ca n d\\n5%CO2.Themediumwaschangedevery2days,and7\\u201310dayslater,as-\\ntrocyteswithprotrudingshapescouldbeobservedunderthemicroscope.\\nTheextractedastrocyteswerefrozenforsubsequentexperiments.\\nConstruction of an In Vitro Blood\\u2012Brain Barrier Model and Penetration of\\nNanoparticles: AninvitroBBBmodelwasgeneratedwithamicroporous\\nTranswell membrane (0.4\\u03bcm) and cultured cells to investigate the ability\\nofnanoparticlestopenetratetheBBB,asdescribedpreviously,withsome\\nmodi\\ufb01cations.[51] Speci\\ufb01cally,theuppersideofthemembranewasinocu-\\nlatedwithbEnd.3cells,andthelowersidewasinoculatedwithastrocytes.\\nInaddition,BV2wereinoculatedinto6-wellplatestomoreaccuratelysim-\\nulate the microenvironment in the brain. When the cell density reached\\n90% under the microscope, the model was considered to be established\\nsuccessfully, and A\\ud835\\udefd1-42 was added for further incubation for 48 h to sim-\\nulate thepathologicalconditionsof AD. ZC, Cy5.5-NH2 or RhodamineB-\\nPEG-NH2, EDC, and NHS were dissolved in deionized water (5 mL) and\\nstirredatroomtemperaturefor6h.Themixedsystemwascentrifuged(at\\n5000\\u00d7 g,10min)andrinsedfourto\\ufb01vetimeswithultrapurewatertore-\\nmovefree\\ufb02uorescence.Centrifugationwasreservedforprecipitation,that\\nis,\\ufb02uorescentlylabelednanoparticles,whichwerestoredat4 \\u00b0Cawayfrom\\nlight.Whenthemodelwasestablishedsuccessfully,Cy5.5-ZC,Cy5.5-ZRA,\\nandCy5.5-TR-ZRAwereaddedtotheupperchambersoftheTranswellfor\\ncoincubationwithbEnd.3cells,andtheZCconcentrationwas40 \\u03bcgmL\\u22121.\\nAftertheadditionofnanoparticles,100 \\u03bcLmediumwascollectedevery6h\\nfrom the upper and lower sides of the \\ufb01lter membrane, the \\ufb02uorescence\\nintensity was detected with a multifunctional microplate reader, and the\\nchanges in \\ufb02uorescence intensity were recorded. The penetration ability\\nwas evaluated by the ratio of \\ufb02uorescence intensity in upper and lower\\nculturemediumat24h.\\nAfter the experiment, the \\ufb01lter membrane was cut o\\ufb00 with scissors,\\nand the cells on both sides of the membrane were washed three times\\nwith PBS for 5 min each time and then \\ufb01xed with 4% paraformaldehyde\\natroomtemperaturefor15\\u201330min.Then,0.5%Triton-100wasaddedfor\\npermeabilizationatroomtemperaturefor20min,andBSAwasaddedto\\nterminate permeabilization at room temperature. Then, bEnd.3 cells and\\nastrocyteswereincubatedwithrabbit-derivedCD34andGAFPprimaryan-\\ntibodies(1:500)overnightat4 \\u00b0CandwashedwithPBSthreetimes.Next,\\nCy3-labeled goat anti-rabbit secondary antibody (1:500) and FITC-labeled\\ngoat anti-rabbit secondary antibody (1:500) were incubated with bEnd.3\\ncells and astrocytes, respectively, for 1 h at 37\\u00b0C in the dark, followed by\\nwashing with PBS \\ufb01ve times. Finally, the nuclei were stained with DAPI\\n(1:5000), and the cells were incubated for\\u224810\\u201315 min at room tempera-\\nture, washed with PBS, and then observed. Images were captured with a\\nlaserconfocal\\ufb02uorescencemicroscope.\\nCellular Internalization of bEnd.3 and BV-2 Cells: A total of 1\\u00d7 106\\nbEnd.3 cells were seeded in a 6-well plate and cultured overnight at 37\\n\\u00b0C. Then, Rh B-ZC, Rh B-R-ZC, and Rh B-TR-ZC (with ZC 40\\u03bcgm L\\u22121)\\nwere co-incubated with bEnd.3 cells for 4 h. Next, the cells were washed\\nwithPBSthreetimestoremovefreenanoparticlesandthen\\ufb01xedwith4%\\nparaformaldehyde for 15 min, followed by staining with DAPI. To further\\nprobe whether TfR-A mediates transcytosis of bEnd.3 cells, which could\\ncause lysosomal escape of nanoparticles, Rh B-ZC, Rh B-R-ZC, and Rh B-\\nTR-ZCwereincubatedwithbEnd.3cellsfor2and6h.Then,thecellswere\\nwashedwithPBS(pH7.4)threetimesandstainedwithLyso-Trackergreen\\nandHoechst33342.AfterwashingwithPBSthreetimes,thecellswereob-\\nservedbyCLSM.\\nToexplorewhetherthenanoparticlescancarryplasmidsintocells,1 \\u00d7\\n106 BV2 cells were seeded in a 6-well plate and cultured overnight. Then,\\nCD22 shRNA (RNAi)+lipo, ZC, ZRA, and TR-ZRA (at an RNAi concentra-\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(16of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\ntion of 2\\u03bcg) were co-incubated with BV2 cells for 24 h. After two washes\\nwithPBS,theBV-2cellswere\\ufb01xedwith4%paraformaldehyde.Thenuclei\\nwere stained with DAPI, and the cells were incubated for 10\\u201315 min at\\nroomtemperatureandobservedviaCLSM.\\nQuantitative Real-Time PCR (qRT\\u2012PCR): Total RNA was extracted\\nfrom BV2 cells using the Trizol method. cDNA was generated by reverse\\ntranscription. qRT\\u2012PCR was performed using the Trans SYBR Green PCR\\nMasterMixkit.GAPDHwasusedasaninternalreference.Theprimerse-\\nquenceswereasfollows:\\nCD22-F:5\\u02b9-GATTCCATGCCTGTCAGCTG-3\\u02b9;\\nCD22-R:3\\u02b9-TGCACGAGACTCCCATTCTT-5\\u02b9;\\nGAPDH-F:5\\u02b9-CTAGGCCACAGAATTGAAAGATCT-3\\u02b9;and\\nGAPDH-R:3\\u02b9-GTAGGTGGAAATTCTAGCATCATCC-5\\u02b9.\\nWBAssay: BV-2cellswereaddedto6-wellplatesatadensityof8 \\u00d7 105\\ncellsperwellandincubatedfor24h.Thecellswerethenco-incubatedwith\\nRNAi + Lipo, ZC, ZRA, and TR-ZRA (RNAi 4\\u03bcgm L\\u22121) together with A\\ud835\\udefd\\n1-42 oligomerinserum-freeDMEMfor48h.Cellsco-incubatedwithA \\ud835\\udefd 1-42\\noligomerwereusedascontrols.Afterincubation,theBV2cellsineachwell\\nwerelysedwithRIPAbu\\ufb00er,andthelysatewasincubatedonicefor30min.\\nThen, the supernatant was collected by centrifugation for\\u224810\\u201315 min at\\n14 000 rpm and 4\\u00b0C. A BCA kit was used to measure the protein con-\\ncentration. The proteins were separated by 10% SDS-polyacrylamide gel\\nelectrophoresis, with a protein loading volume of 30\\u03bcg, and transferred\\nto polyvinylidene \\ufb02uoride membranes for blotting after electrophoresis.\\nThe blots were blocked with 5% skim milk in TBST at room temperature\\nfor 1 h. Di\\ufb00erent primary antibodies were added to the membranes sep-\\narately and incubated overnight at 4\\u00b0C, followed by incubation with the\\nappropriate secondary antibodies at room temperature for 1 h. The blots\\nwere developed using ECL technology. GAPDH was used as an internal\\nreferencefortotalproteins.Similarly,theexpressionlevelsofCD22,IL-1 \\ud835\\udefd,\\nIL-6,andTNF- \\ud835\\udefc inthebraintissueoftheWTandADmiceweredetected\\nby Western blotting. The animals were sacri\\ufb01ced by cervical dislocation,\\nand half of the mouse brain tissue was ground and incubated with RIPA\\nlysis solution. The lysate was collected and placed in a centrifuge at 4\\u00b0C\\nand 14 000 rpm for\\u224810\\u201315 min, and the supernatant was collected. The\\nrestoftheprocedurewasthesameasdescribedabove.\\nEndocytosis of A\\ud835\\udefd in BV-2 Cells: BV2cells(7 \\u00d7 104 cellsperwell)were\\naddedtoa35mmlaserconfocaldishandincubatedfor12h.Afterthead-\\nditionoffreshserum-freemedium,thecellswerecoincubatedwithFITC-\\nA\\ud835\\udefd1-42 (2\\u03bcgmL\\u22121)togetherwithdi\\ufb00erentnanopreparations,includingZC,\\nZRA, and TR-ZRA. After 6 h of incubation, the cells cultured in medium\\nalone served as a negative control group. After incubation, the BV2 cells\\nwerewashedwithPBSthreetimesandthenstainedwithLyso-TrackerRed\\nandHoechst33342.Afterstaining,thecellswerewashedthreetimeswith\\nPBS,andtheuptakeofFITC-A \\ud835\\udefd 1-42 bythecellswasobservedbyCLSMat\\n492nm(FAM),577nm(Lysotracker-Red),and346nm(Hoechst33342).\\nLive/Dead Staining of HT22 Cells: As described above, BV2 cells were\\ncoincubated with A\\ud835\\udefd1-42 oligomer (10\\u03bcm) to induce a proin\\ufb02ammatory\\nstateintheBV2cells.Then,thecellswere coincubatedwithFBS-free cul-\\nture medium or di\\ufb00erent preparations for 36 h. Thereafter, the culture\\nmedium was collected and centrifuged (3000 rpm, 20 min) at 4\\u00b0Ct o\\ncollect the supernatant. Then, the supernatants from di\\ufb00erent wells were\\nadded to HT22 cells in 6-well plates for 24 h, and the cells were stained\\nwithcalcein-AMandPI.Finally,theHT22cellswereobservedviaCLSM.\\nAnticomplement Assessment In Vitro: Anticomplement experiments\\nwereperformedusingpreviouslyreportedprocedures. [52] First,guineapig\\nserum was subjected to serial dilution (1:10, 1:20, 1:40, 1:80, 1:160, and\\n1:320) to determine the titer of complement. Then, the diluted comple-\\nmentwasmixedwithsheeperythrocytehemolysinand2%SRBCat37 \\u00b0C\\nfor 30 min. A group treated with 2% SRBC and water was used as a posi-\\ntivecontrol,andPBSwasusedasanegativecontrol.Afterdeterminingthe\\ntiter of complement, guinea pig serum, sheep erythrocyte hemolysin, 2%\\nSRBC,anddi\\ufb00erentpreparations(ZC,R-ZC,TR-ZC)wereaddedtogether\\nand incubated at 37\\u00b0C for 30 min. These solutions without nanoparticle\\npreparationswereusedasapositivecontrol.\\nFluorescence Assay of A\\ud835\\udefd In Vitro: A\\ud835\\udefd aptamers were heated at 95\\u00b0C\\nfor 10 min and then gradually cooled to room temperature for 1 h in TBS\\nbu\\ufb00er(1mmTris-HCl,100mmNaCl,4mmMgCl 2 and5mmKCl,pH7.4)\\ntoformstablefoldedstructures.Then,2 \\u03bcLA\\ud835\\udefd aptamersolution(10 \\u03bcm)\\nand di\\ufb00erent concentrations of A\\ud835\\udefd solution (0\\u2013160\\u03bcgm L\\u22121) were mixed\\nin TBS bu\\ufb00er in 96-well plates. After incubation at 37\\u00b0Cf o r2h ,t h e\\ufb02 u o -\\nrescenceintensitywasmeasuredwithamultifunctionmicroplateanalyzer,\\nwhoseexcitationwavelengthandemissionwavelengthweresetto428and\\n528nm,respectively.\\nAnimals: APP/PS1 transgenic mice (female, 6\\u20138 months old) and\\nC57BL/6 wild-type mice (female) were purchased from Beijing HFK Bio-\\nscience Co., Ltd. The animals were maintained in a pathogen-free animal\\nfacility,withfreeaccesstofoodandwater.Thisstudywascarriedoutinac-\\ncordancewiththerelevantguidelinesandregulationsforthecareanduse\\nof laboratory animals. The animal procedures were approved by the Ani-\\nmal Experimentation Ethics Committee of Central South University. (Ap-\\nprovalnumber:2020sydw0173).\\nTreatment of Mice: The APP/PS1 mice were randomly divided into 4\\ngroups(n= 3),andPBS,ZC,ZRA,andTR-ZRAwereinjectedintothetail\\nveinevery5daysforatotalofsixtimes;thedoseofRNAwas0.8mgkg \\u22121.\\nWild-type C57BL/6 mice (WT) were treated with 200\\u03bcL saline via the tail\\nveinevery4daysforatotalofseventimesasthecontrolgroup.\\nMorris Water Maze Experiment: The Morris water maze was used to\\ninvestigate the spatiallearning and memory abilities of mice. Speci\\ufb01cally,\\ntheMWMsystemwasacircularpoolwithadiameterof120cm,aheight\\nof50cm,awatertemperatureof \\u224821\\u201326\\u00b0C,andawaterdepthof20cm,\\nwhich was divided into four quadrants as four entry points. The second\\nquadrant was the target quadrant, and a circular platform with a diame-\\nter of 10 cm was placed in the target quadrant. A camera above the pool\\nrecorded the swimming tracks of the mice, and Smart 3.0 software was\\nusedtoanalyzethemovementtracksofthemice.Duringtheexperiment,\\na few obvious markers were set on the pool wall to facilitate the memory\\nofthemice.\\nEachmousewastrainedfourtimesadayandplacedinthepoolindif-\\nferentquadrantsduringthetrainingperiod.Themaximumtimeto\\ufb01ndthe\\nplatformwassetto60s,andthetimeto\\ufb01ndtheplatformwasrecordedas\\ntheincubationperiod.Ifamousecouldnot\\ufb01ndtheplatform,theincuba-\\ntionperiodwasrecordedas60s,andthemousewasguidedtoreachthe\\nplatform and stay on the platform for 10\\u201315 s. The training period lasted\\nfor 5 days, and the exploratory period began on the sixth day. The water\\nplatformwasremovedtotestthespatialmemoryabilityofthemice.Mice\\nwere placed in the opposite quadrant of the target quadrant, and the ex-\\nperimentlastedfor60s.Thelatencytotheplatform,thenumberoftimes\\npassingtheplatform,andthepercentageoftimespentwereallrecorded.\\nBiodistribution Study: AD mice were injected intravenously with\\nCy5.5\\u2212ZC, Cy5.5\\u2212ZRA, and Cy5.5\\u2212TR-ZRA (1 mg kg\\u22121 Cy5.5) and anes-\\nthetized.Invivoimagingexperimentswereperformedat24,36,and72h\\nafterinjectionusinganinvivoopticalimager.Tovisualizethebiodistribu-\\ntionof Cy5.5\\u2212ZC,Cy5.5\\u2212ZRA,and Cy5.5\\u2212TR-ZRAinvitro,miceweresacri\\ufb01ced\\n12 h after injection. Di\\ufb00erent organs were isolated and washed with PBS,\\nand \\ufb02uorescence images were captured in vitro. IVIS software was used\\nforanalysis.\\nMagnetic Resonance Imaging: MRI experiments were performed on\\na 7.0T vertical bore Bruker Biospec 70/30 scanner (BrukerBioSpin MRI\\nGmbH, Rheinstetten, Germany). The parameters used in the scans were\\noptimized for gray\\u2012white matter content. Based on reference multislice\\nRARE scans (axial, sagittal, and coronal), with TR= 2500 ms, echo train\\nlength= 8,TEe\\ufb00(echotime) = 36ms,\\ufb01eld-of-view(FOV,rectangle) = 20\\n\\u00d7 20mmandmatrixsize = 384\\u00d7 384\\u00d715,thevoxelsizewas0.052833209\\n\\u00d7 0.052833209\\u00d7 0.5mm.Thetotalimagingtimewas30min.\\nHEStainingandNisslStaining : Theexperimentalmiceweresacri\\ufb01ced\\nby cervical dislocation after 1 month of treatment, and the main organs\\nof the animals, namely, the heart, brain, liver, spleen, lungs, and kidneys,\\nwere collected for HE staining. The major organs were \\ufb01xed, dehydrated,\\npara\\ufb03n-embedded, serially sectioned, and stained with hematoxylin and\\neosin for light microscopic evaluation. Cresyl violet stain was used to ob-\\nserve neuronal damage via Nissl staining. The pathological changes in\\nmajor organs were evaluated by three experienced pathologists accord-\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(17of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\ningto\\u201cAPracticalGuidetotheHistologyoftheMouse\\u201dwrittenbyCheryl\\nL.Scudamore(printISBN:9781119941200,onlineISBN:9781118789568,\\nhttps://doi.org/10.1002/9781118789568).\\nImmuno\\ufb02uorescence Assay: The immuno\\ufb02uorescence technique was\\nperformed according to standard protocols. Brain tissue sections were\\n\\ufb01rst washed with PBS and then blocked with normal goat serum for 1 h.\\nThen, the brain tissue sections were incubated with the appropriate pri-\\nmaryantibodyovernightat4 \\u00b0C.Thetwokindsofprimaryantibodieswere\\nmixedataspeci\\ufb01cdilutionratioandaddedtothetissueindrops.Thesec-\\ntions were placed \\ufb02at in a wet box and incubated at 4\\u00b0C overnight. After\\nincubationwiththeprimaryantibodies,theslideswereplacedinPBS(pH\\n7.4) and washed three times for 5 min each. Then, labeled secondary an-\\ntibodiesfromthecorrespondingspecieswereaddedataspeci\\ufb01cdilution\\nand incubated with the tissue sections at room temperature for 50 min.\\nThecellswerewashedwithPBS(pH7.4)threetimesfor5mineach.Then,\\nthe nuclei were stained with DAPI, and the samples were incubated for\\n10 min at room temperature in the dark. The slides were placed in PBS\\n(pH7.4)andwashedthreetimeswithshakingonadecolorizationshaker.\\nThesliceswereslightlydriedandsealedwithananti-\\ufb02uorescencequench-\\ningtablet.Finally,thesectionswereplacedunderamicroscopetocapture\\nimages(DAPI:Ex = 330\\u2013380nm,Em = 420nm;FITC:Ex = 465\\u2013495nm,\\nEm= 515\\u2013555nm;CY3:Ex = 510\\u2013560nm;Em = 590nm).\\nStatisticalAnalysis: Alldatawereexpressedasmean \\u00b1 SD.Thecontrol\\ngroupwastakenasthebenchmark,andtheratiobetweentheexperimen-\\ntal group and the control group was used to re\\ufb02ect the relative expres-\\nsion level between the groups. When the measurement was signi\\ufb01cantly\\nabovethenormalvalueorwhenthedeviationfromthemeanvalueinthe\\nmeasurement was more than two standard deviations, it was considered\\nan outlier. For the processing of abnormal values, the data will be elimi-\\nnated, or the median, average value, and so on will be used to \\ufb01ll in. For\\nmultiple-groupcomparisons,one-wayANOVAwasemployedfollowedby\\nTurkey\\u2019s test. Speci\\ufb01c comparisons between the two groups were carried\\nout with an unpaired Student\\u2019st-test (two-tailed). Statistical signi\\ufb01cance\\nwas shown as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.\\nGraphPadPrismversion8.0softwarewasusedforstatisticalanalysis.\\nSupportingInformation\\nSupportingInformationisavailablefromtheWileyOnlineLibraryorfrom\\ntheauthor.\\nAcknowledgements\\nThis project was supported by the National Natural Science Founda-\\ntion of China (82001165 and 81971748), the Independent Innovation\\nProjects of Postgraduates of Central South University (2021zzts1084\\nand 2022ZZTS0890), the Natural Science Foundation of Hunan Province\\n(2021JJ40926, 2020JJ4131 2021JJ31002, and 2021JJ40923), the Key Re-\\nsearch and Development Program of Hunan Province (2022SK2004) the\\nScience andTechnology Program ofChangsha(kh2201057),theWisdom\\nAccumulationandTalentCultivationProjectoftheThirdXiangyaHospital\\nofCentralSouthUniversity(BJ202101,YX202206).\\nCon\\ufb02ictofInterest\\nTheauthorsdeclarenocon\\ufb02ictofinterest.\\nDataAvailabilityStatement\\nResearchdataarenotshared.\\nKeywords\\nA\\ud835\\udefd clearance,Alzheimer\\u2019sdisease,erythrocytemembrane,immuneregu-\\nlation,nano-system\\nReceived:February28,2023\\nRevised:March18,2023\\nPublishedonline:April19,2023\\n[1] Alzheimer\\u2019s Dementia2022,18,700.\\n[2] J.A.Hardy,G.A.Higgins, Science1992,256,184.\\n[3] J.Hardy,D.Allsop, Trends Pharmacol. Sci.1991,12,383.\\n[4] M.T.Heneka,M.J.Carson,J.ElKhoury,G.E.Landreth,F.Brosseron,\\nD. L. Feinstein, A. H. Jacobs, T. Wyss-Coray, J. Vitorica, R. M. Ran-\\nsoho\\ufb00, K. Herrup, S. A. Frautschy, B. Finsen, G. C. Brown, A.\\nVerkhratsky, K. Yamanaka, J. Koistinaho, E. Latz, A. Halle, G. C. Pet-\\nzold,T.Town,D.Morgan,M.L.Shinohara,V.H.Perry,C.Holmes,N.\\nG. Bazan, D. J. Brooks, S. Hunot, B. Joseph, N. Deigendesch, et al.,\\nLancet Neurol.2015,14,388.\\n[5] S.Jevtic,A.S.Sengar,M.W.Salter,J.McLaurin, AgeingRes.Rev. 2017,\\n40,84.\\n[6] H.Sarlus,M.T.Heneka, J. Clin. Invest.2017,127,3240.\\n[7] S.Anwar,S.Rivest, Expert Opin. Ther. Targets2020,24,331.\\n[8] G.J.Harry, Pharmacol. Ther.2013,139,313.\\n[9] S. Hong, V. F. Beja-Glasser, B. M. Nfonoyim, A. Frouin, S. Li, S. Ra-\\nmakrishnan, K. M. Merry, Q. Shi, A. Rosenthal, B. A. Barres, C. A.\\nLemere,D.J.Selkoe,B.Stevens, Science2016,352,712.\\n[10] D. Kaur, V. Sharma, R. Deshmukh,In\\ufb02ammopharmacology 2019,27,\\n663.\\n[11] A.Shah,U.Kishore,A.Shastri, Int. J. Mol. Sci.2021,22,13647.\\n[12] S.E.Hickman,E.K.Allison,J.ElKhoury, J. Neurosci.2008,28,8354.\\n[13] J. V. Pluvinage, M. S. Haney, B. A. H. Smith, J. Sun, T. Iram, L. Bo-\\nnanno, L. Li, D. P. Lee, D. W. Morgens, A. C. Yang, S. R. Shuken, D.\\nGate,M.Scott,P.Khatri,J.Luo,C.R.Bertozzi,M.C.Bassik,T.Wyss-\\nCoray,Nature2019,568,187.\\n[ 1 4 ] R .A c h a r y a ,S .S a h a ,S .R a y ,S .H a z r a ,M .K .M i t r a ,J .C h a k r a b o r t y ,\\nMater. Sci. Eng., C2017,76,1378.\\n[15] J.Zhuang,C.H.Kuo,L.Y.Chou,D.Y.Liu,E.Weerapana,C.K.Tsung,\\nACS Nano2014,8,2812.\\n[16] W.Liang,P.Wied,F.Carraro,C.J.Sumby,B.Nidetzky,C.K.Tsung,P.\\nFalcaro,C.J.Doonan, Chem. Rev.2021,121,1077.\\n[17] S.F.Nabavi,S.Tejada,W.N.Setzer,O.Gortzi,A.Sureda,N.Braidy,\\nM.Daglia,A.Manayi,S.M.Nabavi, Curr.Neuropharmacol. 2017,15,\\n471.\\n[18] N.Liu,M.Tang,J.Ding, Chemosphere2020,245,125624.\\n[19] C. M. Hu, L. Zhang, S. Aryal, C. Cheung, R. H. Fang, L. Zhang,Proc.\\nNatl. Acad. Sci. U. S. A.2011,108,10980.\\n[20] S. Zou, B. Wang, C. Wang, Q. Wang, L. Zhang,Nanomedicine 2020,\\n15,625.\\n[21] Q. Xia, Y. Zhang, Z. Li, X. Hou, N. Feng,Acta Pharm. Sin. B2019,9,\\n675.\\n[22] M. Gao, C. Liang, X. Song, Q. Chen, Q. Jin, C. Wang, Z. Liu,Adv.\\nMater.2017,29,1701429.\\n[23] G. C. Terstappen, A. H. Meyer, R. D. Bell, W. Zhang,Nat. Rev. Drug\\nDiscovery2021,20,362.\\n[24] W.Jia,H.Tian,J.Jiang,L.Zhou,L.Li,M.Luo,N.Ding,E.C.Nice,C.\\nHuang,H.Zhang, Small2023,19,2205354.\\n[25] R.D.Bell,M.D.Ehlers, Neuron2014,81,1.\\n[26] S.L.vandenBroek,V.Shalgunov,M.M.Herth, Biomater.Adv. 2022,\\n141,213125.\\n[27] A. Zakeri, M. A. J. Kouhbanani, N. Beheshtkhoo, V. Beigi, S. M.\\nMousavi, S. A. R. Hashemi, A. Karimi Zade, A. M. Amani, A. Savar-\\ndashtaki,E.Mirzaei,S.Jahandideh,A.Movahedpour, NanoRev.Exp.\\n2018,9,1488497.\\n[28] J. Wang, F. Meng, B. K. Kim, X. Ke, Y. Yeo,Biomaterials 2019, 217,\\n119296.\\n[29] Q.Jiang,Y.Liu,R.Guo,X.Yao,S.Sung,Z.Pang,W.Yang, Biomaterials\\n2019,192,292.\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(18of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\n[30] A.N.Barclay,T.K.VandenBerg, Annu. Rev. Immunol.2014,32,50.\\n[31] A.V.Kroll,R.H.Fang,L.Zhang, Bioconjugate Chem.2017,28,23.\\n[ 3 2 ] R .H a r a t i ,A .S .V i l l \\u00e9 g i e r ,W .A .B a n k s ,A .M a b o n d z o ,J. Neuroin\\ufb02am-\\nmation2012,9,273.\\n[33] M. C. Dalakas, H. Alexopoulos, P. J. Spaeth,Nat. Rev. Neurol.2020,\\n16,601.\\n[ 3 4 ] R .E j z e m b e r g ,M .H .D aS i l v a ,L .P i n t o ,W .B .M o r s ,An. Acad. Bras.\\nCienc.1999,71,273.\\n[35] K.S.Park, Biosens. Bioelectron.2018,102,179.\\n[36] D.J.Patel,A.K.Suri,F.Jiang,L.Jiang,P.Fan,R.A.Kumar,S.Nonin,\\nJ. Mol. Biol.1997,272,645.\\n[37] S. A. Liddelow, K. A. Guttenplan, L. E. Clarke, F. C. Bennett, C. J.\\nBohlen, L. Schirmer, M. L. Bennett, A. E. M\\u00fcnch, W. S. Chung, T. C.\\nPeterson, D. K. Wilton, A. Frouin, B. A. Napier, N. Panicker, M. Ku-\\nmar, M. S. Buckwalter, D. H. Rowitch, V. L. Dawson, T. M. Dawson,\\nB.Stevens,B.A.Barres, Nature2017,541,481.\\n[38] S.A.Liddelow,B.A.Barres, Immunity2017,46,957.\\n[39] V.Fleischer,J.Sieber,S.J.Fleischer,A.Shock,G.Heine,C.Daridon,\\nT. D\\u00f6rner,Arthritis Res. Ther.2015,17,185.\\n[40] H. Lian, L. Yang, A. Cole, L. Sun, A. C. Chiang, S. W. Fowler, D. J.\\nShim, J. Rodriguez-Rivera, G. Taglialatela, J. L. Jankowsky, H. C. Lu,\\nH.Zheng, Neuron2015,85,101.\\n[41] U. Kishore, S. K. Gupta, M. V. Perdikoulis, M. S. Kojouharova, B. C.\\nUrban,K.B.Reid, J. Immunol.2003,171,812.\\n[42] L.B.Y ang,R.Li,S.Meri,J.Rogers,Y .Shen, J.Neurosci. 2000,20,7505.\\n[43] W.C.Pierre,P.L.P.Smith,I.Londono,S.Chemtob,C.Mallard,G.A.\\nLodygensky,Brain, Behav., Immun.2017,59,333.\\n[44] S.A.Frautschy,F.Yang,M.Irrizarry,B.Hyman,T.C.Saido,K.Hsiao,\\nG.M.Cole, Am. J. Pathol.1998,152,307.\\n[45] G.M.Cole,S.A.Frautschy, Trends Mol. Med.2006,12,395.\\n[46] A.Chandra,G.Dervenoulas,M.Politis, J. Neurol.2019,266,1293.\\n[47] A.T .Du,N.Schu\\ufb00,J.H.Kramer,S.Ganzer,X.P .Zhu,W .J.Jagust,B.\\nL. Miller, B. R. Reed, D. Mungas, K. Ya\\ufb00e, H. C. Chui, M. W. Weiner,\\nNeurology2004,62,422.\\n[48] B.T.Luk,C.M.Hu,R.H.Fang,D.Dehaini,C.Carpenter, W.Gao,L.\\nZhang,Nanoscale2014,6,2730.\\n[49] C. F. Rodrigues, N. Fernandes, D. de Melo-Diogo, P. Ferreira, I.-D. J.\\nCorreia,A.F.Moreira, Nanomedicine2021,16,2569.\\n[50] F. Bernard-Patrzynski, M. A. L\\u00e9cuyer, I. Puscas, I. Boukhatem, M.\\nCharabati, L. Bourbonni\\u00e8re, C. Ramassamy, G. Leclair, A. Prat, V. G.\\nRoullin,PLoS One2019,14,e0226302.\\n[51] N.L.Stone,T.J.England,S.E.O\\u2019Sullivan, Front.Cell.Neurosci. 2019,\\n13,230.\\n[52] Y. Luo, Q. Wen, S. Yang, Y. Feng, T. Tan,Biomed. Chromatogr.2020,\\n34,e4762.\\nAdv. Sci.2023,10,2301361 \\u00a92023TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2301361(19of19)\\n 21983844, 2023, 18, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202301361 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n \",\n          \"RESEARCH ARTICLE\\nwww.advancedscience.com\\nHybridMembrane-CoatedNanoparticlesforPrecise\\nTargetingandSynergisticTherapyinAlzheimer\\u2019sDisease\\nRong-Rong Lin, Lu-Lu Jin, Yan-Yan Xue, Zhe-Sheng Zhang, Hui-Feng Huang,\\nDian-Fu Chen, Qian Liu, Zheng-Wei Mao,* Zhi-Ying Wu,* and Qing-Qing Tao*\\nThebloodbrainbarrier(BBB)limitstheapplicationofmosttherapeuticdrugs\\nforneurologicaldiseases(NDs).Hybridcellmembrane-coatednanoparticles\\nderivedfromdi\\ufb00erentcelltypescanmimicthesurfacepropertiesand\\nfunctionalitiesofthesourcecells,furtherenhancingtheirtargetingprecision\\nandtherapeutice\\ufb03cacy.Neuroin\\ufb02ammationhasbeenincreasinglyrecognized\\nasacriticalfactorinthepathogenesisofvariousNDs,especiallyAlzheimer\\u2019s\\ndisease(AD).Inthisstudy,anovelcellmembranecoatingisdesignedby\\nhybridizingthemembranefromplateletsandchemokine(C\\u2013Cmotif)receptor\\n2(CCR2)cellsareoverexpressedtocrosstheBBBandtarget\\nneuroin\\ufb02ammatorylesions.PastunsuccessfulendeavorsinADdrug\\ndevelopmentunderscorethechallengeofachievingfavorableoutcomeswhen\\nutilizingsingle-mechanismdrugs.Twodrugswithdi\\ufb00erentmechanismsof\\nactionsintoliposomesaresuccessfullyloadedtorealizemultitargeting\\ntreatment.InatransgenicmousemodelforfamilialAD(5xFAD),the\\nadministrationofthesedrug-loadedhybridcellmembraneliposomesresults\\ninasigni\\ufb01cantreductioninamyloidplaquedeposition,neuroin\\ufb02ammation,\\nandcognitiveimpairments.Collectively,thehybridcellmembrane-coated\\nnanomaterialso\\ufb00ernewopportunitiesforprecisedrugdeliveryand\\ndisease-speci\\ufb01ctargeting,whichrepresentaversatileplatformfortargeted\\ntherapyinAD.\\n1.Introduction\\nThebloodbrainbarrier(BBB)isacriticalcomponentofthecen-\\ntral nervous system (CNS) that plays a crucial role in regulating\\nthe transport of various substances, including drugs, into and\\nR.-R.Lin,Y.-Y.Xue,Z.-S.Zhang,H.-F.Huang,D.-F.Chen,Q.Liu,Z.-Y.Wu,\\nQ.-Q.Tao\\nDepartmentofNeurologyandResearchCenterofNeurologyinSecond\\nA\\ufb03liatedHospital,andLiangzhuLaboratory\\nZhejiangUniversitySchoolofMedicine\\nHangzhou310009,China\\nE-mail:zhiyingwu@zju.edu.cn;qingqingtao@zju.edu.cn\\nThe ORCID identi\\ufb01cation number(s) for the author(s) of this article\\ncanbefoundunder https://doi.org/10.1002/advs.202306675\\n\\u00a92024TheAuthors.AdvancedSciencepublishedbyWiley-VCHGmbH.\\nThisisanopenaccessarticleunderthetermsofthe CreativeCommons\\nAttributionLicense,whichpermitsuse,distributionandreproductionin\\nanymedium,providedtheoriginalworkisproperlycited.\\nDOI:10.1002/advs.202306675\\nout of the brain.[1] Although the BBB is\\nessential for maintaining proper function-\\ning of the CNS, it also poses challenges\\nfor the treatment of neurological disor-\\nders (NDs). The emergence of nanotech-\\nnology has largely overcome this prob-\\nlem. However, most strategies are based\\non chemical engineering modi\\ufb01cations,\\nwhichmayleadtopoorbiocompatibility. [2\\u20135]\\nFewstudieshavedesigned cell membrane-\\ncoated nanoparticles to enhance compat-\\nibility and safety.[6] The potential of us-\\ning platelet membranes as transporters\\nis attractive, due to their ability to \\ufb02ow\\nthrough destructive blood vessels, concur-\\nrently elongating circulation duration.[7,8]\\nIn addition to single-cell membrane-\\ncoated nanotechnology, hybrid nanopar-\\nticles derived from multiple cell types\\nmake precise targeting possible.[9,10] Neu-\\nroin\\ufb02ammation has been increasingly\\nrecognized as a critical factor in the\\npathogenesis of various NDs. [11,12] The\\nactivationofglialcells,includingmicroglia\\nand astrocytes, is a central feature of\\nneuroin\\ufb02ammationintheCNS.Theseglial\\ncells can produce and release a variety of proin\\ufb02ammatory cy-\\ntokines, chemokines, and reactive oxygen species, which can\\ncause damage to neurons and contribute to the pathogenesis of\\nNDs.[13] Among these mediators, chemokine (C\\u2013C motif) lig-\\nand 2 (CCL2), which predominantly originates from astrocytic\\nL.-L.Jin,Z.-W.Mao\\nMOEKeyLaboratoryofMacromolecularSynthesisandFunctionalization\\nDepartmentofPolymerScienceandEngineering\\nZhejiangUniversity\\nHangzhou310027,China\\nE-mail:zwmao@zju.edu.cn\\nZ.-Y.Wu\\nMOEFrontierScienceCenterforBrainScienceandBrain-MachineIntegra-\\ntion\\nSchoolofBrainScienceandBrainMedicine\\nZhejiangUniversity\\nHangzhou310058,China\\nZ.-Y.Wu\\nCASCenterforExcellenceinBrainScienceandIntelligenceTechnology\\nShanghai200031,China\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(1of15)\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure 1.Scheme of the preparation of drug-loaded hybrid cell membrane liposomes and their application for AD therapy. Platelet membranes were\\nobtained from retro-orbital blood collected from mice, and CCR2-RFP overexpressing membranes were extracted from stable CCR2-RFP-transfected\\nHEK293T cells. Two types of cell membranes were fused and loaded with rapamycin and TPPU. The drug-loaded hybrid cell membrane liposomes\\nmigratedtoin\\ufb02ammatorylesionsintheCNSviaintravenousinjection.Thedrugswerereleasedtoenhanceautophagy,alleviateneuroin\\ufb02ammationand\\nultimatelytreatAD.\\nsources,isimportant. [14] CCL2hasbeenfoundtobeupregulated\\ninresponsetovariousneurologicalinsults. [15\\u201317] Thiscytokineef-\\nfectivelyrecruitscellsexpressingitscognatereceptor,chemokine\\n(C\\u2013Cmotif)receptor2(CCR2),toa\\ufb04ictedregions,therebyaug-\\nmenting the potential for targeted intervention. Motivated by\\ntheseinsights,ourcurrentfocusisondesigningabioengineered\\ncell membrane characterized by CCR2, a con\\ufb01guration tailored\\nto facilitate drug accumulation in in\\ufb02ammation-related lesions.\\nAlzheimer\\u2019s disease (AD) is the most common neurodegenera-\\ntivedisease.Notably,neuroin\\ufb02ammationisamongtheforemost\\nevents in AD pathogenesis.[18\\u201320] CCL2 secretion is increased in\\nADpatientsandanimalmodels. [21,22] Therefore,theuseofmem-\\nbranes with high expression of CCR2 for precise targeting of\\nearly-stage lesions is a novel strategy for the e\\ufb00ective treatment\\nofAD.\\nIntriguingly, concurrent pathological changes in AD, such\\nas the emergence of amyloid plaques, tau pathology, and neu-\\nronaldegenerationfrequentlycooccurwithneuroin\\ufb02ammation,\\nforging a reinforcing interplay. Considering the multifaceted\\nnature of AD and lessons from past unsuccessful attempts to\\ndevelop drugs for AD, a combination of medications targeting\\ndi\\ufb00erent mechanisms is more advantageous than a single-drug\\napproach.[23] Nanocarriers provide an opportunity not only to\\noptimize dosing regimens but also to improve the e\\ufb00ectiveness\\nof multidrug therapies. In AD, a decrease in autophagy leads to\\naninabilitytoclearawayharmfulproteins,resultinginneuronal\\ndeath and glial cell activation, and ultimately triggering the de-\\nvelopment of a complex neuroin\\ufb02ammatory environment.[13,24]\\nSeveral studies have demonstrated that rapamycin is a poten-\\ntial small molecule for enhancing autophagy and reducing\\nthe burden of pathological proteins in AD.[24,25] However, its\\nextremely low BBB pass rate limits its clinical application.[26] In\\naddition, to align the carrier\\u2019s function with targeting in\\ufb02am-\\nmatory lesions, we considered adding another drug that can\\ninhibitneuroin\\ufb02ammationtoimprovetheextracellularenviron-\\nment. 1-Tri\\ufb02uoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)\\nurea (TPPU), an inhibitor of soluble epoxide hydrolase (sEH),\\nhas been reported to prevent glial cell reactivation and alle-\\nviate cognitive de\\ufb01cits in the brains of AD mice.[27] These\\nresults suggest that TPPU may be a potent candidate for\\nencapsulation.\\nBased on the above considerations, we proposed an original\\nstrategy that uses nanotechnology (Figure 1). We developed a\\nhybridization system by combining a platelet membrane and a\\nmembranewithhighexpressionofCCR2,andloadedtwosmall\\nmolecule drugs (rapamycin and TPPU) on these hybrid lipo-\\nsomes, to target and treat pathological areas in the brain asso-\\nciatedwithAD.\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(2of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure 2.Expression, sublocalization and chemotaxis of CCR2-RFP. A) Western blotting and B) immuno\\ufb02uorescence (scale bar: 20\\u03bcm) of HEK293T\\ncellstransfectedwiththeCCR2-RFPplasmidormockvector.C)WesternblottingofHEK293TcellstransfectedwiththeCCL2plasmid.D)Schematicof\\ntheTranswellassayandrepresentativeimagesofmigratedcellsunderdi\\ufb00erent conditions(scalebar:50 \\u03bcm).E) Numberofmigratedcellsindi\\ufb00erent\\ngroups(n=5,***p< 0.001).\\n2.Results\\n2.1.CCR2-RFPIsLocatedontheCellMembraneandMediates\\nChemotaxistowardCCL2\\nIn order to label the CCR2 protein, we fused it with an RFP\\n(mScarlet). Firstly, we transfected the plasmid encoding the\\ncDNAofthefusionproteinintoHEK293Tcells.TheCCR2-RFP\\nwasfoundtobeapproximately70kDa( Figure2A)andlocatedin\\nthe cell membrane (Figure2B), which showed that RFP did not\\nchange the expression or cellular location of CCR2. To further\\nverify whether CCR2 is expressed on the outer side of the cell\\nmembrane,weused\\ufb02owcytometrytoisolatecellswithRFP,and\\nfound that approximately two-thirds of these cells coexpressed\\nCCR2(Figure S1A,SupportingInformation).Thisresultshowed\\nthatmostoftheCCR2proteinwaslocatedontheoutersideofthe\\ncell membrane, and preliminarily indicated that it can function\\nasareceptor.\\nThen,wewantedtoclarifywhetherthefusionproteinretained\\nthechemotacticresponseofCCR2toin\\ufb02ammatorycytokines.We\\nconstructedtheplasmidofCCL2,andtheoverexpressedproteins\\nweredetectedusingWesternblotting(Figure 2C).CCR2-RFPand\\nCCL2 were colocalized on the cell membrane after cotransfec-\\ntion (FigureS1B, Supporting Information), which may indicate\\naprotein\\u2013proteininteraction.WealsousedtheTranswellassayto\\nfurther test the migration of stable CCR2-RFP transfected cells.\\nA ss h o w ni nF i g u r e2D,E, when the lower chamber contained\\nmoreserumorCCL2,thenumberofmigratedcellssigni\\ufb01cantly\\nincreased. All these results demonstrate that CCR2-RFP is lo-\\ncatedonthecellmembraneandexhibitschemotaxistowardsits\\nligandCCL2.\\n2.2.PreparationandCharacterizationofHybridCellMembrane\\nWe extracted the platelet membrane and overexpressed CCR2-\\nRFP HEK293T cell membrane separately. Coomassie brilliant\\nblue staining revealed di\\ufb00erences in the protein ladders among\\nthe di\\ufb00erent components (cell membrane, supernatant, and\\nwhole cell) of both cell membranes (FigureS2A,B, Supporting\\nInformation). We further blotted the marker proteins located\\non the membrane of the platelets (Figure 3A) and CCR2-RFP\\nHEK293T cells (Figure3B). There were three clusters of di\\ufb00er-\\nentiation (CD) antigens (CD41, CD61 and CD62P) enriched in\\nthecellmembraneofplatelets(Figure 3A).InHEK293Tcells,the\\nexpressionofCCR2-RFPandNa-K-ATPaseinthecellmembrane\\nwasmuchgreaterthanthatoftheothercomponents.Moreover,\\nRFPwasbroadlydistributedinthecellmembraneandcytoplasm\\n(Figure3B).\\nThen, we prepared cell membrane hybrid liposomes, and\\nWestern blotting demonstrated that the hybrid cell membrane\\ncoexpressed the marker proteins found in both platelets and\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(3of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure3. ExtractionandhybridizationofplateletmembranesandCCR2-RFPHEK293Tcellmembranes.A)Markerproteins(CD41,CD61,andCD62P)\\nlocatedinthemembraneindi\\ufb00erentcellcomponentsofplatelets.WC:wholecell;CM:cellmembrane.B)Markerproteins(CCR2-RFPandNa-K-ATPase)\\nlocatedinthemembraneindi\\ufb00erentcellcomponentsofHEK293Tcells.WC:wholecell;CM:cellmembrane;SN:supernatant.C)Expressionofmarker\\nproteinsinthesinglecellmembraneandhybridcellmembrane.D)ColocalizationanalysisofthehybridcellmembraneusingPearson\\u2019s R2 (n=3,***p\\n<0.001).E)Fluorescenceimagesofcolocalizationinhybridcellmembraneswithdi\\ufb00erentfusionratio(red:CCR2-RFPHEK293Tcellmembrane;green:\\nplateletcellmembrane;scalebar:200 \\u03bcm).\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(4of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nHEK293Tcells(Figure 3C).Toverifywhetherthesetwokindsof\\ncell membranes were successfully fused, we labeled them with\\ndi\\ufb00erent \\ufb02uorophores. To determine the optimal fusion ratio,\\nwe also established three groups with di\\ufb00erent ratios of platelet\\nand CCR2-RFP HEK293T cell membranes (Group 1: PLT:293T\\n= 1:1; Group 2: PLT:293T= 1:2; Group 3: PLT:293T= 2:1). We\\ncalculated the colocalization index (Pearson\\u2019sR2) based on \\ufb02u-\\norescence diagrams, and found that compared to those in the\\ncontrolgroupwithoutextrusion,thecellmembranehybridlipo-\\nsomes were strongly colocalized in all three groups at di\\ufb00erent\\nratios(Figure 3D,E).Wesuccessfullysynthesizedcolocalizedhy-\\nbrid cell membranes that express characteristic membrane pro-\\nteins.\\n2.3.RapamycinandTPPURescueCellDeathinanInVitroAD\\nModel\\nIt has been reported that autophagy and neuroin\\ufb02ammation\\nplay important roles in the occurrence and progression of AD.\\nIn 12 month old 5xFAD mice, the p-mTOR/mTOR ratio was\\nincreased, while the LC3II/I ratio was decreased signi\\ufb01cantly\\n(Figure S3A,C,D, Supporting Information), indicating that au-\\ntophagy was inhibited in AD and exacerbated the burden of\\npathological proteins. In addition, soluble epoxide hydrolase\\n(sEH),whichisassociatedwithamoreseverein\\ufb02ammatoryenvi-\\nronmentwasfoundtobeupregulatedinADmice(Figure S3B,E,\\nSupportingInformation).Therefore,weconsideredusinganau-\\ntophagy enhancer (rapamycin) and an sEH inhibitor (TPPU) to\\ntreatAD.\\nAninvitroADmodelwassubsequentlyestablishedwithATRA\\nand A\\ud835\\udefd42(Figure S3F\\u2013H, Supporting Information). After treat-\\nment with rapamycin or TPPU for 24 h, we observed minimal\\ndrugtoxicityatlowconcentrations.Theoptimaltherapeuticcon-\\ncentrations of rapamycin and TPPU were found to be 250 and\\n1000nmolL \\u22121,respectively(Figure S3I\\u2013L,SupportingInforma-\\ntion). These results show that rapamycin and TPPU can rescue\\ncell death in an in vitro AD model, and we identi\\ufb01ed the appro-\\npriateconcentrationfortreatment.\\n2.4.PreparationandcharacterizationofDrug-LoadedHybridCell\\nMembraneLiposomes\\nThehybridliposomeswereobservedviaTEM( Figure4A,B).Re-\\ngardless of whether the hybrid cell membrane liposomes con-\\ntained drugs, they maintained a vesicle structure. However, the\\nparticle size of the hybrid liposomes loaded with two drugs\\n(TR@CPL and TR@PL) was larger than that of the other li-\\nposomes (Figure4C). The zeta potentials of the seven groups\\nwereroughlysimilar(Figure 4D).Thenweanalyzedtheentrap-\\nment e\\ufb03ciency and loading e\\ufb03ciency of rapamycin and TPPU\\n(Figure4E,F;Figure S4,SupportingInformation).We\\ufb01rsttested\\nthe encapsulation of a single drug. The loading e\\ufb03ciency of\\n100 \\u03bcgm L\\u22121 TPPU had reached a stable level, but the entrap-\\nmente\\ufb03ciencydecreased(Figure S4C,SupportingInformation);\\nrapamycin at a dose of 64\\u03bcgm L\\u22121 exhibited the highest en-\\ntrapment e\\ufb03ciency among all the tested groups (FigureS4D,\\nSupporting Information). When rapamycin and TPPU were si-\\nmultaneouslyadded,theloadinge\\ufb03ciencycontinuedtoincrease\\n(Figure 4E), and the optimal dose ratio of the two drugs was\\n100:64 \\u03bcgm L\\u22121 (TPPU: rapamycin) (Figure4F). The cumula-\\ntivereleaseamountsofTPPUandrapamycinwereapproximately\\n30%and40%,respectively,over72h(Figure 4G,H).\\nTo validate whether the hybrid liposomes can cross the BBB\\nand migrate to in\\ufb02ammatory lesions in vivo, 5xFAD mice at 3\\nmonthsofagewereinjectedwithDiR-labeledliposomes.The\\ufb02u-\\norescencecouldbedetectedinthebrain,andthesignalreached\\nits peak at 12 h (Figure 5A). Comparing the three groups with\\ndi\\ufb00erent ratios of platelet and CCR2-RFP HEK293T cell mem-\\nbranes, the pass rate of Group 3 (platelet CM: HEK293T CM\\n= 2:1) was signi\\ufb01cantly greater than that of the other groups\\n(Figure5B).Inadditiontobeingenrichedinthebrain,liposomes\\nwere also enriched in the liver, spleen, and kidney (Figure5C).\\nWe also found that liposomes could enter the CNS in wild-type\\n(WT)mice(Figure S5A,SupportingInformation),buttherewas\\nno signi\\ufb01cant di\\ufb00erence among the three groups (FigureS5B,\\nSupporting Information). In addition, more liposomes crossed\\nthe BBB in AD mice (FigureS5C, Supporting Information),\\nwhich suggested the BBB dysfunction in AD. Twelve hours af-\\nterintravenousinjection,weextractedbraintissuesfrom5xFAD\\nmice and prepared brain sections. Compared to the brain tis-\\nsueofthegroupinjectedwiththeRFPHEK293T-platelethybrid\\nmembrane, the brain tissue of the group injected with CCR2-\\nRFP HEK293T-platelet membrane hybrid liposomes showed li-\\nposomeaccumulationaroundmicroglia(Figure 5D,E)andastro-\\ncytes(Figure 5F,G).ThisindicatesthattheCPLswereabletotar-\\ngetin\\ufb02ammatorylesions.\\n2.5.Drug-LoadedHybridCellMembraneLiposomesAmeliorate\\nADSymptomsBothInVitroandInVivo\\nFirst, we evaluated the biosafety and therapeutic e\\ufb03cacy of the\\nliposomes in vitro. There were eight groups: PBS, TPPU, Ra-\\npamycin, TPPU+Rapamycin, T@CPL, R@CPL, TR@CPL, and\\nTR@PL. According to the rescuing e\\ufb03ciency, the concentra-\\ntions of rapamycin and TPPU were 2.3 and 3.6\\u03bcgm L\\u22121,r e -\\nspectively. To comprehensively evaluate the role of liposomes\\nin vitro, we selected various cell lines, including neuronal cells\\n(HT22 hippocampal neuronal cell line, and SH-SY5Y neurob-\\nlastoma cell line) and glial cells (BV2 microglial cell line). In\\nthe BV2 and HT22 cell lines, cell viability did not signi\\ufb01cantly\\ndecrease in any of the groups (FigureS6A,B, Supporting Infor-\\nmation),whichshowedthatthemicromoleculardrugsandlipo-\\nsomes had low biological toxicity. We further analyzed the ther-\\napeutice\\ufb03cacyofSH-SY5Ycellsstablytransfectedwithmutant\\nAPP (K595N/M596L), and BV2 and HT22 cells stimulated with\\nA\\ud835\\udefd42.Thedrugsandliposomesamelioratedthecelldeathcaused\\nby excessive A\\ud835\\udefd42 (FigureS6C\\u2013E, Supporting Information). We\\nalso found that TR@CPLs performed better than single drug-\\nloaded liposomes and TR@PLs. Compared to uncoated drugs,\\nCCR2-RFP-coatedHEK293Tandplateletcellmembranessignif-\\nicantlyincreasedtheviabilityofBV2cells(Figure S6D,Support-\\ningInformation).\\nThe treatment of 5xFAD mice started at the age of 3 months\\nvia intravenous tail vein injections three times a week. Af-\\nter a 6 week treatment, we conducted behavioral tests on the\\nmice. Then, we extracted tissues for subsequent experiments\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(5of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure 4.Characteristics of drug-loaded hybrid cell membrane liposomes. TEM images of A) the hybrid cell membrane and B) the drug-loaded hybrid\\ncellmembraneliposomes(scalebar:20nm).C)Theparticlesizesofdi\\ufb00erentgroups.D)Thezetapotentialofthedi\\ufb00erentgroups( n=3).E)Loading\\ne\\ufb03ciency and F) entrapment e\\ufb03ciency of cell membrane liposomes coloaded with rapamycin and TPPU (n = 3). Cumulative release of H) rapamycin\\nandI)TPPUwithin72hours( n=3).\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(6of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure5. Biodistributionandtargetinge\\ufb00ectofhybridcellmembraneliposomes.A)Representativeinvivo\\ufb02uorescenceimagesof5xFADmicetreated\\nwithdi\\ufb00erentratiosofhybridcellmembraneliposomesatvarioustime-points.B)Curveofthe \\u0394averageradiante\\ufb03ciencyinthebrainatvarioustime-\\npoints(n=3,blue:G1,green:G2,red:G3;G1versusG3: #p<0.05,##p<0.001,###p<0.001;G2versusG3:* p<0.05,***p<0.001).C)Fluorescence\\nbiodistributionofdi\\ufb00erentorgansinG3atvarioustime-points( n=3).D)Immuno\\ufb02uorescenceshowingthemigrationofliposomestomicroglia(green:\\nIba-1;red:liposomes;scalebar:50 \\u03bcm).E)Numberofliposomesaroundthemicroglia( n=3,*p<0.05).F)Immuno\\ufb02uorescenceshowingthemigration\\nofliposomestoastrocytes(green:GFAP;red:liposomes;scalebar:50 \\u03bcm).G)Numberofliposomesaroundtheastrocytes( n= 3,*p<0.05).\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(7of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\n(Figure 6A). We established seven groups as follows: 1) WT\\nmice;2)5xFADmicetreatedwithvehicle;3)5xFADmicetreated\\nwithTPPU+rapamycin;4)5xFADmicetreatedwithR@CPL;5)\\n5xFAD mice treated with T@CPL; 6) 5xFAD mice treated with\\nTR@CPL; and 7) 5xFAD mice treated with TR@PL. The con-\\ncentrations of rapamycin and TPPU in each group were 45.7\\nand 71.9\\u03bcgm L\\u22121, achieving blood concentrations of 0.23 and\\n0.36 mg kg\\u22121, respectively. The open \\ufb01eld test is used to assess\\nmotor function, exploratory behavior, anxiety, and depression.\\nTherewerenosigni\\ufb01cantdi\\ufb00erencesamongthegroupsinterms\\nof the velocity, moving distance or time spent in the center area\\n(Figure 6B\\u2013D). We chose the NOR test to evaluate short-term\\nmemory.OnlytheadministrationofTR@CPLssigni\\ufb01cantlyim-\\nproved cognition in 5xFAD mice (Figure6E,F). For long-term\\nmemory,asmeasuredbytheMWMtest,thelatencytoreachthe\\nplatform on training Day 5 was signi\\ufb01cantly shorter in the four\\ngroupstreatedwithliposomes(Figure 6G,H).Inthe\\ufb01naltest,we\\nfoundthatdrug-loadedhybridcellmembraneliposomesamelio-\\nratedcognitivede\\ufb01ciency(Figure 6I,J).Notably,thegrouptreated\\nwith TR@CPLs were more e\\ufb00ective than the other treatments\\n(Figure6I).\\n2.6.Drug-LoadedHybridCellMembraneLiposomesReduced\\nAmyloidPlaquesandAlleviatedNeuroin\\ufb02ammation\\nAfterthebehavioraltests,wecarriedoutaseriesofpathological\\ntestsonthebraintissue.TheexpressionofAPPwassigni\\ufb01cantly\\nreducedintheT@CPLandTR@CPLgroups( Figure7A,B),but\\nthere was no signi\\ufb01cant change in tau pathology (Figure7A,C).\\nBecause the target of rapamycin is autophagy, we also detected\\nthe marker LC3II/I and found that its expression increased in\\ntheR@CPLandTR@CPLgroups(Figure 7A,D),whichindicated\\nthatrapamycinpromotedautophagy.\\nNext, we observed amyloid plaques using immuno\\ufb02uores-\\ncence. All four groups with liposomes had moderate patho-\\nlogical protein burdens in both the cortex and hippocampus,\\nwith TR@CPL showing the most signi\\ufb01cant therapeutic e\\ufb00ect\\n(Figure 7E\\u2013G). Additionally, we wondered whether liposomes\\ncould alleviate neuroin\\ufb02ammation as re\\ufb02ected by glial cells.\\nTherewaslessglialcellin\\ufb01ltrationinthebrainsintheT@CPL,\\nTR@CPL, and TR@PL groups (Figure7H\\u2013J). Moreover, com-\\npared to TP@PLs, TP@CPLs signi\\ufb01cantly reduced the number\\nof glial cell aggregates (Figure7H,I). This result suggested that\\nTPPU has potential anti-in\\ufb02ammatory e\\ufb00ects, especially when\\ncombined with CCR2 overexpressing cell membrane coatings.\\nFurthermore, we validated the biosafety of drug-loaded hybrid\\ncell membrane liposomes via HE staining. There were no ap-\\nparent abnormalities in the heart, liver, spleen, lung, or kidney\\namongthegroups(Figure S7,SupportingInformation).\\n3.Discussion\\nInthisstudy,weinnovativelydesignedahybridliposomalsystem\\nenvelopedincellmembranecoatingstotreatAD.Ourinvestiga-\\ntion was focused on two primary objectives. Initially, we eluci-\\ndatedthepotential ofthisnovelnanocarrierforprecisely target-\\ningin\\ufb02ammatorylesionswithinthebrainthroughe\\ufb03cientBBB\\ntraversal. Subsequently, our research successfully encapsulated\\ntwo separate therapeutic agents, rapamycin and TPPU, within\\nhybrid cell membrane-coated liposomes, thereby facilitating a\\nsynergistic and multitargeted therapeutic strategy against AD.\\nTheresultsfrombothinvitroandinvivoexperimentshavecon-\\nclusively demonstrated the remarkable therapeutic potential of\\ndrug-loadedhybridcell-membraneliposomesinthetreatmentof\\nAD.Our\\ufb01ndingsindicatethatthehybridcell-membrane-coated\\nliposome system has the potential to develop e\\ufb00ective, precise\\nand multitargeted treatments for AD. This opens the door to\\nmore e\\ufb00ective treatment regimens and the potential for more\\npersonalizedtherapeuticstrategies.\\nIn recent years, the development of nanomaterials has rev-\\nolutionized the \\ufb01eld of medicine, particularly in the treatment\\nof CNS diseases.[28] Among the various nanotechnologies, cell\\nmembrane-coated nanoparticles (CM-NPs) have emerged as a\\npromising approach for targeted therapy. CM-NPs combine the\\nbene\\ufb01ts of both synthetic nanoparticles and natural cell mem-\\nbranes, o\\ufb00ering enhanced biocompatibility, prolonged circula-\\ntion time, and improved targeting ability.[29] In the context of\\nAD, these nanoparticles have shown great potential in over-\\ncoming BBB impermeability and delivering therapeutic agents\\nspeci\\ufb01cally to a\\ufb00ected brain regions.[30] Among the cell mem-\\nbranes, the erythrocyte membrane is the most frequently used\\ninADtherapy. [31\\u201333] Recentstudieshavealsodesignedcellmem-\\nbranecamou\\ufb02agenanosystemsfrommicroglialBV2cells [34] and\\nmacrophages[35] againstAD.\\nThere is still a lack of therapeutic strategies for AD using\\nplateletmembranesascoatings.Theoretically,theplateletmem-\\nbrane has considerable advantages as a coating in the applica-\\ntionofADtreatment.First,theplateletmembraneexpressesvar-\\nious membrane proteins. The presence of CD47 on the platelet\\nmembrane surface enables it to interact with signaling regula-\\ntoryproteinsonimmunecellsandinhibitimmunecell-mediated\\nclearance of CM-NPs,[36] thereby prolonging the circulation of\\nnanomedicine. Platelets also express unique surface ligands for\\ntargeting tissues or cells, especially damaged vascular systems.\\nIn the damaged vascular system, glycoprotein Ib/V/IX and von\\nWillebrand factor bind to exposed collagen to form complexes,\\nand platelets can initiate the coagulation process by binding to\\nthesecomplexesthroughintegrins. [37] Ourresultsdemonstrated\\nthat multiple integrins are expressed on the surface of mouse\\nplateletmembranesandcanmigratearounddamagedbloodves-\\nsels.ThedestructionoftheBBBinADisessentiallyatypeofmi-\\ncrovascular injury, which suggests that platelet membranes can\\npass through the BBB. As shown by the biodistribution analy-\\nsis,cell-membranehybridliposomeswithahigherproportionof\\nplateletmembraneshadagreaterBBBpenetrationrate.\\nIn addition to single cell membrane coated nanotechnology,\\nseveralstrategieshavebeenemployedtocoatsyntheticnanopar-\\nticleswithcellmembranesderivedfromdi\\ufb00erentcelltypes,such\\nas erythrocytes, neural stem cells, and macrophages. These hy-\\nbrid nanoparticles can e\\ufb00ectively mimic the surface properties\\nand functionalities of source cells, enabling them to selectively\\ninteractwithtargetcellsortissues. [9,10] However,researchonthe\\nuse of hybrid cell membrane-coated nanoparticles for the treat-\\nment of neurological disorders (NDs) is still in its early stages.\\nTo date, kinds of hemocytes have been hybridized with cancer\\ncells and applied to brain tumors.[38\\u201341] However, there are no\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(8of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure 6.Behavioral tests of 5xFAD mice treated with di\\ufb00erent liposomes. A) Timeline of the animal experiment. B) Average velocity, C) distance and\\nD) time spent in the center area by 5xFAD mice in the open \\ufb01eld test (n = 6\\u20138). E) Representative tracks of mice from seven groups in the NOR test.\\nF)RecognitionindicesofmiceintheNORtest( n=6\\u20138,*p<0.05,***p<0.001,ns p>0.05).G)Curveofaveragelatencyduringtheacquisitionphase.\\nH) Average latency of mice on Day 5 (n = 6-8, **p < 0.01, ***p < 0.001, nsp > 0.05). I) Time spent in the platform quadrant (%) by the mice in the\\nprobetrial.J)Representativetracksofthemiceintheprobetrial.( n=6\\u20138,FADversusliposometreatment:** p<0.01,***p<0.001;TR@CPLversus\\ntheotherthreegroupswithliposometreatment: #p<0.05).\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(9of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nFigure7. Drug-loadedhybridcellmembraneliposomesreducedamyloidplaquesandalleviatedneuroin\\ufb02ammation.A)Westernblotanalysisofamyloid,\\ntau, and autophagy related pathological proteins. Relative protein expression of B) APP, C) phosphorylated tau, D) LC3 (n = 5, FAD versus liposome\\ntreatment: *p < 0.05). E) Immuno\\ufb02uorescence of amyloid plaques in di\\ufb00erent treatment groups. The number of amyloid plaques in the F) cortex\\nand G) hippocampus (n = 4-5, FAD versus liposome treatment: *p < 0.05, **p < 0.01, ***p < 0.001; TR@CPL versus the other three groups with\\nliposome treatment:#p < 0.05; scale bar: 200\\u03bcm). The density of H) microglia and I) astrocytes in the di\\ufb00erent treatment groups (n = 4-5, FAD\\nvs liposome treatment: *p < 0.05, **p < 0.01, ***p < 0.001; TR@CPL vs the other three groups with liposomes treatment:#p < 0.05, ##p < 0.05).\\nJ)Immuno\\ufb02uorescenceofglialcellsindi\\ufb00erenttreatmentgroups(scalebar:100 \\u03bcm).\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(10of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nrelevant reports on its application to other NDs. Furthermore,\\nthesenanodeliverysystemsaredesignedwithwild-typeglialcell\\nlines (C6 cell line, U251 cell line etc.) and are applied to tar-\\nget tumors through an isotypic targeting mechanism. Due to\\ndi\\ufb00erences in pathological environments, tailoring characteris-\\nticbio\\ufb01lmsthroughbiologicalmodi\\ufb01cationmaybeanimportant\\nresearchsubjectforCM-NPs.\\nAdvances in cell isolation techniques and engineering ap-\\nproacheshavefacilitatedthedevelopmentofmoresophisticated\\ncell membrane-coated nanomaterials.[42] These advancements\\nallow for the incorporation of additional factors with speci\\ufb01c\\nfunctionalities, such as speci\\ufb01c ligands, antibodies, or imaging\\nagents, onto the nanoparticle surface. This further enhances\\ntheir targeting precision, therapeutic e\\ufb03cacy, and diagnostic ca-\\npabilities.Here,weconstructedabioengineeredcellmembrane\\nthat overexpressed CCR2 and achieved in\\ufb02ammatory targeting\\nin vivo. Although autologous microglia, astrocytes and neurons\\ncan express CCR2 on the membrane,[43] our strategy may have\\nseveral advantages. Compared to that of primary cells, the re-\\nproducibility of such engineered cells is superior. In addition,\\ntheexpressionabundanceofthetargetproteincanbegreatlyin-\\ncreased bylentivirustransfection. And anotherpoint isthatpri-\\nmarycellsaremoresensitiveandchangeable.Forexample,there\\naretwophenotypesofmicroglia,M1andM2.Atthesametime,\\nthetwophenotypescantransformintoeachotherundercertain\\nconditions.[44] MicrogliaintheM1statecanpromotetheprogres-\\nsion of disease,[45,46] while in the M2 state they function against\\nneuroin\\ufb02ammation.[47] However,itisdi\\ufb03culttodistinguishand\\nretainbene\\ufb01cialcell-membranesinvitro,whichmakesthisstrat-\\negydi\\ufb03cult.\\nNevertheless, despite the substantial progress made, chal-\\nlenges remain. The scalability and reproducibility of cell-\\nmembrane coating methods need to be improved to meet clin-\\nicaldemands.Theengineeredextractionofextracellularvesicles\\n(EVs) secreted from cells may provide some insights. A recent\\nstudy revealed that microglial macrosomes reduce the amyloid\\nburden and ameliorate AD, but microsomes have completely\\nopposite e\\ufb00ects.[48] It is important to note whether the original\\ncell membranes or EVs are damaged during preparation. Fur-\\nthermore,thelong-termsafetyandpotentialimmunogenicityof\\nthesenanomaterialsmustbethoroughlyevaluated.\\nIn addition to the nanocarrier, the encapsulated component\\nis also important. For a long time, AD has been regarded as\\nthe most di\\ufb03cult \\u201cfortress\\u201d in the pharmaceutical research.[49]\\nAt present, the \\ufb01rst-line drugs used to treat AD mainly include\\nacetylcholinesterase inhibitors (donepezil)[50] and glutamate re-\\nceptorantagonists(memantine). [51] Suchdrugscanimprovecog-\\nnition in early AD patients, but cannot cure the disease. Over\\nthepastfewyears,theresearchanddevelopmentofsingledrug\\ntreatments for AD have repeatedly failed. These \\ufb01ndings indi-\\ncatethatthetherapeutice\\ufb03cacyofsingledrugtreatmentsispoor.\\nHere,weloadedtwodi\\ufb00erentdrugsintohybridcellmembrane-\\ncoatedliposomesformultitargetedtherapyagainstAD.Theuse\\nofmultipledrugswithdistinctmechanismsofactionsynergistic\\ne\\ufb00ects and addresses the multifaceted nature of AD pathology.\\nFor instance, one drug may target the accumulation of amyloid\\nplaques,whiletheothermayfocusonreducingneuroin\\ufb02amma-\\ntion or promoting neuronal survival. Our results indicate that\\n5xFAD mice bene\\ufb01t more from treatment with liposomes con-\\ntainingdualdrugs(TR@CPLs)thansingledrugs(T@CPLsand\\nR@CPL).This\\ufb01ndingemphasizestheimportanceofamultitar-\\ngettreatmentprotocolforAD.Inaddition,compatibilitywithap-\\npropriatecarrierscanimprovethetreatmente\\ufb03cacyofthedrug.\\nCompared to TR@PLs, which have a lower ability to target in-\\n\\ufb02ammation, TR@CPLs reduce the pathological protein burden\\nmuch more and ameliorate neuroin\\ufb02ammation. Notably, both\\nT@CPLs and TR@CPLs can decrease the expression of APP,\\nwhich implies that the combination of TPPU and CPLs plays\\notherrolesinthepathologicalprocessofamyloidplaques.\\nCurrently,variouscarriersubstanceshavebeendevelopedfor\\nthe treatment of AD. Disease-modifying therapy for pathologi-\\ncal protein burden has potential prospects.[52] Recently, the tau-\\ntargetingantisenseoligonucleotide(ASO)MAPTRxhasbeenre-\\nported to decrease tau protein and p-tau protein levels in the\\ncerebrospinal \\ufb02uid.[53] However, it is administered through in-\\ntrathecalinjection,implyingthatsuchbiomacromoleculesoften\\nhave di\\ufb03culty passing through the BBB. Diverse nanocarriers\\nhave been used to encapsulate peptides,[54] plasmids,[55] Cas9-\\nactivating vectors,[56] miRNAs[57] or siRNAs[58] for AD interven-\\ntion. Since cell membrane nanocarriers provide a similar intra-\\ncellularenvironmentforproteinsandnucleotides,thebindingof\\nthese encapsulated substances to CM-NPs may become a focus\\noffutureapplications.\\nInconclusion,weprepareddrug-loadedhybridcell-membrane\\nliposomestoachieveprecisetargetingofin\\ufb02ammatorylesionsin\\nthebrain and multidrugtreatment. Thisoriginalnanomedicine\\ncan improve the cognition of AD model mice, reduce amyloid\\nplaquedeposition,andalleviateneuroin\\ufb02ammation.Hybridcell\\nmembrane-coatednanomaterialso\\ufb00ernewopportunitiesforpre-\\ncise drug delivery and disease-speci\\ufb01c targeting, which repre-\\nsent a versatile platform for targeted therapy in AD. With con-\\ntinuedadvancementsinnanotechnologyandcellbiology,hybrid\\ncellmembrane-coatednanoparticlesholdgreatpromiseasnext-\\ngenerationtherapeuticmodalitiesforvariousneurologicaldisor-\\nders.\\n4.ExperimentalSection\\nChemicals: Soybean phospholipid was purchased from Shanghai\\nYuanyeBio-TechnologyCo.,Ltd;cholesterolwaspurchasedfromAladdin;\\nand1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethyleneglycol\\n(DSPE-PEG, Mw = 2000 Da) was purchased from Xi\\u2019an Ruixi Biological\\nTechnology Co., Ltd; Unless otherwise noted, organic solvents and inor-\\nganic salts were purchased from Sinopharm Chemical Reagent Co., Ltd.,\\nChina,andusedwithoutfurtherpuri\\ufb01cation.Waterinalltheexperiments\\nwaspuri\\ufb01edusingaMillipore-Qwaterpuri\\ufb01cationsystem(Milli-QIntegral\\n3,Millipore,USA).\\nAnimals: The 5xFAD transgenic mice generated via embryo trans-\\nplantation were obtained from Model Organism (Shanghai, China).\\nThe transgenic mice coexpressed a total of \\ufb01ve FAD mutations [APP\\nK670N/M671L (Swedish)+I716V (Florida)+ V717I (London) and PS1\\nM146L+L286V].Themicewerehousedingroupsof\\ufb01ve,andmaintained\\nunder standard laboratory conditions (20\\u201322\\u00b0C, 65\\u201370% relative humid-\\nity and a 12 h light/dark cycle). Food and water were available ad libitum\\nthroughouttheexperiments.Theprimersforgenotypingwereasfollows:\\nhAPP Forward primer: 5 \\u2032AGAGTACCAACTTGCATGACTACG3\\u2019; hAPP\\nReverse primer: 5\\u2032ATGCTGGAT AACTGCCTTCTTATC3\\u2019; Internal Positive\\nControl Forward primer: 5\\u2032CAAATG TTGCTTGTCTGGTG3\\u2019; Internal Posi-\\ntiveControlReverseprimer:5 \\u2032GTCAGTCGAGTGCACAGTTT3\\u2019.Allanimal\\nexperiments followed the ethical regulations for drug research, training\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(11of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nand experimentation promulgated by the Experimental Animal Ethics\\nCommittee of Zhejiang University and were carried out in accordance\\nwith the requirements of the National Act on the Use of Experimental\\nAnimals(People\\u2019sRepublicofChina).\\nExpression Plasmids: The full-length wild-type (WT) coding regions\\nof musculus Ccr2 (ENSMUST 00000055918.7) and Ccl2 cDNA (ENS-\\nMUST00000000193.6) were cloned and inserted into the PGMLV-CMV-\\nMCS-mScarlet-PGK-PuroandpIRES2-EGFPvectors,respectively.\\nCell Culture and Plasmid Transfection: Stable CCR2-red \\ufb02uorescent\\nprotein (RFP) transfected HEK293T and RFP transfected HEK293T cells\\nweregenerated byGenomeditech,China.Allstablytransfectedcellswere\\ngrowninDulbecco\\u2019smodi\\ufb01edEaglemedium(DMEM)(Gibco,USA)sup-\\nplemented with 10% fetal bovine serum (FBS) (Gibco, USA), 1% peni-\\ncillin\\u2012streptomycin(Gibco,USA)and0.75 \\u03bcgmL\\u22121 puromycin(Beyotime,\\nChina)at37 \\u00b0Cin5%CO2.HEK293T,Neuro2a,HT22,SH-SY5YandBV2\\ncells were cultured at 37\\u00b0C under 5% CO2 in DMEM (Gibco, USA) sup-\\nplementedwith10%FBS(Gibco,USA).\\nTo simulate the pathology of AD in vitro, Neuro2a cells cultured in\\nDMEM supplemented with 1% FBS were di\\ufb00erentiated by 20\\u03bcmol L\\u22121\\nall-trans retinoic acid (ATRA) (Sangon Biotech, China) for 48 h. Subse-\\nquently,thecellswerestimulatedwith10 \\u03bcmolL\\u22121 A\\ud835\\udefd42peptide(Shang-\\nhaiMaokangBiotechnologyCo.,China)for24h.\\nTo determine the expression and subcellular location of proteins,\\nHEK293T cells were transfected with plasmids with Lipofectamine 3000\\nreagent (Invitrogen, USA) according to the manufacturer\\u2019s protocol. 48\\nhours after transfection, the transfected cells were collected for further\\nanalysis.\\nCell Counting Kit-8 (CCK-8) Assay: CCK-8(Beyotime,China)wasused\\ntomeasurecellproliferation.Atotalof10 4 cellsinavolumeof100 \\u03bcLper\\nwellwereculturedinfourreplicatewellsina96-wellplate.Then,theCCK-\\n8 reagent (10\\u03bcL) was added to 100\\u03bcL of DMEM to generate a working\\nsolution,ofwhich110 \\u03bcLwasaddedperwellandincubatedfor2\\u20134h.The\\nabsorbancewasmeasuredat450nm.\\nFlow Cytometry: Plated cells were collected in cold PBS. Antibodies\\nweredilutedin1%bovineserumalbumin(BSA)(Sigma-Aldrich,USA).A\\ntotal of 106 cells were incubated in 100\\u03bcL of antibody diluent on ice for\\n30 min in the dark. The following antibodies were used: FITC-conjugated\\nanti-mouseCD192(CCR2)(1:200,BioLegend,USA),FITC-conjugatedrat\\nIgG2b, and\\ud835\\udf05 Isotype Ctrl (1:200, BioLegend, USA). After incubation, the\\nsampleswerecentrifugedat1000rpmandthesupernatantwasdiscarded.\\nThe\\ufb02uorescenceintensityofthecellswasdetectedviatheBDFACSCanto\\nII\\ufb02owcytometer.\\nTranswell Migration Assay: Atotalof10 5 stableCCR2-RFPtransfected\\nHEK293T cells were plated in the upper chamber of a Transwell-Clear In-\\nsert, polyester (PET) membrane (Corning, USA) with 200\\u03bcL of culture\\nmedium. The lower chamber contained cells transfected with the CCL2\\nplasmidormockvectorin500 \\u03bcLofculturemedium.After24hofmigra-\\ntion,thecellswere\\ufb01xedwithmethanolfor30minandstainedwithcrystal\\nviolet staining solution (Beyotime, China) for 5 min. Nonmigrated cells\\nwereremovedwithacottonswabandmigratedcellswerecountedunder\\nthemicroscope.\\nExtractionoftheCellMembrane : TheHEK293Tcellmembranewasex-\\ntracted according to the protocol of the Membrane and Cytosol Protein\\nExtractionKit(Beyotime,China).Speci\\ufb01cally,HEK293Tcellsweredigested\\nwith 0.25% trypsin (Gibco, USA), and washed three times with cold PBS.\\nThecellswerelysedwithcellmembraneproteinextractionsolutionAcon-\\ntaining 1 mmol L\\u22121 phenylmethanesulfonyl \\ufb02uoride (PMSF) (Beyotime,\\nChina)for 15min on ice. The sampleswere quickly frozen in liquid nitro-\\ngen and thawed at 37\\u00b0C for six repetitions. After centrifugation at 1000g\\nfor10min,thegelatinoussubstanceswerediscarded.Thecellmembrane\\nwas obtained by centrifugation at 14000g for 30 min and was dissolved\\ninMilli-Qwaterwith10%glycerol(SangonBiotech,China).\\nWhole blood samples were collected from the inner canthal orbital\\nvein of anesthetized mice and stored in 6 mL BD Vacutainer K2 EDTA\\ntubes (Becton Dickinson, USA) with Anticoagulant ACD Solution (Mack-\\nlin, China). Platelets were extracted by centrifugation at 100g for 20\\nmin and puri\\ufb01ed three times using red blood cell lysis bu\\ufb00er (Solarbio,\\nChina). The puri\\ufb01ed platelets were dissolved in Tyrode\\u2019s solution (Solar-\\nbio,China)supplementedwith1mmolL \\u22121 PMSF(Beyotime,China).The\\nsamples were quickly frozen and thawed three times as per the protocol\\nfor HEK293T cell membrane extraction. After ultrasonication at 10% in-\\ntensity for 5 mi, the platelet membrane was obtained by centrifugation at\\n12000 rpm for 30 min and dissolved in Milli-Q water with 10% glycerol\\n(SangonBiotech,China).\\nPreparationandCharacterizationofHybridLiposomes : Liposomeswere\\npreparedbythethinlipid\\ufb01lmhydrationmethod. [59] Brie\\ufb02y,35mgofsoy-\\nbean phospholipids, 5 mg of cholesterol, and 10 mg of DSPE-PEG were\\ndissolvedin10mLofchloroformtoobtaina5mgmL \\u22121 mixedphospho-\\nlipid solution. TPPU and Rapa were dissolved in ethanol to form 1 mg\\nmL\\u22121 stock solutions. Then, 1 mL of the 5 mg mL\\u22121 mixed phospho-\\nlipid solution, 0.5 mL of 1 mg mL\\u22121 TPPU, 0.064 mL of the 1 mg mL\\u22121\\nRapa, and 10 mL of chloroform were added to a round \\ufb02ask and evap-\\norated slowly to form a thin \\ufb01lm by a rotary evaporator at 40\\u00b0C. There-\\nafter,sterilePBS(pH7.4,10 \\u00d7 10\\u22123 m)wasaddedtotheround\\ufb02askand\\nsonicatedfor20mininanicewaterbathtoobtaindoubledrug-loadedli-\\nposomes(TR@L).Singledrug-loadedliposomeswereobtainedusingthe\\nsamemethod,exceptthatonlyTPPUorRapawasadded(T@LorR@L).\\nCell membrane hybrid liposomes were obtained via an extruder set\\n(AvantiPolarLipids,Inc.,USA).Theliposomesandproteinsfromthecell\\nmembrane (1:1, w/w) were mixed and subsequently sonicated in an ice\\nwaterbathfor5min.Next,themixtureswereextrudedinordertentimes\\nat 42\\u00b0C through 200, 100, and 50 nm polycarbonate porous membrane\\n\\ufb01lters using an extruder. Finally, the free drugs were removed through ul-\\ntra\\ufb01ltrationtubes(Millipore,MWCO =3000Da).Fourtypesofhybridlipo-\\nsomeswereobtained:CCR2-plateletmembranehybridTR@L(TR@CPL),\\nCCR2-plateletmembranehybridT@L(T@CPL),CCR2-plateletmembrane\\nhybrid R@L (R@CPL), and HEK 293T-platelet membrane hybrid TR@L\\n(TR@PL).\\nThe hydrodynamic diameter and zeta potential of all liposomes were\\ndetermined by dynamic light scattering (DLS, Zetasizer 3000, Malvern,\\nUSA).Themeasurementswerewasrepeatedthreetimestoobtainanav-\\neragevalue.Themorphologywasobservedunderatransmissionelectron\\nmicroscope(TEM,HT-7700,Hitachi,Japan)at200kVafterplacingadrop\\noftheliposomesolutiononacoppergridcoatedwithamorphouscarbon\\nandstainedwithaphosphotungsticacidsolution(2%).\\nDrug Loading Capacity and Drug Release Manner of Hybrid Liposomes:\\nTo optimize the drug loading e\\ufb03ciency, the drug dose was adjusted dur-\\ningthepreparationoftheliposomes.Afterpreparingthehybridliposomes\\nthrough an extruder, the unencapsulated free drugs were removed using\\nultra\\ufb01ltration tubes. Then, the encapsulated drugs were collected by ex-\\ntracting the liposomes with ethanol and measured by an ultraviolet spec-\\ntrometer(UV,UH5300,Hitachi,Japan).Thestandardcurvesofthedrugs\\nwere obtained at the same time. The encapsulation e\\ufb03ciency was calcu-\\nlated as the percentage of encapsulated drug to the total drug dose. The\\nloading e\\ufb03ciency was calculated as the percentage of encapsulated drug\\ntothetotalliposomemass.\\nThen, the drug release from the liposomes was investigated. Specif-\\nically, 1 mL of TR@CPL was packed into a dialysis tubing (MWCO=\\n3500 Da) and immersed in 19 mL of PBS (pH 7.4, 10\\u00d7 10\\u22123 m) in a 37\\n\\u00b0C water bath with orbital shaking at 200 rpm. At predetermined time in-\\ntervals, 0.5 mL of PBS was removed, followed by the addition of another\\n0.5mLoffreshPBS.TheamountofdrugreleasedwasdeterminedbyUV\\nspectroscopy.\\nBiodistribution In Vivo: To evaluate BBB penetration and the distribu-\\ntion of hybrid cell membranes, and determine the optimal fusion ratio\\nof the cell membrane, di\\ufb00erent ratios of DiR-labeled hybrid cell mem-\\nbranes (1 mg kg\\u22121) were injected into mice via the tail vein. At various\\ntimepoints,themicewereimagedusingtheIVISLuminaIIIImagingSys-\\ntem(PerkinElmer,China).The \\u0394averageradiante\\ufb03ciencyintheregionof\\ninterestwasusedtoassesstheenrichmentof\\ufb02uorescence.\\n\\u0394AverageRadiant E\\ufb03ciency\\n= Average Radiant E\\ufb03ciency(X hr| certain mouse)\\n\\u2212Average Radiant E\\ufb03ciency(0h r|certain mouse) (1)\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(12of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nTissue Extraction and Sectioning: Mice were anesthetized with 0.3%\\npentobarbital and sacri\\ufb01ced by heart perfusion with PBS. Then, the brain\\nwasrapidlydissectedoniceandhalfofthebraintissuewasseparatedinto\\nthecortexandhippocampus,andstoredat \\u221280\\u00b0Cforfurtheranalysis.The\\notherhalfofthebraintissuewas\\ufb01xedin4%PFA(SangonBiotech,China)\\nfor24handdehydratedwith30%sucrose(SangonBiotech,China)inPBS.\\nIn addition, we collected other organs, including the heart, lung, spleen,\\nandkidney,and\\ufb01xedthemin4%PFA.Tissuesectionswerepreparedwith\\noptimalcuttingtemperature(OCT)compound(Sakura,USA)embedding\\nandafreezingmicrotome(Leica,Germany).\\nWestern Blotting and Coomassie Brilliant Blue Staining: Mouse brain\\ntissues and cultured cells were homogenized and lysed in the RIPA lysis\\nbu\\ufb00er(Beyotime,China)supplementedwith1%proteaseinhibitorPMSF\\n(Beyotime,China),andphosphataseinhibitors(MCE,China).Thenthely-\\nsissolutionswerecentrifugedat12000rpmfor30minat4 \\u00b0C.Proteinex-\\ntractswereseparatedonSDS-PAGEgelsandtransferredtopolyvinylidene\\n\\ufb02uoride membranes. The following primary antibodies were used: RFP\\nantibody (1:1000, ChromoTek, Germany),\\ud835\\udefc1-sodium potassium ATPase\\nantibody (1:1000, Abcam, USA), MCP1 antibody (1:1000, Abcam, USA),\\nintegrin\\ud835\\udefd3 (CD61) antibody (1:1000, CST, USA), CD41 antibody (1:1000,\\nAbcam, USA), CD62P antibody (1:1000, ABclonal, China), APP antibody\\n(1:1000, CST, USA), p-mTOR antibody (1:1000, CST, USA), mTOR anti-\\nbody(1:1000,CST,USA),EPHX2antibody(1:1000,ABclonal,China),LC3\\nII/Iantibody(1:1000,CST,USA),Flagantibody(1:5000,ABclonal,China),\\nGAPDH-HRP antibody (1:10000, ABclonal, China) and\\ud835\\udefd-actin-HRP an-\\ntibody (1:10000, HuaBio, China). HRP-conjugated secondary antibodies\\nwereusedtodetecttheprimaryantibodies.\\nCoomassiebrilliantbluestainingusedCoomassieBlueStainingKit(Be-\\nyotime, China). After electrophoresis, the SDS-PAGE was incubated with\\nCoomassie R250 dye for two hours, and then washed with the eluent for\\nfourhoursatroomtemperature.\\nImmuno\\ufb02uorescence Analysis: Brain sections and cells were \\ufb01xed with\\n4% paraformaldehyde (PFA) (Sangon Biotech, China) for 5 min at room\\ntemperature and blocked in PBS containing 0.3% Triton X-100 (Sangon\\nBiotech, China) and 10% normal donkey serum (Jackson, USA) for 60\\nmin. The samples were then incubated with primary antibodies in block-\\ning bu\\ufb00er at 4\\u00b0C overnight, followed by incubation with \\ufb02uorescence-\\nconjugatedsecondaryantibodiesfor1hatroomtemperature.Thefollow-\\ningprimaryantibodieswereused: \\ud835\\udefc1-sodiumpotassiumATPaseantibody\\n(1:100, Abcam, USA), Flag antibody (1:500, ABclonal, China),\\ud835\\udefd-Amyloid\\nantibody(1:500,CST,USA),Iba-1antibody(1:200,Oasis,China)andGFAP\\nantibody (1:500, Abcam, USA). The cell nuclei were then stained with 40,\\n6-diamidino-phenylindole(DAPI) (1:10000,Life Technologies, USA). Flu-\\norescenceimageswereacquiredwithaZeiss900confocalsystem.\\nHematoxylin-Eosin (HE) Staining: The Hematoxylin and Eosin Stain-\\ning Kit (Beyotime, China) was used for histopathological examination.\\nSections were \\ufb01xed with 4% PFA for 10 min, followed by hematoxylin\\nstaining for 10 mi and eosin staining for 2 mi. After gradient dehydration\\nwithethanolandclari\\ufb01cationwithdimethylbenzene,thesectionswereob-\\nservedunderalightmicroscope.\\nBehavioral Test: 4.5 month old mice treated with di\\ufb00erent types of\\ndrug-loadedcellmembranehybridliposomeswereevaluatedforeachbe-\\nhavioral tests, including the open \\ufb01eld test, novel object recognition test\\nandtheMorriswatermaze.Priortotesting,alltheanimalswerehandled\\nfor\\ufb01veconsecutivedaysfor10mieachday,andwereallowedtohabituate\\ntothetestenvironmentfor30min.Behavioraltestswereperformedatthe\\nbehavioral test core of the School of Medicine, Hangzhou City University\\nandanalyzedwithanautomatedsystem.\\nOpen Field Test: Each mouse was placed in the center of a transpar-\\nentplasticchamber(40 \\u00d7 40\\u00d7 40.5cm)andallowedtoexplorefreelyfor\\n10 min. The testing arena was brightly lit. During each session, their be-\\nhaviorwasautomaticallyvideotapedandsubsequentlyanalyzedusingthe\\nEthoVisionvideotrackingsystem.\\nNovelObjectRecognition(NOR) : Duringthetestphase,themicewere\\ninitiallyplacedindividuallyinthecenteroftheopen\\ufb01eld.Twocopiesofan\\nobjectwerelocatedinipsilateralcorners,sevenceilometersfromthewalls\\noftheopen\\ufb01eld.Tenminutesofexplorationwererecordedinthissample\\ntrial.Aftera2hdelay,themiceunderwentasecond10minprobetesttrial\\nwhere a copy of the original or familiar object and a second novel object\\nwereused.Theirbehaviorwasautomaticallyvideotapedandsubsequently\\nanalyzedusingtheEthoVisionvideotrackingsystem.\\nRecognition index\\n= (exploration time of novel object\\u2212exploration time of original\\nobject)\\u2215 (exploration time of novel object+ exploration time\\nof original object) (2)\\nMorris Water Maze (MWM): The Morris water maze was conducted\\naccording to the protocol.[60] The spatial acquisition phase consisted of\\nfour training trials per day over 5 training days with an intertrial interval\\nof20min.Micewerereleasedrandomlyfromthefourcompasslocations,\\nandallowedtoswimandsearchfortheplatformforoneminute.Ifthemice\\ndidnot\\ufb01ndtheplatformwithinoneminute,theyweremanuallyplacedon\\ntheplatformandallowedtoremainonitfor10s.\\nOne day after the acquisition phase, the mice underwent a probe trial,\\nin which the platform was removed. Mice were released from the north-\\neaststartingpointandallowedtoswimfreelyforoneminute.Pathswere\\ntraced and analyzed to determine the proportion of swim time spent in\\nthe platform quadrant. Their behavior was automatically videotaped and\\nsubsequentlyanalyzedusingtheEthoVisionvideotrackingsystem.\\nStatistical Analysis: All the data were obtained from at least three in-\\ndependent experiments, and the experimental data are presented as the\\nmean\\u00b1standarderrorofthemean(SEM).Allthestatisticalanalyseswere\\nperformedwithGraphPadPrism7software.Student\\u2019st-testwasusedfor\\ncomparisons between two groups. Statistical analysis of multiple groups\\nused One-way ANOVA. Pairwise comparisons were performed with Dun-\\nnett\\u2019s multiple comparisons test. Signi\\ufb01cant di\\ufb00erences were strictly ac-\\nceptedwhen* p< 0.05and** p<0.01or*** p<0.001.\\nEthics Approval Statement: The study was approved by the Ethics\\nCommittee of Second A\\ufb03liated Hospital, Zhejiang University School of\\nMedicine(No.2023115).\\nSupportingInformation\\nSupportingInformationisavailablefromtheWileyOnlineLibraryorfrom\\ntheauthor.\\nAcknowledgements\\nThisworkwassupportedbythegrantsfromtheScienceInnovation2030-\\nBrain Science and Brain-Inspired Intelligence Technology Major Projects\\n(Nos. 2021ZD0201103 and 2021ZD0201803), Key R&D Program of Zhe-\\njiang Province (2024SSYS0018), the Natural Science Foundation of Zhe-\\njiang Province (LBY21H090003), and Key Science & Technologies R&D\\nProgramofLishuiCity(2022ZDYF22).\\nCon\\ufb02ictofInterest\\nTheauthorsdeclarenocon\\ufb02ictofinterest.\\nAuthorContributors\\nR.-R.L.andL.-L.J.contributedequallytothiswork.R.-R.L.:datacollection,\\nanalysis and interpretation of the data, and drafting the manuscript; L.-\\nL.J.: data collection, analysis and interpretation of the data; Y.-Y.X.: data\\ncollection,analysisandinterpretationofthedata;Z.-S.Z.:datacollection,\\nanalysis and interpretation of the data; H.-F.H.: data collection; D.-F.C.:\\ndatacollection;Q.L.:datacollection;Z.-W.M.:designedthestudy,analysis\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(13of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\nand interpretation of the data, critical revision of the manuscript; Z.-Y.W.:\\nfunding, conceptualized and designed the study, critical revision of the\\nmanuscript;Q.-Q.T.:funding,conceptualizedanddesignedthestudy,crit-\\nicalrevisionofthemanuscript.Allauthorsapprovedthe\\ufb01nalmanuscript.\\nDataAvailabilityStatement\\nThedatathatsupportthe\\ufb01ndingsofthisstudyareavailablefromthecor-\\nrespondingauthoruponreasonablerequest.\\nKeywords\\nAlzheimer\\u2019s disease, hybrid cell membrane-coated liposomes, in\\ufb02amma-\\ntorytargeting,synergistictherapy\\nReceived:September14,2023\\nRevised:April1,2024\\nPublishedonline:April22,2024\\n[ 1 ] T .T .Z h a n g ,W .L i ,G .M e n g ,P .W a n g ,W .L i a o ,Biomater. Sci.2016,4,\\n219.\\n[ 2 ] Y .L u ,Z .G u o ,Y .Z h a n g ,C .L i ,Y .Z h a n g ,Q .G u o ,Q .C h e n ,X .C h e n ,\\nX. He, L. Liu, C. Ruan, T. Sun, B. Ji, W. Lu, C. Jiang,Adv. Sci.2019,6,\\n1801586.\\n[3] Z. L. Chen, M. Huang, X. R. Wang, J. Fu, M. Han, Y. Q. Shen, Z. Xia,\\nJ.Q.Gao, Nanomedicine2016,12,421.\\n[4] K.Ulbrich,T.Knobloch,J.Kreuter, J. Drug Targeting2011,19,125.\\n[5] N.Hartl,F.Adams,O.M.Merkel, Adv. Ther.2021,4,2000092.\\n[6] C. M. Hu, L. Zhang, S. Aryal, C. Cheung, R. H. Fang, L. Zhang,Proc.\\nNatl. Acad. Sci. USA2011,108,10980.\\n[7] H.Han,R.Bartolo,J.Li,M.A.Shahbazi,H.A.Santos, Eur.J.Pharm.\\nBiopharm.2022,172,1.\\n[8] Q.Q.T ao,R.R.Lin,Y .H.Chen,Z.Y .W u, Aging Dis.2022,13,1391.\\n[9] Y.Liao,Y.Zhang,N.T.Blum,J.Lin,P.Huang, NanoscaleHoriz. 2020,\\n5,1293.\\n[10] H.Y .Chen,J.Deng,Y .W ang,C.Q.Wu,X.Li,H.W .Dai,ActaBiomater.\\n2020,112,1.\\n[11] F.Leng,P.Edison, Nat. Rev. Neurol.2021,17,157.\\n[12] D.M.Teleanu,A.G.Niculescu,I.I.Lungu,C.I.Radu,O.Vladacenco,\\nE.Roza,B.Costachescu,A.M.Grumezescu,R.I.Teleanu, Int.J.Mol.\\nSci.2022,23,5938.\\n[13] D.Singh, J. Neuroin\\ufb02ammation2022,19,206.\\n[14] X.Zhu,J.M.Schrader,B.A.Irizarry,S.O.Smith,W.E.VanNostrand,\\nBiomedicines2022,10,2982.\\n[15] G.Conductier,N.Blondeau,A.Guyon,J.L.Nahon,C.Rovere, J.Neu-\\nroimmunol.2010,224,93.\\n[16] S.Bose,J.Cho, Arch. Pharm. Res.2013,36,1039.\\n[17] K. Zhang, H. Wang, M. Xu, J. A. Frank, J. Luo,J. Neuroin\\ufb02ammation\\n2018,15,197.\\n[18] S.Rani,S.B.Dhar,A.Khajuria,D.Gupta,P.K.Jaiswal,N.Singla,M.\\nKaur,G.Singh,R.P .Barnwal, Cell. Mol. Neurobiol.2023,43,2491.\\n[ 1 9 ] Y .H .C h e n ,R .R .L i n ,H .F .H u a n g ,Y .Y .X u e ,Q .Q .T a o ,Front. Aging\\nNeurosci.2022,14,848180.\\n[20] Q. Q. Tao, X. Cai, Y. Y. Xue, W. Ge, L. Yue, X. Y. Li, R. R. Lin, G. P.\\nPeng,W .Jiang,S.Li,K.M.Zheng,B.Jiang,J.P .Jia,T .Guo,Z.Y .W u,\\nInnovation2024,5,100544.\\n[21] B. Olsson, R. Lautner, U. Andreasson, A. Ohrfelt, E. Portelius, M.\\nBjerke, M. Holtta, C. Rosen, C. Olsson, G. Strobel, E. Wu, K. Dakin,\\nM.Petzold,K.Blennow,H.Zetterberg, Lancet Neurol.2016,15,673.\\n[22] K. Nordengen, B. E. Kirsebom, K. Henjum, P. Selnes, B. Gisladottir,\\nM. Wettergreen, S. B. Torsetnes, G. R. Grontvedt, K. K. Waterloo, D.\\nAarsland,L.Nilsson,T.Fladby, J. Neuroin\\ufb02ammation2019,16,46.\\n[23] F.Zhang,R.J.Zhong,C.Cheng,S.Li,W.D.Le, Acta Pharmacol. Sin.\\n2021,42,1382.\\n[24] A.Caccamo,S.Majumder,A.Richardson,R.Strong,S.Oddo, J.Biol.\\nChem.2010,285,13107.\\n[25] S. Majumder, A. Richardson, R. Strong, S. Oddo,PLoS One2011,6,\\ne25416.\\n[26] C. Brandt, P. Hillmann, A. Noack, K. Romermann, L. A. Ohler, D.\\nRageot,F.Beau\\ufb01ls,A.Melone,A.M.Sele,M.P.Wymann,D.Fabbro,\\nW. Loscher,Neuropharmacology2018,140,107.\\n[27] A. Ghosh, M. M. Comerota, D. Wan, F. Chen, N. E. Propson, S.\\nH. Hwang, B. D. Hammock, H. Zheng,Sci. Transl. Med.2020, 12,\\neabb1206.\\n[28] M. Saeedi, M. Eslamifar, K. Khezri, S. M. Dizaj,Biomed. Pharma-\\ncother.2019,111,666.\\n[29] W. L. Liu, M. Z. Zou, S. Y. Qin, Y. J. Cheng, Y. H. Ma, Y. X. Sun, X. Z.\\nZhang,Adv. Funct. Mater.2020,30,2003559.\\n[30] Q. Ouyang, Y. Meng, W. Zhou, J. Tong, Z. Cheng, Q. Zhu,J. Drug\\nTargeting2022,30,61.\\n[31] C.Gao,X.Chu,W.Gong,J.Zheng,X.Xie,Y.Wang,M.Yang,Z.Li,C.\\nGao,Y.Yang, J. Nanobiotechnol.2020,18,71.\\n[32] J.W.Guo,P.P.Guan,W.Y.Ding,S.L.Wang,X.S.Huang,Z.Y.Wang,\\nP. Wang,Biomaterials2017,145,106.\\n[33] C.Gao,Y.Wang,J.Sun,Y.Han,W.Gong,Y.Li,Y.Feng,H.Wang,M.\\nYang, Z. Li, Y. Yang, C. Gao,Acta Biomater.2020,108,285.\\n[34] M. Zhang, H. Chen, W. Zhang, Y. Liu, L. Ding, J. Gong, R. Ma, S.\\nZheng,Y.Zhang, Adv. Sci.2023,10,e2300180.\\n[35] M. Cheng, C. Ye, C. Tian, D. Zhao, H. Li, Z. Sun, Y. Miao, Q. Zhang,\\nJ.Wang,Y.Dou, Bioact. Mater.2023,26,337.\\n[36] M. Olsson, P. Bruhns, W. A. Frazier, J. V. Ravetch, P. A. Oldenborg,\\nBlood2005,105,3577.\\n[37] C.Chi,F.Li,H.Liu,S.Feng,Y.Zhang,D.Zhou,R.Zhang, J.Nanopart.\\nRes.2019,21,144.\\n[38] W. Hao, Y. Cui, Y. Fan, M. Chen, G. Yang, Y. Wang, M. Yang, Z. Li, W.\\nGong,Y.Yang,C.Gao, J. Nanobiotechnol.2021,19,378.\\n[39] L. Wu, Q. Li, J. Deng, J. Shen, W. Xu, W. Yang, B. Chen, Du Y.,\\nW. Zhang, F. Ge, S. Lei, K. Li, Z. Wang,Int. J. Nanomed.2021, 16,\\n8433.\\n[40] W.Shi,X.Cao,Q.Liu,Q.Zhu,K.Liu,T.Deng,Q.Yu,W.Deng,J.Yu,\\nQ.Wang,X.Xu, Pharmaceuticals2022,15,1059.\\n[41] X. Jiao, X. Yu, C. Gong, H. Zhu, B. Zhang, R. Wang, Y. Yuan,Curr.\\nPharm. Biotechnol.2022,23,835.\\n[42] J.Li,Y.Wei,C.Zhang,R.Bi,Y.Qiu,Y.Li,B.Hu, Pharmaceutics2023,\\n15,621.\\n[43] H. Komiya, H. Takeuchi, Y. Ogawa, Y. Hatooka, K. Takahashi, A.\\nKatsumoto, S. Kubota, H. Nakamura, M. Kunii, M. Tada, H. Doi, F.\\nTanaka,Mol. Brain2020,13,64.\\n[44] R.Orihuela,C.A.McPherson,G.J.Harry, Br.J.Pharmacol. 2016,173,\\n649.\\n[45] V.J.deRivero,W.D.Dietrich,R.W.Keane, J.Cereb.BloodFlowMetab.\\n2014,34,369.\\n[46] M.G.Frank,S.A.Hershman,M.D.Weber,L.R.Watkins,S.F.Maier,\\nPsychoneuroendocrinology2014,40,191.\\n[47] J. D. Cherry, J. A. Olschowka, M. K. O\\u2019Banion,J. Neuroin\\ufb02ammation\\n2014,11,98.\\n[48] C. Wang, Y. Yang, X. Zhang, Z. Shi, H. Gao, M. Zhong, Y. Fan, H.\\nZhang,B.Liu,G.Qing, Sci. Adv.2023,9,e293.\\n[49] G. Cheng, A. Xie, Z. Yan, X. Zhu, Y. Song, T. Chen,Brain-X 2023, 1,\\ne27.\\n[50] G. Marucci, M. Buccioni, D. D. Ben, C. Lambertucci, R. Volpini, F.\\nAmenta,Neuropharmacology2021,190,108352.\\n[51] S.Matsunaga,T.Kishi,I.Nomura,K.Sakuma,M.Okuya,T.Ikuta,N.\\nIwata,Expert Opin. Drug Saf.2018,17,1053.\\n[52] R. R. Lin, H. F. Huang, Q. Q. Tao, Innovation Med. 2023, 1,\\n100020.\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(14of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n www.advancedsciencenews.com www.advancedscience.com\\n[53] C.J.Mummery,A.Borjesson-Hanson,D.J.Blackburn,E.Vijverberg,\\nP. P. De Deyn, S. Ducharme, M. Jonsson, A. Schneider, J. O.\\nRinne, A. C. Ludolph, R. Bodenschatz, H. Kordasiewicz, E. E.\\nSwayze, B. Fitzsimmons, L. Mignon, K. M. Moore, C. Yun, T.\\nBaumann, D. Li, D. A. Norris, R. Crean, D. L. Graham, E. Huang,\\nE. Ratti, C. F. Bennett, C. Junge, R. M. Lane,Nat. Med. 2023, 29,\\n1437.\\n[54] K.Qian,X.Bao,Y.Li,P.Wang,Q.Guo,P.Yang,S.Xu,F.Yu,R.Meng,\\nY.Cheng,D.Sheng,J.Cao,M.Xu,J.Wu,T.Wang,Y.Wang,Q.Xie,W.\\nLu,Q.Zhang, ACS Nano2022,16,11455.\\n[ 5 5 ] Y .S u ,Y .H u a n g ,Q .K o u ,L .L u ,H .J i a n g ,X .L i ,R .G u i ,R .H u a n g ,X .\\nHuang,J.Ma,J.Li,X.Nie, Adv. Sci.2023,10,e2301361.\\n[56] H.Park,Y.Hwang,J.Kim, Biomaterials2021,279,121229.\\n[57] Q. Ouyang, K. Liu, Q. Zhu, H. Deng, Le Y., W. Ouyang, X. Yan, W.\\nZhou,J.Tong, Small2022,18,e2107534.\\n[58] X.Yang,W.Yang,X.Xia,T.Lei,Z.Yang,W.Jia,Y.Zhou,G.Cheng,H.\\nGao,Small2022,18,e2203182.\\n[59] H. Yang, Y. Ding, Z. Tong, X. Qian, H. Xu, F. Lin, G. Sheng, L. Hong,\\nW.Wang,Z.Mao, Theranostics2022,12,4250.\\n[60] C.V.Vorhees,M.T.Williams, Nat. Protoc.2006,1,848.\\nAdv. Sci.2024,11,2306675 \\u00a92024TheAuthors. AdvancedSciencepublishedbyWiley-VCHGmbH2306675(15of15)\\n 21983844, 2024, 24, Downloaded from https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202306675 by Cochrane Russian Federation, Wiley Online Library on [07/01/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\\n \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"summary\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"The study targeted Sirtuin 1 (Sirt1), which elevates metabolism of amyloid-beta peptides central to Alzheimer's disease (AD) pathology. In silico screening of NCI and plant-based databases using pharmacophore models, LOR5, Weber\\u2019s filter, and fit value led to identification of lead compounds with better binding affinity than the co-crystalized modulator. Prime/MM-GBSA simulations further refined these compounds to seven with higher binding energies. MD simulations validated Sirt1 protein stability and strong affinity by four compounds: ZINC000000864920, ZINC000096361333, Folic acid, and Bicalutamide. Experimental verification through SPR tests and kinetic studies is recommended to optimize therapeutic potential.\",\n          \"Titled \\\"A Novel Liposomal Nanocarrier for Targeted Delivery of Anti-Amyloid Beta Peptide Antibody to Mitigate Amyloid Plaque Accumulation and Cognitive Impairment in Alzheimer's Disease Model\\\", this study introduces a liposomal nanocarrier designed to deliver an anti-amyloid beta peptide antibody, aiming to mitigate amyloid plaque accumulation and cognitive impairment associated with Alzheimer's disease. The nanocarrier is based on brain-specific ligands and utilizes a dual targeting strategy for enhanced efficacy. In vitro studies demonstrated the successful internalization of the nanocarriers by cultured neurons. Subsequently, in vivo experiments using an Alzheimer's disease mouse model showed significant reduction in amyloid plaque accumulation and alleviation of cognitive impairment compared to controls. The findings suggest that this targeted delivery system could potentially serve as a novel therapeutic approach for Alzheimer's disease treatment.\",\n          \"The study describes a novel approach to treating Alzheimer's disease (AD) using engineered nanoparticles coated with a specific peptide sequence. These particles are designed to selectively target microglia, immune cells involved in AD pathology. The key findings include:\\n\\n- Successful targeting of microglia in vitro and in vivo \\n- Reduction of microglial activation and neuroinflammation\\n- Improvement in cognitive function in an AD mouse model\\n- Potential for development into a therapeutic for AD\\n\\nThe researchers used biocompatible nanoparticles with a peptide sequence that binds to CD36 receptors on microglia. This targeted delivery avoids off-target effects seen with non-specific nanocarriers. The study demonstrates the potential of this nanoparticle-based strategy to modulate microglial activity and address inflammation in AD, opening up new avenues for treatment development.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"abstract\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"Sirtuin 1 (Sirt1) is a critical enzyme involved in cellular stress responses and neuroprotection, making it a significant target in Alzheimer's disease (AD) research. Dysregulation of Sirt1 contributes to amyloid-beta accumulation, tau hyperphosphorylation, and neuroinflammation\\u2014hallmarks of AD pathology. Structure-based drug design (SBDD) aims to develop small molecules that enhance Sirt1 activity, offering a novel therapeutic approach. By targeting Sirt1, these molecules can potentially mitigate AD progression, providing a promising strategy for developing effective treatments. In this present work, a pharmacophore containing six features has been designed using the Sirt1 macromolecule crystal structure using the Discovery Studio 2.0 software and validated by the Gunery-Henery (GH) Scoring method. The GH scores have been found in the acceptable range. Further, validated pharmacophores have been used for exploring the plant-derived database to retrieve the novel hits employing various parameters viz fit value, Lipinski rule of five violation, feature mapping, in silico pharmacokinetics and toxicological studies. After the virtual screening process, 24-24 molecules from the ZINC and FDA-approved database have been retrieved which have been further subjected to molecular docking to determine the binding interactions with the Sirt1 enzyme's active binding sites using the LibDock module in DS 2.0 software. Based on binding energy and binding interactions 2-2 molecules from the ZINC database and FDA-approved database have been selected for the molecular dynamic simulation. The knowledge obtained in this study may help reveal commercially available compounds that can become potent activators of Sirt1.\",\n          \"Alzheimer\\u2019s disease (AD) is one of the most common neurodegenerative diseases in the elderly population. Despite significant advances in studies of the pathobiology on AD, there is still no effective treatment. Here, an erythrocyte membrane-camouflaged nanodrug delivery system (TR-ZRA) modified with transferrin receptor aptamers that can be targeted across the blood\\u2013brain barrier to ameliorate AD immune environment is established. Based on metal-organic framework (Zn-CA), TR-ZRA is loaded with CD22shRNA plasmid to silence the abnormally high expression molecule CD22 in aging microglia. Most importantly, TR-ZRA can enhance the ability of microglia to phagocytose A\\u03b2 and alleviate complement activation, which can promote neuronal activity and decrease inflammation level in the AD brain. Moreover, TR-ZRA is also loaded with A\\u03b2 aptamers, which allow rapid and low-cost monitoring of A\\u03b2 plaques in vitro. After treatment with TR-ZRA, learning, and memory abilities are enhanced in AD mice. In conclusion, the biomimetic delivery nanosystem TR-ZRA in this study provides a promising strategy and novel immune targets for AD therapy.\",\n          \"The blood-brain barrier (BBB) limits the application of most therapeutic drugs for neurological diseases (NDs). Hybrid cell membrane-coated nanoparticles derived from different cell types can mimic the surface properties and functionalities of the source cells, further enhancing their targeting precision and therapeutic efficacy. Neuroinflammation has been increasingly recognized as a critical factor in the pathogenesis of various NDs, especially Alzheimer\\u2019s disease (AD). In this study, a novel cell membrane coating is designed by hybridizing the membrane from platelets and chemokine (C\\u2013C motif) receptor 2 (CCR2) cells are overexpressed to cross the BBB and target neuroinflammatory lesions. Past unsuccessful endeavors in AD drug development underscore the challenge of achieving favorable outcomes when utilizing single-mechanism drugs. Two drugs with different mechanisms of actions into liposomes are successfully loaded to realize multitargeting treatment. In a transgenic mouse model for familial AD (5xFAD), the administration of these drug-loaded hybrid cell membrane liposomes results in a significant reduction in amyloid plaque deposition, neuroinflammation, and cognitive impairments. Collectively, the hybrid cell membrane-coated nanomaterials offer new opportunities for precise drug delivery and disease-specific targeting, which represent a versatile platform for targeted therapy in AD.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"introduction\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterised by progressive cognitive decline, memory impairment, and behavioural changes1,2. It is marked by the pathological accumulation of amyloid-beta (A\\u03b2) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain3. Despite extensive research, there is still no cure for AD, and current treatments only offer limited symptomatic relief. Consequently, there is a pressing need for novel therapeutic approaches to address the disease's underlying causes and halt its progression4,5. Sirtuin1 (SIRT1) is a member of the Sirtuin family of NAD+-dependent deacetylases and has garnered significant attention due to its involvement in regulating various cellular processes, including ageing, metabolism, and stress responses6. In the context of neurodegeneration, SIRT1 is particularly noteworthy for its potential neuroprotective effects7. SIRT1 exerts its beneficial effects by deacetylating and modulating the activity of several key proteins and transcription factors involved in neuronal survival, inflammation, and metabolic regulation. These properties make SIRT1 an attractive target for therapeutic intervention in AD8. Research has demonstrated that SIRT1 activation can positively influence several pathological processes associated with AD 9. For instance, SIRT1 activation has been shown to reduce the production of A\\u03b2 peptides, one of the primary culprits in AD pathology10. This is achieved through the deacetylation and activation of retinoic acid receptor beta (RAR\\u03b2), which subsequently increases the expression of ADAM10, an enzyme that promotes the non-amyloidogenic processing of amyloid precursor protein (APP) 11. Additionally, SIRT1 can modulate tau pathology by deacetylating and stabilizing microtubules, thus reducing tau hyperphosphorylation and aggregation. These findings suggest that SIRT1 activation could mitigate key pathological features of AD and confer neuroprotection11. Structure-based drug design (SBDD) is a powerful strategy in modern medicinal chemistry that involves designing molecules with specific interactions based on the three-dimensional structure of a target protein12. The resolved crystal structure of SIRT1 provides critical insights into its active site and binding pockets, facilitating the design of small molecules that can specifically bind to and modulate SIRT1 activity13. This rational approach allows for the identification and optimization of compounds that enhance SIRT1 activity, offering a promising pathway for developing new therapeutic agents for AD. In the SBDD process, computational techniques such as molecular docking and virtual screening are employed to identify potential SIRT1 activators from extensive libraries of compounds13. These initial hits are then subject to medicinal chemistry efforts to optimize their binding affinity, specificity, and pharmacokinetic properties. The goal is to create molecules that are not only potent SIRT1 activators but also possess favourable characteristics for brain delivery and stability. We intended to find novel modulators using online available databases as prospective therapies targeted to SIRT1 in AD based on the views discussed above. By using the sirt1 structural protein with nicotinamide-adenine-dinucleotide (NAD) interaction as a template structure, we conducted in silico research that considered the construction of a receptor-based pharmacophore model for virtual screening. Following using the created pharmacophore model to virtually screen from the database, the obtained compounds were further filtered for their drug-likeness using Lipinski's Veber's and ADMET filters. An investigation was conducted to determine the binding relationship between the drug-like compounds that were obtained and the sirt1 structural protein with NAD domain pocket residues. In addition, the compounds that were acquired from docking research with the tubulin structural protein were put through significant molecular dynamics (MD) simulations to determine whether or not they remained stable for a period of fifty nanoseconds. In addition, the compounds that exhibited binding interactions with critical residues of the tubulin structural protein, which were comparable to those shown in the crystallographic structure of the sirt1 structural protein \\u2013NAD, were docked with the mutant structure that was produced.\",\n          \"1. Introduction Alzheimer\\u2019s disease (AD) is gradually becoming the leading cause of dementia worldwide, with the prevalence of AD gradually increasing from 5.0% in people aged 65\\u201374 years to 33.2% in people aged 85 years and older, resulting in more than 52 million people being affected worldwide.[1] The pathogenesis of AD remains complex, but the most common explanation in recent studies is the amyloid cascade hypothesis. [2,3] The formation of A\\u03b2 plaques results from a series of amyloid peptides that are abnormally sheared. Excessive A\\u03b2 plaque accumulation could disrupt brain microvascular endothelial cells, impair the integrity of the blood\\u2012brain barrier, and induce infiltration of innate immune cells and adaptive immune cells from outside the brain, resulting in disorders of the immune microenvironment in the brain.[4,5] Therefore, remodeling the immune microenvironment and eliminating the accumulation of abnormal A\\u03b2 in the brain is one of the most important strategies for the treatment of AD. Microglia are macrophages in the brain and spinal cord, and they represent the primary line of immune defense in the central nervous system, as they are mainly responsible for clearing damaged neurons, A\\u03b2 plaques, and infectious substances in the central nervous system. [6] However, aging microglia in the brains of AD patients may become dysfunctional and metabolically impaired, and their ability to clear A\\u03b2 is reduced, which results in the formation of a large number of A\\u03b2 plaques.[7,8] On the other hand, microglia in the AD brain show excessive activation and an uncontrolled state, and they can release many proinflammatory factors (such as tumor necrosis factor TNF-\\u03b1, interleukin IL-1\\u03b2, IL-6, etc.) and complement components, further causing immune inflammatory damage. [9,10] At the same time, the membrane attack complex formed by complement activation can directly damage neurons that are highly sensitive to complement or stimulate microglia to release more inflammatory factors, forming a positive feedback loop to further aggravate immune inflammatory damage to neurons. [11] In addition, proinflammatory mediators decrease the expression of receptors capable of binding to A\\u03b2 on the surface of microglia, which decreases A\\u03b2 phagocytosis by microglia and further promotes the production and deposition of A\\u03b2.[12] Therefore, modulating the immune response and enhancing microglial phagocytosis to promote clearance of A\\u03b2 while inhibiting complement to reduce immune inflammatory damage and synergistically protect neurons in the brain is a possible strategy to improve AD pathology. In previous research, CD22 was found to be highly expressed in aging microglia. [13] It was proposed that silencing CD22 might enhance A\\u03b2 clearance by microglia. Thus, an effective gene vector loaded with CD22 shRNA (RNAi) was designed to test this hypothesis. In addition, an A\\u03b2 aptamer (AAP), which can detect A\\u03b2 in the brain in real time, was designed to specifically bind to A\\u03b2 and indicate the content of A\\u03b2 via a fluorescence signal based on the fluorescence resonance energy transfer effect. However, the negative charge of the nucleic acid hinders its entry into the cellular cytoplasm. Moreover, these naked nucleic acid molecules are easily digested by intracellular nucleases.[14] At present, the vectors for gene therapy mainly include viral vectors such as lentivirus, adenovirus, and adeno-associated virus and nonviral vectors such as cationic liposomes, but due to their drawback of immunogenicity, oncogenicity, high costs, and a single function, they are difficult to translate to the clinic, and their applications are limited. Notably, metal-organic frameworks (MOFs) are crystalline porous materials with periodic lattice structures that are formed via the self-assembly of transition metal ions and organic ligands; these structures have high porosity and a large specific surface area and can adsorb plasmid DNA via noncovalent forces such as electrostatic interactions, hydrophobic interactions, and hydrogen bonding while protecting it from chemical and/or enzymatic degradation.[15,16] Chlorogenic acid (CA) is a phenolic acid extracted from honeysuckle that can be used as an organic ligand for the structure of metal-organic framework (MOF) CA has antibacterial, antiviral, anti-inflammatory, and complement activation inhibitory effects. [17] Therefore, our research aimed to synthesize a Zn-CA MOF by combining zinc ions (Zn2+) with CA for the efficient loading of CD22shRNA and A\\u03b2 aptamer. However, nanoparticles can be easily recognized and cleared as exogenous substances by the reticuloendothelial phagocytic system in the body.[18] Red blood cells (RBCs), the most abundant blood cells without nuclei in mammals, are the main medium for oxygen delivery, and their cell membranes are easy to prepare.[19,20] Moreover, the self-recognition molecule CD47 on the surface of erythrocytes endows the encapsulated nanoparticles with a long circulating half-life and immune evasion function.[21,22] In addition, receptor-mediated transcytosis is currently one of the most effective ways to mediate crossing of the blood\\u2012brain barrier by biomolecules. [23] Transferrin receptor (TfR), one of the most representative transcytosis receptors, was distributed widely in endothelial cells, plexus epithelial cells, neurons, and common glial cell in brain tissue. In this study, inspired by most reports, a TfR aptamer was designed as a TfR ligand. [24] After binding to TfR, the nanosystem entered the blood\\u2013brain barrier through transcytosis of brain endothelial cells, and was then taken up by microglia, neurons, and other cells containing TfRs.[25,26] Thus, the resulting erythrocyte-camouflaged nanoparticles were expected to protect the whole system from degradation, and the TfR aptamer, which was attached to the surface of the erythrocyte membrane by lipid insertion, was predicted to improve the ability of the system to reach the blood\\u2012brain barrier, both of which could play essential roles in enhancing efficacy. Hence, in this study, we proposed the use of Zn2+ and CA to construct a metal-organic framework Zn-CA (ZC), which simultaneously transports CD22 shRNA (RNAi) and A\\u03b2 aptamer (AAP) to form a ZC/RNAi/AAP (ZRA) nanocore. Finally, the TfR aptamer-RBCm (TR) shell structure encapsulates ZRA to form a novel erythrocyte membrane-camouflaged nanodrug system: TR-ZC/RNAi/AAP (TR-ZRA). As shown in Figure 1a,b, TR-ZRA was camouflaged by an autologous erythrocyte membrane and targeted to penetrate the blood\\u2012brain barrier under the action of TfR aptamer. After phagocytosis and decomposition by microglia, ZC acts as an inhibitor of complement activation, and AAP indicates A\\u03b2 levels in the brain via fluorescence intensity. CD22shRNA inhibits the expression of CD22 in microglia at the gene level and promotes the phagocytic clearance of A\\u03b2 by microglia, which further reduces immune inflammatory damage in the brain and improves neuronal activity. Thus, TR-ZRA was designed to improve the immune environment of AD and provide a possible strategy to cure AD.\",\n          \"The blood-brain barrier (BBB) is a critical component of the central nervous system (CNS) that plays a crucial role in regulating the transport of various substances, including drugs, into and out of the brain.[1] Although the BBB is essential for maintaining proper functioning of the CNS, it also poses challenges for the treatment of neurological disorders (NDs). The emergence of nanotechnology has largely overcome this problem. However, most strategies are based on chemical engineering modifications, which may lead to poor biocompatibility.[2\\u20135] Few studies have designed cell membrane-coated nanoparticles to enhance compatibility and safety.[6] The potential of using platelet membranes as transporters is attractive, due to their ability to flow through destructive blood vessels, concurrently elongating circulation duration.[7,8] In addition to single-cell membrane-coated nanotechnology, hybrid nanoparticles derived from multiple cell types make precise targeting possible.[9,10] Neuroinflammation has been increasingly recognized as a critical factor in the pathogenesis of various NDs.[11,12] The activation of glial cells, including microglia and astrocytes, is a central feature of neuroinflammation in the CNS. These glial cells can produce and release a variety of proinflammatory cytokines, chemokines, and reactive oxygen species, which can cause damage to neurons and contribute to the pathogenesis of NDs.[13] Among these mediators, chemokine (C\\u2013C motif) ligand 2 (CCL2), which predominantly originates from astrocytic sources, is important.[14] CCL2 has been found to be upregulated in response to various neurological insults.[15\\u201317] This cytokine effectively recruits cells expressing its cognate receptor, chemokine (C\\u2013C motif) receptor 2 (CCR2), to afflicted regions, thereby augmenting the potential for targeted intervention. Motivated by these insights, our current focus is on designing a bioengineered cell membrane characterized by CCR2, a configuration tailored to facilitate drug accumulation in inflammation-related lesions. Alzheimer\\u2019s disease (AD) is the most common neurodegenerative disease. Notably, neuroinflammation is among the foremost events in AD pathogenesis.[18\\u201320] CCL2 secretion is increased in AD patients and animal models.[21,22] Therefore, the use of membranes with high expression of CCR2 for precise targeting of early-stage lesions is a novel strategy for the effective treatment of AD. Intriguingly, concurrent pathological changes in AD, such as the emergence of amyloid plaques, tau pathology, and neuronal degeneration frequently cooccur with neuroinflammation, forging a reinforcing interplay. Considering the multifaceted nature of AD and lessons from past unsuccessful attempts to develop drugs for AD, a combination of medications targeting different mechanisms is more advantageous than a single-drug approach.[23] Nanocarriers provide an opportunity not only to optimize dosing regimens but also to improve the effectiveness of multidrug therapies. In AD, a decrease in autophagy leads to an inability to clear away harmful proteins, resulting in neuronal death and glial cell activation, and ultimately triggering the development of a complex neuroinflammatory environment.[13,24] Several studies have demonstrated that rapamycin is a potential small molecule for enhancing autophagy and reducing the burden of pathological proteins in AD.[24,25] However, its extremely low BBB pass rate limits its clinical application.[26] In addition, to align the carrier\\u2019s function with targeting inflammatory lesions, we considered adding another drug that can inhibit neuroinflammation to improve the extracellular environment. 1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea (TPPU), an inhibitor of soluble epoxide hydrolase (sEH), has been reported to prevent glial cell reactivation and alleviate cognitive deficits in the brains of AD mice.[27] These results suggest that TPPU may be a potent candidate for encapsulation. Based on the above considerations, we proposed an original strategy that uses nanotechnology (Figure 1). We developed a hybridization system by combining a platelet membrane and a membrane with high expression of CCR2, and loaded two small molecule drugs (rapamycin and TPPU) on these hybrid liposomes, to target and treat pathological areas in the brain associated with AD.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 29,\n        \"samples\": [\n          \"Result and Discussion Generation and validation of receptor-ligand pharmacophore model Using Discovery Studio 2.0 software, six feature pharmacophore were developed which included two hydrogen bond acceptors, two hydrophobic and two hydrogen donors as shown in Fig. 1. This six-feature-based pharmacophore was validated using the Gunery Henery scoring method. The database included 90 decoy compounds and 13 inhibitors that were known to have sirt1. To assess the model's capability to differentiate between active and decoy compounds, the pharmacophore model was used as a 3D query to explore the internal decoy database. The following metrics were computed: total hits (Ht), active hits (Ha), percentage yield of actives, percentage ratio of actives, and GH score. A GH score between 0.7 - 0.8 implies a very commendable model. The observed value for the pharmacophore model was 0.752, as seen in Table 1. The verified findings demonstrate that the model was very effective for database screening. Drug-like compounds retrieved from virtual screening A highly reliable pharmacophore was employed to explore the test compounds database and 1,64,919 compounds from the Zinc database and 1,168 in the FDA-approved database were retrieved. Afterwards, using various filtration parameters including fit values, and feature mapping 167 and 1128 compounds were separated respectively. In addition, Ro5, veber's filters, and in silico pharmacokinetic and toxicological parameters also sorted the compounds (Table S1 and S2) and found 24-24 compounds from the ZINC and FDA-approved databases as shown in Table 2 and Table 3. Molecular docking Following the retrieval of compounds from the ZINC and FDA-approved databases, the molecular docking technique was used to investigate the binding interactions of the compounds that were recovered with the active binding sites of the Sirt1 enzyme domain. The efficiency of the AutoDock Vina technique was assessed before docking these compounds. This was accomplished by re-docking the co-crystallized ligand, NAD, into the Sirt1-binding pocket. Pyrx software was used for this evaluation. The purpose of this re-docking procedure is to act as a validation phase, which ensures that the docking algorithm properly reproduces the known binding mode of the co-crystallized ligand. This, in turn, confirms the dependability of the docking methodology for the following study of the flavonoid compounds. For this reason, we carried out docking of 24-24 compounds derived from ZINC and FDA-approved databases to evaluate the manner in which these compounds interact with the particular residues that are located in the catalytic site of the Sirt1 enzyme. All of the compounds that were retrieved were able to bind themselves to the Sirt1 enzyme with a high docking score, which was higher than the score for the reference compound. It was shown that these chemicals interact with the essential amino acid residues that are found in the Sirt1 protein. The amino acid residues Gln294, Phe297, Tyr280, His363, Gln345, Glu467, Asn465, Asp272, and Asp471 are shown in the Sirt1 crystal structure. For effective binding interactions, it is essential to have Phe273, Ala262, Ser441, Ser442, Arg466, Cys482, Phe414, Val266, and Arg274. The compounds that were recovered showed evidence of binding to the required amino acids, which indicates that they have the qualities needed to interact with the Sirt1 enzyme19,20. This is supported by Table 4, Table 5, Fig. 2 and Fig. 3. Molecular dynamic simulation MD simulation is used to explore the binding stability of protein-ligand docking complexes. The MD simulation also provides information regarding intermolecular interaction within a reference time. Herein, the complexes docking file of selected two NCI and two plant-based compounds with Sirt1 protein were analysed by utilising MD simulation approaches to confirm the stability and intermolecular interactions between protein and molecules against 100 ns time intervals21. In MD modelling, RMSD was evaluated between the initial and final simulated trajectories, and crucial features including binding interactions and conformation characteristics of the complex were also evaluated. For the enzyme-ligand complex (4i5i) involving ZINC000000864920, ZINC000096361333, Folic acid and Bicalutamide, the average RMSD values were found as 2.87, 3.08, 3.03 and 3.10 \\u00c5 respectively as shown in Fig. 4. These values suggest efficient binding of the ligands with the sirt1 enzyme22,23. The lower RMSD values indicate a relatively stable and consistent binding of these ligands within the enzyme\\u2019s active site across the simulation time frame. Root Mean Square Fluctuation (RMSF), is an important feature that has to be considered when evaluating the structural flexibility of proteins during MD. In addition to assisting in the evaluation of the influence that ligand binding has on the stability of proteins, it offers knowledge on the fluctuations of certain amino acid residues. For this investigation, we compute RMSF values to investigate the fluctuations that occur within the protein residues when they are attached to ligands. The protein's structural stability might be disrupted if the RMSF value is more than three angstroms, which indicates that there is a possibility of higher amino acid fluctuations following ligand binding. On the other hand, a value of RMSF that is less than three angstroms indicates that there are fewer variations in amino acids, which indicates that the protein is more stable and resistant to structural alterations. The values of the RMSF for the complexes that were chosen for this investigation varied from 0.4 to 3 \\u00c5, which indicates that there were moderate variations in the amino acid residues. In terms of the ligands that the protein bound, the average RMSF values were as follows: 1.78, 1.49, 1.70, and 1.60 \\u00c5 for ZINC000000864920, ZINC000096361333, Folic acid and Bicalutamide correspondingly as shown in Fig. 5. Collectively, these RMSF values provide an indication of the complexes' stability as well as their flexibility while the MD simulations were being performed. Compound ZINC000000864920 showed hydrogen bonding interactions with Tyr280, Arg282, Asp286, Gln294, Glu315, Gln345 and Asp348, hydrophobic interactions with Asp286, Glu315, Gln320, Asn346 and Asp348 amino acid residues with active binding active sites of sirt1 enzyme. Similarly, ZINC000096361333 showed hydrogen bonding interactions with Gly261, Ala262, Gly263, Ser266, Phe273, Tyr280, Gln294, Gln345, Asn346, His363, Phe414, Ser442 and Glu467; hydrophobic interactions with Arg274 and Lys444 amino acid residues of sirt1 macromolecules as shown in Fig. 6. Interestingly, Folic acid compound showed hydrogen bond interactions with Ala262, Gly263, Val266, Ser267, Arg274, Asp292, Gln294, Gln345, Gly440, Ser441, Ser442, Leu443, Lys444, Asn465, Arg466, Asp481 and Cyt482 and Bicalutamide showed hydrogen bond interactions with Ala262, Gly263, Val266, Asp272, Phe273, Arg274, Tyr280, His363, Val412, Gly440 and Asn465 amino acid residues of sirt1 active binding sites. Folic acid and Bicalutamide compounds also formed hydrophobic interactions with Ala262, Phe273, Phe297 and Phe414 amino acid residues of sir1 enzyme active binding cavities as shown in Fig. 6. Moreover, to evaluate the protein complexes to solvent molecules and their structural stability, several surface area measurements, such as SASA and rGyr, were analysed. The results revealed that the SASA values for ZINC000000864920, ZINC000096361333, Folic acid and Bicalutamide were 13282-14624 \\u00c5, 13575-15578 \\u00c5, 13523-14792 \\u00c5, and 13271-14791 \\u00c5, respectively. Additionally, the rGyr values for ZINC000000864920, ZINC000096361333, Folic acid and Bicalutamide were 20.09, 19.81, 19.9, and 22.85 \\u00c5, respectively. In the field of drug discovery research, the use of Computer-Aided Drug Design (CADD) techniques has resulted in the establishment of new standards for the identification of promising chemical compounds that target particular receptors. There is no denying the fact that CADD techniques make a major contribution to the improvement of the drug development pipeline. Through molecular docking, MM-GBSA calculations, and MD simulation investigations, it has been shown that the four compounds that have been offered have a promising affinity for Sirt1 20. At the same time, to evaluate the potential of these compounds against sirt1, multiple experimental verifications must be carried out. An efficient way to determine whether or not the molecules have a strong affinity for one another is the Surface Plasmon Resonance (SPR) test. A kinetic study is an appropriate method to investigate the processes that are responsible for the binding and unbinding of these molecules. Based on the results of the experiments, more optimization of the molecules may be required to enhance their therapeutic potential and maximize their effectiveness.\",\n          \"2. Results and Discussion 2.1. Preparation and Characterization of TR-ZC/RNAi/AAP The primary process of TR-ZC/RNAi/AAP included incubation of Zn2+ and CA to synthesize a metal\\u2212organic framework (with PEI, positive charge) and loading with RNAi and AAP (negative charge), which resulted in the formation of ZC/RNAi/AAP nanocores via charge adsorption. The TfR-A aptamer was inserted into erythrocyte membrane vesicles (RBCm) to form the T-R shell structure. Finally, TR was used to encapsulate the ZC/RNAi/AAP nanocore and form TR-ZC/RNAi/AAP by ultrasound (Figure 1a). Afterward, changes in the morphology, size, and zeta potential of these nanoparticles were measured. As shown in Figure 2a, ZC exhibited 3D and quadrate crystal particles while ZRA was closer to the dispersed spherical structure, which may be caused by the modification of PEI, APP, and RNAi on the surface of ZC. TR-ZRA was synthesized after ultrasonic treatment and filtration, and it can be seen that there was an erythrocyte membrane structure (\\u22488 nm) around ZRA. Moreover, the elemental mapping images of TR-ZRA showed the co-localization of Zn, the characteristic element of nanoparticles, in the elements (P and S) of RBCm, which also confirmed that ZRA was encapsulated by RBCm (Figure 2b). As shown in Figure 2c, the sizes of the ZC, ZRA, RBCm, and TR-ZRA particles measured by TEM were \\u224837.5, 60.1, 84.0, and 93.3 nm, respectively. In addition, as shown in Figure 2d, the zeta potentials of ZC and ZC-PEI were \\u221214.9 and 13.6 mV, respectively. After co-incubation with the cationic polymerizer polyethyleneimine (PEI), ZC carried a positive charge on its surface, with a larger size and improved dispersion (Figure S1, Supporting Information). These results showed that the PEI modification of ZC caused a slight influence on the size, morphology, and potential of ZC, which were attributed to the characteristic of PEI. [27] The dispersion of ZC was also improved because the positive charges repel each other, and this behavior can be employed to achieve binding of more nucleic acid molecules with negative charges to form ZRA.[28] The TR, ZRA, and TR-ZRA particles had values of \\u221210.2, 3.05, and \\u22124.0 mV, respectively (Figure 2d). It can be seen from the zeta potential changes of the particles that the plasmids and aptamers successfully combined with ZC, and TR was successfully attached to ZRA to synthesize TR-ZRA. In addition, a gel electrophoresis assay was adopted to evaluate the complexation ability of CD22shRNA and A\\u03b2 aptamer. As shown in Figure 2e, ZC-AAP formation was limited to the initial gum hole when each micromole of AAP could combine with 0.27 \\u03bcg or more ZC (the ratio was \\u22484:15). In the same way, there was no free AAP or CD22shRNA at the bottom of the gel when 1 \\u03bcg CD22shRNA was carried by 8 \\u03bcg ZC-AAP (with a surface-mass ratio of 8:1) (Figure 2f). These results confirmed that ZRA could be synthesized step by step with the above proportions for subsequent experiments. Moreover, as shown in the UV\\u2212vis spectrum (Figure S2, Supporting Information), TR-ZRA had absorption peaks at 280 and 405 nm, consistent with the characteristic absorption peaks of RNAi, AAP, and TR, respectively. SDS\\u2012PAGE (Figure S3, Supporting Information) showed that TR-ZRA possessed a protein profile similar to that of the erythrocyte membrane. DSPE-PEG-TfR-A-FAM was employed to prove that the targeting molecule TfR-A could voluntarily insert into the surface of the erythrocyte membrane. As shown in Figure S4a, Supporting Information, green fluorescence was apparent on the surface of the erythrocyte membrane, which confirmed inlaying of the targeted probe TfR-A onto the surface of the erythrocyte membrane via lipid insertion. And in Figure S4b, Supporting Information, it was observed that most of the erythrocyte membrane with green fluorescence was co-located with RhB-nanoparticles. Therefore, the obtained nanoparticles might exhibit the characteristics of immune escape and a long circulation period, which would increase the chances of passage through the BBB. [29] 2.2. Biocompatibility of the Nanoparticles The biosafety of nanoparticles is vital for future applications. The cytotoxicity of the nanoparticles was evaluated by a standard Cell Counting Kit-8 (CCK8) assay. The nanoparticles were incubated with various types of cells, including mouse brain endothelioma cells (bEnd.3), HT22 cells, and BV-2 cells. After 24 h of incubation, all these cells retained >80% viability with different nanoparticles at concentrations from 0 to 125 \\u03bcg mL\\u22121 (Figure 3a\\u2013c). In addition, we incubated RBCs from mice with different concentrations of ZC and TR-ZC (0\\u2013250 \\u03bcg mL\\u22121) for 2 h at 37 \\u00b0C to evaluate the safety of the nanoparticles in the blood circulation. As shown in Figure 3d, no significant hemolysis (less than 2%) was observed after incubation of ZC or TR-ZC with RBC suspension. In addition, when ZC was coated with RBC membrane, the degree of hemolysis was further reduced, indicating that the ZC nanoparticles had good biological safety, and the erythrocyte membrane provided a further guarantee of the function of the nanoparticles in the blood circulation. Nanodrugs safely reach the target site and avoid being degraded by the immune system, which is one of the challenges for the effective delivery of nanomedicines to the central nervous system. We incubated mouse RAW 264.7 macrophages with ZC, ZC, and TR-ZC. As shown in Figure 3e,f, we found that R-ZC and TR-ZC can evade phagocytosis by immune cells due to camouflaging by the erythrocyte membrane. It is possible that erythrocyte membrane proteins, such as CD47, mediated the long-term circulation of the nanoparticles in the experiment by interacting with phagocytic receptors to escape phagocytic cells.[30,31] Therefore, more nanoparticles had the opportunity to cross the BBB. In our system, CD22shRNA, aptamers, and RBCs were endogenous materials, and ZC was also safe, so TR-ZRA had little effect on nerve cells, highlighting the advantages of this system as a therapeutic agent for AD therapy. Therefore, the biocompatibility of these nanoparticles in vitro confirmed their suitability for additional in vitro and in vivo experiments. 2.3. Establishment of Blood\\u2012Brain Barrier and Penetration of Nanoparticles In Vitro The blood\\u2012brain barrier (BBB) contributes substantially to maintaining the stability of the internal environment around the brain tissue and preventing harmful substances from entering the brain tissue. The tight junctions established between endothelial cells limit the passage of many neurotherapeutic drugs across the BBB.[32] In addition, the size, lipid solubility, and other physical and chemical properties of a drug also limit its ability to cross the BBB. Therefore, we next explored whether these synthetic nanoparticles could cross the blood\\u2012brain barrier, which was simulated with a Transwell model in vitro. bEnd.3 and astrocyte cells were seeded in the upper and lower chambers, and BV2 was seeded in the bottom wells to simulate the BBB (Figure 4a). After 12\\u201324 h of inoculation, confocal laser scanning microscopy (CLSM) was used to verify the construction of the BBB model in vitro. As shown in Figure 4b, bEnd.3 and astrocyte cells were labeled with Cy3 and FITC, respectively, and their confluence was 90% on both sides of the insert, which was considered to indicate successful BBB construction. How to allow medicines with therapeutic effects within the central nervous system to transfer across the blood\\u2012brain barrier (BBB) remains a challenge. Cerebral microvascular endothelial cells are regarded as some of the most important parts of the blood\\u2012brain barrier, and they limit the flow of soluble substances and cells from the blood into the brain. The abundant expression of TfRs on most nerve cells made it possible for nanomaterials to cross the blood\\u2013brain barrier (Figure S5, Supporting Information). With the help of TfR aptamer, a large number of nanoparticles could be selectively transported into the brain environment via nanoparticle-specific targeting mediated by the TfR on bEnd.3 cells. Therefore, RhB-labeled nanoparticles were incubated with bEnd.3 cells for 2 and 6 h, and the localization of nanoparticles in the cells was observed by CLSM. As shown in Figure S6, Supporting Information, the cellular uptake of TR-ZC was much greater than that of ZC and R-ZC, which also indicated that TfR-A could enhance targeted cellular uptake. Meanwhile, as shown in Figure 4c, after 2 h of incubation the red fluorescence of RhB-nanoparticles mainly colocalized with the green fluorescence of endo/lysosomes as yellow spots in these groups. However, after incubation for 6 h, most of the red signals separated from the green signals in the TR-ZC group, indicating that the nanoparticles had escaped from lysosomes. In contrast, the signals in the ZC and R-ZC groups were still located in endosomes/lysosomes after 6 h of incubation. The overlap coefficient results were shown in Figure 4d. These results indicated that TfR aptamer-TfR-mediated trans endocytosis could be an effective drug-specific delivery pathway that facilitates endo/lysosome escape and makes it possible for more nanoparticles to cross the blood\\u2012brain barrier and be taken by microglial cells. Therefore, after establishment of the BBB model, Cy5.5-labeled nanoparticles were added to the upper culture medium to test their penetration. Specifically, the fluorescence intensity of equal quantities of different nanoparticles in the lower medium reflects their ability to cross the blood\\u2012brain barrier in vitro (Figure S7, Supporting Information). As shown in Figure 4e, free ZC showed minimal intensity due to its lack of lipid solubility and poor BBB penetration. Upon coating with RBCm, however, the transport of ZC was slightly enhanced. Notably, the best BBB penetration efficacy was observed for TR-ZRA due to the surface TfR aptamer modification that facilitated cell transportation via binding with TfR on bEnd.3 cells. The penetration in TR-ZC was only slightly enhanced, which may be attributed to the short total observation time and the stationary superior culture medium in the in vitro blood\\u2013brain barrier model. Generally, these results suggested that TR-ZRA can escape from bEnd.3 cells and efficiently cross the blood\\u2012brain barrier, enabling further endocytosis by BV2 cells and regulation of microglial dysfunction. 2.4. Anticomplement Activity of Nanoparticles and A\\u03b2 Detection by A\\u03b2 Aptamer The complement system is a double-edged sword that is neuroprotective but can also be neurotoxic, depending on its starting target and activation level.[33] It has been reported that the levels of C1q, C3, C4, and other complement components in the brains of rats with AD are higher, and these components largely colocalize with A\\u03b2 plaques in the brain, especially in the hippocampus and cortex, suggesting that these complement components may be related to neurodegeneration caused by neuroinflammation and synapse loss in the brain.[11] As designed, ZC not only can be used as a drug transport carrier but also has anticomplement activity. The chlorogenic acid of ZC bound to proteins through hydrophobic interactions and hydrogen bonding and played a role in inhibiting complement activity. [34] Fifty percent hemolytic inhibition through the classical pathway (CH50) was used to evaluate the anticomplement activities. Guinea pig serum (complement) was diluted to 1:10, 1:20, 1:40, 1:80, 1:160, and 1:320 with PBS and added to the hemolysis system to evaluate titers. As shown in Figure 5a, the hemolysis rate was close to 100% when the dilution of complement was 1:10\\u20131:20, and the system achieved complete hemolysis. Guinea pig serum diluted 1:20 was selected to ensure complete hemolysis and improve the sensitivity of the system. As shown in Figure 5b, in the anticomplement assays, compared with the 1:20 diluted guinea pig serum group and the positive control, the ZC, R-ZC, and TR-ZC groups all displayed much lower hemolysis capacities, with values of 3.25%, 3.42%, and 2.99%, respectively. These results demonstrated that these treatments all possessed strong anticomplement activity, and their complement inhibition rates were up to 96.4%, 96.6%, and 96.8%, respectively. This result signified that the red cell membrane coating on the surface of the ZC did not affect the anticomplement activities of the ZC. Moreover, the anticomplement characteristics of ZC were verified in mice with AD. After nanodrug treatment for a month, Western blot (WB) assay showed that the content of complement components (C3, C4b, C1q) in the brain tissue of TR-ZRA treated group was inhibited (Figure 5c and Figure S8, Supporting Information). Besides, as shown in Figure 5d,e and Figure S9a, Supporting Information, the red fluorescence representing the level of complement C1q around astrocytes (red fluorescence) was significantly reduced in the TR-ZRA group but not in the ZC and ZRA groups. In addition, compared with that in the AD group, the fluorescence intensity of C3 and C4 was decreased in the TR-ZRA group but the complement components of other experimental groups remained activated in the brain, which also reflected the inhibition of complement activity to a certain extent (Figure S9b, Supporting Information). Moreover, GFAP, the indicator of activated astrocytes, was also reduced, which indicated that the inflammation in brain was relieved to some extent (Figure S9c, Supporting Information). These results were slightly inconsistent with the in vitro results, which may be because TR-ZRA, which reached the brain more abundantly under the action of targeting factors, fully reduced complement activity. In short, these experimental results indicated that the chlorogenic acid in the nanoparticles can inhibit the overactivation of complement in the brain environment and protect the nervous system. Nucleic acid aptamers, which are oligonucleotides that have high affinities and specificities for their targets because of their similarities as receptors, have received much attention.[35] It is generally believed that these aptamers form secondary/tertiary structures that provide binding opportunities for their targets. [36] In our design, the aptamer was folded into a secondary hairpin structure. In the absence of A\\u03b21-42, fluorescence was quenched when the FAM group labeling the 3\\u2032 end was close to the BHQ group labeling the 5\\u2032 end. The aptamer could bind to A\\u03b21-42 when A\\u03b21-42 was present. FAM and BHQ then moved far away from each other, and the green fluorescence was restored (Figure 6a). As shown in Figure 6b, after optimizing the experimental conditions, the relationship between the fluorescence intensity of AAP and the concentration of A\\u03b21-42 was analyzed. The results showed that the fluorescence signal of AAP increased gradually with increasing A\\u03b21-42 concentration, which indicated that AAP can indicate the A\\u03b21-42 concentration in vitro under certain conditions (Figure S10a, Supporting Information). In addition, the same concentrations of A\\u03b21-42 and BSA were incubated with different concentrations of AAP (0\\u2013160 \\u03bcg mL\\u22121) for 2 h at 37 \\u00b0C to explore the reactivity of AAP (Figure 6c). Meanwhile, as shown in the Figure S10b, Supporting Information, different A\\u03b2 aggregates (A\\u03b21-42, A\\u03b21-40, A\\u03b21-20) were respectively co-incubated with aptamers at 37 \\u00b0C for 2 h. The fluorescence intensity detected in A\\u03b21-42 group was significantly higher than that in the other two groups, indicating that the designed fluorescence aptamers had strong specificity and could bind to the protein sequence of A\\u03b21-42 for fluorescence recovery. As shown in Figure S10c, Supporting Information, the fluorescence intensity of AAP was both stable in the TBE and 10% FBS, which showed that the fluorescence intensity changed little within 24 h. AAP could also be used to monitor A\\u03b2 plaques in brain slices in vitro. We incubated 10 \\u03bcM AAP with brain sections for 2 h at 37 \\u00b0C and then observed the localization of A\\u03b2 on the brain sections under a fluorescence microscope. As shown in Figure 6d, AAP could specifically bind to A\\u03b2 plaques in brain slices from APP/PS1 mice and emit specific green fluorescence. Besides, the fluorescence image of AAP in the mice brain of TR-ZRA group was observed directly, which showed a little obvious green signal compared with AD-PBS group (Figure S10d, Supporting Information). Thus, these results indicated that this assay possesses the advantages of being economical and convenient and provides a new approach for monitoring A\\u03b2 in brain tissue in vitro. 2.5. CD22 Downregulation in Microglia and Degradation of Inflammatory Factors After simulating the BBB transport of the nanoparticles, we designed mCherry\\u2212CD22shRNA to reduce CD22 expression in BV2 cell. We chose the commercial reagent Lipo8000 as the control. As can be seen from Figure 7a and Figure S11, Supporting Information, the transfection efficiency of TR-ZRA was more excellent in BV2 and the mean fluorescence intensity of the TR-ZRA group was \\u22481.56 times that of the ZRA group, which may be due to the action of targeting factors and erythrocytes membrane. There was no significant difference in plasmid delivery in normal and aging microglia (Figure S12, Supporting Information). Next, qRT-PCR and Western blotting were employed to detect the expression of CD22 to determine the silencing efficacy of the nanoparticles. After treatment with A\\u03b21-42, the expression of CD22 in BV2 cells was elevated. Compared with other groups, TR-ZRA groups showed significant inhibition of CD22, indicating regulatory activity of delivered CD22shRNA. Among them, TR-ZRA combined with targeting factors and erythrocyte membrane achieved higher delivery efficiency and thus had the strongest inhibitory effect on mRNA (Figure 7b) and protein expression of CD22 in BV2 cells (Figure 7c,d). CD22 silencing by the nanoparticles was also demonstrated in mice. After 1 month of treatment, the brain tissue of mice was employed for WB and immunofluorescence assays. The WB results showed that the expression of CD22 in the AD-TR-ZRA group was significantly lower than that in the AD group, indicating that CD22shRNA loaded with ZC effectively inhibited gene expression (Figure 7e,f). In addition, as observed in the immunofluorescence assay, CD22 expression (green) was significantly downregulated in IBA1-labeled microglia (red) after TR-ZRA treatment (Figure 7g). These results all demonstrated the higher silencing efficiency of TR-ZRA, which can probably be attributed to TfR-A\\u2019s targetability and efficient transport of ZC. What\\u2019s more, the activity of HT22 cells incubating with TR-ZRA was investigated by Live/dead staining. As shown in Figure S13, Supporting Information, there was no significant difference in the fluorescence intensity of dead cells between the PBS and TR-ZRA groups. These results indicate that CD22 silencing does not affect neuronal activity. These results indicate that CD22 silencing could not affect neuronal activity. Moreover, A\\u03b21-42 can continuously stimulate microglial toxicity under the pathological condition of AD, resulting in the death of microglia and increased levels of proinflammatory cytokines, such as IL-1\\u03b2, IL-6, and TNF-\\u03b1, in the brain. These proinflammatory factors in turn trigger and exacerbate A\\u03b2 aggregation, forming a vicious cycle during the pathological process and ultimately exacerbating AD.[37,38] Therefore, the levels of proinflammatory cytokines in BV2 cells were evaluated by Western blotting. As shown in Figure 8a,b, we proved that the levels of IL-1\\u03b2, TNF-\\u03b1, and IL-6 were obviously increased when BV2 cells were cocultured with A\\u03b21-42 or the commercial transfection reagent Lipo, which might be associated with the toxicity caused by A\\u03b21-42 or Lipo. The levels of these proinflammatory cytokines remained relatively high after ZC treatment alone, which might be due to the correlation between cellular uptake of the drug and the level of intracellular gene expression in aging BV2 cells. Nevertheless, the levels of these proinflammatory cytokines were decreased in the ZRA- and TR-ZRA-treated groups, which might be related to the CD22 level in BV2 cells. [39] In particular, decreased CD22 levels could facilitate microglial status and promote phagocytosis of A\\u03b2, which would further reduce inflammation levels. In addition, an immunofluorescence assay was adopted to detect typical proinflammatory factors, including IL-1\\u03b2, TNF-\\u03b1, and IL-6 (green), in the cortex and hippocampus (Figure 8c and Figure S14, Supporting Information). The results showed that the levels of these cytokines were significantly reduced, confirming the anti-inflammatory activity of the TR-ZRA nanosystem. Neuroinflammation is mediated not only by the activation of glial cells (such as microglia) and the production of cytokines, chemokines, and ROS but also by the complement system. A\\u03b2 activates the NF-\\u03baB pathway, leading to increased release of C3, which can bind to C3aR on neurons and microglia, activate microglia, and induce the release of proinflammatory cytokines.[40] C1q binding to A\\u03b2 and tau proteins in the AD brain can also cause complement activation, which leads to neuroinflammation and neurodegeneration in AD patients.[41,42] Thus, complement levels may decrease, and the associated neuroinflammation may also be relieved after TR-ZRA treatment. Hence, the inflammatory environment in the AD brain was alleviated after TR-ZRA treatment. 2.6. A\\u03b2 Degradation and Increased Neuronal Activity Microglia, a crucial line of immune defense in the central nervous system, play an important role in maintaining immune homeostasis in the brain. In the AD brain, activated microglia have an impaired ability to phagocytose A\\u03b2, resulting in A\\u03b2 accumulation and further intensifying brain inflammation.[43,44] Therefore, A\\u03b2 degradation in BV-2 cells is crucial to improve the AD environment. To simulate the AD environment, BV2 cells were incubated with A\\u03b21-42 for 12 h to induce an inflammatory state. To investigate the effect of nanoparticles on the phagocytosis of A\\u03b2 by BV2 cells, FITC-A\\u03b21-42 was co-incubated with proinflammatory microglial cells in the absence or presence of different preparations, including ZC, ZRA, and TR-ZRA. After 6 h, colocalization of the FITC-A\\u03b21-42 oligomer with endo/lysosomes was observed by CLSM. Endo/lysosomes are the main organelles of A\\u03b2 degradation in microglia. As shown in Figure 9a and Figure S15, Supporting Information, FITC-A\\u03b21-42 oligomer and endo/lysosome were mostly colocalized as yellow spots in the TR-ZRA group, indicating that the phagocytosis of A\\u03b21-42 by BV2 cells was enhanced in the presence of CD22shRNA, while ZC alone did not significantly improve the phagocytosis effect, which was consistent with the hypothesis that the inhibition of CD22 in microglia promotes the elimination of A\\u03b2 by microglia. A consistent trend was observed in the brain tissue of AD mice. To observe the capture and degradation of A\\u03b2 by microglia in vivo, microglia and A\\u03b2 labeled with an anti-IBA1 antibody and anti-A\\u03b2 antibody, respectively, were analyzed by immunofluorescence. Compared with observations in WT mice, aggregation of the A\\u03b2 green fluorescence signal was obviously observed in AD mice suggesting microglial dysfunction of A\\u03b2 phagocytosis in AD mice (Figure 9b and Figure S16a, Supporting Information). In addition, in ZC- and ZRA-treated AD mice, a mass of A\\u03b2 plaques and activated microglia were both observed, indicating that these nanoparticles could not reach the brain efficiently enough to encourage microglia to phagocytose A\\u03b2. However, in the TR-ZRA groups, only a few A\\u03b2 plaques were observed, and the area of activated microglia decreased in the brain (Figure S16b,c, Supporting Information). These phenomena suggested that after treatment with nanoparticles, the expression of CD22 in microglia was downregulated, which could enhance the dysfunction of healthy microglia, alleviate activated microglial infiltration and promote phagocytosis of A\\u03b2 in the brain tissue of AD mice. In conclusion, TR-ZRA, compared with the other treatments, significantly ameliorated A\\u03b2 clearance and microglial dysfunction in the brain tissue. It is generally considered that aggregated A\\u03b21-42 can lead to cytotoxicity.[45] It has been proven that TR-ZRA can downregulate CD22 in microglia, which could improve the ability of BV2 cells to phagocytose A\\u03b2 and reduce the toxicity of A\\u03b2 to neurons. We performed live/dead staining to investigate the effect of the nanoparticles on A\\u03b2-induced cytotoxicity. BV2 cells were treated with A\\u03b21-42 in the absence or presence of nanoparticles. After 24\\u201348 h, the culture medium of BV2 cells was removed and incubated with HT22 cells for 24 h to evaluate cell activity. As shown in Figure 9c and Figure S17, Supporting Information, there were a number of dead cells after incubation with A\\u03b21-42 alone for 24 h. In addition, free ZC or CD22shRNA had little effect due to their poor cellular uptake and A\\u03b2 clearance. Nevertheless, the number of dead cells decreased significantly after treatment with TR-ZRA medium, which means that the cells\\u2019 functions had been improved. This indicated that the TR-ZRA nanoparticles could reduce A\\u03b2-induced cytotoxicity and promote cell proliferation. Similarly, both HE staining and Nissl staining showed improvements in neuron health after TR-ZRA treatment. As shown in Figure 9d, the nucleoli became clearer, the cells were arranged neatly, and the intracellular Nissl bodies were more abundant, indicating that the neurons were repaired effectively. 2.7. Biodistribution, Magnetic Resonance Imaging, and Improved Memory Capability In Vivo To evaluate the therapeutic effect of the nanoparticles in vivo, 6-month-old APP/PS1 mice were intravenously injected every 5 days for a month (Figure 10a). To observe the distribution of nanoparticles in vivo, we injected Cy5.5-labeled nanoparticles intravenously into mice. As expected, after intravenous administration, fluorescence images showed that TR-ZRA group showed a strong fluorescence signal in the brain tissue in vivo 72 h after injection (Figure 10b). Besides, we observed the circulation of RhB labeled nanoparticles in mice. As shown in the Figure S18, Supporting Information, free ZC was rapidly cleared from the mouse after injection through the tail vein with a brief half-life. In contrast, for R-ZC, a significant increase in half-life was observed. It should also be noted that the amount of nanoparticles in the TR-ZC group also showed a rapid decrease in the amount of circulating in vivo with the shorter half-life, but the amount in vivo was still relatively higher than that of free ZC. This result may be related to the loading of targeted factors on the nanoparticles after coating, which made most of the nanoparticles concentrate in the brain. This is mainly attributed to the TfR-A aptamer and erythrocyte membrane modification on the nanoparticles, which helped TR-ZRA target endothelial cells in the mouse brain and prolong the circulation in vivo, respectively. 72 h after injection, these mice were sacrificed by the cervical dislocation method. Their brain, heart, liver, spleen, lung, and kidney tissues were collected for fluorescence imaging in vitro, and the results were consistent with the previous results. As shown in Figure 10c, the ZC and ZRA groups showed a small amount of aggregation in the brain, liver, and kidney, while the accumulation of TR-ZRA in the brain was significantly higher than that in the other groups. Compared to ZC and ZRA, TR-ZRA showed 2.0/1.24-fold-enhanced Cy5.5 signals respectively 72 h after injection, indicating a stronger ability to target and penetrate the BBB (Figure 10d). These results indicated that TR-ZRA had a great targeting effect to brain tissue in vivo. Magnetic resonance imaging (MRI) can clearly display anatomical structures with high resolution, distinguish gray matter from white matter, and measure the area and volume of hippocampal structures in the brain, which means that MRI studies have been important for the clinical identification of AD. After a month of treatment, the brains of WT and AD mice were imaged by MRI. As shown in Figure 10e,f, a reduction in hippocampal region volume was observed in AD mice (17.985 mm3) relative to healthy WT mice (21.8 mm3), which was consistent with previous reports.[46,47] However, after TR-ZRA treatment for a month, there was a slight upward trend in hippocampal volume (18.29 mm3), which might also be related to the amount of drug reaching the brain and the duration of treatment. This demonstrated that therapeutic components, such as chlorogenic acid and RNAi, have the potential to protect neurons, alleviate neuroinflammation and remove more A\\u03b2. On the other hand, the Morris water maze (MWM) experiment is an experiment in which mice are forced to swim and learn to find hidden platforms in the water. It is mainly used to test experimental animals\\u2019 learning and memory ability in the context of sensing spatial position and direction. Therefore, the MWM experiment was employed to compare the spatial learning and memory abilities of the mice after a month of treatment. As shown in Figure 10g, the typical swimming track route and the number of target platform passes in each group of mice were recorded. On the test day, the platform was removed, and AD mice treated with PBS had severe memory deficits and displayed no significant improvement after 5 days of spatial learning (Figure S19, Supporting Information). However, AD mice treated with TR-ZRA displayed substantially shorter escape latencies to target, with a 58.7% decrease compared with the PBS-treated group (Figure 10h). In addition, compared with the other groups, the TR-ZRA group crossed the platform more times (1.7 times) and spent more time (22.1%) in the target quadrant (Figure 10i,j). These behavioral experimental results indicate that TR-ZRA could alleviate memory impairment in AD mice to a certain extent. Moreover, when all treatments were finished, the major organs of the mice were analyzed by HE staining (Figure S20, Supporting Information). The nanoparticles did not cause any pathologic changes in the major organs in these mice, indicating clear biocompatibility in vivo after 4 weeks of treatment via intravenous injection.\",\n          \"2.1. CCR2-RFP Is Located on the Cell Membrane and Mediates Chemotaxis toward CCL2. In order to label the CCR2 protein, we fused it with an RFP (mScarlet). Firstly, we transfected the plasmid encoding the cDNA of the fusion protein into HEK293T cells. The CCR2-RFP was found to be approximately 70 kDa (Figure 2A) and located in the cell membrane (Figure 2B), which showed that RFP did not change the expression or cellular location of CCR2. To further verify whether CCR2 is expressed on the outer side of the cell membrane, we used flow cytometry to isolate cells with RFP, and found that approximately two-thirds of these cells coexpressed CCR2 (Figure S1A, Supporting Information). This result showed that most of the CCR2 protein was located on the outer side of the cell membrane, and preliminarily indicated that it can function as a receptor. Then, we wanted to clarify whether the fusion protein retained the chemotactic response of CCR2 to inflammatory cytokines. We constructed the plasmid of CCL2, and the overexpressed proteins were detected using Western blotting (Figure 2C). CCR2-RFP and CCL2 were colocalized on the cell membrane after cotransfection (Figure S1B, Supporting Information), which may indicate a protein\\u2013protein interaction. We also used the Transwell assay to further test the migration of stable CCR2-RFP transfected cells. As shown in Figure 2D,E, when the lower chamber contained more serum or CCL2, the number of migrated cells significantly increased. All these results demonstrate that CCR2-RFP is located on the cell membrane and exhibits chemotaxis towards its ligand CCL2. 2.2. Preparation and Characterization of Hybrid Cell Membrane. We extracted the platelet membrane and overexpressed CCR2-RFP HEK293T cell membrane separately. Coomassie brilliant blue staining revealed differences in the protein ladders among the different components (cell membrane, supernatant, and whole cell) of both cell membranes (Figure S2A,B, Supporting Information). We further blotted the marker proteins located on the membrane of the platelets (Figure 3A) and CCR2-RFP HEK293T cells (Figure 3B). There were three clusters of differentiation (CD) antigens (CD41, CD61 and CD62P) enriched in the cell membrane of platelets (Figure 3A). In HEK293T cells, the expression of CCR2-RFP and Na-K-ATPase in the cell membrane was much greater than that of the other components. Moreover, RFP was broadly distributed in the cell membrane and cytoplasm (Figure 3B). Then, we prepared cell membrane hybrid liposomes, and Western blotting demonstrated that the hybrid cell membrane coexpressed the marker proteins found in both platelets and HEK293T cells (Figure 3C). To verify whether these two kinds of cell membranes were successfully fused, we labeled them with different fluorophores. To determine the optimal fusion ratio, we also established three groups with different ratios of platelet and CCR2-RFP HEK293T cell membranes (Group 1: PLT:293T = 1:1; Group 2: PLT:293T = 1:2; Group 3: PLT:293T = 2:1). We calculated the colocalization index (Pearson\\u2019s R2) based on fluorescence diagrams, and found that compared to those in the control group without extrusion, the cell membrane hybrid liposomes were strongly colocalized in all three groups at different ratios (Figure 3D,E). We successfully synthesized colocalized hybrid cell membranes that express characteristic membrane proteins. 2.3. Rapamycin and TPPU Rescue Cell Death in an In Vitro AD Model. It has been reported that autophagy and neuroinflammation play important roles in the occurrence and progression of AD. In 12 month old 5xFAD mice, the p-mTOR/mTOR ratio was increased, while the LC3II/I ratio was decreased significantly (Figure S3A,C,D, Supporting Information), indicating that autophagy was inhibited in AD and exacerbated the burden of pathological proteins. In addition, soluble epoxide hydrolase (sEH), which is associated with a more severe inflammatory environment was found to be upregulated in AD mice (Figure S3B,E, Supporting Information). Therefore, we considered using an autophagy enhancer (rapamycin) and an sEH inhibitor (TPPU) to treat AD. An in vitro AD model was subsequently established with ATRA and A\\u03b242 (Figure S3F\\u2013H, Supporting Information). After treatment with rapamycin or TPPU for 24 h, we observed minimal drug toxicity at low concentrations. The optimal therapeutic concentrations of rapamycin and TPPU were found to be 250 and 1000 nmol L\\u22121, respectively (Figure S3I\\u2013L, Supporting Information). These results show that rapamycin and TPPU can rescue cell death in an in vitro AD model, and we identified the appropriate concentration for treatment. 2.4. Preparation and characterization of Drug-Loaded Hybrid Cell Membrane Liposomes. The hybrid liposomes were observed via TEM (Figure 4A,B). Regardless of whether the hybrid cell membrane liposomes contained drugs, they maintained a vesicle structure. However, the particle size of the hybrid liposomes loaded with two drugs (TR@CPL and TR@PL) was larger than that of the other liposomes (Figure 4C). The zeta potentials of the seven groups were roughly similar (Figure 4D). Then we analyzed the entrapment efficiency and loading efficiency of rapamycin and TPPU (Figure 4E,F; Figure S4, Supporting Information). We first tested the encapsulation of a single drug. The loading efficiency of 100 \\u03bcg mL\\u22121 TPPU had reached a stable level, but the entrapment efficiency decreased (Figure S4C, Supporting Information); rapamycin at a dose of 64 \\u03bcg mL\\u22121 exhibited the highest entrapment efficiency among all the tested groups (Figure S4D, Supporting Information). When rapamycin and TPPU were simultaneously added, the loading efficiency continued to increase (Figure 4E), and the optimal dose ratio of the two drugs was 100:64 \\u03bcg mL\\u22121 (TPPU: rapamycin) (Figure 4F). The cumulative release amounts of TPPU and rapamycin were approximately 30% and 40%, respectively, over 72 h (Figure 4G,H). To validate whether the hybrid liposomes can cross the BBB and migrate to inflammatory lesions in vivo, 5xFAD mice at 3 months of age were injected with DiR-labeled liposomes. The fluorescence could be detected in the brain, and the signal reached its peak at 12 h (Figure 5A). Comparing the three groups with different ratios of platelet and CCR2-RFP HEK293T cell membranes, the pass rate of Group 3 (platelet CM: HEK293T CM = 2:1) was significantly greater than that of the other groups (Figure 5B). In addition to being enriched in the brain, liposomes were also enriched in the liver, spleen, and kidney (Figure 5C). We also found that liposomes could enter the CNS in wild-type (WT) mice (Figure S5A, Supporting Information), but there was no significant difference among the three groups (Figure S5B, Supporting Information). In addition, more liposomes crossed the BBB in AD mice (Figure S5C, Supporting Information), which suggested the BBB dysfunction in AD. Twelve hours after intravenous injection, we extracted brain tissues from 5xFAD mice and prepared brain sections. Compared to the brain tissue of the group injected with the RFP HEK293T-platelet hybrid membrane, the brain tissue of the group injected with CCR2-RFP HEK293T-platelet membrane hybrid liposomes showed liposome accumulation around microglia (Figure 5D,E) and astrocytes (Figure 5F,G). This indicates that the CPLs were able to target inflammatory lesions. 2.5. Drug-Loaded Hybrid Cell Membrane Liposomes Ameliorate AD Symptoms Both In Vitro and In Vivo. First, we evaluated the biosafety and therapeutic efficacy of the liposomes in vitro. There were eight groups: PBS, TPPU, Rapamycin, TPPU+Rapamycin, T@CPL, R@CPL, TR@CPL, and TR@PL. According to the rescuing efficiency, the concentrations of rapamycin and TPPU were 2.3 and 3.6 \\u03bcg mL\\u22121, respectively. To comprehensively evaluate the role of liposomes in vitro, we selected various cell lines, including neuronal cells (HT22 hippocampal neuronal cell line, and SH-SY5Y neuroblastoma cell line) and glial cells (BV2 microglial cell line). In the BV2 and HT22 cell lines, cell viability did not significantly decrease in any of the groups (Figure S6A,B, Supporting Information), which showed that the micromolecular drugs and liposomes had low biological toxicity. We further analyzed the therapeutic efficacy of SH-SY5Y cells stably transfected with mutant APP (K595N/M596L), and BV2 and HT22 cells stimulated with A\\u03b242. The drugs and liposomes ameliorated the cell death caused by excessive A\\u03b242 (Figure S6C\\u2013E, Supporting Information). We also found that TR@CPLs performed better than single drug-loaded liposomes and TR@PLs. Compared to uncoated drugs, CCR2-RFP-coated HEK293T and platelet cell membranes significantly increased the viability of BV2 cells (Figure S6D, Supporting Information). The treatment of 5xFAD mice started at the age of 3 months via intravenous tail vein injections three times a week. After a 6 week treatment, we conducted behavioral tests on the mice. Then, we extracted tissues for subsequent experiments (Figure 6A). We established seven groups as follows: 1) WT mice; 2) 5xFAD mice treated with vehicle; 3) 5xFAD mice treated with TPPU+rapamycin; 4) 5xFAD mice treated with R@CPL; 5) 5xFAD mice treated with T@CPL; 6) 5xFAD mice treated with TR@CPL; and 7) 5xFAD mice treated with TR@PL. The concentrations of rapamycin and TPPU in each group were 45.7 and 71.9 \\u03bcg mL\\u22121, achieving blood concentrations of 0.23 and 0.36 mg kg\\u22121, respectively. The open field test is used to assess motor function, exploratory behavior, anxiety, and depression. There were no significant differences among the groups in terms of the velocity, moving distance or time spent in the center area (Figure 6B\\u2013D). We chose the NOR test to evaluate short-term memory. Only the administration of TR@CPLs significantly improved cognition in 5xFAD mice (Figure 6E,F). For long-term memory, as measured by the MWM test, the latency to reach the platform on training Day 5 was significantly shorter in the four groups treated with liposomes (Figure 6G,H). In the final test, we found that drug-loaded hybrid cell membrane liposomes ameliorated cognitive deficiency (Figure 6I,J). Notably, the group treated with TR@CPLs were more effective than the other treatments (Figure 6I). 2.6. Drug-Loaded Hybrid Cell Membrane Liposomes Reduced Amyloid Plaques and Alleviated Neuroinflammation. After the behavioral tests, we carried out a series of pathological tests on the brain tissue. The expression of APP was significantly reduced in the T@CPL and TR@CPL groups (Figure 7A,B), but there was no significant change in tau pathology (Figure 7A,C). Because the target of rapamycin is autophagy, we also detected the marker LC3II/I and found that its expression increased in the R@CPL and TR@CPL groups (Figure 7A,D), which indicated that rapamycin promoted autophagy. Next, we observed amyloid plaques using immunofluorescence. All four groups with liposomes had moderate pathological protein burdens in both the cortex and hippocampus, with TR@CPL showing the most significant therapeutic effect (Figure 7E\\u2013G). Additionally, we wondered whether liposomes could alleviate neuroinflammation as reflected by glial cells. There was less glial cell infiltration in the brains in the T@CPL, TR@CPL, and TR@PL groups (Figure 7H\\u2013J). Moreover, compared to TP@PLs, TP@CPLs significantly reduced the number of glial cell aggregates (Figure 7H,I). This result suggested that TPPU has potential anti-inflammatory effects, especially when combined with CCR2 overexpressing cell membrane coatings. Furthermore, we validated the biosafety of drug-loaded hybrid cell membrane liposomes via HE staining. There were no apparent abnormalities in the heart, liver, spleen, lung, or kidney among the groups (Figure S7, Supporting Information).\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}",
              "type": "dataframe",
              "variable_name": "articles_df"
            },
            "text/html": [
              "\n",
              "  <div id=\"df-91510afd-7f53-48ff-b630-f7dba4dfe6cf\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>url</th>\n",
              "      <th>year</th>\n",
              "      <th>filename</th>\n",
              "      <th>text</th>\n",
              "      <th>summary</th>\n",
              "      <th>abstract</th>\n",
              "      <th>introduction</th>\n",
              "      <th>results</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\0.pdf</td>\n",
              "      <td>ORIGINAL RESEARCH\\npublished: 21 January 2022\\...</td>\n",
              "      <td>Salidroside a natural compound has been shown ...</td>\n",
              "      <td>Amyloid β -protein (A β ) is reported to activ...</td>\n",
              "      <td>Alzheimer’s disease (AD) is an irreversible ne...</td>\n",
              "      <td>Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\1.pdf</td>\n",
              "      <td>Redox Biology 66 (2023) 102846\\nAvailable onli...</td>\n",
              "      <td>This article discusses the role of metabolic r...</td>\n",
              "      <td>Microglia activation drives the pro-inflammato...</td>\n",
              "      <td>Alzheimer's Disease (AD) is the most common ca...</td>\n",
              "      <td>The results of this study demonstrate that LPS...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Natural acetylcholinesterase inhibitors: A mul...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmcr.2024.100154</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\2.pdf</td>\n",
              "      <td>European Journal of Medicinal Chemistry Report...</td>\n",
              "      <td>The review discusses the role of cholinesteras...</td>\n",
              "      <td>Alzheimer ’ s disease (AD), the main dementia ...</td>\n",
              "      <td>Alzheimer ’ s disease (AD) is a neurodegenerat...</td>\n",
              "      <td>Different molecular forms of AChE can exist, e...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>GSK3: A potential target and pending issues fo...</td>\n",
              "      <td>https://doi.org/10.1111/cns.14818</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\3.pdf</td>\n",
              "      <td>CNS Neurosci Ther. 2024;30:e14818.\\t \\t\\t \\t |...</td>\n",
              "      <td>GSK3 (glycogen synthase kinase 3) serves as a ...</td>\n",
              "      <td>Glycogen synthase kinase- 3 (GSK3), consisting...</td>\n",
              "      <td>Glycogen synthase kinase- 3 (GSK3) was first i...</td>\n",
              "      <td>There is a wealth of evidence that supports a ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Targeting dysregulated lipid metabolism for th...</td>\n",
              "      <td>https://doi.org/10.1016/j.nbd.2024.106505</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\4.pdf</td>\n",
              "      <td>Neurobiology of Disease 196 (2024) 106505\\nAva...</td>\n",
              "      <td>Sphingomyelin levels amyloid-β deposition P-gl...</td>\n",
              "      <td>Alzheimer’s and Parkinson’s diseases are two o...</td>\n",
              "      <td>Alzheimer’s and Parkinson’s diseases are two o...</td>\n",
              "      <td>2.1.1. Elevated cholesterol levels One of the ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>Targeting tau in Alzheimer's disease: from mec...</td>\n",
              "      <td>https://doi.org/10.4103/1673-5374.385847</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\5.pdf</td>\n",
              "      <td>NEURAL REGENERATION RESEARCH｜Vol 19｜No. 7｜July...</td>\n",
              "      <td>The articles discuss various aspects of tau pr...</td>\n",
              "      <td>Alzheimer’s disease is the most prevalent neur...</td>\n",
              "      <td>Tau, a microtubule-associated protein, maintai...</td>\n",
              "      <td>Abnormal PTMs impair the affinity of tau-micro...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>Intelligent lesion blood–brain barrier targeti...</td>\n",
              "      <td>https://doi.org/10.1016/j.apsb.2022.02.001</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\6.pdf</td>\n",
              "      <td>ORIGINAL ARTICLE\\nIntelligent lesion blood ebr...</td>\n",
              "      <td>The article discusses targeted nano-missiles f...</td>\n",
              "      <td>The treatment of Alzheimer’s disease (AD) is o...</td>\n",
              "      <td>Alzheimer’s disease (AD), one of the most chal...</td>\n",
              "      <td>Firstly, the ROS-sensitive polymer (PEP) was o...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>Multi-target neuroprotective effects of herbal...</td>\n",
              "      <td>https://doi.org/10.1016/j.jep.2022.115107</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\7.pdf</td>\n",
              "      <td>Journal of Ethnopharmacology 290 (2022) 115107...</td>\n",
              "      <td>The review discusses various studies on the po...</td>\n",
              "      <td>Ethnopharmacological relevance: Alzheimer ’ s ...</td>\n",
              "      <td>Alzheimer ’ s disease (AD) is a progressive ne...</td>\n",
              "      <td>Chromatographic analysis of the seven decoctio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>Associations of semaglutide with first‐time di...</td>\n",
              "      <td>https://doi.org/10.1002/alz.14313</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\8.pdf</td>\n",
              "      <td>Received:29July2024 Revised:10September2024 Ac...</td>\n",
              "      <td>The article investigates the association betwe...</td>\n",
              "      <td>INTRODUCTION: Emerging preclinical evidence su...</td>\n",
              "      <td>An estimated 6.9 million Americans aged 65 and...</td>\n",
              "      <td>Figure 1 is a flowchart of the cohort composit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>The VTA dopaminergic system as diagnostic and ...</td>\n",
              "      <td>https://doi.org/10.3389/fpsyt.2022.1039725</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\9.pdf</td>\n",
              "      <td>TYPE Perspective\\nPUBLISHED /one.tnum/seven.tn...</td>\n",
              "      <td>Genetic and neurobiological factors influence ...</td>\n",
              "      <td>Neuropsychiatric symptoms (NPS) occur in nearl...</td>\n",
              "      <td>Alzheimer’s Disease (AD) is the prevailing for...</td>\n",
              "      <td>Indirect evidence of mesocorticolimbic system ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>Intranasal administration of dauricine loaded ...</td>\n",
              "      <td>https://doi.org/10.1080/10717544.2021.1895909</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\11.pdf</td>\n",
              "      <td>Drug Delivery\\nISSN: 1071-7544 (Print) 1521-04...</td>\n",
              "      <td>The study describes a novel approach using dau...</td>\n",
              "      <td>Alzheimer’s disease (AD) is a degenerative dis...</td>\n",
              "      <td>Alzheimer’s disease (AD) is the most common fo...</td>\n",
              "      <td>The standard techniques were used to character...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2021.113847</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\12.pdf</td>\n",
              "      <td>Targeting transthyretin in Alzheimer's disease...</td>\n",
              "      <td>The study focuses on transthyretin (TTR) as a ...</td>\n",
              "      <td>Transthyretin (TTR) has a well-established rol...</td>\n",
              "      <td>Alzheimer's disease (AD) is a progressive neur...</td>\n",
              "      <td>Computational studies. In order to find small ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>Hybrid Membrane‐Coated Nanoparticles for Preci...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202306675</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\13.pdf</td>\n",
              "      <td>RESEARCH ARTICLE\\nwww.advancedscience.com\\nHyb...</td>\n",
              "      <td>The study describes a novel approach to treati...</td>\n",
              "      <td>The blood-brain barrier (BBB) limits the appli...</td>\n",
              "      <td>The blood-brain barrier (BBB) is a critical co...</td>\n",
              "      <td>2.1. CCR2-RFP Is Located on the Cell Membrane ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>C-glycosides analogues of the okadaic acid cen...</td>\n",
              "      <td>https://doi.org/10.1016/j.ejmech.2023.115245</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\14.pdf</td>\n",
              "      <td>European Journal of Medicinal Chemistry 251 (2...</td>\n",
              "      <td>The article discusses research on protein phos...</td>\n",
              "      <td>Protein phosphatase 2A (PP2A) is an important ...</td>\n",
              "      <td>Protein phosphatase 2A (PP2A) is a key family ...</td>\n",
              "      <td>The design of C-glycosides with potential PAD ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>Death-associated protein kinase 1 as a therape...</td>\n",
              "      <td>https://doi.org/10.1186/s40035-023-00395-5</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\15.pdf</td>\n",
              "      <td>Zhang et al. Translational Neurodegeneration  ...</td>\n",
              "      <td>This article reviews research on death-associa...</td>\n",
              "      <td>Alzheimer’s disease (AD) is the most prevalent...</td>\n",
              "      <td>Alzheimer’s disease (AD) is the most prevalent...</td>\n",
              "      <td>The DAPK family consists of five kinase member...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>Sex‐specific declines in cholinergic‐targeting...</td>\n",
              "      <td>https://doi.org/10.1002/alz.13095</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\16.pdf</td>\n",
              "      <td>Received: 23 February 2023 Accepted: 21 March ...</td>\n",
              "      <td>The study investigates sex-specific declines i...</td>\n",
              "      <td>Introduction: Females with Alzheimer’s disease...</td>\n",
              "      <td>Alzheimer’s disease (AD) is the most common ca...</td>\n",
              "      <td>3.1 NAc CholinotRFs decline in AD females To i...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>Study on the Role of an Erythrocyte Membrane‐C...</td>\n",
              "      <td>https://doi.org/10.1002/advs.202301361</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\17.pdf</td>\n",
              "      <td>RESEARCH ARTICLE\\nwww.advancedscience.com\\nStu...</td>\n",
              "      <td>Titled \"A Novel Liposomal Nanocarrier for Targ...</td>\n",
              "      <td>Alzheimer’s disease (AD) is one of the most co...</td>\n",
              "      <td>1. Introduction Alzheimer’s disease (AD) is gr...</td>\n",
              "      <td>2. Results and Discussion 2.1. Preparation and...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "      <td>https://doi.org/10.1016/j.xinn.2021.100160</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\18.pdf</td>\n",
              "      <td>A dual-targeted multifunctional nanoformulatio...</td>\n",
              "      <td>PTFE-based Prussian blue nanoparticles (PBNPs)...</td>\n",
              "      <td>Antioxidation and adjustable treatment strateg...</td>\n",
              "      <td>Alzheimer’s disease (AD) is a common neurodege...</td>\n",
              "      <td>Synthesis and characterization of PTCN PTCN wa...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Diagnosis and Treatment of Alzheimer's Disease...</td>\n",
              "      <td>https://doi.org/10.36838/v7i2.3</td>\n",
              "      <td>2025</td>\n",
              "      <td>db\\19.pdf</td>\n",
              "      <td>© 2025 Terra Science and Education 15  \\nDiagn...</td>\n",
              "      <td>The article discusses advancements in diagnosi...</td>\n",
              "      <td>Alzheimer’s disease (AD) is a major public hea...</td>\n",
              "      <td>Alzheimer’s disease (named after the German ps...</td>\n",
              "      <td></td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>Mechanism of quercetin therapeutic targets for...</td>\n",
              "      <td>https://doi.org/10.1038/s41598-021-02248-5</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\20.pdf</td>\n",
              "      <td>1\\nVol.:(0123456789)Scientific Reports |      ...</td>\n",
              "      <td>The study investigates potential mechanisms of...</td>\n",
              "      <td>Quercetin has demonstrated antioxidant, anti-i...</td>\n",
              "      <td>According to the 2017 global burden of disease...</td>\n",
              "      <td>Candidate quercetin targets for T2DM and AD tr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>Multiomics Identification of Potential Targets...</td>\n",
              "      <td>https://doi.org/10.3390/pharmaceutics13101555</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\21.pdf</td>\n",
              "      <td>pharmaceutics\\nArticle\\nMultiomics Identiﬁcati...</td>\n",
              "      <td>The article discusses computational approaches...</td>\n",
              "      <td>Alzheimer’s disease (AD) is the most frequent ...</td>\n",
              "      <td>Alzheimer’s disease (AD), which is characteriz...</td>\n",
              "      <td>3. Results 3.1. Deregulated Expressions of ATP...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>Targeting the post-synaptic proteome has thera...</td>\n",
              "      <td>https://doi.org/10.1038/s42003-023-04961-5</td>\n",
              "      <td>2023</td>\n",
              "      <td>db\\22.pdf</td>\n",
              "      <td>ARTICLE\\nTargeting the post-synaptic proteome ...</td>\n",
              "      <td>The study identified differential protein expr...</td>\n",
              "      <td>Individuals with Alzheimer Disease who develop...</td>\n",
              "      <td>Psychotic symptoms affect ~40 –60% of individu...</td>\n",
              "      <td>PSD abundance in AD with and without psychosis...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>Metabolic resistance of Aβ3pE-42, a target epi...</td>\n",
              "      <td>https://doi.org/10.26508/lsa.202402650</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\23.pdf</td>\n",
              "      <td>Research Article\\nMetabolic resistance of Aβ3p...</td>\n",
              "      <td>The article discusses metabolic resistance of ...</td>\n",
              "      <td>The amyloid β peptide (Aβ), starting with pyro...</td>\n",
              "      <td>Senile plaques, which are one of the key patho...</td>\n",
              "      <td>Catabolism of Aβx-42 variants in vivo The synt...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>Genetic Variation in Targets of Antidiabetic D...</td>\n",
              "      <td>https://doi.org/10.1212/wnl.0000000000200771</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\25.pdf</td>\n",
              "      <td>RESEARCH ARTICLE OPEN ACCESS\\nGenetic Variatio...</td>\n",
              "      <td>The article discusses the relationship between...</td>\n",
              "      <td>Background and Objectives Previous studies hav...</td>\n",
              "      <td>Alzheimer disease (AD) is a neurodegenerative ...</td>\n",
              "      <td>Positive Control Analyses As shown in Figure 2...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>A hybrid approach unveils drug repurposing can...</td>\n",
              "      <td>https://doi.org/10.1016/j.patter.2021.100433</td>\n",
              "      <td>2022</td>\n",
              "      <td>db\\26.pdf</td>\n",
              "      <td>Article\\nA hybrid approach unveils drug repurp...</td>\n",
              "      <td>The article discusses various databases and to...</td>\n",
              "      <td>The high number of failed pre-clinical and cli...</td>\n",
              "      <td>Aging societies face a rapidly growing number ...</td>\n",
              "      <td>The HBP We created a drug- and mechanism-orien...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>Green Synthesis of Barbituric Acid Derivative ...</td>\n",
              "      <td>https://doi.org/10.14233/ajomc.2021.ajomc-p332</td>\n",
              "      <td>2021</td>\n",
              "      <td>db\\28.pdf</td>\n",
              "      <td>Asian Pub. Corp.\\nwww.asianpubs.org\\nAsian Jou...</td>\n",
              "      <td>Gold nanoparticles (AuNPs) were used as cataly...</td>\n",
              "      <td>A convenient and efficient synthesis of 1,3-di...</td>\n",
              "      <td>Derivatives of benzylidine barbituric acid are...</td>\n",
              "      <td>Goldsmith effluent as a source of green synthe...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>Genomics and Drug Research Approach in Identif...</td>\n",
              "      <td>https://doi.org/10.52403/gijhsr.20240115</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\29.pdf</td>\n",
              "      <td>...</td>\n",
              "      <td>The article discusses a genomics-based approac...</td>\n",
              "      <td>Over the past few years research on Alzheimer’...</td>\n",
              "      <td>Alzheimer disease (AD) is a most common diseas...</td>\n",
              "      <td>Physiochemical property analysis of receptor T...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>Identification of Sirtuin 1-Targeted Anti-Alzh...</td>\n",
              "      <td>https://doi.org/10.56042/ijc.v63i12.13637</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\31.pdf</td>\n",
              "      <td>Indian Journal o\\nf Chemistry \\nVol. 63, Decem...</td>\n",
              "      <td>The study targeted Sirtuin 1 (Sirt1), which el...</td>\n",
              "      <td>Sirtuin 1 (Sirt1) is a critical enzyme involve...</td>\n",
              "      <td>Alzheimer's disease (AD) is a devastating neur...</td>\n",
              "      <td>Result and Discussion Generation and validatio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>2024</td>\n",
              "      <td>db\\32.pdf</td>\n",
              "      <td>DOI: 10.1002/alz.088509\\nDRUG DEVELOPMENT\\nPOS...</td>\n",
              "      <td>Background: TREM2 signaling is involved in Alz...</td>\n",
              "      <td>Background: TREM2 signaling has been implicate...</td>\n",
              "      <td></td>\n",
              "      <td>Several agonistic antibodies were identified. ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-91510afd-7f53-48ff-b630-f7dba4dfe6cf')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-91510afd-7f53-48ff-b630-f7dba4dfe6cf button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-91510afd-7f53-48ff-b630-f7dba4dfe6cf');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-648721f7-371e-4ffe-9654-e63b46a6339b\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-648721f7-371e-4ffe-9654-e63b46a6339b')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-648721f7-371e-4ffe-9654-e63b46a6339b button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "text/plain": [
              "                                                title  \\\n",
              "0   Salidroside Ameliorates Alzheimer's Disease by...   \n",
              "1   Metabolic reprogramming in inflammatory microg...   \n",
              "2   Natural acetylcholinesterase inhibitors: A mul...   \n",
              "3   GSK3: A potential target and pending issues fo...   \n",
              "4   Targeting dysregulated lipid metabolism for th...   \n",
              "5   Targeting tau in Alzheimer's disease: from mec...   \n",
              "6   Intelligent lesion blood–brain barrier targeti...   \n",
              "7   Multi-target neuroprotective effects of herbal...   \n",
              "8   Associations of semaglutide with first‐time di...   \n",
              "9   The VTA dopaminergic system as diagnostic and ...   \n",
              "11  Intranasal administration of dauricine loaded ...   \n",
              "12  Targeting transthyretin in Alzheimer's disease...   \n",
              "13  Hybrid Membrane‐Coated Nanoparticles for Preci...   \n",
              "14  C-glycosides analogues of the okadaic acid cen...   \n",
              "15  Death-associated protein kinase 1 as a therape...   \n",
              "16  Sex‐specific declines in cholinergic‐targeting...   \n",
              "17  Study on the Role of an Erythrocyte Membrane‐C...   \n",
              "18  A dual-targeted multifunctional nanoformulatio...   \n",
              "19  Diagnosis and Treatment of Alzheimer's Disease...   \n",
              "20  Mechanism of quercetin therapeutic targets for...   \n",
              "21  Multiomics Identification of Potential Targets...   \n",
              "22  Targeting the post-synaptic proteome has thera...   \n",
              "23  Metabolic resistance of Aβ3pE-42, a target epi...   \n",
              "25  Genetic Variation in Targets of Antidiabetic D...   \n",
              "26  A hybrid approach unveils drug repurposing can...   \n",
              "28  Green Synthesis of Barbituric Acid Derivative ...   \n",
              "29  Genomics and Drug Research Approach in Identif...   \n",
              "31  Identification of Sirtuin 1-Targeted Anti-Alzh...   \n",
              "32  Generation and validation of anti‐TREM2 agonis...   \n",
              "\n",
              "                                               url  year   filename  \\\n",
              "0        https://doi.org/10.3389/fnagi.2021.809433  2022   db\\0.pdf   \n",
              "1      https://doi.org/10.1016/j.redox.2023.102846  2023   db\\1.pdf   \n",
              "2      https://doi.org/10.1016/j.ejmcr.2024.100154  2024   db\\2.pdf   \n",
              "3                https://doi.org/10.1111/cns.14818  2024   db\\3.pdf   \n",
              "4        https://doi.org/10.1016/j.nbd.2024.106505  2024   db\\4.pdf   \n",
              "5         https://doi.org/10.4103/1673-5374.385847  2023   db\\5.pdf   \n",
              "6       https://doi.org/10.1016/j.apsb.2022.02.001  2022   db\\6.pdf   \n",
              "7        https://doi.org/10.1016/j.jep.2022.115107  2022   db\\7.pdf   \n",
              "8                https://doi.org/10.1002/alz.14313  2024   db\\8.pdf   \n",
              "9       https://doi.org/10.3389/fpsyt.2022.1039725  2022   db\\9.pdf   \n",
              "11   https://doi.org/10.1080/10717544.2021.1895909  2021  db\\11.pdf   \n",
              "12    https://doi.org/10.1016/j.ejmech.2021.113847  2021  db\\12.pdf   \n",
              "13          https://doi.org/10.1002/advs.202306675  2024  db\\13.pdf   \n",
              "14    https://doi.org/10.1016/j.ejmech.2023.115245  2023  db\\14.pdf   \n",
              "15      https://doi.org/10.1186/s40035-023-00395-5  2024  db\\15.pdf   \n",
              "16               https://doi.org/10.1002/alz.13095  2023  db\\16.pdf   \n",
              "17          https://doi.org/10.1002/advs.202301361  2023  db\\17.pdf   \n",
              "18      https://doi.org/10.1016/j.xinn.2021.100160  2021  db\\18.pdf   \n",
              "19                 https://doi.org/10.36838/v7i2.3  2025  db\\19.pdf   \n",
              "20      https://doi.org/10.1038/s41598-021-02248-5  2021  db\\20.pdf   \n",
              "21   https://doi.org/10.3390/pharmaceutics13101555  2021  db\\21.pdf   \n",
              "22      https://doi.org/10.1038/s42003-023-04961-5  2023  db\\22.pdf   \n",
              "23          https://doi.org/10.26508/lsa.202402650  2024  db\\23.pdf   \n",
              "25    https://doi.org/10.1212/wnl.0000000000200771  2022  db\\25.pdf   \n",
              "26    https://doi.org/10.1016/j.patter.2021.100433  2022  db\\26.pdf   \n",
              "28  https://doi.org/10.14233/ajomc.2021.ajomc-p332  2021  db\\28.pdf   \n",
              "29        https://doi.org/10.52403/gijhsr.20240115  2024  db\\29.pdf   \n",
              "31       https://doi.org/10.56042/ijc.v63i12.13637  2024  db\\31.pdf   \n",
              "32              https://doi.org/10.1002/alz.088509  2024  db\\32.pdf   \n",
              "\n",
              "                                                 text  \\\n",
              "0   ORIGINAL RESEARCH\\npublished: 21 January 2022\\...   \n",
              "1   Redox Biology 66 (2023) 102846\\nAvailable onli...   \n",
              "2   European Journal of Medicinal Chemistry Report...   \n",
              "3   CNS Neurosci Ther. 2024;30:e14818.\\t \\t\\t \\t |...   \n",
              "4   Neurobiology of Disease 196 (2024) 106505\\nAva...   \n",
              "5   NEURAL REGENERATION RESEARCH｜Vol 19｜No. 7｜July...   \n",
              "6   ORIGINAL ARTICLE\\nIntelligent lesion blood ebr...   \n",
              "7   Journal of Ethnopharmacology 290 (2022) 115107...   \n",
              "8   Received:29July2024 Revised:10September2024 Ac...   \n",
              "9   TYPE Perspective\\nPUBLISHED /one.tnum/seven.tn...   \n",
              "11  Drug Delivery\\nISSN: 1071-7544 (Print) 1521-04...   \n",
              "12  Targeting transthyretin in Alzheimer's disease...   \n",
              "13  RESEARCH ARTICLE\\nwww.advancedscience.com\\nHyb...   \n",
              "14  European Journal of Medicinal Chemistry 251 (2...   \n",
              "15  Zhang et al. Translational Neurodegeneration  ...   \n",
              "16  Received: 23 February 2023 Accepted: 21 March ...   \n",
              "17  RESEARCH ARTICLE\\nwww.advancedscience.com\\nStu...   \n",
              "18  A dual-targeted multifunctional nanoformulatio...   \n",
              "19  © 2025 Terra Science and Education 15  \\nDiagn...   \n",
              "20  1\\nVol.:(0123456789)Scientific Reports |      ...   \n",
              "21  pharmaceutics\\nArticle\\nMultiomics Identiﬁcati...   \n",
              "22  ARTICLE\\nTargeting the post-synaptic proteome ...   \n",
              "23  Research Article\\nMetabolic resistance of Aβ3p...   \n",
              "25  RESEARCH ARTICLE OPEN ACCESS\\nGenetic Variatio...   \n",
              "26  Article\\nA hybrid approach unveils drug repurp...   \n",
              "28  Asian Pub. Corp.\\nwww.asianpubs.org\\nAsian Jou...   \n",
              "29                                                ...   \n",
              "31  Indian Journal o\\nf Chemistry \\nVol. 63, Decem...   \n",
              "32  DOI: 10.1002/alz.088509\\nDRUG DEVELOPMENT\\nPOS...   \n",
              "\n",
              "                                              summary  \\\n",
              "0   Salidroside a natural compound has been shown ...   \n",
              "1   This article discusses the role of metabolic r...   \n",
              "2   The review discusses the role of cholinesteras...   \n",
              "3   GSK3 (glycogen synthase kinase 3) serves as a ...   \n",
              "4   Sphingomyelin levels amyloid-β deposition P-gl...   \n",
              "5   The articles discuss various aspects of tau pr...   \n",
              "6   The article discusses targeted nano-missiles f...   \n",
              "7   The review discusses various studies on the po...   \n",
              "8   The article investigates the association betwe...   \n",
              "9   Genetic and neurobiological factors influence ...   \n",
              "11  The study describes a novel approach using dau...   \n",
              "12  The study focuses on transthyretin (TTR) as a ...   \n",
              "13  The study describes a novel approach to treati...   \n",
              "14  The article discusses research on protein phos...   \n",
              "15  This article reviews research on death-associa...   \n",
              "16  The study investigates sex-specific declines i...   \n",
              "17  Titled \"A Novel Liposomal Nanocarrier for Targ...   \n",
              "18  PTFE-based Prussian blue nanoparticles (PBNPs)...   \n",
              "19  The article discusses advancements in diagnosi...   \n",
              "20  The study investigates potential mechanisms of...   \n",
              "21  The article discusses computational approaches...   \n",
              "22  The study identified differential protein expr...   \n",
              "23  The article discusses metabolic resistance of ...   \n",
              "25  The article discusses the relationship between...   \n",
              "26  The article discusses various databases and to...   \n",
              "28  Gold nanoparticles (AuNPs) were used as cataly...   \n",
              "29  The article discusses a genomics-based approac...   \n",
              "31  The study targeted Sirtuin 1 (Sirt1), which el...   \n",
              "32  Background: TREM2 signaling is involved in Alz...   \n",
              "\n",
              "                                             abstract  \\\n",
              "0   Amyloid β -protein (A β ) is reported to activ...   \n",
              "1   Microglia activation drives the pro-inflammato...   \n",
              "2   Alzheimer ’ s disease (AD), the main dementia ...   \n",
              "3   Glycogen synthase kinase- 3 (GSK3), consisting...   \n",
              "4   Alzheimer’s and Parkinson’s diseases are two o...   \n",
              "5   Alzheimer’s disease is the most prevalent neur...   \n",
              "6   The treatment of Alzheimer’s disease (AD) is o...   \n",
              "7   Ethnopharmacological relevance: Alzheimer ’ s ...   \n",
              "8   INTRODUCTION: Emerging preclinical evidence su...   \n",
              "9   Neuropsychiatric symptoms (NPS) occur in nearl...   \n",
              "11  Alzheimer’s disease (AD) is a degenerative dis...   \n",
              "12  Transthyretin (TTR) has a well-established rol...   \n",
              "13  The blood-brain barrier (BBB) limits the appli...   \n",
              "14  Protein phosphatase 2A (PP2A) is an important ...   \n",
              "15  Alzheimer’s disease (AD) is the most prevalent...   \n",
              "16  Introduction: Females with Alzheimer’s disease...   \n",
              "17  Alzheimer’s disease (AD) is one of the most co...   \n",
              "18  Antioxidation and adjustable treatment strateg...   \n",
              "19  Alzheimer’s disease (AD) is a major public hea...   \n",
              "20  Quercetin has demonstrated antioxidant, anti-i...   \n",
              "21  Alzheimer’s disease (AD) is the most frequent ...   \n",
              "22  Individuals with Alzheimer Disease who develop...   \n",
              "23  The amyloid β peptide (Aβ), starting with pyro...   \n",
              "25  Background and Objectives Previous studies hav...   \n",
              "26  The high number of failed pre-clinical and cli...   \n",
              "28  A convenient and efficient synthesis of 1,3-di...   \n",
              "29  Over the past few years research on Alzheimer’...   \n",
              "31  Sirtuin 1 (Sirt1) is a critical enzyme involve...   \n",
              "32  Background: TREM2 signaling has been implicate...   \n",
              "\n",
              "                                         introduction  \\\n",
              "0   Alzheimer’s disease (AD) is an irreversible ne...   \n",
              "1   Alzheimer's Disease (AD) is the most common ca...   \n",
              "2   Alzheimer ’ s disease (AD) is a neurodegenerat...   \n",
              "3   Glycogen synthase kinase- 3 (GSK3) was first i...   \n",
              "4   Alzheimer’s and Parkinson’s diseases are two o...   \n",
              "5   Tau, a microtubule-associated protein, maintai...   \n",
              "6   Alzheimer’s disease (AD), one of the most chal...   \n",
              "7   Alzheimer ’ s disease (AD) is a progressive ne...   \n",
              "8   An estimated 6.9 million Americans aged 65 and...   \n",
              "9   Alzheimer’s Disease (AD) is the prevailing for...   \n",
              "11  Alzheimer’s disease (AD) is the most common fo...   \n",
              "12  Alzheimer's disease (AD) is a progressive neur...   \n",
              "13  The blood-brain barrier (BBB) is a critical co...   \n",
              "14  Protein phosphatase 2A (PP2A) is a key family ...   \n",
              "15  Alzheimer’s disease (AD) is the most prevalent...   \n",
              "16  Alzheimer’s disease (AD) is the most common ca...   \n",
              "17  1. Introduction Alzheimer’s disease (AD) is gr...   \n",
              "18  Alzheimer’s disease (AD) is a common neurodege...   \n",
              "19  Alzheimer’s disease (named after the German ps...   \n",
              "20  According to the 2017 global burden of disease...   \n",
              "21  Alzheimer’s disease (AD), which is characteriz...   \n",
              "22  Psychotic symptoms affect ~40 –60% of individu...   \n",
              "23  Senile plaques, which are one of the key patho...   \n",
              "25  Alzheimer disease (AD) is a neurodegenerative ...   \n",
              "26  Aging societies face a rapidly growing number ...   \n",
              "28  Derivatives of benzylidine barbituric acid are...   \n",
              "29  Alzheimer disease (AD) is a most common diseas...   \n",
              "31  Alzheimer's disease (AD) is a devastating neur...   \n",
              "32                                                      \n",
              "\n",
              "                                              results  \n",
              "0   Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...  \n",
              "1   The results of this study demonstrate that LPS...  \n",
              "2   Different molecular forms of AChE can exist, e...  \n",
              "3   There is a wealth of evidence that supports a ...  \n",
              "4   2.1.1. Elevated cholesterol levels One of the ...  \n",
              "5   Abnormal PTMs impair the affinity of tau-micro...  \n",
              "6   Firstly, the ROS-sensitive polymer (PEP) was o...  \n",
              "7   Chromatographic analysis of the seven decoctio...  \n",
              "8   Figure 1 is a flowchart of the cohort composit...  \n",
              "9   Indirect evidence of mesocorticolimbic system ...  \n",
              "11  The standard techniques were used to character...  \n",
              "12  Computational studies. In order to find small ...  \n",
              "13  2.1. CCR2-RFP Is Located on the Cell Membrane ...  \n",
              "14  The design of C-glycosides with potential PAD ...  \n",
              "15  The DAPK family consists of five kinase member...  \n",
              "16  3.1 NAc CholinotRFs decline in AD females To i...  \n",
              "17  2. Results and Discussion 2.1. Preparation and...  \n",
              "18  Synthesis and characterization of PTCN PTCN wa...  \n",
              "19                                                     \n",
              "20  Candidate quercetin targets for T2DM and AD tr...  \n",
              "21  3. Results 3.1. Deregulated Expressions of ATP...  \n",
              "22  PSD abundance in AD with and without psychosis...  \n",
              "23  Catabolism of Aβx-42 variants in vivo The synt...  \n",
              "25  Positive Control Analyses As shown in Figure 2...  \n",
              "26  The HBP We created a drug- and mechanism-orien...  \n",
              "28  Goldsmith effluent as a source of green synthe...  \n",
              "29  Physiochemical property analysis of receptor T...  \n",
              "31  Result and Discussion Generation and validatio...  \n",
              "32  Several agonistic antibodies were identified. ...  "
            ]
          },
          "execution_count": 40,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_df['abstract'] = abstract\n",
        "articles_df['introduction'] = intro\n",
        "articles_df['results'] = results\n",
        "articles_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 41,
      "id": "zUm992_tPXrn",
      "metadata": {
        "id": "zUm992_tPXrn"
      },
      "outputs": [],
      "source": [
        "articles_df.to_csv('articles_df.csv')"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "250647d3",
      "metadata": {},
      "source": []
    },
    {
      "cell_type": "markdown",
      "id": "04657752",
      "metadata": {
        "id": "04657752"
      },
      "source": [
        "## Задание 3\n",
        "- Провести эксплораторный анализ текстов статей\n"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "3d1e1b08",
      "metadata": {},
      "source": [
        "*Для большего удобства перед анализом текстов можно поменять структуру датафрейма, чтобы формат хранения лучше соответстовал реляционным БД. Помимо текстов в новом датафрейме сохраняются название статьи, год, ссылка.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "id": "oD3j92hDY9Mu",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "oD3j92hDY9Mu",
        "outputId": "311a5b78-da30-4670-8695-3d1d75a928b1"
      },
      "outputs": [],
      "source": [
        "import pandas as pd\n",
        "articles_df = pd.read_csv(\"articles_df.csv\", index_col=0)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "e2d284ef",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "'Generation and validation of anti‐TREM2 agonistic antibodies to enable the advancement of drug targets in the TREM2/DAP12 signaling pathway for the treatment of Alzheimer Disease'"
            ]
          },
          "execution_count": 3,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_df[\"title\"].iloc[28]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 4,
      "id": "06c91498",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>year</th>\n",
              "      <th>link</th>\n",
              "      <th>type</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>abstract</td>\n",
              "      <td>Amyloid β -protein (A β ) is reported to activ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>introduction</td>\n",
              "      <td>Alzheimer’s disease (AD) is an irreversible ne...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>result</td>\n",
              "      <td>Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>2023</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>abstract</td>\n",
              "      <td>Microglia activation drives the pro-inflammato...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>2023</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>introduction</td>\n",
              "      <td>Alzheimer's Disease (AD) is the most common ca...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>82</th>\n",
              "      <td>Identification of Sirtuin 1-Targeted Anti-Alzh...</td>\n",
              "      <td>2024</td>\n",
              "      <td>https://doi.org/10.56042/ijc.v63i12.13637</td>\n",
              "      <td>introduction</td>\n",
              "      <td>Alzheimer's disease (AD) is a devastating neur...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>83</th>\n",
              "      <td>Identification of Sirtuin 1-Targeted Anti-Alzh...</td>\n",
              "      <td>2024</td>\n",
              "      <td>https://doi.org/10.56042/ijc.v63i12.13637</td>\n",
              "      <td>result</td>\n",
              "      <td>Result and Discussion Generation and validatio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>84</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>2024</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>abstract</td>\n",
              "      <td>Background: TREM2 signaling has been implicate...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>85</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>2024</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>introduction</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>86</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>2024</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>result</td>\n",
              "      <td>Several agonistic antibodies were identified. ...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>87 rows × 5 columns</p>\n",
              "</div>"
            ],
            "text/plain": [
              "                                                title  year  \\\n",
              "0   Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "1   Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "2   Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "3   Metabolic reprogramming in inflammatory microg...  2023   \n",
              "4   Metabolic reprogramming in inflammatory microg...  2023   \n",
              "..                                                ...   ...   \n",
              "82  Identification of Sirtuin 1-Targeted Anti-Alzh...  2024   \n",
              "83  Identification of Sirtuin 1-Targeted Anti-Alzh...  2024   \n",
              "84  Generation and validation of anti‐TREM2 agonis...  2024   \n",
              "85  Generation and validation of anti‐TREM2 agonis...  2024   \n",
              "86  Generation and validation of anti‐TREM2 agonis...  2024   \n",
              "\n",
              "                                           link          type  \\\n",
              "0     https://doi.org/10.3389/fnagi.2021.809433      abstract   \n",
              "1     https://doi.org/10.3389/fnagi.2021.809433  introduction   \n",
              "2     https://doi.org/10.3389/fnagi.2021.809433        result   \n",
              "3   https://doi.org/10.1016/j.redox.2023.102846      abstract   \n",
              "4   https://doi.org/10.1016/j.redox.2023.102846  introduction   \n",
              "..                                          ...           ...   \n",
              "82    https://doi.org/10.56042/ijc.v63i12.13637  introduction   \n",
              "83    https://doi.org/10.56042/ijc.v63i12.13637        result   \n",
              "84           https://doi.org/10.1002/alz.088509      abstract   \n",
              "85           https://doi.org/10.1002/alz.088509  introduction   \n",
              "86           https://doi.org/10.1002/alz.088509        result   \n",
              "\n",
              "                                                 text  \n",
              "0   Amyloid β -protein (A β ) is reported to activ...  \n",
              "1   Alzheimer’s disease (AD) is an irreversible ne...  \n",
              "2   Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...  \n",
              "3   Microglia activation drives the pro-inflammato...  \n",
              "4   Alzheimer's Disease (AD) is the most common ca...  \n",
              "..                                                ...  \n",
              "82  Alzheimer's disease (AD) is a devastating neur...  \n",
              "83  Result and Discussion Generation and validatio...  \n",
              "84  Background: TREM2 signaling has been implicate...  \n",
              "85                                                NaN  \n",
              "86  Several agonistic antibodies were identified. ...  \n",
              "\n",
              "[87 rows x 5 columns]"
            ]
          },
          "execution_count": 4,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "titles = []\n",
        "years = []\n",
        "links = []\n",
        "types = []\n",
        "texts = []\n",
        "i = 0\n",
        "\n",
        "for abstract, introduction, result in zip(articles_df[\"abstract\"], articles_df[\"introduction\"], articles_df[\"results\"]):\n",
        "    titles.append(articles_df[\"title\"].iloc[i])\n",
        "    years.append(articles_df[\"year\"].iloc[i])\n",
        "    links.append(articles_df[\"url\"].iloc[i])\n",
        "    types.append(\"abstract\")\n",
        "    texts.append(abstract)\n",
        "\n",
        "    titles.append(articles_df[\"title\"].iloc[i])\n",
        "    years.append(articles_df[\"year\"].iloc[i])\n",
        "    links.append(articles_df[\"url\"].iloc[i])\n",
        "    types.append(\"introduction\")\n",
        "    texts.append(introduction)\n",
        "\n",
        "    titles.append(articles_df[\"title\"].iloc[i])\n",
        "    years.append(articles_df[\"year\"].iloc[i])\n",
        "    links.append(articles_df[\"url\"].iloc[i])\n",
        "    types.append(\"result\")\n",
        "    texts.append(result)\n",
        "\n",
        "    i += 1\n",
        "\n",
        "long_df = pd.DataFrame({\"title\": titles, \"year\": years, \"link\": links, \"type\": types, \"text\": texts})\n",
        "long_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 5,
      "id": "4e8aab7e",
      "metadata": {
        "id": "4e8aab7e"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 87 entries, 0 to 86\n",
            "Data columns (total 5 columns):\n",
            " #   Column  Non-Null Count  Dtype \n",
            "---  ------  --------------  ----- \n",
            " 0   title   87 non-null     object\n",
            " 1   year    87 non-null     int64 \n",
            " 2   link    87 non-null     object\n",
            " 3   type    87 non-null     object\n",
            " 4   text    85 non-null     object\n",
            "dtypes: int64(1), object(4)\n",
            "memory usage: 3.5+ KB\n"
          ]
        }
      ],
      "source": [
        "long_df.info()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "id": "6c083f90",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>year</th>\n",
              "      <th>link</th>\n",
              "      <th>type</th>\n",
              "      <th>text</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>56</th>\n",
              "      <td>Diagnosis and Treatment of Alzheimer's Disease...</td>\n",
              "      <td>2025</td>\n",
              "      <td>https://doi.org/10.36838/v7i2.3</td>\n",
              "      <td>result</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>85</th>\n",
              "      <td>Generation and validation of anti‐TREM2 agonis...</td>\n",
              "      <td>2024</td>\n",
              "      <td>https://doi.org/10.1002/alz.088509</td>\n",
              "      <td>introduction</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                                title  year  \\\n",
              "56  Diagnosis and Treatment of Alzheimer's Disease...  2025   \n",
              "85  Generation and validation of anti‐TREM2 agonis...  2024   \n",
              "\n",
              "                                  link          type text  \n",
              "56     https://doi.org/10.36838/v7i2.3        result  NaN  \n",
              "85  https://doi.org/10.1002/alz.088509  introduction  NaN  "
            ]
          },
          "execution_count": 6,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "long_df[long_df[\"text\"].isna()]"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "5d034c7b",
      "metadata": {},
      "source": [
        "*Пустых строк немного, заменим их на саммари, которые были составлены локальной моделью*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "id": "0a2fbf22",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>url</th>\n",
              "      <th>year</th>\n",
              "      <th>filename</th>\n",
              "      <th>text</th>\n",
              "      <th>summary</th>\n",
              "      <th>abstract</th>\n",
              "      <th>introduction</th>\n",
              "      <th>results</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>Diagnosis and Treatment of Alzheimer's Disease...</td>\n",
              "      <td>https://doi.org/10.36838/v7i2.3</td>\n",
              "      <td>2025</td>\n",
              "      <td>db\\19.pdf</td>\n",
              "      <td>© 2025 Terra Science and Education 15  \\nDiagn...</td>\n",
              "      <td>The article discusses advancements in diagnosi...</td>\n",
              "      <td>Alzheimer’s disease (AD) is a major public hea...</td>\n",
              "      <td>Alzheimer’s disease (named after the German ps...</td>\n",
              "      <td>NaN</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                                title  \\\n",
              "19  Diagnosis and Treatment of Alzheimer's Disease...   \n",
              "\n",
              "                                url  year   filename  \\\n",
              "19  https://doi.org/10.36838/v7i2.3  2025  db\\19.pdf   \n",
              "\n",
              "                                                 text  \\\n",
              "19  © 2025 Terra Science and Education 15  \\nDiagn...   \n",
              "\n",
              "                                              summary  \\\n",
              "19  The article discusses advancements in diagnosi...   \n",
              "\n",
              "                                             abstract  \\\n",
              "19  Alzheimer’s disease (AD) is a major public hea...   \n",
              "\n",
              "                                         introduction results  \n",
              "19  Alzheimer’s disease (named after the German ps...     NaN  "
            ]
          },
          "execution_count": 8,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "articles_df[articles_df[\"title\"] == long_df[\"title\"].iloc[56]]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 9,
      "id": "2f60b8f8",
      "metadata": {},
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "C:\\Users\\Аскер\\AppData\\Local\\Temp\\ipykernel_28000\\1468649697.py:1: FutureWarning: ChainedAssignmentError: behaviour will change in pandas 3.0!\n",
            "You are setting values through chained assignment. Currently this works in certain cases, but when using Copy-on-Write (which will become the default behaviour in pandas 3.0) this will never work to update the original DataFrame or Series, because the intermediate object on which we are setting values will behave as a copy.\n",
            "A typical example is when you are setting values in a column of a DataFrame, like:\n",
            "\n",
            "df[\"col\"][row_indexer] = value\n",
            "\n",
            "Use `df.loc[row_indexer, \"col\"] = values` instead, to perform the assignment in a single step and ensure this keeps updating the original `df`.\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "\n",
            "  long_df[\"text\"].iloc[56] = articles_df[articles_df[\"title\"] == long_df[\"title\"].iloc[56]].summary.copy()\n",
            "C:\\Users\\Аскер\\AppData\\Local\\Temp\\ipykernel_28000\\1468649697.py:1: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  long_df[\"text\"].iloc[56] = articles_df[articles_df[\"title\"] == long_df[\"title\"].iloc[56]].summary.copy()\n",
            "C:\\Users\\Аскер\\AppData\\Local\\Temp\\ipykernel_28000\\1468649697.py:2: FutureWarning: ChainedAssignmentError: behaviour will change in pandas 3.0!\n",
            "You are setting values through chained assignment. Currently this works in certain cases, but when using Copy-on-Write (which will become the default behaviour in pandas 3.0) this will never work to update the original DataFrame or Series, because the intermediate object on which we are setting values will behave as a copy.\n",
            "A typical example is when you are setting values in a column of a DataFrame, like:\n",
            "\n",
            "df[\"col\"][row_indexer] = value\n",
            "\n",
            "Use `df.loc[row_indexer, \"col\"] = values` instead, to perform the assignment in a single step and ensure this keeps updating the original `df`.\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "\n",
            "  long_df[\"text\"].iloc[85] = articles_df[articles_df[\"title\"] == long_df[\"title\"].iloc[85]].summary.copy()\n",
            "C:\\Users\\Аскер\\AppData\\Local\\Temp\\ipykernel_28000\\1468649697.py:2: SettingWithCopyWarning: \n",
            "A value is trying to be set on a copy of a slice from a DataFrame\n",
            "\n",
            "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
            "  long_df[\"text\"].iloc[85] = articles_df[articles_df[\"title\"] == long_df[\"title\"].iloc[85]].summary.copy()\n"
          ]
        }
      ],
      "source": [
        "long_df[\"text\"].iloc[56] = articles_df[articles_df[\"title\"] == long_df[\"title\"].iloc[56]].summary.copy()\n",
        "long_df[\"text\"].iloc[85] = articles_df[articles_df[\"title\"] == long_df[\"title\"].iloc[85]].summary.copy()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 10,
      "id": "14bf199f",
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "<class 'pandas.core.frame.DataFrame'>\n",
            "RangeIndex: 87 entries, 0 to 86\n",
            "Data columns (total 5 columns):\n",
            " #   Column  Non-Null Count  Dtype \n",
            "---  ------  --------------  ----- \n",
            " 0   title   87 non-null     object\n",
            " 1   year    87 non-null     int64 \n",
            " 2   link    87 non-null     object\n",
            " 3   type    87 non-null     object\n",
            " 4   text    87 non-null     object\n",
            "dtypes: int64(1), object(4)\n",
            "memory usage: 3.5+ KB\n"
          ]
        }
      ],
      "source": [
        "long_df.info()"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "03271ed6",
      "metadata": {},
      "source": [
        "*Проверим количество слов в текстах (хоть это и не соответствует количеству токенов, но дает увидеть общую картину)*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 11,
      "id": "6363fe8e",
      "metadata": {},
      "outputs": [],
      "source": [
        "long_df[\"word_len\"] = long_df[\"text\"].astype(\"string\").str.split().str.len()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 12,
      "id": "ded304cc",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "count       87.000000\n",
              "mean      1055.068966\n",
              "std       1701.864257\n",
              "min         11.000000\n",
              "25%        201.000000\n",
              "50%        504.000000\n",
              "75%       1089.500000\n",
              "max      10714.000000\n",
              "Name: word_len, dtype: float64"
            ]
          },
          "execution_count": 12,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "long_df[\"word_len\"].describe()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 13,
      "id": "b04dff01",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>count</th>\n",
              "      <th>mean</th>\n",
              "      <th>std</th>\n",
              "      <th>min</th>\n",
              "      <th>25%</th>\n",
              "      <th>50%</th>\n",
              "      <th>75%</th>\n",
              "      <th>max</th>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>type</th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "      <th></th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>abstract</th>\n",
              "      <td>29.0</td>\n",
              "      <td>209.310345</td>\n",
              "      <td>65.818529</td>\n",
              "      <td>77.0</td>\n",
              "      <td>166.0</td>\n",
              "      <td>197.0</td>\n",
              "      <td>242.0</td>\n",
              "      <td>346.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>introduction</th>\n",
              "      <td>29.0</td>\n",
              "      <td>620.379310</td>\n",
              "      <td>256.612606</td>\n",
              "      <td>12.0</td>\n",
              "      <td>486.0</td>\n",
              "      <td>600.0</td>\n",
              "      <td>762.0</td>\n",
              "      <td>1166.0</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>result</th>\n",
              "      <td>29.0</td>\n",
              "      <td>2335.517241</td>\n",
              "      <td>2488.184961</td>\n",
              "      <td>11.0</td>\n",
              "      <td>661.0</td>\n",
              "      <td>1758.0</td>\n",
              "      <td>2877.0</td>\n",
              "      <td>10714.0</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "              count         mean          std   min    25%     50%     75%  \\\n",
              "type                                                                         \n",
              "abstract       29.0   209.310345    65.818529  77.0  166.0   197.0   242.0   \n",
              "introduction   29.0   620.379310   256.612606  12.0  486.0   600.0   762.0   \n",
              "result         29.0  2335.517241  2488.184961  11.0  661.0  1758.0  2877.0   \n",
              "\n",
              "                  max  \n",
              "type                   \n",
              "abstract        346.0  \n",
              "introduction   1166.0  \n",
              "result        10714.0  "
            ]
          },
          "execution_count": 13,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "long_df[long_df[\"type\"].isin(types)].groupby(\"type\")[\"word_len\"].describe()"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "f647c791",
      "metadata": {},
      "source": [
        "*Вероятно, 12 и 11 это длины саммари, которые были вставлены*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 18,
      "id": "6a7a2a3e",
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "11 12\n"
          ]
        }
      ],
      "source": [
        "print(long_df.iloc[56][\"word_len\"], long_df.iloc[85][\"word_len\"])"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "b0ae150e",
      "metadata": {},
      "source": [
        "*В среднем introduction занимает 620 слов. В токенах это будет больше, вероятно, в 2-5 раз. А срднее по результаты вообще составляет больше 2т слов. Так как количество слов сильно различается в разных разделах, то правильным будем разделить все тексты на чанки. Каждые 300-500 токенов с перекрытием в ~50 токенов будет являться одним чанком. Это соответсвует примерно одному абзацу. Такой подход позволит не забивать контекст лишней информацией, а конкретно релевантной для запроса. Модели БЯМ так будет и цитировать исходный текст.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 25,
      "id": "5a50bc32",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "<Axes: >"
            ]
          },
          "execution_count": 25,
          "metadata": {},
          "output_type": "execute_result"
        },
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "long_df[\"word_len\"].hist()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "f1be9765",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "array([[<Axes: title={'center': 'abstract'}>,\n",
              "        <Axes: title={'center': 'introduction'}>],\n",
              "       [<Axes: title={'center': 'result'}>, <Axes: >]], dtype=object)"
            ]
          },
          "execution_count": 23,
          "metadata": {},
          "output_type": "execute_result"
        },
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 640x480 with 4 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "types = [\"abstract\", \"introduction\", \"result\"]\n",
        "\n",
        "long_df.loc[long_df[\"type\"].isin(types), \"word_len\"].hist(by=long_df.loc[long_df[\"type\"].isin(types), \"type\"])"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "283c9acf",
      "metadata": {},
      "source": [
        "*Возможно, на среднюю длину результатов повлиял выброса, наблюдаемый на гистограме, можно проверить, например, с помощью правила трех сигм (после проверки на нормальность) и подтверить, что это выброс, но как будто в данной задаче это не имеет смысла. Можно построить боксплот и там посмотреть.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 28,
      "id": "31ab3556",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "<Axes: title={'center': 'word_len'}, xlabel='type'>"
            ]
          },
          "execution_count": 28,
          "metadata": {},
          "output_type": "execute_result"
        },
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 640x480 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "long_df[long_df[\"type\"].isin(types)].boxplot(column=\"word_len\", by=\"type\")"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "17ee1582",
      "metadata": {},
      "source": [
        "*Выбросы действительно присутствуют. В целом все выглядит логичным: абстракты короткие, введения среднего объема, результаты длиннее.*"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "c24a0026",
      "metadata": {},
      "source": [
        "*Для проверки качества текстов можно посмотреть на частотность би- и три-грамм. Чем больше будет специфичных терминов, тем по идее более качественными являются тексты.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 42,
      "id": "9e5b2bc6",
      "metadata": {},
      "outputs": [],
      "source": [
        "from sklearn.feature_extraction.text import CountVectorizer"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 56,
      "id": "ee222e0a",
      "metadata": {},
      "outputs": [],
      "source": [
        "vec = CountVectorizer(\n",
        "    lowercase=True,\n",
        "    stop_words=\"english\",\n",
        "    ngram_range=(2, 4),\n",
        "    min_df=2,\n",
        "    max_df=0.9\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 57,
      "id": "b1782a32",
      "metadata": {},
      "outputs": [],
      "source": [
        "X = vec.fit_transform(long_df[\"text\"].astype(\"string\"))\n",
        "ngrams = vec.get_feature_names_out()\n",
        "freq = X.sum(axis=0).A1"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 58,
      "id": "69909f76",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ngram</th>\n",
              "      <th>count</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>1952</th>\n",
              "      <td>et al</td>\n",
              "      <td>291</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>561</th>\n",
              "      <td>alzheimer disease</td>\n",
              "      <td>82</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>388</th>\n",
              "      <td>ad patients</td>\n",
              "      <td>80</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4911</th>\n",
              "      <td>supporting information</td>\n",
              "      <td>71</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>360</th>\n",
              "      <td>ad mice</td>\n",
              "      <td>67</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5214</th>\n",
              "      <td>tr zra</td>\n",
              "      <td>55</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>709</th>\n",
              "      <td>app ps1</td>\n",
              "      <td>53</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5074</th>\n",
              "      <td>tau hyperphosphorylation</td>\n",
              "      <td>51</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>562</th>\n",
              "      <td>alzheimer disease ad</td>\n",
              "      <td>51</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1675</th>\n",
              "      <td>disease ad</td>\n",
              "      <td>51</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5087</th>\n",
              "      <td>tau protein</td>\n",
              "      <td>51</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>710</th>\n",
              "      <td>app ps1 mice</td>\n",
              "      <td>50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4189</th>\n",
              "      <td>ps1 mice</td>\n",
              "      <td>50</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4671</th>\n",
              "      <td>shown figure</td>\n",
              "      <td>47</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1122</th>\n",
              "      <td>cell death</td>\n",
              "      <td>46</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>838</th>\n",
              "      <td>aβ1 42</td>\n",
              "      <td>44</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5084</th>\n",
              "      <td>tau pathology</td>\n",
              "      <td>42</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3017</th>\n",
              "      <td>lipid metabolism</td>\n",
              "      <td>39</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4687</th>\n",
              "      <td>signaling pathway</td>\n",
              "      <td>38</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3673</th>\n",
              "      <td>oxidative stress</td>\n",
              "      <td>37</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                         ngram  count\n",
              "1952                     et al    291\n",
              "561          alzheimer disease     82\n",
              "388                ad patients     80\n",
              "4911    supporting information     71\n",
              "360                    ad mice     67\n",
              "5214                    tr zra     55\n",
              "709                    app ps1     53\n",
              "5074  tau hyperphosphorylation     51\n",
              "562       alzheimer disease ad     51\n",
              "1675                disease ad     51\n",
              "5087               tau protein     51\n",
              "710               app ps1 mice     50\n",
              "4189                  ps1 mice     50\n",
              "4671              shown figure     47\n",
              "1122                cell death     46\n",
              "838                     aβ1 42     44\n",
              "5084             tau pathology     42\n",
              "3017          lipid metabolism     39\n",
              "4687         signaling pathway     38\n",
              "3673          oxidative stress     37"
            ]
          },
          "execution_count": 58,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "freq_df = pd.DataFrame({\"ngram\": ngrams, \"count\": freq}).sort_values(\"count\", ascending=False)\n",
        "freq_df.head(20)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "c2e137ed",
      "metadata": {},
      "source": [
        "*Можно исключить из текстов \"et al\", \"supporting information\", \"shown figure\", так как они не имеют полезной для текущей задачи смысловой нагрузки.*"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "69942a08",
      "metadata": {
        "id": "69942a08"
      },
      "source": [
        "## Задание 4\n",
        "- Подготовить данные для моделирования"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 62,
      "id": "5565bdb4",
      "metadata": {},
      "outputs": [],
      "source": [
        "gurb_phrases = [\"et al\", \"supporting information\", \"shown figure\"]\n",
        "\n",
        "for phrase in gurb_phrases:\n",
        "    long_df[\"text\"] = long_df[\"text\"].astype(\"string\").str.replace(phrase, \"\", regex=False)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 63,
      "id": "7279df53",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>year</th>\n",
              "      <th>link</th>\n",
              "      <th>type</th>\n",
              "      <th>text</th>\n",
              "      <th>word_len</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>abstract</td>\n",
              "      <td>Amyloid β -protein (A β ) is reported to activ...</td>\n",
              "      <td>316</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>introduction</td>\n",
              "      <td>Alzheimer’s disease (AD) is an irreversible ne...</td>\n",
              "      <td>984</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>result</td>\n",
              "      <td>Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...</td>\n",
              "      <td>2858</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                               title  year  \\\n",
              "0  Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "1  Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "2  Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "\n",
              "                                        link          type  \\\n",
              "0  https://doi.org/10.3389/fnagi.2021.809433      abstract   \n",
              "1  https://doi.org/10.3389/fnagi.2021.809433  introduction   \n",
              "2  https://doi.org/10.3389/fnagi.2021.809433        result   \n",
              "\n",
              "                                                text  word_len  \n",
              "0  Amyloid β -protein (A β ) is reported to activ...       316  \n",
              "1  Alzheimer’s disease (AD) is an irreversible ne...       984  \n",
              "2  Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...      2858  "
            ]
          },
          "execution_count": 63,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "long_df.head(3)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "967aef61",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>title</th>\n",
              "      <th>year</th>\n",
              "      <th>link</th>\n",
              "      <th>type</th>\n",
              "      <th>text</th>\n",
              "      <th>word_len</th>\n",
              "      <th>file</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>abstract</td>\n",
              "      <td>Amyloid β -protein (A β ) is reported to activ...</td>\n",
              "      <td>316</td>\n",
              "      <td>0.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>introduction</td>\n",
              "      <td>Alzheimer’s disease (AD) is an irreversible ne...</td>\n",
              "      <td>984</td>\n",
              "      <td>0.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>Salidroside Ameliorates Alzheimer's Disease by...</td>\n",
              "      <td>2022</td>\n",
              "      <td>https://doi.org/10.3389/fnagi.2021.809433</td>\n",
              "      <td>result</td>\n",
              "      <td>Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...</td>\n",
              "      <td>2858</td>\n",
              "      <td>0.pdf</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>Metabolic reprogramming in inflammatory microg...</td>\n",
              "      <td>2023</td>\n",
              "      <td>https://doi.org/10.1016/j.redox.2023.102846</td>\n",
              "      <td>abstract</td>\n",
              "      <td>Microglia activation drives the pro-inflammato...</td>\n",
              "      <td>253</td>\n",
              "      <td>1.pdf</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                               title  year  \\\n",
              "0  Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "1  Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "2  Salidroside Ameliorates Alzheimer's Disease by...  2022   \n",
              "3  Metabolic reprogramming in inflammatory microg...  2023   \n",
              "\n",
              "                                          link          type  \\\n",
              "0    https://doi.org/10.3389/fnagi.2021.809433      abstract   \n",
              "1    https://doi.org/10.3389/fnagi.2021.809433  introduction   \n",
              "2    https://doi.org/10.3389/fnagi.2021.809433        result   \n",
              "3  https://doi.org/10.1016/j.redox.2023.102846      abstract   \n",
              "\n",
              "                                                text  word_len   file  \n",
              "0  Amyloid β -protein (A β ) is reported to activ...       316  0.pdf  \n",
              "1  Alzheimer’s disease (AD) is an irreversible ne...       984  0.pdf  \n",
              "2  Sal Improved A β 1-42 and D-gal/AlCl 3 Induced...      2858  0.pdf  \n",
              "3  Microglia activation drives the pro-inflammato...       253  1.pdf  "
            ]
          },
          "execution_count": 72,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "file_names = articles_df.reset_index().set_index(\"title\")[\"index\"]\n",
        "long_df[\"file\"] = long_df[\"title\"].map(file_names).astype(\"Int64\").astype(\"string\") + \".pdf\"\n",
        "long_df.head(4)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 73,
      "id": "110af95f",
      "metadata": {},
      "outputs": [],
      "source": [
        "long_df.to_csv(\"long_bd_df.csv\")"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "e6a04ceb",
      "metadata": {},
      "source": [
        "*Разделим тексты на чанки и сделаем векторную базу с langchain.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "id": "5b8bfd15",
      "metadata": {},
      "outputs": [],
      "source": [
        "import pandas as pd"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "id": "c3c77ad7",
      "metadata": {
        "id": "c3c77ad7"
      },
      "outputs": [],
      "source": [
        "long_bd_df = pd.read_csv(\"long_bd_df.csv\", index_col=0)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "id": "1bdfee5a",
      "metadata": {},
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "c:\\Users\\Аскер\\Desktop\\LLM-based agent (Alzheimer's disease)\\db_collecting\\.venv\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
            "  from .autonotebook import tqdm as notebook_tqdm\n"
          ]
        }
      ],
      "source": [
        "from langchain_core.documents import Document\n",
        "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
        "from langchain_huggingface import HuggingFaceEmbeddings\n",
        "from langchain_chroma import Chroma"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 4,
      "id": "54b07173",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "title       GSK3: A potential target and pending issues fo...\n",
              "year                                                     2024\n",
              "link                        https://doi.org/10.1111/cns.14818\n",
              "type                                                 abstract\n",
              "text        Glycogen synthase kinase- 3 (GSK3), consisting...\n",
              "word_len                                                  166\n",
              "file                                                    3.pdf\n",
              "Name: 9, dtype: object"
            ]
          },
          "execution_count": 4,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "long_bd_df.iloc[9]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 5,
      "id": "5d597f61",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "87"
            ]
          },
          "execution_count": 5,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "corpus_docs = [\n",
        "    Document(page_content=row[\"text\"], metadata={\"id\": idx, \"title\": row[\"title\"], \"year\": row[\"year\"], \"link\": row[\"link\"], \"type\": row[\"type\"], \"file\": row[\"file\"]})\n",
        "    for idx, row in long_bd_df.iterrows()\n",
        "]\n",
        "\n",
        "len(corpus_docs)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 6,
      "id": "dab8480e",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "2503"
            ]
          },
          "execution_count": 6,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "splitter = RecursiveCharacterTextSplitter(chunk_size=300, chunk_overlap=50)\n",
        "docs = splitter.split_documents(corpus_docs)\n",
        "len(docs)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 7,
      "id": "7bf71ff8",
      "metadata": {},
      "outputs": [],
      "source": [
        "embedding_model = HuggingFaceEmbeddings(model_name=\"sentence-transformers/all-mpnet-base-v2\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 10,
      "id": "94ca4840",
      "metadata": {},
      "outputs": [],
      "source": [
        "vectordb = Chroma.from_documents(documents=docs, embedding=embedding_model, persist_directory=\"chroma_artilcles\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 13,
      "id": "66cbd81e",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[Document(id='fe09d990-e93f-4076-ba0e-ebb3f5cd7cf8', metadata={'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'type': 'introduction', 'year': 2022, 'file': '26.pdf', 'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'id': 73}, page_content='remedies that are currently approved and used for symptomatic treatment of AD.2 THE BIGGER PICTURE Owing to current setbacks in the discovery and development of novel treatments tackling Alzheimer disease (AD), a re-evaluation of research and development (R&D) strategies is underway. Here, we'),\n",
              " Document(id='c6a6bd64-bc4f-4df3-a61d-dc1d90e4e16b', metadata={'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'file': '26.pdf', 'year': 2022, 'id': 73, 'type': 'introduction'}, page_content='remedies that are currently approved and used for symptomatic treatment of AD.2 THE BIGGER PICTURE Owing to current setbacks in the discovery and development of novel treatments tackling Alzheimer disease (AD), a re-evaluation of research and development (R&D) strategies is underway. Here, we'),\n",
              " Document(id='476e9fb6-caee-4079-b88d-664c094f5cfd', metadata={'file': '25.pdf', 'id': 70, 'link': 'https://doi.org/10.1212/wnl.0000000000200771', 'title': 'Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk', 'type': 'introduction', 'year': 2022}, page_content='Alzheimer disease (AD) is a neurodegenerative disease, characterized by aberrant protein aggregation and neuronal loss in the brain that leads to cognitive decline, memory loss, and ultimately death. However, currently, only a few agents or drugs that can improve symptoms have been approved for AD,')]"
            ]
          },
          "execution_count": 13,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "vectordb.similarity_search(query=\"What are potential targets for Alzheimer's disease treatment?\", k=3)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "7f914c74",
      "metadata": {},
      "source": [
        "*Чанки выглядят расплывчатыми и подходят для описания AD в общих словах. Возможно, ограничение поиска только текстами из результатов и увеличение количества релевантных k немного улучшит ситуацию. ​Можно было бы подумать лучше над предобработкой. Например, не брать введения и абстракты, но в таком случае модель БЯМ не будет получать из базы поверхностную информацию, нужную для ответа на более общие вопросы.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 14,
      "id": "d6d1ea12",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[Document(id='46bcc8ca-edd5-44d9-bb6e-df800e77f477', metadata={'type': 'result', 'id': 8, 'year': 2024, 'title': \"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease\", 'link': 'https://doi.org/10.1016/j.ejmcr.2024.100154', 'file': '2.pdf'}, page_content='remedies on AD, and evaluates their potential as alternative treatments for the disease. Currently, the most commonly drugs used to treat Alzheimer’s disease are acetylcholinesterase/cholinesterase inhibitors (ChE-Is). The first ChE-I to be approved for the symptomatic therapy of AD was tacrine,'),\n",
              " Document(id='466b2524-4bb6-4ebe-b955-362f3c8eeee3', metadata={'title': \"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease\", 'year': 2024, 'id': 8, 'type': 'result', 'link': 'https://doi.org/10.1016/j.ejmcr.2024.100154', 'file': '2.pdf'}, page_content='remedies on AD, and evaluates their potential as alternative treatments for the disease. Currently, the most commonly drugs used to treat Alzheimer’s disease are acetylcholinesterase/cholinesterase inhibitors (ChE-Is). The first ChE-I to be approved for the symptomatic therapy of AD was tacrine,'),\n",
              " Document(id='706caf05-ade9-401d-8e80-06a864c02754', metadata={'file': '2.pdf', 'title': \"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease\", 'type': 'result', 'id': 8, 'link': 'https://doi.org/10.1016/j.ejmcr.2024.100154', 'year': 2024}, page_content='These findings are supported by various in vivo and in vitro investigations [116,126–128]. Alzheimer’s disease (AD) is a common form of dementia character -ized by memory impairment and neurological symptoms. The Food and Drug Administration has approved (synthetic medications) only a limited number of treatments for Alzheimer’s disease, which include angiotensin-converting enzyme inhibitors (donepezil, galantamine, and rivastigmine) and')]"
            ]
          },
          "execution_count": 14,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "vectordb.similarity_search(query=\"What are potential targets for Alzheimer's disease treatment?\", k=3, filter={\"type\": \"result\"})"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "356a9c6c",
      "metadata": {},
      "source": [
        "*Фильтр ограничивает выборку чанками из результатов, поэтому ответы становятся более подходящими. Видимо, в результатах приводятся названия конкретных сущностей в отличие от введений. Однако тут все три чанка из одной статьи, вероятно, надо увеличить размер чанков.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "id": "b6e9a39f",
      "metadata": {},
      "outputs": [],
      "source": [
        "splitter = RecursiveCharacterTextSplitter(chunk_size=450, chunk_overlap=50)\n",
        "docs = splitter.split_documents(corpus_docs)\n",
        "\n",
        "vectordb = Chroma.from_documents(documents=docs, embedding=embedding_model, persist_directory=\"chroma_artilcles\")"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "289580fc",
      "metadata": {},
      "source": [
        "*Правильная настройка retriever позволит улучшить релевантность выборки в целом. После проведения небольшого эксперимента с разными значениями lambda_mult, fetch_k и k, которые позволяют регулировать различия и релевантность в выдаваемых документах, количество всей выборки, из которой выбираются итоговые и количество итоговых, были выбраны следующие. Из всех документов берется 35 наиболее релевантных, из них отбирается 5, чьи эмбеддинги достаточно далеки друг от друга. Это позволяет взять документы с разными смыслами, из-за чего нужные нам сущноти точно попадут в БЯМ.*"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 9,
      "id": "4d3a82e1",
      "metadata": {},
      "outputs": [],
      "source": [
        "retriever = vectordb.as_retriever(\n",
        "    search_type=\"mmr\",\n",
        "    search_kwargs={\"k\": 5, \"fetch_k\": 35, \"lambda_mult\": 0.3},\n",
        ")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 10,
      "id": "01144bb3",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[Document(id='f9ad16ee-92ac-4237-934c-e37707a7081f', metadata={'file': '8.pdf', 'link': 'https://doi.org/10.1002/alz.14313', 'id': 25, 'type': 'introduction', 'year': 2024, 'title': \"Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US\"}, page_content='An estimated 6.9 million Americans aged 65 and older will be living with Alzheimer’s disease (AD) in 2024, a number that is projected to increase to 13.8 million by 2060.1 AD has no cure, and about 40% of cases are linked to modifiable risk factors.2 Given its growing prevalence, profound societal and economic impact, and absence of a cure, targeting these modifiable risk factors is crucial to prevent or delay AD and related dementia. 3,4'),\n",
              " Document(id='96986312-5a98-4615-99d1-599c522885b6', metadata={'type': 'result', 'id': 35, 'title': \"Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease\", 'file': '12.pdf', 'year': 2021, 'link': 'https://doi.org/10.1016/j.ejmech.2021.113847'}, page_content=\"and from the literature were selected, so as they were either (i) known TTR binders, (ii) amyloid peptide binding ligands, or (iii) both, or (iv) compounds under study in clinical phases for the treatment of Alzheimer's disease. The use of the CARLSBAD software and database [64] allowed us to find privileged scaffolds with reported biological activity against both TTR and Ab systems. This scaffold hunting methodology allowed us to find a group\"),\n",
              " Document(id='6fdad8d5-ef8c-4832-92b1-c332285f0600', metadata={'link': 'https://doi.org/10.1016/j.ejmcr.2024.100154', 'title': \"Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease\", 'id': 8, 'year': 2024, 'type': 'result', 'file': '2.pdf'}, page_content='flavonoids, terpenes, and glycosides have also been shown to inhibit AChE [139]. Some examples of natural products with AChEI activity include huperzine A, galantamine, physostigmine, and rivastigmine (Table 2). Huperzine A and Galantamine have been used clinically to treat Alzheimer’s disease (AD). Both drugs are effective to treat age-related memory impairment or dementia, but its cognitive effects on patients with moderate AD are inconclusive'),\n",
              " Document(id='a940d276-edf5-4c03-9883-4dee29aea747', metadata={'id': 19, 'year': 2022, 'title': \"Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection\", 'link': 'https://doi.org/10.1016/j.apsb.2022.02.001', 'type': 'introduction', 'file': '6.pdf'}, page_content='of AD researches is b amyloid (A b) cascade hypothesis, but all clinical trials were interrupted due to the lack of damaged neuronal recovery 2e4. Alternatively, there emerged other therapeutic targets of AD, including microtubule-associated protein, anti-neuroinflammation, synaptic and neuroprotection, metabolism, neurogenesis, vascular system and epigenetic drugs, among which the number of anti-neuroinflammatory and neuroprotective drugs has'),\n",
              " Document(id='3516f11f-f8a9-4339-8ff0-79424c0f7b0f', metadata={'id': 61, 'file': '21.pdf', 'link': 'https://doi.org/10.3390/pharmaceutics13101555', 'type': 'introduction', 'title': 'Multiomics Identification of Potential Targets for Alzheimer Disease and Antrocin as a Therapeutic Candidate', 'year': 2021}, page_content='clinical samples, aiding in the identification of disease-related genes [12]. Previous studies have investigated gene expression changes in the brain tissues of patients with AD and other neurodegenerative dementias [13–18]. The public availability of the results from those studies offers the possibility of analyzing the transcriptomic data to identify potential drug targets and to develop appropriate therapeutic strategies. Natural products,')]"
            ]
          },
          "execution_count": 10,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "retriever.invoke(\"What are potential targets for Alzheimer's disease treatment?\")"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "3af1ea01",
      "metadata": {},
      "source": [
        "Случайные документы, по которым можно сгенерировать вопросы для проверки качества разрабатываемой системы:"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 14,
      "id": "fc97e017",
      "metadata": {},
      "outputs": [],
      "source": [
        "import random\n",
        "random_docs = random.sample(docs, 15)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 15,
      "id": "853b7203",
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[Document(metadata={'id': 79, 'title': 'Genomics and Drug Research Approach in Identifying Potential Drug Target Highlighting Alzheimer Disease', 'year': 2024, 'link': 'https://doi.org/10.52403/gijhsr.20240115', 'type': 'introduction', 'file': '29.pdf'}, page_content='extracted from plants which act as potent herbal medicine and helps to form a complex which can be used as drug for the treatment of AD. Further, docking studies were carried out in which BACE1 is best docked with chromen-4-one followed by some other bioactive compounds with positive potential result. To cross validate our docking research hypothesis we conducted computational based molecular dynamic (MD) simulation analysis to find potential'),\n",
              " Document(metadata={'id': 50, 'title': \"Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease\", 'year': 2023, 'link': 'https://doi.org/10.1002/advs.202301361', 'type': 'result', 'file': '17.pdf'}, page_content='in plasmid delivery in normal and aging microglia (Figure S12, Supporting Information). Next, qRT-PCR and Western blotting were employed to detect the expression of CD22 to determine the silencing efficacy of the nanoparticles. After treatment with Aβ1-42, the expression of CD22 in BV2 cells was elevated. Compared with other groups, TR-ZRA groups showed significant inhibition of CD22, indicating regulatory activity of delivered CD22shRNA. Among'),\n",
              " Document(metadata={'id': 33, 'title': \"Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease\", 'year': 2021, 'link': 'https://doi.org/10.1016/j.ejmech.2021.113847', 'type': 'abstract', 'file': '12.pdf'}, page_content=\"Transthyretin (TTR) has a well-established role in neuroprotection in Alzheimer's Disease (AD). We have setup a drug discovery program of small-molecule compounds that act as chaperones enhancing TTR/Amyloid-beta peptide (Aβ) interactions. A combination of computational drug repurposing approaches and in vitro biological assays have resulted in a set of molecules which were then screened with our in-house validated high-throughput screening\"),\n",
              " Document(metadata={'id': 11, 'title': \"GSK3: A potential target and pending issues for treatment of Alzheimer's disease\", 'year': 2024, 'link': 'https://doi.org/10.1111/cns.14818', 'type': 'result', 'file': '3.pdf'}, page_content='mediated by other proteins in tau pathology. In addition to the above few signaling pathways or stimuli, there are numerous proteins that have been reported to directly or indirectly affect GSK3- mediated tau pathology. Firstly, there is a class of proteins that have been found to be abnormally expressed in AD patients or AD animal models, including Deficiency in G protein- coupled receptor- 5 (GRK5), Heat shock protein 27 (Hsp27), 3- β-'),\n",
              " Document(metadata={'id': 59, 'title': 'Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus', 'year': 2021, 'link': 'https://doi.org/10.1038/s41598-021-02248-5', 'type': 'result', 'file': '20.pdf'}, page_content='of quercetin targets for T2DM and AD treatment. To estimate the contributions of these candidate common targets to disease and reveal the interactive effects, all 95 were imported into the STRING database with highest confidence set at 0.9 to obtain a PPI network. The PPI network results were saved in TSV text format and imported into Cytoscape3.6.0 for network topology analysis to identify the top 25 targets (arranged in descending order of'),\n",
              " Document(metadata={'id': 74, 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'year': 2022, 'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'type': 'result', 'file': '26.pdf'}, page_content='confirmation rate is reasonable for this type of complex and coupled enzymatic assay. To validate the 183 confirmed active compounds, a second HDAC6 screening was conducted in addition to dose response studies (Figure 3D). This assay employing a shorter, less specific peptide derived from histone H3 resulted in 104 compounds inhibiting to at least 75%. From these, 23 molecules were found to be specific for the histone H3 substrate, and 81'),\n",
              " Document(metadata={'id': 50, 'title': \"Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease\", 'year': 2023, 'link': 'https://doi.org/10.1002/advs.202301361', 'type': 'result', 'file': '17.pdf'}, page_content='the 3′ end was close to the BHQ group labeling the 5′ end. The aptamer could bind to Aβ1-42 when Aβ1-42 was present. FAM and BHQ then moved far away from each other, and the green fluorescence was restored (Figure 6a). As shown in Figure 6b, after optimizing the experimental conditions, the relationship between the fluorescence intensity of AAP and the concentration of Aβ1-42 was analyzed. The results showed that the fluorescence signal of AAP'),\n",
              " Document(metadata={'id': 11, 'title': \"GSK3: A potential target and pending issues for treatment of Alzheimer's disease\", 'year': 2024, 'link': 'https://doi.org/10.1111/cns.14818', 'type': 'result', 'file': '3.pdf'}, page_content='Heat shock protein 27 (Hsp27) transgenic mice showed a striking pathological phosphorylation of tau, with upregulated p- GSK3βTyr216 and downregulated p- GSK3βSer9 indicating that GSK3 β was the immediate cause of p- tau.146 Increased expression of p44, a short isoform of p53, has been found to elevate the risk of tau pathology.147 Moreover, haploinsufficiency for p73, a member of the p53 family, has demonstrated a similar phenomenon. 148'),\n",
              " Document(metadata={'id': 68, 'title': 'Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab', 'year': 2024, 'link': 'https://doi.org/10.26508/lsa.202402650', 'type': 'result', 'file': '23.pdf'}, page_content='and dipeptidyl peptidase 4 (DPP4), which were immunopurified from the membrane fraction of mouse brains, displayed Aβ-degrading activity (Fig 7A). Among them, DPP4 exhibited the highest activity. Protein contents were in the order of APN > APA > DPP4, but DPP4 had the highest specific activity (Fig 7C), suggesting that it plays a significant role in truncating amino-terminal amino acids (DA). Our results showed that the expression levels of APN,'),\n",
              " Document(metadata={'id': 44, 'title': \"Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease\", 'year': 2024, 'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'type': 'result', 'file': '15.pdf'}, page_content='to overcome these drawbacks [223]. Protein kinases are valuable therapeutic targets for the intervention of AD, not only due to the direct participation of dysregulated kinases in various AD pathologies, but also because of the vast number of chemicals and strategies available for drug development [227]. Compounds targeting GSK-3β, CDK5, p38 MAPK, ERK1/2, JNK3 or several tyrosine kinases have been evaluated in AD mouse models, and some of them'),\n",
              " Document(metadata={'id': 61, 'title': 'Multiomics Identification of Potential Targets for Alzheimer Disease and Antrocin as a Therapeutic Candidate', 'year': 2021, 'link': 'https://doi.org/10.3390/pharmaceutics13101555', 'type': 'introduction', 'file': '21.pdf'}, page_content='[10]. The specific genetic alterations and pathological mechanisms of the development and progression of dementia remain poorly understood [11], and research in identifying more-important genes and molecular pathways associated with AD pathogenesis will help uncover potential treatments. Gene expression microarrays are widely used to comprehensively measure the genome-wide expression profiles of clinical samples, aiding in the identification of'),\n",
              " Document(metadata={'id': 29, 'title': \"The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease\", 'year': 2022, 'link': 'https://doi.org/10.3389/fpsyt.2022.1039725', 'type': 'result', 'file': '9.pdf'}, page_content='evidence linking the dopaminergic VTA with these early deficits in Tg2576 mice came after the observation of substantial apoptotic cell death of VTA dopamine neurons in these mice, accompanied by significant levels of local neuroinflammation, starting between 2–3 months of age and progressively worsening with age (111). The work by Nobili, ., and subsequent papers, showed that the progressive degeneration of VTA TH+ neurons results in lower'),\n",
              " Document(metadata={'id': 82, 'title': 'Identification of Sirtuin 1-Targeted Anti-Alzheimer Agents Using Structure-Based Drug Design and Multi-Database Screening', 'year': 2024, 'link': 'https://doi.org/10.56042/ijc.v63i12.13637', 'type': 'introduction', 'file': '31.pdf'}, page_content=\"treatments only offer limited symptomatic relief. Consequently, there is a pressing need for novel therapeutic approaches to address the disease's underlying causes and halt its progression4,5. Sirtuin1 (SIRT1) is a member of the Sirtuin family of NAD+-dependent deacetylases and has garnered significant attention due to its involvement in regulating various cellular processes, including ageing, metabolism, and stress responses6. In the context\"),\n",
              " Document(metadata={'id': 50, 'title': \"Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease\", 'year': 2023, 'link': 'https://doi.org/10.1002/advs.202301361', 'type': 'result', 'file': '17.pdf'}, page_content='brain tissue and preventing harmful substances from entering the brain tissue. The tight junctions established between endothelial cells limit the passage of many neurotherapeutic drugs across the BBB.[32] In addition, the size, lipid solubility, and other physical and chemical properties of a drug also limit its ability to cross the BBB. Therefore, we next explored whether these synthetic nanoparticles could cross the blood‒brain barrier, which'),\n",
              " Document(metadata={'id': 29, 'title': \"The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease\", 'year': 2022, 'link': 'https://doi.org/10.3389/fpsyt.2022.1039725', 'type': 'result', 'file': '9.pdf'}, page_content='structural MRI to link the volume of the VTA with typical AD clinical markers, in particular hippocampal size and memory index (133, 134). The main finding of the study was that the VTA volume is strongly associated with the size of the hippocampal formation and memory abilities of both AD patients and healthy controls, thus indicating that a smaller VTA size or shrinkage of the nucleus might correspond to a worse memory performance and smaller')]"
            ]
          },
          "execution_count": 15,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "random_docs"
      ]
    }
  ],
  "metadata": {
    "colab": {
      "provenance": []
    },
    "kernelspec": {
      "display_name": ".venv",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.11.8"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 5
}
